

Staging of brain pathology related to sporadic Parkinson

Neurobiology of Aging

24, 197-211

DOI: [10.1016/s0197-4580\(02\)00065-9](https://doi.org/10.1016/s0197-4580(02)00065-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	REM sleep behavior disorder in the elderly. , 0, , 241-247.		0
2	The Effect of a Prior Probability and Complexity on Decision Making in a Supervisory Control Task. Human Factors, 1996, 38, 65-78.	2.1	28
4	Emotional processing in Parkinson's disease. Journal of Neurology, 2002, 249, 993-1000.	1.8	20
5	Protein Accumulation in Traumatic Brain Injury. NeuroMolecular Medicine, 2003, 4, 59-72.	1.8	126
6	Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathologica, 2003, 106, 188-189.	3.9	15
7	Î±-Synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution—a pilot study. Acta Neuropathologica, 2003, 106, 191-202.	3.9	169
8	Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission, 2003, 110, 517-536.	1.4	1,323
9	Olfaction in neurodegenerative disorder. Movement Disorders, 2003, 18, 364-372.	2.2	265
10	Neuropathological spectrum of synucleinopathies. Movement Disorders, 2003, 18, 2-12.	2.2	301
11	Toward a molecular neuropsychiatry of neurodegenerative diseases. Annals of Neurology, 2003, 54, 147-154.	2.8	87
12	Involvement of precerebellar nuclei in multiple system atrophy. Neuropathology and Applied Neurobiology, 2003, 29, 60-76.	1.8	86
13	14-3-3 proteins in the nervous system. Nature Reviews Neuroscience, 2003, 4, 752-762.	4.9	405
14	Age-dependent synuclein pathology following traumatic brain injury in mice. Experimental Neurology, 2003, 184, 214-224.	2.0	103
15	Part II: Î±-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45, 14-44.	2.0	254
16	Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Molecular and Cellular Neurosciences, 2003, 24, 419-429.	1.0	189
17	Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science, 2003, 302, 819-822.	6.0	1,530
18	Pharmacotherapy of dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2003, 4, 2027-2037.	0.9	38
19	The Future of Cell-Based Transplantation Therapies for Neurodegenerative Disorders. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 635-642.	1.8	24

#	ARTICLE	IF	CITATIONS
20	Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. <i>Neurology</i> , 2003, 61, 40-45.	1.5	376
21	Î±-Synuclein Accumulates in Purkinje Cells in Lewy Body Disease but not in Multiple System Atrophy. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2003, 62, 812-819.	0.9	66
22	Subthalamic Stimulation for Parkinson's Disease " Living Better Electrically?. <i>New England Journal of Medicine</i> , 2003, 349, 1888-1891.	13.9	12
24	Title is missing!. <i>Current Opinion in Neurology</i> , 2003, 16, 459-463.	1.8	5
25	Brain banking for neurodegenerative diseases. <i>Current Opinion in Neurology</i> , 2003, 16, 459-463.	1.8	21
27	DEMENTIA WITH LEWY BODIES. , 2004, , 911-926.		0
28	Parkin genetics: one model for Parkinson's disease. <i>Human Molecular Genetics</i> , 2004, 13, 127R-133.	1.4	153
29	Proteolytic Dysfunction in Neurodegenerative Disorders. <i>International Review of Neurobiology</i> , 2004, 62, 95-119.	0.9	19
30	Biomarker identification in neurologic diseases: improving diagnostics and therapeutics. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 361-375.	1.5	6
31	Loss of locus coeruleus neurons and reduced startle in parkin null mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10744-10749.	3.3	317
32	Pathology and Neurotransmitter Abnormalities of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 3-14.	0.7	62
33	The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. <i>Brain</i> , 2004, 127, 2657-2671.	3.7	493
34	Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for Î±-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. <i>Brain</i> , 2004, 128, 126-137.	3.7	402
35	Tissue transglutaminase catalyzes the formation of alphaÎ±synuclein crosslinks in Parkinson's disease. <i>FASEB Journal</i> , 2004, 18, 932-934.	0.2	114
36	Dementia with Lewy bodies: Reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. <i>Neuropathology</i> , 2004, 24, 72-78.	0.7	50
37	Genetic clues to the pathogenesis of Parkinson's disease. <i>Nature Medicine</i> , 2004, 10, S58-S62.	15.2	216
38	Dopamine depletion impairs precursor cell proliferation in Parkinson disease. <i>Nature Neuroscience</i> , 2004, 7, 726-735.	7.1	842
39	Movement disorders: Parkinson's disease dominates. <i>Lancet Neurology</i> , The, 2004, 3, 15.	4.9	1

#	ARTICLE	IF	CITATIONS
40	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.	4.9	302
41	Lewy-body formation is an aggresome-related process: a hypothesis. <i>Lancet Neurology</i> , The, 2004, 3, 496-503.	4.9	278
42	Manganese-Induced Parkinsonism and Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2004, 1012, 209-223.	1.8	423
43	The Degeneration of Dopamine Neurons in Parkinson's Disease: Insights from Embryology and Evolution of the Mesostriatocortical System. <i>Annals of the New York Academy of Sciences</i> , 2004, 1035, 231-249.	1.8	68
44	Genetics of parkin-linked disease. <i>Human Genetics</i> , 2004, 114, 327-336.	1.8	98
45	Parkin-associated Parkinson's disease. <i>Cell and Tissue Research</i> , 2004, 318, 175-184.	1.5	126
46	Neuronal pathology in Parkinson's disease. <i>Cell and Tissue Research</i> , 2004, 318, 135-147.	1.5	79
47	Stages in the development of Parkinson's disease-related pathology. <i>Cell and Tissue Research</i> , 2004, 318, 121-134.	1.5	2,272
48	Parkinson's disease: clinical aspects. <i>Cell and Tissue Research</i> , 2004, 318, 115-120.	1.5	117
49	Redox imbalance. <i>Cell and Tissue Research</i> , 2004, 318, 201-213.	1.5	181
50	Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease. <i>Acta Neuropathologica</i> , 2004, 108, 121-8.	3.9	70
51	Life style risks of Parkinson's disease: Association between decreased water intake and constipation. <i>Journal of Neurology</i> , 2004, 251, vii18-vii23.	1.8	111
52	Diagnostic staging of Parkinson's disease: conceptual aspects. <i>Journal of Neural Transmission</i> , 2004, 111, 201-216.	1.4	133
53	Lewy body-related α -synucleinopathy in the aged human brain. <i>Journal of Neural Transmission</i> , 2004, 111, 1219-1235.	1.4	243
54	Significance of ^{123}I -MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. <i>Annals of Nuclear Medicine</i> , 2004, 18, 453-461.	1.2	128
55	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 761-765.	2.8	95
56	Idiopathic hyposmia as a preclinical sign of Parkinson's disease. <i>Annals of Neurology</i> , 2004, 56, 173-181.	2.8	672
57	The preclinical detection of Parkinson's disease: Ready for prime time?. <i>Annals of Neurology</i> , 2004, 56, 169-171.	2.8	32

#	ARTICLE	IF	CITATIONS
58	Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. <i>Annals of Neurology</i> , 2004, 56, 149-162.	2.8	498
59	Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations. <i>Annals of Neurology</i> , 2004, 56, 599-603.	2.8	83
61	A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 687-692.	2.2	294
62	Differential Cytotoxicity of Human Wild Type and Mutant α -Synuclein in Human Neuroblastoma SH-SY5Y Cells in the Presence of Dopamine. <i>Biochemistry</i> , 2004, 43, 5539-5550.	1.2	45
63	Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α -Synuclein. <i>Journal of Neuroscience</i> , 2004, 24, 9434-9440.	1.7	428
64	Neuroprotective agents in Parkinson's disease: clinical evidence and caveats. <i>Neurologic Clinics</i> , 2004, 22, S1-S17.	0.8	5
65	REM Sleep Behavior Disorder in Parkinson's Disease and Dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 146-157.	1.2	229
66	Neuroimaging in Parkinson's disease. <i>NeuroRx</i> , 2004, 1, 243-254.	6.0	82
67	Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. <i>Experimental Neurology</i> , 2004, 186, 235-241.	2.0	93
68	Genotype-phenotype correlations in FTDP-17: does form follow function?. <i>Experimental Neurology</i> , 2004, 187, 229-234.	2.0	12
69	Mutation E46K increases phospholipid binding and assembly into filaments of human α -synuclein. <i>FEBS Letters</i> , 2004, 576, 363-368.	1.3	241
70	Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. <i>Biochemical and Biophysical Research Communications</i> , 2004, 324, 118-126.	1.0	41
71	Response to Obeso et al.: Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. <i>Trends in Neurosciences</i> , 2004, 27, 127-128.	4.2	19
72	Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. <i>Trends in Neurosciences</i> , 2004, 27, 691-697.	4.2	170
73	Genes, proteins, and neurotoxins involved in Parkinson's disease. <i>Progress in Neurobiology</i> , 2004, 73, 151-177.	2.8	162
74	Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. <i>Neurobiology of Aging</i> , 2004, 25, 1253-1262.	1.5	143
75	Hypocretine system deficiency in Parkinson's disease. <i>Sleep Medicine</i> , 2004, 5, 91-92.	0.8	0
76	Alpha-synuclein and transgenic mouse models. <i>Neurobiology of Disease</i> , 2004, 17, 123-130.	2.1	187

#	ARTICLE	IF	CITATIONS
77	Poor and protracted myelination as a contributory factor to neurodegenerative disorders. <i>Neurobiology of Aging</i> , 2004, 25, 19-23.	1.5	137
78	Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 112-119.	1.2	39
79	Pathobiological features in neurodegenerative diseases: an overview. <i>International Congress Series</i> , 2004, 1260, 69-75.	0.2	2
80	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
81	Linkage Disequilibrium and Association of MAPT H1 in Parkinson Disease. <i>American Journal of Human Genetics</i> , 2004, 75, 669-677.	2.6	145
82	Parkinson's disease. <i>Lancet, The</i> , 2004, 363, 1783-1793.	6.3	1,095
83	Parkinson Disease: An Update. <i>Neurologist</i> , 2004, 10, 185-194.	0.4	29
84	Olfaction and Parkinson's syndromes: its role in differential diagnosis. <i>Current Opinion in Neurology</i> , 2004, 17, 417-423.	1.8	137
85	Dementia in Parkinson's disease: cause and treatment. <i>Current Opinion in Neurology</i> , 2004, 17, 399-404.	1.8	71
86	Regional Distribution of Proteinase K-Resistant α -Synuclein Correlates with Lewy Body Disease Stage. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 1225-1235.	0.9	55
87	Lewy Body-Related α -Synucleinopathy in Aging. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 742-749.	0.9	175
88	Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 7-21.	0.3	24
89	A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2004, 10, 689-697.	1.2	81
90	Human Wild-Type α -Synuclein Impairs Neurogenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 1155-1166.	0.9	143
91	Pain in Parkinson disease. <i>Neurology</i> , 2004, 62, 2156-2157.	1.5	29
92	Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 469-474.	1.2	10
93	Chapter 54 Sleep in aging and neurodegenerative diseases. <i>Supplements To Clinical Neurophysiology</i> , 2004, 57, 508-520.	2.1	4
94	Olfactory involvement in aging and Alzheimer's disease: An autopsy study. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 149-157.	1.2	127

#	ARTICLE	IF	CITATIONS
95	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 1058-1066.	0.9	55
96	Stem cell treatment for Parkinson's disease: an update for 2005. <i>Current Opinion in Neurology</i> , 2005, 18, 376-385.	1.8	88
97	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. <i>Current Opinion in Neurology</i> , 2005, 18, 706-711.	1.8	62
98	Effects of Parkinson Disease on Two Putative Nondeclarative Learning Tasks. <i>Cognitive and Behavioral Neurology</i> , 2005, 18, 185-192.	0.5	89
99	Alzheimer's Disease and Other Neurodegenerative Diseases. , 2005, , 71-83.		0
100	Chapter 21 The nocturnal manifestations of waking movement disorders: focus on Parkinson's disease. <i>Handbook of Clinical Neurophysiology</i> , 2005, , 263-272.	0.0	2
101	Smell and Taste. , 0, , 1249-1258.		0
102	Neurodegenerative Disorders as Proteinopathies: Phenotypic Relationships. <i>Research and Perspectives in Alzheimer's Disease</i> , 2005, , 1-10.	0.1	0
103	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. <i>Clinical Science</i> , 2005, 109, 343-354.	1.8	15
104	Role of Chronic Infection and Inflammation in the Gastrointestinal Tract in the Etiology and Pathogenesis of Idiopathic Parkinsonism. Part 3: Predicted Probability and Gradients of Severity of Idiopathic Parkinsonism Based on H. pylori Antibody Profile. <i>Helicobacter</i> , 2005, 10, 288-297.	1.6	46
105	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> , 2005, 65, 1863-1872.	1.5	4,604
106	Why Bother Testing the Sense of Smell?. <i>Practical Neurology</i> , 2005, 5, 224-229.	0.5	3
107	sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2005, 21, 301-316.	1.2	28
108	Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. <i>Neuropathology</i> , 2005, 25, 188-194.	0.7	27
109	Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. <i>Neuropathology</i> , 2005, 25, 304-314.	0.7	71
110	The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 270-279.	1.8	60
111	Neurons inflict self-harm. <i>Nature Medicine</i> , 2005, 11, 1159-1161.	15.2	17
112	TLRs play good cop, bad cop in the lung. <i>Nature Medicine</i> , 2005, 11, 1161-1162.	15.2	44

#	ARTICLE	IF	CITATIONS
113	While you were sleeping. <i>Nature</i> , 2005, 437, 1220-1222.	13.7	17
114	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 201-207.	2.2	70
115	Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. <i>Lancet Neurology</i> , The, 2005, 4, 605-610.	4.9	294
116	Clarifying Lewy-body parkinsonism with visual hallucinations. <i>Lancet Neurology</i> , The, 2005, 4, 588-589.	4.9	3
117	±-Synuclein pathology does not predict extrapyramidal symptoms or dementia. <i>Annals of Neurology</i> , 2005, 57, 82-91.	2.8	287
118	Partial dopamine loss enhances activated caspase-3 activity: Differential outcomes in striatal projection systems. <i>Journal of Neuroscience Research</i> , 2005, 82, 387-396.	1.3	14
119	No global loss of neocortical neurons in parkinson's disease: A quantitative stereological study. <i>Movement Disorders</i> , 2005, 20, 164-171.	2.2	50
120	Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. <i>Movement Disorders</i> , 2005, 20, 130-140.	2.2	289
121	Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 271-282.	2.2	79
122	Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. <i>Movement Disorders</i> , 2005, 20, 1299-1309.	2.2	48
124	Pain in Parkinson's disease and multiple sclerosis: Its relation to the medial and lateral pain systems. <i>Neuroscience and Biobehavioral Reviews</i> , 2005, 29, 1047-1056.	2.9	81
125	Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. <i>Acta Neuropathologica</i> , 2005, 109, 141-150.	3.9	119
126	±-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. <i>Acta Neuropathologica</i> , 2005, 110, 19-26.	3.9	120
127	Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. <i>Journal of Neurology</i> , 2005, 252, 1345-1352.	1.8	129
128	Determinants of autonomic dysfunction in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2005, 252, 1530-1536.	1.8	29
129	REM sleep behaviour disorder. <i>Neurological Sciences</i> , 2005, 26, s186-s192.	0.9	31
130	Sleep disorders in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005, 112, 1669-1675.	1.4	76
132	Phenotypical Characterization of Genetic Mouse Models of Parkinson Disease. , 2005, , 183-192.		4

#	ARTICLE	IF	CITATIONS
133	The Medical Management of Parkinson's Disease. , 2005, , 119-143.		3
134	Neuropathology of Parkinson's disease. , 2005, , 575-585.		0
135	The role of radiotracer imaging in Parkinson disease. Neurology, 2005, 64, 208-215.	1.5	315
136	The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology, 2005, 64, 1397-1403.	1.5	160
137	Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology, 2005, 64, 1404-1410.	1.5	509
138	Sensory-Motor Integration in the Medial Medulla. Current Neuropharmacology, 2005, 3, 115-143.	1.4	4
139	Idiopathic REM sleep behavior disorder. Neurology, 2005, 64, 780-786.	1.5	133
140	Anosmia is very common in the Lewy body variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1342-1347.	0.9	100
141	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128, 2977-2986.	3.7	241
142	Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. Journal of Neuroscience, 2005, 25, 6721-6728.	1.7	140
143	Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology, 2005, 65, 247-252.	1.5	330
144	Expression Profiling of Substantia Nigra in Parkinson Disease, Progressive Supranuclear Palsy, and Frontotemporal Dementia With Parkinsonism. Archives of Neurology, 2005, 62, 917-21.	4.9	146
145	Visual dysfunction in Parkinson disease without dementia. Neurology, 2005, 65, 1907-1913.	1.5	268
146	Recognition Memory in Parkinson's Disease With and Without Dementia: Evidence Inconsistent with the Retrieval Deficit Hypothesis. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 516-528.	0.8	76
147	Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1204-1210.	0.9	78
148	Dementia with Lewy Bodies: Current Concepts. Dementia and Geriatric Cognitive Disorders, 2005, 20, 306-320.	0.7	13
149	Progression of Parkinson Disease. Archives of Neurology, 2005, 62, 351.	4.9	79
150	Autophagy and Its Possible Roles in Nervous System Diseases, Damage and Repair. Autophagy, 2005, 1, 11-22.	4.3	422

#	ARTICLE	IF	CITATIONS
151	Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 816-830.	0.9	222
152	Increased myocardial N-myristoyltransferase activity in rotenone model of Parkinsonism. <i>International Journal of Molecular Medicine</i> , 2005, 15, 987.	1.8	2
153	Î±-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. <i>Brain</i> , 2005, 128, 2654-2664.	3.7	187
154	Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 156-162.	0.9	134
155	Staging of Sporadic Parkinson Disease-Related Î±-Synuclein Pathology: Inter- and Intra-Rater Reliability. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 623-628.	0.9	85
156	Î±-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 554-554.	0.9	7
157	Molecular pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2005, 14, 2749-2755.	1.4	187
158	Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2005, 116, 2091-2098.	0.7	32
159	Essential Tremor Associated With Focal Nonnigral Lewy Bodies. <i>Archives of Neurology</i> , 2005, 62, 1004-7.	4.9	116
160	[^{99m} Tc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. <i>Neurology</i> , 2005, 64, 1716-1720.	1.5	150
161	REM sleep behaviour disorder: Clinical profiles and pathophysiology. <i>International Review of Psychiatry</i> , 2005, 17, 293-300.	1.4	14
162	Cell-based therapies for disorders of the CNS. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1361-1376.	2.4	3
163	How proteomics reveals potential biomarkers in brain diseases. <i>Expert Review of Proteomics</i> , 2005, 2, 901-913.	1.3	14
164	Present and future drug treatment for Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1472-1478.	0.9	129
165	Genetic Mapping of Canine Multiple System Degeneration and Ectodermal Dysplasia Loci. <i>Journal of Heredity</i> , 2005, 96, 727-734.	1.0	37
166	Î±-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. <i>Journal of Neuroscience</i> , 2005, 25, 5544-5552.	1.7	237
167	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. <i>Annual Review of Neuroscience</i> , 2005, 28, 57-87.	5.0	1,111
168	Stem cells may reshape the prospect of Parkinson's disease therapy. <i>Molecular Brain Research</i> , 2005, 134, 34-51.	2.5	55

#	ARTICLE	IF	CITATIONS
169	Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. <i>Molecular Brain Research</i> , 2005, 134, 109-118.	2.5	227
170	The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. <i>Trends in Molecular Medicine</i> , 2005, 11, 488-495.	3.5	49
171	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. <i>Neurobiology of Disease</i> , 2005, 20, 401-411.	2.1	40
172	Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. <i>Neurobiology of Disease</i> , 2005, 20, 685-693.	2.1	103
173	Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. <i>Neuroscience Letters</i> , 2005, 373, 189-194.	1.0	36
174	Lewy bodies in Parkinson's disease: Protectors or perpetrators?. <i>Experimental Neurology</i> , 2005, 195, 1-6.	2.0	24
175	Neuroinflammatory processes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, S9-S15.	1.1	181
176	Dementia with Lewy bodies and Parkinson's disease with dementia: Are they different?. <i>Parkinsonism and Related Disorders</i> , 2005, 11, S47-S51.	1.1	135
177	Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 475-484.	1.1	30
178	To die or grow: Parkinson's disease and cancer. <i>Trends in Neurosciences</i> , 2005, 28, 348-352.	4.2	110
179	Progressive sleep "destructuring"™ in Parkinson's disease. A polysomnographic study in 46 patients. <i>Sleep Medicine</i> , 2005, 6, 313-318.	0.8	120
180	Excessive daytime sleepiness and subsequent development of Parkinson disease. <i>Neurology</i> , 2005, 65, 1442-1446.	1.5	381
181	Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. <i>Journal of Neuroinflammation</i> , 2005, 2, 14.	3.1	324
182	Parkinson's disease as a disorder of the aging. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 299-305.	0.5	2
185	THE BIOCHEMISTRY OF PARKINSON'S DISEASE. <i>Annual Review of Biochemistry</i> , 2005, 74, 29-52.	5.0	595
186	Parkinson's disease: premotor clinico-pathological correlations. , 2006, , 309-319.		154
188	Beta-Amyloid 1â€“42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 200-208.	0.7	114
189	Multiple system atrophy and autonomic failure. , 2006, , 343-347.		10

#	ARTICLE	IF	CITATIONS
190	Neuroproteases in Peptide Neurotransmission and Neurodegenerative Diseases. <i>BioDrugs</i> , 2006, 20, 105-119.	2.2	10
191	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006, 66, 845-851.	1.5	371
192	Sleep-related problems of Parkinson's disease. <i>Age and Ageing</i> , 2006, 35, 220-228.	0.7	140
193	Existing dopaminergic therapies for Parkinson's disease. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1613-1625.	2.4	13
194	Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. <i>NeuroImage</i> , 2006, 33, 636-643.	2.1	27
195	Resting state oscillatory brain dynamics in Parkinson's disease: An MEG study. <i>Clinical Neurophysiology</i> , 2006, 117, 2521-2531.	0.7	173
196	Medical Management of Advanced Parkinson's Disease. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 753-772.	1.0	4
197	Human brain tissue microarrays as a platform to investigate diseases of the nervous system. <i>Brain Research</i> , 2006, 1089, 33-43.	1.1	16
199	New face of neuromelanin. , 2006, , 119-123.		26
200	Cardiovascular dysautonomia in de novo Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 241, 59-65.	0.3	62
201	Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. <i>Journal of the Neurological Sciences</i> , 2006, 243, 57-60.	0.3	19
202	The morphological basis of mental dysfunction in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 167-172.	0.3	37
203	Cognitive decline correlates with neuropathological stage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 255-258.	0.3	157
204	Neuropathologic findings in essential tremor. <i>Neurology</i> , 2006, 66, 1756-1759.	1.5	147
205	Neuropsychological Differentiation of Dementia with Lewy Bodies from Normal Aging and Alzheimer's Disease. <i>Clinical Neuropsychologist</i> , 2006, 20, 623-636.	1.5	170
206	Cortical and subcortical diseases: Do true neuropsychological differences exist?†. <i>Archives of Clinical Neuropsychology</i> , 2006, 21, 29-40.	0.3	19
207	Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. <i>Experimental Neurology</i> , 2006, 197, 113-121.	2.0	141
208	Hero versus antihero: The multiple roles of α -synuclein in neurodegeneration. <i>Experimental Neurology</i> , 2006, 199, 238-242.	2.0	18

#	ARTICLE	IF	CITATIONS
209	Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: Results from an in vitro model system. <i>Experimental Neurology</i> , 2006, 201, 234-243.	2.0	39
210	Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. <i>Behavioural Brain Research</i> , 2006, 172, 97-105.	1.2	113
211	Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 967-972.	1.0	175
212	Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. <i>Brain Research Bulletin</i> , 2006, 70, 386-390.	1.4	133
213	Dreaming: A Neurological View. , 2006, , 351-387.		5
214	Gastric α -synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. <i>Neuroscience Letters</i> , 2006, 396, 67-72.	1.0	1,170
215	The diagnosis of manganese-induced parkinsonism. <i>NeuroToxicology</i> , 2006, 27, 340-346.	1.4	203
216	Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2006, 7, 333-339.	0.8	45
217	Association of daytime napping and Parkinsonian signs in Alzheimer's disease. <i>Sleep Medicine</i> , 2006, 7, 614-618.	0.8	12
218	Pathological substrate of dementia in Parkinson's disease—its relation to DLB and DLBD. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 119-120.	1.1	16
219	Natural history of Parkinson's disease: From dopamine to multiple system involvement. <i>Parkinsonism and Related Disorders</i> , 2006, 12, S40-S46.	1.1	25
220	Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, S92-S98.	1.1	26
221	Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2006, 27, 530-545.	1.5	144
222	Deep Brain Stimulation for Neurologic and Neuropsychiatric Disorders. <i>Neuron</i> , 2006, 52, 197-204.	3.8	311
223	Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. <i>Neuroscience</i> , 2006, 141, 1033-1046.	1.1	32
224	Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α -synuclein. <i>Neuroscience</i> , 2006, 142, 1245-1253.	1.1	96
225	In vitro evaluation of nicotinic acetylcholine receptors with 2-[¹⁸ F]F-A85380 in Parkinson's disease. <i>Nuclear Medicine and Biology</i> , 2006, 33, 305-309.	0.3	21
226	Diagnosis and treatment of Parkinson disease: molecules to medicine. <i>Journal of Clinical Investigation</i> , 2006, 116, 1744-1754.	3.9	538

#	ARTICLE	IF	CITATIONS
227	Clinicopathological analysis of dementia disorders in the elderly – An update. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 61-70.	1.2	116
228	Absence of Rapid Eye Movement Sleep Behavior Disorder in 11 Members of the Pallidopontonigral Degeneration Kindred. <i>Archives of Neurology</i> , 2006, 63, 268.	4.9	27
229	A vaccine for Parkinson's disease?. <i>Future Neurology</i> , 2006, 1, 21-23.	0.9	0
230	Olfaction in Parkinsonian Syndromes. , 0, , 279-295.		0
231	Relationship of Apolipoprotein E and Age at Onset to Parkinson Disease Neuropathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 116-123.	0.9	132
232	Alzheimer Disease With Amygdala Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 685-697.	0.9	279
233	Relationship Among α -Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 808-815.	0.9	79
234	Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. <i>Behavioural Pharmacology</i> , 2006, 17, 383-391.	0.8	59
235	Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-7-carbolinium ion, a 7-carboline occurring in the human brain. <i>Behavioural Pharmacology</i> , 2006, 17, 463-473.	0.8	17
236	Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. <i>Behavioural Pharmacology</i> , 2006, 17, 453-462.	0.8	46
237	Cell Therapy for Parkinson's Disease: Only Young Onset Patients Allowed? Reflections about the Results of Recent Clinical Trials with Cell Therapy and the Progression of Parkinson's Disease. <i>Cell Transplantation</i> , 2006, 15, 463-473.	1.2	10
238	Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models. <i>Cell Transplantation</i> , 2006, 15, 251-265.	1.2	49
239	Cognitive Change in Parkinson Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 302-310.	0.6	51
240	Quantification of Electromyographic Activity During Sleep: A Phasic Electromyographic Metric. <i>Journal of Clinical Neurophysiology</i> , 2006, 23, 59-67.	0.9	55
241	Lewy Body Pathology in Familial Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 370.	4.9	122
242	Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 35-44.	1.2	158
243	The Relationship between Lewy Body Disease, Parkinson's Disease, and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2003, 991, 167-170.	1.8	16
244	Spinocerebellar Ataxia Type 3 (SCA3): Thalamic Neurodegeneration Occurs Independently from Thalamic Ataxin-3 Immunopositive Neuronal Intranuclear Inclusions. <i>Brain Pathology</i> , 2006, 16, 218-227.	2.1	61

#	ARTICLE	IF	CITATIONS
245	Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. <i>Journal of Neurochemistry</i> , 2006, 96, 950-959.	2.1	12
246	Effect of sublethal 6-hydroxydopamine on the response to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. <i>Journal of Neurochemistry</i> , 2006, 99, 1151-1163.	2.1	33
247	Parkinson's disease: the genetics of a heterogeneous disorder. <i>European Journal of Neurology</i> , 2006, 13, 616-627.	1.7	41
248	Predictors of gastric emptying in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2006, 18, 369-375.	1.6	149
249	Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 119-130.	1.8	197
250	Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 157-169.	1.8	14
251	alpha-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 284-295.	1.8	295
252	Novel pharmacological targets for the treatment of Parkinson's disease. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 845-854.	21.5	262
253	Ageing and neuronal vulnerability. <i>Nature Reviews Neuroscience</i> , 2006, 7, 278-294.	4.9	895
254	<i>Drosophila pink1</i> is required for mitochondrial function and interacts genetically with parkin. <i>Nature</i> , 2006, 441, 1162-1166.	13.7	1,574
255	Parkinson's Disease α -Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death. <i>Journal of Neuroscience</i> , 2006, 26, 41-50.	1.7	620
256	Cellular and Molecular Mechanisms of Parkinson's Disease: Neurotoxins, Causative Genes, and Inflammatory Cytokines. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 779-800.	1.7	107
257	Skin biopsy for assessment of autonomic denervation in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006, 113, 1169-1176.	1.4	86
258	Proteomics in neurodegeneration – disease driven approaches. <i>Journal of Neural Transmission</i> , 2006, 113, 1055-1073.	1.4	31
259	Characteristics of alpha-synucleinopathy in centenarians. <i>Acta Neuropathologica</i> , 2006, 111, 450-458.	3.9	48
260	Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid- β protein aggregation and cerebrovascular amyloid- β toxicity. <i>Acta Neuropathologica</i> , 2006, 111, 139-149.	3.9	125
261	Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. <i>Acta Neuropathologica</i> , 2006, 112, 253-260.	3.9	137
262	Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. <i>Acta Neuropathologica</i> , 2006, 112, 115-126.	3.9	85

#	ARTICLE	IF	CITATIONS
263	Tau and α -synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. <i>Acta Neuropathologica</i> , 2006, 113, 53-62.	3.9	77
264	Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. <i>Acta Neuropathologica</i> , 2006, 113, 81-86.	3.9	115
265	The natural history of Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, vii2-vii6.	1.8	106
266	The impact of ventrolateral thalamotomy on tremor and voluntary motor behavior in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2006, 170, 160-171.	0.7	47
267	PARK8 LRRK2 parkinsonism. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 287-294.	2.0	19
268	Preclinical diagnosis of parkinson's disease: Are we there yet?. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 295-301.	2.0	51
269	Olfactory dysfunction as a predictor of neurodegenerative disease. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 379-386.	2.0	125
270	Non-motor symptoms of Parkinson's disease: diagnosis and management. <i>Lancet Neurology</i> , The, 2006, 5, 235-245.	4.9	2,202
271	Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. <i>Lancet Neurology</i> , The, 2006, 5, 424-432.	4.9	380
272	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. <i>Lancet Neurology</i> , The, 2006, 5, 572-577.	4.9	901
273	Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder. <i>Lancet Neurology</i> , The, 2006, 5, 552-553.	4.9	20
274	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2006, 5, 1013-1020.	4.9	167
275	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. <i>Neurobiology of Disease</i> , 2006, 21, 404-412.	2.1	982
276	Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2006, 22, 265-273.	2.1	59
277	Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease. <i>Neuropsychologia</i> , 2006, 44, 1290-1304.	0.7	29
278	Functional investigations into the role of dopamine and serotonin in partial bilateral striatal 6-hydroxydopamine lesioned rats. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 83, 175-185.	1.3	13
279	Nurr1 in Parkinson's disease and related disorders. <i>Journal of Comparative Neurology</i> , 2006, 494, 495-514.	0.9	190
280	Hippocampal neuron and glial cell numbers in Parkinson's disease—A stereological study. <i>Hippocampus</i> , 2006, 16, 826-833.	0.9	63

#	ARTICLE	IF	CITATIONS
281	Positron emission tomography changes in PARK1 mutation. <i>Movement Disorders</i> , 2006, 21, 127-130.	2.2	6
282	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1123-1130.	2.2	374
283	Melanized nigral neuronal numbers in Nigerian and British individuals. <i>Movement Disorders</i> , 2006, 21, 1239-1241.	2.2	13
284	Electromyography patterns of propriospinal myoclonus can be mimicked voluntarily. <i>Movement Disorders</i> , 2006, 21, 1241-1244.	2.2	62
285	Behavioral models of Parkinson's disease in rodents: A new look at an old problem. <i>Movement Disorders</i> , 2006, 21, 1595-1606.	2.2	200
286	Ubiquitinâ€“proteasome system and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1806-1823.	2.2	175
287	Fulminant Lewy body disease. <i>Movement Disorders</i> , 2006, 21, 1748-1751.	2.2	13
288	Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. <i>Movement Disorders</i> , 2006, 21, 1751-1754.	2.2	60
289	Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. <i>Movement Disorders</i> , 2006, 21, 2042-2051.	2.2	548
290	Correlation between cardiac ^{123I} -MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 1975-1977.	2.2	76
291	Camptocormia induced by atypical antipsychotics and resolved by electroconvulsive therapy. <i>Movement Disorders</i> , 2006, 21, 1977-1980.	2.2	27
292	Cardiac [^{123I}]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. <i>Movement Disorders</i> , 2006, 21, 1990-1994.	2.2	27
293	Biochemical and pathological characterization of Lrrk2. <i>Annals of Neurology</i> , 2006, 59, 315-322.	2.8	229
294	Neuropathology of dementia in Parkinson's disease. <i>Annals of Neurology</i> , 2006, 59, 727-727.	2.8	9
295	Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. <i>Annals of Neurology</i> , 2006, 60, 264-268.	2.8	128
296	Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 278-288.	0.9	95
297	Lewy Bodies in Progressive Supranuclear Palsy Represent an Independent Disease Process. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 387-395.	0.9	53
298	Disgust-specific impairment of facial expression recognition in Parkinson's disease. <i>Brain</i> , 2006, 129, 707-717.	3.7	208

#	ARTICLE	IF	CITATIONS
299	Rate of progression determines the clinical outcome after neural transplantation in Parkinson's disease. <i>Brain</i> , 2006, 129, E48-E48.	3.7	3
300	Exploring the recognition memory deficit in Parkinson's disease: estimates of recollection versus familiarity. <i>Brain</i> , 2006, 129, 1768-1779.	3.7	64
301	Clinical Implications of Parkinson's Disease Genetics. <i>Seminars in Neurology</i> , 2006, 26, 492-498.	0.5	13
304	Olfaction in Neurodegenerative Disorder. , 2006, 63, 133-151.		116
305	PINK1 protein in normal human brain and Parkinson's disease. <i>Brain</i> , 2006, 129, 1720-1731.	3.7	291
306	Chapter 50 Pain in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2006, 81, 747-760.	1.0	11
307	Î±-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. <i>Neurology</i> , 2006, 66, 1100-1102.	1.5	122
308	Differences in neuropathologic characteristics across the Lewy body dementia spectrum. <i>Neurology</i> , 2006, 67, 1931-1934.	1.5	299
309	The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach. <i>Neuropsychopharmacology</i> , 2006, 31, 1009-1015.	2.8	43
310	Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1136-1142.	0.9	141
311	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. <i>Aging Health</i> , 2006, 2, 967-982.	0.3	19
312	Clinical phenotype of Parkinson disease dementia. <i>Neurology</i> , 2006, 67, 1605-1611.	1.5	222
313	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006, 129, 538-542.	3.7	120
315	Lewy bodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1661-1668.	3.3	401
316	Predicting Parkinson's disease: worthwhile but are we there yet?. <i>Practical Neurology</i> , 2006, 6, 272-277.	0.5	12
317	Autonomic dysfunction in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 671-677.	0.9	192
318	p53 Mediates Nontranscriptional Cell Death in Dopaminergic Cells in Response to Proteasome Inhibition. <i>Journal of Biological Chemistry</i> , 2006, 281, 39550-39560.	1.6	85
319	Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of Î±-Synucleinopathy. <i>Journal of Neuroscience</i> , 2006, 26, 3685-3696.	1.7	86

#	ARTICLE	IF	CITATIONS
320	Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α -Synuclein(1-120): Implications for Lewy Body Disorders. <i>Journal of Neuroscience</i> , 2006, 26, 3942-3950.	1.7	302
323	Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. <i>Regenerative Medicine</i> , 2007, 2, 425-446.	0.8	55
324	Different Species of α -Synuclein Oligomers Induce Calcium Influx and Seeding. <i>Journal of Neuroscience</i> , 2007, 27, 9220-9232.	1.7	708
325	Do α -synuclein aggregates in autonomic plexuses predate Lewy body disorders?: A cohort study. <i>Neurology</i> , 2007, 68, 2012-2018.	1.5	184
326	Assembly of Lysine 63-linked Ubiquitin Conjugates by Phosphorylated α -Synuclein Implies Lewy Body Biogenesis. <i>Journal of Biological Chemistry</i> , 2007, 282, 14558-14566.	1.6	45
327	Proteomics Identification of Proteins in Human Cortex Using Multidimensional Separations and MALDI Tandem Mass Spectrometer. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1818-1823.	2.5	44
328	Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13804-13809.	3.3	170
329	A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine. <i>Journal of Neuroscience</i> , 2007, 27, 981-992.	1.7	136
330	Beating a dead horse. <i>Neurology</i> , 2007, 69, 1701-1711.	1.5	136
332	Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?. <i>Neurology</i> , 2007, 69, 1478-1479.	1.5	24
334	Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. <i>Brain</i> , 2007, 130, 442-449.	3.7	44
335	Sensorimotor integration is abnormal in asymptomatic <i>Parkin</i> mutation carriers. <i>Neurology</i> , 2007, 69, 1976-1981.	1.5	33
336	Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. <i>Brain</i> , 2007, 130, 1847-1860.	3.7	232
337	Clinical correlates of Lewy-body-related disorders: splitting and lumping or lumping and splitting?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 308-309.	2.7	0
338	Dementia: Many roads, but not built in a day. <i>Neurology</i> , 2007, 69, 2193-2194.	1.5	5
339	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1130.	4.9	185
340	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. <i>Neurodegenerative Diseases</i> , 2007, 4, 366-375.	0.8	65
341	Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies. <i>American Journal of Psychiatry</i> , 2007, 164, 1491-1498.	4.0	102

#	ARTICLE	IF	CITATIONS
342	Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. <i>Brain</i> , 2007, 130, 2123-2128.	3.7	172
343	Neuropathological changes in essential tremor: 33 cases compared with 21 controls. <i>Brain</i> , 2007, 130, 3297-3307.	3.7	523
344	Managing sleep disorders in Parkinson's disease. <i>Aging Health</i> , 2007, 3, 49-66.	0.3	1
345	Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease. <i>Regenerative Medicine</i> , 2007, 2, 447-455.	0.8	4
346	Divergent Mechanisms of Paraquat, MPP+, and Rotenone Toxicity: Oxidation of Thioredoxin and Caspase-3 Activation. <i>Toxicological Sciences</i> , 2007, 95, 163-171.	1.4	118
348	Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. <i>Neurology</i> , 2007, 69, 2093-2104.	1.5	191
349	The progression of Parkinson disease. <i>Neurology</i> , 2007, 68, 948-952.	1.5	109
350	GABAergic circuits in the basal ganglia and movement disorders. <i>Progress in Brain Research</i> , 2007, 160, 287-312.	0.9	62
351	Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. <i>Human Molecular Genetics</i> , 2007, 16, 651-666.	1.4	68
352	Erectile Function and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2007, 166, 1446-1450.	1.6	102
353	Parkinson's disease. <i>Human Molecular Genetics</i> , 2007, 16, R183-R194.	1.4	691
354	Circuits and Circuit Disorders of the Basal Ganglia. <i>Archives of Neurology</i> , 2007, 64, 20.	4.9	927
355	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 825-831.	0.9	88
356	Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. <i>Practical Neurology</i> , 2007, 7, 374-382.	0.5	79
357	Delayed blink reflex in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1137-1139.	0.9	26
358	Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1250-1252.	0.9	57
359	Parkinson Disease: Molecular Insights. , 2007, , 221-239.		0
360	Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. <i>Neurology</i> , 2007, 68, 356-363.	1.5	62

#	ARTICLE	IF	CITATIONS
361	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
362	Redox Imbalance. , 2007, , 183-200.		3
363	The Relationship of Parkinson Disease With Aging. <i>Archives of Neurology</i> , 2007, 64, 1242.	4.9	192
365	Chapter 7 Ubiquitinopathies. <i>Blue Books of Neurology</i> , 2007, , 165-185.	0.1	2
366	Chapter 9 Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Blue Books of Neurology</i> , 2007, , 216-238.	0.1	1
367	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. <i>Archives of Neurology</i> , 2007, 64, 431.	4.9	326
368	Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease. <i>CNS Spectrums</i> , 2007, 12, 275-286.	0.7	4
369	DEMENTIA WITH LEWY BODIES. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2007, 13, 69-86.	0.4	1
370	THE DOPAMINERGIC NIGROSTRIATAL SYSTEM AND PARKINSON'S DISEASE. <i>Neurosurgery</i> , 2007, 60, 17-30.	0.6	57
371	Expression of Nrf2 in Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 75-85.	0.9	604
372	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	0.9	104
373	Analysis of the Adrenal Gland Is Useful for Evaluating Pathology of the Peripheral Autonomic Nervous System in Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 354-362.	0.9	107
375	Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. <i>Sleep Medicine</i> , 2007, 8, 60-64.	0.8	153
376	Deep brain stimulation in neurologic disorders. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 1-16.	1.1	112
377	The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 243-245.	1.1	39
378	Non-motor dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 323-332.	1.1	171
379	The premotor phase of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S2-S7.	1.1	130
380	Age-dependent cognitive decline and amygdala pathology in α -synuclein transgenic mice. <i>Neurobiology of Aging</i> , 2007, 28, 1421-1435.	1.5	154

#	ARTICLE	IF	CITATIONS
381	Role of Cdk5-Mediated Phosphorylation of Prx2 in MPTP Toxicity and Parkinson's Disease. <i>Neuron</i> , 2007, 55, 37-52.	3.8	225
382	Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. <i>Neuroscience</i> , 2007, 144, 616-622.	1.1	47
383	The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. <i>Neuroscience</i> , 2007, 146, 741-755.	1.1	83
384	La Maladie de Parkinson. , 2007, , 11-88.		1
385	Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α -synuclein fibril formation in vitro. <i>Experimental Neurology</i> , 2007, 203, 579-583.	2.0	12
386	Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. <i>Experimental Neurology</i> , 2007, 207, 4-12.	2.0	190
387	Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease. <i>Neuroscience Letters</i> , 2007, 415, 205-209.	1.0	66
388	The thiol antioxidant 1,2-dithiole-3-thione stimulates the expression of heat shock protein 70 in dopaminergic PC12 cells. <i>Neuroscience Letters</i> , 2007, 416, 76-81.	1.0	7
389	Metabolic brain networks associated with cognitive function in Parkinson's disease. <i>NeuroImage</i> , 2007, 34, 714-723.	2.1	309
390	Trastornos del movimiento (I): conceptos generales. Clasificaci?n de los s?ndromes parkinsonianos. <i>Enfermedad de Parkinson. Medicine</i> , 2007, 9, 4719-4729.	0.0	1
391	3,4-Dihydroxy-6-[18F]-Fluoro-L-Phenylalanine Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 440-450.	2.5	32
392	Linking Selective Vulnerability to Cell Death Mechanisms in Parkinson's Disease. <i>American Journal of Pathology</i> , 2007, 170, 16-19.	1.9	32
393	Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- β -Mediated Cell Death of Cerebrovascular Cells. <i>American Journal of Pathology</i> , 2007, 171, 1989-1999.	1.9	120
394	Olfaction in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S225-S228.	1.1	78
395	Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S259-S262.	1.1	55
396	Positron emission tomography in premotor Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S421-S424.	1.1	46
397	Stage-dependent patterns of disturbed neural synchrony in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S440-S445.	1.1	35
398	A Temporal Lobe Factor in Verb Fluency. <i>Cortex</i> , 2007, 43, 607-615.	1.1	23

#	ARTICLE	IF	CITATIONS
400	Ubiquitinâ€“proteasome system dysfunction in Parkinsonâ€™s disease: current evidence and controversies. Expert Review of Proteomics, 2007, 4, 769-781.	1.3	68
401	Association of Low Plasma A β ⁴² /A β ⁴⁰ Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2007, 64, 354.	4.9	400
402	Dementia with Lewy Bodies. Neurologic Clinics, 2007, 25, 741-760.	0.8	59
403	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. , 2007, , 91-104.		66
404	Expanding Insights on the Involvement of Endoplasmic Reticulum Stress in Parkinson's Disease. Antioxidants and Redox Signaling, 2007, 9, 553-561.	2.5	97
405	Role of Mitochondrial Dysfunction in Parkinson's Disease. Drugs and Aging, 2007, 24, 95-105.	1.3	18
406	Early detection of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 457-477.	1.0	1
407	The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 30-35.	0.9	230
408	Autosomal dominant Parkinsonâ€™s disease and the route to new therapies. Expert Review of Neurotherapeutics, 2007, 7, 649-656.	1.4	2
409	Neurophysiologic study of central pain in patients with Parkinson disease. Neurology, 2007, 69, 2162-2169.	1.5	211
410	The neuropathology of parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 205-215.	1.0	3
411	Proteinâ€“handling dysfunction in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 571-590.	1.0	0
412	Epidemiology of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 129-151.	1.0	50
413	Transgenic Mice with Human Mutant Genes Causing Parkinson's Disease and Amyotrophic Lateral Sclerosis Provide Common Insight into Mechanisms of Motor Neuron Selective Vulnerability to Degeneration. Reviews in the Neurosciences, 2007, 18, 115-36.	1.4	55
414	Dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 531-548.	1.0	21
415	Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 401-419.	1.0	13
416	Sensory symptoms in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 377-384.	1.0	2
417	Hypocretin (orexin) loss in Parkinson's disease. Brain, 2007, 130, 1577-1585.	3.7	407

#	ARTICLE	IF	CITATIONS
418	Anatomy and physiology of the basal ganglia: relevance to Parkinson's disease and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 1-18.	1.0	51
419	Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain, 2007, 130, 2770-2788.	3.7	883
420	Asymmetry in the emotional content of lateralised multimodal hallucinations following right thalamic stroke. Cognitive Neuropsychiatry, 2007, 12, 422-436.	0.7	5
421	Hypocretin (orexin) cell loss in Parkinson's disease. Brain, 2007, 130, 1586-1595.	3.7	499
422	Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain, 2007, 131, e87-e87.	3.7	41
423	New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Review of Neurotherapeutics, 2007, 7, 1731-1750.	1.4	35
425	Non-motor Symptoms of Parkinson's Disease. International Journal of Gerontology, 2007, 1, 53-64.	0.7	44
426	Neuropsicología de las demencias. , 2007, , 206-285.		0
427	Lewy Body Disorders. , 2007, , 267-343.		4
428	Current Concepts on the Etiology and Pathogenesis of Parkinson Disease. , 2007, , 105-127.		0
429	Parkinson's disease and sexuality. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 644-647.	0.2	11
430	The Degenerative Dementias. , 2007, , 699-733.		4
431	Parkinson's Disease (PD). , 2007, , 178-179.		0
432	Declínio cognitivo e demência associados à doença de Parkinson: características clínicas e tratamento. Revista De Psiquiatria Clínica, 2007, 34, 176-183.	0.6	18
434	Olfactory loss may be a first sign of idiopathic Parkinson's disease. Movement Disorders, 2007, 22, 839-842.	2.2	309
435	Controlled study of decision-making and cognitive impairment in Parkinson's disease. Movement Disorders, 2007, 22, 1430-1435.	2.2	116
436	Bowel movement frequency in late-life and incidental Lewy bodies. Movement Disorders, 2007, 22, 1581-1586.	2.2	206
437	Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. Movement Disorders, 2007, 22, 1510-1514.	2.2	21

#	ARTICLE	IF	CITATIONS
438	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	2.2	838
439	Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait. <i>Movement Disorders</i> , 2007, 22, 2176-2182.	2.2	42
440	Cognitive dysfunction and dementia in Parkinson disease. <i>Movement Disorders</i> , 2007, 22, S358-S366.	2.2	188
441	Dysautonomia and cognitive dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, S374-S378.	2.2	50
442	Sleep disorders in Parkinson's disease: An overview. <i>Movement Disorders</i> , 2007, 22, S367-S373.	2.2	190
444	Height as a potential indicator of early life events predicting Parkinson's disease: A case-control study. <i>Movement Disorders</i> , 2007, 22, 2263-2267.	2.2	10
445	Does motoneuron adaptation contribute to muscle fatigue?. <i>Muscle and Nerve</i> , 2007, 35, 135-158.	1.0	39
446	RNA interference-mediated knockdown of α -synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport. <i>Journal of Neuroscience Research</i> , 2007, 85, 351-363.	1.3	118
447	Positron emission tomography imaging of neuroinflammation. <i>Neurotherapeutics</i> , 2007, 4, 443-452.	2.1	119
448	Role of the ubiquitin proteasome system in Parkinson's disease. <i>BMC Biochemistry</i> , 2007, 8, S13.	4.4	99
449	Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of α -synuclein overexpression. <i>Synapse</i> , 2007, 61, 991-1001.	0.6	171
450	Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson's Disease. <i>Brain Pathology</i> , 2007, 17, 24-30.	2.1	247
451	Proteomic Identification of Novel Proteins in Cortical Lewy Bodies. <i>Brain Pathology</i> , 2007, 17, 139-145.	2.1	194
452	Regulation of the norepinephrine transporter by α -synuclein-mediated interactions with microtubules. <i>European Journal of Neuroscience</i> , 2007, 26, 1509-1520.	1.2	39
453	Lewy body variant of Alzheimer's disease or cerebral type Lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem. <i>Neuropathology</i> , 2007, 27, 21-35.	0.7	25
454	The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α -synuclein aggregates. <i>Neuropathology</i> , 2007, 27, 494-506.	0.7	415
455	Parkinson's disease: a dual-hit hypothesis. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 599-614.	1.8	776
456	Alpha-synuclein pathology in the olfactory pathways of dementia patients. <i>Journal of Anatomy</i> , 2007, 211, 117-124.	0.9	87

#	ARTICLE	IF	CITATIONS
457	Classical Parkinson disease versus Parkinson complex ? Reflections against staging and in favour of heterogeneity. <i>European Journal of Neurology</i> , 2007, 14, 721-728.	1.7	28
458	Reappraisal of a consecutive autopsy series of patients with primary degenerative dementia: Lewy-related pathology. <i>Apmis</i> , 2007, 115, 820-827.	0.9	12
459	A cell-based model of α -synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 616-626.	2.8	11
460	Pharmacotherapy for Parkinson's Disease. <i>Pharmacotherapy</i> , 2007, 27, 161S-173S.	1.2	80
461	Norepinephrine: The redheaded stepchild of Parkinson's disease. <i>Biochemical Pharmacology</i> , 2007, 74, 177-190.	2.0	225
462	Nicotinic receptors as CNS targets for Parkinson's disease. <i>Biochemical Pharmacology</i> , 2007, 74, 1224-1234.	2.0	90
463	Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. <i>Brain Research</i> , 2007, 1139, 42-47.	1.1	30
464	Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. <i>Brain Research</i> , 2007, 1173, 137-144.	1.1	8
465	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. <i>Brain Research</i> , 2007, 1176, 53-61.	1.1	34
466	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. , 2007, 114, 34-55.		43
467	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , 2007, 25, 473-482.	2.1	111
468	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. <i>Neurobiology of Disease</i> , 2007, 26, 312-322.	2.1	64
469	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of parkinsonian diseases. <i>Neurobiology of Disease</i> , 2007, 27, 238-247.	2.1	32
470	Cerebral compensation during motor imagery in Parkinson's disease. <i>Neuropsychologia</i> , 2007, 45, 2201-2215.	0.7	160
471	Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis. <i>Stem Cells</i> , 2007, 25, 263-270.	1.4	79
472	Recognition, recollection, familiarity and executive function in medicated patients with moderate Parkinson's disease. <i>Journal of Neuropsychology</i> , 2007, 1, 131-147.	0.6	28
473	Comorbidity implications in brain disease: Neuronal substrates of symptom profiles. <i>Neurotoxicity Research</i> , 2007, 12, 1-15.	1.3	11
475	Functional and Anatomical Magnetic Resonance Imaging in Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2007, 9, 234-242.	1.3	50

#	ARTICLE	IF	CITATIONS
476	Movement disorders: Neurodevelopment and neurobehavioural expression. <i>Journal of Neural Transmission</i> , 2007, 114, XXXIII-XLI.	1.4	3
477	Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. <i>Acta Neuropathologica</i> , 2007, 113, 253-263.	3.9	42
478	Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. <i>Acta Neuropathologica</i> , 2007, 113, 421-429.	3.9	308
479	Lewy body dysphagia. <i>Acta Neuropathologica</i> , 2007, 114, 295-298.	3.9	19
480	Development of α -synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. <i>Acta Neuropathologica</i> , 2007, 114, 231-241.	3.9	358
481	Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 84-90.	1.8	114
482	Olfactory dysfunction in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, IV2-IV7.	1.8	6
483	REM sleep behaviour disorder in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, IV8-IV14.	1.8	2
484	Where do we stand in the treatment of Parkinson's disease?. <i>Journal of Neurology</i> , 2007, 254, 13-18.	1.8	7
485	Dementia in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 41-48.	1.8	8
486	Depression in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 49-55.	1.8	34
487	REM sleep disorders and parkinsonism. <i>Journal of Neurology</i> , 2007, 254, 56-60.	1.8	3
488	Idiopathic rapid eye movement sleep behaviour disorder. <i>Neurological Sciences</i> , 2007, 28, S15-S20.	0.9	9
489	Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. <i>Cell and Tissue Banking</i> , 2008, 9, 181-194.	0.5	151
490	Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice. <i>Cellular and Molecular Neurobiology</i> , 2008, 28, 971-979.	1.7	11
491	Neuropsychological Characteristics of Dementia with Lewy Bodies and Parkinson's Disease with Dementia: Differentiation, Early Detection, and Implications for "Mild Cognitive Impairment" and Biomarkers. <i>Neuropsychology Review</i> , 2008, 18, 103-119.	2.5	161
492	Metabolomic analysis of urine and serum in Parkinson's disease. <i>Metabolomics</i> , 2008, 4, 191-201.	1.4	86
495	LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. <i>Journal of Biomedical Science</i> , 2008, 15, 661-7.	2.6	50

#	ARTICLE	IF	CITATIONS
496	Neurotrophic Factors in Autonomic Nervous System Plasticity and Dysfunction. <i>NeuroMolecular Medicine</i> , 2008, 10, 157-168.	1.8	19
497	Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [¹²³ I]β-CIT SPECT study. <i>Journal of Neural Transmission</i> , 2008, 115, 721-729.	1.4	53
498	Cerebral amyloid angiopathy in Lewy body disease. <i>Journal of Neural Transmission</i> , 2008, 115, 473-482.	1.4	41
499	Neuroproteomics as a promising tool in Parkinson's disease research. <i>Journal of Neural Transmission</i> , 2008, 115, 1413-1430.	1.4	26
500	On the key role played by altered protein conformation in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2008, 115, 1285-1299.	1.4	6
501	Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. <i>Journal of Neural Transmission</i> , 2008, 115, 1385-1392.	1.4	33
503	Twenty-first century brain banking. Processing brains for research: the Columbia University methods. <i>Acta Neuropathologica</i> , 2008, 115, 509-532.	3.9	140
504	Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. <i>Acta Neuropathologica</i> , 2008, 115, 445-451.	3.9	116
505	α-Synuclein pathology in the neostriatum in Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 453-459.	3.9	52
506	Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson's disease patients. <i>Acta Neuropathologica</i> , 2008, 115, 417-425.	3.9	146
507	The progression of pathology in longitudinally followed patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 409-415.	3.9	337
508	Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 437-444.	3.9	329
509	Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. <i>Acta Neuropathologica</i> , 2008, 115, 399-407.	3.9	294
510	Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. <i>Acta Neuropathologica</i> , 2008, 115, 427-436.	3.9	212
511	Animal models of Parkinson's disease progression. <i>Acta Neuropathologica</i> , 2008, 115, 385-398.	3.9	190
512	Clarifying the pathological progression of Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 377-378.	3.9	10
513	A not entirely benign procedure: progression of Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 379-384.	3.9	51
514	Controversies over the staging of α-synuclein pathology in Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 116, 125-128.	3.9	61

#	ARTICLE	IF	CITATIONS
515	Co-localization of tau and α -synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. <i>Acta Neuropathologica</i> , 2008, 116, 17-24.	3.9	70
516	Reply to "Controversies over the staging of α -synuclein pathology in Parkinson's disease". <i>Acta Neuropathologica</i> , 2008, 116, 129-131.	3.9	21
517	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. <i>Acta Neuropathologica</i> , 2008, 116, 215-220.	3.9	124
518	A critical reappraisal of current staging of Lewy-related pathology in human brain. <i>Acta Neuropathologica</i> , 2008, 116, 1-16.	3.9	208
519	Is REM sleep Behaviour Disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?. <i>Journal of Neurology</i> , 2008, 255, 192-196.	1.8	121
520	A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 367-370.	1.8	87
521	Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. <i>Journal of Neurology</i> , 2008, 255, 1324-1331.	1.8	123
522	Epidemiology of Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 18-32.	1.8	314
523	Early Parkinson's disease and non-motor issues. <i>Journal of Neurology</i> , 2008, 255, 33-38.	1.8	95
524	Parkinson's disease-related disorders in the impulsive-compulsive spectrum. <i>Journal of Neurology</i> , 2008, 255, 48-56.	1.8	64
525	Update on the pathogenesis of Parkinson's disease. <i>Journal of Neurology</i> , 2008, 255, 3-7.	1.8	258
526	Voluntary Cough Production and Swallow Dysfunction in Parkinson's Disease. <i>Dysphagia</i> , 2008, 23, 297-301.	1.0	121
527	Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. <i>Molecular Neurodegeneration</i> , 2008, 3, 21.	4.4	96
529	Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1484-1497.	0.8	20
530	Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. <i>Journal of Neuroscience Research</i> , 2008, 86, 108-117.	1.3	54
531	Advanced glycation end products induce in vitro cross-linking of α -synuclein and accelerate the process of intracellular inclusion body formation. <i>Journal of Neuroscience Research</i> , 2008, 86, 2071-2082.	1.3	76
532	Olfaction testing in PD: Risky conclusions. <i>Movement Disorders</i> , 2008, 23, 1060-1060.	2.2	3
533	The emerging neuropathology of essential tremor. <i>Movement Disorders</i> , 2008, 23, 174-182.	2.2	155

#	ARTICLE	IF	CITATIONS
534	Dominant vs. Nondominant posterior alien limbâ€”Is it the same phenomenon?. <i>Movement Disorders</i> , 2008, 23, 1060-1062.	2.2	1
535	Parkinson's disease and aging: Same or different process?. <i>Movement Disorders</i> , 2008, 23, 47-53.	2.2	43
536	Fatal gastroparesis in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 152-153.	2.2	2
537	The <i>DRD2 TaqIA</i> polymorphism and demand of dopaminergic medication in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 599-602.	2.2	61
538	Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. <i>Movement Disorders</i> , 2008, 23, 596-599.	2.2	59
539	Perceived imbalance and risk of Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 613-616.	2.2	48
540	A previously undiagnosed case of Gerstmannâ€”Strâ€”Ausslerâ€”Scheinker disease revealed by <i>PRNP</i> gene analysis in patients with adultâ€”onset ataxia. <i>Movement Disorders</i> , 2008, 23, 1468-1471.	2.2	10
541	Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1085-1092.	2.2	167
542	A novel mutation of the Î²â€”sarcoglycan gene in a Chinese family with myoclonusâ€”dystonia syndrome. <i>Movement Disorders</i> , 2008, 23, 1472-1475.	2.2	13
543	Genderâ€”related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. <i>Movement Disorders</i> , 2008, 23, 1407-1413.	2.2	85
544	Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honoluluâ€”Asia Aging Study. <i>Movement Disorders</i> , 2008, 23, 1013-1018.	2.2	106
545	Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: An autopsy case report. <i>Movement Disorders</i> , 2008, 23, 1055-1057.	2.2	23
546	Lack of trigeminoâ€”cervical reflexes in progressive supranuclear palsy. <i>Movement Disorders</i> , 2008, 23, 1475-1479.	2.2	14
547	Levodopa unresponsive symptoms in Parkinson disease. <i>Movement Disorders</i> , 2008, 23, S521-S533.	2.2	132
548	Olfactory pathogenesis of idiopathic Parkinson disease revisited. <i>Movement Disorders</i> , 2008, 23, 1076-1084.	2.2	73
549	Multiregional brain iron deficiency in restless legs syndrome. <i>Movement Disorders</i> , 2008, 23, 1184-1187.	2.2	126
550	Quantitative measures of fine motor, limb, and postural bradykinesia in very early stage, untreated Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1262-1268.	2.2	47
551	Cognitive dysfunction in Nigerians with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1378-1383.	2.2	26

#	ARTICLE	IF	CITATIONS
552	Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. <i>Movement Disorders</i> , 2008, 23, 1665-1672.	2.2	159
553	Do Parkinson's disease and dementia with Lewy bodies differ by route of environmental precipitant?. <i>Movement Disorders</i> , 2008, 23, 1617-1617.	2.2	1
554	Evaluating Parkinson's disease patients at home: Utility of selfâ€wideootaping for objective motor, dyskinesia, and ONâ€OFF assessments. <i>Movement Disorders</i> , 2008, 23, 1479-1482.	2.2	24
555	Familial Parkinsonism with digenic <i>parkin</i> and <i>PINK1</i> mutations. <i>Movement Disorders</i> , 2008, 23, 1461-1465.	2.2	51
556	A comparative study of odor identification and odor discrimination deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1984-1990.	2.2	127
557	Emergence of Parkinson's disease in essential tremor: A study of the clinical correlates in 53 patients. <i>Movement Disorders</i> , 2008, 23, 1602-1605.	2.2	94
558	Distribution of motor impairment influences quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1466-1468.	2.2	21
559	Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1458-1461.	2.2	11
560	Nigral burden of α -synuclein correlates with striatal dopamine deficit. <i>Movement Disorders</i> , 2008, 23, 1608-1612.	2.2	53
561	A randomized, doubleâ€blind, placeboâ€controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	2.2	162
562	The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?. <i>Movement Disorders</i> , 2008, 23, 1799-1807.	2.2	115
563	Predictors of prognosis in patients with olfactory disturbance. <i>Annals of Neurology</i> , 2008, 63, 159-166.	2.8	157
564	A tale of two etiologies: Loss and recovery of olfactory function. <i>Annals of Neurology</i> , 2008, 63, 132-134.	2.8	3
565	Neurofibrillary tau pathology modulated by genetic variation of α -synuclein. <i>Annals of Neurology</i> , 2008, 64, 348-352.	2.8	22
566	A critical evaluation of the Braak staging scheme for Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, 485-491.	2.8	331
567	Spheramine for Treatment of Parkinsonâ€™s Disease. <i>Neurotherapeutics</i> , 2008, 5, 252-259.	2.1	55
568	<i>Helicobacter</i> Hypothesis for Idiopathic Parkinsonism: Before and Beyond. <i>Helicobacter</i> , 2008, 13, 309-322.	1.6	58
569	The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. <i>Brain</i> , 2008, 131, 1969-1978.	3.7	488

#	ARTICLE	IF	CITATIONS
570	The Bac Transgenic Approach to Study Parkinson's Disease in Mice. , 2008, , 247-268.		2
571	Extranigral Neurodegeneration in Parkinson's Disease. Annals of the New York Academy of Sciences, 2008, 1139, 331-336.	1.8	19
572	Methamphetamine Fails to Alter the Noradrenergic Integrity of the Heart. Annals of the New York Academy of Sciences, 2008, 1139, 337-344.	1.8	9
573	Impulse Control and Related Disorders in Parkinson's Disease. Annals of the New York Academy of Sciences, 2008, 1142, 85-107.	1.8	109
574	Depressive illness in Parkinson's disease – indication of a more advanced and widespread neurodegenerative process?. Acta Neurologica Scandinavica, 2008, 117, 295-304.	1.0	44
575	Cerebral Mitochondrial Metabolism in Early Parkinson's Disease. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1754-1760.	2.4	32
576	Research in motion: the enigma of Parkinson's disease pathology spread. Nature Reviews Neuroscience, 2008, 9, 741-745.	4.9	296
577	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 2008, 14, 501-503.	15.2	1,595
578	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 2008, 14, 504-506.	15.2	1,472
579	Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 441-444.	2.4	121
580	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy-Related Pathology in the Dementia Patient. Brain Pathology, 2008, 18, 220-224.	2.1	106
581	Three-layered Structure Shared Between Lewy Bodies and Lewy Neurites – Three-Dimensional Reconstruction of Triple-labeled Sections. Brain Pathology, 2008, 18, 415-422.	2.1	50
582	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	2.1	361
583	Non-motor symptoms in Parkinson's disease. European Journal of Neurology, 2008, 15, 14-20.	1.7	524
584	Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. Journal of Neurochemistry, 2008, 104, 1309-1320.	2.1	23
585	Parkin mediates the degradation-independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819.	2.1	101
586	Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members. Journal of Neurochemistry, 2008, 105, 2091-2097.	2.1	51
587	Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. Journal of Neurochemistry, 2008, 106, 860-874.	2.1	22

#	ARTICLE	IF	CITATIONS
588	Dementia and lower urinary dysfunction: With a reference to anticholinergic use in elderly population. <i>International Journal of Urology</i> , 2008, 15, 778-788.	0.5	74
589	Olfactory deficits in mice overexpressing human wildtype α -synuclein. <i>European Journal of Neuroscience</i> , 2008, 28, 247-256.	1.2	182
590	LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 272-283.	1.8	69
591	The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α -synuclein staging. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 284-295.	1.8	186
592	The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 466-467.	1.8	83
593	Review: Familial Parkinson's disease " genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 255-271.	1.8	105
594	Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. <i>Brain Research</i> , 2008, 1217, 203-212.	1.1	21
595	Increased electrical and metabolic activity in the dorsal raphe nucleus of Parkinsonian rats. <i>Brain Research</i> , 2008, 1221, 93-97.	1.1	32
596	Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. <i>Brain Research</i> , 2008, 1222, 222-229.	1.1	23
597	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , The, 2008, 7, 927-938.	4.9	106
598	Amiloride is neuroprotective in an MPTP model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2008, 31, 334-341.	2.1	116
599	Specific impairments in the recognition of emotional facial expressions in Parkinson's disease. <i>Neuropsychologia</i> , 2008, 46, 2300-2309.	0.7	142
600	Management of non-motor symptoms in advanced Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2008, 266, 216-228.	0.3	97
601	Variability in the clinical expression of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2008, 266, 197-203.	0.3	64
602	Further Structure-Activity Relationships Study of Hybrid 7-[2-(4-Phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol Analogues: Identification of a High-Affinity D3-Preferring Agonist with Potent in Vivo Activity with Long Duration of Action. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 101-117.	2.9	46
603	Neuroinflammation in Early Stages of Alzheimer's Disease and Parkinson's Disease. , 2008, , 113-121.		0
604	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. <i>Advances in Anatomy, Embryology and Cell Biology</i> , 2008, , .	1.0	85
605	Genetics of Parkinson's Disease. , 2008, , 9-33.		2

#	ARTICLE	IF	CITATIONS
608	Nitration of soluble proteins in organotypic culture models of Parkinson's disease. <i>Neurochemistry International</i> , 2008, 52, 487-494.	1.9	17
609	Î±-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. <i>Neurochemistry International</i> , 2008, 53, 263-269.	1.9	53
610	Selective hyposmia in Parkinson disease: Association with hippocampal dopamine activity. <i>Neuroscience Letters</i> , 2008, 447, 12-16.	1.0	90
611	Early Î±-synuclein lipoxidation in neocortex in Lewy body diseases. <i>Neurobiology of Aging</i> , 2008, 29, 408-417.	1.5	67
612	Mutant Î±-synuclein exacerbates age-related decrease of neurogenesis. <i>Neurobiology of Aging</i> , 2008, 29, 913-925.	1.5	106
613	Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. <i>Neurobiology of Aging</i> , 2008, 29, 1027-1039.	1.5	146
614	Mitochondria in Neuroplasticity and Neurological Disorders. <i>Neuron</i> , 2008, 60, 748-766.	3.8	875
615	Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for Î±-synuclein fibrils in vitro. <i>Neuropharmacology</i> , 2008, 54, 620-627.	2.0	51
616	Phosphorylation of tau and Î±-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related Î±-synucleinopathies. <i>Neuroscience</i> , 2008, 152, 913-923.	1.1	129
617	Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. <i>Neuroscience</i> , 2008, 154, 1388-1397.	1.1	106
618	Decrease in myocardial 123I-MIBG radioactivity in REM sleep behavior disorder: Two patients with different clinical progression. <i>Sleep Medicine</i> , 2008, 9, 583-585.	0.8	20
619	Autonomic dysfunction in RBD – What can it teach us about disease progression?. <i>Sleep Medicine</i> , 2008, 9, 473-474.	0.8	7
620	Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 338-341.	1.1	38
621	Nonmotor symptoms of Parkinson's disease: Prevalence and awareness of patients and families. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 286-290.	1.1	83
622	Activation of the calpain/cdk5/p25 pathway in the gyrus cinguli in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 309-313.	1.1	53
623	Olfactory tests in the diagnosis of essential tremor. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 563-568.	1.1	67
624	Strengths and limitations of genetic mouse models of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S84-S87.	1.1	71
625	Experimental studies of pedunculopontine functions: Are they motor, sensory or integrative?. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S194-S198.	1.1	62

#	ARTICLE	IF	CITATIONS
626	The neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype. <i>Progress in Neurobiology</i> , 2008, 85, 176-193.	2.8	31
627	Progress in Parkinson's disease—Where do we stand?. <i>Progress in Neurobiology</i> , 2008, 85, 376-392.	2.8	164
628	Digital Image Compression in Dermatology: Format Comparison. <i>Telemedicine Journal and E-Health</i> , 2008, 14, 666-670.	1.6	12
629	Human-based studies on α -synuclein deposition and relationship to Parkinson's disease symptoms. <i>Experimental Neurology</i> , 2008, 209, 12-21.	2.0	39
630	The role of MPTP in Parkinson's disease: Connecting brain and gut?. <i>Experimental Neurology</i> , 2008, 210, 281-285.	2.0	8
631	Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered. <i>Experimental Neurology</i> , 2008, 212, 226-229.	2.0	98
632	Stimulus timing by people with Parkinson's disease. <i>Brain and Cognition</i> , 2008, 67, 264-279.	0.8	65
633	The recognition of facial emotion expressions in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, 835-848.	0.3	97
634	Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 274-286.	2.5	21
635	Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 553-557.	1.1	134
636	Increased cortico-cortical functional connectivity in early-stage Parkinson's disease: An MEG study. <i>NeuroImage</i> , 2008, 41, 212-222.	2.1	158
637	Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. <i>Alzheimer's and Dementia</i> , 2008, 4, 421-427.	0.4	67
638	Hsp104 antagonizes α -synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. <i>Journal of Clinical Investigation</i> , 2008, 118, 3087-3097.	3.9	184
639	Benign nocturnal alternating hemiplegia of childhood: The first clinical report with paroxysmal events home-video recordings. <i>Movement Disorders</i> , 2008, 23, 1605-1608.	2.2	11
640	The search for biomarkers in Parkinson's disease: a critical review. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1841-1852.	1.4	31
641	The Effects of Withdrawal of Dopaminergic Medication in Nursing Home Patients With Advanced Parkinsonism. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 670-675.	1.2	15
643	Sleep Disorders in Parkinson's Disease. <i>Sleep Medicine Clinics</i> , 2008, 3, 325-335.	1.2	3
644	Les comportements oniriques chez le patient parkinsonien. <i>Médecine Du Sommeil</i> , 2008, 5, 16-22.	0.3	0

#	ARTICLE	IF	CITATIONS
645	Invited Article: Nervous system pathology in sporadic Parkinson disease. <i>Neurology</i> , 2008, 70, 1916-1925.	1.5	471
646	The relationship between nosology, etiology and pathogenesis in neurodegenerative diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 189-192.	1.0	2
647	Disorders of Taste and Smell. , 2008, , 859-887.		4
648	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
649	Axonal α -synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. <i>Brain</i> , 2008, 131, 642-650.	3.7	416
650	Serum Uric Acid and Clinical Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 698-9.	4.9	12
651	Chapter 29 Neuropsychology of dementia with Lewy bodies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 88, 549-566.	1.0	5
652	Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 423-432.	0.7	23
653	Olfactory Dysfunction in Parkinson's Disease. <i>NeuroSignals</i> , 2008, 16, 35-40.	0.5	74
654	A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson's Disease versus Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 301-308.	0.7	40
655	Argyrophilic grain disease. <i>Brain</i> , 2008, 131, 1416-1432.	3.7	183
656	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. <i>Brain</i> , 2008, 131, 690-705.	3.7	292
657	Cognitive Impairment in Parkinson's Disease and Dementia with Lewy Bodies: A Spectrum of Disease. <i>NeuroSignals</i> , 2008, 16, 24-34.	0.5	46
658	Mutations in <i>LRRK2</i> as a Cause of Parkinson's Disease. <i>NeuroSignals</i> , 2008, 16, 99-105.	0.5	48
659	Effects of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Olfactory Function in Parkinson's Disease Patients. <i>Stereotactic and Functional Neurosurgery</i> , 2008, 86, 237-244.	0.8	46
660	Drosophila Orthologues to Human Disease Genes: An Update on Progress. <i>Progress in Molecular Biology and Translational Science</i> , 2008, 82, 1-32.	1.9	14
661	Patterns and stages of α -synucleinopathy. <i>Neurology</i> , 2008, 70, 1042-1048.	1.5	226
662	What more can we learn from studying the REM sleep behaviour disorder-Parkinson's disease association?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1087-1087.	0.9	1

#	ARTICLE	IF	CITATIONS
663	Odor Identification and Progression of Parkinsonian Signs in Older Persons. <i>Experimental Aging Research</i> , 2008, 34, 173-187.	0.6	22
664	A novel <i>PSEN2</i> mutation associated with a peculiar phenotype. <i>Neurology</i> , 2008, 70, 1549-1554.	1.5	62
665	Incidental Lewy Body Disease and Preclinical Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1074-80.	4.9	166
666	Central and peripheral autonomic integrity in Parkinson's disease. <i>Age and Ageing</i> , 2008, 37, 578-581.	0.7	9
667	Hyposmia in G2019S LRRK2-related parkinsonism. <i>Neurology</i> , 2008, 71, 1021-1026.	1.5	82
668	Animal Models of Parkinson's Disease to Aid Drug Discovery and Development. , 2008, , 159-205.		3
669	Biologic models of neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 173-188.	1.0	3
670	IN DEMENTIA WITH LEWY BODIES, BRAAK STAGE DETERMINES PHENOTYPE, NOT LEWY BODY DISTRIBUTION. <i>Neurology</i> , 2008, 70, 407-408.	1.5	13
671	Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?. <i>Neurology</i> , 2008, 71, 1877-1882.	1.5	57
672	Designing care environments for persons with Alzheimer's disease: visuoperceptual considerations. <i>Reviews in Clinical Gerontology</i> , 2008, 18, 13-37.	0.5	26
673	α -Synuclein Aggregates Interfere with Parkin Solubility and Distribution. <i>Journal of Biological Chemistry</i> , 2008, 283, 6979-6987.	1.6	54
674	Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.	1.5	73
675	The Therapeutical Potential of Alpha-Synuclein Antiaggregatory Agents for Dementia with Lewy Bodies. <i>Current Medicinal Chemistry</i> , 2008, 15, 2748-2759.	1.2	22
676	Neurobiology of Sleep Disturbances in Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3430-3445.	0.9	55
679	Single photon-emission computed tomography imaging in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1853-1864.	1.4	4
680	Update on the functional biology of <i>Lrrk2</i> . <i>Future Neurology</i> , 2008, 3, 669-681.	0.9	31
681	REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1117-1121.	0.9	218
682	Tremor: From Pathogenesis to Treatment. <i>Synthesis Lectures on Biomedical Engineering</i> , 2008, 3, 1-212.	0.1	33

#	ARTICLE	IF	CITATIONS
683	Fatigue in levodopa-naïve subjects with Parkinson disease. <i>Neurology</i> , 2008, 71, 481-485.	1.5	141
684	Progress in the pathogenesis and genetics of Parkinson's disease. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2008, 363, 2215-2227.	1.8	63
685	Physiology of Parkinson's Disease. , 2008, , 25-36.		9
686	Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2008, 70, 1470-1477.	1.5	212
687	Phantomias and Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1237-9.	4.9	47
688	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
689	Managing the Non-Motor Symptoms of Parkinson's Disease. , 2008, , 91-120.		2
690	Pramipexole in the management of Parkinson's disease. <i>Aging Health</i> , 2008, 4, 225-235.	0.3	0
691	Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.. <i>Neuropsychology</i> , 2008, 22, 729-737.	1.0	72
692	Cortical Lewy body disease: dementia with Lewy bodies and Parkinson's disease with dementia. , 2008, , 293-320.		0
693	REM Sleep Behaviour Disorder. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2008, 97, 1078-1080.	0.0	0
696	Sleep Disturbances and Parkinson's Disease. <i>CNS Spectrums</i> , 2008, 13, 12-17.	0.7	24
697	Dopaminergic Lesion Enhances Growth Factor-Induced Striatal Neuroblast Migration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 105-116.	0.9	52
698	Assessment of α -Synuclein Pathology: A Study of the BrainNet Europe Consortium. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 125-143.	0.9	73
699	Mortalin: A Protein Associated With Progression of Parkinson Disease?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 117-124.	0.9	77
700	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions Visualized With Ubiquitin-Binding Protein p62 Immunohistochemistry. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 280-298.	0.9	76
701	Striatal β -Amyloid Deposition in Parkinson Disease With Dementia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 484.1-484.	0.9	10
702	Lewy Body Pathology Involves Cutaneous Nerves. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 945-953.	0.9	182

#	ARTICLE	IF	CITATIONS
703	Incidence and Extent of Lewy Body-Related α -Synucleinopathy in Aging Human Olfactory Bulb. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 1072-1083.	0.9	117
704	α -Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3247-3266.	0.9	48
705	Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1049-1067.	1.0	56
706	Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds. <i>Current Pharmaceutical Design</i> , 2008, 14, 3280-3294.	0.9	30
707	Neurodegenerative disorders. , 2008, , 39-89.		1
708	Delayed Blink Reflex in Dementia With Lewy Bodies Is Sensitive to Cholinergic Modulation. <i>Clinical Neuropharmacology</i> , 2008, 31, 231-237.	0.2	9
709	Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease. <i>Neurologist</i> , 2008, 14, 89-99.	0.4	60
710	F2 Isoprostane Levels in Plasma and Urine do not Support Increased Lipid Peroxidation in Cognitively Impaired Parkinson Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2008, 21, 83-86.	0.5	22
711	Abnormal colonic motility in mice overexpressing human wild-type α -synuclein. <i>NeuroReport</i> , 2008, 19, 873-876.	0.6	110
712	Dopamine in behavioral state control. , 0, , 179-223.		5
713	Dementia and functional decline in patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 96-101.	0.3	4
714	Subcortical Language Mechanisms. , 2008, , 329-340.		7
715	Rasagiline in treatment of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008, , 11.	1.0	8
716	A therapeutic maneuver for oropharyngeal dysphagia in patients with parkinson's disease. <i>Clinics</i> , 2008, 63, 661-666.	0.6	71
717	Endogenous Defenses that Protect Dopamine Neurons. , 2008, , 173-194.		0
718	Systems Level Physiology of the Basal Ganglia, and Pathophysiology of Parkinson's Disease. , 2008, , 55-63.		1
719	Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part II: Physiological and Pharmacological Manipulations and Pathological Alterations of Locus Coeruleus Activity in Humans. <i>Current Neuropharmacology</i> , 2008, 6, 254-285.	1.4	369
720	Can anti-inflammatory agents protect against Parkinson's disease?. <i>Future Neurology</i> , 2008, 3, 107-111.	0.9	0

#	ARTICLE	IF	CITATIONS
721	Parkinsonian Syndromes. , 2009, , 453-459.		0
722	Neurodegenerative diseases that affect olfaction. , 2009, , 153-214.		0
723	Dementia with Lewy bodies. , 0, , 7-26.		2
725	Sleep in Parkinson's disease. , 0, , 195-213.		0
726	Parkinsonâ€™s Disease: Alpha-Synuclein and Neurodegeneration. , 2009, , 461-467.		0
727	Non-Motor Off Symptoms in Parkinson's Disease. Journal of Korean Medical Science, 2009, 24, 311.	1.1	26
728	A Cross-Study Transcriptional Analysis of Parkinson's Disease. PLoS ONE, 2009, 4, e4955.	1.1	81
729	Regional Brain Stem Atrophy in Idiopathic Parkinson's Disease Detected by Anatomical MRI. PLoS ONE, 2009, 4, e8247.	1.1	60
730	Marking 20 years of Parkinson's disease nurse specialists: Looking to the future. British Journal of Neuroscience Nursing, 2009, 5, 450-455.	0.1	5
731	Animal Models of Parkinsonâ€™s Disease. , 2009, , 455-463.		3
732	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evidence, 2009, , 1.	4.7	5
733	Excessive Muscle Activity Increases Over Time in Idiopathic REM Sleep Behavior Disorder. Sleep, 2009, 32, 1149-1153.	0.6	99
734	Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another?. Neuropsychopharmacology, 2009, 34, 254-254.	2.8	40
735	Parkinson's Disease and Residential Exposure to Maneb and Paraquat From Agricultural Applications in the Central Valley of California. American Journal of Epidemiology, 2009, 169, 919-926.	1.6	482
736	Parkinsonâ€™s Disease with and without REM Sleep Behaviour Disorder: Are There Any Clinical Differences?. European Neurology, 2009, 61, 164-170.	0.6	102
737	Mice with Reduced Vesicular Monoamine Storage Content Display Nonmotor Features of Parkinson's Disease: Table 1.. Journal of Neuroscience, 2009, 29, 12842-12844.	1.7	6
738	The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology, 2009, 72, S1-136.	1.5	685
739	Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain, 2009, 132, 3285-3297.	3.7	191

#	ARTICLE	IF	CITATIONS
740	Is Parkinson's disease a prion disorder?. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12571-12572.	3.3	242
741	Aggressive Blood Pressure Lowering in Acute Ischemic Stroke. Archives of Neurology, 2009, 66, 804.	4.9	0
742	Parkinson Disease: Extranigral, Multisystem, and α -Synuclein α -Plus α . Archives of Neurology, 2009, 66, 910.	4.9	6
743	Sudomotor, skin vasomotor, and cardiovascular reflexes in 3 clinical forms of Lewy body disease. Neurology, 2009, 73, 59-65.	1.5	44
744	Dysfunction of the Default Mode Network in Parkinson Disease. Archives of Neurology, 2009, 66, 877-83.	4.9	243
745	Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity. Journal of Neuroscience, 2009, 29, 8103-8113.	1.7	241
746	Bacterial Artificial Chromosome Transgenic Mice Expressing a Truncated Mutant Parkin Exhibit Age-Dependent Hypokinetic Motor Deficits, Dopaminergic Neuron Degeneration, and Accumulation of Proteinase K-Resistant α -Synuclein. Journal of Neuroscience, 2009, 29, 1962-1976.	1.7	168
747	Lewy Body Pathology in Normal Elderly Subjects. Journal of Neuropathology and Experimental Neurology, 2009, 68, 816-822.	0.9	178
748	Hyposmia in pure autonomic failure. Neurology, 2009, 72, 1677-1681.	1.5	49
749	Animal Models for Alzheimer's Disease and Frontotemporal Dementia: A Perspective. ASN Neuro, 2009, 1, AN20090042.	1.5	31
750	The expanding realm of prion phenomena in neurodegenerative disease. Prion, 2009, 3, 74-77.	0.9	32
751	Prion-like propagation of cytosolic protein aggregates. Prion, 2009, 3, 206-212.	0.9	43
752	DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain. Journal of Neuropathology and Experimental Neurology, 2009, 68, 880-891.	0.9	162
753	Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future. Antioxidants and Redox Signaling, 2009, 11, 2189-2208.	2.5	31
754	Significance of Brain Lesions in Parkinson Disease Dementia and Lewy Body Dementia. Frontiers of Neurology and Neuroscience, 2009, 24, 114-125.	3.0	68
755	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	3.7	612
756	Effects of Dopamine D1 and D2 Receptor Antagonists on Laryngeal Neurophysiology in the Rat. Journal of Neurophysiology, 2009, 102, 1193-1205.	0.9	13
757	A new sensitive imaging biomarker for Parkinson disease?. Neurology, 2009, 72, 1374-1375.	1.5	15

#	ARTICLE	IF	CITATIONS
758	Can we image premotor Parkinson disease?. <i>Neurology</i> , 2009, 72, S21-6.	1.5	84
759	Treatments for Parkinson diseaseâ€”past achievements and current clinical needs. <i>Neurology</i> , 2009, 72, S65-73.	1.5	122
762	Handbook of Movement Disorders. , 2009, , .		2
763	Cholinergic denervation occurs early in Parkinson disease. <i>Neurology</i> , 2009, 73, 256-257.	1.5	64
764	The rostral migratory stream and olfactory system: smell, disease and slippery cells. <i>Progress in Brain Research</i> , 2009, 175, 33-42.	0.9	17
765	White Matter Involvement in Idiopathic Parkinson Disease: A Diffusion Tensor Imaging Study. <i>American Journal of Neuroradiology</i> , 2009, 30, 1222-1226.	1.2	215
766	Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2009, 10, 2510-2557.	1.8	65
767	â€œFrontotemporoparietalâ€”dementia. <i>Neurology</i> , 2009, 73, 1367-1374.	1.5	45
768	A clinico-pathological study of subtypes in Parkinson's disease. <i>Brain</i> , 2009, 132, 2947-2957.	3.7	385
769	Parasomnias. , 2009, , 591-605.		0
770	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.9	172
771	Olfactory Disturbance in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 805.	4.9	11
772	Olfactory Disturbance in Parkinson Diseaseâ€”Reply. <i>Archives of Neurology</i> , 2009, 66, 805.	4.9	7
773	Aggressive Blood Pressure Lowering in Acute Ischemic Strokeâ€”Reply. <i>Archives of Neurology</i> , 2009, 66, 804.	4.9	0
774	Olfactory Impairment Predicts Brain Atrophy in Parkinson's Disease: Figure 1.. <i>Journal of Neuroscience</i> , 2009, 29, 15410-15413.	1.7	132
775	Biomarker discovery in neurodegenerative diseases: A proteomic approach. <i>Neurobiology of Disease</i> , 2009, 35, 157-164.	2.1	102
776	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. <i>Neurobiology of Disease</i> , 2009, 35, 296-301.	2.1	15
777	Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. <i>Neurobiology of Disease</i> , 2009, 36, 96-102.	2.1	200

#	ARTICLE	IF	CITATIONS
778	Differential DJ-1 gene expression in Parkinson's disease. <i>Neurobiology of Disease</i> , 2009, 36, 393-400.	2.1	42
779	Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. <i>Neurobiology of Disease</i> , 2009, 36, 494-508.	2.1	57
780	Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 406-414.	0.7	144
781	Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1117-1127.	0.7	55
782	Parkinson Disease and the Nurse Practitioner: Diagnostic and Management Challenges. <i>Journal for Nurse Practitioners</i> , 2009, 5, 195-206.	0.4	7
783	Role of chemoreceptors in mediating dyspnea. <i>Respiratory Physiology and Neurobiology</i> , 2009, 167, 9-19.	0.7	63
784	Dorsal Motor Nucleus of Vagus protein aggregates in Lewy Body Disease with autonomic dysfunction. <i>Brain Research</i> , 2009, 1286, 165-173.	1.1	11
785	In vitro characterisation of BF227 binding to α -synuclein/Lewy bodies. <i>European Journal of Pharmacology</i> , 2009, 617, 54-58.	1.7	88
786	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. <i>Lancet Neurology</i> , The, 2009, 8, 382-397.	4.9	1,648
787	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. <i>Lancet Neurology</i> , The, 2009, 8, 464-474.	4.9	1,367
788	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	4.9	734
789	Drug selection and timing of initiation of treatment in early Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, S47-S55.	2.8	29
790	Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment. <i>Annals of Neurology</i> , 2008, 64, S139-S147.	2.8	54
791	Biomarkers for Parkinson's disease: Tools to assess Parkinson's disease onset and progression. <i>Annals of Neurology</i> , 2008, 64, S111-S121.	2.8	35
792	Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. <i>Annals of Neurology</i> , 2009, 66, 39-47.	2.8	301
793	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	2.8	80
794	Advanced time-series analysis of MEG data as a method to explore olfactory function in healthy controls and Parkinson's disease patients. <i>Human Brain Mapping</i> , 2009, 30, 3020-3030.	1.9	15
795	Development of vaccination approaches for the treatment of neurological diseases. <i>Journal of Comparative Neurology</i> , 2009, 515, 4-14.	0.9	12

#	ARTICLE	IF	CITATIONS
796	Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. <i>Journal of Neuroscience Research</i> , 2009, 87, 1002-1013.	1.3	50
797	Heavy alcohol consumption and neuropathological lesions: A post-mortem human study. <i>Journal of Neuroscience Research</i> , 2009, 87, 2786-2792.	1.3	27
798	Clinical and pathological characteristics of patients with Leucine-rich repeat kinase-2 mutations. <i>Movement Disorders</i> , 2009, 24, 32-39.	2.2	44
799	Lesions outside the CNS in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 793-800.	2.2	62
800	Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects. <i>Movement Disorders</i> , 2009, 24, 204-210.	2.2	33
801	Extended testing across, not within, tasks raises diagnostic accuracy of smell testing in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 85-90.	2.2	24
802	Odor identification test as an indicator of idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 268-273.	2.2	57
803	Premotor Parkinson's disease: Clinical features and detection strategies. <i>Movement Disorders</i> , 2009, 24, S665-70.	2.2	40
804	Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. <i>Movement Disorders</i> , 2009, 24, 579-582.	2.2	85
805	Progression of dysprosody in Parkinson's disease over time—A longitudinal study. <i>Movement Disorders</i> , 2009, 24, 716-722.	2.2	200
806	Psychotic and compulsive symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 738-744.	2.2	33
807	Biopsies of olfactory epithelium in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 906-914.	2.2	142
808	Serotonin and Parkinson's disease: On movement, mood, and madness. <i>Movement Disorders</i> , 2009, 24, 1255-1266.	2.2	146
809	Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson's disease with dementia. <i>Movement Disorders</i> , 2009, 24, 1740-1746.	2.2	63
810	Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory?. <i>Movement Disorders</i> , 2009, 24, 1747-1751.	2.2	53
811	Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. <i>Movement Disorders</i> , 2009, 24, 1600-1605.	2.2	78
812	Clinical measures of progression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S671-6.	2.2	77
813	Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach. <i>Movement Disorders</i> , 2009, 24, S703-10.	2.2	62

#	ARTICLE	IF	CITATIONS
814	MRI and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S748-53.	2.2	66
815	When does Parkinson's disease begin?. <i>Movement Disorders</i> , 2009, 24, S656-64.	2.2	113
816	Hybrid cars may interfere with implanted deep brain stimulators. <i>Movement Disorders</i> , 2009, 24, 2290-2291.	2.2	2
817	Quantitative lateralized measures of bradykinesia at different stages of Parkinson's disease: The role of the less affected side. <i>Movement Disorders</i> , 2009, 24, 1991-1997.	2.2	35
818	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. <i>Movement Disorders</i> , 2009, 24, 2128-2135.	2.2	13
819	Brain atrophy and white matter hyperintensities in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2233-2241.	2.2	50
820	Idiopathic REM sleep behavior disorder in the transition to degenerative disease. <i>Movement Disorders</i> , 2009, 24, 2225-2232.	2.2	100
821	Deep brain stimulation in acute management of status dystonicus. <i>Movement Disorders</i> , 2009, 24, 2291-2292.	2.2	43
822	Plasma phenylalanine level in dopa-responsive dystonia. <i>Movement Disorders</i> , 2009, 24, 2289-2290.	2.2	3
823	Incidental Lewy body disease restricted to the heart and stellate ganglia. <i>Movement Disorders</i> , 2009, 24, 2299-2301.	2.2	55
824	Restless legs syndrome as an initial manifestation of metastatic conus medullaris lesion. <i>Movement Disorders</i> , 2009, 24, 2294-2296.	2.2	1
825	Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. <i>Movement Disorders</i> , 2009, 24, 2293-2294.	2.2	64
826	Eating dystonia. <i>Movement Disorders</i> , 2009, 24, 2303-2304.	2.2	1
827	Giant somatosensory evoked potential in a patient with shaking TIA. <i>Movement Disorders</i> , 2009, 24, 2301-2303.	2.2	5
828	Unilateral periodic limb movements: Is this a pointer for atypical presentation of corticobasal degeneration syndrome? A case report. <i>Movement Disorders</i> , 2009, 24, 2298-2299.	2.2	4
829	Paraneoplastic chorea associated with breast cancer. <i>Movement Disorders</i> , 2009, 24, 2296-2297.	2.2	9
830	Complex movement disorders in a sporadic Boucher-Neuhäuser Syndrome: Phenotypic manifestations beyond the triad. <i>Movement Disorders</i> , 2009, 24, 2304-2306.	2.2	9
831	Opsoclonus myoclonus syndrome in the context of Salmonellosis. <i>Movement Disorders</i> , 2009, 24, 2306-2308.	2.2	12

#	ARTICLE	IF	CITATIONS
832	Gene regulatory networks in embryonic stem cells and brain development. Birth Defects Research Part C: Embryo Today Reviews, 2009, 87, 182-191.	3.6	1
833	MEG resting state functional connectivity in Parkinson's disease related dementia. Journal of Neural Transmission, 2009, 116, 193-202.	1.4	81
834	The neurogenic niche in the carotid body and its applicability to antiparkinsonian cell therapy. Journal of Neural Transmission, 2009, 116, 975-982.	1.4	25
835	Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro- β -carboline. Journal of Neural Transmission, 2009, 116, 1267-1271.	1.4	7
836	Beyond tremor and rigidity: non-motor features of Parkinson's disease. Journal of Neural Transmission, 2009, 116, 1483-1492.	1.4	76
838	Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 478-500.	2.2	247
839	Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?. Acta Neuropathologica, 2009, 117, 101-110.	3.9	47
840	Assessment of β -amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	3.9	143
841	Staging/typing of Lewy body related α -synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	3.9	249
842	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica, 2009, 117, 613-634.	3.9	553
843	Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathologica, 2009, 118, 777-784.	3.9	67
844	The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathologica, 2009, 118, 587-598.	3.9	77
845	Morphological differences in Parkinson's disease with and without rest tremor. Journal of Neurology, 2009, 256, 256-263.	1.8	108
846	Non-motor symptoms in Parkinson's disease. Journal of Neurology, 2009, 256, 293-298.	1.8	207
847	Formation and development of Lewy pathology: a critical update. Journal of Neurology, 2009, 256, 270-279.	1.8	179
848	Linking brain dynamics, neural mechanisms, and deep brain stimulation in Parkinson's disease: An integrated perspective. Medical Engineering and Physics, 2009, 31, 615-623.	0.8	30
849	Interleukin-6 Serum Levels in Patients with Parkinson's Disease. Neurochemical Research, 2009, 34, 1401-1404.	1.6	75
850	Modulation of α -Synuclein Aggregation by Dopamine: A Review. Neurochemical Research, 2009, 34, 1838-1846.	1.6	101

#	ARTICLE	IF	CITATIONS
851	Systemic Administration of Proteasome Inhibitor Protects Against MPTP Neurotoxicity in Mice. Cellular and Molecular Neurobiology, 2009, 29, 769-777.	1.7	9
852	Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease. Neurotoxicity Research, 2009, 16, 127-139.	1.3	86
853	Velocity control in Parkinson's disease: a quantitative analysis of isochrony in scribbling movements. Experimental Brain Research, 2009, 194, 259-283.	0.7	27
854	Toward a Successful Clinical Neuroproteomics The 11th HUPO Brain Proteome Project Workshop 3 March, 2009, Kolymbari, Greece. Proteomics - Clinical Applications, 2009, 3, 1012-1016.	0.8	3
855	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32.	4.4	34
856	Conditional transgenic mice expressing C-terminally truncated human α -synuclein (α Syn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Molecular Neurodegeneration, 2009, 4, 34.	4.4	79
857	Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Molecular Neurodegeneration, 2009, 4, 37.	4.4	51
858	α -Synuclein and neuronal cell death. Molecular Neurodegeneration, 2009, 4, 9.	4.4	314
859	The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathology and Applied Neurobiology, 2009, 35, 406-416.	1.8	186
860	Evidence against a reliable staging system of α -synuclein pathology in Parkinson's disease. Neuropathology and Applied Neurobiology, 2009, 35, 125-126.	1.8	17
861	Spinocerebellar ataxia type 6 (SCA6): neurodegeneration goes beyond the known brain predilection sites. Neuropathology and Applied Neurobiology, 2009, 35, 515-527.	1.8	44
862	Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing G α s, a G-protein subunit genetically linked to schizophrenia. Molecular Psychiatry, 2009, 14, 398-415.	4.1	59
863	Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death and Differentiation, 2009, 16, 449-464.	5.0	156
864	Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biology, 2009, 11, 909-913.	4.6	1,515
865	Brain banking: opportunities, challenges and meaning for the future. Nature Reviews Neuroscience, 2009, 10, 70-78.	4.9	106
866	Slow wave sleep and dopaminergic treatment in Parkinson's disease: a polysomnographic study. Acta Neurologica Scandinavica, 2009, 120, 308-313.	1.0	19
867	Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS Journal, 2009, 276, 5041-5052.	2.2	44
868	Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of α -synuclein. European Journal of Neuroscience, 2009, 29, 879-890.	1.2	68

#	ARTICLE	IF	CITATIONS
869	PPAR γ -mediated neuroprotection in a chronic mouse model of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2009, 29, 954-963.	1.2	186
870	The second brain and Parkinson's disease. <i>European Journal of Neuroscience</i> , 2009, 30, 735-741.	1.2	189
871	Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. <i>European Journal of Neuroscience</i> , 2009, 30, 1162-1171.	1.2	160
872	Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1170, 615-622.	1.8	233
873	Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death. <i>Brain Pathology</i> , 2009, 19, 91-107.	2.1	159
874	Frontotemporal lobar degeneration and dementia with Lewy bodies: Clinicopathological issues associated with antemortem diagnosis. <i>Psychogeriatrics</i> , 2009, 9, 91-102.	0.6	3
875	Functional dissection of the α -synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. <i>Journal of Neurochemistry</i> , 2009, 110, 1479-1490.	2.1	49
876	Seeding induced by α -synuclein oligomers provides evidence for spreading of α -synuclein pathology. <i>Journal of Neurochemistry</i> , 2009, 111, 192-203.	2.1	254
877	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 1090-1099.	1.7	64
878	Proteomics in human Parkinson's disease research. <i>Journal of Proteomics</i> , 2009, 73, 10-29.	1.2	98
879	Investigation of various N-heterocyclic substituted piperazine versions of 5/7-[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: Effect on affinity and selectivity for dopamine D3 receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3923-3933.	1.4	20
880	Treatment options for the management of parkinsonism. <i>The Prescriber</i> , 2009, 20, 32-45.	0.1	0
881	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α -synuclein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13010-13015.	3.3	1,308
882	Widespread thalamic and cerebellar degeneration in a patient with a complicated hereditary spastic paraplegia (HSP). <i>Annals of Anatomy</i> , 2009, 191, 203-211.	1.0	11
884	Chapter 12 Dementia In Parkinson's Disease. <i>International Review of Neurobiology</i> , 2009, 84, 229-244.	0.9	14
885	Challenges in molecular imaging of Parkinson's disease: A brief overview. <i>Brain Research Bulletin</i> , 2009, 78, 105-108.	1.4	7
886	Neuropathology of Lewy body disorders. <i>Brain Research Bulletin</i> , 2009, 80, 203-210.	1.4	59
887	Anti-aggregation and fibril-destabilizing effects of sex hormones on α -synuclein fibrils in vitro. <i>Experimental Neurology</i> , 2009, 217, 434-439.	2.0	47

#	ARTICLE	IF	CITATIONS
888	The cybrid model of sporadic Parkinson's disease. <i>Experimental Neurology</i> , 2009, 218, 320-325.	2.0	47
889	Mitochondrial dynamics in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 218, 247-256.	2.0	112
890	Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model. <i>Experimental Neurology</i> , 2009, 219, 574-582.	2.0	124
891	A critical evaluation of current staging of α -synuclein pathology in Lewy body disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 730-740.	1.8	194
892	Viral parkinsonism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 714-721.	1.8	241
893	Targets for neuroprotection in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 676-687.	1.8	147
894	Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 68-74.	1.8	44
895	Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 625-633.	1.8	91
896	Genetic models of Parkinson disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 604-615.	1.8	50
897	The role of the basal ganglia in learning and memory: Neuropsychological studies. <i>Behavioural Brain Research</i> , 2009, 199, 53-60.	1.2	217
898	Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. <i>Behavioural Brain Research</i> , 2009, 198, 434-439.	1.2	31
899	The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. <i>Sleep Medicine Reviews</i> , 2009, 13, 385-401.	3.8	256
900	Neurobiology and treatment of Parkinson's disease. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 41-47.	4.0	193
901	Clinical and pathological features of an Alzheimer's disease patient with the MAPT Δ K280 mutation. <i>Neurobiology of Aging</i> , 2009, 30, 388-393.	1.5	55
902	Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. <i>Neurobiology of Aging</i> , 2009, 30, 847-863.	1.5	57
903	Alterations in corticostriatal synaptic plasticity in mice overexpressing human α -synuclein. <i>Neuroscience</i> , 2009, 159, 501-513.	1.1	90
904	Imaging the impact of genes on Parkinson's disease. <i>Neuroscience</i> , 2009, 164, 191-204.	1.1	27
905	Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. <i>Sleep Medicine</i> , 2009, 10, 407-415.	0.8	80

#	ARTICLE	IF	CITATIONS
906	Three-year follow-up on the accumulation of cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2009, 10, 1066-1067.	0.8	9
907	Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 187-195.	1.1	82
908	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 226-231.	1.1	163
909	Abnormality of taste and smell in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 232-237.	1.1	79
910	Prevalence and clinical correlates of apathy in Parkinson's disease: A community-based study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 295-299.	1.1	146
911	Prevalence of smell loss in Parkinson's disease – A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 490-494.	1.1	329
912	Parkinson's disease dementia – A diminished role for the Lewy body. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 572-575.	1.1	17
913	A global view of Parkinson's disease pathogenesis: Implications for natural history and neuroprotection. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 401-405.	1.1	17
914	Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 640-643.	1.1	21
915	Evaluation of gastric emptying in familial and sporadic Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 692-696.	1.1	40
916	Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 721-727.	1.1	49
917	Delivery of peptide and protein drugs over the blood-brain barrier. <i>Progress in Neurobiology</i> , 2009, 87, 212-251.	2.8	245
918	Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects. <i>Progress in Neurobiology</i> , 2009, 88, 89-103.	2.8	92
919	The influence of microglia on the pathogenesis of Parkinson's disease. <i>Progress in Neurobiology</i> , 2009, 89, 277-287.	2.8	247
920	PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death. <i>Molecular Cell</i> , 2009, 33, 627-638.	4.5	584
921	Regional differences in the severity of Lewy body pathology across the olfactory cortex. <i>Neuroscience Letters</i> , 2009, 453, 77-80.	1.0	110
922	Desipramine induced changes in the norepinephrine transporter, α - and β -synuclein in the hippocampus, amygdala and striatum. <i>Neuroscience Letters</i> , 2009, 467, 86-89.	1.0	15
923	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. <i>Neuroscience Letters</i> , 2009, 467, 203-207.	1.0	75

#	ARTICLE	IF	CITATIONS
924	High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. <i>Neurology</i> , 2009, 72, 1378-1384.	1.5	409
925	Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2009, 276, 79-83.	0.3	68
926	Systemic postganglionic adrenergic studies do not distinguish parkinson's disease from multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2009, 281, 15-19.	0.3	10
927	Protein Misfolding and Aggregation in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 2119-2134.	2.5	90
928	The Localization of Inhibitory Neurotransmitter Receptors on Dopaminergic Neurons of the Human Substantia Nigra. , 2009, , 59-70.		3
929	Olfactory dysfunction as a diagnostic marker for Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1773-1779.	1.4	101
930	Age and Parkinsonâ€™s Disease-Related Neuronal Death in the Substantia Nigra Pars Compacta. , 2009, , 203-213.		19
933	Gait dynamics in Parkinsonâ€™s disease: Common and distinct behavior among stride length, gait variability, and fractal-like scaling. <i>Chaos</i> , 2009, 19, 026113.	1.0	466
936	Hallucinations in Parkinson disease. <i>Nature Reviews Neurology</i> , 2009, 5, 331-342.	4.9	272
937	Statins and the risk of Parkinson disease: an update on the controversy. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 261-271.	1.0	17
938	Pain sensitivity and descending inhibition of pain in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 24-28.	0.9	123
939	Recognition and management of Parkinsonâ€™s disease during the premotor (prodromal) phase. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 847-857.	1.4	13
940	Diagnosis and the premotor phase of Parkinson disease. <i>Neurology</i> , 2009, 72, S12-20.	1.5	210
941	Systems Biology: The interplay of systems and control research and biology?. , 2009, , .		0
942	Abnormal regional brain function in Parkinson's disease: truth or fiction?. <i>NeuroImage</i> , 2009, 45, 260-266.	2.1	48
943	Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. <i>Experimental Neurology</i> , 2009, 220, 109-119.	2.0	56
944	Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. <i>Experimental Neurology</i> , 2009, 220, 374-382.	2.0	30
945	Glutamate, excitotoxicity, and programmed cell death in parkinson disease. <i>Experimental Neurology</i> , 2009, 220, 230-233.	2.0	85

#	ARTICLE	IF	CITATIONS
946	Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. <i>European Journal of Neuroscience</i> , 2009, 30, 207-216.	1.2	45
947	Identification of Glutathione S-Transferase Pi as a Protein Involved in Parkinson Disease Progression. <i>American Journal of Pathology</i> , 2009, 175, 54-65.	1.9	75
948	Neuropathology of non-motor features of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S1-S5.	1.1	228
949	Non-motor extranigral signs and symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S6-S12.	1.1	104
950	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S13-S16.	1.1	17
951	Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S26-S30.	1.1	52
952	Non-motor features of Parkinson's disease: depression and dementia. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S87-S92.	1.1	45
953	Predicting Parkinson's disease " why, when, and how?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S105-S109.	1.1	52
954	Dissecting the potential molecular mechanisms underlying α -synuclein cell-to-cell transfer in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S143-S147.	1.1	81
955	The clinical progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S28-S32.	1.1	123
956	Parkinson's disease. <i>Lancet, The</i> , 2009, 373, 2055-2066.	6.3	1,835
957	Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1233-1250.	1.4	65
958	Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 157-182.	1.9	33
959	Etiology and Pathogenesis of Parkinson Disease. <i>Neurologic Clinics</i> , 2009, 27, 583-603.	0.8	105
960	Molecular basis of Parkinson's disease. <i>NeuroReport</i> , 2009, 20, 150-156.	0.6	69
961	Cognitive and Neuropsychiatric Profile of the Synucleinopathies. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 365-370.	0.6	104
962	REM Sleep Behavior Disorder Associated with Progressive Neurological Disorders. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2009, 9, 24.	0.0	0
963	Comparison of Risk Factor Profiles in Incidental Lewy Body Disease and Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1114-9.	4.9	34

#	ARTICLE	IF	CITATIONS
964	Commentary: DLB and PDD: the same or different? Is there a debate?. <i>International Psychogeriatrics</i> , 2009, 21, 220.	0.6	24
965	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	0.9	173
966	The Parkinson chimera. <i>Neurology</i> , 2009, 72, S2-11.	1.5	61
967	Persistent Short-Term Memory Defects Following Sleep Deprivation in a <i>Drosophila</i> Model of Parkinson Disease. <i>Sleep</i> , 2009, 32, 984-992.	0.6	51
968	Alzheimer's Disease Selective Vulnerability and Modeling in Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 243-251.	1.2	29
969	Targeting the Progression of Parkinsons Disease. <i>Current Neuropharmacology</i> , 2009, 7, 9-36.	1.4	69
970	Hyperphosphorylated Tau in the Occipital Cortex in Aged Nondemented Subjects. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 653-660.	0.9	18
971	Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications. <i>Current Protein and Peptide Science</i> , 2009, 10, 476-482.	0.7	23
972	Early-Onset Familial Lewy Body Dementia With Extensive Tauopathy: A Clinical, Genetic, and Neuropathological Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 73-82.	0.9	33
973	Parkinsons Disease Dementia. <i>Current Psychiatry Reviews</i> , 2009, 5, 218-225.	0.9	4
974	Leucine-Rich Repeat Kinase 2 Is Associated With the Endoplasmic Reticulum in Dopaminergic Neurons and Accumulates in the Core of Lewy Bodies in Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 959-972.	0.9	62
975	Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinsons Disease. <i>Current Protein and Peptide Science</i> , 2010, 11, 334-342.	0.7	42
976	Inverse Relationship Between Cerebrovascular Lesions and Severity of Lewy Body Pathology in Patients With Lewy Body Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 442-448.	0.9	71
978	An Overview of Surgical Therapy for Movement Disorders. <i>Proceedings of Singapore Healthcare</i> , 2010, 19, 303-311.	0.2	0
979	Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 229-234.	0.3	3
980	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinsonâ€™s disease models. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 194-208.	1.2	159
981	Effect of Dopaminergic Medications on the Time Course of Explicit Motor Sequence Learning in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2010, 103, 942-949.	0.9	74
983	Increased GABAergic activity in the region of the pedunculopontine and deep mesencephalic reticular nuclei reduces REM sleep and impairs learning in rats.. <i>Behavioral Neuroscience</i> , 2010, 124, 79-86.	0.6	14

#	ARTICLE	IF	CITATIONS
984	Mitochondrial Pathobiology in Parkinson's Disease and Amyotrophic Lateral Sclerosis. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S335-S356.	1.2	27
985	Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease—Two Sides of One Coin?. <i>Sleep</i> , 2010, 33, 731-732.	0.6	5
986	Diffusion Tensor Imaging in Idiopathic REM Sleep Behavior Disorder Reveals Microstructural Changes in the Brainstem, Substantia Nigra, Olfactory Region, and Other Brain Regions. <i>Sleep</i> , 2010, 33, 767-773.	0.6	175
987	Differential Effect of <i>Helicobacter pylori</i> Eradication on Time-trends in Brady/Hypokinesia and Rigidity in Idiopathic Parkinsonism. <i>Helicobacter</i> , 2010, 15, 279-294.	1.6	61
988	Single-Photon Emission Computed Tomography in Diagnosis and Differential Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 319-329.	0.8	17
990	Rivastigmine for the treatment of Parkinson's disease dementia. <i>Aging Health</i> , 2010, 6, 277-284.	0.3	0
991	Emergence and natural selection of drug-resistant prions. <i>Molecular BioSystems</i> , 2010, 6, 1115.	2.9	48
992	Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. <i>Neurobiology of Aging</i> , 2010, 31, 104-113.	1.5	56
993	Cell-to-cell transmission of non-prion protein aggregates. <i>Nature Reviews Neurology</i> , 2010, 6, 702-706.	4.9	269
994	Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3865-3882.	2.4	21
997	Laryngeal somatosensory deficits in Parkinson's disease: implications for speech respiratory and phonatory control. <i>Experimental Brain Research</i> , 2010, 201, 401-409.	0.7	86
998	α -Synuclein pathology in the spinal cord autonomic nuclei associates with α -synuclein pathology in the brain: a population-based Vantaa 85+ study. <i>Acta Neuropathologica</i> , 2010, 119, 715-722.	3.9	36
999	Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. <i>Acta Neuropathologica</i> , 2010, 119, 703-713.	3.9	258
1000	Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. <i>Acta Neuropathologica</i> , 2010, 120, 155-167.	3.9	25
1001	Proteinase K-resistant α -synuclein is deposited in presynapses in human Lewy body disease and A53T α -synuclein transgenic mice. <i>Acta Neuropathologica</i> , 2010, 120, 145-154.	3.9	87
1002	Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. <i>Acta Neuropathologica</i> , 2010, 120, 67-74.	3.9	58
1003	α -Synucleinopathy in the human olfactory system in Parkinson's disease: involvement of calcium-binding protein- and substance P-positive cells. <i>Acta Neuropathologica</i> , 2010, 119, 723-735.	3.9	87
1004	Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. <i>Acta Neuropathologica</i> , 2010, 120, 1-12.	3.9	131

#	ARTICLE	IF	CITATIONS
1005	Capillary cerebral amyloid angiopathy identifies a distinct APOE ϵ 4-associated subtype of sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 120, 169-183.	3.9	81
1006	The synaptic pathology of α -synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. <i>Acta Neuropathologica</i> , 2010, 120, 131-143.	3.9	496
1007	Glucocerebrosidase is present in α -synuclein inclusions in Lewy body disorders. <i>Acta Neuropathologica</i> , 2010, 120, 641-649.	3.9	169
1008	Neuropathology in Parkinson's disease with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2010, 120, 829-830.	3.9	39
1009	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2010, 257, 217-223.	1.8	87
1010	Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 969-976.	1.8	49
1011	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. <i>Journal of Neurology</i> , 2010, 257, 1524-1532.	1.8	106
1012	The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> , 2010, 257, 1882-1889.	1.8	39
1013	Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. <i>Brain Structure and Function</i> , 2010, 214, 303-317.	1.2	140
1014	A positive correlation between fractional white matter volume and the response of Parkinson disease patients to subthalamic stimulation. <i>Acta Neurochirurgica</i> , 2010, 152, 997-1006.	0.9	10
1015	Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease. <i>Acta Neurochirurgica</i> , 2010, 152, 2063-2068.	0.9	3
1016	Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. <i>Journal of Neural Transmission</i> , 2010, 117, 353-367.	1.4	10
1017	Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"? <i>Journal of Neural Transmission</i> , 2010, 117, 605-612.	1.4	62
1018	CSF markers of neurodegeneration in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1177-1181.	1.4	57
1019	Microglia activation is related to substantia nigra echogenicity. <i>Journal of Neural Transmission</i> , 2010, 117, 1287-1292.	1.4	83
1020	Immediate Effects of Thermal "Tactile Stimulation on Timing of Swallow in Idiopathic Parkinson's Disease. <i>Dysphagia</i> , 2010, 25, 207-215.	1.0	63
1021	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. <i>EPMA Journal</i> , 2010, 1, 273-292.	3.3	28
1022	Synaptic Depression and Aberrant Excitatory Network Activity in Alzheimer's Disease: Two Faces of the Same Coin?. <i>NeuroMolecular Medicine</i> , 2010, 12, 48-55.	1.8	138

#	ARTICLE	IF	CITATIONS
1023	Chronic Administration with Rotenone does not Enhance MPTP Neurotoxicity in C57BL/6 Mice. <i>Journal of Molecular Neuroscience</i> , 2010, 41, 17-24.	1.1	4
1024	Global microRNA Expression Profiling of <i>Caenorhabditis elegans</i> Parkinson's Disease Models. <i>Journal of Molecular Neuroscience</i> , 2010, 41, 210-218.	1.1	96
1025	̂±-Synuclein Transgenic Mice Reveal Compensatory Increases in Parkinson's Disease-Associated Proteins DJ-1 and Parkin and Have Enhanced ̂±-Synuclein and PINK1 Levels After Rotenone Treatment. <i>Journal of Molecular Neuroscience</i> , 2010, 42, 243-254.	1.1	37
1026	Parkinson's Disease Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 292-298.	2.0	18
1027	Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. <i>Lancet Neurology</i> , The, 2010, 9, 149-158.	4.9	291
1028	Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. <i>Lancet Neurology</i> , The, 2010, 9, 613-622.	4.9	172
1029	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2010, 9, 1200-1213.	4.9	753
1030	Are synucleinopathies prion-like disorders?. <i>Lancet Neurology</i> , The, 2010, 9, 1128-1138.	4.9	226
1031	Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. <i>Neurobiology of Disease</i> , 2010, 37, 455-460.	2.1	46
1032	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010, 40, 216-221.	2.1	213
1033	Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson's. <i>Neuropsychologia</i> , 2010, 48, 1367-1375.	0.7	23
1034	Rule-based categorization deficits in focal basal ganglia lesion and Parkinson's disease patients. <i>Neuropsychologia</i> , 2010, 48, 2974-2986.	0.7	26
1035	From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and ̂±2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. , 2010, 128, 229-273.		68
1036	CSF from Parkinson disease Patients Differentially Affects Cultured Microglia and Astrocytes. <i>BMC Neuroscience</i> , 2010, 11, 151.	0.8	20
1037	Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. <i>BMC Medicine</i> , 2010, 8, 80.	2.3	46
1038	Spontaneous language production in bilingual Parkinson's disease patients: Evidence of greater phonological, morphological and syntactic impairments in native language. <i>Brain and Language</i> , 2010, 113, 84-89.	0.8	50
1039	The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. <i>Brain Research</i> , 2010, 1354, 236-242.	1.1	7
1040	MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. <i>Brain Research</i> , 2010, 1355, 195-206.	1.1	76

#	ARTICLE	IF	CITATIONS
1041	Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α -synuclein neuropathology required and feasible?. Brain Research Reviews, 2010, 65, 28-55.	9.1	39
1042	Olfactory epithelium amyloid β and paired helical filament τ pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 462-469.	2.8	167
1043	First appraisal of brain pathology owing to A30P mutant alpha β -synuclein. Annals of Neurology, 2010, 67, 684-689.	2.8	91
1044	Clinical progression in Parkinson disease and the neurobiology of axons. Annals of Neurology, 2010, 67, 715-725.	2.8	778
1045	Phasic muscle activity in sleep and clinical features of Parkinson disease. Annals of Neurology, 2010, 68, 353-359.	2.8	55
1046	Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α -synuclein, and tau. BioEssays, 2010, 32, 227-235.	1.2	61
1047	Glycoproteomics in neurodegenerative diseases. Mass Spectrometry Reviews, 2010, 29, 79-125.	2.8	99
1048	Pathogenesis of PD: Missing the point. Movement Disorders, 2010, 25, 122-123.	2.2	2
1049	Selective MAO β inhibitors have low potential for the tyramine effect. Movement Disorders, 2010, 25, 123-124.	2.2	4
1050	Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis. Movement Disorders, 2010, 25, 124-125.	2.2	3
1051	Botulinum toxin type a for painful limbs moving extremities. Movement Disorders, 2010, 25, 125-125.	2.2	3
1052	Evidence in favor of Braak staging of Parkinson's disease. Movement Disorders, 2010, 25, S78-82.	2.2	112
1053	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	2.2	43
1054	Parkinson's at risk syndrome: Can Parkinson's disease be predicted?. Movement Disorders, 2010, 25, S89-93.	2.2	73
1055	Advances in environmental epidemiology. Movement Disorders, 2010, 25, S58-62.	2.2	73
1056	Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. Movement Disorders, 2010, 25, 125-126.	2.2	6
1057	Evaluation of the Braak staging scheme for Parkinson's disease: Introduction to a panel presentation. Movement Disorders, 2010, 25, S76-7.	2.2	14
1058	The nonmotor symptoms of Parkinson's disease—An overview. Movement Disorders, 2010, 25, S123-30.	2.2	130

#	ARTICLE	IF	CITATIONS
1059	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	2.2	106
1060	Parkinson's disease: 10 years of progress, 1997-2007. <i>Movement Disorders</i> , 2010, 25, S2-14.	2.2	40
1061	Nocturnal eating in restless legs syndrome. <i>Movement Disorders</i> , 2010, 25, 126-127.	2.2	9
1062	Spinocerebellar ataxia type 12 identified in two Italian families may mimic sporadic ataxia. <i>Movement Disorders</i> , 2010, 25, 1269-1273.	2.2	25
1063	Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 623-628.	2.2	35
1064	Tongue protrusion and feeding dystonia: A hallmark of chorea-acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 127-129.	2.2	59
1065	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 629-633.	2.2	61
1066	Carisbamate in essential tremor: Brief report of a proof of concept study. <i>Movement Disorders</i> , 2010, 25, 634-638.	2.2	15
1067	Pain and dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 130-132.	2.2	11
1068	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	2.2	25
1069	Singing-induced cervical dystonia. <i>Movement Disorders</i> , 2010, 25, 129-130.	2.2	1
1070	Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. <i>Movement Disorders</i> , 2010, 25, 1284-1288.	2.2	44
1071	Nonmotor symptoms in <i>Parkin</i> gene-related parkinsonism. <i>Movement Disorders</i> , 2010, 25, 1279-1284.	2.2	31
1072	Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 638-642.	2.2	33
1073	Functional correlates of lower cognitive test scores in essential tremor. <i>Movement Disorders</i> , 2010, 25, 481-485.	2.2	37
1074	External validation of abbreviated versions of the activities-specific balance confidence scale in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 485-489.	2.2	34
1075	Plasma α -synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010, 25, 489-493.	2.2	93
1076	Pyridostigmine-induced dystonic blepharospasm in a patient with ocular myasthenia gravis. <i>Movement Disorders</i> , 2010, 25, 1299-1300.	2.2	5

#	ARTICLE	IF	CITATIONS
1077	Muscular pain in Parkinson's disease and nociceptive processing assessed with CO ₂ laser-evoked potentials. <i>Movement Disorders</i> , 2010, 25, 213-220.	2.2	44
1078	Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease?. <i>Movement Disorders</i> , 2010, 25, 493-496.	2.2	37
1079	Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study. <i>Movement Disorders</i> , 2010, 25, 882-887.	2.2	43
1080	Incidental Lewy body disease: Clinical comparison to a control cohort. <i>Movement Disorders</i> , 2010, 25, 642-646.	2.2	109
1081	Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. <i>Movement Disorders</i> , 2010, 25, 496-499.	2.2	72
1082	Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1082-1086.	2.2	1
1083	Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1143-1149.	2.2	42
1084	Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. <i>Movement Disorders</i> , 2010, 25, 1086-1090.	2.2	22
1085	Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1091-1096.	2.2	181
1086	Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. <i>Movement Disorders</i> , 2010, 25, 1364-1372.	2.2	77
1087	Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1292-1292.	2.2	7
1088	Camptocormia associated with an expanded allele in the TATA box-binding protein gene. <i>Movement Disorders</i> , 2010, 25, 1293-1295.	2.2	5
1089	Pallidal neuronal activity in diabetic hemichorea-hemiballism. <i>Movement Disorders</i> , 2010, 25, 1295-1297.	2.2	16
1090	Punding in Parkinson's disease: The impact of patient's awareness on diagnosis. <i>Movement Disorders</i> , 2010, 25, 1297-1299.	2.2	16
1091	Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease. <i>Movement Disorders</i> , 2010, 25, 1246-1252.	2.2	71
1092	Sensory alien hand syndrome in corticobasal degeneration: A cerebral blood flow study. <i>Movement Disorders</i> , 2010, 25, 1288-1291.	2.2	10
1093	Dementia with Lewy bodies associated with ataxia, myoclonus, and cortical blindness. <i>Movement Disorders</i> , 2010, 25, 1301-1302.	2.2	0
1094	Paradoxical kinesia in parkinsonian patients surviving earthquake. <i>Movement Disorders</i> , 2010, 25, 1302-1304.	2.2	29

#	ARTICLE	IF	CITATIONS
1095	Dysphagia in symptomatic palatal tremor. <i>Movement Disorders</i> , 2010, 25, 1304-1305.	2.2	4
1096	Paroxysmal kinesigenic dyskinesia sans dyskinesia or paroxysmal kinesigenic dysesthesia?. <i>Movement Disorders</i> , 2010, 25, 1305-1306.	2.2	0
1097	Adult-onset leg dystonia due to a missense mutation in <i>THAP1</i> . <i>Movement Disorders</i> , 2010, 25, 1306-1307.	2.2	21
1098	Reversible hyperkinetic movement disorder associated with quetiapine withdrawal. <i>Movement Disorders</i> , 2010, 25, 1308-1309.	2.2	5
1099	Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study. <i>Movement Disorders</i> , 2010, 25, 1157-1162.	2.2	77
1100	Reduced facial nerve hyperexcitability from contralateral cerebral stroke in hemifacial spasm. <i>Movement Disorders</i> , 2010, 25, 1310-1312.	2.2	4
1101	Isolated continuous lingual myoclonus: unusual presentation of amyotrophic lateral sclerosis. <i>Movement Disorders</i> , 2010, 25, 1309-1310.	2.2	3
1102	Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1150-1156.	2.2	48
1103	Sensory tricks in hemichorea and in Parkinson's disease tremor. <i>Movement Disorders</i> , 2010, 25, 1312-1313.	2.2	6
1104	Enlarged hyperchogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010, 25, 1464-1469.	2.2	45
1105	REM sleep behavior disorder is not linked to postural instability and gait dysfunction in Parkinson. <i>Movement Disorders</i> , 2010, 25, 1597-1604.	2.2	31
1106	Staging of α -synuclein in the olfactory bulb in a model of Parkinson's disease: Cell types involved. <i>Movement Disorders</i> , 2010, 25, 1701-1707.	2.2	24
1107	Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study. <i>Movement Disorders</i> , 2010, 25, 1888-1894.	2.2	101
1108	Retina thickness in Parkinson's disease and essential tremor. <i>Movement Disorders</i> , 2010, 25, 2461-2462.	2.2	57
1109	Acute renal failure in patients with bilateral deep brain stimulation. <i>Movement Disorders</i> , 2010, 25, 2462-2464.	2.2	5
1110	ADEM presenting as a movement disorder. <i>Movement Disorders</i> , 2010, 25, 2464-2466.	2.2	4
1111	Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2099-2104.	2.2	53
1112	Pet findings in reversible improvement of olfactory dysfunction after STN stimulation in a Parkinson's disease patient. <i>Movement Disorders</i> , 2010, 25, 2466-2468.	2.2	6

#	ARTICLE	IF	CITATIONS
1113	Familial nonkinesigenic paroxysmal dyskinesia and intracranial calcifications: A new syndrome?. <i>Movement Disorders</i> , 2010, 25, 2468-2470.	2.2	2
1114	The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2361-2368.	2.2	93
1115	Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. <i>Movement Disorders</i> , 2010, 25, 2470-2472.	2.2	26
1116	Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model. <i>Movement Disorders</i> , 2010, 25, 2508-2515.	2.2	117
1117	Complex hyperkinetic movement disorders associated with <i>POLG</i> mutations. <i>Movement Disorders</i> , 2010, 25, 2472-2475.	2.2	14
1118	Neuroleptic malignant syndrome with aripiprazole in Huntington's disease. <i>Movement Disorders</i> , 2010, 25, 2475-2476.	2.2	7
1119	Electrophysiological evaluation of thalamic DBS for orthostatic tremor. <i>Movement Disorders</i> , 2010, 25, 2476-2477.	2.2	25
1120	Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2010, 25, 2304-2310.	2.2	135
1121	Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2296-2303.	2.2	79
1122	Cardiac denervation in rapid eye movement sleep behavior disorder and Parkinson's disease: Getting to the heart of the matter. <i>Movement Disorders</i> , 2010, 25, 2269-2271.	2.2	6
1123	α -synuclein induced synapse damage is enhanced by amyloid- β 1-42. <i>Molecular Neurodegeneration</i> , 2010, 5, 55.	4.4	43
1124	The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. <i>Synapse</i> , 2010, 64, 241-250.	0.6	32
1125	The sour side of neurodegenerative disorders: the effects of protein glycation. <i>Journal of Pathology</i> , 2010, 221, 13-25.	2.1	138
1126	A deformation-based morphometry study of patients with early-stage Parkinson's disease. <i>European Journal of Neurology</i> , 2010, 17, 314-320.	1.7	80
1127	Sleep disorders in neurodegenerative diseases. <i>European Journal of Neurology</i> , 2010, 17, 1326-1338.	1.7	56
1128	Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. <i>European Journal of Neurology</i> , 2010, 17, 1428-1436.	1.7	98
1129	CHANGES IN THE SERUM BONE METABOLISM MARKERS OF ELDERLY ALCOHOLICS DURING ABSTINENCE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 984-986.	1.3	2
1130	PARKINSON'S DISEASE IN OLDER ADULTS: A NEW SCENARIO FOR THIS OLD ACTOR?. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 982-984.	1.3	4

#	ARTICLE	IF	CITATIONS
1131	Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. <i>Journal of Neurochemistry</i> , 2010, 112, 773-783.	2.1	87
1132	Non-classical exocytosis of α -synuclein is sensitive to folding states and promoted under stress conditions. <i>Journal of Neurochemistry</i> , 2010, 113, 1263-1274.	2.1	241
1133	α -Synuclein expression is induced by depolarization and cyclic AMP in enteric neurons. <i>Journal of Neurochemistry</i> , 2010, 115, 694-706.	2.1	26
1134	Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. <i>Journal of Neurochemistry</i> , 2010, 115, 1363-1373.	2.1	41
1135	Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 407-421.	1.0	96
1136	Serum somatostatin in early-stage Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 225-229.	1.0	6
1137	Protein aggregation in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 82-87.	1.0	26
1138	Brain pathology in three subjects from the same pedigree with presenilin-1 (<i>PSEN1</i>) P264L mutation. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 41-54.	1.8	22
1139	The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. <i>Nature Reviews Neuroscience</i> , 2010, 11, 791-797.	4.9	480
1140	Secrets of the shaking palsy. <i>Nature</i> , 2010, 466, S2-S5.	13.7	15
1141	Missing pieces in the Parkinson's disease puzzle. <i>Nature Medicine</i> , 2010, 16, 653-661.	15.2	621
1142	REM sleep behavior disorder. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 15-54.	1.8	531
1143	The progression of pathology in Parkinson's disease. <i>Annals of the New York Academy of Sciences</i> , 2010, 1184, 188-195.	1.8	214
1144	Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 945-951.	2.1	60
1145	Neuroimaging of Parkinson's disease. , 2010, , 361-370.		0
1146	Current concepts in the management of Parkinson disease. <i>Medical Journal of Australia</i> , 2010, 192, 144-149.	0.8	37
1147	Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease?. <i>Frontiers in Psychiatry</i> , 2010, 1, 128.	1.3	37
1148	Executive dysfunction and motor symptoms in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2010, 68, 246-251.	0.3	20

#	ARTICLE	IF	CITATIONS
1149	Alpha-Synuclein Stimulation of Astrocytes: Potential Role for Neuroinflammation and Neuroprotection. <i>Oxidative Medicine and Cellular Longevity</i> , 2010, 3, 283-287.	1.9	133
1150	Treatment of Advanced Parkinson's Disease. <i>Parkinson's Disease</i> , 2010, 2010, 1-9.	0.6	55
1151	Braak Classification. , 2010, , 150-157.		0
1152	Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. <i>Frontiers in Neuroanatomy</i> , 2010, 4, 140.	0.9	55
1153	Parkinson's Disease: General Features, Effects of Levodopa Treatment and Future Directions. <i>Frontiers in Neuroanatomy</i> , 2010, 4, 146.	0.9	9
1154	Neurologic Signs in the Elderly. , 2010, , 101-105.		1
1155	IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes. <i>Nuklearmedizin - Nuclear Medicine</i> , 2010, 49, 139-147.	0.3	6
1156	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. <i>PLoS ONE</i> , 2010, 5, e11464.	1.1	119
1157	Î±-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra. <i>PLoS ONE</i> , 2010, 5, e12122.	1.1	138
1158	Neuroanatomical Study of the A11 Diencephalospinal Pathway in the Non-Human Primate. <i>PLoS ONE</i> , 2010, 5, e13306.	1.1	82
1159	Temblor ortostático como causa de inestabilidad postural en enfermedad de Parkinson: Caso clínico. <i>Revista Medica De Chile</i> , 2010, 138, 1410-1413.	0.1	0
1160	Olfactory function and Parkinson's disease in Southern Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2010, 68, 252-257.	0.3	22
1161	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2010, , 551-571.		0
1162	Olfactory dysfunction in Parkinson's disease: Benefits of quantitative odorant examination. <i>International Journal of General Medicine</i> , 2010, 3, 181.	0.8	7
1163			

#	ARTICLE	IF	CITATIONS
1167	Recent development of acupuncture on Parkinson's disease. <i>Neurological Research</i> , 2010, 32, 5-9.	0.6	28
1168	FUS mutations in sporadic juvenile ALS: Another step toward understanding ALS pathogenesis. <i>Neurology</i> , 2010, 75, 584-585.	1.5	6
1169	Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. <i>Behavioural Pharmacology</i> , 2010, 21, 627-637.	0.8	70
1170	When Does Parkinson Disease Start?. <i>Archives of Neurology</i> , 2010, 67, 798-801.	4.9	251
1171	Preclinical Assessment of Stem Cell Therapies for Neurological Diseases. <i>ILAR Journal</i> , 2010, 51, 24-41.	1.8	28
1172	Pathology of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 132-154.	0.1	6
1173	Depression Impairs Learning Whereas Anticholinergics Impair Transfer Generalization in Parkinson Patients Tested on Dopaminergic Medications. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 98-105.	0.5	21
1174	Anxiety Affects Working Memory Only in Left Hemibody Onset Parkinson Disease Patients. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 14-18.	0.5	15
1175	Verbal and Visuospatial Memory in Lateral Onset Parkinson Disease: Time is of the Essence. <i>Cognitive and Behavioral Neurology</i> , 2010, 23, 19-25.	0.5	11
1176	The challenge of non-motor symptoms in Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 325-341.	0.9	142
1177	Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1008-1013.	0.9	92
1178	Functional Imaging of Cognitive Impairment in Parkinson's Disease. <i>Clinical EEG and Neuroscience</i> , 2010, 41, 119-126.	0.9	4
1179	Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. <i>Neurology</i> , 2010, 74, 885-892.	1.5	299
1180	Progression from Unilateral to Bilateral Parkinsonism in Early Parkinson Disease: Implication of Mesocortical Dopamine Dysfunction by PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1250-1257.	2.8	37
1181	Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated α -synuclein gene mutations precede central nervous system changes. <i>Human Molecular Genetics</i> , 2010, 19, 1633-1650.	1.4	237
1182	Clinical Criteria for the Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 284-290.	0.8	104
1183	Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains. <i>Journal of Neuroscience</i> , 2010, 30, 6355-6359.	1.7	364
1184	Imaging Approaches to Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2010, 51, 596-609.	2.8	178

#	ARTICLE	IF	CITATIONS
1185	Narcolepsy in Parkinson's disease. Expert Review of Neurotherapeutics, 2010, 10, 879-884.	1.4	28
1186	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. Journal of the International Neuropsychological Society, 2010, 16, 867-876.	1.2	49
1187	Brain α -synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain, 2010, 133, 172-188.	3.7	172
1188	Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert Review of Molecular Diagnostics, 2010, 10, 1035-1050.	1.5	14
1189	Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid- β 242 Levels in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 22, 933-938.	1.2	23
1190	A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 941-952.	0.2	99
1191	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
1192	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain, 2010, 133, 1755-1762.	3.7	349
1193	A meta-analysis of two-dimensional electrophoresis pattern of the Parkinson's disease-related protein DJ-1. Bioinformatics, 2010, 26, 946-952.	1.8	23
1194	Current management of Parkinson's disease. Annals of African Medicine, 2010, 9, 55.	0.2	17
1195	Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology, 2010, 74, 239-244.	1.5	195
1196	Parkinsonism and Other Movement Disorders. , 2010, , 511-519.		1
1197	Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 455-470.	0.8	9
1198	HDAC inhibitors conquer polycomb proteins. Cell Cycle, 2010, 9, 2713-2721.	1.3	29
1199	Multiple non-cell autonomous actions of α -synuclein in neurodegenerative diseases. Cell Cycle, 2010, 9, 2696-2697.	1.3	6
1200	mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: A sensitized matter. Cell Cycle, 2010, 9, 2785-2790.	1.3	21
1201	Using Voluntary Cough To Detect Penetration and Aspiration During Oropharyngeal Swallowing in Patients With Parkinson Disease. Chest, 2010, 138, 1426-1431.	0.4	75
1202	Olfaction as a biomarker in Parkinson's disease. Biomarkers in Medicine, 2010, 4, 661-670.	0.6	42

#	ARTICLE	IF	CITATIONS
1203	Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2010, 16, 2799-2817.	0.9	103
1204	Abnormal metabolic brain networks in Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 160-176.	0.9	26
1205	Dementia with Lewy bodies and Alzheimer disease. <i>Neurology</i> , 2010, 74, 1814-1821.	1.5	195
1206	Surgical management of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 903-914.	1.4	72
1209	Non-mammalian animal models of Parkinson's disease for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 165-176.	2.5	5
1210	Trichloroethylene and Parkinson's disease: dissolving the puzzle. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 835-837.	1.4	25
1211	Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia?. <i>Current Medicinal Chemistry</i> , 2010, 17, 3253-3261.	1.2	24
1212	In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. <i>Neurology</i> , 2010, 74, 77-84.	1.5	165
1213	The decrease of β -synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. <i>Brain</i> , 2010, 133, 3724-3733.	3.7	35
1214	Transcranial Sonography in the Premotor Diagnosis of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2010, 90, 93-106.	0.9	17
1215	Distinct Region-Specific α -Synuclein Oligomers in A53T Transgenic Mice: Implications for Neurodegeneration. <i>Journal of Neuroscience</i> , 2010, 30, 3409-3418.	1.7	89
1216	SPECT and PET in Atypical Parkinsonism. <i>PET Clinics</i> , 2010, 5, 65-74.	1.5	0
1219	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. <i>EMC - Neurologia</i> , 2010, 10, 1-29.	0.0	0
1220	Genetic mouse models of Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 53-87.	0.9	127
1221	Using "omics" to define pathogenesis and biomarkers of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 925-942.	1.4	71
1222	Altered Resting State Cortico-Striatal Connectivity in Mild to Moderate Stage Parkinson's Disease. <i>Frontiers in Systems Neuroscience</i> , 2010, 4, 143.	1.2	173
1223	Nonmotor Aspects of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 229-251.	0.1	9
1224	Development of Parkinson's disease biomarkers. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1811-1825.	1.4	9

#	ARTICLE	IF	CITATIONS
1225	Gastrointestinal dysfunction in Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 69-73.	0.3	180
1226	Brainstem pathology and non-motor symptoms in PD. <i>Journal of the Neurological Sciences</i> , 2010, 289, 81-88.	0.3	137
1227	Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 119-122.	0.3	58
1228	Olfactory system pathology as a model of Lewy neurodegenerative disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 49-54.	0.3	68
1229	Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. <i>NeuroImage</i> , 2010, 51, 512-520.	2.1	143
1230	Hyperammonemia Induces Neuroinflammation That Contributes to Cognitive Impairment in Rats With Hepatic Encephalopathy. <i>Gastroenterology</i> , 2010, 139, 675-684.	0.6	278
1231	Systems of Biology and the Spirit of Tustin [Perspectives]. <i>IEEE Control Systems</i> , 2010, 30, 57-102.	1.0	4
1232	Prion-like disorders: blurring the divide between transmissibility and infectivity. <i>Journal of Cell Science</i> , 2010, 123, 1191-1201.	1.2	268
1233	Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease. <i>International Journal of Speech-Language Pathology</i> , 2010, 12, 405-413.	0.6	18
1234	Deep brain stimulation. <i>Progress in Brain Research</i> , 2010, 184, 311-324.	0.9	56
1235	Transcranial direct current stimulation for the treatment of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1105-1111.	0.9	276
1236	DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726.	3.7	575
1237	Spatial Remapping of Cortico-striatal Connectivity in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1175-1186.	1.6	375
1238	Quantification of α -synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , 2010, 4, 683-699.	0.6	113
1239	Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. <i>Brain</i> , 2010, 133, 1747-1754.	3.7	263
1240	Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. <i>Trends in Molecular Medicine</i> , 2010, 16, 27-36.	3.5	72
1241	Perivascular nerve fiber α -synuclein regulates contractility of mouse aorta: A link to autonomic dysfunction in Parkinson's disease. <i>Neurochemistry International</i> , 2010, 56, 991-998.	1.9	13
1242	Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 469, 357-359.	1.0	105

#	ARTICLE	IF	CITATIONS
1243	The probable relation between <i>Toxoplasma gondii</i> and Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 475, 129-131.	1.0	107
1244	(+)-Cholesten-3-one induces differentiation of neural stem cells into dopaminergic neurons through BMP signaling. <i>Neuroscience Research</i> , 2010, 68, 176-184.	1.0	10
1245	Overgeneral autobiographical memory in Parkinson's disease. <i>Cortex</i> , 2010, 46, 787-793.	1.1	20
1246	Linguistic correlates of asymmetric motor symptom severity in Parkinson's Disease. <i>Brain and Cognition</i> , 2010, 72, 189-196.	0.8	24
1247	Impaired emotion recognition in music in Parkinson's disease. <i>Brain and Cognition</i> , 2010, 74, 58-65.	0.8	28
1248	Behavioral phenotyping of mouse models of Parkinson's disease. <i>Behavioural Brain Research</i> , 2010, 211, 1-10.	1.2	147
1249	Converse modulation of toxic α -synuclein oligomers in living cells by <i>N</i> -benzylidene-benzohydrazide derivatives and ferric iron. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 461-466.	1.0	52
1250	Mechanisms Underlying Inflammation in Neurodegeneration. <i>Cell</i> , 2010, 140, 918-934.	13.5	2,860
1251	Factors related to clinically probable REM sleep behavior disorder in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 105-108.	1.1	79
1252	A timeline for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 79-84.	1.1	470
1253	Hiccups in Parkinson's disease: An overlooked non-motor symptom?. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 249-251.	1.1	17
1254	Probable REM sleep behaviour disorder and STN-DBS outcome in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 265-269.	1.1	16
1255	Selective noradrenergic vulnerability in alpha-synuclein transgenic mice. <i>Neurobiology of Aging</i> , 2010, 31, 2103-2114.	1.5	51
1256	Increased Expression of α -Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis. <i>Neuron</i> , 2010, 65, 66-79.	3.8	885
1257	The Dance of the Perivascular and Endothelial Cells: Mechanisms of Brain Response to Immune Signaling. <i>Neuron</i> , 2010, 65, 4-6.	3.8	22
1258	α -Synuclein at the Synaptic Gate. <i>Neuron</i> , 2010, 65, 3-4.	3.8	9
1259	Genetic Analysis of Pathways to Parkinson Disease. <i>Neuron</i> , 2010, 68, 201-206.	3.8	249
1260	Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. <i>Sleep Medicine</i> , 2010, 11, 361-365.	0.8	65

#	ARTICLE	IF	CITATIONS
1261	Olfactory dysfunction in narcolepsy with and without cataplexy. <i>Sleep Medicine</i> , 2010, 11, 558-561.	0.8	18
1262	A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. <i>Methods</i> , 2010, 52, 359-366.	1.9	24
1263	The propagation of prion-like protein inclusions in neurodegenerative diseases. <i>Trends in Neurosciences</i> , 2010, 33, 317-325.	4.2	402
1264	Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. <i>American Journal of Geriatric Pharmacotherapy</i> , 2010, 8, 294-315.	3.0	63
1265	Ageing and neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2010, 9, S36-S46.	5.0	174
1266	PGC-1 α , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease. <i>Science Translational Medicine</i> , 2010, 2, 52ra73.	5.8	691
1267	Parkinson's Disease: Definition, Diagnosis, and Management. , 2010, , 405-412.		4
1268	Molecular and clinical prodrome of Parkinson disease: implications for treatment. <i>Nature Reviews Neurology</i> , 2010, 6, 309-317.	4.9	166
1269	Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. <i>Pharmaceuticals</i> , 2010, 3, 839-915.	1.7	179
1270	Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 35-51.	0.9	38
1271	Neuroprotection in Parkinson's Disease: a Realistic Goal?. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 327-329.	1.9	9
1272	Viral vector-mediated overexpression of α -synuclein as a progressive model of Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 89-111.	0.9	99
1273	Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis. <i>Expert Review of Proteomics</i> , 2010, 7, 205-226.	1.3	19
1274	Nuclear Receptors, Inflammation, and Neurodegenerative Diseases. <i>Advances in Immunology</i> , 2010, 106, 21-59.	1.1	32
1275	Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 197-205.	1.4	107
1276	Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?. <i>Experimental Neurology</i> , 2010, 225, 48-50.	2.0	0
1277	fMRI correlates of apraxia in Parkinson's disease patients OFF medication. <i>Experimental Neurology</i> , 2010, 225, 416-422.	2.0	24
1278	Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study. <i>NeuroImage</i> , 2010, 49, 772-781.	2.1	78

#	ARTICLE	IF	CITATIONS
1279	Imaging correlates of pathology in corticobasal syndrome. <i>Neurology</i> , 2010, 75, 1879-1887.	1.5	203
1280	Stress-Activated Cap'n'collar Transcription Factors in Aging and Human Disease. <i>Science Signaling</i> , 2010, 3, re3.	1.6	660
1281	5-HT Neurons and Central CO ₂ Chemoreception. <i>Handbook of Behavioral Neuroscience</i> , 2010, , 293-305.	0.7	0
1282	Immunohistology of the Nervous System. , 2010, , 820-889.		8
1283	The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. <i>Progress in Brain Research</i> , 2010, 184, 133-157.	0.9	121
1284	Genetics and Genomics of Dementia. , 2010, , 687-699.		1
1285	Place Value of Transcranial Sonography in Early Diagnosis of Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 291-299.	0.8	11
1286	Levodopa in Parkinson's disease: from the past to the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 627-635.	0.9	54
1287	The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 937-942.	1.2	32
1288	Deep-Brain Stimulation for Neurologic and Psychiatric Disorders. <i>Handbook of Behavioral Neuroscience</i> , 2010, , 659-681.	0.7	4
1289	What have we learned from Drosophila models of Parkinson's disease?. <i>Progress in Brain Research</i> , 2010, 184, 2-16.	0.9	29
1290	Visual-spatial disembedding in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 190-200.	0.8	15
1291	Applying Hsp104 to protein-misfolding disorders This paper is one of a selection of papers published in this special issue entitled 8th International Conference on AAA Proteins and has undergone the Journal's usual peer review process.. <i>Biochemistry and Cell Biology</i> , 2010, 88, 1-13.	0.9	73
1292	REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. <i>Neurology</i> , 2010, 75, 494-499.	1.5	347
1293	Polyamine pathway contributes to the pathogenesis of Parkinson disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16970-16975.	3.3	122
1294	Neuroproteomics and Parkinson's disease: don't forget human samples. <i>Expert Review of Proteomics</i> , 2011, 8, 291-294.	1.3	6
1295	Predictors of HVOT Performance in Parkinson's Disease. <i>Applied Neuropsychology</i> , 2011, 18, 210-215.	1.5	5
1296	Heat shock protein 70 modulates toxic extracellular α -synuclein oligomers and rescues trans-synaptic toxicity. <i>FASEB Journal</i> , 2011, 25, 326-336.	0.2	276

#	ARTICLE	IF	CITATIONS
1297	Brain asymmetry: both sides of the story. <i>Expert Review of Proteomics</i> , 2011, 8, 693-703.	1.3	15
1298	Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. <i>Experimental and Molecular Medicine</i> , 2011, 43, 216.	3.2	117
1299	Use of MRI to monitor Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2011, 1, 67-77.	1.2	3
1300	Premotor Symptoms and Early Diagnosis of Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2011, 121, 3-8.	0.8	20
1301	The treatment of early Parkinson's disease: levodopa rehabilitated. <i>Practical Neurology</i> , 2011, 11, 145-152.	0.5	19
1302	Pupil Light Reflex in Parkinson's Disease: Evaluation With Pupillometry. <i>International Journal of Neuroscience</i> , 2011, 121, 37-43.	0.8	63
1303	Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 297-317.	1.5	79
1304	Cardiovascular Autonomic Dysfunction in Animal Models of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 321-327.	1.5	11
1305	MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. <i>Human Molecular Genetics</i> , 2011, 20, 3067-3078.	1.4	433
1306	Neuronal Hemoglobin is Reduced in Alzheimer's Disease, Argrophilic Grain Disease, Parkinson's Disease, and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 537-550.	1.2	86
1307	REM Sleep Behavior Disorder. <i>Sleep Medicine Clinics</i> , 2011, 6, 459-468.	1.2	1
1309	Deep-brain stimulation for basal ganglia disorders. <i>Basal Ganglia</i> , 2011, 1, 65-77.	0.3	72
1311	Clinical evidence linking coffee and tea intake with Parkinson's disease. <i>Basal Ganglia</i> , 2011, 1, 127-130.	0.3	8
1312	The mesopontine rostromedial tegmental nucleus: An integrative modulator of the reward system. <i>Basal Ganglia</i> , 2011, 1, 191-200.	0.3	50
1313	The primate thalamostriatal systems: Anatomical organization, functional roles and possible involvement in Parkinson's disease. <i>Basal Ganglia</i> , 2011, 1, 179-189.	0.3	57
1314	Convergence of Two Independent Mental Disease Genes on the Protein Level: Recruitment of Dysbindin to Cell-Invasive Disrupted-In-Schizophrenia 1 Aggregates. <i>Biological Psychiatry</i> , 2011, 70, 604-610.	0.7	72
1315	Identifying Consensus Disease Pathways in Parkinson's Disease Using an Integrative Systems Biology Approach. <i>PLoS ONE</i> , 2011, 6, e16917.	1.1	72
1322	Generalization of the Prion Hypothesis to Other Neurodegenerative Diseases: An Imperfect Fit. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2011, 74, 1433-1459.	1.1	63

#	ARTICLE	IF	CITATIONS
1323	Mitochondrial Fission-Fusion and Parkinson's Disease: A Dynamic Question of Compensatory Networks. , 2011, , 197-213.		1
1324	Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. Journal of the Neurological Sciences, 2011, 306, 1-8.	0.3	52
1325	Synuclein deposition and non-motor symptoms in Parkinson disease. Journal of the Neurological Sciences, 2011, 310, 107-111.	0.3	85
1326	View point: Etiology in Parkinson's disease. Dual hit or spreading intoxication. Journal of the Neurological Sciences, 2011, 310, 9-11.	0.3	56
1327	Progress in defining the premotor phase of Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 4-8.	0.3	47
1328	Neuropsychological correlates of olfactory dysfunction in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 228-230.	0.3	18
1329	Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. Journal of the Neurological Sciences, 2011, 310, 112-117.	0.3	26
1330	Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: Four cases. Journal of the Neurological Sciences, 2011, 310, 100-106.	0.3	29
1331	Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 21-24.	0.3	111
1332	Emotion recognition impairment in Parkinson's disease patients without dementia. Journal of the Neurological Sciences, 2011, 310, 237-240.	0.3	43
1333	Dopamine-depletion and increased α -synuclein load induce degeneration of cortical cholinergic fibers in mice. Journal of the Neurological Sciences, 2011, 310, 90-95.	0.3	25
1334	Is there a need to redefine Parkinson's disease?. Journal of the Neurological Sciences, 2011, 310, 2-3.	0.3	3
1335	Instrumental activities of daily living in Parkinson's disease dementia as compared with Alzheimer's disease: Relationship to motor disability and cognitive deficits: A pilot study. Journal of the Neurological Sciences, 2011, 310, 279-282.	0.3	23
1336	Sleep-wake changes in the premotor stage of Parkinson disease. Journal of the Neurological Sciences, 2011, 310, 283-285.	0.3	37
1337	Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 70-74.	0.3	71
1338	Patterns of cortical thickness and surface area in early Parkinson's disease. NeuroImage, 2011, 55, 462-467.	2.1	162
1339	Parkinson's Disease: Genetics and Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 193-222.	9.6	654
1340	The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson's Disease. Drugs, 2011, 71, 273-286.	4.9	57

#	ARTICLE	IF	CITATIONS
1345	Neurogenesis in the Adult Brain II. , 2011, , .		3
1346	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
1347	Impaired GABA and Glycine Transmission Triggers Cardinal Features of Rapid Eye Movement Sleep Behavior Disorder in Mice. Journal of Neuroscience, 2011, 31, 7111-7121.	1.7	111
1348	Basal Ganglia. , 2011, , 495-564.		3
1350	Biomaterials for Central Nervous System Regeneration. , 2011, , 455-466.		1
1351	Diagnostic Findings. , 2011, , 103-187.		0
1352	Animal Models of Movement Disorders. Neuromethods, 2011, , .	0.2	14
1353	Impact of omega-3 fatty acids in Parkinson's disease. Ageing Research Reviews, 2011, 10, 453-463.	5.0	98
1354	Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis. American Journal of Pathology, 2011, 179, 2152-2156.	1.9	33
1355	Evaluation of cerebral vasomotor reactivity in Parkinson's disease: Is there any association with orthostatic hypotension?. Clinical Neurology and Neurosurgery, 2011, 113, 368-372.	0.6	12
1356	Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders. Clinical Neurophysiology, 2011, 122, 2426-2432.	0.7	10
1357	Is neurophysiology a valuable marker of pre-clinical stages of Lewy Body Disorders?. Clinical Neurophysiology, 2011, 122, 2330-2331.	0.7	0
1358	Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. European Journal of Radiology, 2011, 77, 269-273.	1.2	99
1359	Circadian rhythm of rest activity and autonomic nervous system activity at different stages in Parkinson's disease. Autonomic Neuroscience: Basic and Clinical, 2011, 165, 195-200.	1.4	61
1360	The cholinergic system and Parkinson disease. Behavioural Brain Research, 2011, 221, 564-573.	1.2	432
1361	Drug treatment and familiar music aids an attention shift from vision to somatosensation in Parkinson's disease on the reach-to-eat task. Behavioural Brain Research, 2011, 217, 391-398.	1.2	27
1362	Modeling Parkinson's disease genetics: Altered function of the dopamine system in Adh4 knockout mice. Behavioural Brain Research, 2011, 217, 439-445.	1.2	12
1363	Spinal cord and parkinsonism: Neuromorphological evidences in humans and experimental studies. Journal of Chemical Neuroanatomy, 2011, 42, 327-340.	1.0	14

#	ARTICLE	IF	CITATIONS
1364	A novel mechanism of non-A β component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). <i>Neurochemistry International</i> , 2011, 58, 206-214.	1.9	20
1365	Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α -synuclein in a cellular model of Parkinson's disease. <i>Neurochemistry International</i> , 2011, 58, 785-793.	1.9	34
1366	Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats. <i>Neurochemistry International</i> , 2011, 58, 839-849.	1.9	34
1367	Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. <i>Neuroscience Letters</i> , 2011, 487, 153-157.	1.0	16
1368	Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α -synuclein fibril formation. <i>Neuroscience Letters</i> , 2011, 491, 48-52.	1.0	15
1369	Age- and duration-dependent effects of MPTP on cortical serotonin systems. <i>Neuroscience Letters</i> , 2011, 504, 160-164.	1.0	7
1370	Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. <i>Neuroscience Research</i> , 2011, 70, 339-348.	1.0	154
1371	Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. <i>NeuroToxicology</i> , 2011, 32, 215-226.	1.4	74
1372	Biochemical and toxicological evidence of neurological effects of pesticides: The example of Parkinson's disease. <i>NeuroToxicology</i> , 2011, 32, 383-391.	1.4	110
1373	Gender-Related Patterns of Dysprosody in Parkinson Disease and Correlation Between Speech Variables and Motor Symptoms. <i>Journal of Voice</i> , 2011, 25, 76-82.	0.6	73
1374	Intonation and Speech Rate in Parkinson's Disease: General and Dynamic Aspects and Responsiveness to Levodopa Admission. <i>Journal of Voice</i> , 2011, 25, e199-e205.	0.6	95
1375	A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. <i>Molecular and Cellular Neurosciences</i> , 2011, 46, 597-606.	1.0	68
1376	Animal Models of Neurodegenerative Diseases. <i>Advances in Neurobiology</i> , 2011, , 49-101.	1.3	0
1377	Sleep disorders and the natural history of Parkinson's disease: The contribution of epidemiological studies. <i>Sleep Medicine Reviews</i> , 2011, 15, 41-50.	3.8	86
1378	Glucocerebrosidase mutations in diffuse Lewy body disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 55-57.	1.1	43
1379	Parkinson's disease: The non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 717-723.	1.1	313
1380	Subclinical signs in LRRK2 mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 528-532.	1.1	33
1381	The serotonergic system in Parkinson's disease. <i>Progress in Neurobiology</i> , 2011, 95, 163-212.	2.8	156

#	ARTICLE	IF	CITATIONS
1382	Imaging biomarkers in Parkinson's disease. <i>Progress in Neurobiology</i> , 2011, 95, 614-628.	2.8	151
1383	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. <i>Progress in Neurobiology</i> , 2011, 95, 649-662.	2.8	47
1384	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. <i>Progress in Neurobiology</i> , 2011, 95, 601-613.	2.8	32
1385	Epigenetics in neurodegeneration: A new layer of complexity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 348-355.	2.5	84
1386	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. <i>Neurobiology of Aging</i> , 2011, 32, 631-645.	1.5	32
1387	Novel role of transglutaminase 1 in corpora amylacea formation?. <i>Neurobiology of Aging</i> , 2011, 32, 845-856.	1.5	35
1388	Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?. <i>Neurobiology of Aging</i> , 2011, 32, 857-863.	1.5	136
1389	Constructing and Deconstructing Stem Cell Models of Neurological Disease. <i>Neuron</i> , 2011, 70, 626-644.	3.8	141
1390	Exogenous α -Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. <i>Neuron</i> , 2011, 72, 57-71.	3.8	1,249
1391	Serotonin-dependent depression in Parkinson's disease: A role for the subthalamic nucleus?. <i>Neuropharmacology</i> , 2011, 61, 387-399.	2.0	68
1392	Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction. <i>Neuroscience</i> , 2011, 172, 379-386.	1.1	23
1394	Daytime sleepiness in mild Alzheimer's disease with and without parkinsonian features. <i>Sleep Medicine</i> , 2011, 12, 397-402.	0.8	11
1396	Sensory Symptoms. , 2011, , 73-77.		1
1397	An in-Depth Look at the Non Motor Symptom Scale. , 2011, , 37-43.		0
1399	Severe Alterations in Lipid Composition of Frontal Cortex Lipid Rafts from Parkinson's Disease and Incidental Parkinson's Disease. <i>Molecular Medicine</i> , 2011, 17, 1107-1118.	1.9	308
1400	Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 345-367.	1.9	28
1401	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	1.9	61
1402	The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain. <i>Brain</i> , 2011, 134, 3249-3263.	3.7	103

#	ARTICLE	IF	CITATIONS
1403	Dopaminergic imaging: clinical utility now and in the future. <i>International Psychogeriatrics</i> , 2011, 23, S32-S40.	0.6	9
1404	Interaction between $\hat{\iota}$ -synuclein and tau in Parkinson's disease. <i>Experimental Neurology</i> , 2011, 227, 13-18.	2.0	20
1405	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011, 7, e60-e76.	0.4	75
1406	Loss-of-Function Rodent Models for Parkin and PINK1. <i>Journal of Parkinson's Disease</i> , 2011, 1, 229-251.	1.5	30
1407	O ciclo da vesícula sináptica, espinhos dendríticos e a transdução de sinal. <i>Medicina</i> , 2011, 44, 157-171.	0.0	0
1408	The Potential of Neurotrophic Factors for the Treatment of Parkinson's Disease. , 2011, , .		1
1409	Pesticides and Parkinson's Disease. , 0, , .		3
1410	Excessive daytime sleepiness in a prevalent population of people with Parkinson's disease. <i>British Journal of Neuroscience Nursing</i> , 2011, 7, 629-633.	0.1	2
1411	Effects of Alpha-Synuclein on Cellular Homeostasis. , 0, , .		0
1413	Cell Death in the Olfactory System. , 0, , 194-200.		0
1414	Dementia and parkinsonism. , 2011, , 74-83.		0
1415	The Noradrenergic System is a Major Component in Parkinson's Disease. , 0, , .		1
1416	El núcleo subtalámico en la fisiopatología de la enfermedad de Parkinson y su rol como diana quirúrgica. <i>Revista Chilena De Neuro-Psiquiatria</i> , 2011, 49, 62-68.	0.0	2
1417	Trastornos autonómicos en enfermedad de Parkinson. <i>Revista Medica De Chile</i> , 2011, 139, 100-106.	0.1	2
1418	Interaction between $\hat{\iota}$ -Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 271-276.	1.5	14
1419	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 277-286.	1.5	106
1420	Idiopathic REM Sleep Behavior Disorder: Implications for the Pathogenesis of Lewy Body Diseases. <i>Parkinson's Disease</i> , 2011, 2011, 1-8.	0.6	8
1421	Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. <i>Experimental Neurobiology</i> , 2011, 20, 181-188.	0.7	39

#	ARTICLE	IF	CITATIONS
1422	Mitochondria and Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	0.6	3
1423	Estudio de correlación clínicoradiológica, sensibilidad y especificidad de ecotomografía transcraneana en enfermedad de Parkinson y otros trastornos del movimiento. Revista Medica De Chile, 2011, 139, 54-59.	0.1	2
1424	Pesticides and Parkinson's Disease. , 2011, , .		0
1425	Combinations of Markers Provide Clues to the Underlying Neurodegenerative Disorder in REM Sleep Behavior Disorder. , 0, , .		0
1426	Nocturnal Disturbances in Patients with Parkinson's Disease. , 0, , .		1
1427	Psychiatric disorders in primary focal dystonia and in Parkinson's disease. Neuropsychiatric Disease and Treatment, 2011, 7, 111.	1.0	7
1428	Effects of Human Alpha-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease. Parkinson's Disease, 2011, 2011, 1-11.	0.6	44
1429	VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-9.	0.6	75
1430	Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-13.	0.6	51
1431	Olfactory Loss in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-6.	0.6	78
1432	Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders. Scientific World Journal, The, 2011, 11, 1893-1907.	0.8	57
1434	Sleep disturbances in Parkinson's disease patients and management options. Nature and Science of Sleep, 2011, 3, 125.	1.4	20
1435	Alpha-Synuclein and the Immune Response in Parkinson's Disease. , 0, , .		1
1436	Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Scientific World Journal, The, 2011, 11, 1726-1734.	0.8	76
1437	Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	0.6	1
1438	Mitochondrial Dysfunction in Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-18.	0.6	100
1439	Mitochondrial Fusion/Fission, Transport and Autophagy in Parkinson's Disease: When Mitochondria Get Nasty. Parkinson's Disease, 2011, 2011, 1-13.	0.6	43
1440	Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease. Frontiers in Endocrinology, 2011, 2, 82.	1.5	9

#	ARTICLE	IF	CITATIONS
1441	Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling. <i>Frontiers in Neuroanatomy</i> , 2011, 5, 38.	0.9	18
1442	L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 71.	1.0	147
1443	Brainstem: Neglected Locus in Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2011, 2, 42.	1.1	69
1444	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 395-415.	1.2	24
1445	Diagnosis and Differential Diagnosis of Parkinson's Disease. , 0, , .		2
1446	Drug discovery in Parkinson's disease: update and developments in the use of cellular models. <i>International Journal of High Throughput Screening</i> , 2011, 2011, 15.	0.5	19
1447	Epidemiological Neuropathology: The MRC Cognitive Function and Aging Study Experience. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 359-372.	1.2	106
1448	Etiology and Pathogenesis of Parkinson's Disease. , 2011, , .		0
1449	Dementia in Parkinson's Disease: A Clinical Review. <i>American Journal of Neuroscience</i> , 2011, 2, 35-47.	0.4	3
1450	Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction. <i>Anatomy and Cell Biology</i> , 2011, 44, 135.	0.5	13
1451	Assessment of α -Synuclein Secretion in Mouse and Human Brain Parenchyma. <i>PLoS ONE</i> , 2011, 6, e22225.	1.1	145
1452	Oxidation of DJ-1 Induced by 6-Hydroxydopamine Decreasing Intracellular Glutathione. <i>PLoS ONE</i> , 2011, 6, e27883.	1.1	29
1454	Synphilin-1-Binding Protein NUB1 is Colocalized With Nonfibrillar, Proteinase K-Resistant α -Synuclein in Presynapses in Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 879-889.	0.9	15
1455	Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration. <i>Current Medicinal Chemistry</i> , 2011, 18, 2459-2476.	1.2	80
1456	Glycosaminoglycans, Protein Aggregation and Neurodegeneration. <i>Current Protein and Peptide Science</i> , 2011, 12, 258-268.	0.7	36
1457	Localization of MAP1-LC3 in Vulnerable Neurons and Lewy Bodies in Brains of Patients With Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 264-280.	0.9	55
1458	A Review of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson's Disease and a Proposal of Preliminary Research Criteria. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 393-406.	1.2	42
1459	Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 960-969.	0.9	1,562

#	ARTICLE	IF	CITATIONS
1460	Stereopsis in Drug Naïve Parkinson's Disease Patients. Canadian Journal of Neurological Sciences, 2011, 38, 299-302.	0.3	24
1461	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.. Neuropsychology, 2011, 25, 114-124.	1.0	88
1462	Frequency and Characteristics of Taste Impairment in Patients with Parkinson's Disease: Results of a Clinical Interview. Internal Medicine, 2011, 50, 2311-2315.	0.3	36
1463	Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Reports, 2011, 2011, bcr0120113685-bcr0120113685.	0.2	20
1464	Animal Models of Gastrointestinal Problems in Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 137-149.	1.5	11
1469	Longitudinal Study of Cognitive Function in Idiopathic REM Sleep Behavior Disorder. Sleep, 0, , .	0.6	36
1470	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology, 2011, 43, 93-102.	0.3	7
1471	Neurodegenerative disease and adult neurogenesis. European Journal of Neuroscience, 2011, 33, 1139-1151.	1.2	352
1472	Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology, 2011, 31, 561-568.	0.7	60
1473	Comparison of the clinical features of rapid eye movement sleep behavior disorder in patients with Parkinson's disease and multiple system atrophy. Psychiatry and Clinical Neurosciences, 2011, 65, 264-271.	1.0	38
1474	Anhedonia in Japanese patients with Parkinson's disease. Geriatrics and Gerontology International, 2011, 11, 275-281.	0.7	15
1475	LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathology and Applied Neurobiology, 2011, 37, 777-790.	1.8	44
1476	Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease. Neuropathology and Applied Neurobiology, 2011, 37, 791-802.	1.8	40
1477	DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity. Journal of Neurochemistry, 2011, 117, 375-387.	2.1	71
1478	Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. Journal of Neurochemistry, 2011, 118, 326-338.	2.1	20
1479	Mutant α -synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Aging Cell, 2011, 10, 255-262.	3.0	28
1480	A magnetization transfer study of mild and advanced Parkinson's disease. European Journal of Neurology, 2011, 18, 471-477.	1.7	33
1481	Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. European Journal of Neurology, 2011, 18, 590-596.	1.7	54

#	ARTICLE	IF	CITATIONS
1482	TREATMENT OF TAUNTING BEHAVIOR IN VASCULAR DEMENTIA WITH VALPROIC ACID. Journal of the American Geriatrics Society, 2011, 59, 929-930.	1.3	4
1483	COMBINED USE OF CARDIAC M-1123-IODOBENZYLGUANIDINE SCINTIGRAPHY AND 123I-FP-CIT SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY IN OLDER ADULTS WITH RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER. Journal of the American Geriatrics Society, 2011, 59, 928-929.	1.3	11
1484	Microglial cell origin and phenotypes in health and disease. Nature Reviews Immunology, 2011, 11, 775-787.	10.6	897
1485	Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nature Reviews Neuroscience, 2011, 12, 359-366.	4.9	358
1486	The role of immunity in Huntington's disease. Molecular Psychiatry, 2011, 16, 889-902.	4.1	54
1487	Presence of Tissue Transglutaminase in Granular Endoplasmic Reticulum is Characteristic of Melanized Neurons in Parkinson's Disease Brain. Brain Pathology, 2011, 21, 130-139.	2.1	51
1488	Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenes. Journal of Cellular and Molecular Medicine, 2011, 15, 701-717.	1.6	50
1489	LRRK2 signaling pathways: the key to unlocking neurodegeneration?. Trends in Cell Biology, 2011, 21, 257-265.	3.6	73
1490	Î±-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease. Neurobiology of Disease, 2011, 41, 71-82.	2.1	36
1491	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiology of Disease, 2011, 42, 360-367.	2.1	612
1492	Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiology of Disease, 2011, 43, 690-697.	2.1	102
1493	Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiology of Disease, 2011, 44, 192-204.	2.1	28
1495	Functional network disruption in the degenerative dementias. Lancet Neurology, The, 2011, 10, 829-843.	4.9	422
1496	Pathological roles of Î±-synuclein in neurological disorders. Lancet Neurology, The, 2011, 10, 1015-1025.	4.9	328
1497	Advances in imaging in Parkinson's disease. Lancet Neurology, The, 2011, 10, 987-1001.	4.9	99
1498	Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Molecular Brain, 2011, 4, 43.	1.3	39
1499	Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Research, 2011, 1373, 240-252.	1.1	96
1500	Differential expression of 14-3-3 protein isoforms in developing rat hippocampus, cortex, rostral migratory stream, olfactory bulb, and white matter. Brain Research, 2011, 1410, 1-11.	1.1	16

#	ARTICLE	IF	CITATIONS
1501	Preservation of function in Parkinson's disease: What's learning got to do with it?. <i>Brain Research</i> , 2011, 1423, 96-113.	1.1	27
1502	Sleep problems in Parkinson's disease patients. <i>Neurodegenerative Disease Management</i> , 2011, 1, 307-321.	1.2	2
1504	Genetic Models of Parkinson's Disease. <i>Neuromethods</i> , 2011, , 243-265.	0.2	1
1505	Recent Advances in the Genetics of Parkinson's Disease. <i>Annual Review of Genomics and Human Genetics</i> , 2011, 12, 301-325.	2.5	355
1507	Î±-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 715-725.	3.9	722
1508	Mild cognitive impairment in Parkinson's disease: a critical update. <i>Aging Health</i> , 2011, 7, 103-106.	0.3	4
1509	Molecular Imaging and the Neuropathologies of Parkinson's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 11, 117-148.	0.8	14
1510	The national DBS brain tissue network pilot study: need for more tissue and more standardization. <i>Cell and Tissue Banking</i> , 2011, 12, 219-231.	0.5	18
1511	Experimental Modeling of Functional Deficiency of the Nigrostriatal Dopaminergic System in Mice. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 671-679.	0.2	1
1512	Mice Lacking Major Brain Gangliosides Develop Parkinsonism. <i>Neurochemical Research</i> , 2011, 36, 1706-1714.	1.6	101
1513	Evaluation of Markers of Oxidative Stress, Antioxidant Function and Astrocytic Proliferation in the Striatum and Frontal Cortex of Parkinson's Disease Brains. <i>Neurochemical Research</i> , 2011, 36, 1452-1463.	1.6	129
1514	Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. <i>Acta Neuropathologica</i> , 2011, 121, 39-57.	3.9	105
1515	The pathological process underlying Alzheimer's disease in individuals under thirty. <i>Acta Neuropathologica</i> , 2011, 121, 171-181.	3.9	654
1516	Changes in the solubility and phosphorylation of Î±-synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	3.9	108
1517	A peculiar constellation of tau pathology defines a subset of dementia in the elderly. <i>Acta Neuropathologica</i> , 2011, 122, 205-222.	3.9	80
1518	Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. <i>Acta Neuropathologica</i> , 2011, 122, 75-86.	3.9	127
1519	Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. <i>Acta Neuropathologica</i> , 2011, 122, 61-74.	3.9	151
1520	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	3.9	357

#	ARTICLE	IF	CITATIONS
1521	Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. <i>Acta Neuropathologica</i> , 2011, 122, 577-589.	3.9	95
1522	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. <i>Acta Neuropathologica</i> , 2011, 122, 737-745.	3.9	15
1523	Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 50-55.	1.8	48
1524	Gene therapy: a viable therapeutic strategy for Parkinson's disease?. <i>Journal of Neurology</i> , 2011, 258, 179-188.	1.8	25
1525	Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?. <i>Journal of Neurology</i> , 2011, 258, 982-990.	1.8	89
1526	Taste function in patients with Parkinson disease. <i>Journal of Neurology</i> , 2011, 258, 1076-1079.	1.8	37
1527	Basic science in Parkinson's disease: its impact on clinical practice. <i>Journal of Neurology</i> , 2011, 258, 299-306.	1.8	6
1528	Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1871-1876.	1.8	23
1529	Vagus nerve somatosensory evoked potentials in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 2276-2277.	1.8	16
1530	Genetic variability in SNCA and Parkinson's disease. <i>Neurogenetics</i> , 2011, 12, 283-293.	0.7	30
1531	Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. <i>Journal of Neural Transmission</i> , 2011, 118, 821-839.	1.4	156
1532	Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. <i>Journal of Neural Transmission</i> , 2011, 118, 809-819.	1.4	25
1533	Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. <i>Journal of Neural Transmission</i> , 2011, 118, 613-619.	1.4	27
1534	Striatal β -amyloid in dementia with Lewy bodies but not Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 713-719.	1.4	82
1535	Mild cognitive impairment exists in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 1179-1183.	1.4	7
1536	Dream features in the early stages of Parkinson's Disease. <i>Journal of Neural Transmission</i> , 2011, 118, 1613-1619.	1.4	35
1537	Parkinson's disease mouse models in translational research. <i>Mammalian Genome</i> , 2011, 22, 401-419.	1.0	65
1538	Next-Generation Sequencing Reveals Regional Differences of the α -Synuclein Methylation State Independent of Lewy Body Disease. <i>NeuroMolecular Medicine</i> , 2011, 13, 310-320.	1.8	61

#	ARTICLE	IF	CITATIONS
1539	JNK Isoforms Differentially Regulate Neurite Growth and Regeneration in Dopaminergic Neurons In Vitro. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 284-293.	1.1	27
1540	Molecular Dissection of TDP-43 Proteinopathies. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 480-485.	1.1	49
1541	Spinocerebellar Ataxia Type 2 (SCA2): Identification of Early Brain Degeneration in One Monozygous Twin in the Initial Disease Stage. <i>Cerebellum</i> , 2011, 10, 245-253.	1.4	26
1542	Torpedoes in the Cerebellar Vermis in Essential Tremor Cases vs. Controls. <i>Cerebellum</i> , 2011, 10, 812-819.	1.4	74
1543	Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions. <i>Neurotoxicity Research</i> , 2011, 19, 211-234.	1.3	25
1544	Neuroimaging in Parkinson's Disease. <i>Neurotherapeutics</i> , 2011, 8, 72-81.	2.1	59
1545	Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?. <i>Brain Imaging and Behavior</i> , 2011, 5, 25-35.	1.1	30
1546	A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2011, 5, 203-211.	1.1	12
1547	An Update on Gene Therapy in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 362-370.	2.0	25
1548	Mild Cognitive Impairment in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 371-378.	2.0	131
1549	Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. <i>BMC Neuroscience</i> , 2011, 12, 79.	0.8	31
1550	Pros and cons of a prion-like pathogenesis in Parkinson's disease. <i>BMC Neurology</i> , 2011, 11, 74.	0.8	13
1551	Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. <i>BMC Neurology</i> , 2011, 11, 88.	0.8	46
1552	CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2011, 8, 154.	3.1	118
1553	Dopamine and α -synuclein dysfunction in Smad3 null mice. <i>Molecular Neurodegeneration</i> , 2011, 6, 72.	4.4	48
1554	Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. <i>Molecular Neurodegeneration</i> , 2011, 6, 83.	4.4	30
1555	Tremor's some controversial aspects. <i>Movement Disorders</i> , 2011, 26, 18-23.	2.2	169
1556	Clinical correlates of similar pathologies in parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 499-506.	2.2	17

#	ARTICLE	IF	CITATIONS
1557	Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study. <i>Movement Disorders</i> , 2011, 26, 59-64.	2.2	30
1558	The most cited works in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 380-390.	2.2	54
1559	Glia: Initiators and progressors of pathology in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 6-17.	2.2	383
1560	Facilitated temporal summation of pain at spinal level in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 442-448.	2.2	51
1561	The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 653-658.	2.2	138
1562	Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 621-628.	2.2	72
1563	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.	2.2	128
1564	Milestones in Parkinson's disease—Clinical and pathologic features. <i>Movement Disorders</i> , 2011, 26, 1015-1021.	2.2	150
1565	Cardiac autonomic denervation in Parkinson's disease is linked to REM sleep behavior disorder. <i>Movement Disorders</i> , 2011, 26, 1529-1533.	2.2	73
1566	Acoustic assessment of voice and speech disorders in Parkinson's disease through quick vocal test. <i>Movement Disorders</i> , 2011, 26, 1951-1952.	2.2	40
1567	THAP1 mutations are infrequent in spasmodic dysphonia. <i>Movement Disorders</i> , 2011, 26, 1952-1954.	2.2	12
1568	Successful deep brain stimulation in a case of posttraumatic tremor and hemiparkinsonism. <i>Movement Disorders</i> , 2011, 26, 1954-1955.	2.2	18
1569	Lack of association of the <i>UCHL1</i> gene with Parkinson's disease in a greek cohort: A haplotype-tagging approach. <i>Movement Disorders</i> , 2011, 26, 1955-1957.	2.2	2
1570	Development of Holmes' tremor following hemispheric cerebellar infarction. <i>Movement Disorders</i> , 2011, 26, 1957-1959.	2.2	11
1571	Palatal tremor visualized by cine MRI. <i>Movement Disorders</i> , 2011, 26, 1959-1960.	2.2	0
1572	Fragile X-associated tremor ataxia syndrome sine tremor. <i>Movement Disorders</i> , 2011, 26, 1960-1962.	2.2	2
1573	Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2011, 26, 1717-1724.	2.2	78
1574	Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1677-1683.	2.2	14

#	ARTICLE	IF	CITATIONS
1575	Severe intracranial bleeding related to vitamin K Antagonistâ€Ropinirole interaction. Movement Disorders, 2011, 26, 1962-1963.	2.2	2
1576	Action observation treatment improves autonomy in daily activities in Parkinson's disease patients: Results from a pilot study. Movement Disorders, 2011, 26, 1963-1964.	2.2	78
1577	Mood and cognition in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease. Movement Disorders, 2011, 26, 1875-1880.	2.2	40
1578	Progressive supranuclear palsyâ€like phenotype caused by progranulin p.Thr272fs mutation. Movement Disorders, 2011, 26, 1964-1966.	2.2	20
1579	Has â€levodopaâ€induced neuropathyâ€been reported in Parkinson's disease clinical trials?. Movement Disorders, 2011, 26, 1966-1967.	2.2	9
1580	Relationship between sleep and dysautonomic symptoms assessed by selfâ€report scales. Movement Disorders, 2011, 26, 1967-1968.	2.2	6
1581	Parkinson's disease, proteins, and prions: Milestones. Movement Disorders, 2011, 26, 1056-1071.	2.2	36
1582	Olfactory deficits and cardiac ¹²³ Iâ€MIBG in Parkinson's disease related to the <i>LRRK2</i> /i> R1441G and G2019S mutations. Movement Disorders, 2011, 26, 2026-2031.	2.2	51
1583	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Movement Disorders, 2011, 26, 2051-2057.	2.2	67
1584	Do nonmotor symptoms in Parkinson's disease differ from normal aging?. Movement Disorders, 2011, 26, 2110-2113.	2.2	75
1585	Reply: Cortically evoked responses of human pallidal neurons. Movement Disorders, 2011, 26, 2583-2584.	2.2	0
1586	Cortically evoked responses of human pallidal neurons. Movement Disorders, 2011, 26, 2583-2583.	2.2	1
1587	Parkinson's disease and Î±â€synuclein expression. Movement Disorders, 2011, 26, 2160-2168.	2.2	186
1588	Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2584-2585.	2.2	2
1589	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	2.2	0
1590	Cell Transplantation and Gene Therapy in Parkinson's Disease. Mount Sinai Journal of Medicine, 2011, 78, 126-158.	1.9	43
1591	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 2011, 69, 655-663.	2.8	126
1592	Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Annals of Neurology, 2011, 69, 811-818.	2.8	213

#	ARTICLE	IF	CITATIONS
1593	Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. <i>Annals of Neurology</i> , 2011, 70, 532-540.	2.8	536
1594	Development of bladder dysfunction in a rat model of dopaminergic brain lesion. <i>Neurourology and Urodynamics</i> , 2011, 30, 188-193.	0.8	33
1595	Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic parkinson syndrome and healthy controls. <i>Human Brain Mapping</i> , 2011, 32, 1905-1915.	1.9	122
1596	Synphilin suppresses α -synuclein neurotoxicity in a Parkinson's disease Drosophila model. <i>Genesis</i> , 2011, 49, 392-402.	0.8	23
1597	Identification of blood microRNAs associated to Parkinson's disease. <i>Journal of Biotechnology</i> , 2011, 152, 96-101.	1.9	244
1598	Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. <i>Brain</i> , 2011, 134, 2057-2073.	3.7	103
1599	Olfactory dysfunction in <i>LRRK2</i> G2019S mutation carriers. <i>Neurology</i> , 2011, 77, 319-324.	1.5	70
1600	Demise of the Flies. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 100, 483-498.	0.9	6
1601	Sleep disorders in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 99, 997-1010.	1.0	6
1602	Experimental Models of L-DOPA-Induced Dyskinesia. <i>International Review of Neurobiology</i> , 2011, 98, 55-93.	0.9	4
1604	Deglutition and Cough in Different Degrees of Parkinson Disease. <i>Arquivos Internacionais De Otorrinolaringologia</i> , 2011, 15, 181-188.	0.2	7
1606	Evaluation and management of the non-motor features of Parkinson's disease. <i>Therapeutic Advances in Chronic Disease</i> , 2011, 2, 69-85.	1.1	21
1608	Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. <i>Neurology</i> , 2011, 77, 101-109.	1.5	84
1609	Novel therapy in Parkinson's disease: adenosine A_{2A} receptor antagonists. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 441-455.	1.5	24
1610	Early and Presenting Symptoms of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 202-208.	0.7	77
1611	Hsc70 Protein Interaction with Soluble and Fibrillar α -Synuclein. <i>Journal of Biological Chemistry</i> , 2011, 286, 34690-34699.	1.6	103
1612	10 Commonly Asked Questions About Parkinson Disease. <i>Neurologist</i> , 2011, 17, 57-62.	0.4	0
1613	Neuroprotective Role of Dopamine Agonists. <i>Neurologist</i> , 2011, 17, S54-S66.	0.4	21

#	ARTICLE	IF	CITATIONS
1614	Peroxiredoxin-2 Protects against 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration via Attenuation of the Apoptosis Signal-Regulating Kinase (ASK1) Signaling Cascade. <i>Journal of Neuroscience</i> , 2011, 31, 247-261.	1.7	136
1615	Mouse Models of Cognitive Deficits Due to Alpha-Synuclein Pathology. <i>Journal of Parkinson's Disease</i> , 2011, 1, 217-227.	1.5	20
1616	GDNF and protection of adult central catecholaminergic neurons. <i>Journal of Molecular Endocrinology</i> , 2011, 46, R83-R92.	1.1	59
1617	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.9	125
1618	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. <i>Brain</i> , 2011, 134, 1493-1505.	3.7	497
1619	Prospective Research on Parkinson Nonmotor Symptoms—Reply. <i>Archives of Neurology</i> , 2011, 68, 135.	4.9	0
1620	Prospective Research on Parkinson Nonmotor Symptoms. <i>Archives of Neurology</i> , 2011, 68, 135.	4.9	3
1621	Ecology of the Aging Human Brain. <i>Archives of Neurology</i> , 2011, 68, 1049.	4.9	161
1622	Structural Brain Abnormalities in Patients with Parkinson Disease: A Comparative Voxel-Based Analysis Using T1-Weighted MR Imaging and Magnetization Transfer Imaging. <i>American Journal of Neuroradiology</i> , 2011, 32, 2080-2086.	1.2	30
1623	Sleep Disturbance in Dementia with Lewy Bodies and Alzheimer's Disease: A Multicenter Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 239-246.	0.7	75
1624	Prevalence and Pathology of Dementia with Lewy Bodies in the Oldest Old: A Comparison with Other Dementing Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 309-316.	0.7	39
1625	Correlation between Progressive Changes in Piriform Cortex and Olfactory Performance in Early Parkinson's Disease. <i>European Neurology</i> , 2011, 66, 98-105.	0.6	51
1626	Î±-Synuclein in Parkinson disease and other neurodegenerative disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 403-408.	1.4	63
1627	Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 157-163.	1.7	186
1628	A Prospective Study of Bowel Movement Frequency and Risk of Parkinson's Disease. <i>American Journal of Epidemiology</i> , 2011, 174, 546-551.	1.6	95
1629	Phenotype in parkinsonian and nonparkinsonian <i>LRRK2</i> G2019S mutation carriers. <i>Neurology</i> , 2011, 77, 325-333.	1.5	163
1630	A Lysosomal Lair for a Pathogenic Protein Pair. <i>Science Translational Medicine</i> , 2011, 3, 91ps28.	5.8	11
1631	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0

#	ARTICLE	IF	CITATIONS
1632	Current concepts on the etiology and pathogenesis of Parkinson disease. , 2011, , 93-118.		2
1634	Preclinical Biomarkers of Parkinson Disease. Archives of Neurology, 2011, 68, 22-30.	4.9	141
1635	Association of Olfactory Bulb Volume and Olfactory Sulcus Depth with Olfactory Function in Patients with Parkinson Disease. American Journal of Neuroradiology, 2011, 32, 677-681.	1.2	118
1636	Neuropathology of Sleep Disorders: A Review. Journal of Neuropathology and Experimental Neurology, 2011, 70, 243-252.	0.9	39
1637	Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain, 2011, 134, 50-58.	3.7	112
1638	Nonmotor Disturbances in Parkinson's Disease. Neurodegenerative Diseases, 2011, 8, 95-108.	0.8	42
1639	α6 and α4 Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease. Pharmacological Reviews, 2011, 63, 938-966.	7.1	174
1640	Urinary dysfunction in early and untreated Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1382-1386.	0.9	80
1641	REM sleep parasomnias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 99, 869-882.	1.0	3
1642	Influence of left versus right hemibody onset Parkinson's disease on cardiovascular control. Laterality, 2011, 16, 164-173.	0.5	5
1643	Rest tremor in advanced essential tremor: a post-mortem study of nine cases. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 261-265.	0.9	72
1644	Odor Identification and Mortality in Old Age. Chemical Senses, 2011, 36, 63-67.	1.1	93
1645	Lewy Bodies and Olfactory Dysfunction in Old Age. Chemical Senses, 2011, 36, 367-373.	1.1	73
1646	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	3.7	132
1647	The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain, 2011, 134, 3146-3166.	3.7	174
1648	Does levodopa accelerate the pathologic process in Parkinson disease brain?. Neurology, 2011, 77, 1420-1426.	1.5	59
1649	Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease. Neurology India, 2011, 59, 659.	0.2	13
1650	A family with parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology, 2011, 76, 1623-1630.	1.5	29

#	ARTICLE	IF	CITATIONS
1651	Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. <i>Neurology</i> , 2011, 77, 1357-1362.	1.5	79
1652	Gene Expression Profiles in Parkinson Disease Prefrontal Cortex Implicate FOXO1 and Genes under Its Transcriptional Regulation. <i>PLoS Genetics</i> , 2012, 8, e1002794.	1.5	76
1653	Parkinson Hastalığına Klinik Subtipleri Arasında Kokuların Tanıma Yeteneğini Farklılaşık Glukokortikosteroid mi?. <i>Türk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2012, 18, 151-154.	0.1	0
1654	Pupillometry and 123I-DaTSCAN imaging in Parkinson's Disease: A Comparison Study. <i>International Journal of Neuroscience</i> , 2012, 122, 26-34.	0.8	15
1655	What is the most promising treatment for Parkinson's disease: genes, cells, growth factors or none of the above?. <i>Regenerative Medicine</i> , 2012, 7, 617-621.	0.8	6
1656	Bone Mineral Density (BMD) in Male Patients with Parkinson's Disease. <i>International Journal of Neuroscience</i> , 2012, 122, 523-527.	0.8	8
1657	The relationship between subcortical tau pathology and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2012, 40, 711-715.	1.6	67
1658	The Role of Free Radicals in the Aging Brain and Parkinson's Disease: Convergence and Parallelism. <i>International Journal of Molecular Sciences</i> , 2012, 13, 10478-10504.	1.8	174
1659	Visual hallucinations in the differential diagnosis of parkinsonism: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 448-452.	0.9	54
1660	SPECT Molecular Imaging in Parkinson's Disease. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-11.	3.0	37
1661	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Disease Patients Treated with Dopamine Grafts. <i>Science Translational Medicine</i> , 2012, 4, 128ra41.	5.8	107
1662	Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson's Disease. <i>Frontiers in Physiology</i> , 2012, 3, 171.	1.3	18
1663	Nonmotor Manifestations in Parkinson Disease. <i>Neurologist</i> , 2012, 18, 1-16.	0.4	69
1664	Parkinson's Disease and Sleep/Wake Disturbances. <i>Parkinson's Disease</i> , 2012, 2012, 1-14.	0.6	19
1665	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81.	1.2	78
1666	Pathologic Lesions in Neurodegenerative Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 1-40.	0.9	22
1667	Genomics and Bioinformatics of Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009449-a009449.	2.9	24
1668	Separation of Parkinson's patients in early and mature stages from control subjects using one EOG channel. , 2012, 2012, 2941-4.		7

#	ARTICLE	IF	CITATIONS
1669	Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008870-a008870.	2.9	288
1670	Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain, 2012, 135, 3355-3370.	3.7	142
1672	Aggregated proteins in schizophrenia and other chronic mental diseases. Prion, 2012, 6, 134-141.	0.9	47
1673	Intracerebral inoculation of pathological α -synuclein initiates a rapidly progressive neurodegenerative α -synucleinopathy in mice. Journal of Experimental Medicine, 2012, 209, 975-986.	4.2	910
1674	Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin. Antioxidants and Redox Signaling, 2012, 16, 935-949.	2.5	76
1675	Implicit olfactory abilities in traumatic brain injured patients. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 977-988.	0.8	4
1676	Joint symbolic dynamics as a model-free approach to study interdependence in cardio-respiratory time series. , 2012, 2012, 3680-3.		3
1677	Neurotransmitters and Disorders of the Basal Ganglia. , 2012, , 856-871.		4
1678	Increased α -synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death and Disease, 2012, 3, e315-e315.	2.7	58
1679	Compensatory Activity in the Extrastriate Body Area of Parkinson's Disease Patients. Journal of Neuroscience, 2012, 32, 9546-9553.	1.7	66
1680	Parkinson's disease " pathology, aetiology and diagnosis. Reviews in Clinical Gerontology, 2012, 22, 165-178.	0.5	5
1681	White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract-Specific Analysis. American Journal of Neuroradiology, 2012, 33, 890-895.	1.2	86
1682	Innate Inflammation in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009373-a009373.	2.9	97
1683	Involvement of the Spinal Cord in Parkinson's Disease. International Journal of Neuroscience, 2012, 122, 1-8.	0.8	19
1684	Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1019-1021.	0.9	31
1685	Polymorphisms in Neuropsychiatric and Neuroinflammatory Disorders and the Role of Next Generation Sequencing in Early Diagnosis and Treatment. Advances in Protein Chemistry and Structural Biology, 2012, 89, 85-116.	1.0	2
1686	Physiological Phenotype and Vulnerability in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009290-a009290.	2.9	97
1687	α -Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics, 2012, 21, 3173-3192.	1.4	228

#	ARTICLE	IF	CITATIONS
1688	Clock Test Deficits Related to the Global Cognitive State in Alzheimer's and Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 59-72.	0.7	16
1689	An evaluation of the impact of <i>MAPT</i> , <i>SNCA</i> and <i>APOE</i> on the burden of Alzheimer's and Lewy body pathology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 424-429.	0.9	50
1690	Clinico-Pathological Correlations of the Most Common Neurodegenerative Dementias. <i>Frontiers in Neurology</i> , 2012, 3, 68.	1.1	31
1691	Cognitive Impairment and Dementia in Parkinson's Disease: Clinical Features, Diagnosis, and Management. <i>Frontiers in Neurology</i> , 2012, 3, 88.	1.1	125
1692	Efficacy of a Multimodal Cognitive Rehabilitation Including Psychomotor and Endurance Training in Parkinson's Disease. <i>Journal of Aging Research</i> , 2012, 2012, 1-15.	0.4	57
1693	Cellular Programming and Reprogramming: Sculpting Cell Fate for the Production of Dopamine Neurons for Cell Therapy. <i>Stem Cells International</i> , 2012, 2012, 1-17.	1.2	11
1694	Cognition in Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2012, 3, 82.	1.1	56
1695	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2012, 3, 159.	1.1	31
1696	An Integrated Ontology-Based Model for the Early Diagnosis of Parkinson's Disease. <i>International Federation for Information Processing</i> , 2012, , 442-450.	0.4	2
1697	Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis. <i>Frontiers in Neurology</i> , 2012, 3, 5.	1.1	23
1698	Analysis of voice and speech performance in Parkinson's disease: a promising tool for the monitoring of disease progression and differential diagnosis. <i>Neurodegenerative Disease Management</i> , 2012, 2, 535-545.	1.2	5
1699	Effect of Subthalamic Nucleus Deep Brain Stimulation on the Autonomic Nervous System in Parkinson's Disease Patients Assessed by Spectral Analyses of R-R Interval Variability and Blood Pressure Variability. <i>Stereotactic and Functional Neurosurgery</i> , 2012, 90, 248-254.	0.8	14
1700	Immunopathogenesis of Neurodegenerative Diseases: Current Therapeutic Models of Neuroprotection with Special Reference to Natural Products. <i>Current Pharmaceutical Design</i> , 2012, 18, 34-42.	0.9	48
1701	Reply: Quantitative evaluation of the human subventricular zone. <i>Brain</i> , 2012, 135, e222-e222.	3.7	2
1702	A transgenic mouse model of dementia with Lewy bodies suggests a link between α -synuclein expression, presynaptic vesicle pathology and cognitive deficit. <i>Future Neurology</i> , 2012, 7, 13-17.	0.9	1
1703	Deep Brain Stimulation for Movement Disorders. <i>Frontiers in Integrative Neuroscience</i> , 2012, 6, 2.	1.0	56
1704	Impaired Complex-I Mitochondrial Biogenesis in Parkinson Disease Frontal Cortex. <i>Journal of Parkinson's Disease</i> , 2012, 2, 67-76.	1.5	43
1707	Prospective Study of Statin Use and Risk of Parkinson Disease. <i>Archives of Neurology</i> , 2012, 69, 380.	4.9	107

#	ARTICLE	IF	CITATIONS
1708	Differentiating dementia with Lewy bodies and Alzheimer's disease using MRI. <i>Neurodegenerative Disease Management</i> , 2012, 2, 411-420.	1.2	8
1709	Treatment of Moderate Parkinson's Disease. , 2012, , 1043-1050.		0
1710	Role of α -Synuclein in Adult Neurogenesis and Neuronal Maturation in the Dentate Gyrus. <i>Journal of Neuroscience</i> , 2012, 32, 16906-16916.	1.7	99
1711	Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 421-432.	1.5	58
1712	Pathological α -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. <i>Science</i> , 2012, 338, 949-953.	6.0	2,024
1713	Correlations between cortical and subcortical tau pathology. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 582-590.	1.8	45
1714	EFNS Guidelines on the diagnosis and management of disorders associated with dementia. <i>European Journal of Neurology</i> , 2012, 19, 1159-1179.	1.7	239
1715	Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. <i>Brain</i> , 2012, 135, 2798-2808.	3.7	161
1716	Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?. <i>Journal of Parkinson's Disease</i> , 2012, 2, 7-18.	1.5	33
1717	Evaluation of olfactory dysfunction in neurodegenerative diseases. <i>Journal of the Neurological Sciences</i> , 2012, 323, 16-24.	0.3	167
1718	Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. <i>Neurology</i> , 2012, 79, 2307-2314.	1.5	127
1719	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. <i>Methods</i> , 2012, 56, 508-513.	1.9	38
1720	Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?. <i>Brain</i> , 2012, 135, 3206-3226.	3.7	421
1721	Late-onset Parkinsonism in NF κ B/c-Rel-deficient mice. <i>Brain</i> , 2012, 135, 2750-2765.	3.7	66
1722	Mitochondrial Quality Control and Dynamics in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 869-882.	2.5	99
1723	New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1429-1438.	1.4	18
1724	Sleep disorders in Parkinson's disease: Many causes, few therapeutic options. <i>Journal of the Neurological Sciences</i> , 2012, 314, 12-19.	0.3	78
1725	Selective Frontoinsular von Economo Neuron and Fork Cell Loss in Early Behavioral Variant Frontotemporal Dementia. <i>Cerebral Cortex</i> , 2012, 22, 251-259.	1.6	169

#	ARTICLE	IF	CITATIONS
1726	Regional susceptibilities to mitochondrial dysfunctions in the CNS. <i>Biological Chemistry</i> , 2012, 393, 275-281.	1.2	17
1727	DBS and Electrical Neuro-Network Modulation to Treat Neurological Disorders. <i>International Review of Neurobiology</i> , 2012, 107, 253-282.	0.9	8
1728	<i>SCA6</i> presenting with young–onset parkinsonism without ataxia. <i>Movement Disorders</i> , 2012, 27, 1067-1068.	2.2	11
1729	Vaccination for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S11-S13.	1.1	72
1730	Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S28-S30.	1.1	54
1731	Neuronal vulnerability in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S52-S54.	1.1	49
1732	Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: the case for a higher priority and stronger evidence. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S110-S113.	1.1	22
1733	Presymptomatic Parkinson's disease: The Arizona experience. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S203-S206.	1.1	6
1734	Neuroinflammation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S210-S212.	1.1	516
1735	Clinical rating scales. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S229-S232.	1.1	6
1736	Synucleinopathies from bench to bedside. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S24-S27.	1.1	33
1737	Neuropathologic substrates of Parkinson disease dementia. <i>Annals of Neurology</i> , 2012, 72, 587-598.	2.8	401
1738	Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission?. <i>Annals of Neurology</i> , 2012, 72, 832-836.	2.8	15
1739	Meta–analysis of early nonmotor features and risk factors for Parkinson disease. <i>Annals of Neurology</i> , 2012, 72, 893-901.	2.8	607
1740	Neuron–neuron transmission of Î±–synuclein fibrils through axonal transport. <i>Annals of Neurology</i> , 2012, 72, 517-524.	2.8	305
1741	Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1625-1631.	2.2	36
1742	An evidence base for noradrenergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1589-1591.	2.2	7
1743	Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , 2012, 27, 1583-1584.	2.2	0

#	ARTICLE	IF	CITATIONS
1744	Reply: Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , 2012, 27, 1584-1585.	2.2	0
1745	Head injury and the risk of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1592-1594.	2.2	1
1746	Progression of cortical thinning in early Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1746-1753.	2.2	104
1748	REM sleep behavior disorder in Japanese patients with Parkinson's disease: a multicenter study using the REM sleep behavior disorder screening questionnaire. <i>Journal of Neurology</i> , 2012, 259, 1606-1612.	1.8	40
1749	Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2012, 119, 1515-1521.	1.4	33
1750	Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats. <i>Pharmaceutical Research</i> , 2012, 29, 2367-2376.	1.7	37
1751	Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012, 169, 77-86.	1.4	65
1752	Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. <i>Experimental Neurology</i> , 2012, 237, 318-334.	2.0	194
1753	The search for genetic mouse models of prodromal Parkinson's disease. <i>Experimental Neurology</i> , 2012, 237, 267-273.	2.0	24
1754	Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease's resemblance to the effect of amphetamine drugs of abuse. <i>Free Radical Biology and Medicine</i> , 2012, 53, 1791-1806.	1.3	89
1755	[¹²³ I]-N-(2-fluoropropyl)-2-carbomethoxy-3-(4-iodophenyl)nortropine single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2012, 8, 74-83.	0.4	5
1756	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 1-13.	0.4	1,968
1757	Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 2147-2164.	2.9	224
1758	Closing the gap between clinic and cage: Sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 2305-2324.	2.9	18
1759	Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in α -synucleinopathy. <i>Neuroscience Letters</i> , 2012, 527, 16-21.	1.0	24
1760	Central mechanisms for force and motion: Towards computational synthesis of human movement. <i>Neural Networks</i> , 2012, 36, 167-178.	3.3	6
1761	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	1.4	7
1762	The need to unify neuropathological assessments of vascular alterations in the ageing brain. <i>Experimental Gerontology</i> , 2012, 47, 825-833.	1.2	57

#	ARTICLE	IF	CITATIONS
1763	Early Visuospatial Deficits Predict the Occurrence of Visual Hallucinations in Autopsy-Confirmed Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 773-781.	0.6	45
1764	Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures. <i>Pharmacological Reports</i> , 2012, 64, 1359-1367.	1.5	29
1765	Artificial Intelligence Applications and Innovations. <i>International Federation for Information Processing</i> , 2012, , .	0.4	0
1766	Does a prion-like mechanism play a major role in the apparent spread of α -synuclein pathology?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 48.	3.0	5
1767	Olfactory dysfunction in Parkinson disease. <i>Nature Reviews Neurology</i> , 2012, 8, 329-339.	4.9	546
1768	Olfactory dysfunction and parasympathetic dysautonomia in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2012, 22, 161-166.	1.4	25
1769	Cardiovascular variability in Parkinson's disease and extrapyramidal motor slowing. <i>Clinical Autonomic Research</i> , 2012, 22, 191-196.	1.4	15
1770	Detection of Asymptomatic Nigrostriatal Dopaminergic Lesion in Rats by Exhaled Air Analysis Using Carbon Nanotube Sensors. <i>ACS Chemical Neuroscience</i> , 2012, 3, 161-166.	1.7	51
1771	Standardized Extracts of <i>Bacopa monniera</i> Protect Against MPP ⁺ - and Paraquat-Induced Toxicity by Modulating Mitochondrial Activities, Proteasomal Functions, and Redox Pathways. <i>Toxicological Sciences</i> , 2012, 125, 219-232.	1.4	37
1772	Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. <i>Neuropsychopharmacology</i> , 2012, 37, 213-246.	2.8	185
1774	Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2012, 33, 35-42.	1.5	54
1775	Disturbed sleep/wake rhythms and neuronal cell loss in lateral hypothalamus and retina of mice with a spontaneous deletion in the ubiquitin carboxyl-terminal hydrolase L1 gene. <i>Neurobiology of Aging</i> , 2012, 33, 393-403.	1.5	20
1776	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. <i>Neurobiology of Aging</i> , 2012, 33, 814-823.	1.5	184
1777	Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. <i>Neurobiology of Aging</i> , 2012, 33, 1265-1272.	1.5	74
1778	Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1228-1236.	1.5	39
1779	Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomammillary nucleus. <i>Neurobiology of Aging</i> , 2012, 33, 1343-1344.	1.5	34
1780	Screening for VPS35 mutations in Parkinson's disease. <i>Neurobiology of Aging</i> , 2012, 33, 838.e1-838.e5.	1.5	53
1781	Tau acts as an independent genetic risk factor in pathologically proven PD. <i>Neurobiology of Aging</i> , 2012, 33, 838.e7-838.e11.	1.5	23

#	ARTICLE	IF	CITATIONS
1782	The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. <i>Neurobiology of Aging</i> , 2012, 33, 2231.e7-2231.e14.	1.5	60
1783	Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. <i>Neuropharmacology</i> , 2012, 62, 2154-2168.	2.0	248
1784	Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. <i>Neuroscience</i> , 2012, 218, 257-267.	1.1	39
1785	Asymmetry in parkinsonism, spreading pathogens and the nose. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1-9.	1.1	20
1786	Validation of the non-motor symptoms questionnaire (NMS-Quest). <i>Parkinsonism and Related Disorders</i> , 2012, 18, 54-58.	1.1	101
1787	First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 332-338.	1.1	40
1788	Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 358-361.	1.1	49
1789	Gastroparesis and Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 433-440.	1.1	140
1790	Magnetization transfer and adiabatic R1ρ-MRI in the brainstem of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 623-625.	1.1	14
1791	Heart rate variability in patients with idiopathic Parkinson's disease with and without obstructive sleep apnea syndrome. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 525-531.	1.1	23
1792	Non-motor symptoms of Parkinson's disease in China: A review of the literature. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 446-452.	1.1	39
1793	Can Parkinson's disease pathology be propagated from one neuron to another?. <i>Progress in Neurobiology</i> , 2012, 97, 205-219.	2.8	97
1794	Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. <i>Progress in Neurobiology</i> , 2012, 98, 222-238.	2.8	84
1795	Late-stage Parkinson disease. <i>Nature Reviews Neurology</i> , 2012, 8, 435-442.	4.9	183
1796	Detection of α -Synuclein Aggregates by Fluorescence Microscopy. <i>Rejuvenation Research</i> , 2012, 15, 213-216.	0.9	6
1797	Spinal cord lesions in sporadic Parkinson's disease. <i>Acta Neuropathologica</i> , 2012, 124, 643-664.	3.9	130
1798	Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. <i>Neurology</i> , 2012, 79, 1323-1331.	1.5	121
1799	Identification of Protein Interfaces between α -Synuclein, the Principal Component of Lewy Bodies in Parkinson Disease, and the Molecular Chaperones Human Hsc70 and the Yeast Ssa1p. <i>Journal of Biological Chemistry</i> , 2012, 287, 32630-32639.	1.6	40

#	ARTICLE	IF	CITATIONS
1800	Molecular analysis and biochemical classification of TDP-43 proteinopathy. <i>Brain</i> , 2012, 135, 3380-3391.	3.7	95
1801	Corruption and Spread of Pathogenic Proteins in Neurodegenerative Diseases. <i>Journal of Biological Chemistry</i> , 2012, 287, 33109-33115.	1.6	63
1802	Beyond α -synuclein transfer: pathology propagation in Parkinson's disease. <i>Trends in Molecular Medicine</i> , 2012, 18, 248-255.	3.5	69
1803	Sympathetic skin response in Parkinson's disease before and after mental stress. <i>Neurophysiologie Clinique</i> , 2012, 42, 125-131.	1.0	12
1804	The influence of electrical stimulation of vagus nerve on elemental composition of dopamine related brain structures in rats. <i>Neurochemistry International</i> , 2012, 61, 156-165.	1.9	12
1805	Neurofilament protein levels: Quantitative analysis in essential tremor cerebellar cortex. <i>Neuroscience Letters</i> , 2012, 518, 49-54.	1.0	23
1806	Basal ganglia circuits changes in Parkinson's disease patients. <i>Neuroscience Letters</i> , 2012, 524, 55-59.	1.0	115
1807	A study of voice profiles and acoustic signs in patients with Parkinson's disease in North India. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1125-1129.	0.8	15
1808	Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease. <i>Journal of Proteomics</i> , 2012, 75, 4656-4667.	1.2	53
1809	Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: Neuropsychological evidence. <i>Brain and Cognition</i> , 2012, 79, 23-33.	0.8	32
1810	Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: A self-perpetuating crosstalk?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 176-184.	1.8	24
1811	Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. <i>Behavioural Brain Research</i> , 2012, 228, 30-43.	1.2	88
1812	Gene expression in the Parkinson's disease brain. <i>Brain Research Bulletin</i> , 2012, 88, 302-312.	1.4	42
1813	The immunological challenges of cell transplantation for the treatment of Parkinson's disease. <i>Brain Research Bulletin</i> , 2012, 88, 320-331.	1.4	25
1814	Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. <i>Free Radical Biology and Medicine</i> , 2012, 53, 983-992.	1.3	48
1815	Small vessel disease in patients with Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2012, 27, 1506-1512.	2.2	49
1816	Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. <i>BMC Neurology</i> , 2012, 12, 163.	0.8	9
1817	Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. <i>Gut Pathogens</i> , 2012, 4, 12.	1.6	46

#	ARTICLE	IF	CITATIONS
1818	Pains in Parkinson diseaseâ€”many syndromes under one umbrella. <i>Nature Reviews Neurology</i> , 2012, 8, 284-294.	4.9	191
1819	Spinocerebellar ataxia type 1 (SCA1): new pathoanatomical and clinicoâ€”pathological insights. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 665-680.	1.8	66
1820	Pick's pathology in Parkinson's disease with dementia. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 737-743.	1.8	3
1821	Molecular Insights into Parkinson's Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 125-188.	0.9	83
1822	Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 399-406.	2.8	227
1823	Fecal Microbiota Transplantation. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 781-803.	1.0	116
1825	Biochemical Increase in Phosphorylated Alphaâ€”Synuclein Precedes Histopathology of Lewyâ€”Type Synucleinopathies. <i>Brain Pathology</i> , 2012, 22, 745-756.	2.1	62
1826	Critical Role of Truncated Î±â€”Synuclein and Aggregates in Parkinson's Disease and Incidental Lewy Body Disease. <i>Brain Pathology</i> , 2012, 22, 811-825.	2.1	49
1827	Astrocyte-Specific Overexpression of Nrf2 Delays Motor Pathology and Synuclein Aggregation throughout the CNS in the Alpha-Synuclein Mutant (A53T) Mouse Model. <i>Journal of Neuroscience</i> , 2012, 32, 17775-17787.	1.7	160
1828	The role of iron in neurodegenerationâ€”MÃ¶ssbauer spectroscopy, electron microscopy, enzyme-linked immunosorbent assay and neuroimaging studies. <i>Journal of Physics Condensed Matter</i> , 2012, 24, 244106.	0.7	22
1829	Neurotrophic Factors and Neurodegenerative Diseases. <i>International Review of Neurobiology</i> , 2012, 102, 207-247.	0.9	26
1830	Sleep disturbance in Parkinson disease. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2012, 3, 53-61.	0.7	9
1832	Reconciling Braakâ€™s model of Parkinsonâ€™s disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012, 2, 167-170.	0.3	2
1833	Basal ganglia sonography: Will it mature into a preclinical diagnostic tool for Parkinsonâ€™s disease?. <i>Basal Ganglia</i> , 2012, 2, 183-187.	0.3	0
1834	Tongue force and tongue motility are differently affected by unilateral vs bilateral nigrostriatal dopamine depletion in rats. <i>Behavioural Brain Research</i> , 2012, 234, 343-348.	1.2	27
1835	From Î±-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. <i>Brain Research</i> , 2012, 1476, 183-202.	1.1	89
1836	Computer detection approaches for the identification of phasic electromyographic (EMG) activity during human sleep. <i>Biomedical Signal Processing and Control</i> , 2012, 7, 606-615.	3.5	16
1837	Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. <i>NeuroImage</i> , 2012, 59, 2743-2750.	2.1	82

#	ARTICLE	IF	CITATIONS
1838	Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. <i>NeuroImage</i> , 2012, 59, 3339-3346.	2.1	58
1839	Impaired olfactory bulb neurogenesis depends on the presence of human wild-type alpha-synuclein. <i>Neuroscience</i> , 2012, 222, 343-355.	1.1	15
1841	REM sleep behaviour disorder and autonomic failure: Presentation of two cases. <i>Neurologia (English Edition)</i> , 2012, 27, 55-57.	0.2	0
1842	Thermal and mechanical pain thresholds in patients with fluctuating Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 953-957.	1.1	21
1843	Olfaction, dyskinesia and profile of weight change in Parkinson's disease: Identifying neurodegenerative phenotypes. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 964-970.	1.1	32
1844	Cerebral oxygen metabolism in patients with early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 313, 123-128.	0.3	26
1845	Parkinson's disease: Acquired frailty of archaic neural networks?. <i>Journal of the Neurological Sciences</i> , 2012, 314, 143-151.	0.3	18
1846	Application of odor identification test in Parkinson's disease in China: A matched case-control study. <i>Journal of the Neurological Sciences</i> , 2012, 316, 47-50.	0.3	43
1847	Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. <i>Journal of the Neurological Sciences</i> , 2012, 317, 1-5.	0.3	256
1848	The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: A double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. <i>Journal of the Neurological Sciences</i> , 2012, 320, 121-126.	0.3	37
1850	Alpha-synuclein: from secretion to dysfunction and death. <i>Cell Death and Disease</i> , 2012, 3, e350-e350.	2.7	239
1853	Biology of Mitochondria in Neurodegenerative Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 355-415.	0.9	141
1854	Management of Pain in Parkinson's Disease. <i>CNS Drugs</i> , 2012, 26, 937-948.	2.7	47
1855	Parkinson's Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 389-455.	1.0	283
1856	Motor Control and Biomechanics of Laryngeal and Pharyngeal Muscles. , 2012, , 167-183.		0
1857	In Search of an Immunobiomarker for Parkinson's Disease. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 719-721.	2.1	0
1858	Sleep Disturbances in Alzheimer's and Parkinson's Diseases. <i>NeuroMolecular Medicine</i> , 2012, 14, 194-204.	1.8	76
1859	Primary Skin Fibroblasts as a Model of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2012, 46, 20-27.	1.9	121

#	ARTICLE	IF	CITATIONS
1860	Evidence for Synergism Between Cell Death Mechanisms in a Cellular Model of Neurodegeneration in Parkinson's Disease. <i>Neurotoxicity Research</i> , 2012, 22, 355-364.	1.3	12
1861	Systems Biology of Parkinson's Disease. , 2012, , .		8
1863	Sleep in Parkinson's Disease and Dementia with Lewy Bodies. <i>Advances in Biological Psychiatry</i> , 2012, , 61-70.	0.2	4
1864	Drosophila as a Model to Study Mitochondrial Dysfunction in Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009944-a009944.	2.9	76
1865	When does Parkinson's disease begin? From prodromal disease to motor signs. <i>Revue Neurologique</i> , 2012, 168, 809-814.	0.6	37
1866	Neuroprevention: A new challenge?. <i>Revue Neurologique</i> , 2012, 168, 796-801.	0.6	6
1867	Â-Synuclein in Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009399-a009399.	2.9	958
1868	Essential tremor is not a neurodegenerative disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 259-268.	1.2	47
1869	Visual hallucinations: a review for ophthalmologists. <i>Expert Review of Ophthalmology</i> , 2012, 7, 471-479.	0.3	0
1870	?7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson's Disease. <i>Current Drug Targets</i> , 2012, 13, 623-630.	1.0	39
1871	Brain Imaging in Behavioral Neuroscience. <i>Current Topics in Behavioral Neurosciences</i> , 2012, , .	0.8	3
1872	Animal Models of Movement Disorders. <i>Neuromethods</i> , 2012, , .	0.2	1
1873	Age, drugs, or disease: What alters the macrostructure of sleep in Parkinson's disease?. <i>Sleep Medicine</i> , 2012, 13, 1178-1183.	0.8	33
1874	Exosomal cell-to-cell transmission of alpha synuclein oligomers. <i>Molecular Neurodegeneration</i> , 2012, 7, 42.	4.4	708
1875	Suppression of dynamin GTPase decreases Î±-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. <i>Molecular Neurodegeneration</i> , 2012, 7, 38.	4.4	107
1876	In vivo imaging of the integration and function of nigral grafts in clinical trials. <i>Progress in Brain Research</i> , 2012, 200, 199-220.	0.9	16
1877	Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons In Vivo. <i>PLoS ONE</i> , 2012, 7, e39465.	1.1	218
1878	Evaluation of Parkinson Disease Risk Variants as Expression-QTLs. <i>PLoS ONE</i> , 2012, 7, e46199.	1.1	36

#	ARTICLE	IF	CITATIONS
1879	Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS. PLoS ONE, 2012, 7, e30918.	1.1	156
1880	Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of Scans Without Evidence of Dopaminergic Deficit (SWEDDs). Arquivos De Neuro-Psiquiatria, 2012, 70, 667-673.	0.3	21
1881	Sequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration. Frontiers in Pharmacology, 2012, 3, 184.	1.6	24
1882	A Comparison of Facial Emotion Processing in Neurological and Psychiatric Conditions. Frontiers in Psychology, 2012, 3, 98.	1.1	45
1883	Frontostriatal Cognitive Staging in Parkinson's Disease. Parkinson's Disease, 2012, 2012, 1-8.	0.6	33
1884	Studies of Depression-Related States in Animal Models of Parkinsonism. Journal of Parkinson's Disease, 2012, 2, 87-106.	1.5	17
1885	Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects. Parkinson's Disease, 2012, 2012, 1-15.	0.6	79
1886	Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	31
1887	Oxidative Stress in Genetic Mouse Models of Parkinson's Disease. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-25.	1.9	71
1888	The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5' Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease, 2012, 2012, 1-13.	0.6	37
1889	Posture and Locomotion Coupling: A Target for Rehabilitation Interventions in Persons with Parkinson's Disease. Parkinson's Disease, 2012, 2012, 1-10.	0.6	25
1890	Dementia in Parkinson's Disease Correlates with α -Synuclein Pathology but Not with Cortical Astroglia. Parkinson's Disease, 2012, 2012, 1-13.	0.6	15
1891	Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. Patient Preference and Adherence, 2012, 6, 49.	0.8	7
1892	The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Frontiers in Behavioral Neuroscience, 2012, 6, 48.	1.0	100
1893	A role for locus coeruleus in Parkinson tremor. Frontiers in Human Neuroscience, 2011, 5, 179.	1.0	51
1894	Epidemiology of Psychiatric Symptoms in Parkinson's Disease. Advances in Biological Psychiatry, 2012, , 1-12.	0.2	5
1895	Parkinson's Disease with Dementia. Advances in Biological Psychiatry, 2012, , 103-124.	0.2	2
1896	Successes of Modelling Parkinson Disease in Drosophila. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
1897	Brain Energy Metabolism in Health and Disease. , 0, , .		3
1898	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. Journal of Alzheimer's Disease, 2012, 33, S385-S396.	1.2	5
1901	Acetyl-L-Carnitine in Parkinsonâ€™s Disease. , 2012, , .		1
1902	Limbic and Nigral Lewy Bodies and Alzheimer's Disease Pathology Mimicking Progressive Supranuclear Palsy in a 75-Year-Old Man with Preserved Cardiac Uptake of MIBG. Journal of Alzheimer's Disease, 2012, 32, 889-894.	1.2	3
1903	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5
1904	Dopamine Transporter Imaging for Distinguishing Between Idiopathic Parkinsonâ€™s Disease and Secondary Parkinsonism. , 0, , .		0
1905	Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease?. Journal of Parkinson's Disease, 2012, 2, 249-267.	1.5	72
1906	Telomere Length and Aging. , 0, , .		5
1908	Adjunctive therapy in Parkinson's disease: the role of rasagiline. Neuropsychiatric Disease and Treatment, 2012, 8, 285.	1.0	5
1909	Effects of Panax ginseng in Neurodegenerative Diseases. Journal of Ginseng Research, 2012, 36, 342-353.	3.0	186
1910	Variants in the 3â€™UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. European Journal of Human Genetics, 2012, 20, 1265-1269.	1.4	19
1911	Co-occurrence of Different Pathologies in Dementia: Implications for Dementia Diagnosis. Journal of Alzheimer's Disease, 2012, 30, 909-917.	1.2	31
1912	In Vivo Alterations in Calcium Buffering Capacity in Transgenic Mouse Model of Synucleinopathy. Journal of Neuroscience, 2012, 32, 9992-9998.	1.7	36
1913	Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. Journal of Neuroscience Research, 2012, 90, 1997-2008.	1.3	134
1914	Dreaming in dementiaâ€™REM sleep behavior disorder and synucleinopathy. Movement Disorders, 2012, 27, 6-7.	2.2	5
1915	Toward a redefinition of Parkinson's disease. Movement Disorders, 2012, 27, 54-60.	2.2	165
1916	Lewy pathology and neurodegeneration in premotor Parkinson's disease. Movement Disorders, 2012, 27, 597-607.	2.2	141
1917	Premotor Parkinson's disease: Concepts and definitions. Movement Disorders, 2012, 27, 608-616.	2.2	140

#	ARTICLE	IF	CITATIONS
1918	The neuropathology of genetic Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 831-842.	2.2	229
1919	To sleep, perchance to dement: RBD and cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 671-673.	2.2	6
1920	Neuroimaging: Current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 634-643.	2.2	26
1921	Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. <i>Movement Disorders</i> , 2012, 27, 656-665.	2.2	113
1922	Identifying prodromal Parkinson's disease: Pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 617-626.	2.2	443
1923	Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2012, 27, 1068-1069.	2.2	15
1924	Attenuated heart rate response in REM sleep behavior disorder and Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 888-894.	2.2	42
1925	Magnetic resonance imaging of the substantia nigra in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 822-830.	2.2	80
1926	The significance of defining preclinical or prodromal Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 666-669.	2.2	69
1927	Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. <i>Movement Disorders</i> , 2012, 27, 716-719.	2.2	383
1928	<i>C9ORF72</i> expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. <i>Movement Disorders</i> , 2012, 27, 1072-1074.	2.2	45
1929	Nicotine as a potential neuroprotective agent for Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 947-957.	2.2	193
1930	Brain amyloid and cognition in Lewy body diseases. <i>Movement Disorders</i> , 2012, 27, 965-973.	2.2	150
1931	A colonic biomarker of Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 674-676.	2.2	8
1932	Decreased olfactory bulb volume in idiopathic Parkinson's disease detected by 3.0-Tesla magnetic resonance imaging. <i>Movement Disorders</i> , 2012, 27, 1019-1025.	2.2	71
1933	Quantitative neurodegenerative pathology does not explain the degree of hippocampal atrophy on MRI in degenerative dementia. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1267-1274.	1.3	9
1934	Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. <i>Human Brain Mapping</i> , 2012, 33, 2521-2534.	1.9	184
1935	Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models. <i>Critical Reviews in Toxicology</i> , 2012, 42, 613-632.	1.9	156

#	ARTICLE	IF	CITATIONS
1936	Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Review of Neurotherapeutics, 2012, 12, 687-696.	1.4	118
1937	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. Expert Review of Neurotherapeutics, 2012, 12, 673-686.	1.4	63
1938	Solvent exposures and parkinson disease risk in twins. Annals of Neurology, 2012, 71, 776-784.	2.8	130
1939	Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Annals of Neurology, 2012, 71, 560-568.	2.8	206
1940	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2012, 520, 2591-2607.	0.9	76
1941	Interaction between pathogenic proteins in neurodegenerative disorders. Journal of Cellular and Molecular Medicine, 2012, 16, 1166-1183.	1.6	104
1942	A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (A61) Mice. Neurotherapeutics, 2012, 9, 297-314.	2.1	248
1943	Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD. Journal of Molecular Neuroscience, 2012, 47, 139-143.	1.1	40
1945	Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in α -synucleinopathy. Acta Neuropathologica, 2012, 124, 173-186.	3.9	92
1946	Art and Parkinson's disease: a dramatic change in an artist's style as an initial symptom. Journal of Neurology, 2012, 259, 879-881.	1.8	23
1947	Personality traits in patients with Parkinson's disease: assessment and clinical implications. Journal of Neurology, 2012, 259, 1029-1038.	1.8	74
1948	α -Synuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections. Brain Structure and Function, 2012, 217, 447-458.	1.2	29
1949	Axonal degeneration as a therapeutic target in the CNS. Cell and Tissue Research, 2012, 349, 289-311.	1.5	224
1950	Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?. Journal of Neural Transmission, 2012, 119, 597-604.	1.4	8
1951	Neuromelanin enhances the toxicity of α -synuclein in SK-N-SH cells. Journal of Neural Transmission, 2012, 119, 685-691.	1.4	18
1952	New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases. Neurogenetics, 2012, 13, 61-72.	0.7	17
1953	Parkinson's disease showing progressive conduction aphasia. Neurological Sciences, 2012, 33, 399-402.	0.9	3
1954	The Parkinson disease before James Parkinson. Neurological Sciences, 2012, 33, 945-948.	0.9	31

#	ARTICLE	IF	CITATIONS
1955	Pale Neurites, Premature α -Synuclein Aggregates with Centripetal Extension from Axon Collaterals. <i>Brain Pathology</i> , 2012, 22, 67-78.	2.1	51
1956	α -Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. <i>Journal of Neurochemistry</i> , 2012, 120, 440-452.	2.1	94
1957	Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. <i>European Journal of Neuroscience</i> , 2012, 35, 870-882.	1.2	87
1958	Lewy body-related α -synucleinopathy in the spinal cord of cases with incidental Lewy body disease. <i>Neuropathology</i> , 2012, 32, 13-22.	0.7	30
1959	Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions. <i>Neuropathology</i> , 2012, 32, 60-68.	0.7	1
1960	Hirano body-rich subtypes of Creutzfeldt-Jakob disease. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 153-161.	1.8	8
1961	Calpain activation is involved in acute manganese neurotoxicity in the rat striatum in vivo. <i>Experimental Neurology</i> , 2012, 233, 182-192.	2.0	14
1962	Parkinson's disease (PD) in the elderly: An example of geriatric syndrome (GS)? <i>Archives of Gerontology and Geriatrics</i> , 2012, 54, 242-246.	1.4	23
1963	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. <i>Brain Research</i> , 2012, 1432, 95-113.	1.1	39
1964	The effects of nigrostriatal dopamine depletion on the thalamic parafascicular nucleus. <i>Brain Research</i> , 2012, 1446, 46-55.	1.1	13
1965	Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 361-368.	4.9	201
1966	Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: Possible role of the noradrenergic nervous system. <i>Epilepsia</i> , 2012, 53, 61-66.	2.6	76
1967	Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson's disease. <i>FEBS Journal</i> , 2012, 279, 1167-1176.	2.2	30
1968	The Proteome of the Locus Ceruleus in Parkinson's Disease: Relevance to Pathogenesis. <i>Brain Pathology</i> , 2012, 22, 485-498.	2.1	53
1969	Clinical heterogeneity in Parkinson's disease revisited: a latent profile analysis. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 311-318.	1.0	20
1970	Current status and future directions of gene expression profiling in Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 45, 76-82.	2.1	29
1971	REM sleep behavior disorder: From dreams to neurodegeneration. <i>Neurobiology of Disease</i> , 2012, 46, 553-558.	2.1	95
1972	Neurochemistry and the non-motor aspects of PD. <i>Neurobiology of Disease</i> , 2012, 46, 508-526.	2.1	73

#	ARTICLE	IF	CITATIONS
1973	Emerging dysfunctions consequent to combined monoaminergic depletions in parkinsonism. <i>Neurobiology of Disease</i> , 2012, 45, 763-773.	2.1	94
1974	Olfaction in Parkinson's disease and related disorders. <i>Neurobiology of Disease</i> , 2012, 46, 527-552.	2.1	351
1975	Animal models of the non-motor features of Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 46, 597-606.	2.1	131
1976	Cognitive impairment and dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2012, 46, 590-596.	2.1	198
1977	Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. <i>Neurobiology of Disease</i> , 2012, 48, 9-19.	2.1	74
1979	Voltage-gated calcium channels and Parkinson's disease. , 2012, 133, 324-333.		37
1980	The role of α -synuclein in neurodegeneration " An update. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	16
1981	Increased number of Purkinje cell dendritic swellings in essential tremor. <i>European Journal of Neurology</i> , 2012, 19, 625-630.	1.7	72
1982	Subjective sleep problems in patients with early Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 1575-1581.	1.7	19
1983	Targeting metabolic inflammation in Parkinson's disease: Implications for prospective therapeutic strategies. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 577-585.	0.9	27
1984	Phosphorylated α -synuclein immunoreactivity in the posterior pituitary lobe. <i>Neuropathology</i> , 2012, 32, 385-389.	0.7	15
1985	Structure-oriented review of 14-3-3 protein isoforms in geriatric neuroscience. <i>Geriatrics and Gerontology International</i> , 2012, 12, 586-599.	0.7	9
1986	Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?. <i>European Journal of Neuroscience</i> , 2012, 35, 1894-1907.	1.2	46
1987	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α -synuclein mutation. <i>Translational Neurodegeneration</i> , 2012, 1, 2.	3.6	24
1988	Cognitive status correlates with white matter alteration in Parkinson's disease. <i>Human Brain Mapping</i> , 2012, 33, 727-739.	1.9	180
1989	Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. <i>Movement Disorders</i> , 2012, 27, 8-30.	2.2	356
1990	Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2012, 27, 65-71.	2.2	72
1991	Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. <i>Movement Disorders</i> , 2012, 27, 72-78.	2.2	99

#	ARTICLE	IF	CITATIONS
1992	Severe dysphagia as a presentation of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 457-458.	2.2	24
1993	Unilateral basal ganglia atrophy in a patient with tuberous sclerosis complex and hemichorea. <i>Movement Disorders</i> , 2012, 27, 458-460.	2.2	5
1994	Emotional processing in Parkinson's disease: A systematic review. <i>Movement Disorders</i> , 2012, 27, 186-199.	2.2	143
1995	Dentatorubral-pallidoluysian atrophy: Haplotype of Asian origin in 2 Italian families. <i>Movement Disorders</i> , 2012, 27, 460-461.	2.2	4
1996	Parkinson's disease patients cannot get their dopamine replacement: The 8-sinemet limit. <i>Movement Disorders</i> , 2012, 27, 461-462.	2.2	0
1997	Re-emergent tremor in a dystonic SWEDD case. <i>Movement Disorders</i> , 2012, 27, 462-463.	2.2	12
1998	The normal parkin sequence. <i>Movement Disorders</i> , 2012, 27, 463-464.	2.2	0
1999	Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 559-561.	2.2	102
2000	Increased levels of 5-HT _{1A} receptor binding in ventral visual pathways in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 735-742.	2.2	23
2001	Nigral pathology and parkinsonian signs in elders without Parkinson disease. <i>Annals of Neurology</i> , 2012, 71, 258-266.	2.8	171
2002	Neurotrophic Effects of Growth/Differentiation Factor 5 in a Neuronal Cell Line. <i>Neurotoxicity Research</i> , 2012, 21, 256-265.	1.3	14
2003	Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson's Disease. <i>Neurochemical Research</i> , 2012, 37, 358-369.	1.6	133
2004	Kynurenines in Parkinson's disease: therapeutic perspectives. <i>Journal of Neural Transmission</i> , 2012, 119, 275-283.	1.4	34
2005	A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. <i>Journal of Neural Transmission</i> , 2012, 119, 297-312.	1.4	30
2006	Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. <i>Acta Neuropathologica</i> , 2012, 123, 173-188.	3.9	118
2007	National Institute on Aging's Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. <i>Acta Neuropathologica</i> , 2012, 123, 1-11.	3.9	2,002
2008	Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. <i>Acta Neuropathologica</i> , 2012, 123, 449-452.	3.9	35
2009	Psychiatric symptoms screening in the early stages of Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 124-131.	1.8	25

#	ARTICLE	IF	CITATIONS
2010	The topography of brain damage at different stages of Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 2798-2807.	1.9	61
2011	Neuronal vulnerability, pathogenesis, and Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 41-50.	2.2	199
2012	Neuropathologic analysis of Lewy-related α -synucleinopathy in olfactory mucosa. <i>Neuropathology</i> , 2013, 33, 47-58.	0.7	42
2013	Frequencies of falls and associated features at different stages of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 160-166.	1.7	35
2014	Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1 α -knockout mice. <i>Journal of Neuroinflammation</i> , 2013, 10, 50.	3.1	18
2015	Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies. <i>Neurotherapeutics</i> , 2013, 10, 371-382.	2.1	33
2016	Gene Therapy for Misfolding Protein Diseases of the Central Nervous System. <i>Neurotherapeutics</i> , 2013, 10, 498-510.	2.1	16
2017	Targeted training of the decision rule benefits rule-guided behavior in Parkinson's disease. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2013, 13, 830-846.	1.0	6
2018	Alteration in Glutathione Content and Associated Enzyme Activities in the Synaptic Terminals but not in the Non-synaptic Mitochondria from the Frontal Cortex of Parkinson's Disease Brains. <i>Neurochemical Research</i> , 2013, 38, 186-200.	1.6	19
2019	The serotonergic system in motor and non-motor manifestations of Parkinson's disease. <i>Experimental Brain Research</i> , 2013, 230, 463-476.	0.7	60
2020	Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. <i>Neuroradiology</i> , 2013, 55, 483-492.	1.1	70
2021	Enteric α -synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. <i>Movement Disorders</i> , 2013, 28, 237-241.	2.2	105
2022	Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease's resemblance to the effect of amphetamine drugs of abuse. <i>Free Radical Biology and Medicine</i> , 2013, 62, 186-201.	1.3	97
2023	Parkinson's Disease and Nonmotor Dysfunction. , 2013, , .		9
2024	Neuroimaging of Movement Disorders. , 2013, , .		1
2025	Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. <i>Nature Reviews Neuroscience</i> , 2013, 14, 626-636.	4.9	673
2026	Dementia and Sleep. , 2013, , 370-373.		0
2027	Neuroprotective mechanisms of the standardized extract of <i>Bacopa monnieri</i> in a paraquat/diquat-mediated acute toxicity. <i>Neurochemistry International</i> , 2013, 62, 530-539.	1.9	31

#	ARTICLE	IF	CITATIONS
2028	Neurotrophic factor expression in expandable cell populations from brain samples in living patients with Parkinson's disease. <i>FASEB Journal</i> , 2013, 27, 4157-4168.	0.2	17
2029	Conformational templating of α -synuclein aggregates in neuronal-glia cultures. <i>Molecular Neurodegeneration</i> , 2013, 8, 17.	4.4	61
2030	Cardiac autonomic impairment during sleep is linked with disease severity in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2013, 124, 1163-1168.	0.7	26
2031	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. <i>Acta Neuropathologica</i> , 2013, 126, 365-384.	3.9	264
2032	Amyloid or tau: the chicken or the egg?. <i>Acta Neuropathologica</i> , 2013, 126, 609-613.	3.9	33
2033	Probable rapid eye movement sleep behavior disorder, nocturnal disturbances and quality of life in patients with Parkinson's disease: a case-controlled study using the rapid eye movement sleep behavior disorder screening questionnaire. <i>BMC Neurology</i> , 2013, 13, 18.	0.8	29
2034	Resident adult neural stem cells in Parkinson's disease: The brain's own repair system?. <i>European Journal of Pharmacology</i> , 2013, 719, 117-127.	1.7	34
2035	<i>Parkinson's Disease and Sleep.</i> , 2013, , 345-349.		0
2037	Parkinson Disease and Sleep: Sleep-Wake Changes in the Premotor Stage of Parkinson Disease; Impaired Olfaction and Other Prodromal Features. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 373.	2.0	22
2038	Induction of CNS α -synuclein pathology by fibrillar and non-amyloidogenic recombinant α -synuclein. <i>Acta Neuropathologica Communications</i> , 2013, 1, 38.	2.4	78
2039	Extensive aggregation of α -synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. <i>Acta Neuropathologica Communications</i> , 2013, 1, 12.	2.4	36
2040	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2013, 1, 11.	2.4	61
2041	Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. <i>Acta Neuropathologica Communications</i> , 2013, 1, 1-11.	2.4	13
2042	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.	2.4	205
2043	Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach. <i>Journal of Neurology</i> , 2013, 260, 2951-2958.	1.8	34
2044	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730.	1.8	45
2045	Pramipexole Reduces Phosphorylation of α -Synuclein at Serine-129. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 573-580.	1.1	14
2046	<i>Basal Ganglia Disorders.</i> , 2013, , 1-39.		0

#	ARTICLE	IF	CITATIONS
2047	Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. <i>Sleep Medicine</i> , 2013, 14, 744-748.	0.8	688
2048	Somatic alpha-synuclein mutations in Parkinson's disease: Hypothesis and preliminary data. <i>Movement Disorders</i> , 2013, 28, 705-712.	2.2	53
2050	Can parkin be a target for future treatment of Parkinson's disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1133-1144.	1.5	13
2051	Amyloid and tau: neither chicken nor egg but two partners in crime!. <i>Acta Neuropathologica</i> , 2013, 126, 619-621.	3.9	19
2052	The therapeutics of Alzheimer's disease: Where we stand and where we are heading. <i>Annals of Neurology</i> , 2013, 74, 328-336.	2.8	101
2054	Cholinergic Dysfunction in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 377.	2.0	193
2055	Sleepiness at the Time of Testing Impairs Olfactory Performance. <i>European Neurology</i> , 2013, 69, 58-64.	0.6	8
2056	Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys. <i>Acta Neuropathologica</i> , 2013, 126, 411-425.	3.9	26
2057	Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. <i>Nature</i> , 2013, 501, 45-51.	13.7	1,331
2058	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	0.6	26
2059	Parkinson's Disease: Diagnosis, Motor Symptoms and Non-motor Features. , 2013, , .		2
2060	Is rapid eye movement sleep behavior disorder in Parkinson disease a specific disease subtype?. <i>Sleep Medicine</i> , 2013, 14, 931-933.	0.8	10
2061	Clinical markers of early nigrostriatal neurodegeneration in idiopathic rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2013, 14, 1064-1070.	0.8	33
2062	Review: Electrophysiology of Basal Ganglia and Cortex in Models of Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 241-254.	1.5	53
2063	Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. <i>Progress in Neurobiology</i> , 2013, 104, 38-66.	2.8	283
2064	Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. <i>Neurobiology of Disease</i> , 2013, 59, 38-51.	2.1	38
2065	Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 673-681.	1.4	16
2066	SUMO and Parkinson's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 737-759.	1.8	46

#	ARTICLE	IF	CITATIONS
2067	Neuronal vulnerability, pathogenesis, and Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 715-724.	2.2	145
2068	Prion-like Properties of Pathological TDP-43 Aggregates from Diseased Brains. <i>Cell Reports</i> , 2013, 4, 124-134.	2.9	418
2069	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. <i>Sleep Medicine</i> , 2013, 14, 775-781.	0.8	94
2070	The remarkable conformational plasticity of alpha-synuclein: blessing or curse?. <i>Trends in Molecular Medicine</i> , 2013, 19, 368-377.	3.5	79
2071	Beta oscillations in the cortico-basal ganglia loop during parkinsonism. <i>Experimental Neurology</i> , 2013, 245, 52-59.	2.0	162
2072	Higher iron in the red nucleus marks Parkinson's dyskinesia. <i>Neurobiology of Aging</i> , 2013, 34, 1497-1503.	1.5	76
2073	Mindfulness based intervention in Parkinson's disease leads to structural brain changes on MRI. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 2419-2425.	0.6	147
2074	Î±-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. <i>Human Pathology</i> , 2013, 44, 1171-1176.	1.1	26
2075	Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2013, 288, 22809-22820.	1.6	74
2076	Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. <i>Brain</i> , 2013, 136, 2077-2097.	3.7	144
2077	D-512 and D-440 as Novel Multifunctional Dopamine Agonists: Characterization of Neuroprotection Properties and Evaluation of In Vivo Efficacy in a Parkinson's Disease Animal Model. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1382-1392.	1.7	25
2078	Parkin disease and the Lewy body conundrum. <i>Movement Disorders</i> , 2013, 28, 702-704.	2.2	34
2079	Primary progressive aphasia with parkinsonism. <i>Movement Disorders</i> , 2013, 28, 741-746.	2.2	3
2080	Altered resting-state functional connectivity of the dentate nucleus in Parkinson's disease. <i>Psychiatry Research - Neuroimaging</i> , 2013, 211, 64-71.	0.9	45
2081	Advanced Parkinson's disease: Clinical characteristics and treatment (part 1). <i>Neurología (English)</i> Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	0.2	26
2082	Dopamine Imaging in Idiopathic Parkinson Disease and Other Parkinsonisms. , 2013, , 129-141.		1
2083	Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 116, 469-483.	1.0	8
2084	Structural and functional characterization of two alpha-synuclein strains. <i>Nature Communications</i> , 2013, 4, 2575.	5.8	721

#	ARTICLE	IF	CITATIONS
2085	Effects of rotigotine on Parkinson's disease-related sleep disturbances. Expert Opinion on Pharmacotherapy, 2013, 14, 2571-2580.	0.9	7
2086	Boosting chaperone-mediated autophagy in vivo mitigates α -synuclein-induced neurodegeneration. Brain, 2013, 136, 2130-2146.	3.7	175
2087	Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease. Cellular Signalling, 2013, 25, 2863-2870.	1.7	59
2088	Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography. Current Neurology and Neuroscience Reports, 2013, 13, 405.	2.0	8
2089	Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry. Experimental Neurology, 2013, 247, 19-24.	2.0	29
2090	Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations. Behavioural Brain Research, 2013, 252, 252-259.	1.2	33
2091	Can Mild Cognitive Impairment in Parkinson Disease Predict the Development of Dementia?. JAMA Neurology, 2013, 70, 553.	4.5	3
2092	Non-dopaminergic Treatments for Motor Control in Parkinson's Disease. Drugs, 2013, 73, 1405-1415.	4.9	127
2093	Transmission of multiple system atrophy prions to transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19555-19560.	3.3	359
2094	Amyotrophic lateral sclerosis "a model of corticofugal axonal spread. Nature Reviews Neurology, 2013, 9, 708-714.	4.9	432
2095	<i>In Vivo</i> Detection of Cerebral Cortical Microinfarcts with High-Resolution 7T MRI. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 322-329.	2.4	177
2096	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	0.9	47
2097	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Reviews in the Neurosciences, 2013, 24, 267-78.	1.4	152
2098	Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 2013, 45, 511-521.	1.5	107
2099	A progressive dopaminergic phenotype associated with neurotoxic conversion of α -synuclein in BAC-transgenic rats. Brain, 2013, 136, 412-432.	3.7	132
2100	The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease. , 2013, , 651-678.		0
2101	Proteopathic Seeds and Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , .	0.1	4
2102	How pain arises in Parkinson's disease?. European Journal of Neurology, 2013, 20, 1517-1523.	1.7	46

#	ARTICLE	IF	CITATIONS
2103	Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains. <i>Brain</i> , 2013, 136, 3051-3061.	3.7	145
2104	Axon degeneration in Parkinson's disease. <i>Experimental Neurology</i> , 2013, 246, 72-83.	2.0	367
2105	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 101-113.	1.2	79
2106	Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2013, 332, 136-140.	0.3	122
2107	Reduced sympathetic activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 179, 138-141.	1.4	46
2108	Cognitive dysfunction and REM sleep behavior disorder: Key findings in the literature and preliminary longitudinal findings. <i>International Journal of Psychophysiology</i> , 2013, 89, 213-217.	0.5	31
2109	Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. <i>Translational Neurodegeneration</i> , 2013, 2, 20.	3.6	71
2110	Transfer of human α -synuclein from the olfactory bulb to interconnected brain regions in mice. <i>Acta Neuropathologica</i> , 2013, 126, 555-573.	3.9	224
2111	Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2013, 2, 19.	3.6	59
2112	Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease. <i>Journal of Neurology</i> , 2013, 260, 3002-3009.	1.8	15
2113	A predictive model of neurodegeneration in idiopathic REM-sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1009-1012.	1.1	3
2114	Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. <i>Journal of Parkinson's Disease</i> , 2013, 3, 1-11.	1.5	79
2115	Neuropathological findings in benign tremulous Parkinsonism. <i>Movement Disorders</i> , 2013, 28, 145-152.	2.2	68
2117	Is there a one-way street from essential tremor to Parkinson's disease? Possible biological ramifications. <i>European Journal of Neurology</i> , 2013, 20, 1440-1444.	1.7	17
2118	The Function of α -Synuclein. <i>Neuron</i> , 2013, 79, 1044-1066.	3.8	664
2119	Neurodegenerative lesions: Seeding and spreading. <i>Revue Neurologique</i> , 2013, 169, 825-833.	0.6	24
2120	Selective Ablation of Dopamine β -Hydroxylase Neurons in the Brain by Immunotoxin-Mediated Neuronal Targeting. <i>Advances in Pharmacology</i> , 2013, 68, 155-166.	1.2	7
2121	Sesamol and naringenin reverse the effect of rotenone-induced PD rat model. <i>Neuroscience</i> , 2013, 254, 379-394.	1.1	61

#	ARTICLE	IF	CITATIONS
2122	The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease. <i>Pharmacological Reviews</i> , 2013, 65, 171-222.	7.1	279
2123	Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. <i>Journal of Neurology</i> , 2013, 260, 1332-1338.	1.8	247
2124	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. <i>Journal of Neurochemistry</i> , 2013, 125, 491-511.	2.1	116
2125	Quantification of cerebellar hemispheric purkinje cell linear density: 32 ET cases versus 16 controls. <i>Movement Disorders</i> , 2013, 28, 1854-1859.	2.2	64
2126	Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core. <i>Chemical Communications</i> , 2013, 49, 11212.	2.2	26
2127	Neuroimmunological Processes in Parkinson's Disease and their Relation to α -Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity. <i>ASN Neuro</i> , 2013, 5, AN20120066.	1.5	197
2128	The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. <i>Brain</i> , 2013, 136, 2120-2129.	3.7	250
2129	Advances in catheter-ablation treatment of AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 63-64.	6.1	7
2130	Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons. <i>Neurobiology of Aging</i> , 2013, 34, 286-297.	1.5	19
2131	Impairment of the septal cholinergic neurons in MPTP-treated A30P α -synuclein mice. <i>Neurobiology of Aging</i> , 2013, 34, 589-601.	1.5	16
2132	Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 131-137.	1.8	72
2133	Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. <i>Journal of Neural Transmission</i> , 2013, 120, 157-167.	1.4	29
2134	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. <i>Experimental Neurology</i> , 2013, 241, 148-155.	2.0	34
2135	Advancing research towards novel therapeutic approaches. <i>Nature Reviews Neurology</i> , 2013, 9, 70-71.	4.9	0
2136	Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant α -synuclein. <i>Neurobiology of Aging</i> , 2013, 34, 928-935.	1.5	58
2137	Phenotypic variability in three families with valosin-containing protein mutation. <i>European Journal of Neurology</i> , 2013, 20, 251-258.	1.7	66
2138	Epigenetics in Parkinson's and Alzheimer's Diseases. <i>Sub-Cellular Biochemistry</i> , 2013, 61, 507-525.	1.0	33
2139	100 years of Lewy pathology. <i>Nature Reviews Neurology</i> , 2013, 9, 13-24.	4.9	939

#	ARTICLE	IF	CITATIONS
2140	Inflammation and α -Synuclein's Prion-like Behavior in Parkinson's Disease—Is There a Link?. <i>Molecular Neurobiology</i> , 2013, 47, 561-574.	1.9	186
2141	α -Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	2.8	255
2142	Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression. , 2013, 137, 1-21.		10
2143	Biomarkers of Parkinson's disease: current status and future perspectives. <i>Drug Discovery Today</i> , 2013, 18, 155-162.	3.2	52
2144	Synucleins: Are they two-edged swords?. <i>Journal of Neuroscience Research</i> , 2013, 91, 161-166.	1.3	40
2145	Neuropathology of dementia in a large cohort of patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 864-868.	1.1	102
2146	A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming. <i>NeuroImage: Clinical</i> , 2013, 2, 95-102.	1.4	41
2147	Parallel PARKing: Parkinson's Genes Function in Common Pathway. <i>Neuron</i> , 2013, 77, 377-379.	3.8	3
2148	Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice. <i>Brain Research</i> , 2013, 1497, 85-100.	1.1	30
2149	Nucleotide excision repair in chronic neurodegenerative diseases. <i>DNA Repair</i> , 2013, 12, 568-577.	1.3	25
2150	Zonisamide for seizures in Parkinson's disease with dementia. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2013, 22, 324-325.	0.9	10
2151	The behavioural and neuropathological impact of intranigral AAV- α -synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. <i>Behavioural Brain Research</i> , 2013, 243, 6-15.	1.2	26
2152	Le systÃ©me nerveux entÃ©rique: une fenÃ©tre sur lâ€™atteinte du systÃ©me nerveux central dans la maladie de Parkinson. <i>Pratique Neurologique - FMC</i> , 2013, 4, 229-232.	0.1	0
2153	Prevalence and profile of Restless Legs Syndrome in Parkinson's disease and other neurodegenerative disorders: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 426-430.	1.1	84
2154	Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. <i>Artificial Intelligence in Medicine</i> , 2013, 58, 195-202.	3.8	50
2155	Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 227-231.	1.1	50
2156	Divergent α -synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. <i>Neurobiology of Disease</i> , 2013, 58, 183-190.	2.1	44
2157	Preclinical and clinical neural network changes in SCA2 parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 158-164.	1.1	17

#	ARTICLE	IF	CITATIONS
2158	Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2737-2750.	2.9	111
2159	Nonmotor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 581-583.	1.4	15
2160	Functional neuroanatomy of the central noradrenergic system. <i>Journal of Psychopharmacology</i> , 2013, 27, 659-693.	2.0	258
2161	Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: Comparison with conventional diffusion tensor imaging. <i>Magnetic Resonance Imaging</i> , 2013, 31, 1501-1506.	1.0	76
2162	Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein. <i>NeuroToxicology</i> , 2013, 37, 144-153.	1.4	19
2163	Î±-Synuclein mutations cluster around a putative protein loop. <i>Neuroscience Letters</i> , 2013, 546, 67-70.	1.0	36
2165	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 869-877.	1.1	119
2166	Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. <i>Neuroscience Letters</i> , 2013, 541, 93-98.	1.0	144
2168	Lewy pathology in an autopsy case of FTLD-MND with reduced cardiac MIBG uptake and depletion of cardiac sympathetic fibers. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 472-473.	1.1	2
2169	Neuropsychiatric Features of Frontal Lobe Dysfunction in Autopsy-Confirmed Patients with Lewy Bodies and Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 509-519.	0.6	22
2170	Expression of human E46K-mutated Î±-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. <i>Experimental Neurology</i> , 2013, 240, 44-56.	2.0	61
2171	Parkinson's disease cognitive network correlates with caudate dopamine. <i>NeuroImage</i> , 2013, 78, 204-209.	2.1	83
2172	Early cortical gray matter loss and cognitive correlates in non-demented Parkinson's patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1088-1093.	1.1	52
2173	Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease. <i>Neuroscience Letters</i> , 2013, 550, 64-68.	1.0	87
2174	SKF-96365 attenuates toxin-induced neuronal injury through opposite regulatory effects on Homer1a and Homer1b/c in cultured rat mesencephalic cells. <i>Neuroscience Letters</i> , 2013, 543, 183-188.	1.0	6
2175	Parasomnies et agitations nocturnes. <i>Pratique Neurologique - FMC</i> , 2013, 4, 119-123.	0.1	0
2176	Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. <i>NeuroImage</i> , 2013, 81, 484-495.	2.1	135
2177	Resting-state functional connectivity as a marker of disease progression in Parkinson's disease: A longitudinal MEG study. <i>NeuroImage: Clinical</i> , 2013, 2, 612-619.	1.4	74

#	ARTICLE	IF	CITATIONS
2178	Striatal shape in Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2510-2516.	1.5	60
2179	Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculo-pontine Nucleus in Parkinson Disease. <i>American Journal of Pathology</i> , 2013, 183, 1826-1840.	1.9	53
2180	Neuronal histaminergic system in aging and age-related neurodegenerative disorders. <i>Experimental Gerontology</i> , 2013, 48, 603-607.	1.2	27
2181	Topography of the sleep/wake states related EEG microstructure and transitions structure differentiates the functionally distinct cholinergic innervation disorders in rat. <i>Behavioural Brain Research</i> , 2013, 256, 108-118.	1.2	19
2182	Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease – A randomized study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 670-675.	1.1	137
2183	ATF4 Protects Against Neuronal Death in Cellular Parkinson's Disease Models by Maintaining Levels of Parkin. <i>Journal of Neuroscience</i> , 2013, 33, 2398-2407.	1.7	106
2184	Lewy body pathology in a patient with a homozygous <i>Parkin</i> deletion. <i>Movement Disorders</i> , 2013, 28, 388-391.	2.2	38
2185	Cerebrospinal fluid biomarkers in Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 131-140.	4.9	177
2186	Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinson's disease. <i>Brain</i> , 2013, 136, e234-e234.	3.7	34
2187	Mapping the Subcellular Distribution of α -Synuclein in Neurons using Genetically Encoded Probes for Correlated Light and Electron Microscopy: Implications for Parkinson's Disease Pathogenesis. <i>Journal of Neuroscience</i> , 2013, 33, 2605-2615.	1.7	121
2188	Parkin Disease. <i>JAMA Neurology</i> , 2013, 70, 571.	4.5	119
2189	LRRK2 interactions with α -synuclein in Parkinson's disease brains and in cell models. <i>Journal of Molecular Medicine</i> , 2013, 91, 513-522.	1.7	68
2190	The Lewy Body in Parkinson's Disease and Related Neurodegenerative Disorders. <i>Molecular Neurobiology</i> , 2013, 47, 495-508.	1.9	323
2191	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. <i>Acta Neuropathologica</i> , 2013, 125, 425-438.	3.9	20
2192	X-ray fluorescence analysis of iron and manganese distribution in primary dopaminergic neurons. <i>Journal of Neurochemistry</i> , 2013, 124, 250-261.	2.1	44
2193	Parkinson disease: from pathology to molecular disease mechanisms. <i>Free Radical Biology and Medicine</i> , 2013, 62, 132-144.	1.3	550
2194	Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. <i>Neurobiology of Disease</i> , 2013, 51, 35-42.	2.1	387
2195	Many roads lead to Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 122-123.	2.2	3

#	ARTICLE	IF	CITATIONS
2196	Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. <i>Movement Disorders</i> , 2013, 28, 131-144.	2.2	99
2197	Î±-Synuclein Elevation in Human Neurodegenerative Diseases: Experimental, Pathogenetic, and Therapeutic Implications. <i>Molecular Neurobiology</i> , 2013, 47, 484-494.	1.9	45
2198	Pain in Parkinson disease: A review of the literature. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 285-294.	1.1	122
2199	Cellular Aspects of Prion Replication In Vitro. <i>Viruses</i> , 2013, 5, 374-405.	1.5	53
2200	Molecular Chaperones, Alpha-Synuclein, and Neurodegeneration. <i>Molecular Neurobiology</i> , 2013, 47, 552-560.	1.9	47
2201	Parkinson's disease in the nuclear age of neuroinflammation. <i>Trends in Molecular Medicine</i> , 2013, 19, 187-196.	3.5	101
2202	Aggregation and neurotoxicity of recombinant Î±-synuclein aggregates initiated by dimerization. <i>Molecular Neurodegeneration</i> , 2013, 8, 5.	4.4	71
2203	The cerebellum in Parkinson's disease. <i>Brain</i> , 2013, 136, 696-709.	3.7	589
2204	Substantia Nigra Volume Loss Before Basal Forebrain Degeneration in Early Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 241.	4.5	56
2205	Î±-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. <i>Acta Neuropathologica</i> , 2013, 125, 753-769.	3.9	369
2206	Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 61-70.	1.2	2
2207	Proteolytic clearance of extracellular Î±-synuclein as a new therapeutic approach against Parkinson disease. <i>Prion</i> , 2013, 7, 121-126.	0.9	20
2208	In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 571-576.	1.4	40
2209	The pathology roadmap in Parkinson disease. <i>Prion</i> , 2013, 7, 85-91.	0.9	56
2210	Heat-mediated enrichment of Î±-synuclein from cells and tissue for assessing post-translational modifications. <i>Journal of Neurochemistry</i> , 2013, 126, 673-684.	2.1	21
2211	Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration. <i>Neurochemistry International</i> , 2013, 62, 776-783.	1.9	29
2212	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	4.9	602
2213	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 469-482.	4.9	164

#	ARTICLE	IF	CITATIONS
2214	Changes in properties of serine 129 phosphorylated α -synuclein with progression of Lewy-type histopathology in human brains. <i>Experimental Neurology</i> , 2013, 240, 190-204.	2.0	120
2215	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	4.9	126
2216	Association of pain, Parkinson's disease, and restless legs syndrome. <i>Journal of the Neurological Sciences</i> , 2013, 327, 32-34.	0.3	34
2217	Neuropsychological Deficits Associated with Destruction of the Right Nigrostriatal Pathway. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 729-734.	1.2	1
2218	Genetics and iron in the systems biology of Parkinson's disease and some related disorders. <i>Neurochemistry International</i> , 2013, 62, 637-652.	1.9	56
2219	Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. <i>Metallomics</i> , 2013, 5, 91.	1.0	64
2220	Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. <i>Nanomedicine</i> , 2013, 8, 43-56.	1.7	172
2221	Structures and Free Energy Landscapes of the A53T Mutant-Type α -Synuclein Protein and Impact of A53T Mutation on the Structures of the Wild-Type α -Synuclein Protein with Dynamics. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1101-1113.	1.7	66
2222	Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation. <i>Sleep Medicine Reviews</i> , 2013, 17, 367-375.	3.8	89
2223	Handbook of Parkinson's Disease. , 2013, , .		14
2224	Differences in Brain Activation Between Tremor- and Nontremor-Dominant Parkinson Disease. <i>JAMA Neurology</i> , 2013, 70, 100.	4.5	72
2225	Parkinson's disease: an update on pathogenesis and treatment. <i>Journal of Neurology</i> , 2013, 260, 1433-1440.	1.8	29
2226	Circadian and sleep disorders in Parkinson's disease. <i>Experimental Neurology</i> , 2013, 243, 45-56.	2.0	190
2227	Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 717-724.	1.1	133
2228	α -Synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. <i>Journal of Molecular Medicine</i> , 2013, 91, 693-703.	1.7	55
2229	Applying chaperones to protein-misfolding disorders: Molecular chaperones against α -synuclein in Parkinson's disease. <i>International Journal of Biological Macromolecules</i> , 2013, 60, 196-205.	3.6	38
2230	Subthalamic nucleus: A key structure for emotional component synchronization in humans. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 358-373.	2.9	142
2231	Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. <i>Movement Disorders</i> , 2013, 28, 597-604.	2.2	182

#	ARTICLE	IF	CITATIONS
2232	Stages of pTDP ⁴³ pathology in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2013, 74, 20-38.	2.8	820
2233	Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration. <i>Molecular Neurobiology</i> , 2013, 47, 509-524.	1.9	112
2234	Behavioral testing regimens in genetic-based animal models of Parkinson's disease: Cogencies and caveats. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 846-859.	2.9	11
2235	Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?. , 2013, 140, 34-52.		193
2236	Is there a need to redefine Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2013, 120, 9-17.	1.4	11
2237	Mitochondrial dynamics in neurodegeneration. <i>Trends in Cell Biology</i> , 2013, 23, 64-71.	3.6	409
2238	In Vitro Human Corticogenesis. <i>Neuron</i> , 2013, 77, 379-381.	3.8	2
2239	Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?. <i>Movement Disorders</i> , 2013, 28, 31-40.	2.2	320
2240	Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 695-705.	1.4	11
2241	New perspectives on the pathophysiology of Parkinson's disease as assessed by saccade performance: A clinical review. <i>Clinical Neurophysiology</i> , 2013, 124, 1491-1506.	0.7	102
2242	Regulation of dopamine D3 receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. <i>Neuroscience</i> , 2013, 248, 112-126.	1.1	25
2243	Distinct α -Synuclein Strains Differentially Promote Tau Inclusions in Neurons. <i>Cell</i> , 2013, 154, 103-117.	13.5	574
2244	Behavioural recovery on simple and complex tasks by means of cell replacement therapy in unilateral 6-hydroxydopamine-lesioned mice. <i>European Journal of Neuroscience</i> , 2013, 37, 1691-1704.	1.2	9
2245	Adult neurogenesis in Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 459-473.	2.4	129
2246	Sleep disorders in Parkinson's disease: a narrative review of the literature. <i>Reviews in the Neurosciences</i> , 2013, 24, 279-91.	1.4	43
2247	Functional MRI in Idiopathic Parkinson Disease and Parkinsonism. , 2013, , 143-157.		1
2248	Colonic inflammation in Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 50, 42-48.	2.1	482
2249	Specific frequency band of amplitude low-frequency γ -rhythm predicts Parkinson's disease. <i>Behavioural Brain Research</i> , 2013, 252, 18-23.	1.2	56

#	ARTICLE	IF	CITATIONS
2250	Nighttime Blood Pressure and White Matter Hyperintensities in Patients With Parkinson Disease. <i>Chronobiology International</i> , 2013, 30, 811-817.	0.9	33
2251	Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. <i>Neuropharmacology</i> , 2013, 65, 48-57.	2.0	21
2252	Impaired pain processing in Parkinson's disease and its relative association with the sense of smell. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 43-46.	1.1	9
2253	InÂvivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 47-52.	1.1	185
2254	Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 27-31.	1.1	40
2255	Foveal vision is impaired in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1-14.	1.1	59
2257	Cortical thinning is associated with disease stages and dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 875-882.	0.9	155
2258	Orthostatic hypotension, non-dipping and striatal dopamine in Parkinson disease. <i>Neurological Sciences</i> , 2013, 34, 557-560.	0.9	20
2259	Visualizing Neurotransmitters and Metabolites in the Central Nervous System by High Resolution and High Accuracy Mass Spectrometric Imaging. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1049-1056.	1.7	29
2260	Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models. <i>Learning and Memory</i> , 2013, 20, 592-600.	0.5	54
2261	Gender and onset age-related features of non-motor symptoms of patients with Parkinson's disease – A study from Southwest China. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 961-965.	1.1	75
2262	Clinical features and nigrostriatal dysfunction in patients with combined postural and resting tremors. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1118-1122.	1.1	3
2263	Implicit olfactory processing attenuates motor disturbances in idiopathic Parkinson's disease. <i>Cortex</i> , 2013, 49, 1241-1251.	1.1	7
2264	Diffusion Tensor Imaging Reveals White Matter Changes Associated With Cognitive Status in Patients With Parkinson's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 154-164.	0.9	60
2265	Disturbed sleep in Parkinson's disease: anatomical and pathological correlates. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 644-653.	1.8	63
2266	Î±-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. <i>Brain Structure and Function</i> , 2014, 219, 1513-26.	1.2	52
2267	Pathogenesis of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 24-30.	2.2	256
2268	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 738-744.	1.3	22

#	ARTICLE	IF	CITATIONS
2269	Movement Disorders with Dementia in Older Adults. , 2013, , 333-361.		1
2270	Parkinson's disease subtypes: lost in translation?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 409-415.	0.9	181
2271	Attenuated neural response to gamble outcomes in drug-naive patients with Parkinsonâ€™s disease. Brain, 2013, 136, 1192-1203.	3.7	38
2272	Brainstem Aminergic Nuclei and Late-Life Depressive Symptoms. JAMA Psychiatry, 2013, 70, 1320.	6.0	58
2273	Keap1 Is Localized in Neuronal and Glial Cytoplasmic Inclusions in Various Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2013, 72, 18-28.	0.9	61
2274	Reply: Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinsonâ€™s disease. Brain, 2013, 136, e235-e235.	3.7	3
2275	Safinamide: a novel anti-Parkinsonian drug with multiple actions. Neurodegenerative Disease Management, 2013, 3, 231-240.	1.2	6
2276	Olfaction and imaging biomarkers in premotor <i>LRRK2</i> G2019S-associated Parkinson disease. Neurology, 2013, 80, 621-626.	1.5	81
2277	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology, 2013, 81, 1226-1234.	1.5	153
2278	Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives. Current Medicinal Chemistry, 2013, 20, 735-750.	1.2	7
2282	Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: The Progression Markers in the Premotor Phase Study. Neuroepidemiology, 2013, 41, 174-182.	1.1	20
2283	Thalamic Projection Fiber Integrity in de novo Parkinson Disease. American Journal of Neuroradiology, 2013, 34, 74-79.	1.2	48
2284	Evaluation of Parkinson Disease and Alzheimer Disease with the Use of Neuromelanin MR Imaging and¹²³I-Metaiodobenzylguanidine Scintigraphy. American Journal of Neuroradiology, 2013, 34, 2113-2118.	1.2	45
2285	Adaptive changes in autophagy after UPS impairment in Parkinson's disease. Acta Pharmacologica Sinica, 2013, 34, 667-673.	2.8	47
2286	Tubulin Polymerization-promoting Protein (TPPP/p25 ^{1±}) Promotes Unconventional Secretion of α -Synuclein through Exophagy by Impairing Autophagosome-Lysosome Fusion. Journal of Biological Chemistry, 2013, 288, 17313-17335.	1.6	189
2287	An ERP study of vocal emotion processing in asymmetric Parkinsonâ€™s disease. Social Cognitive and Affective Neuroscience, 2013, 8, 918-927.	1.5	36
2288	Use of Indian smell identification test for evaluating olfaction in idiopathic Parkinsonâ€™s disease patients in India. Neurology India, 2013, 61, 365.	0.2	18
2289	Molecular Events Underlying Parkinsonâ€™s Disease â€“ An Interwoven Tapestry. Frontiers in Neurology, 2013, 4, 33.	1.1	57

#	ARTICLE	IF	CITATIONS
2290	Impaired Baroreflex Function in Mice Overexpressing Alpha-Synuclein. <i>Frontiers in Neurology</i> , 2013, 4, 103.	1.1	20
2291	Granulocyte-colony stimulating factor improves Parkinson's disease associated with co-morbid depression: An experimental exploratory study. <i>Indian Journal of Pharmacology</i> , 2013, 45, 612.	0.4	13
2292	Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-9.	1.0	20
2293	Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a <i>Drosophila</i> MJD/SCA3 Model. <i>PLoS Genetics</i> , 2013, 9, e1003781.	1.5	73
2294	Research on the Premotor Symptoms of Parkinson's Disease: Clinical and Etiological Implications. <i>Environmental Health Perspectives</i> , 2013, 121, 1245-1252.	2.8	68
2295	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 544-551.	0.9	94
2296	Early Alzheimer's and Parkinson's Disease Pathology in Urban Children: Friend versus Foe Responses? It Is Time to Face the Evidence. <i>BioMed Research International</i> , 2013, 2013, 1-16.	0.9	96
2297	Biophysical Insights into How Surfaces, Including Lipid Membranes, Modulate Protein Aggregation Related to Neurodegeneration. <i>Frontiers in Neurology</i> , 2013, 4, 17.	1.1	94
2298	Do swallowing exercises improve swallowing dynamic and quality of life in Parkinson's disease?. <i>NeuroRehabilitation</i> , 2013, 32, 949-955.	0.5	53
2299	White matter microstructure deteriorates across cognitive stages in Parkinson disease. <i>Neurology</i> , 2013, 80, 1841-1849.	1.5	129
2300	Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment. <i>Restorative Neurology and Neuroscience</i> , 2013, 31, 155-167.	0.4	28
2301	Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction. <i>RNA Biology</i> , 2013, 10, 1093-1106.	1.5	44
2302	Pedunculopontine Cholinergic Cell Loss in Hallucinating Parkinson Disease Patients but Not in Dementia With Lewy Bodies Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1162-1170.	0.9	38
2303	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. <i>Journal of Parkinson's Disease</i> , 2013, 3, 415-459.	1.5	68
2304	The pallidopyramidal syndromes. <i>Current Opinion in Neurology</i> , 2013, 26, 381-394.	1.8	25
2305	The Neurobiology of Sleep. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 19-31.	0.4	38
2306	Non-Motor Symptoms and Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 1-2.	0.3	23
2307	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 774-783.	0.9	199

#	ARTICLE	IF	CITATIONS
2308	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.	4.5	132
2309	Genetic Variations of GAK in Two Chinese Parkinson's Disease Populations: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e67506.	1.1	18
2310	Mortalin's multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration. <i>Acta Virologica</i> , 2013, 57, 3-15.	0.3	63
2311	Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. <i>Neurology</i> , 2013, 80, 1202-1208.	1.5	222
2312	Cognitive Change in Newly-Diagnosed Patients with Parkinson's Disease: A 5-Year Follow-up Study. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 695-708.	1.2	74
2313	Microarray Analysis of Transcriptome of Medulla Identifies Potential Biomarkers for Parkinson's Disease. <i>International Journal of Genomics</i> , 2013, 2013, 1-7.	0.8	12
2314	Neuroprotective Function of 14-3-3 Proteins in Neurodegeneration. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	75
2315	Parkinson's disease in the elderly and the comprehensive geriatric assessment. <i>Nigerian Medical Journal</i> , 2013, 54, 146.	0.6	3
2316	Erken Evre Parkinson Hastalarında Motor Olmayan Semptomların Değerlendirilmesi. <i>Türk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2013, 19, 97-103.	0.1	4
2317	Change in Plasma Levels of Amino Acid Neurotransmitters and its Correlation with Clinical Heterogeneity in Early Parkinson's Disease Patients. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 889-896.	1.9	24
2318	Autobiographical memory in Parkinson's disease: A retrieval deficit. <i>Journal of Neuropsychology</i> , 2013, 7, 164-178.	0.6	10
2319	The hallmarks of Parkinson's disease. <i>FEBS Journal</i> , 2013, 280, 5981-5993.	2.2	214
2320	Mind the gut: secretion of α -synuclein by enteric neurons. <i>Journal of Neurochemistry</i> , 2013, 125, 487-490.	2.1	30
2321	Characteristics of rapid eye movement sleep behavior disorder in narcolepsy. <i>Sleep and Biological Rhythms</i> , 2013, 11, 65-74.	0.5	2
2322	Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 362-370.	1.0	35
2323	Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study. <i>European Journal of Neurology</i> , 2013, 20, 1398-1404.	1.7	58
2324	Caudo-rostral brain spreading of α -synuclein through vagal connections. <i>EMBO Molecular Medicine</i> , 2013, 5, 1119-1127.	3.3	223
2325	Regional vulnerability of hippocampal subfields and memory deficits in Parkinson's disease. <i>Hippocampus</i> , 2013, 23, 720-728.	0.9	63

#	ARTICLE	IF	CITATIONS
2326	History of the researches on rapid eye movement sleep behavior disorder in Japan. <i>Sleep and Biological Rhythms</i> , 2013, 11, 1-5.	0.5	2
2327	The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. <i>Journal of Neurochemistry</i> , 2013, 125, 932-943.	2.1	52
2328	Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. <i>European Journal of Neurology</i> , 2013, 20, 1459.	1.7	11
2329	Second-generation dopamine agonists and recollection impairments in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 284-305.	0.6	9
2330	Physiotherapy management of Parkinson's and of older people. , 2013, , 539-559.		0
2331	Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. <i>RSC Drug Discovery Series</i> , 2013, , 392-413.	0.2	1
2332	Not all sounds sound the same: Parkinson's disease affects differently emotion processing in music and in speech prosody. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 373-392.	0.8	47
2333	Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 504-509.	2.2	132
2334	The Pathophysiology and Clinical Relevance of Rapid Eye Movement Sleep Behavior Disorder. <i>Internal Medicine</i> , 2013, 52, 521-522.	0.3	0
2335	Bright light exposure reduces TH-positive dopamine neurons: implications of light pollution in Parkinson's disease epidemiology. <i>Scientific Reports</i> , 2013, 3, 1395.	1.6	44
2336	Predictors of Mild Cognitive Impairment in Early-Stage Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 168-178.	0.6	23
2337	Working memory in Parkinson's disease: The effects of depression and side of onset of motor symptoms.. <i>Neuropsychology</i> , 2013, 27, 303-313.	1.0	13
2338	Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 281-290.	0.6	7
2340	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
2342	Early cognitive impairment. , 0, , 163-176.		1
2343	Parkinson's disease dementia. , 0, , 177-191.		0
2344	Sleep disturbances. , 0, , 192-210.		0
2346	Barriers to novel therapeutics in amyotrophic lateral sclerosis. <i>Neurodegenerative Disease Management</i> , 2013, 3, 525-537.	1.2	0

#	ARTICLE	IF	CITATIONS
2347	Mild depressive symptoms are associated with gait impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 634-639.	2.2	38
2348	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2013, 3, 105-107.	1.2	0
2349	Parkinson's disease vaccine: clinical trial challenges when striving for disease modification. <i>Clinical Investigation</i> , 2013, 3, 1-4.	0.0	1
2350	Essential Tremor Followed by Progressive Supranuclear Palsy: Postmortem Reports of 11 Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 8-17.	0.9	40
2351	Nonmotor Symptoms in Drug-Induced Parkinsonism and Drug-Naïve Parkinson Disease. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 36-41.	0.3	35
2352	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.3	27
2353	Visual Hallucinations and Cognitive Impairment in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 657-662.	0.3	29
2354	Functional Genomics Reveals Dysregulation of Cortical Olfactory Receptors in Parkinson Disease: Novel Putative Chemoreceptors in the Human Brain. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 524-539.	0.9	111
2355	Many roads to Parkinson's disease neurodegeneration: Head trauma "A road more traveled than we know?". <i>Movement Disorders</i> , 2013, 28, 1167-1170.	2.2	4
2356	Unimpaired postprandial pancreatic polypeptide secretion in Parkinson's disease and REM sleep behavior disorder. <i>Movement Disorders</i> , 2013, 28, 529-533.	2.2	9
2357	Stereopsis and extrastriate cortical atrophy in Parkinson's disease. <i>NeuroReport</i> , 2013, 24, 229-232.	0.6	23
2358	Review: management of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 321.	1.0	51
2363	Neurodegenerative disorders. , 0, , 23-71.		0
2364	Muscle strength and executive function as complementary parameters for the assessment of impairment in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 948-954.	0.3	2
2365	Availability of olfactory bulb: experience from a British Brain Bank. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 110-112.	0.3	1
2366	Role of Autophagy in Parkinson's Disease. , 2013, , .		1
2367	Attenuated Heart Rate Response is Associated with Hypocretin Deficiency in Patients with Narcolepsy. <i>Sleep</i> , 2013, 36, 91-98.	0.6	47
2368	Magnetic resonance spectroscopy in Parkinson's disease. , 0, , 229-237.		0

#	ARTICLE	IF	CITATIONS
2369	DYSPHAGIA AND SIALORRHEA: Arquivos De Gastroenterologia, 2013, 50, 42-49.	0.3	37
2370	Differentiating Non-Motor Symptoms in Parkinson's Disease from Controls and Hemifacial Spasm. PLoS ONE, 2013, 8, e49596.	1.1	9
2371	Low CSF Levels of Both α -Synuclein and the α -Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	1.1	123
2372	Protective Effects of SKF-96365, a Non-Specific Inhibitor of SOCE, against MPP+-Induced Cytotoxicity in PC12 Cells: Potential Role of Homer1. PLoS ONE, 2013, 8, e55601.	1.1	45
2373	Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional Profiling. PLoS ONE, 2013, 8, e63862.	1.1	185
2374	Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors. PLoS ONE, 2013, 8, e64844.	1.1	21
2375	Olfaction in Three Genetic and Two MPTP-Induced Parkinson's Disease Mouse Models. PLoS ONE, 2013, 8, e77509.	1.1	32
2376	Sleep Disorders in Parkinson's Disease: Clinical Features, Iron Metabolism and Related Mechanism. PLoS ONE, 2013, 8, e82924.	1.1	28
2377	LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease. Experimental Neurobiology, 2013, 22, 249-257.	0.7	18
2378	Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective. Experimental Neurobiology, 2013, 22, 77-83.	0.7	31
2379	Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes. CNS and Neurological Disorders - Drug Targets, 2013, 999, 19-20.	0.8	9
2380	Dopamine prevents lipid peroxidation-induced accumulation of toxic α -synuclein oligomers by preserving autophagy-lysosomal function. Frontiers in Cellular Neuroscience, 2013, 7, 81.	1.8	14
2381	Neuropathological Diagnostic Considerations in Hyperkinetic Movement Disorders. Frontiers in Neurology, 2013, 4, 7.	1.1	17
2382	Motor Cortical Plasticity in Parkinson's Disease. Frontiers in Neurology, 2013, 4, 128.	1.1	64
2383	Dopamine system: manager of neural pathways. Frontiers in Human Neuroscience, 2013, 7, 854.	1.0	16
2384	Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Frontiers in Neuroscience, 2013, 7, 52.	1.4	15
2385	Neural and behavioral substrates of subtypes of Parkinson's disease. Frontiers in Systems Neuroscience, 2013, 7, 117.	1.2	24
2386	Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. Clinical and Developmental Immunology, 2013, 2013, 1-20.	3.3	30

#	ARTICLE	IF	CITATIONS
2387	Visual Hallucinations in PD and Lewy Body Dementias: Old and New Hypotheses. Behavioural Neurology, 2013, 27, 479-493.	1.1	68
2388	Autophagy: A Possible Defense Mechanism in Parkinson's Disease?. , 0, , .		0
2389	Olfactory Dysfunction. Deutsches Ärztblatt International, 2013, 110, 1-7, e1.	0.6	97
2390	Motor Parkinson's disease and structure. , 0, , 26-43.		0
2391	Neuroimaging of idiopathic REM sleep behavior disorder. , 0, , 316-332.		0
2394	Parkinson's disease: making the diagnosis and monitoring progression. British Journal of Neuroscience Nursing, 2013, 9, 167-171.	0.1	2
2395	Insomnia and Sleepiness in Parkinson Disease: Associations with Symptoms and Comorbidities. Journal of Clinical Sleep Medicine, 2013, 09, 1131-1137.	1.4	74
2396	PARK2 Induces Autophagy Removal of Impaired Mitochondria via Ubiquitination. , 2014, , 175-188.		0
2398	Protein Transmission, Seeding and Degradation: Key Steps for Î±-Synuclein Prion-Like Propagation. Experimental Neurobiology, 2014, 23, 324-336.	0.7	45
2399	Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?. Frontiers in Bioscience - Landmark, 2014, 19, 272.	3.0	78
2400	Dopamine Reduction in the Substantia Nigra of Parkinson's Disease Patients Confirmed by In Vivo Magnetic Resonance Spectroscopic Imaging. PLoS ONE, 2014, 9, e84081.	1.1	80
2401	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. PLoS ONE, 2014, 9, e98906.	1.1	24
2402	Reduced Topological Efficiency in Cortical-Basal Ganglia Motor Network of Parkinson's Disease: A Resting State fMRI Study. PLoS ONE, 2014, 9, e108124.	1.1	40
2403	Nonmotor Symptoms in LRRK2 G2019S Associated Parkinsonâ€™s Disease. PLoS ONE, 2014, 9, e108982.	1.1	79
2404	Neural Substrates of Cognitive Subtypes in Parkinson's Disease: A 3-Year Longitudinal Study. PLoS ONE, 2014, 9, e110547.	1.1	25
2405	Diffusion Tensor Imaging of Parkinsonâ€™s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study. PLoS ONE, 2014, 9, e112638.	1.1	72
2406	Differential Changes in Postsynaptic Density Proteins in Postmortem Huntingtonâ€™s Disease and Parkinsonâ€™s Disease Human Brains. Journal of Neurodegenerative Diseases, 2014, 2014, 1-14.	1.1	29
2407	Complex Network-Driven View of Genomic Mechanisms Underlying Parkinsonâ€™s Disease: Analyses in Dorsal Motor Vagal Nucleus, Locus Coeruleus, and Substantia Nigra. BioMed Research International, 2014, 2014, 1-16.	0.9	26

#	ARTICLE	IF	CITATIONS
2408	Alterations of Eye Movement Control in Neurodegenerative Movement Disorders. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-11.	0.6	54
2409	Delayed latencies of auditory evoked potential P300 are associated with the severity of Parkinson's disease in older patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 296-300.	0.3	24
2410	TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 137-149.	0.8	29
2411	Differential role of CSF alpha-synuclein species, tau, and A β 242 in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 53.	1.7	139
2412	<i>Caenorhabditis elegans</i> : a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 89.	1.7	53
2413	Alpha and beta EEG power reflects L-dopa acute administration in parkinsonian patients. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 302.	1.7	62
2414	Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 275.	1.8	67
2415	Dopamine and the Biology of Creativity: Lessons from Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 55.	1.1	42
2416	The functional significance of newly born neurons integrated into olfactory bulb circuits. <i>Frontiers in Neuroscience</i> , 2014, 8, 121.	1.4	69
2417	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 57.	1.4	73
2418	Prions and Prion-Like Pathogens in Neurodegenerative Disorders. <i>Pathogens</i> , 2014, 3, 149-163.	1.2	14
2419	Dysautonomia in Narcolepsy: Evidence by Questionnaire Assessment. <i>Journal of Clinical Neurology</i>		

#	ARTICLE	IF	CITATIONS
2427	Olfactory dysfunction in dementia. <i>World Journal of Clinical Cases</i> , 2014, 2, 661.	0.3	75
2428	<i>Neuropathology of Dementia Disorders.</i> , 2014, 04, .		10
2429	<i>Neuronal Inclusions.</i> , 2014, , 441-455.		1
2430	<i>Parkinson's disease and other movement disorders.</i> , 0, , 567-584.		0
2431	<i>Melatonin in Parkinsonâ€™s Disease.</i> , 2014, , .		5
2433	<i>Neurological Diseases and Olfactory Disorders.</i> , 2014, , .		0
2435	Use of Hyposmia and Other Non-Motor Symptoms to Distinguish between Drug-Induced Parkinsonism and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 169-173.	1.5	20
2436	Solving the puzzle of Parkinsonâ€™s disease using induced pluripotent stem cells. <i>Experimental Biology and Medicine</i> , 2014, 239, 1421-1432.	1.1	16
2437	Vaccination strategies for Parkinson disease. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 852-867.	1.4	35
2438	Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons. <i>Brain</i> , 2014, 137, 354-365.	3.7	41
2439	Autophagy modulates SNCA/ α -synuclein release, thereby generating a hostile microenvironment. <i>Autophagy</i> , 2014, 10, 2171-2192.	4.3	174
2440	Muscle artifacts in single trial EEG data distinguish patients with Parkinson's disease from healthy individuals. , 2014, 2014, 3292-5.		3
2441	Accumulation of α -synuclein in dementia with Lewy bodies is associated with decline in the α -synuclein-degrading enzymes kallikrein-6 and calpain-1. <i>Acta Neuropathologica Communications</i> , 2014, 2, 164.	2.4	13
2442	T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. <i>Journal of Neuroinflammation</i> , 2014, 11, 201.	3.1	183
2443	In vitro aggregation assays for the characterization of α -synuclein prion-like properties. <i>Prion</i> , 2014, 8, 19-32.	0.9	66
2445	Alpha-synuclein biology in Lewy body diseases. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 73.	3.0	288
2446	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 76.	3.0	45
2447	Chronic neurodegenerative consequences of traumatic brain injury. <i>Restorative Neurology and Neuroscience</i> , 2014, 32, 337-365.	0.4	99

#	ARTICLE	IF	CITATIONS
2448	Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 779-786.	1.3	7
2449	Analysis of cerebral blood flow in Parkinson's disease with dementia versus subcortical ischemic vascular dementia using single photon emission computed tomography. <i>International Journal of Imaging Systems and Technology</i> , 2014, 24, 306-312.	2.7	2
2450	Neurodegenerative disorders: Dysregulation of a carefully maintained balance?. <i>Experimental Gerontology</i> , 2014, 58, 279-291.	1.2	17
2451	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	0.9	90
2452	Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System. <i>Frontiers in Endocrinology</i> , 2014, 5, 142.	1.5	28
2453	Influence of Deep Breathing on Heart Rate Variability in Parkinson's Disease: Co-relation with Severity of Disease and Non-Motor Symptom Scale Score. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, BC01-3.	0.8	5
2454	REM sleep diversity following the pedunculopontine tegmental nucleus lesion in rat. <i>Behavioural Brain Research</i> , 2014, 271, 258-268.	1.2	16
2455	Abnormal metabolic network activity in REM sleep behavior disorder. <i>Neurology</i> , 2014, 82, 620-627.	1.5	151
2456	Physical Exercise-Induced Adult Neurogenesis: A Good Strategy to Prevent Cognitive Decline in Neurodegenerative Diseases?. <i>BioMed Research International</i> , 2014, 2014, 1-20.	0.9	82
2457	Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.. <i>Behavioral Neuroscience</i> , 2014, 128, 110-121.	0.6	39
2458	When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?. <i>Vojnosanitetski Pregled</i> , 2014, 71, 346-351.	0.1	10
2459	Cerebellar Influence on Motor Cortex Plasticity: Behavioral Implications for Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 68.	1.1	38
2460	Preclinical Polymodal Hallucinations for 13 Years before Dementia with Lewy Bodies. <i>Behavioural Neurology</i> , 2014, 2014, 1-13.	1.1	3
2461	Parkinson's Disease and the Claustrum. , 2014, , 277-297.		4
2462	Axon degeneration and PGC1 α -mediated protection in a vertebrate model of α -synuclein toxicity. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 571-82.	1.2	65
2463	Anterior Temporal Atrophy and Posterior Progression in Patients with Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2014, 14, 125-132.	0.8	22
2464	Functional Anatomy of Essential Tremor: Lessons from Neuroimaging. <i>American Journal of Neuroradiology</i> , 2014, 35, 1450-1457.	1.2	18
2465	Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 8.	2.2	17

#	ARTICLE	IF	CITATIONS
2466	<i>In vitro</i> dopaminergic neurotoxicity of pesticides: a link with neurodegeneration?. <i>Veterinary Quarterly</i> , 2014, 34, 120-131.	3.0	12
2467	Safinamide for the treatment of Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 747-759.	1.3	17
2468	Proteomics as a new paradigm to tackle Parkinson's disease research challenges. <i>Translational Proteomics</i> , 2014, 4-5, 1-17.	1.2	11
2469	Review: The future of cell therapies and brain repair: Parkinson's disease leads the way. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 60-70.	1.8	71
2470	Gut feelings about smoking and coffee in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 976-979.	2.2	91
2471	Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. <i>Movement Disorders</i> , 2014, 29, 1010-1018.	2.2	297
2472	Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1244-1251.	2.2	122
2473	Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy. <i>Molecular Therapy</i> , 2014, 22, 487-497.	3.7	141
2474	Olfactory Identification and Cognitive Performance in Community-Dwelling Older Adults With Mild Cognitive Impairment. <i>Chemical Senses</i> , 2014, 39, 39-46.	1.1	39
2475	Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α -synuclein. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00065.	1.1	40
2476	M. paratuberculosis and Parkinson's disease – Is this a trigger. <i>Medical Hypotheses</i> , 2014, 83, 709-712.	0.8	26
2477	Emergence of Deglutology: A Transdisciplinary Field. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2046-2048.	2.4	2
2478	Morbidity in early Parkinson's disease and prior to diagnosis. <i>Brain and Behavior</i> , 2014, 4, 446-452.	1.0	15
2479	Neuropathologic Assessment of Dementia Markers in Identical and Fraternal Twins. <i>Brain Pathology</i> , 2014, 24, 317-333.	2.1	12
2480	Reduced α -synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. <i>European Journal of Neurology</i> , 2014, 21, 388-394.	1.7	67
2481	Motor impulsivity in Parkinson disease: Associations with COMT and DRD2 polymorphisms. <i>Scandinavian Journal of Psychology</i> , 2014, 55, 278-286.	0.8	17
2482	<i>N</i> -acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. <i>Brain and Behavior</i> , 2014, 4, 108-122.	1.0	323
2483	Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. <i>Human Brain Mapping</i> , 2014, 35, 792-809.	1.9	58

#	ARTICLE	IF	CITATIONS
2484	Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: The role of rule reconfiguration. <i>Journal of Neuropsychology</i> , 2014, 8, 53-74.	0.6	9
2485	Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 300-306.	1.0	25
2486	Are there roles for brain cell senescence in aging and neurodegenerative disorders?. <i>Biogerontology</i> , 2014, 15, 643-660.	2.0	101
2487	Advances in Intravital Microscopy. , 2014, , .		4
2488	Concomitant accumulation of Î±-synuclein and TDP-43 in a patient with corticobasal degeneration. <i>Journal of Neurology</i> , 2014, 261, 2209-2217.	1.8	11
2489	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. <i>Movement Disorders</i> , 2014, 29, 1476-1485.	2.2	384
2490	Olfactory identification in <i><sc>LRRK</sc> 2</i> G2019S mutation carriers: a relevant marker?. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 670-678.	1.7	43
2491	Alpha-Î±synuclein in the appendiceal mucosa of neurologically intact subjects. <i>Movement Disorders</i> , 2014, 29, 991-998.	2.2	107
2492	The high-Î±ffinity D2/D3 agonist D512 protects <sc>PC</sc>12 cells from 6-Î±-OHDA</sc>-induced apoptotic cell death and rescues dopaminergic neurons in the <sc>MPTP</sc> mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2014, 131, 74-85.	2.1	26
2495	Suprathreshold odor intensity perception in early-Î±stage Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1208-1212.	2.2	11
2496	Does it talk the talk? On the role of basal ganglia in emotive speech processing. <i>Behavioral and Brain Sciences</i> , 2014, 37, 556-557.	0.4	2
2497	The basal ganglia within a cognitive system in birds and mammals. <i>Behavioral and Brain Sciences</i> , 2014, 37, 568-569.	0.4	6
2498	Association of Parkinson Disease Risk Loci With Mild Parkinsonian Signs in Older Persons. <i>JAMA Neurology</i> , 2014, 71, 429.	4.5	38
2499	The sensorimotor and social sides of the architecture of speech. <i>Behavioral and Brain Sciences</i> , 2014, 37, 569-570.	0.4	33
2500	Speech, vocal production learning, and the comparative method. <i>Behavioral and Brain Sciences</i> , 2014, 37, 566-567.	0.4	1
2501	The sound of one hand clapping: Overdetermination and the pansensory nature of communication. <i>Behavioral and Brain Sciences</i> , 2014, 37, 546-547.	0.4	0
2502	The evolution of coordinated vocalizations before language. <i>Behavioral and Brain Sciences</i> , 2014, 37, 549-550.	0.4	6
2503	Why we can talk, debate, and change our minds: Neural circuits, basal ganglia operations, and transcriptional factors. <i>Behavioral and Brain Sciences</i> , 2014, 37, 561-562.	0.4	2

#	ARTICLE	IF	CITATIONS
2504	Functional neuroimaging of human vocalizations and affective speech. Behavioral and Brain Sciences, 2014, 37, 554-555.	0.4	9
2505	Speech prosody, reward, and the corticobulbar system: An integrative perspective. Behavioral and Brain Sciences, 2014, 37, 573-574.	0.4	1
2506	Brain mechanisms of acoustic communication in humans and nonhuman primates: An evolutionary perspective. Behavioral and Brain Sciences, 2014, 37, 529-546.	0.4	173
2507	Beyond cry and laugh: Toward a multilevel model of language production. Behavioral and Brain Sciences, 2014, 37, 548-549.	0.4	3
2510	Early human communication helps in understanding language evolution. Behavioral and Brain Sciences, 2014, 37, 560-561.	0.4	3
2511	Comparative analyses of speech and language converge on birds. Behavioral and Brain Sciences, 2014, 37, 547-548.	0.4	4
2512	Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS. Orphanet Journal of Rare Diseases, 2014, 9, 86.	1.2	27
2513	The role of the LRRK2 gene in Parkinsonism. Molecular Neurodegeneration, 2014, 9, 47.	4.4	180
2514	The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimer's Research and Therapy, 2014, 6, 46.	3.0	181
2515	Prevalence of mixed pathologies in the aging brain. Alzheimer's Research and Therapy, 2014, 6, 82.	3.0	232
2516	TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2014, 2, 171.	2.4	78
2517	Understanding Parkinson disease. Nurse Practitioner, 2014, 39, 1-10.	0.2	3
2518	Unilateral olfactory deficit in a hemiparkinsonâ€™s disease mouse model. NeuroReport, 2014, 25, 948-953.	0.6	14
2519	Very young infants' responses to human and nonhuman primate vocalizations. Behavioral and Brain Sciences, 2014, 37, 553-554.	0.4	1
2520	Vocal learning, prosody, and basal ganglia: Don't underestimate their complexity. Behavioral and Brain Sciences, 2014, 37, 570-571.	0.4	7
2521	Physical mechanisms may be as important as brain mechanisms in evolution of speech. Behavioral and Brain Sciences, 2014, 37, 552-553.	0.4	5
2522	Environments organize the verbal brain. Behavioral and Brain Sciences, 2014, 37, 550-551.	0.4	1
2523	Why vocal production of atypical sounds in apes and its cerebral correlates have a lot to say about the origin of language. Behavioral and Brain Sciences, 2014, 37, 565-566.	0.4	3

#	ARTICLE	IF	CITATIONS
2524	En route to disentangle the impact and neurobiological substrates of early vocalizations: Learning from Rett syndrome. <i>Behavioral and Brain Sciences</i> , 2014, 37, 562-563.	0.4	7
2525	Perceptual elements in brain mechanisms of acoustic communication in humans and nonhuman primates. <i>Behavioral and Brain Sciences</i> , 2014, 37, 571-572.	0.4	1
2526	Differences in auditory timing between human and nonhuman primates. <i>Behavioral and Brain Sciences</i> , 2014, 37, 557-558.	0.4	32
2527	Vocal communication is multi-sensorimotor coordination within and between individuals. <i>Behavioral and Brain Sciences</i> , 2014, 37, 572-573.	0.4	0
2528	Evolution of affective and linguistic disambiguation under social eavesdropping pressures. <i>Behavioral and Brain Sciences</i> , 2014, 37, 551-552.	0.4	7
2529	Neanderthals did speak, but FOXP2 doesn't prove it. <i>Behavioral and Brain Sciences</i> , 2014, 37, 558-559.	0.4	2
2530	Role of Aberrant Î±-Synucleinâ€™s Membrane Interactions in Parkinsonâ€™s Disease. , 2014, , 443-452.		0
2531	Voluntary and involuntary processes affect the production of verbal and non-verbal signals by the human voice. <i>Behavioral and Brain Sciences</i> , 2014, 37, 564-565.	0.4	7
2532	Contribution of the basal ganglia to spoken language: Is speech production like the other motor skills?. <i>Behavioral and Brain Sciences</i> , 2014, 37, 576-576.	0.4	14
2533	Phonation takes precedence over articulation in development as well as evolution of language. <i>Behavioral and Brain Sciences</i> , 2014, 37, 567-568.	0.4	3
2534	Working Memory and Facial Expression Recognition in Patients with Parkinsonâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 496-505.	1.2	20
2535	Functions of the cortico-basal ganglia circuits for spoken language may extend beyond emotional-affective modulation in adults. <i>Behavioral and Brain Sciences</i> , 2014, 37, 555-556.	0.4	1
2536	Modification of spectral features by nonhuman primates. <i>Behavioral and Brain Sciences</i> , 2014, 37, 574-576.	0.4	5
2537	Brain Morphometry and the Neurobiology of Levodopa-Induced Dyskinesias: Current Knowledge and Future Potential for Translational Pre-Clinical Neuroimaging Studies. <i>Frontiers in Neurology</i> , 2014, 5, 95.	1.1	23
2538	Neuropathology of Parkinsonâ€™s Disease. , 2014, , 25-74.		12
2539	Sensorimotor Connectivity in Parkinsonâ€™s Disease: The Role of Functional Neuroimaging. <i>Frontiers in Neurology</i> , 2014, 5, 180.	1.1	63
2540	Adult Hippocampal Neurogenesis in Parkinsonâ€™s Disease: Impact on Neuronal Survival and Plasticity. <i>Neural Plasticity</i> , 2014, 2014, 1-12.	1.0	62
2541	Role of Trichloroethylene in Parkinsonâ€™s Disease. <i>Molecular and Integrative Toxicology</i> , 2014, , 91-129.	0.5	0

#	ARTICLE	IF	CITATIONS
2542	Phylogenetic reorganization of the basal ganglia: A necessary, but not the only, bridge over a primate Rubicon of acoustic communication. <i>Behavioral and Brain Sciences</i> , 2014, 37, 577-604.	0.4	18
2543	Inflammation and the Pathophysiology of Astrocytes in Neurodegenerative Diseases. , 2014, , 61-80.		0
2544	Speech as a breakthrough signaling resource in the cognitive evolution of biological complex adaptive systems. <i>Behavioral and Brain Sciences</i> , 2014, 37, 563-564.	0.4	2
2545	Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease. <i>Neurology</i> , 2014, 82, 1093-1098.	1.5	49
2546	Hippocampal Proliferation Is Increased in Presymptomatic Parkinson's Disease and due to Microglia. <i>Neural Plasticity</i> , 2014, 2014, 1-13.	1.0	20
2547	Neuropathologic Changes of Multiple System Atrophy and Diffuse Lewy Body Disease. <i>Seminars in Neurology</i> , 2014, 34, 210-216.	0.5	15
2548	Adaptation and Sensitization to Proteotoxic Stress. <i>Dose-Response</i> , 2014, 12, dose-response.1.	0.7	14
2549	MRI Reveals Brain Abnormalities in Drug-Naive Parkinson's Disease. <i>Exercise and Sport Sciences Reviews</i> , 2014, 42, 12-22.	1.6	13
2551	Early and Persistent Expression of Phosphorylated α -Synuclein in the Enteric Nervous System of A53T Mutant Human α -Synuclein Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 1144-1151.	0.9	35
2552	Update on SPECT and PET in parkinsonism " part 2. <i>Current Opinion in Neurology</i> , 2014, 27, 398-404.	1.8	14
2553	Reduced Purkinje cell dendritic arborization and loss of dendritic spines in essential tremor. <i>Brain</i> , 2014, 137, 3142-3148.	3.7	103
2554	Abnormal visual gain control in a Parkinson's disease model. <i>Human Molecular Genetics</i> , 2014, 23, 4465-4478.	1.4	39
2555	Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 347-353.	1.0	12
2556	The forgotten role of consonant-like calls in theories of speech evolution. <i>Behavioral and Brain Sciences</i> , 2014, 37, 559-560.	0.4	12
2557	The Significance of α -Synuclein, Amyloid- β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. <i>Neurodegenerative Diseases</i> , 2014, 13, 154-156.	0.8	83
2558	α -Synuclein in Parkinson's Disease: Pathogenic Function and Translation into Animal Models. <i>Neurodegenerative Diseases</i> , 2014, 14, 1-17.	0.8	39
2559	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 530.	0.4	18
2560	Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 65, 112-123.	2.1	38

#	ARTICLE	IF	CITATIONS
2561	Management of the aging risk factor for Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 847-857.	1.5	41
2562	La définition de la maladie de Parkinson est-elle clinique? <i>Pratique Neurologique - FMC</i> , 2014, 5, 152-158.	0.1	1
2563	A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. <i>Neurobiology of Aging</i> , 2014, 35, 1125-1131.	1.5	83
2564	Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem. <i>Neurobiology of Aging</i> , 2014, 35, 1065-1073.	1.5	47
2565	Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 685-694.	1.1	52
2566	Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. <i>Journal of Psychiatric Research</i> , 2014, 51, 49-59.	1.5	41
2567	Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement. <i>International Journal of Neuroscience</i> , 2014, 124, 175-180.	0.8	2
2568	Increased Amoeboid Microglial Density in the Olfactory Bulb of Parkinson's and Alzheimer's Patients. <i>Brain Pathology</i> , 2014, 24, 152-165.	2.1	70
2569	Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map. <i>Molecular Neurobiology</i> , 2014, 49, 88-102.	1.9	231
2570	Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 317-331.	1.8	39
2571	Reassessment of the Role of the Central Cholinergic System. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 352-358.	1.1	9
2572	Linking pathways in the developing and aging brain with neurodegeneration. <i>Neuroscience</i> , 2014, 269, 152-172.	1.1	56
2573	Protein aggregation and prionopathies. <i>Pathologie Et Biologie</i> , 2014, 62, 162-168.	2.2	23
2574	Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 59-72.	1.0	141
2575	A role for the proteasome in the turnover of S ^{up35p} and in [PSI ⁺] prion propagation. <i>Molecular Microbiology</i> , 2014, 92, 507-528.	1.2	17
2576	Clinical case conference: A 41-year-old woman with progressive weakness and sensory loss. <i>Annals of Neurology</i> , 2014, 75, 9-19.	2.8	4
2577	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.	1.4	19
2578	Mechanisms of action of brain insulin against neurodegenerative diseases. <i>Journal of Neural Transmission</i> , 2014, 121, 611-626.	1.4	20

#	ARTICLE	IF	CITATIONS
2579	Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P] β -Syn transgenic mice. <i>Human Molecular Genetics</i> , 2014, 23, 3975-3989.	1.4	97
2580	Olfactory bulb involvement in neurodegenerative diseases. <i>Acta Neuropathologica</i> , 2014, 127, 459-475.	3.9	258
2581	A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. <i>Neuroradiology</i> , 2014, 56, 251-258.	1.1	94
2582	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). <i>Acta Neuropathologica</i> , 2014, 127, 423-439.	3.9	237
2583	Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. <i>Acta Neuropathologica</i> , 2014, 127, 477-494.	3.9	28
2584	Can lesions to the motor cortex induce amyotrophic lateral sclerosis?. <i>Journal of Neurology</i> , 2014, 261, 283-290.	1.8	20
2585	The timing between REM sleep behavior disorder and Parkinson's disease. <i>Sleep and Breathing</i> , 2014, 18, 319-323.	0.9	24
2586	Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in Parkinson's Disease Brain is Region Dependent. <i>Brain Pathology</i> , 2014, 24, 584-598.	2.1	73
2587	Torpedo Formation and Purkinje Cell Loss: Modeling their Relationship in Cerebellar Disease. <i>Cerebellum</i> , 2014, 13, 433-439.	1.4	46
2588	Nocturnal manifestations of Parkinson's disease and atypical Parkinsonism. <i>Journal of Neural Transmission</i> , 2014, 121, 1-2.	1.4	1
2589	Neuropathology of prodromal Lewy body disease. <i>Movement Disorders</i> , 2014, 29, 410-415.	2.2	71
2590	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <i>Biochemical Pharmacology</i> , 2014, 88, 508-516.	2.0	196
2591	Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against β -synuclein-induced synapse damage. <i>Neuroscience Letters</i> , 2014, 570, 126-131.	1.0	47
2592	Environmental Toxins and Parkinson's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 141-164.	4.2	352
2593	Clinical REM sleep behavior disorder and motor subtypes in Parkinson's disease: A questionnaire-based study. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 54-58.	0.6	10
2594	Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. <i>Experimental Neurology</i> , 2014, 257, 25-38.	2.0	52
2595	Alzheimer's and ABC transporters – new opportunities for diagnostics and treatment. <i>Neurobiology of Disease</i> , 2014, 72, 54-60.	2.1	66
2596	Neuropathological features of multiple system atrophy with cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 884-888.	2.2	38

#	ARTICLE	IF	CITATIONS
2597	Resting State Functional Magnetic Resonance Imaging in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 448.	2.0	74
2598	Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective. <i>Movement Disorders</i> , 2014, 29, 597-607.	2.2	192
2599	Are patients with Parkinson's disease blind to blindsight?. <i>Brain</i> , 2014, 137, 1838-1849.	3.7	56
2600	Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. <i>Journal of Comparative Neurology</i> , 2014, 522, 2465-2480.	0.9	110
2601	Prodromal features for Parkinson's disease – baseline data from the TREND study. <i>European Journal of Neurology</i> , 2014, 21, 766-772.	1.7	99
2602	Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1205-1208.	2.2	51
2603	MIBG myocardial scintigraphy in pre-motor Parkinson's disease: A review. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 267-273.	1.1	91
2604	Modeling Lewy pathology propagation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S85-S87.	1.1	104
2605	Staged pathology in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S57-S61.	1.1	11
2606	Central Functions of the Ghrelin Receptor. <i>Receptors</i> , 2014, , .	0.2	1
2607	What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition. <i>Neurodegenerative Disease Management</i> , 2014, 4, 127-136.	1.2	2
2608	The pathomechanisms underlying Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 199-215.	1.4	61
2609	Sleep Disorders in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 211-221.	1.5	99
2610	Sleep disordered breathing in Parkinson's disease: A critical appraisal. <i>Sleep Medicine Reviews</i> , 2014, 18, 173-178.	3.8	62
2611	Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. <i>Neuroscience</i> , 2014, 272, 167-179.	1.1	109
2613	Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α -Synuclein externalization via exosomes. <i>Human Molecular Genetics</i> , 2014, 23, 2816-2833.	1.4	205
2614	Effects of Pontine Lesions on REM Sleep. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 460.	2.0	6
2615	Causes and Consequences of Degeneration of the Dorsal Motor Nucleus of the Vagus Nerve in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 649-667.	2.5	51

#	ARTICLE	IF	CITATIONS
2616	Relationship between poor decision-making process and fatigue perception in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2014, 337, 167-172.	0.3	20
2617	Viral Vector-Based Models of Parkinson's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 22, 271-301.	0.8	35
2618	Premotor parkinsonism models. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S17-S19.	1.1	15
2619	Autonomic disorders predicting Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S94-S98.	1.1	99
2620	Treatment of Parkinson's Disease: What's in the Non-dopaminergic Pipeline?. <i>Neurotherapeutics</i> , 2014, 11, 34-46.	2.1	26
2621	Autonomic dysfunction according to disease progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 303-307.	1.1	54
2622	REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 560-566.	0.9	150
2623	Do non-motor symptoms in Parkinson's disease differ from essential tremor before initial diagnosis? A clinical and scintigraphic study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 17-21.	1.1	21
2624	A quantitative study of α -synuclein pathology in fifteen cases of dementia associated with Parkinson disease. <i>Journal of Neural Transmission</i> , 2014, 121, 171-181.	1.4	37
2625	Parkinson's disease in a dish " Using stem cells as a molecular tool. <i>Neuropharmacology</i> , 2014, 76, 88-96.	2.0	71
2626	α -Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	1.1	272
2627	Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson's disease. <i>Brain</i> , 2014, 137, 834-848.	3.7	397
2628	Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1111-1115.	1.5	174
2629	Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1208-1218.	1.8	231
2630	Hyposmia: a possible biomarker of Parkinson's disease. <i>Neuroscience Bulletin</i> , 2014, 30, 134-140.	1.5	45
2631	Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. <i>Behavioural Brain Research</i> , 2014, 263, 158-168.	1.2	22
2632	Copper pathology in vulnerable brain regions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 858-866.	1.5	188
2633	Alpha-synuclein transfers from neurons to oligodendrocytes. <i>Glia</i> , 2014, 62, 387-398.	2.5	215

#	ARTICLE	IF	CITATIONS
2634	Phenotypic Screens Targeting Neurodegenerative Diseases. <i>Journal of Biomolecular Screening</i> , 2014, 19, 1-16.	2.6	26
2635	Clinical subtypes in Parkinson's disease: the impact of MAPT haplotypes. <i>Journal of Neural Transmission</i> , 2014, 121, 353-356.	1.4	10
2637	Lewy body extracts from Parkinson disease brains trigger α -synuclein pathology and neurodegeneration in mice and monkeys. <i>Annals of Neurology</i> , 2014, 75, 351-362.	2.8	521
2638	Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β -hydroxylase and is associated with abnormal adaptive responses to immobilization stress. <i>Experimental Neurology</i> , 2014, 252, 63-74.	2.0	34
2639	Can stress trigger Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 878-881.	0.9	70
2640	Epigenetic regulation in neurodevelopment and neurodegenerative diseases. <i>Neuroscience</i> , 2014, 264, 99-111.	1.1	80
2641	Accumulation of α -synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 127, 235-241.	3.9	272
2642	Formation of α -synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. <i>Molecular Biology of the Cell</i> , 2014, 25, 4010-4023.	0.9	202
2643	Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases. <i>Journal of the Iranian Chemical Society</i> , 2014, 11, 1503-1512.	1.2	3
2644	First pathological anatomical investigation of the brain of a SCA19 patient. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 640-644.	1.8	8
2645	Parkinson's disease with a predominant right-sided putaminal FP-CIT SPECT deficiency shows stronger decline of asymmetry over time. <i>Basal Ganglia</i> , 2014, 4, 101-108.	0.3	1
2646	Activity-dependent regulation of NMDA receptors in substantia nigra dopaminergic neurones. <i>Journal of Physiology</i> , 2014, 592, 653-668.	1.3	12
2647	Transgenic Rodent Models to Study Alpha-Synuclein Pathogenesis, with a Focus on Cognitive Deficits. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 22, 303-330.	0.8	30
2648	Reduced Vascular Endothelial Growth Factor and Capillary Density in the Occipital Cortex in Dementia with Lewy Bodies. <i>Brain Pathology</i> , 2014, 24, 334-343.	2.1	39
2649	Three presenile patients in which neuropsychological and neuroimaging examinations suggest possible progression to dementia with Lewy bodies. <i>Psychogeriatrics</i> , 2014, 14, 72-80.	0.6	3
2650	Degeneration of nigrostriatal dopaminergic neurons in an experimental model of the early clinical stage of Parkinson's disease. <i>Neurochemical Journal</i> , 2014, 8, 184-192.	0.2	4
2651	Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. <i>Neurology</i> , 2014, 82, 419-426.	1.5	116
2652	Cellular density in the cerebellar molecular layer in essential tremor, spinocerebellar ataxia, and controls. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1270-1273.	1.1	7

#	ARTICLE	IF	CITATIONS
2653	Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: A national register-based study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1124-1128.	1.1	26
2654	Topographic pattern of cortical thinning with consideration of motor laterality in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1186-1190.	1.1	27
2655	Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. <i>Magnetic Resonance Imaging</i> , 2014, 32, 1301-1306.	1.0	115
2656	Exploring recollection and familiarity impairments in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 494-506.	0.8	7
2657	A Myristoylated Cell-Penetrating Peptide Bearing a Transferrin Receptor-Targeting Sequence for Neuro-Targeted siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2014, 11, 486-495.	2.3	66
2659	Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. <i>Practical Neurology</i> , 2014, 14, 310-322.	0.5	167
2660	Resting-state fMRI study on drug-naïve patients with Parkinson's disease and with depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 675-683.	0.9	83
2662	Parkinson's disease pharmacogenomics: new findings and perspectives. <i>Pharmacogenomics</i> , 2014, 15, 1253-1271.	0.6	35
2663	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. <i>Nature Medicine</i> , 2014, 20, 130-138.	15.2	547
2664	Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement. <i>Movement Disorders</i> , 2014, 29, 1710-1719.	2.2	190
2665	Focusing Brain Therapeutic Interventions in Space and Time for Parkinson's Disease. <i>Current Biology</i> , 2014, 24, R898-R909.	1.8	18
2666	Submandibular gland needle biopsy for the diagnosis of Parkinson disease. <i>Neurology</i> , 2014, 82, 858-864.	1.5	120
2667	Dopamine and Cu ²⁺ can induce oligomerization of α -synuclein in the absence of oxygen: Two types of oligomerization mechanisms for α -synuclein and related cell toxicity studies. <i>Journal of Neuroscience Research</i> , 2014, 92, 359-368.	1.3	16
2668	Comment: Braak staging in clinical practice?. <i>Neurology</i> , 2014, 82, 862-862.	1.5	0
2669	Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. <i>Acta Neuropathologica</i> , 2014, 128, 805-820.	3.9	708
2670	α -Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α -Synuclein and Neurodegeneration. <i>Cell Reports</i> , 2014, 7, 2054-2065.	2.9	287
2671	Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. <i>Nature Neuroscience</i> , 2014, 17, 1064-1072.	7.1	152
2672	Addition of exogenous α -synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α -synuclein to Lewy body and Lewy neurite-like aggregates. <i>Nature Protocols</i> , 2014, 9, 2135-2146.	5.5	496

#	ARTICLE	IF	CITATIONS
2673	Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. <i>Cortex</i> , 2014, 59, 12-21.	1.1	37
2674	Peripheral alpha-synuclein and Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 963-966.	2.2	32
2675	The small GTPase Rab11 co-localizes with A-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. <i>Human Molecular Genetics</i> , 2014, 23, 6732-6745.	1.4	73
2676	Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. <i>Laboratory Investigation</i> , 2014, 94, 1161-1172.	1.7	28
2677	Pentose-phosphate pathway disruption in the pathogenesis of Parkinson's disease. <i>Translational Neuroscience</i> , 2014, 5, .	0.7	3
2678	Prion-like Mechanisms in the Pathogenesis of Tauopathies and Synucleinopathies. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 495.	2.0	111
2679	Imaging prodromal Parkinson disease. <i>Neurology</i> , 2014, 83, 1739-1746.	1.5	138
2680	Pathological alpha-synuclein propagates through neural networks. <i>Acta Neuropathologica Communications</i> , 2014, 2, 88.	2.4	203
2681	Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. <i>Acta Neuropathologica Communications</i> , 2014, 2, 90.	2.4	140
2682	Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot. <i>Acta Neuropathologica Communications</i> , 2014, 2, 130.	2.4	8
2683	Heat shock proteins in neurodegenerative disorders and aging. <i>Journal of Cell Communication and Signaling</i> , 2014, 8, 293-310.	1.8	145
2684	Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. <i>Brain Research</i> , 2014, 1593, 95-105.	1.1	62
2685	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. <i>Acta Neuropathologica</i> , 2014, 128, 423-437.	3.9	203
2686	Impact of aging on heat shock protein expression in the substantia nigra and striatum of the female rat. <i>Cell and Tissue Research</i> , 2014, 357, 43-54.	1.5	25
2687	Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. <i>Journal of Neural Transmission</i> , 2014, 121, 1493-1505.	1.4	14
2688	Sleep/wake problems in Parkinson's disease: pathophysiology and clinicopathologic correlations. <i>Journal of Neural Transmission</i> , 2014, 121, 3-13.	1.4	45
2689	Biophysical groundwork as a hinge to unravel the biology of alpha-synuclein aggregation and toxicity. <i>Quarterly Reviews of Biophysics</i> , 2014, 47, 1-48.	2.4	32
2690	MAP1B rescues LRRK2 mutant-mediated cytotoxicity. <i>Molecular Brain</i> , 2014, 7, 29.	1.3	13

#	ARTICLE	IF	CITATIONS
2691	Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. <i>Translational Neurodegeneration</i> , 2014, 3, 10.	3.6	36
2692	Dopaminergic modulation of motor coordination in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 64-68.	1.1	46
2694	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	2.2	112
2695	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
2696	Matching Asymmetry of Tremor with Asymmetry of Postmortem Cerebellar Hemispheric Changes in Essential Tremor. <i>Cerebellum</i> , 2014, 13, 462-470.	1.4	17
2697	Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued. <i>CNS Drugs</i> , 2014, 28, 455-474.	2.7	164
2698	Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1797-1810.	0.9	50
2699	Î±-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. <i>Neurobiology of Disease</i> , 2014, 70, 149-161.	2.1	84
2700	Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease. <i>NeuroImage</i> , 2014, 99, 498-508.	2.1	58
2701	Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates. <i>ACS Chemical Neuroscience</i> , 2014, 5, 700-717.	1.7	21
2702	Î±-Synuclein in the inner retina in parkinson disease. <i>Annals of Neurology</i> , 2014, 75, 964-966.	2.8	148
2704	Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. <i>Brain</i> , 2014, 137, 197-207.	3.7	224
2705	Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 980-985.	1.1	98
2706	Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 999-1009.	2.2	202
2707	Immunolocalization of human alpha-synuclein in the Thy1-aSyn (Line 61) transgenic mouse line. <i>Neuroscience</i> , 2014, 277, 647-664.	1.1	12
2708	Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. <i>Human Molecular Genetics</i> , 2014, 23, 767-781.	1.4	20
2709	Data-driven modeling of sleep EEG and EOG reveals characteristics indicative of pre-Parkinson's and Parkinson's disease. <i>Journal of Neuroscience Methods</i> , 2014, 235, 262-276.	1.3	36
2710	Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1371-1375.	1.1	97

#	ARTICLE	IF	CITATIONS
2711	Intramuscular injection of α -synuclein induces CNS α -synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10732-10737.	3.3	277
2712	Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: Beyond cognition. , 2014, 10, 171-178.		18
2713	Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α -synuclein BAC transgenic mouse. Neurobiology of Disease, 2014, 62, 193-207.	2.1	46
2714	Structural Modifications of Neuroprotective Anti-Parkinsonian (α -)-N-(6-(2-(4-(Biphenyl-4-yl)piperazin-1-yl)-ethyl)-6-propyl-4,5,6,7-tetrahydrobenzo[<i>d</i>]thiazole-2,6-diamine (D-264): An Effort toward the Improvement of in Vivo Efficacy of the Parent Molecule. Journal of Medicinal Chemistry, 2014, 57, 1557-1572.	2.9	28
2715	Morbus Parkinson "A synaptic disorder?". Basal Ganglia, 2014, 4, 3-8.	0.3	1
2716	Quantification of α -synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?. Parkinsonism and Related Disorders, 2014, 20, S76-S79.	1.1	36
2717	Impaired motor coordination in Pitx3 overexpression mice. Biochemical and Biophysical Research Communications, 2014, 446, 1211-1218.	1.0	7
2718	Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress. Neuropharmacology, 2014, 77, 350-357.	2.0	48
2719	Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study. Neurobiology of Aging, 2014, 35, 431-441.	1.5	145
2720	Neuropsychiatric symptoms in Parkinson's disease: Fronto-striatal atrophy contributions. Parkinsonism and Related Disorders, 2014, 20, 867-872.	1.1	32
2721	Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. Journal of Neuroscience Methods, 2014, 222, 230-237.	1.3	221
2722	Advances in Dementia Imaging. Seminars in Roentgenology, 2014, 49, 53-63.	0.2	2
2723	Dementia "The real problem for patients with Parkinson's disease. Basal Ganglia, 2014, 4, 9-13.	0.3	6
2724	Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies. Neuroscience Letters, 2014, 569, 68-73.	1.0	25
2725	Parkinson's with tardive Creutzfeldt-Jakob disease: When there is more to it than meets the eye. Revue Neurologique, 2014, 170, 148-150.	0.6	2
2726	Functional role of Barrington's nucleus in the micturition reflex: Relevance in the surgical treatment of Parkinson's disease. Neuroscience, 2014, 266, 150-161.	1.1	12
2727	La d�finition de la maladie de Parkinson est-elle anatomo-pathologique?. Pratique Neurologique - FMC, 2014, 5, 159-163.	0.1	0
2728	Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology, 2014, 76, 97-105.	2.0	58

#	ARTICLE	IF	CITATIONS
2729	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. <i>Lancet, The</i> , 2014, 384, 545-555.	6.3	336
2730	Pathological α -synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb. <i>Nature Communications</i> , 2014, 5, 3915.	5.8	22
2731	Clinical Implication of REM Sleep Behavior Disorder in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 237-244.	1.5	35
2732	Nocturnal Manifestations of Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2014, 4, 223-236.	1.5	8
2733	Neuroprotective Effects of Metallothionein Against Rotenone-Induced Myenteric Neurodegeneration in Parkinsonian Mice. <i>Neurotoxicity Research</i> , 2014, 26, 285-298.	1.3	37
2735	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. <i>Acta Neuropathologica</i> , 2014, 128, 99-109.	3.9	203
2737	Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease. <i>Cell Death and Differentiation</i> , 2014, 21, 369-380.	5.0	172
2738	Clinical and Pathological Features of Parkinson's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 22, 205-220.	0.8	94
2739	Rhinorrhea in Parkinson's disease: A consecutive multicenter study in Japan. <i>Journal of the Neurological Sciences</i> , 2014, 343, 88-90.	0.3	6
2740	Cognitive profiling in relation to short latency afferent inhibition of frontal cortex in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 632-636.	1.1	21
2741	Isolation of the Sapogenin from Defatted Seeds of <i>Camellia oleifera</i> and Its Neuroprotective Effects on Dopaminergic Neurons. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 6175-6182.	2.4	17
2742	Early phenotypic differences between Parkinson's disease patients with and without freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 604-607.	1.1	31
2743	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	1.1	18
2744	Intracellular processing of disease-associated α -synuclein in the human brain suggests prion-like cell-to-cell spread. <i>Neurobiology of Disease</i> , 2014, 69, 76-92.	2.1	110
2745	Protective effects of <i>Gynostemma pentaphyllum</i> polysaccharides on PC12 cells impaired by MPP+. <i>International Journal of Biological Macromolecules</i> , 2014, 69, 171-175.	3.6	24
2746	Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. <i>Neurobiology of Disease</i> , 2014, 69, 206-214.	2.1	91
2747	Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 520-524.	1.1	29
2748	Decreased sleep spindle density in patients with idiopathic REM sleep behavior disorder and patients with Parkinson's disease. <i>Clinical Neurophysiology</i> , 2014, 125, 512-519.	0.7	75

#	ARTICLE	IF	CITATIONS
2749	Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2014, 15, 647-653.	0.8	62
2750	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. <i>Biological Psychiatry</i> , 2014, 75, 701-710.	0.7	56
2751	Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease. <i>Brain Structure and Function</i> , 2014, 219, 381-394.	1.2	67
2752	DTI correlates of distinct cognitive impairments in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 1325-1333.	1.9	146
2753	Application of the University of Pennsylvania Smell Identification Test (Traditional Chinese Version) for Detecting Olfactory Deficits in Early Parkinson's Disease in a Taiwanese Cohort. <i>Journal of Parkinson's Disease</i> , 2014, 4, 175-180.	1.5	14
2754	Advances in non-dopaminergic treatments for Parkinson's disease. <i>Frontiers in Neuroscience</i> , 2014, 8, 113.	1.4	72
2755	Alpha-synuclein spreading in Parkinson's disease. <i>Frontiers in Neuroanatomy</i> , 2014, 8, 159.	0.9	148
2756	Viability Assays for Cells in Culture. <i>Journal of Visualized Experiments</i> , 2014, , e50645.	0.2	34
2757	A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 290.	1.0	110
2758	Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. <i>Frontiers in Neuroanatomy</i> , 2014, 8, 152.	0.9	171
2760	A Clinical Approach Towards Smell Loss in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 189-195.	1.5	41
2761	Sudomotor and Cardiovascular Dysfunction in Patients with Early Untreated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 385-393.	1.5	25
2762	Specific Clinical Contexts - Part 2: The Patient with Neurological Disease. <i>Frontiers of Gastrointestinal Research</i> , 2014, , 141-149.	0.1	0
2763	Familial Coaggregation of Alzheimer's Disease and Parkinson's Disease: Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2014, 42, 69-80.	1.1	9
2764	Forensic Aspects of Adult and General Neuropathology. , 2014, , 89-262.		0
2765	Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson's Disease. <i>Tohoku Journal of Experimental Medicine</i> , 2014, 232, 129-136.	0.5	22
2766	Overview of Mouse Models of Parkinson's Disease. <i>Current Protocols in Mouse Biology</i> , 2014, 4, 121-139.	1.2	13
2767	Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease. <i>Journal of Gene Medicine</i> , 2014, 16, 300-308.	1.4	10

#	ARTICLE	IF	CITATIONS
2768	Characterizing Premotor Parkinson's Disease: Clinical Features and Objective Markers. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 299-306.	0.8	74
2769	Mental Disturbances in Parkinson's Disease and Related Disorders: The Role of Excitotoxins. <i>Journal of Parkinson's Disease</i> , 2014, 4, 139-150.	1.5	11
2770	Cortical gyrification reductions and subcortical atrophy in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 122-126.	2.2	44
2771	Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. <i>Movement Disorders</i> , 2014, 29, 126-130.	2.2	52
2772	Frequency-dependent neural activity in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 5815-5833.	1.9	68
2773	Melatonin: Its Hepatoprotective Actions and the Role of Melatonin Receptors. , 2014, , 170-183.		0
2774	Non-motor symptoms: the core of multi-morbid Parkinson's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 18-24.	0.2	38
2776	Reduced vocal variability in a zebra finch model of dopamine depletion: implications for Parkinson disease. <i>Physiological Reports</i> , 2015, 3, e12599.	0.7	22
2777	Ten <sc>Y</sc>ears and <sc>C</sc>ounting: <sc>M</sc>oving <sc>L</sc>eucineâ€<sc>R</sc>ich <sc>Repeat</sc><sc>K</sc>inase 2 <sc>I</sc>nhibitors to the <sc>C</sc>linic. <i>Movement Disorders</i> , 2015, 30, 180-189.	2.2	60
2778	Review: Prion-like mechanisms of transactive response DNA binding protein of 43â€%kDa (<sc>TDP</sc>â€43) in amyotrophic lateral sclerosis (<sc>ALS</sc>). <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 578-597.	1.8	76
2779	The range and nature of non-motor symptoms in drug-naive Parkinsonâ€™s disease patients: a state-of-the-art systematic review. <i>Npj Parkinson's Disease</i> , 2015, 1, 15013.	2.5	67
2780	Kiss of the muse for the chosen ones: De novo schizotypal traits and lifetime creative achievement are related to changes in divergent thinking during dopaminergic therapy in Parkinsonâ€™s disease.. <i>Psychology of Aesthetics, Creativity, and the Arts</i> , 2015, 9, 328-339.	1.0	13
2781	Non-invasive brain stimulation for Parkinsonâ€™s disease: Current concepts and outlook 2015. <i>NeuroRehabilitation</i> , 2015, 37, 11-24.	0.5	52
2782	Intrinsic excitability of human motoneurons in biceps brachii versus triceps brachii. <i>Journal of Neurophysiology</i> , 2015, 113, 3692-3699.	0.9	57
2783	I. New Insights into Symptoms in Parkinson's Disease Including Non Motor Features. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 1546-1551.	0.0	1
2784	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 175-185.	1.5	16
2786	Parkinsonâ€™s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. <i>Journal of Parkinson's Disease</i> , 2015, 5, 269-279.	1.5	82
2787	Total and Proteinase K-Resistant Î±-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinsonâ€™s Disease. <i>Scientific Reports</i> , 2015, 5, 11120.	1.6	44

#	ARTICLE	IF	CITATIONS
2788	Is Parkinson's Disease Truly a Prion-Like Disorder? An Appraisal of Current Evidence. <i>Neurology Research International</i> , 2015, 2015, 1-8.	0.5	23
2789	Optimizing Western Blots for the Detection of Endogenous α -Synuclein in the Enteric Nervous System. <i>Journal of Parkinson's Disease</i> , 2015, 5, 765-772.	1.5	17
2790	Narrative Discourse Cohesion in Early Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 403-411.	1.5	15
2792	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 561-567.	1.5	13
2793	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	1.5	195
2794	Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. <i>ENeurologicalSci</i> , 2015, 1, 3-6.	0.5	9
2796	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. <i>Molecular Neurodegeneration</i> , 2015, 10, 41.	4.4	90
2798	Sleep in Neurodegenerative Disorders. <i>Current Sleep Medicine Reports</i> , 2015, 1, 81-90.	0.7	8
2799	TDP-43 Pathology Progression Along the Olfactory Pathway as a Possible Substrate for Olfactory Impairment in Amyotrophic Lateral Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 547-556.	0.9	41
2800	Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. <i>Acta Neuropathologica Communications</i> , 2015, 3, 75.	2.4	115
2801	Altered machinery of protein synthesis is region- and stage-dependent and is associated with α -synuclein oligomers in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2015, 3, 76.	2.4	87
2802	Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. <i>Human Brain Mapping</i> , 2015, 36, 4407-4420.	1.9	181
2803	Patterns of cortical thinning in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2015, 30, 680-687.	2.2	83
2804	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. <i>Movement Disorders</i> , 2015, 30, 859-862.	2.2	31
2805	Diminished event-related cortical arousals and altered heart rate response in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 866-870.	2.2	15
2806	Appendectomy may delay Parkinson's disease Onset. <i>Movement Disorders</i> , 2015, 30, 1404-1407.	2.2	46
2807	Different Patterns of Spontaneous Brain Activity between Tremor-Dominant and Postural Instability/Gait Difficulty Subtypes of Parkinson's Disease: A Resting-state fMRI Study. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 855-866.	1.9	52
2808	Purine metabolism gene deregulation in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 926-940.	1.8	59

#	ARTICLE	IF	CITATIONS
2809	Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1350, 37-47.	1.8	80
2810	Relationship of orexin (hypocretin) system and astrocyte activation in Parkinson's disease with hypersomnolence. <i>Sleep and Biological Rhythms</i> , 2015, 13, 252-260.	0.5	8
2811	Electroacupuncture remediates glial dysfunction and ameliorates neurodegeneration in the astrocytic α -synuclein mutant mouse model. <i>Journal of Neuroinflammation</i> , 2015, 12, 103.	3.1	25
2812	Studies of lipopolysaccharide effects on the induction of α -synuclein pathology by exogenous fibrils in transgenic mice. <i>Molecular Neurodegeneration</i> , 2015, 10, 32.	4.4	29
2813	No apparent transmission of transgenic α -synuclein into nigrostriatal dopaminergic neurons in multiple mouse models. <i>Translational Neurodegeneration</i> , 2015, 4, 23.	3.6	7
2814	Distribution of α -synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. <i>Acta Neuropathologica Communications</i> , 2015, 3, 57.	2.4	54
2815	Brain gray matter volume changes associated with motor symptoms in patients with Parkinson's disease. <i>Chinese Neurosurgical Journal</i> , 2015, 1, .	0.3	5
2816	Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a <i>PINK1</i> gene knockout rat model of Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2015, 93, 1713-1727.	1.3	83
2817	Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1874-1884.	2.2	39
2818	Propagation of Pathology through Brain Networks in Neurodegenerative Diseases: From Molecules to Clinical Phenotypes. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 754-767.	1.9	38
2819	Isopentenyl diphosphate isomerase, a cholesterol synthesizing enzyme, is localized in Lewy bodies. <i>Neuropathology</i> , 2015, 35, 432-440.	0.7	31
2820	The Rationale for Exercise in the Management of Pain in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 229-239.	1.5	47
2821	Patterns of Tau and α -Synuclein Pathology in the Visual System. <i>Journal of Parkinson's Disease</i> , 2015, 5, 333-340.	1.5	15
2822	Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 727-732.	1.9	23
2823	The Neuropathology of Chronic Traumatic Encephalopathy. <i>Brain Pathology</i> , 2015, 25, 350-364.	2.1	411
2824	Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. <i>British Journal of Pharmacology</i> , 2015, 172, 4200-4215.	2.7	46
2825	Promising Targets for the Treatment of Neurodegenerative Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 492-501.	2.3	22
2826	Medial temporal regional argyrophilic grain as a possible important factor affecting dementia in Parkinson's disease. <i>Neuropathology</i> , 2015, 35, 441-451.	0.7	12

#	ARTICLE	IF	CITATIONS
2827	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1639-1647.	2.2	123
2828	Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease. <i>Movement Disorders</i> , 2015, 30, 1275-1279.	2.2	22
2829	Can <sc>P</sc>arkinson's <sc>D</sc>isease <sc>C</sc>ome <sc>F</sc>rom the <sc>G</sc>ut?. <i>Movement Disorders</i> , 2015, 30, 1325-1325.	2.2	3
2830	Olfactory identification deficits and increased mortality in the community. <i>Annals of Neurology</i> , 2015, 78, 401-411.	2.8	107
2831	Dopaminergic correlates of metabolic network activity in Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 3575-3585.	1.9	71
2832	Minimal change multiple system atrophy: An aggressive variant?. <i>Movement Disorders</i> , 2015, 30, 960-967.	2.2	45
2833	Colonic bacterial composition in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1351-1360.	2.2	932
2834	The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies. <i>Brain Pathology</i> , 2015, 25, 121-135.	2.1	214
2835	Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 135, 589-597.	2.1	53
2836	Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1783-1795.	1.6	23
2837	Genome-wide Meta-analysis on the Sense of Smell Among US Older Adults. <i>Medicine (United States)</i> , 2015, 94, e1892.	0.4	12
2839	Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India. <i>International Journal of Emergency Mental Health</i> , 0, s2, .	0.3	0
2840	Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2015, 8, 92-97.	0.7	109
2841	The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2865.	1.0	31
2842	Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. <i>Journal of Parkinson's Disease</i> , 2015, 5, 217-227.	1.5	107
2843	I716F A12PP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid-12 and 12-Synucleinopathy with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 103-114.	1.2	13
2844	Diagnosis of Parkinson's disease: progress and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 0, , 19.	0.8	3
2845	Brain-gut-microbiota axis in Parkinson's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 10609.	1.4	438

#	ARTICLE	IF	CITATIONS
2846	Parkinson's Disease - Just another Infectious Disease. <i>Journal of Neuroinfectious Diseases</i> , 2015, 06, .	0.2	0
2847	The Intestinal Barrier in Air Pollution-Associated Neural Involvement in Mexico City Residents: Mind the Gut, the Evolution of a Changing Paradigm Relevant to Parkinson Disease Risk. , 2015, 05, .		1
2848	The behavior of migraine in patients with Parkinson's disease. <i>Neurology International</i> , 2015, 7, 6133.	1.3	4
2849	Neurodegenerative changes in the brainstem and olfactory bulb in people older than 50 years old: a descriptive study. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 569-577.	0.3	2
2850	Target Selection Recommendations Based on Impact of Deep Brain Stimulation Surgeries on Nonmotor Symptoms of Parkinson's Disease. <i>Chinese Medical Journal</i> , 2015, 128, 3371-3380.	0.9	13
2852	L-Dopa and Brain Serotonin System Dysfunction. <i>Toxics</i> , 2015, 3, 75-88.	1.6	42
2853	Myocardial ¹²³ I-MIBG Uptake and Cardiovascular Autonomic Function in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-5.	0.6	9
2854	Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models. <i>Biomolecules</i> , 2015, 5, 1634-1651.	1.8	33
2855	Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. <i>Biomolecules</i> , 2015, 5, 2675-2700.	1.8	49
2856	Emotion recognition in early Parkinson's disease patients undergoing deep brain stimulation or dopaminergic therapy: a comparison to healthy participants. <i>Frontiers in Aging Neuroscience</i> , 2015, 6, 349.	1.7	27
2857	Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 5.	0.9	153
2858	Novel subcellular localization for alpha-synuclein: possible functional consequences. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 17.	0.9	45
2859	Midbrain catecholaminergic neurons co-express alpha-synuclein and tau in progressive supranuclear palsy. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 25.	0.9	6
2860	Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer's disease. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 26.	0.9	16
2861	Relevance of chronic stress and the two faces of microglia in Parkinson's disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 312.	1.8	36
2862	Sleep spindle alterations in patients with Parkinson's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 233.	1.0	42
2863	Disease-modifying therapeutic directions for Lewy-Body dementias. <i>Frontiers in Neuroscience</i> , 2015, 9, 293.	1.4	23
2864	Abnormal Paraplegin Expression in Swollen Neurites, alpha-Synuclein Pathology in a Case of Hereditary Spastic Paraplegia SPG7 with an Ala510Val Mutation. <i>International Journal of Molecular Sciences</i> , 2015, 16, 25050-25066.	1.8	18

#	ARTICLE	IF	CITATIONS
2865	Olfactory Dysfunction and Neurotransmitter Disturbance in Olfactory Bulb of Transgenic Mice Expressing Human A53T Mutant α -Synuclein. <i>PLoS ONE</i> , 2015, 10, e0119928.	1.1	57
2866	Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease. <i>PLoS ONE</i> , 2015, 10, e0125204.	1.1	52
2867	Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0128651.	1.1	114
2868	The Progressive BSSG Rat Model of Parkinson's: Recapitulating Multiple Key Features of the Human Disease. <i>PLoS ONE</i> , 2015, 10, e0139694.	1.1	39
2869	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). <i>PLoS ONE</i> , 2015, 10, e0145493.	1.1	14
2870	The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. <i>Frontiers in Physiology</i> , 2015, 6, 277.	1.3	45
2871	Emotional processing in Parkinson's disease and schizophrenia: evidence for response bias deficits in PD. <i>Frontiers in Psychology</i> , 2015, 6, 1417.	1.1	7
2872	Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28194-28217.	1.8	111
2873	Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27796-27815.	1.8	118
2874	Non-motor signs in Parkinson's disease: a review. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 454-462.	0.3	57
2875	Sirtuins and Proteolytic Systems: Implications for Pathogenesis of Synucleinopathies. <i>Biomolecules</i> , 2015, 5, 735-757.	1.8	11
2877	Freezing of Gait and its Associations in the Early and Advanced Clinical Motor Stages of Parkinson's Disease: A Cross-Sectional Study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 881-891.	1.5	24
2878	Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	0.7	46
2879	Salivary Acetylcholinesterase Activity Is Increased in Parkinson's Disease: A Potential Marker of Parasympathetic Dysfunction. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	28
2880	Effect and Potential Mechanism of Electroacupuncture Add-On Treatment in Patients with Parkinson's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-11.	0.5	31
2881	The Interaction between Obstructive Sleep Apnea and Parkinson's Disease: Possible Mechanisms and Implications for Cognitive Function. <i>Parkinson's Disease</i> , 2015, 2015, 1-11.	0.6	36
2882	Mitochondrial Dysfunction and α -Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?. <i>Parkinson's Disease</i> , 2015, 2015, 1-10.	0.6	62
2883	Neurophysiology of <i>Drosophila</i> Models of Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-11.	0.6	28

#	ARTICLE	IF	CITATIONS
2884	The Role of α -Synuclein and LRRK2 in Tau Phosphorylation. <i>Parkinson's Disease</i> , 2015, 2015, 1-10.	0.6	11
2885	Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression. <i>Behavioural Neurology</i> , 2015, 2015, 1-5.	1.1	41
2886	Resveratrol Protects PC12 Cell against 6-OHDA Damage via CXCR4 Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-12.	0.5	21
2887	Lipid rafts involvement in the pathogenesis of Parkinson's disease. <i>Frontiers in Bioscience - Landmark</i> , 2015, 20, 263-279.	3.0	25
2888	Network structure of brain atrophy in de novo Parkinson's disease. <i>ELife</i> , 2015, 4, .	2.8	187
2889	α -Synuclein Amyloid Fibrils Formed of Two Protofibrils. <i>Microscopy and Microanalysis</i> , 2015, 21, 1285-1286.	0.2	0
2890	Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases. <i>Journal of Nippon Medical School</i> , 2015, 82, 266-273.	0.3	25
2891	Frontotemporal Lobar Degeneration with Accumulation of Argyrophilic Grains and Lewy Bodies: A Clinicopathological Report. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 55-58.	1.2	2
2893	Expanding the spectrum of neuronal pathology in multiple system atrophy. <i>Brain</i> , 2015, 138, 2293-2309.	3.7	178
2894	Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes. <i>Clinical and Translational Imaging</i> , 2015, 3, 57-64.	1.1	22
2895	Olfactory function combined with morphology distinguishes Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 771-777.	1.1	24
2896	The Interplay between Alpha-Synuclein Clearance and Spreading. <i>Biomolecules</i> , 2015, 5, 435-471.	1.8	79
2897	Hippocampal Neurogenesis in Neurodegenerative Movement Disorders. <i>Pancreatic Islet Biology</i> , 2015, , 79-105.	0.1	0
2898	Insomnia in Parkinson's Disease. , 2015, , 79-91.		0
2899	Behavioral impairments and serotonin reductions in rats after chronic L-dopa. <i>Psychopharmacology</i> , 2015, 232, 3203-3213.	1.5	18
2900	Targeting α -synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. <i>Lancet Neurology</i> , The, 2015, 14, 855-866.	4.9	393
2901	Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. <i>Current Topics in Behavioral Neurosciences</i> , 2015, , .	0.8	13
2902	Parkinson's Disease Dementia. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , 53-77.	0.3	0

#	ARTICLE	IF	CITATIONS
2903	Calcium CaV1 Channel Subtype mRNA Expression in Parkinson's Disease Examined by In Situ Hybridization. <i>Journal of Molecular Neuroscience</i> , 2015, 55, 715-724.	1.1	17
2904	Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2015, 57, 48-62.	1.1	19
2905	Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. <i>Molecular Neurobiology</i> , 2015, 52, 57-63.	1.9	20
2906	Exosomes as drug delivery vehicles for Parkinson's disease therapy. <i>Journal of Controlled Release</i> , 2015, 207, 18-30.	4.8	1,363
2907	Aneuploidy in Lewy body diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1253-1260.	1.5	23
2908	Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 923-928.	1.1	19
2909	The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research. <i>Psychiatric Clinics of North America</i> , 2015, 38, 309-322.	0.7	12
2910	Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role. <i>Biomolecules</i> , 2015, 5, 865-892.	1.8	37
2911	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. <i>Brain</i> , 2015, 138, 1642-1657.	3.7	211
2912	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.5	130
2913	Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model. <i>Neuroscience</i> , 2015, 300, 585-592.	1.1	29
2914	Clinicopathological Study of Patients With <i>C9ORF72</i> -Associated Frontotemporal Dementia Presenting With Delusions. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 99-107.	1.2	41
2915	GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2015, 82, 99-113.	2.1	45
2916	α -Synuclein-Induced Synapse Damage in Cultured Neurons Is Mediated by Cholesterol-Sensitive Activation of Cytoplasmic Phospholipase A2. <i>Biomolecules</i> , 2015, 5, 178-193.	1.8	25
2917	Rational drug discovery design approaches for treating Parkinson's disease. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 713-741.	2.5	16
2918	The serum lipid profile of Parkinson's disease patients: a study from China. <i>International Journal of Neuroscience</i> , 2015, 125, 838-844.	0.8	48
2919	CORTICAL THINNING AND COGNITIVE IMPAIRMENT IN PARKINSON'S DISEASE WITHOUT DEMENTIA. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2015, 15, 1-1.	1.9	31
2920	Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3 ^{-/-} mice. <i>Neurobiology of Aging</i> , 2015, 36, 3314-3320.	1.5	21

#	ARTICLE	IF	CITATIONS
2921	Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. The Cochrane Library, 2015, 2015, CD010633.	1.5	48
2922	Genome-wide association study of neocortical Lewy-related pathology. Annals of Clinical and Translational Neurology, 2015, 2, 920-931.	1.7	25
2923	Parkinson's disease, anxious depression and serotonin " zooming in on hippocampal neurogenesis. Journal of Neurochemistry, 2015, 135, 441-444.	2.1	9
2924	Autonomic dysfunction in subjects at high risk for Parkinson's disease. Journal of Neurology, 2015, 262, 2643-2652.	1.8	17
2925	Investigation of tyrosine hydroxylase and BDNF in a low-dose rotenone model of Parkinson's disease. Journal of Chemical Neuroanatomy, 2015, 70, 33-41.	1.0	26
2926	Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons. Cell Death and Disease, 2015, 6, e1832-e1832.	2.7	50
2928	Memory Similarities Between Essential Tremor and Parkinson's Disease: A Final Common Pathway?. Clinical Neuropsychologist, 2015, 29, 985-1001.	1.5	13
2929	MRI Correlates of Parkinson's Disease Progression: A Voxel Based Morphometry Study. Parkinson's Disease, 2015, 2015, 1-8.	0.6	34
2930	The olfactory bulb volume in patients with idiopathic Parkinson's disease. European Journal of Neurology, 2015, 22, 1068-1073.	1.7	37
2931	Recent Research Progress in and Future Perspective on Treatment of Parkinson's Disease. Integrative Medicine International, 2015, 1, 67-79.	0.6	27
2932	Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurology, The, 2015, 14, 57-64.	4.9	487
2933	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.4	66
2934	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain, 2015, 138, 653-663.	3.7	135
2935	Management of constipation in Parkinson's disease. Expert Opinion on Pharmacotherapy, 2015, 16, 547-557.	0.9	45
2936	Interaction of Noradrenergic Pharmacological Manipulation and Subthalamic Stimulation on Movement Initiation Control in Parkinson's Disease. Brain Stimulation, 2015, 8, 27-35.	0.7	22
2937	Beyond Mitophagy: Cytosolic PINK1 as a Messenger of Mitochondrial Health. Antioxidants and Redox Signaling, 2015, 22, 1047-1059.	2.5	26
2938	Ginsenosides as Food Supplements and Their Potential Role in Immunological and Neurodegenerative Disorders. , 2015, , 303-309.		7
2939	Validation of the nonmotor symptoms questionnaire for Parkinson's disease: results from a Chinese pilot study. International Journal of Neuroscience, 2015, 125, 929-935.	0.8	12

#	ARTICLE	IF	CITATIONS
2940	Megacities air pollution problems: Mexico City Metropolitan Area critical issues on the central nervous system pediatric impact. <i>Environmental Research</i> , 2015, 137, 157-169.	3.7	101
2941	Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. <i>Neurobiology of Aging</i> , 2015, 36, 1097-1104.	1.5	133
2942	Dopaminergic medication alters auditory distractor processing in Parkinson's disease. <i>Acta Psychologica</i> , 2015, 156, 45-56.	0.7	22
2943	Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 133, 750-765.	2.1	54
2944	Nonmotor symptoms in essential tremor: Comparison with Parkinson's disease and normal control. <i>Journal of the Neurological Sciences</i> , 2015, 349, 168-173.	0.3	41
2945	Heat shock protein responses to aging and proteotoxicity in the olfactory bulb. <i>Journal of Neurochemistry</i> , 2015, 133, 780-794.	2.1	16
2946	NREM sleep alpha and sigma activity in Parkinson's disease: Evidence for conflicting electrophysiological activity?. <i>Clinical Neurophysiology</i> , 2015, 126, 951-958.	0.7	17
2947	Formaldehyde-fixed brain tissue from spontaneously ill α -synuclein transgenic mice induces fatal α -synucleinopathy in transgenic hosts. <i>Acta Neuropathologica</i> , 2015, 129, 157-159.	3.9	34
2948	Assessing the non-motor symptoms of Parkinson's disease: MDS and UPDRS and NMS Scale. <i>European Journal of Neurology</i> , 2015, 22, 37-43.	1.7	82
2949	Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Radiology</i> , 2015, 275, 430-437.	3.6	39
2950	Drosophila Models of Parkinson Disease. , 2015, , 345-354.		7
2951	Abnormal functional connectivity density in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 280, 113-118.	1.2	31
2952	Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres. <i>Life Sciences</i> , 2015, 124, 136-143.	2.0	15
2953	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. <i>Neurobiology of Aging</i> , 2015, 36, 1160-1173.	1.5	29
2954	Associations between neuropsychiatric symptoms and cognition in Chinese idiopathic Parkinson's disease patients. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 578-582.	0.8	5
2955	Compensatory fronto-parietal hyperactivation during set-shifting in unmedicated patients with Parkinson's disease. <i>Neuropsychologia</i> , 2015, 68, 107-116.	0.7	42
2956	Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease. <i>Metallomics</i> , 2015, 7, 395-404.	1.0	126
2957	The relation between α -synuclein and microglia in Parkinson's disease: Recent developments. <i>Neuroscience</i> , 2015, 302, 47-58.	1.1	141

#	ARTICLE	IF	CITATIONS
2958	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.	4.9	2
2959	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. <i>Neurology</i> , 2015, 84, 654-658.	1.5	164
2960	Resting-state frontostriatal functional connectivity in Parkinson's disease-related apathy. <i>Movement Disorders</i> , 2015, 30, 671-679.	2.2	97
2961	Decreased behavioral response to intranigally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA. <i>Behavioural Brain Research</i> , 2015, 283, 203-214.	1.2	9
2962	Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2015, 46, 154-167.	2.0	42
2963	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <i>Nature Reviews Neuroscience</i> , 2015, 16, 109-120.	4.9	611
2964	Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning. <i>Cytotherapy</i> , 2015, 17, 199-214.	0.3	38
2965	Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 105-110.	1.0	43
2966	Effects of levodopa on regional cerebral metabolism and blood flow. <i>Movement Disorders</i> , 2015, 30, 54-63.	2.2	37
2967	Role of α -Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 1-19.	1.5	174
2968	Does Response Inhibition Have Pre- and Postdiagnostic Utility in Parkinson's Disease?. <i>Journal of Motor Behavior</i> , 2015, 47, 29-45.	0.5	12
2969	The power in numbers: Gut microbiota in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 296-298.	2.2	25
2970	Reasons for mild parkinsonian signs – Which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 126-130.	1.1	15
2971	Neuroprotective Effects of Hydrogen Sulfide in Parkinson's Disease Animal Models. <i>Methods in Enzymology</i> , 2015, 554, 169-186.	0.4	24
2972	Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 238-244.	2.2	112
2973	Attenuation of neuroinflammatory responses and behavioral deficits by <i>Ligusticum officinale</i> (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson's disease. <i>Journal of Ethnopharmacology</i> , 2015, 164, 388-397.	2.0	30
2974	Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α -synuclein aggregates which incite parkinsonian-like symptoms. <i>Behavioural Brain Research</i> , 2015, 279, 191-201.	1.2	9
2975	Parkinson's disease as a result of aging. <i>Aging Cell</i> , 2015, 14, 293-308.	3.0	165

#	ARTICLE	IF	CITATIONS
2976	Evolution of Prodromal Clinical Markers of Parkinson Disease in a <i>GBA</i> Mutation-Positive Cohort. <i>JAMA Neurology</i> , 2015, 72, 201.	4.5	180
2977	Are Sleep Disturbances Preclinical Markers of Parkinson's Disease?. <i>Neurochemical Research</i> , 2015, 40, 421-427.	1.6	26
2978	Morphometric Parameters of the Neurodegenerative Process in Parkinson's Disease and Chronic Cerebral Ischemia. <i>Neuroscience and Behavioral Physiology</i> , 2015, 45, 327-331.	0.2	0
2979	Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms. <i>Journal of Neuroinflammation</i> , 2015, 12, 9.	3.1	192
2980	Prodromal dementia with Lewy bodies. <i>Geriatrics and Gerontology International</i> , 2015, 15, 817-826.	0.7	55
2981	<i>DNAJC13</i> genetic variants in parkinsonism. <i>Movement Disorders</i> , 2015, 30, 273-278.	2.2	42
2982	Î±-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease. <i>Neurobiology of Disease</i> , 2015, 76, 112-125.	2.1	85
2983	Abnormalities of vestibular-evoked myogenic potentials in idiopathic Parkinson's disease are associated with clinical evidence of brainstem involvement. <i>Neurological Sciences</i> , 2015, 36, 995-1001.	0.9	66
2984	Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 349-362.	1.2	259
2985	The Enteric Glia: Identity and Functions. <i>Glia</i> , 2015, 63, 921-935.	2.5	86
2986	Potential of Cellular and Animal Models Based on a Prion-Like Propagation of Î±-Synuclein for Assessing Antiparkinson Agents. <i>Molecular Neurobiology</i> , 2015, 52, 226-235.	1.9	6
2987	Potential of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. <i>Human Molecular Genetics</i> , 2015, 24, 1061-1076.	1.4	53
2988	<i>Substantia nigra</i> neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 953-959.	2.2	69
2989	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. <i>Acta Neuropathologica</i> , 2015, 129, 729-748.	3.9	168
2990	Correlates of cerebrospinal fluid levels of oligomeric- and total-Î±-synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
2991	Sleep-related behaviors in Alzheimer's disease and dementia with Lewy bodies. <i>Reviews in the Neurosciences</i> , 2015, 26, 31-8.	1.4	7
2992	Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 882-887.	1.1	54
2993	Posttranslational Modifications and Clearing of Î±-Synuclein Aggregates in Yeast. <i>Biomolecules</i> , 2015, 5, 617-634.	1.8	33

#	ARTICLE	IF	CITATIONS
2994	Frequency of REM sleep behavior disorders in patients with Parkinson's disease. <i>Vojnosanitetski Pregled</i> , 2015, 72, 442-446.	0.1	10
2995	A30P α -Synuclein interferes with the stable integration of adult-born neurons into the olfactory network. <i>Scientific Reports</i> , 2014, 4, 3931.	1.6	19
2996	The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. <i>Acta Neuropathologica</i> , 2015, 130, 315-331.	3.9	305
2997	Depression's risk factor or early symptom in Parkinson disease?. <i>Nature Reviews Neurology</i> , 2015, 11, 432-433.	4.9	18
2998	Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson's disease. <i>Nature Neuroscience</i> , 2015, 18, 1299-1309.	7.1	137
2999	Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled α 2, tau, and α -synuclein. <i>Science</i> , 2015, 349, 1255-1259.	6.0	753
3000	The vulnerable ventral tegmental area in Parkinson's disease. <i>Basal Ganglia</i> , 2015, 5, 51-55.	0.3	130
3001	Deep Brain Stimulation. <i>Brain Stimulation</i> , 2015, 8, 432.	0.7	4
3002	Parkinson's disease: disturbed vestibular function and levodopa. <i>Journal of the Neurological Sciences</i> , 2015, 353, 49-58.	0.3	20
3003	Receptor for advanced glycation end-products in neurodegenerative diseases. <i>Reviews in the Neurosciences</i> , 2015, 26, 691-698.	1.4	53
3004	Environment-contact administration of rotenone: A new rodent model of Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 294, 149-161.	1.2	49
3005	Cell-based therapies for Parkinson disease's past insights and future potential. <i>Nature Reviews Neurology</i> , 2015, 11, 492-503.	4.9	242
3006	Parkinson's disease as a member of Prion-like disorders. <i>Virus Research</i> , 2015, 207, 38-46.	1.1	30
3008	Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. <i>Brain</i> , 2015, 138, 2964-2973.	3.7	164
3009	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , 2015, 14, 786-788.	4.9	38
3010	Crocicidin protects PC12 cells against MPP ⁺ -induced injury through inhibition of mitochondrial dysfunction and ER stress. <i>Neurochemistry International</i> , 2015, 89, 101-110.	1.9	48
3011	Paired neurophysiological and clinical study of the brainstem at different stages of Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2015, 126, 1871-1878.	0.7	51
3012	Paradoxical Effect of Dopamine Medication on Cognition in Parkinson's Disease: Relationship to Side of Motor Onset. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 259-270.	1.2	29

#	ARTICLE	IF	CITATIONS
3013	Evidence of an amnesia-like cued-recall memory impairment in nondementing idiopathic Parkinson's disease. <i>Cortex</i> , 2015, 71, 85-101.	1.1	16
3014	Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations. <i>International Journal of Molecular Sciences</i> , 2015, 16, 9772-9793.	1.8	62
3015	Excessive Daytime Sleepiness and Unintended Sleep Episodes Associated with Parkinson's Disease. <i>Oman Medical Journal</i> , 2015, 30, 3-10.	0.3	21
3016	Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. <i>Stem Cells Translational Medicine</i> , 2015, 4, 564-575.	1.6	38
3017	A new dopaminergic nigro-olfactory projection. <i>Acta Neuropathologica</i> , 2015, 130, 333-348.	3.9	89
3018	Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition. <i>European Journal of Cell Biology</i> , 2015, 94, 148-161.	1.6	29
3019	Interactions of the histamine and hypocretin systems in CNS disorders. <i>Nature Reviews Neurology</i> , 2015, 11, 401-413.	4.9	80
3020	Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease. <i>Regenerative Medicine</i> , 2015, 10, 431-446.	0.8	59
3021	Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. <i>Cell Death and Disease</i> , 2015, 6, e1811-e1811.	2.7	102
3022	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Neuropsychologia</i> , 2015, 75, 548-555.	0.7	8
3023	Increased oligomerization and phosphorylation of α -synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. <i>Neurobiology of Aging</i> , 2015, 36, 2649-2659.	1.5	54
3024	How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 53.	2.0	5
3025	Rifampicin attenuates rotenone-induced inflammation via suppressing NLRP3 inflammasome activation in microglia. <i>Brain Research</i> , 2015, 1622, 43-50.	1.1	38
3026	α -Synuclein in Parkinson's disease: getting to the core of the matter. <i>Lancet Neurology</i> , The, 2015, 14, 785-786.	4.9	11
3027	Dopamine Transporter Activity Is Modulated by α -synuclein. <i>Journal of Biological Chemistry</i> , 2015, , jbc.M115.639880.	1.6	2
3028	The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 667-673.	0.9	104
3029	Clinical Determinants of Progression of Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 859.	4.5	4
3030	Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion. <i>Behavioural Brain Research</i> , 2015, 291, 361-371.	1.2	17

#	ARTICLE	IF	CITATIONS
3031	Intrastriatal injection of pre-formed mouse α -synuclein fibrils into rats triggers α -synuclein pathology and bilateral nigrostriatal degeneration. <i>Neurobiology of Disease</i> , 2015, 82, 185-199.	2.1	285
3032	Biomarkers of Parkinson's Disease. <i>Biomarkers in Disease</i> , 2015, , 1009-1030.	0.0	0
3033	Functional Studies of Parkinson's Disease. , 2015, , 713-720.		0
3034	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. <i>Neurochemistry International</i> , 2015, 85-86, 14-23.	1.9	30
3035	Non-motor symptoms in an Indian cohort of Parkinson's disease patients and correlation of progression of non-motor symptoms with motor worsening. <i>Neurology India</i> , 2015, 63, 166.	0.2	18
3036	Overview of Neurodegenerative Disorders and Susceptibility Factors in Neurodegenerative Processes. , 2015, , 197-210.		1
3037	Genetic Models of Parkinson's Disease. , 2015, , 289-314.		0
3038	Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 610-614.	1.1	38
3039	Selective changes of ocular vestibular myogenic potentials in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 584-589.	2.2	29
3040	Clinical prodromes of neurodegeneration in Anderson-Fabry disease. <i>Neurology</i> , 2015, 84, 1454-1464.	1.5	58
3041	A novel role of microglial NADPH oxidase in mediating extra-synaptic function of norepinephrine in regulating brain immune homeostasis. <i>Glia</i> , 2015, 63, 1057-1072.	2.5	53
3042	Parkinson's disease dementia: a neural networks perspective. <i>Brain</i> , 2015, 138, 1454-1476.	3.7	333
3043	Heat shock protein defenses in the neocortex and allocortex of the telencephalon. <i>Neurobiology of Aging</i> , 2015, 36, 1924-1937.	1.5	15
3044	Rodent Models of Treatment-Related Complications in Parkinson Disease. , 2015, , 373-386.		0
3045	Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. <i>Lancet Neurology</i> , The, 2015, 14, 518-531.	4.9	387
3046	Nonmotor symptoms in sporadic versus familial forms of Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 147-153.	1.2	4
3047	Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 893-905.	1.8	24
3048	Side of motor onset is associated with hemisphere-specific memory decline and lateralized gray matter loss in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 465-470.	1.1	26

#	ARTICLE	IF	CITATIONS
3049	Parkinson's disease and enhanced inflammatory response. <i>Experimental Biology and Medicine</i> , 2015, 240, 1387-1395.	1.1	116
3050	Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.	6.3	4,079
3051	Control tissue in brain banking: the importance of thorough neuropathological assessment. <i>Journal of Neural Transmission</i> , 2015, 122, 949-956.	1.4	13
3052	Efficient Conversion of Spermatogonial Stem Cells to Phenotypic and Functional Dopaminergic Neurons via the PI3K/Akt and P21/Smurf2/Nolz1 Pathway. <i>Molecular Neurobiology</i> , 2015, 52, 1654-1669.	1.9	27
3054	Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (Neuroprotection). <i>Neurotherapeutics</i> , 2015, 12, 449-454.	2.1	25
3056	LRRK2 mutations and neurotoxicant susceptibility. <i>Experimental Biology and Medicine</i> , 2015, 240, 752-759.	1.1	28
3057	Astrocytes in Neurodegenerative Disease: Table 1.. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a020628.	2.3	312
3058	Clinical markers for identifying cholinergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 269-273.	2.2	54
3059	Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model. <i>Brain Pathology</i> , 2015, 25, 377-390.	2.1	76
3060	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 549-562.	0.5	1
3061	Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 19.	3.0	11
3062	Structural alterations of the intestinal epithelial barrier in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2015, 3, 12.	2.4	204
3063	Neuron-to-neuron α -synuclein propagation in vivo is independent of neuronal injury. <i>Acta Neuropathologica Communications</i> , 2015, 3, 13.	2.4	75
3064	Lexical diversity in Parkinson's disease. <i>Journal of Clinical Movement Disorders</i> , 2015, 2, 5.	2.2	18
3065	The Prion Hypothesis of Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 28.	2.0	64
3066	Therapeutical Implications of Melatonin in Alzheimer's and Parkinson's Diseases. <i>Molecular and Integrative Toxicology</i> , 2015, , 197-238.	0.5	0
3068	Neuropathobiology of non-motor symptoms in Parkinson disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1429-1440.	1.4	134
3069	Peripheral Vagus Nerve Stimulation Significantly Affects Lipid Composition and Protein Secondary Structure Within Dopamine-Related Brain Regions in Rats. <i>NeuroMolecular Medicine</i> , 2015, 17, 178-191.	1.8	19

#	ARTICLE	IF	CITATIONS
3070	Brainstem raphe and substantia nigra echogenicity in idiopathic REM sleep behavior disorder with comorbid depression. <i>Journal of Neurology</i> , 2015, 262, 1665-1672.	1.8	31
3071	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. <i>Journal of Neural Transmission</i> , 2015, 122, 975-991.	1.4	8
3072	Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. <i>Journal of Neurology</i> , 2015, 262, 1568-1578.	1.8	59
3073	Towards an Expert System for Accurate Diagnosis and Progress Monitoring of Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2015, 822, 151-164.	0.8	3
3074	To rise and to fall: functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1727-1735.	1.5	119
3075	Extracellular vesicle sorting of α -Synuclein is regulated by sumoylation. <i>Acta Neuropathologica</i> , 2015, 129, 695-713.	3.9	136
3076	Parkinson's disease: diagnosis and current management. <i>The Prescriber</i> , 2015, 26, 16-23.	0.1	6
3078	Functional connectome assessed using graph theory in drug-naive Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 1557-1567.	1.8	98
3079	Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1036-1041.	2.8	25
3080	Review of delirium in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2401-2410.	1.8	82
3081	The trajectory of disturbed resting-state cerebral function in Parkinson's disease at different Hoehn and Yahr stages. <i>Human Brain Mapping</i> , 2015, 36, 3104-3116.	1.9	28
3082	Prediagnostic presentation of Parkinson's disease in primary care: A case-control study. <i>Movement Disorders</i> , 2015, 30, 787-787.	2.2	2
3083	Trastornos del movimiento (I): Conceptos generales, clasificaci3n de los sÃndromes parkinsonianos y enfermedad de Parkinson. <i>Medicine</i> , 2015, 11, 4415-4426.	0.0	1
3084	Heart rate variability and the risk of Parkinson disease: The Atherosclerosis Risk in Communities study. <i>Annals of Neurology</i> , 2015, 77, 877-883.	2.8	74
3085	5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. <i>Behavioural Pharmacology</i> , 2015, 26, 45-58.	0.8	34
3086	Automatic identification of dysprosody in idiopathic Parkinson's disease. <i>Biomedical Signal Processing and Control</i> , 2015, 17, 47-54.	3.5	26
3087	Cognitive impairment in Parkinson's disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 212-220.	0.9	50
3088	Adult Neurogenesis in Neurodegenerative Diseases: Figure 1.. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a021287.	2.3	258

#	ARTICLE	IF	CITATIONS
3089	Parkinson disease with REM sleep behavior disorder. <i>Neurology</i> , 2015, 84, 888-894.	1.5	77
3090	Dopaminergic differentiation of stem cells from human deciduous teeth and their therapeutic benefits for Parkinsonian rats. <i>Brain Research</i> , 2015, 1613, 59-72.	1.1	87
3091	Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 362-371.	2.3	25
3094	Editorial. <i>Journal of Neural Transmission</i> , 2015, 122, 933-936.	1.4	0
3095	Recognition and treatment of autonomic disturbances in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1189-1203.	1.4	20
3096	No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. <i>Brain</i> , 2015, 138, 3316-3326.	3.7	54
3097	Complex liaisons moving forward the Parkinson's disease? An appraisal. <i>Basal Ganglia</i> , 2015, 5, 77-87.	0.3	1
3098	Bent out of shape: α -Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. <i>FEBS Letters</i> , 2015, 589, 3749-3759.	1.3	50
3099	Lesion of medullary catecholaminergic neurons is associated with cardiovascular dysfunction in rotenone-induced Parkinson's disease rats. <i>European Journal of Neuroscience</i> , 2015, 42, 2346-2355.	1.2	18
3100	Adenosine A _{2A} Receptors Modulate α -Synuclein Aggregation and Toxicity. <i>Cerebral Cortex</i> , 2017, 27, bhv268.	1.6	66
3101	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. <i>Brain</i> , 2015, 138, 3327-3344.	3.7	96
3102	Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1435-1440.	1.1	21
3103	Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. <i>Nature Reviews Neurology</i> , 2015, 11, 625-636.	4.9	465
3104	123I-MIBG myocardial scintigraphy and neurocirculatory abnormalities in patients with dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2015, 357, 173-177.	0.3	17
3105	Dopamine Transporter Activity Is Modulated by α -Synuclein. <i>Journal of Biological Chemistry</i> , 2015, 290, 29542-29554.	1.6	82
3106	Lewy body dementias. <i>Lancet, The</i> , 2015, 386, 1683-1697.	6.3	422
3107	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1407-1414.	1.1	56
3108	A diagnostic algorithm for Parkinson's disease: what next?. <i>Lancet Neurology, The</i> , 2015, 14, 971-973.	4.9	3

#	ARTICLE	IF	CITATIONS
3109	Neuroinflammation in Lewy body dementia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1398-1406.	1.1	68
3110	Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson's disease: Indications of a principal role of the brainstem. <i>NeuroImage: Clinical</i> , 2015, 9, 264-274.	1.4	46
3111	MS-based methods for biomarkers of Parkinson's disease: what is the future?. <i>Bioanalysis</i> , 2015, 7, 149-151.	0.6	2
3112	Low levels of astroglial markers in Parkinson's disease: relationship to α -synuclein accumulation. <i>Neurobiology of Disease</i> , 2015, 82, 243-253.	2.1	90
3113	Aging and Parkinson's disease as functional models of temporal order perception. <i>Neuropsychologia</i> , 2015, 78, 1-9.	0.7	5
3114	The Neuropathology of Huntington's Disease: Classical Findings, Recent Developments and Correlation to Functional Neuroanatomy. <i>Advances in Anatomy, Embryology and Cell Biology</i> , 2015, , .	1.0	31
3115	Adenosine A2A Receptor Antagonists as Drugs for Symptomatic Control of Parkinson's Disease in Preclinical Studies. <i>Current Topics in Neurotoxicity</i> , 2015, , 127-148.	0.4	0
3116	Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1893-1900.	2.2	42
3117	Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. <i>Pharmacological Reviews</i> , 2015, 67, 1005-1024.	7.1	144
3118	Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1231-1240.	1.4	22
3120	2-Aminopyrimidines as dual adenosine A1/A2A antagonists. <i>European Journal of Medicinal Chemistry</i> , 2015, 104, 177-188.	2.6	25
3121	Fall risk is associated with amplified functional connectivity of the central executive network in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2448-2456.	1.8	23
3122	Propagation of prions causing synucleinopathies in cultured cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4949-58.	3.3	191
3123	Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/ α -synuclein aggregation. <i>Autophagy</i> , 2015, 11, 1745-1759.	4.3	88
3124	A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role?. <i>Cortex</i> , 2015, 73, 80-105.	1.1	161
3125	Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α -Synuclein Gene-induced Neurodegeneration. <i>Journal of Biological Chemistry</i> , 2015, 290, 19433-19444.	1.6	171
3126	The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus. <i>Journal of Neuroscience</i> , 2015, 35, 11190-11195.	1.7	54
3127	Transcellular spreading of huntingtin aggregates in the <i>Drosophila</i> brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5427-33.	3.3	105

#	ARTICLE	IF	CITATIONS
3128	Cineradiographic analysis of respiratory movements in a mouse model for early Parkinson's disease. <i>Respiratory Physiology and Neurobiology</i> , 2015, 218, 40-45.	0.7	4
3129	Is normosmic Parkinson disease a unique clinical phenotype?. <i>Neurology</i> , 2015, 85, 1270-1275.	1.5	53
3130	Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 1054-1064.	4.9	56
3131	Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2015, 5, 279-281.	1.2	0
3132	Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson's disease. <i>Brain Research</i> , 2015, 1625, 255-274.	1.1	44
3133	Overnight S100B in Parkinson's Disease: A glimpse into sleep-related neuroinflammation. <i>Neuroscience Letters</i> , 2015, 608, 57-63.	1.0	13
3134	Common therapeutic mechanisms of pallidal deep brain stimulation for hypo- and hyperkinetic movement disorders. <i>Journal of Neurophysiology</i> , 2015, 114, 2090-2104.	0.9	10
3135	Pedunculopontine arousal system physiology in Deep brain stimulation (DBS). <i>Sleep Science</i> , 2015, 8, 153-161.	0.4	14
3136	TDP-43 is intercellularly transmitted across axon terminals. <i>Journal of Cell Biology</i> , 2015, 211, 897-911.	2.3	263
3138	Diagnostic value of combined assessment of olfaction and substantia nigra hyperechogenicity for Parkinson's disease. <i>Neurologia (English Edition)</i> , 2015, 30, 496-501.	0.2	3
3139	MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 427-453.	1.4	13
3141	Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α -synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. <i>Neuroscience</i> , 2015, 286, 383-392.	1.1	81
3142	Substantia nigra neuromelanin magnetic resonance imaging in <i>de novo</i> Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015, 22, 540-546.	1.7	90
3143	From Man to Mouse. , 2015, , 287-306.		4
3144	Parkinson Disease and Other Synucleinopathies. , 2015, , 281-302.		5
3145	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0
3146	Does dominant pedunculopontine nucleus exist? Probably not. <i>Brain</i> , 2015, 138, e346-e346.	3.7	2
3147	Sleep disturbances and dementia. <i>Psychogeriatrics</i> , 2015, 15, 65-74.	0.6	111

#	ARTICLE	IF	CITATIONS
3148	An update on the rotenone models of Parkinson's disease: Their ability to reproduce the features of clinical disease and model gene-environment interactions. <i>NeuroToxicology</i> , 2015, 46, 101-116.	1.4	251
3149	Gut microbiota are related to Parkinson's disease and clinical phenotype. <i>Movement Disorders</i> , 2015, 30, 350-358.	2.2	1,457
3150	Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. <i>Neurobiology of Aging</i> , 2015, 36, 505-518.	1.5	42
3151	Mutual exacerbation of peroxisome proliferator-activated receptor δ coactivator 1 α deregulation and α -synuclein oligomerization. <i>Annals of Neurology</i> , 2015, 77, 15-32.	2.8	112
3152	Role of Inflammation in Neurodegenerative Diseases. , 2015, , 380-395.		2
3153	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402
3155	The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure. <i>NeuroToxicology</i> , 2015, 46, 1-11.	1.4	5
3156	Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease. <i>Neurologic Clinics</i> , 2015, 33, 1-17.	0.8	84
3157	Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 120-125.	1.1	48
3159	Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome. <i>Proteomics - Clinical Applications</i> , 2015, 9, 848-871.	0.8	11
3160	Invited review: Prion-like transmission and spreading of tau pathology. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 47-58.	1.8	130
3161	Treatment Strategies in Early and Advanced Parkinson Disease. <i>Neurologic Clinics</i> , 2015, 33, 19-37.	0.8	27
3162	In vivo gastric detection of α -synuclein inclusions in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 517-524.	2.2	111
3163	Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. <i>Brain Structure and Function</i> , 2015, 220, 703-727.	1.2	58
3164	Valor de la evaluación combinada de olfación e hipercogenidad de sustancia negra en el diagnóstico de la enfermedad de Parkinson. <i>Neurología</i> , 2015, 30, 496-501.	0.3	10
3165	Steadiness of syllable repetition in early motor stages of Parkinson's disease. <i>Biomedical Signal Processing and Control</i> , 2015, 17, 55-59.	3.5	12
3166	Effects of dopaminergic treatment on functional cortico-cortical connectivity in Parkinson's disease. <i>Experimental Brain Research</i> , 2015, 233, 329-337.	0.7	10
3167	The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. <i>Neuropeptides</i> , 2015, 49, 1-5.	0.9	35

#	ARTICLE	IF	CITATIONS
3168	Synthetic prions and other human neurodegenerative proteinopathies. <i>Virus Research</i> , 2015, 207, 25-37.	1.1	15
3169	GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model. <i>Experimental Neurology</i> , 2015, 263, 177-189.	2.0	74
3170	Inflammation is genetically implicated in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 89-102.	1.1	182
3172	G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients. <i>Molecular Neurobiology</i> , 2015, 52, 386-398.	1.9	18
3173	Glial activation is associated with L-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2015, 73, 377-387.	2.1	79
3174	Î±-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved. <i>European Journal of Neuroscience</i> , 2015, 41, 137-146.	1.2	9
3175	Serotonin in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 277, 136-145.	1.2	224
3176	A cell culture model for monitoring Î±-synuclein cell-to-cell transfer. <i>Neurobiology of Disease</i> , 2015, 77, 266-275.	2.1	72
3177	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	2.1	144
3178	Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: High-resolution fast spin-echo T1-weighted imaging. <i>Geriatrics and Gerontology International</i> , 2015, 15, 334-340.	0.7	76
3179	Preconditioning as a Potential Strategy for the Prevention of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 313-330.	1.9	21
3180	Spreading of Î±-synuclein in the face of axonal transport deficits in Parkinson's disease: A speculative synthesis. <i>Neurobiology of Disease</i> , 2015, 77, 276-283.	2.1	59
3181	Interneurons, tau and amyloid-Î² in the piriform cortex in Alzheimer's disease. <i>Brain Structure and Function</i> , 2015, 220, 2011-2025.	1.2	64
3182	Neurotoxicology. , 0, , .		0
3183	Park sleep: a non-motor dominant Parkinson's disease phenotype. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215213.	0.2	0
3184	Increased Motor Activity During REM Sleep Is Linked with Dopamine Function in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 895-903.	1.4	30
3185	Nrf2 and Parkinson's Disease. , 2016, , .		0
3186	Consequences of Gut Dysbiosis on the Human Brain. , 0, , .		1

#	ARTICLE	IF	CITATIONS
3187	Parkinsonâ€™s Disease (Pathogenesis and Its Management): An Overview. , 2016, 06, .		0
3188	Alterations in Olfaction during Alzheimer Disease, Parkinson Disease and Lewy Body Disease. , 2016, 6, .		1
3189	Diffusion Tensor Imaging in Neurodegenerative Disorders. , 2016, , .		0
3190	Variation in Recent Onset Parkinsonâ€™s Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	1.5	21
3191	Determinants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease. Handbook of Behavioral Neuroscience, 2016, 24, 821-837.	0.7	0
3192	Deep-Brain Stimulation for Neurologic and Neuropsychiatric Disorders. Handbook of Behavioral Neuroscience, 2016, 24, 971-995.	0.7	2
3193	The impact of cognitive performance on quality of life in individuals with Parkinson's disease. Dementia E Neuropsychologia, 2016, 10, 303-309.	0.3	11
3194	Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria. Revista De Psiquiatria Clinica, 2016, 43, 139-142.	0.6	5
3196	The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group. Journal of Clinical		

#	ARTICLE	IF	CITATIONS
3206	Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[¹⁸ F]Fluoro-L-m-tyrosine Uptake in the Locus Coeruleus. <i>Parkinson's Disease</i> , 2016, 2016, 1-5.	0.6	18
3207	Melatonergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-31.	1.9	64
3208	Clinical Pain and Neuropsychological Functioning in Parkinson's Disease: Are They Related?. <i>Parkinson's Disease</i> , 2016, 2016, 1-9.	0.6	3
3209	5-HT _{2A} Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.	0.6	5
3210	Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. <i>Neural Plasticity</i> , 2016, 2016, 1-15.	1.0	186
3211	Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression. <i>Journal of Parkinson's Disease</i> , 2016, 6, 557-567.	1.5	31
3212	Etiology and Progression of Parkinson's Disease: Cross-Talk Between Environmental Factors and Genetic Vulnerability. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 803-819.	0.7	1
3213	Nanomaterials for Neurology: State-of-the-Art. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1306-1324.	0.8	12
3214	Protective Microglia and Their Regulation in Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 89.	1.4	91
3215	Parkinson's Disease: Assay of Phosphorylated α -Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma. <i>Brain Sciences</i> , 2016, 6, 17.	1.1	8
3216	Recent Advances of the NLRP3 Inflammasome in Central Nervous System Disorders. <i>Journal of Immunology Research</i> , 2016, 2016, 1-9.	0.9	132
3217	Mouse Genetic Models of Human Brain Disorders. <i>Frontiers in Genetics</i> , 2016, 7, 40.	1.1	46
3218	Parkin Regulation and Neurodegenerative Disorders. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 248.	1.7	62
3219	Astrocytes As the Main Players in Primary Degenerative Disorders of the Human Central Nervous System. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 45.	1.7	25
3220	A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 117.	1.7	20
3221	The Alterations of Cortical Volume, Thickness, Surface, and Density in the Intermediate Sporadic Parkinson's Disease from the Han Population of Mainland China. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 185.	1.7	7
3222	Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 303.	1.7	215
3223	Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 16.	1.8	9

#	ARTICLE	IF	CITATIONS
3224	Early Degeneration of Both Dopaminergic and Serotonergic Axons â€” A Common Mechanism in Parkinsonâ€™s Disease. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 293.	1.8	92
3225	Altered Kinematics of Facial Emotion Expression and Emotion Recognition Deficits Are Unrelated in Parkinsonâ€™s Disease. <i>Frontiers in Neurology</i> , 2016, 7, 230.	1.1	33
3226	Subcortical Volumes Differ in Parkinsonâ€™s Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 356.	1.0	45
3227	Structural and Functional MRI Differences in Master Sommeliers: A Pilot Study on Expertise in the Brain. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 414.	1.0	22
3228	Parkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 431.	1.0	4
3229	More than a Rumor Spreads in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 608.	1.0	11
3230	Evaluation of Models of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 503.	1.4	150
3231	Multimodal Imaging Signatures of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2016, 10, 131.	1.4	24
3232	Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis. <i>Frontiers in Neuroscience</i> , 2016, 10, 269.	1.4	110
3233	Commentary: Evaluation of Models of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2016, 10, 283.	1.4	17
3234	Alpha-Synuclein Oligomersâ€”Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. <i>Frontiers in Neuroscience</i> , 2016, 10, 408.	1.4	288
3235	Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of <i>Caenorhabditis elegans</i> , a Potential Etiology of Parkinsonâ€™s Disease. <i>Frontiers in Nutrition</i> , 2016, 3, 7.	1.6	11
3236	Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinsonâ€™s Disease-Lessons from Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2016, 17, 151.	1.8	58
3237	Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimerâ€™s and Parkinsonâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 173.	1.8	196
3238	Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2016, 17, 189.	1.8	223
3239	Neuroprotective and Therapeutic Strategies against Parkinsonâ€™s Disease: Recent Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 904.	1.8	146
3240	Changes in Olfactory Bulb Volume in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0149286.	1.1	51
3241	Vascular Risk Factors and Diseases Modulate Deficits of Reward-Based Reversal Learning in Acute Basal Ganglia Stroke. <i>PLoS ONE</i> , 2016, 11, e0155267.	1.1	1

#	ARTICLE	IF	CITATIONS
3242	The Role of MAPT Haplotype H2 and Isoform 1N/4R in Parkinsonism of Older Adults. PLoS ONE, 2016, 11, e0157452.	1.1	25
3243	Mannose 6-Phosphate Receptor Is Reduced in α -Synuclein Overexpressing Models of Parkinsons Disease. PLoS ONE, 2016, 11, e0160501.	1.1	19
3244	Striatal Dopamine Depletion Patterns and Early Non-Motor Burden in Parkinsons Disease. PLoS ONE, 2016, 11, e0161316.	1.1	11
3245	The Relationship between Parkinson Disease and Brain Tumor: A Meta-Analysis. PLoS ONE, 2016, 11, e0164388.	1.1	22
3246	Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes. PLoS ONE, 2016, 11, e0168700.	1.1	61
3247	Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?. Frontiers in Psychiatry, 2016, 7, 91.	1.3	28
3248	Classification and Characteristics of Pain Associated with Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-8.	0.6	23
3250	Dopaminergic Therapy Modulates Cortical Perfusion in Parkinson Disease With and Without Dementia According to Arterial Spin Labeled Perfusion Magnetic Resonance Imaging. Medicine (United States), 2016, 95, e2206.	0.4	28
3251	Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease. Journal of Neural Transmission, 2016, 123, 1331-1339.	1.4	21
3252	Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients. Human Brain Mapping, 2016, 37, 1136-1147.	1.9	36
3253	LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. Journal of Neuroscience Research, 2016, 94, 717-735.	1.3	37
3254	Purkinje cell loss in essential tremor: Random sampling quantification and nearest neighbor analysis. Movement Disorders, 2016, 31, 393-401.	2.2	73
3255	Interference of α -Synuclein Uptake by Monomeric β -Amyloid1-40 and Potential Core Acting Site of the Interference. Neurotoxicity Research, 2016, 30, 479-485.	1.3	10
3256	Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future. Journal of Neurochemistry, 2016, 139, 76-90.	2.1	7
3257	Chronic and progressive Parkinson's disease <scp>MPTP</scp> model in adult and aged mice. Journal of Neurochemistry, 2016, 136, 373-387.	2.1	67
3258	Pisa syndrome in a patient with pathologically confirmed Parkinson's disease. Neuropathology and Applied Neurobiology, 2016, 42, 654-658.	1.8	6
3259	Intracellular soluble α -synuclein oligomers reduce pyramidal cell excitability. Journal of Physiology, 2016, 594, 2751-2772.	1.3	41
3260	Active immunization therapies for Parkinson's disease and multiple system atrophy. Movement Disorders, 2016, 31, 214-224.	2.2	67

#	ARTICLE	IF	CITATIONS
3261	Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update. <i>Muscle and Nerve</i> , 2016, 53, 842-849.	1.0	12
3263	Exocytosis and Spreading of Normal and Aberrant α -Synuclein. <i>Brain Pathology</i> , 2016, 26, 398-403.	2.1	59
3264	Resting-state functional connectivity of the striatum in early-stage Parkinson's disease: Cognitive decline and motor symptomatology. <i>Human Brain Mapping</i> , 2016, 37, 648-662.	1.9	74
3265	Neuropathology of α -synuclein propagation and Braak hypothesis. <i>Movement Disorders</i> , 2016, 31, 152-160.	2.2	111
3266	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016, 31, 1095-1102.	2.2	254
3267	Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?. <i>Movement Disorders</i> , 2016, 31, 937-946.	2.2	99
3268	Alteration of Upstream Autophagy-Related Proteins (ULK1, ULK2) in Parkinson's Disease. <i>Journal of Neuroinflammation</i> , 2016, 13, 100.	2.1	40
3269	Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dual-hit hypothesis of neurodegeneration. <i>Hippocampus</i> , 2016, 26, 980-994.	0.9	20
3270	α -Synuclein propagation: New insights from animal models. <i>Movement Disorders</i> , 2016, 31, 161-168.	2.2	100
3271	Combination therapies: The next logical step for the treatment of synucleinopathies?. <i>Movement Disorders</i> , 2016, 31, 225-234.	2.2	45
3272	Neuropathological basis of nonmotor manifestations of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1114-1119.	2.2	173
3273	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. <i>Movement Disorders</i> , 2016, 31, 802-813.	2.2	127
3274	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. <i>Movement Disorders</i> , 2016, 31, 771-781.	2.2	88
3275	Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. <i>Journal of Neuroinflammation</i> , 2016, 13, 174.	3.1	40
3277	The Effect of Fragmented Pathogenic α -Synuclein Seeds on Prion-like Propagation. <i>Journal of Biological Chemistry</i> , 2016, 291, 18675-18688.	1.6	88
3278	Pathological α -synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. <i>Annals of Neurology</i> , 2016, 79, 940-949.	2.8	314
3279	Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 167-177.	1.9	18
3280	Dysautonomia in prodromal α -synucleinopathy: peripheral versus central autonomic degeneration. <i>European Journal of Neurology</i> , 2016, 23, 878-890.	1.7	13

#	ARTICLE	IF	CITATIONS
3281	Lewy and Alzheimer type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 451-462.	1.8	26
3282	Î±-Synuclein pathology in the cranial and spinal nerves in Lewy body disease. <i>Neuropathology</i> , 2016, 36, 262-269.	0.7	17
3283	Structural and functional properties of prefibrillar Î±-synuclein oligomers. <i>Scientific Reports</i> , 2016, 6, 24526.	1.6	125
3284	Melatonin attenuates hLRRK2-induced sleep disturbances and synaptic dysfunction in a <i>Drosophila</i> model of Parkinson's disease. <i>Molecular Medicine Reports</i> , 2016, 13, 3936-3944.	1.1	30
3285	Nanomechanical properties of distinct fibrillar polymorphs of the protein Î±-synuclein. <i>Scientific Reports</i> , 2016, 6, 37970.	1.6	52
3286	Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson's disease?. <i>Translational Neurodegeneration</i> , 2016, 5, 10.	3.6	4
3287	Merging DBS with viral vector or stem cell implantation: a hybrid stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 15051.	1.8	14
3288	Classification of Scans Without Evidence of Dopamine Deficit (SWEDD) According to the Olfactory Function. <i>Journal of Parkinson's Disease</i> , 2016, 6, 771-778.	1.5	6
3291	Impaired Pain Processing Correlates with Cognitive Impairment in Parkinson's Disease. <i>Internal Medicine</i> , 2016, 55, 3113-3118.	0.3	6
3292	Knockdown of NogoA prevents MPP+-induced neurotoxicity in PC12 cells via the mTOR/STAT3 signaling pathway. <i>Molecular Medicine Reports</i> , 2016, 13, 1427-1433.	1.1	4
3293	Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson's Disease: A Retrospective Study. <i>Journal of Parkinson's Disease</i> , 2016, 6, 183-190.	1.5	12
3294	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016, 6, e010357.	0.8	57
3295	Creation of a library of induced pluripotent stem cells from Parkinsonian patients. <i>Npj Parkinson's Disease</i> , 2016, 2, 16009.	2.5	74
3297	Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1112-1122.	0.9	35
3298	White matter microstructural characteristics in newly diagnosed Parkinson's disease: An unbiased whole-brain study. <i>Scientific Reports</i> , 2016, 6, 35601.	1.6	35
3299	Unmet needs in Parkinson's disease: New horizons in a changing landscape. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S2-S8.	1.1	19
3300	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. <i>Acta Neuropathologica Communications</i> , 2016, 4, 66.	2.4	58
3301	Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 609-619.	1.2	14

#	ARTICLE	IF	CITATIONS
3302	Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders. <i>Translational Neurodegeneration</i> , 2016, 5, 17.	3.6	28
3303	Clinicopathological case: rapid cognitive decline in an older man. <i>Practical Neurology</i> , 2016, 16, 466-474.	0.5	0
3304	Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction. <i>Journal of Parkinson's Disease</i> , 2016, 6, 441-451.	1.5	18
3306	Presymptomatic anterior frontal involvement in corticobasal degeneration. <i>Brain</i> , 2016, 139, 3059-3062.	3.7	3
3307	Neuroinvasion of α -Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation. <i>Journal of Virology</i> , 2016, 90, 9182-9193.	1.5	79
3308	Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. <i>Current Opinion in Neurology</i> , 2016, 29, 727-734.	1.8	55
3309	Newly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort Study. <i>Scientific Reports</i> , 2016, 6, 29651.	1.6	35
3310	Connecting Ca ²⁺ and Lysosomes to Parkinson Disease. <i>Messenger (Los Angeles, Calif: Print)</i> , 2016, 5, 76-86.	0.3	5
3311	The nonmotor features of Parkinson's disease: pathophysiology and management advances. <i>Current Opinion in Neurology</i> , 2016, 29, 467-473.	1.8	44
3312	Virtual reality systems in the rehabilitation of Parkinson's disease. , 2016, , .		6
3313	Biomarkers in Prodromal Parkinson Disease: a Qualitative Review. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 956-967.	1.2	19
3314	Serotonergic dysfunctions and abnormal iron metabolism: Relevant to mental fatigue of Parkinson disease. <i>Scientific Reports</i> , 2016, 6, 19.	1.6	72
3315	Reduction of Immunoreactivity Against the C-Terminal Region of the Intracellular α -Synuclein by Exogenous α -Synuclein Aggregates: Possibility of Conformational Changes. <i>Journal of Parkinson's Disease</i> , 2016, 6, 569-579.	1.5	5
3316	Three-dimensional and stereological characterization of the human substantia nigra during aging. <i>Brain Structure and Function</i> , 2016, 221, 3393-3403.	1.2	14
3317	Associations of olfactory bulb and depth of olfactory sulcus with basal ganglia and hippocampus in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 620, 111-114.	1.0	23
3318	Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease. <i>Behavioural Brain Research</i> , 2016, 307, 54-64.	1.2	20
3319	Animal behavioral assessments in current research of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 63-94.	2.9	63
3320	Chemical anatomy of pallidal afferents in primates. <i>Brain Structure and Function</i> , 2016, 221, 4291-4317.	1.2	24

#	ARTICLE	IF	CITATIONS
3321	Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 61-77.	2.5	209
3322	Alpha-Synuclein as a Diagnostic Biomarker for Parkinson's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 215-234.	0.1	1
3323	A Japanese multicenter survey characterizing pain in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 365, 162-166.	0.3	8
3324	FDG-PET in Dementia. , 2016, , 73-87.		0
3325	Vagal neurocircuitry and its influence on gastric motility. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 389-401.	8.2	207
3327	Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System. <i>Journal of Neuroscience</i> , 2016, 36, 5608-5622.	1.7	89
3329	Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. <i>Clinical Neurology and Neurosurgery</i> , 2016, 146, 35-39.	0.6	41
3330	Geniposide reduces α -synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models. <i>Brain Research</i> , 2016, 1644, 98-106.	1.1	60
3331	Subcortical volume changes in dementia with Lewy bodies and Alzheimer's disease. A comparison with healthy aging. <i>International Psychogeriatrics</i> , 2016, 28, 529-536.	0.6	31
3332	Neuropsychiatric Issues in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 49.	2.0	68
3333	Trastorno de conducta durante el sueño REM: a propósito de un caso concomitante con depresión. <i>Psiquiatría Biológica</i> , 2016, 23, 80-83.	0.0	0
3334	Protective Effects of Paeoniflorin Against MPP+-induced Neurotoxicity in PC12 Cells. <i>Neurochemical Research</i> , 2016, 41, 1323-1334.	1.6	15
3335	Imaging Systemic Dysfunction in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 51.	2.0	23
3336	DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. <i>Brain</i> , 2016, 139, 1680-1687.	3.7	89
3337	Une atteinte neuropathologique spécifique et clinique spécifique pour chaque patient?. <i>Pratique Neurologique - FMC</i> , 2016, 7, 123-125.	0.1	0
3339	Immunotherapy of Parkinson's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 85-108.	0.1	0
3340	A core deficit in Parkinson disease?. <i>Neurología (English Edition)</i> , 2016, 31, 223-230.	0.2	2
3341	Monitoring of 30 marker candidates in early Parkinson disease as progression markers. <i>Neurology</i> , 2016, 87, 168-177.	1.5	133

#	ARTICLE	IF	CITATIONS
3342	An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms. Expert Review of Neurotherapeutics, 2016, 16, 711-722.	1.4	10
3343	<i>In vivo</i> imaging of neuromelanin in Parkinson's disease using ¹⁸ F-AV-1451 PET. Brain, 2016, 139, 2039-2049.	3.7	113
3344	[123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1060-1066.	3.3	55
3345	The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease. Journal of Neural Transmission, 2016, 123, 583-588.	1.4	11
3346	Paradoxical kinesia in Parkinson's disease revisited: Anticipation of temporal constraints is critical. Neuropsychologia, 2016, 86, 38-44.	0.7	15
3347	Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews, 2016, 28, 72-84.	5.0	122
3348	Extracellular vesicles in neurodegenerative disease – pathogenesis to biomarkers. Nature Reviews Neurology, 2016, 12, 346-357.	4.9	299
3349	Progression and biomarkers for Parkinson disease. Neurology, 2016, 87, 128-129.	1.5	5
3350	Nrf2: a modulator of Parkinson's disease?. Journal of Neural Transmission, 2016, 123, 611-619.	1.4	73
3351	New concepts in the pathogenesis and presentation of Parkinson's disease. Clinical Medicine, 2016, 16, 365-370.	0.8	47
3352	Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management, 2016, 6, 385-398.	1.2	2
3353	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	0.8	64
3354	Clinical markers of neurodegeneration in Chinese patients with idiopathic rapid eye movement sleep behavior disorder. Clinical Neurology and Neurosurgery, 2016, 150, 105-109.	0.6	9
3355	Electrophysiological assessment of nociception in patients with Parkinson's disease: A multi-methods approach. Journal of the Neurological Sciences, 2016, 368, 59-69.	0.3	13
3356	Epidemiology of Parkinson Disease. Neurologic Clinics, 2016, 34, 955-965.	0.8	242
3357	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	4.4	39
3358	Clinical Manifestation of Parkinson's Disease in Association with Rapid Eye Movement Sleep Behavior Disorder Onset. European Neurology, 2016, 76, 154-160.	0.6	8
3359	Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. Brain and Behavior, 2016, 6, e00573.	1.0	79

#	ARTICLE	IF	CITATIONS
3360	Diffusion alterations associated with Parkinson's disease symptomatology: A review of the literature. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 12-26.	1.1	70
3361	Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. <i>Cell Reports</i> , 2016, 16, 3373-3387.	2.9	141
3362	Pathological α -synuclein transmission initiated by binding lymphocyte-activation gene 3. <i>Science</i> , 2016, 353, .	6.0	521
3363	Optic nerve integrity as a visuospatial cognitive predictor in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 41-45.	1.1	7
3365	Shared and Distinct Patterns of Oligodendroglial Response in α -Synucleinopathies and Tauopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 1100-1109.	0.9	35
3366	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 102-106.	1.1	8
3367	Tunneling nanotubes spread fibrillar α -synuclein by intercellular trafficking of lysosomes. <i>EMBO Journal</i> , 2016, 35, 2120-2138.	3.5	286
3368	Schlafmedizin bei Neurodegenerativen Erkrankungen. <i>Neurophysiologie-Labor</i> , 2016, 38, 117-126.	0.0	0
3369	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2016, 48, 153-160.	1.5	79
3370	Environmental and genetic factors support the dissociation between α -synuclein aggregation and toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6506-E6515.	3.3	75
3371	Knowledge gaps and research recommendations for essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 27-35.	1.1	46
3372	Prion diseases: New considerations. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 125-132.	0.6	11
3373	From the Cover: Alterations in Optineurin Expression and Localization in Pre-clinical Parkinson's Disease Models. <i>Toxicological Sciences</i> , 2016, 153, 372-381.	1.4	14
3374	Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 1121-1141.	2.6	58
3375	TSPO imaging in parkinsonian disorders. <i>Clinical and Translational Imaging</i> , 2016, 4, 183-190.	1.1	56
3376	Imaging in Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 254-260.	1.2	16
3377	Disruption of motor behavior and injury to the CNS induced by 3-thienylboronic acid in mice. <i>Toxicology and Applied Pharmacology</i> , 2016, 307, 130-137.	1.3	10
3378	Widespread transneuronal propagation of α -synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. <i>Journal of Experimental Medicine</i> , 2016, 213, 1759-1778.	4.2	309

#	ARTICLE	IF	CITATIONS
3379	Prodromal symptoms of Parkinson's disease: Implications for epidemiological studies of disease etiology. <i>Revue Neurologique</i> , 2016, 172, 503-511.	0.6	21
3380	Deep brain stimulation and sleep-wake functions in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 12-19.	1.1	22
3381	Distribution and Load of Amyloid- β^2 Pathology in Parkinson Disease and Dementia with Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 936-945.	0.9	109
3382	Neurodegenerative and neurological disorders by small inhaled particles. <i>NeuroToxicology</i> , 2016, 56, 94-106.	1.4	246
3383	Basolateral but not corticomedial amygdala shows neuroarchitectural changes in schizophrenia. <i>Journal of Neuroscience Research</i> , 2016, 94, 544-547.	1.3	8
3384	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 53-58.	0.8	1
3385	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016, 31, 86-94.	2.2	78
3386	Neuroimaging correlates of blinking abnormalities in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 138-143.	2.2	13
3387	Serum immune markers and disease progression in an incident Parkinson's disease cohort (MICICLE-PD). <i>Movement Disorders</i> , 2016, 31, 995-1003.	2.2	211
3388	Patterns of cortical thinning in nondemented Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 699-708.	2.2	71
3389	Medical Computer Vision: Algorithms for Big Data. <i>Lecture Notes in Computer Science</i> , 2016, , .	1.0	0
3390	Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 441-450.	1.1	9
3391	Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. <i>Journal of Neurochemistry</i> , 2016, 139, 275-289.	2.1	77
3392	The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 137, 331-359.	2.1	186
3393	Review: The spectrum of clinical features seen with alpha synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 6-19.	1.8	67
3394	Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model. <i>European Journal of Neuroscience</i> , 2016, 43, 41-52.	1.2	39
3395	How can rAAV- α -synuclein and the fibril β -synuclein models advance our understanding of Parkinson's disease?. <i>Journal of Neurochemistry</i> , 2016, 139, 131-155.	2.1	84
3396	Diversity matters – heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease. <i>Journal of Neurochemistry</i> , 2016, 139, 8-26.	2.1	57

#	ARTICLE	IF	CITATIONS
3397	The clinical symptoms of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 139, 318-324.	2.1	830
3398	Review: Parkinson's disease: from synaptic loss to connectome dysfunction. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 77-94.	1.8	163
3399	Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 33-50.	1.8	309
3400	Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of α -synuclein. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 51-76.	1.8	65
3401	Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. <i>Human Brain Mapping</i> , 2016, 37, 4500-4510.	1.9	75
3402	199 Years of Parkinson disease – what have we learned and what is the path to the future?. <i>Journal of Neurochemistry</i> , 2016, 139, 3-7.	2.1	23
3403	Subcortical contributions to large-scale network communication. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 313-322.	2.9	129
3404	Potential Pathways of Abnormal Tau and α -Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a023630.	2.3	101
3405	Immunotherapy Against α -Synuclein Pathology. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 63-72.	0.1	2
3406	Circadian regulation and its disorders in Parkinson's disease patients. Part 1: The role of dopamine in circadian dysfunction. <i>Human Physiology</i> , 2016, 42, 444-453.	0.1	2
3407	Image-guided ultrasound phased arrays are a disruptive technology for non-invasive therapy. <i>Physics in Medicine and Biology</i> , 2016, 61, R206-R248.	1.6	98
3408	Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 279-288.	1.1	23
3409	Pathogenic mechanisms of prion protein, amyloid β and α -synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. <i>Journal of Neurochemistry</i> , 2016, 139, 162-180.	2.1	77
3410	Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 368, 235-239.	0.3	26
3411	Mechanisms for cell-to-cell propagation no longer lag behind. <i>Movement Disorders</i> , 2016, 31, 1798-1799.	2.2	2
3412	Ventilatory Dysfunction in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 463-471.	1.5	52
3413	Total α -synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 7669-7677.	1.9	22
3415	Porto-Port delivery: Mobilization of toxic sphingolipids via extracellular vesicles. <i>Journal of Neuroscience Research</i> , 2016, 94, 1333-1340.	1.3	24

#	ARTICLE	IF	CITATIONS
3416	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. , 2016, , .		10
3417	Beyond Krabbe's disease: The potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies. <i>Journal of Neuroscience Research</i> , 2016, 94, 1328-1332.	1.3	39
3418	Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 628-635.	0.9	59
3419	Constipation: an emerging risk factor for Parkinson's disease?. <i>European Journal of Neurology</i> , 2016, 23, 1606-1613.	1.7	68
3420	Unmasking levodopa resistance in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1602-1609.	2.2	80
3421	Progressive Supranuclear Palsy and Related Parkinsonian Disorders. , 2016, , 283-300.		1
3422	A New Neuroanatomy of Basal Ganglia Circuitry. , 2016, , 301-315.		0
3423	Deubiquitinase Usp8 regulates α -synuclein clearance and modifies its toxicity in Lewy body disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4688-97.	3.3	99
3424	Transmission of α -synucleinopathy from olfactory structures deep into the temporal lobe. <i>Molecular Neurodegeneration</i> , 2016, 11, 49.	4.4	56
3425	Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and <i>Caenorhabditis elegans</i> . <i>Scientific Reports</i> , 2016, 6, 34477.	1.6	319
3426	Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status. <i>CNS Drugs</i> , 2016, 30, 1127-1135.	2.7	27
3427	Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. <i>Drugs and Aging</i> , 2016, 33, 855-863.	1.3	31
3428	Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease. <i>Neurology</i> , 2016, 87, 2540-2545.	1.5	32
3429	Cryopreserved Adipose Tissue-Derived Stromal/Stem Cells: Potential for Applications in Clinic and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 951, 137-146.	0.8	16
3430	Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. <i>Scientific Reports</i> , 2016, 6, 34579.	1.6	41
3431	Higher Frequency and Complexity of Sleep Disturbances in Dementia with Lewy Bodies as Compared to Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 152-160.	0.8	34
3432	Dominant-side onset in Parkinson's disease and better motor performance?. <i>Movement Disorders</i> , 2016, 31, 1586-1586.	2.2	1
3433	Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15030.	2.5	24

#	ARTICLE	IF	CITATIONS
3434	Enteric neurons from Parkinson's disease patients display ex vivo aberrations in mitochondrial structure. <i>Scientific Reports</i> , 2016, 6, 33117.	1.6	22
3435	Pathology: The prion principle. <i>Nature</i> , 2016, 538, S13-S16.	13.7	23
3436	Two hundred steps. <i>Nature</i> , 2016, 538, S2-S3.	13.7	3
3437	Advances in markers of prodromal Parkinson disease. <i>Nature Reviews Neurology</i> , 2016, 12, 622-634.	4.9	272
3438	Astroglial pathology predominates the earliest stage of corticobasal degeneration pathology. <i>Brain</i> , 2016, 139, 3237-3252.	3.7	107
3439	Genetics of Parkinson's disease. <i>Molecular and Cellular Probes</i> , 2016, 30, 386-396.	0.9	282
3441	Adaptive Brain Stimulation for Parkinson's Disease. , 2016, , 213-222.		2
3442	Posterior Ventricular Enlargement to Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1237-1243.	1.2	6
3443	A Mathematical Model for the Proliferation, Accumulation and Spread of Pathogenic Proteins Along Neuronal Pathways with Locally Anomalous Trapping. <i>Mathematical Modelling of Natural Phenomena</i> , 2016, 11, 142-156.	0.9	4
3444	Spontaneous Swallowing during All-Night Sleep in Patients with Parkinson Disease in Comparison with Healthy Control Subjects. <i>Sleep</i> , 2016, 39, 847-854.	0.6	10
3445	Functionally different α -synuclein inclusions yield insight into Parkinson's disease pathology. <i>Scientific Reports</i> , 2016, 6, 23116.	1.6	30
3446	Regenerative potential of the brain: Composition and forming of regulatory microenvironment in neurogenic niches. <i>Human Physiology</i> , 2016, 42, 865-873.	0.1	6
3447	REM sleep behavior disorder was associated with Parkinson's disease: a community-based study. <i>BMC Neurology</i> , 2016, 16, 123.	0.8	20
3448	Post-mortem assessment in vascular dementia: advances and aspirations. <i>BMC Medicine</i> , 2016, 14, 129.	2.3	99
3449	The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. <i>Acta Neuropathologica Communications</i> , 2016, 4, 128.	2.4	35
3451	Management of pain and neuromuscular complications in Parkinson's disease. , 0, , 162-174.		0
3452	Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	22
3453	Nonmotor symptoms in patients with Parkinson disease. <i>Medicine (United States)</i> , 2016, 95, e5400.	0.4	48

#	ARTICLE	IF	CITATIONS
3454	Sleep-wake disturbances in the premotor and early stage of Parkinson's disease. <i>Current Opinion in Neurology</i> , 2016, 29, 763-772.	1.8	35
3455	Lysosomal Dysfunction and α -Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. <i>Movement Disorders</i> , 2016, 31, 791-801.	2.2	125
3456	Glucosylation in Parkinson's disease and Alzheimer's disease. <i>Movement Disorders</i> , 2016, 31, 782-790.	2.2	104
3457	Hippocampal α -synuclein and interneurons in Parkinson's disease: Data from human and mouse models. <i>Movement Disorders</i> , 2016, 31, 979-988.	2.2	26
3458	Brain region-dependent differential expression of α -synuclein. <i>Journal of Comparative Neurology</i> , 2016, 524, 1236-1258.	0.9	88
3459	Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. <i>BMC Medical Genomics</i> , 2016, 9, 12.	0.7	29
3460	Adrenergic receptor-mediated modulation of striatal firing patterns. <i>Neuroscience Research</i> , 2016, 112, 47-56.	1.0	8
3461	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 10-16.	1.1	29
3462	Patients with Parkinson's Disease Show Impaired Use of Priors in Conditions of Sensory Uncertainty. <i>Current Biology</i> , 2016, 26, 1902-1910.	1.8	43
3463	Aggregated α -Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2016, 186, 2152-2161.	1.9	17
3464	ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 363-379.	0.2	14
3465	Prediction of individual clinical scores in patients with Parkinson's disease using resting-state functional magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 2016, 366, 27-32.	0.3	27
3466	Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 77-84.	2.5	24
3467	Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex. <i>Neuroscience Letters</i> , 2016, 627, 121-125.	1.0	38
3469	Association of rapid eye movement sleep behavior disorder with sleep-disordered breathing in Parkinson's disease. <i>Sleep Medicine</i> , 2016, 20, 110-115.	0.8	30
3470	Subcortical matter in the α -synucleinopathies spectrum: an MRI pilot study. <i>Journal of Neurology</i> , 2016, 263, 1575-1582.	1.8	12
3471	From sweet to sweat: Hedonic olfactory range is impaired in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 9-14.	1.1	22
3472	Malattie da prioni o encefalopatie spongiformi trasmissibili. <i>EMC - Neurologia</i> , 2016, 16, 1-21.	0.0	0

#	ARTICLE	IF	CITATIONS
3473	An update on the diagnosis and treatment of Parkinson disease. <i>Cmaj</i> , 2016, 188, 1157-1165.	0.9	286
3474	Sleep Spindle Deficit in Schizophrenia: Contextualization of Recent Findings. <i>Current Psychiatry Reports</i> , 2016, 18, 72.	2.1	25
3475	Joint feature-sample selection and robust diagnosis of Parkinson's disease from MRI data. <i>NeuroImage</i> , 2016, 141, 206-219.	2.1	87
3476	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2016, 139, 161-173.	3.7	88
3477	Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment. <i>Journal of Neuroscience Research</i> , 2016, 94, 685-692.	1.3	21
3478	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 668-675.	2.2	31
3479	Synaptic failure and α -synuclein. <i>Movement Disorders</i> , 2016, 31, 169-177.	2.2	126
3480	Development of passive immunotherapies for synucleinopathies. <i>Movement Disorders</i> , 2016, 31, 203-213.	2.2	79
3481	Emotional manifestations of PD: Neurobiological basis. <i>Movement Disorders</i> , 2016, 31, 1103-1113.	2.2	79
3482	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2016, 31, 1066-1070.	2.2	34
3483	Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network. <i>Journal of Pineal Research</i> , 2016, 61, 96-107.	3.4	64
3484	Cortical Lewy bodies and $A\beta$ burden are associated with prevalence and timing of dementia in Lewy body diseases. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 436-450.	1.8	67
3485	Neurodegeneration in tauopathies and synucleinopathies. <i>Revue Neurologique</i> , 2016, 172, 709-714.	0.6	9
3486	Association Between Autonomic Impairment and Structural Deficit in Parkinson Disease. <i>Medicine (United States)</i> , 2016, 95, e3086.	0.4	18
3487	α -Synuclein as a Biomarker for Parkinson's Disease. <i>Brain Pathology</i> , 2016, 26, 410-418.	2.1	217
3488	Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2016, 53, 1181-1194.	1.9	1,438
3489	Rapid eye movement sleep behavior disorder in patients with probable Alzheimer's disease. <i>Ageing Clinical and Experimental Research</i> , 2016, 28, 951-957.	1.4	23
3490	A smaller amygdala is associated with anxiety in Parkinson's disease: a combined FreeSurfer-VBM study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 493-500.	0.9	62

#	ARTICLE	IF	CITATIONS
3491	Multimodal imaging evaluation of excessive daytime sleepiness in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2016, 126, 422-428.	0.8	19
3492	Differential expression of calbindin in nigral dopaminergic neurons in two mice strains with differential susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 82-89.	1.0	17
3493	Induction of α -synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 481-494.	3.7	349
3494	Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats. <i>Behavioural Brain Research</i> , 2016, 301, 226-237.	1.2	16
3495	Autonomic dysfunction in primary sleep disorders. <i>Sleep Medicine</i> , 2016, 19, 40-49.	0.8	79
3496	Altered Mitochondrial DNA Methylation Pattern in Alzheimer Disease-Related Pathology and in Parkinson Disease. <i>American Journal of Pathology</i> , 2016, 186, 385-397.	1.9	150
3497	Accuracy of clinical diagnosis of Parkinson disease. <i>Neurology</i> , 2016, 86, 566-576.	1.5	547
3498	Dysphagia in Parkinson's Disease. <i>Dysphagia</i> , 2016, 31, 24-32.	1.0	313
3499	How well do Parkinson's disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 10-16.	1.1	46
3500	Neural substrates of rapid eye movement sleep behavior disorder in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 31-36.	1.1	56
3501	Course and risk factors for excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 34-40.	1.1	70
3502	Enhancing Rehabilitative Therapies with Vagus Nerve Stimulation. <i>Neurotherapeutics</i> , 2016, 13, 382-394.	2.1	79
3503	Epidemiology of Parkinson's disease. <i>Revue Neurologique</i> , 2016, 172, 14-26.	0.6	292
3504	Air pollution, a rising environmental risk factor for cognition, neuroinflammation and neurodegeneration: The clinical impact on children and beyond. <i>Revue Neurologique</i> , 2016, 172, 69-80.	0.6	157
3505	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 57-87.	2.5	16
3506	α -Synuclein aggregation in the olfactory bulb of middle-aged common marmoset. <i>Neuroscience Research</i> , 2016, 106, 55-61.	1.0	7
3507	Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease. <i>Journal of Voice</i> , 2016, 30, 766.e1-766.e11.	0.6	31
3508	Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment. <i>Neuroscience</i> , 2016, 314, 22-34.	1.1	5

#	ARTICLE	IF	CITATIONS
3509	Somatic mtDNA variation is an important component of Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e1-217.e6.	1.5	61
3510	Assessment of voice and speech symptoms in early Parkinson's disease by the Robertson dysarthria profile. <i>Neurological Sciences</i> , 2016, 37, 443-449.	0.9	32
3511	DYT6 Dystonia: A Neuropathological Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 273-278.	0.8	18
3512	Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 1-8.	1.1	148
3513	Challenges of modifying disease progression in prediagnostic Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 637-648.	4.9	78
3514	Nanoscope insights into seeding mechanisms and toxicity of α -synuclein species in neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3815-3819.	3.3	63
3515	Excessive Iron and α -Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 187-194.	1.2	18
3516	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2016, 17, 251-260.	4.9	251
3517	Altered Proteins in the Aging Brain. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 316-325.	0.9	153
3518	Pathophysiology of Small-Fiber Sensory System in Parkinson's Disease. <i>Medicine (United States)</i> , 2016, 95, e3058.	0.4	21
3519	Therapeutic approaches in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 346-352.	2.1	46
3520	Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. <i>Movement Disorders</i> , 2016, 31, 135-138.	2.2	64
3521	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2016, 139, 1005-1007.	3.7	6
3522	Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 95-106.	1.8	29
3523	α -Synuclein strains and the variable pathologies of synucleinopathies. <i>Journal of Neurochemistry</i> , 2016, 139, 256-274.	2.1	72
3524	Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1206-15.	3.3	181
3525	Stage-dependent loss of cortical gyrification as Parkinson disease unfolds. <i>Neurology</i> , 2016, 86, 1143-1151.	1.5	36
3526	The peripheral nerve involvement in Parkinson Disease: A multifaceted phenomenon. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 17-20.	1.1	22

#	ARTICLE	IF	CITATIONS
3527	Neural Control of Walking in People with Parkinsonism. <i>Physiology</i> , 2016, 31, 95-107.	1.6	112
3528	A review of current and novel levodopa formulations for the treatment of Parkinson's disease. <i>Therapeutic Delivery</i> , 2016, 7, 179-191.	1.2	19
3529	Sleep in Neurodegenerative Diseases. <i>Sleep Medicine Clinics</i> , 2016, 11, 1-18.	1.2	77
3530	Proaggregant nuclear factor(s) trigger rapid formation of α -synuclein aggregates in apoptotic neurons. <i>Acta Neuropathologica</i> , 2016, 132, 77-91.	3.9	27
3531	Computer-based magnetic resonance imaging as a tool in clinical diagnosis in neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 295-306.	1.4	20
3532	Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal follow-up study. <i>Cephalalgia</i> , 2016, 36, 1316-1323.	1.8	19
3533	α -Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils. <i>Journal of Biological Chemistry</i> , 2016, 291, 2310-2318.	1.6	48
3534	Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder. <i>Journal of the Neurological Sciences</i> , 2016, 362, 59-63.	0.3	47
3535	Prions and Protein Assemblies that Convey Biological Information in Health and Disease. <i>Neuron</i> , 2016, 89, 433-448.	3.8	74
3536	Brain Connectivity Alterations Are Associated with the Development of Dementia in Parkinson's Disease. <i>Brain Connectivity</i> , 2016, 6, 216-224.	0.8	30
3537	The function of orthologues of the human Parkinson's disease gene <i>LRRK2</i> across species: implications for disease modelling in preclinical research. <i>Biochemical Journal</i> , 2016, 473, 221-232.	1.7	27
3538	The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature. <i>Journal of Neural Transmission</i> , 2016, 123, 241-250.	1.4	40
3539	The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2016, 139, 1180-1188.	3.7	148
3540	Diseases in the Elderly. , 2016, , .		3
3541	123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α -synucleinopathies. <i>Ageing Research Reviews</i> , 2016, 30, 122-133.	5.0	65
3542	Hippocampal Sclerosis but Not Normal Aging or Alzheimer Disease Is Associated With TDP-43 Pathology in the Basal Forebrain of Aged Persons. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 397-407.	0.9	40
3543	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 10-16.	1.1	60
3544	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 45-51.	1.1	97

#	ARTICLE	IF	CITATIONS
3545	Nanoparticle transport across the blood brain barrier. <i>Tissue Barriers</i> , 2016, 4, e1153568.	1.6	121
3546	What lysosomes actually tell us about Parkinson's disease?. <i>Ageing Research Reviews</i> , 2016, 32, 140-149.	5.0	19
3547	Neurological Disorders and Related Problems in the Elderly. , 2016, , 151-213.		2
3548	Screening for prodromal Parkinson's disease in the general community: a sleep-based approach. <i>Sleep Medicine</i> , 2016, 21, 101-105.	0.8	48
3549	Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?. <i>Neurotherapeutics</i> , 2016, 13, 264-283.	2.1	120
3550	The effect of subthalamic deep brain stimulation on gastric motility in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 35-40.	1.1	26
3551	Protein aggregates stimulate macropinocytosis facilitating their propagation. <i>Prion</i> , 2016, 10, 119-126.	0.9	20
3552	What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?. <i>Translational Psychiatry</i> , 2016, 6, e753-e753.	2.4	60
3553	Role of neuroinflammation in neurodegenerative diseases (Review). <i>Molecular Medicine Reports</i> , 2016, 13, 3391-3396.	1.1	673
3554	Brain propagation of transduced α -synuclein involves non-fibrillar protein species and is enhanced in α -synuclein null mice. <i>Brain</i> , 2016, 139, 856-870.	3.7	78
3555	Pathological α -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. <i>Acta Neuropathologica</i> , 2016, 131, 393-409.	3.9	123
3556	Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α -synuclein abnormalities in the substantia nigra. <i>Toxicology Letters</i> , 2016, 243, 7-21.	0.4	74
3557	Dopamine selectively remediates ϵ -model-based reward learning: a computational approach. <i>Brain</i> , 2016, 139, 355-364.	3.7	111
3558	Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats. <i>Behavioural Brain Research</i> , 2016, 301, 43-54.	1.2	27
3559	BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson's disease. <i>Brain Research</i> , 2016, 1631, 34-45.	1.1	11
3560	The neuronal extracellular matrix restricts distribution and internalization of aggregated Tau-protein. <i>Neuroscience</i> , 2016, 313, 225-235.	1.1	33
3561	Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate. <i>Neuroscience Letters</i> , 2016, 614, 16-23.	1.0	15
3562	Neuroscience: A Distributed Neural Network Controls REM Sleep. <i>Current Biology</i> , 2016, 26, R34-R35.	1.8	47

#	ARTICLE	IF	CITATIONS
3563	Loss of awareness of hyposmia is associated with mild cognitive impairment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 74-79.	1.1	33
3564	Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2016, 37, 897-903.	1.2	23
3565	Î±-Synuclein aggregation, seeding and inhibition by scyllo-inositol. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 529-534.	1.0	25
3566	Free-water imaging in Parkinson's disease and atypical parkinsonism. <i>Brain</i> , 2016, 139, 495-508.	3.7	165
3567	Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 1-8.	1.1	52
3568	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. <i>Acta Neuropathologica</i> , 2016, 131, 49-73.	3.9	179
3569	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. <i>Translational Research</i> , 2016, 175, 4-16.	2.2	23
3570	Laboratory assessments in the course of Parkinson's disease: a clinician's perspective. <i>Journal of Neural Transmission</i> , 2016, 123, 65-71.	1.4	5
3572	Current disease modifying approaches to treat Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1365-1379.	2.4	88
3573	Specific small-RNA signatures in the amygdala at premotor and motor stages of Parkinson's disease revealed by deep sequencing analysis. <i>Bioinformatics</i> , 2016, 32, 673-681.	1.8	29
3574	Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 40-50.	0.8	51
3575	Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1301-1310.	1.5	9
3576	The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions. <i>Journal of Neurology</i> , 2016, 263, 68-75.	1.8	63
3577	Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC Î±-synuclein transgenic rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2016, 85, 206-217.	2.1	77
3578	Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. <i>European Radiology</i> , 2016, 26, 2567-2577.	2.3	100
3579	Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 531-538.	0.8	56
3580	Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats. <i>Brain Structure and Function</i> , 2016, 221, 2319-2341.	1.2	17
3581	Primary motor cortex of the parkinsonian monkey: altered encoding of active movement. <i>Brain</i> , 2016, 139, 127-143.	3.7	59

#	ARTICLE	IF	CITATIONS
3582	Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. <i>Journal of NeuroVirology</i> , 2016, 22, 22-32.	1.0	42
3583	Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations. <i>Molecular Genetics and Metabolism</i> , 2016, 117, 179-185.	0.5	21
3584	Gene expression profiling predicts pathways and genes associated with Parkinson's disease. <i>Neurological Sciences</i> , 2016, 37, 73-79.	0.9	15
3585	The utility of α -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	0.6	86
3586	Emotional memory impairments induced by AAV-mediated overexpression of human α -synuclein in dopaminergic neurons of the ventral tegmental area. <i>Behavioural Brain Research</i> , 2016, 296, 129-133.	1.2	13
3587	Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis. <i>Neuropeptides</i> , 2016, 56, 69-74.	0.9	21
3588	The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: A critical review of the literature. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S166-S170.	1.1	57
3589	Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α -synuclein. <i>Journal of Neuroscience Research</i> , 2016, 94, 62-73.	1.3	31
3590	Non motor subtypes and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S41-S46.	1.1	268
3591	Parkinson's disease between internal medicine and neurology. <i>Journal of Neural Transmission</i> , 2016, 123, 3-17.	1.4	34
3592	Neurophysiological biomarkers for Lewy body dementias. <i>Clinical Neurophysiology</i> , 2016, 127, 349-359.	0.7	40
3593	The Chemistry of Neurodegeneration: Kinetic Data and Their Implications. <i>Molecular Neurobiology</i> , 2016, 53, 3400-3415.	1.9	62
3594	Effect of palmitic acid on the characteristics and release profiles of rotigotine-loaded microspheres. <i>Pharmaceutical Development and Technology</i> , 2016, 21, 3-7.	1.1	11
3595	Clia and alpha-synuclein in neurodegeneration: A complex interaction. <i>Neurobiology of Disease</i> , 2016, 85, 262-274.	2.1	156
3596	Sleep stability and transitions in patients with idiopathic REM sleep behavior disorder and patients with Parkinson's disease. <i>Clinical Neurophysiology</i> , 2016, 127, 537-543.	0.7	37
3597	The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2016, 10, 79-91.	1.1	36
3598	Novel subventricular zone early progenitor cell-specific adenovirus for in vivo therapy of central nervous system disorders reinforces brain stem cell heterogeneity. <i>Brain Structure and Function</i> , 2016, 221, 2049-2059.	1.2	8
3599	Drugs of abuse and Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 209-217.	2.5	20

#	ARTICLE	IF	CITATIONS
3600	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
3601	Chrelin and Neurodegenerative Disorders—a Review. <i>Molecular Neurobiology</i> , 2017, 54, 1144-1155.	1.9	52
3602	Altered modular organization of intrinsic brain functional networks in patients with Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2017, 11, 430-443.	1.1	27
3603	Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides. <i>Progress in Neurobiology</i> , 2017, 155, 120-148.	2.8	130
3604	Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. <i>Progress in Neurobiology</i> , 2017, 155, 96-119.	2.8	490
3605	Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1311-1325.	2.4	57
3606	Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32. <i>Molecular Neurobiology</i> , 2017, 54, 4257-4270.	1.9	11
3607	Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease. <i>Progress in Neurobiology</i> , 2017, 155, 76-95.	2.8	111
3608	Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 34-56.	1.0	96
3609	Altered Expression of Growth Associated Protein-43 and Rho Kinase in Human Patients with Parkinson's Disease. <i>Brain Pathology</i> , 2017, 27, 13-25.	2.1	35
3610	Decreased intestinal acetylcholinesterase in early Parkinson disease. <i>Neurology</i> , 2017, 88, 775-781.	1.5	75
3611	Selective neuronal vulnerability in Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 101-113.	4.9	711
3612	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	4.9	141
3613	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
3614	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	4.5	48
3615	Changes in functional organization and white matter integrity in the connectome in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 13, 395-404.	1.4	43
3616	Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry. <i>NeuroImage: Clinical</i> , 2017, 13, 405-414.	1.4	33
3617	Esophageal dysfunction in different stages of Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12915.	1.6	63

#	ARTICLE	IF	CITATIONS
3618	The Nucleation of Protein Aggregates - From Crystals to Amyloid Fibrils. <i>International Review of Cell and Molecular Biology</i> , 2017, 329, 187-226.	1.6	46
3619	Personality in Parkinson's disease: Clinical, behavioural and cognitive correlates. <i>Journal of the Neurological Sciences</i> , 2017, 374, 17-25.	0.3	35
3620	Pathology of Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a028035.	2.3	865
3621	Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils. <i>Redox Biology</i> , 2017, 11, 429-437.	3.9	33
3622	Epidemiology of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 901-905.	1.4	1,593
3624	Parkinson's disease alters multisensory perception: Insights from the Rubber Hand Illusion. <i>Neuropsychologia</i> , 2017, 97, 38-45.	0.7	25
3625	Parkinson's disease as a multisystem disorder. <i>Journal of Neural Transmission</i> , 2017, 124, 709-713.	1.4	43
3626	Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 209-215.	1.9	76
3627	Ferroptosis and cell death mechanisms in Parkinson's disease. <i>Neurochemistry International</i> , 2017, 104, 34-48.	1.9	260
3628	Neurodegeneration. , 2017, , 345-354.		3
3629	Sleep and Neurodegeneration. <i>Chest</i> , 2017, 151, 1375-1386.	0.4	40
3630	Blood RNA biomarkers in prodromal PARK4 and REM sleep behavior disorder show role of complexin-1 loss for risk of Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 619-631.	1.2	20
3631	Management of sleep disorders in Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 659-668.	2.2	66
3632	Kernel-based Joint Feature Selection and Max-Margin Classification for Early Diagnosis of Parkinson's Disease. <i>Scientific Reports</i> , 2017, 7, 41069.	1.6	42
3633	Biochemical analysis of α -synuclein extracted from control and Parkinson's disease colonic biopsies. <i>Neuroscience Letters</i> , 2017, 641, 81-86.	1.0	17
3634	Targeting α -Synuclein as a therapy for Parkinson's disease: The battle begins. <i>Movement Disorders</i> , 2017, 32, 203-207.	2.2	26
3635	The use of fish models to study human neurological disorders. <i>Neuroscience Research</i> , 2017, 120, 1-7.	1.0	21
3636	Treatment of Older Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 381-405.	0.9	15

#	ARTICLE	IF	CITATIONS
3637	Effect of anatomical variability in brain on transcranial magnetic stimulation treatment. <i>AIP Advances</i> , 2017, 7, .	0.6	17
3638	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	1.5	27
3639	Paraquat and maneb co-exposure induces noradrenergic locus coeruleus neurodegeneration through NADPH oxidase-mediated microglial activation. <i>Toxicology</i> , 2017, 380, 1-10.	2.0	40
3640	Impairment in the mesohippocampal dopamine circuit following exposure to the brominated flame retardant, HBCDD. <i>Environmental Toxicology and Pharmacology</i> , 2017, 50, 167-174.	2.0	11
3641	Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 14, 591-601.	1.4	87
3642	Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1111-1116.	2.8	18
3643	Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication. <i>NeuroImage: Clinical</i> , 2017, 14, 417-421.	1.4	23
3644	Idiopathic Parkinson's disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. <i>Journal of Neuroscience Research</i> , 2017, 95, 1829-1837.	1.3	28
3645	Cognitive-behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review. <i>Evidence-Based Mental Health</i> , 2017, 20, 15-20.	2.2	72
3646	The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats. <i>Neurochemical Research</i> , 2017, 42, 1104-1115.	1.6	125
3647	Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. <i>BMC Neurology</i> , 2017, 17, 23.	0.8	62
3648	Propagation of pathological α -synuclein in marmoset brain. <i>Acta Neuropathologica Communications</i> , 2017, 5, 12.	2.4	142
3649	Does apolipoprotein A1 predict microstructural changes in subgenual cingulum in early Parkinson?. <i>Journal of Neurology</i> , 2017, 264, 684-693.	1.8	13
3650	α -synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. <i>Nature Medicine</i> , 2017, 23, 1-13.	15.2	688
3651	Depressive disorder may be associated with raphe nuclei lesions in patients with brainstem infarction. <i>Journal of Affective Disorders</i> , 2017, 213, 191-198.	2.0	14
3652	Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson's disease model. <i>European Journal of Pharmacology</i> , 2017, 798, 26-34.	1.7	32
3653	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
3654	Clinical Features and Differential Diagnosis of Parkinson's Disease. , 2017, , 103-115.		5

#	ARTICLE	IF	CITATIONS
3655	Endothelin-converting enzymes degrade α -synuclein and are reduced in dementia with Lewy bodies. <i>Journal of Neurochemistry</i> , 2017, 141, 275-286.	2.1	7
3656	Alpha-synuclein and iron: two keys unlocking Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 973-981.	1.4	34
3657	Neuroprotective and Therapeutic Effect of Caffeine on the Rat Model of Parkinson's Disease Induced by Rotenone. <i>Journal of Dietary Supplements</i> , 2017, 14, 553-572.	1.4	67
3658	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. <i>Acta Neuropathologica</i> , 2017, 133, 337-352.	3.9	193
3659	Single cell imaging and quantification of TDP-43 and α -synuclein intercellular propagation. <i>Scientific Reports</i> , 2017, 7, 544.	1.6	16
3660	Excessive Daytime Sleepiness Predicts Neurodegeneration in Idiopathic REM Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	40
3661	Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2017, 32, 636-644.	2.2	48
3662	Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis. <i>Cortex</i> , 2017, 92, 119-138.	1.1	101
3663	Lewy Body Dementias. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 85-100.	0.4	2
3664	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 2.	2.2	27
3665	Appendectomy History is not Related to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 347-352.	1.5	23
3666	Disease progression in LRRK2 parkinsonism. <i>Lancet Neurology</i> , The, 2017, 16, 334-335.	4.9	1
3667	Lewy Body Disorders. <i>Neurologic Clinics</i> , 2017, 35, 325-338.	0.8	51
3668	Interactions of pathological proteins in neurodegenerative diseases. <i>Acta Neuropathologica</i> , 2017, 134, 187-205.	3.9	288
3669	Transfer of pathogenic and nonpathogenic cytosolic proteins between spinal cord motor neurons in vivo in chimeric mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3139-E3148.	3.3	18
3671	The <sc>PRIAMO</sc> study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 788-795.	1.7	37
3672	Sepiapterin reductase gene-disrupted mice suffer from hypertension with fluctuation and bradycardia. <i>Physiological Reports</i> , 2017, 5, e13196.	0.7	11
3673	Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. <i>Movement Disorders</i> , 2017, 32, 865-873.	2.2	102

#	ARTICLE	IF	CITATIONS
3674	Genetic analysis of α -synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2017, 13, 1237-1250.	0.4	26
3675	The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 3.	2.5	388
3677	Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson's disease: a comparison of 33 human and animal studies. <i>BMC Neurology</i> , 2017, 17, 58.	0.8	22
3678	In vitro α -synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. <i>Neurobiology of Disease</i> , 2017, 103, 101-112.	2.1	96
3679	Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. <i>Journal of Parkinson's Disease</i> , 2017, 7, 369-376.	1.5	13
3680	Parkinson Symptoms in Dementia with Lewy Bodies. , 2017, , 93-109.		1
3681	Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 724-730.	2.5	17
3682	Polymorphisms of <i>COMT</i> (c.649G>A), <i>MAO-A</i> (c.1460C>T), <i>NET</i> (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease. <i>DNA and Cell Biology</i> , 2017, 36, 501-512.	0.9	2
3683	A Comprehensive Approach to Care in Parkinson's Disease Adds Quality to the Current Gold Standard. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 743-749.	0.8	10
3684	Higher levels of myelin phospholipids in brains of neuronal α -Synuclein transgenic mice precede myelin loss. <i>Acta Neuropathologica Communications</i> , 2017, 5, 37.	2.4	19
3685	Redefinition of Parkinson's Disease. <i>Neurology International Open</i> , 2017, 1, E65-E70.	0.4	0
3687	Pathophysiology and Management of Parkinsonian Tremor. <i>Seminars in Neurology</i> , 2017, 37, 127-134.	0.5	18
3688	Diagnosis and Management of Parkinson's Disease. <i>Seminars in Neurology</i> , 2017, 37, 118-126.	0.5	80
3689	Chronic intermittent hypoxia induces oxidative stress and inflammation in brain regions associated with early-stage neurodegeneration. <i>Physiological Reports</i> , 2017, 5, e13258.	0.7	121
3691	Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	138
3692	α -Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 874-883.	2.2	37
3693	Imaging Parkinson's disease below the neck. <i>Npj Parkinson's Disease</i> , 2017, 3, 15.	2.5	19
3694	HIV, Tat and dopamine transmission. <i>Neurobiology of Disease</i> , 2017, 105, 51-73.	2.1	52

#	ARTICLE	IF	CITATIONS
3695	Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update. ACS Chemical Neuroscience, 2017, 8, 973-986.	1.7	37
3696	Sleep Disturbances in the Prodromal Stage of Parkinson Disease. Current Treatment Options in Neurology, 2017, 19, 22.	0.7	43
3697	Limbic grey matter changes in early Parkinson's disease. Human Brain Mapping, 2017, 38, 3566-3578.	1.9	25
3698	Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Annals of Neurology, 2017, 81, 898-903.	2.8	44
3699	Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α -synuclein pathology. Movement Disorders, 2017, 32, 884-892.	2.2	55
3700	Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease. Current Opinion in Genetics and Development, 2017, 44, 149-155.	1.5	13
3701	Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation. Scientific Reports, 2017, 7, 45465.	1.6	196
3702	Validating the Predicted Effect of Astemizole and Ketoconazole Using a <i>Drosophila</i> Model of Parkinson's Disease. Assay and Drug Development Technologies, 2017, 15, 106-112.	0.6	9
3703	Preventing Parkinson disease by vagotomy. Neurology, 2017, 88, 1982-1983.	1.5	9
3704	Resistance Training Improves Sleep Quality in Subjects With Moderate Parkinson's Disease. Journal of Strength and Conditioning Research, 2017, 31, 2270-2277.	1.0	42
3706	Multifactorial sleep disturbance in Parkinson's disease. Sleep Medicine, 2017, 35, 41-48.	0.8	71
3707	Old and new challenges in Parkinson's disease therapeutics. Progress in Neurobiology, 2017, 156, 69-89.	2.8	69
3708	Altered neural responses to heat pain in drug-naïve patients with Parkinson disease. Pain, 2017, 158, 1408-1416.	2.0	11
3709	Dopamine Transporter Imaging. , 2017, , 141-155.		0
3710	Targeting the norepinephrinergetic system in Parkinson's disease and related disorders: The locus coeruleus story. Neurochemistry International, 2017, 102, 22-32.	1.9	95
3711	Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. , 2017, 172, 22-33.		52
3712	Biomarkers of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 183-196.	0.9	18
3713	Premotor symptoms and the risk of Parkinson's disease: A case-control study in Mexican population. Clinical Neurology and Neurosurgery, 2017, 160, 46-49.	0.6	14

#	ARTICLE	IF	CITATIONS
3714	Neurodegenerative signaling factors and mechanisms in Parkinson's pathology. <i>Toxicology in Vitro</i> , 2017, 43, 104-112.	1.1	35
3715	Regional Overlap of Pathologies in Lewy Body Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 216-224.	0.9	45
3716	The implication of neuron-immunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3741-3768.	2.4	9
3718	Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 561-567.	1.5	45
3719	Epigenetics in Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 978, 363-390.	0.8	50
3720	Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease. <i>Experimental Neurology</i> , 2017, 298, 162-171.	2.0	49
3721	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. <i>Acta Neuropathologica</i> , 2017, 134, 113-127.	3.9	78
3722	New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 407-452.	0.9	7
3723	Brain correlates of progressive olfactory loss in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 44-50.	1.1	32
3724	Olfaction in <i>Parkin</i> carriers in Chinese patients with Parkinson disease. <i>Brain and Behavior</i> , 2017, 7, e00680.	1.0	11
3725	Comparison of Dopamine Transporter SPECT and 123I-MIBG Myocardial Scintigraphy to Assess Clinical Severity in Patients With Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2017, 42, 7-14.	0.7	7
3726	Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. <i>Acta Neuropathologica Communications</i> , 2017, 5, 41.	2.4	78
3727	Bedside Approach to Autonomic Disorders. , 2017, , .		2
3728	Neuroimaging in pre-motor Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 15, 215-227.	1.4	71
3729	Pareidolias in REM Sleep Behavior Disorder: A Possible Predictive Marker of Lewy Body Diseases?. <i>Sleep</i> , 2017, 40, .	0.6	20
3730	Psychosis in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 585-622.	0.9	30
3731	Wild-Type Monomeric α -Synuclein Can Impair Vesicle Endocytosis and Synaptic Fidelity via Tubulin Polymerization at the Calyx of Held. <i>Journal of Neuroscience</i> , 2017, 37, 6043-6052.	1.7	51
3732	Parkinson's disease; the hibernating spore hypothesis. <i>Medical Hypotheses</i> , 2017, 104, 48-53.	0.8	18

#	ARTICLE	IF	CITATIONS
3733	Non-motor features of Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 435-450.	4.9	1,182
3734	Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. <i>Brain</i> , 2017, 140, 1959-1976.	3.7	391
3735	Astrocytes in a dish: Using pluripotent stem cells to model neurodegenerative and neurodevelopmental disorders. <i>Brain Pathology</i> , 2017, 27, 530-544.	2.1	5
3736	Prion-Like Seeding of Misfolded α -Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC. <i>Molecular Neurobiology</i> , 2018, 55, 3916-3930.	1.9	55
3737	Altered Brain Wiring in Parkinson's Disease: A Structural Connectome-Based Analysis. <i>Brain Connectivity</i> , 2017, 7, 347-356.	0.8	29
3738	Relationship between pain and motor and non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2017, 24, 974-980.	1.7	26
3739	Pain in early-stage Parkinson's disease: Implications from clinical features to pathophysiology mechanisms. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 571-581.	0.8	32
3740	Downregulation of miR-7116 ^{5p} in microglia by MPP ⁺ sensitizes TNF α production to induce dopaminergic neuron damage. <i>Glia</i> , 2017, 65, 1251-1263.	2.5	54
3741	Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1211-1220.	2.2	17
3742	Dopamine system, cerebellum, and nucleus ruber in fish and mammals. <i>Development Growth and Differentiation</i> , 2017, 59, 219-227.	0.6	26
3743	Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 653-662.	0.9	78
3744	Axonal dystrophy in the brain of mice with Sanfilippo syndrome. <i>Experimental Neurology</i> , 2017, 295, 243-255.	2.0	32
3747	Classification of advanced stages of Parkinson's disease: translation into stratified treatments. <i>Journal of Neural Transmission</i> , 2017, 124, 1015-1027.	1.4	64
3748	The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. <i>Glycobiology</i> , 2017, 27, 501-510.	1.3	123
3749	A sensitive assay reveals structural requirements for α -synuclein fibril growth. <i>Journal of Biological Chemistry</i> , 2017, 292, 9034-9050.	1.6	18
3750	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	18.1	3,048
3751	Conditional deletion of <i>Ndufs4</i> in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. <i>Scientific Reports</i> , 2017, 7, 44989.	1.6	40
3752	Neurotransmission systems in Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2017, 28, 509-536.	1.4	54

#	ARTICLE	IF	CITATIONS
3753	Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 34.	2.0	100
3754	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. <i>Translational Neurodegeneration</i> , 2017, 6, 4.	3.6	19
3755	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 37-43.	1.1	44
3756	Diffusion kurtosis imaging for diagnosis of Parkinson's disease: A novel software tool proposal. <i>Journal of X-Ray Science and Technology</i> , 2017, 25, 561-571.	0.7	1
3757	Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex. <i>Movement Disorders</i> , 2017, 32, 487-497.	2.2	25
3758	Non-motor symptoms and quality of life in subjects with mild parkinsonian signs. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 495-500.	1.0	12
3759	Trajectories of prediagnostic functioning in Parkinson's disease. <i>Brain</i> , 2017, 140, 429-441.	3.7	124
3760	RNA-binding proteins with prion-like domains in health and disease. <i>Biochemical Journal</i> , 2017, 474, 1417-1438.	1.7	347
3761	The Nonmotor Features of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 33-54.	0.9	56
3762	In vivo evaluation of central cholinergic circuits in Parkinson's disease using transcranial magnetic stimulation. <i>Clinical Neurophysiology</i> , 2017, 128, 1028-1029.	0.7	0
3763	Novel conformation-specific alpha-synuclein antibodies raised against different <i>in vitro</i> fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 604-620.	1.8	51
3764	Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. <i>Journal of Parkinson's Disease</i> , 2017, 7, S71-S85.	1.5	252
3765	Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease. <i>Molecular Pain</i> , 2017, 13, 174480691769152.	1.0	31
3766	Interaction of LRRK2 and α -Synuclein in Parkinson's Disease. <i>Advances in Neurobiology</i> , 2017, 14, 209-226.	1.3	18
3767	LRRK2 and the Immune System. <i>Advances in Neurobiology</i> , 2017, 14, 123-143.	1.3	42
3769	Impaired cholinergic transmission in patients with Parkinson's disease and olfactory dysfunction. <i>Journal of the Neurological Sciences</i> , 2017, 377, 55-61.	0.3	31
3770	Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 951-971.	1.9	199
3771	Mapping Neurodegenerative Disease Onset and Progression. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a023622.	2.3	67

#	ARTICLE	IF	CITATIONS
3773	The two-century journey of Parkinson disease research. <i>Nature Reviews Neuroscience</i> , 2017, 18, 251-259.	4.9	250
3774	Multiple system atrophy: insights into a rare and debilitating movement disorder. <i>Nature Reviews Neurology</i> , 2017, 13, 232-243.	4.9	128
3775	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. <i>Journal of Neural Transmission</i> , 2017, 124, 671-683.	1.4	21
3776	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. <i>Lancet Neurology</i> , The, 2017, 16, 351-359.	4.9	96
3777	Conformation-Specific Detection of α -Synuclein. <i>JAMA Neurology</i> , 2017, 74, 146.	4.5	5
3778	Cardiac parasympathetic dysfunction in the early phase of Parkinson's disease. <i>Journal of Neurology</i> , 2017, 264, 333-340.	1.8	28
3779	Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. <i>Clinical and Translational Imaging</i> , 2017, 5, 3-14.	1.1	38
3780	Paradoxical lower sensitivity of Locus Coeruleus than Substantia Nigra pars compacta neurons to acute actions of rotenone. <i>Experimental Neurology</i> , 2017, 287, 34-43.	2.0	11
3781	The Transcellular Propagation and Intracellular Trafficking of α -Synuclein. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024380.	2.9	28
3782	Biology and Genetics of PrP Prion Strains. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026922.	2.9	11
3783	Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α -synuclein in axons of cholinergic enteric neurons in the guinea pig ileum. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12985.	1.6	14
3784	New olfactometric findings in Parkinson's disease. <i>Clinical Otolaryngology</i> , 2017, 42, 837-843.	0.6	14
3785	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. <i>Annals of Neurology</i> , 2017, 81, 171-180.	2.8	77
3786	Macrophages, Microglia and Dendritic Cell Function. , 2017, , 155-166.		0
3787	Exosomes in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 331-338.	1.5	97
3788	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	1.5	2
3789	Regional volumetric change in Parkinson's disease with cognitive decline. <i>Journal of the Neurological Sciences</i> , 2017, 373, 88-94.	0.3	24
3790	Parkinson's: a syndrome rather than a disease?. <i>Journal of Neural Transmission</i> , 2017, 124, 907-914.	1.4	168

#	ARTICLE	IF	CITATIONS
3791	Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. <i>Neurobiology of Disease</i> , 2017, 105, 328-335.	2.1	74
3792	Hippocampal α -Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. <i>Journal of Neuroscience</i> , 2017, 37, 1675-1684.	1.7	92
3794	Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys. <i>Neurobiology of Disease</i> , 2017, 100, 9-18.	2.1	29
3796	A New Perspective for Parkinson's Disease: Circadian Rhythm. <i>Neuroscience Bulletin</i> , 2017, 33, 62-72.	1.5	62
3797	Role of the VPS35 D620N mutation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 10-18.	1.1	24
3798	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	2.2	39
3799	Altered Functional Connectivity Between Precuneus and Motor Systems in Parkinson's Disease Patients. <i>Brain Connectivity</i> , 2017, 7, 643-647.	0.8	28
3800	Cognitive and Neuropsychiatric Features of Early Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 769-785.	0.3	34
3801	Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease. <i>CNS Drugs</i> , 2017, 31, 975-989.	2.7	11
3802	Evaluation of the Braak staging of brain pathology with 1 H-MRS in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2017, 660, 57-62.	1.0	10
3803	In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. <i>NeuroImage</i> , 2017, 163, 150-159.	2.1	117
3804	A Nigro-Vagal Pathway Controls Gastric Motility and Is Affected in a Rat Model of Parkinsonism. <i>Gastroenterology</i> , 2017, 153, 1581-1593.	0.6	92
3805	Tctex1 plays a key role in the α -synuclein autophagy lysosomal degradation pathway. <i>Neuroscience Letters</i> , 2017, 661, 90-95.	1.0	2
3806	Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 483-492.	1.5	27
3807	Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease. <i>Neuroscience</i> , 2017, 365, 70-82.	1.1	22
3808	Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 557-563.	1.4	47
3809	Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies?. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 69-74.	1.1	20
3810	The BSSG rat model of Parkinson's disease: progressing towards a valid, predictive model of disease. <i>EPMA Journal</i> , 2017, 8, 261-271.	3.3	21

#	ARTICLE	IF	CITATIONS
3811	Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. <i>Ageing Research Reviews</i> , 2017, 40, 149-167.	5.0	47
3812	Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 203-212.	0.7	16
3813	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
3814	Parkinson's Disease Is Not Simply a Prion Disorder. <i>Journal of Neuroscience</i> , 2017, 37, 9799-9807.	1.7	144
3815	Prying into the Prion Hypothesis for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 9808-9818.	1.7	213
3816	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. <i>Metallomics</i> , 2017, 9, 1447-1455.	1.0	89
3817	Dysphagia in Parkinson's Disease. <i>Medical Radiology</i> , 2017, , 175-198.	0.0	0
3818	Gastrointestinal Transit Time in Parkinson's Disease Using a Magnetic Tracking System. <i>Journal of Parkinson's Disease</i> , 2017, 7, 471-479.	1.5	46
3819	Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging β -synuclein aggregates. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6398-6403.	1.4	17
3820	In vivo staging of regional amyloid deposition. <i>Neurology</i> , 2017, 89, 2031-2038.	1.5	321
3821	Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 714-721.	1.7	12
3822	Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2017, 40, .	0.6	55
3823	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias. <i>Archives of Clinical Neuropsychology</i> , 2017, 32, 786-801.	0.3	27
3824	A ventral glomerular deficit in Parkinson's disease revealed by whole olfactory bulb reconstruction. <i>Brain</i> , 2017, 140, 2722-2736.	3.7	53
3825	Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 515-525.	1.5	200
3826	<i>N</i> -Acetyl-L-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione. <i>Molecular Pharmacology</i> , 2017, 92, 564-575.	1.0	25
3827	Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 9361-9379.	1.7	26
3828	5-HT modulation of pain perception in humans. <i>Psychopharmacology</i> , 2017, 234, 2929-2939.	1.5	40

#	ARTICLE	IF	CITATIONS
3829	Understanding and Treating Pain Syndromes in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 827-858.	0.9	26
3830	The Gut and Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 787-809.	0.9	47
3831	The Oligomer Hypothesis in α -Synucleinopathy. <i>Neurochemical Research</i> , 2017, 42, 3362-3371.	1.6	53
3832	Sleep Disturbance, Cognitive Decline, and Dementia: A Review. <i>Seminars in Neurology</i> , 2017, 37, 395-406.	0.5	164
3833	Current and investigational non-dopaminergic agents for management of motor symptoms (including) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	8
3834	Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson's disease: Comparison with surgical specimens. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 73-78.	1.1	29
3835	Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α -Synuclein Expression in a Model of Parkinson's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 57-68.	2.3	105
3836	Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α -synuclein aggregates. <i>Scientific Reports</i> , 2017, 7, 7690.	1.6	73
3837	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
3838	The Genetics of Parkinson's Disease. <i>Advances in Genetics</i> , 2017, 98, 43-62.	0.8	9
3839	Trigeminal system in Parkinson's disease: A potential avenue to detect Parkinson-specific olfactory dysfunction. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 85-90.	1.1	23
3840	Milestones of Parkinson's Disease Research: 200 Years of History and Beyond. <i>Neuroscience Bulletin</i> , 2017, 33, 598-602.	1.5	27
3841	Loss of MicroRNA-7 Regulation Leads to α -Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo. <i>Molecular Therapy</i> , 2017, 25, 2404-2414.	3.7	101
3842	E46K α -synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8274-E8283.	3.3	35
3843	CSF1 deficiency impairs autophagy and reduces alpha-synuclein phagocytosis by microglia. <i>Journal of Neurochemistry</i> , 2017, 143, 584-594.	2.1	85
3844	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. <i>Progress in Medicinal Chemistry</i> , 2017, 56, 37-80.	4.1	17
3845	Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson's Disease via Activation of TRPV1. <i>Neurochemical Research</i> , 2017, 42, 3431-3438.	1.6	20
3846	Vaccination strategies in tauopathies and synucleinopathies. <i>Journal of Neurochemistry</i> , 2017, 143, 467-488.	2.1	30

#	ARTICLE	IF	CITATIONS
3847	Biomarkers for early detection of Parkinson disease. <i>Neurology</i> , 2017, 89, 1432-1434.	1.5	11
3848	Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters. <i>Scientific Reports</i> , 2017, 7, 10547.	1.6	50
3849	Metal concentrations and distributions in the human olfactory bulb in Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 10454.	1.6	31
3850	Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models. <i>NeuroMolecular Medicine</i> , 2017, 19, 241-255.	1.8	25
3851	Altered N100-potential associates with working memory impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1197-1203.	1.4	6
3852	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	2.5	91
3853	The Role of Recollection and Familiarity in Nondemented Parkinson's Patients. <i>Journal of General Psychology</i> , 2017, 144, 230-243.	1.6	4
3854	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
3855	A translational approach to capture gait signatures of neurological disorders in mice and humans. <i>Scientific Reports</i> , 2017, 7, 3225.	1.6	48
3856	α -Synucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 754-758.	0.9	13
3858	Assessments of plasma ghrelin levels in the early stages of parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1487-1491.	2.2	47
3859	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	2.2	60
3860	CDK5-mediated phosphorylation of XBP1s contributes to its nuclear translocation and activation in MPP+-induced Parkinson's disease model. <i>Scientific Reports</i> , 2017, 7, 5622.	1.6	11
3861	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. <i>Journal of Neural Transmission</i> , 2017, 124, 1029-1036.	1.4	18
3862	Baicalein blocks α -synuclein secretion from SN4741 cells and facilitates α -synuclein polymerization to big complex. <i>Neuroscience Letters</i> , 2017, 655, 109-114.	1.0	10
3863	Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 6306.	1.6	41
3864	Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 275-294.	0.9	34
3865	The cellular prion protein (PrP ^C) as neuronal receptor for α -synuclein. <i>Prion</i> , 2017, 11, 226-233.	0.9	29

#	ARTICLE	IF	CITATIONS
3866	The role of neurotransmitters in the development of Parkinson's disease-related psychosis. <i>European Journal of Neurology</i> , 2017, 24, 1244-1254.	1.7	48
3867	Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to \pm -synuclein targeted disease modification. <i>Experimental Neurology</i> , 2017, 298, 172-179.	2.0	45
3868	Losing ground: Frontostriatal atrophy disrupts language embodiment in Parkinson's and Huntington's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 673-687.	2.9	83
3869	Sleep and Circadian Rhythm Disorders in Parkinson's Disease. <i>Current Sleep Medicine Reports</i> , 2017, 3, 222-234.	0.7	17
3870	Apathy in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 657-678.	0.9	27
3871	Premotor Diagnosis of Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 526-534.	1.5	53
3872	Clinical Significance of REM Sleep Behavior Disorders and Other Non-motor Symptoms of Parkinsonism. <i>Neuroscience Bulletin</i> , 2017, 33, 576-584.	1.5	26
3873	The importance of developing strain-specific models of neurodegenerative disease. <i>Acta Neuropathologica</i> , 2017, 134, 809-812.	3.9	2
3874	Alpha-synuclein oligomers: a new hope. <i>Acta Neuropathologica</i> , 2017, 134, 819-838.	3.9	260
3875	Protein astrogliopathies in human neurodegenerative diseases and aging. <i>Brain Pathology</i> , 2017, 27, 675-690.	2.1	68
3876	Non-CNS pathogenic origin of Parkinson's disease. <i>Journal of Neurology</i> , 2017, 264, 2027-2030.	1.8	9
3877	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. <i>European Journal of Neurology</i> , 2017, 24, 1326.	1.7	71
3878	Alterations in striato-thalamo-pallidal intrinsic functional connectivity as a prodrome of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 313-318.	1.4	29
3879	Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal. <i>Journal of Neural Transmission</i> , 2017, 124, 1417-1429.	1.4	14
3880	The Lewy body dementias. , 0, , 278-300.		0
3881	Combustion-derived nanoparticles, the neuroenteric system, cervical vagus, hyperphosphorylated alpha synuclein and tau in young Mexico City residents. <i>Environmental Research</i> , 2017, 159, 186-201.	3.7	32
3882	What goes around comes around: cognitive impairment as prodromal parkinsonism?. <i>Nature Reviews Neurology</i> , 2017, 13, 709-710.	4.9	1
3883	Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations. <i>Cell</i> , 2017, 171, 1001-1014.	13.5	39

#	ARTICLE	IF	CITATIONS
3884	DJ-1 as a Biomarker of Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1037, 149-171.	0.8	29
3885	The Biology of REM Sleep. <i>Current Biology</i> , 2017, 27, R1237-R1248.	1.8	212
3886	Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. <i>Movement Disorders</i> , 2017, 32, 1504-1523.	2.2	229
3887	Neurodegenerative diseases: The immunological perspective. <i>Journal of Neuroimmunology</i> , 2017, 313, 109-115.	1.1	76
3888	The Biology and Pathobiology of α -Synuclein. , 2017, , 109-130.		1
3889	Altered neurofilament protein expression in the lateral vestibular nucleus in Parkinson's disease. <i>Experimental Brain Research</i> , 2017, 235, 3695-3708.	0.7	22
3890	Depression and associated factors in nondemented Chinese patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 163, 142-148.	0.6	12
3891	Hypothesis of Ascension in Idiopathic Parkinson's Disease. <i>Neurology International Open</i> , 2017, 01, E28-E35.	0.4	0
3892	Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1729-1737.	2.2	57
3893	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	2.5	29
3894	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017, 30, 196-205.	1.2	8
3895	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. <i>Acta Neuropathologica</i> , 2017, 134, 459-473.	3.9	180
3896	Embryonic development of selectively vulnerable neurons in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 21.	2.5	19
3897	Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy. <i>Nano Research</i> , 2017, 10, 3496-3508.	5.8	27
3898	The shedding protease ADAM17: Physiology and pathophysiology. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 2059-2070.	1.9	246
3899	Role of Apolipoproteins and α -Synuclein in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2017, 62, 344-355.	1.1	36
3900	Visual System Involvement in Patients with Newly Diagnosed Parkinson Disease. <i>Radiology</i> , 2017, 285, 885-895.	3.6	42
3901	A clinicopathological approach to the diagnosis of dementia. <i>Nature Reviews Neurology</i> , 2017, 13, 457-476.	4.9	233

#	ARTICLE	IF	CITATIONS
3902	Altered brain metabolic connectivity at multiscale level in early Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 4256.	1.6	64
3903	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. <i>Advances in Neurobiology</i> , 2017, 15, 55-92.	1.3	2
3904	Methyl-4-phenylpyridinium (MPP+) differentially affects monoamine release and re-uptake in murine embryonic stem cell-derived dopaminergic and serotonergic neurons. <i>Molecular and Cellular Neurosciences</i> , 2017, 83, 37-45.	1.0	22
3905	Physico-Pathologic Mechanisms Involved in Neurodegeneration: Misfolded Protein-Plasma Membrane Interactions. <i>Neuron</i> , 2017, 95, 33-50.	3.8	83
3906	Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under α -synuclein-induced toxicity. <i>Neuroscience</i> , 2017, 358, 336-348.	1.1	18
3908	Rest tremor revisited: Parkinson's disease and other disorders. <i>Translational Neurodegeneration</i> , 2017, 6, 16.	3.6	33
3909	Drug-induced Parkinson's disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb. <i>Behavioral and Brain Functions</i> , 2017, 13, 1.	1.4	14
3911	Neuropathology of Nonmotor Symptoms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 13-62.	0.9	39
3912	Brain infusion of α -synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. <i>Behavioural Brain Research</i> , 2017, 333, 150-160.	1.2	27
3913	Use of intraoperative local field potential spectral analysis to differentiate basal ganglia structures in Parkinson's disease patients. <i>Physiological Reports</i> , 2017, 5, e13322.	0.7	15
3914	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. <i>Neurobiology of Aging</i> , 2017, 58, 239.e1-239.e7.	1.5	6
3915	Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra. <i>Journal of Neurology</i> , 2017, 264, 1497-1505.	1.8	16
3916	Synucleinopathies: common features and hippocampal manifestations. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1485-1501.	2.4	33
3917	Major neurocognitive disorder following isolated hippocampal ischemic lesions. <i>Journal of the Neurological Sciences</i> , 2017, 372, 496-500.	0.3	3
3918	The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease. <i>Brain</i> , 2017, 140, 118-131.	3.7	154
3919	Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. <i>Molecular Neurobiology</i> , 2017, 54, 7639-7655.	1.9	9
3920	Cortical gray and subcortical white matter associations in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 49, 100-108.	1.5	18
3921	α -synuclein aggregation and its modulation. <i>International Journal of Biological Macromolecules</i> , 2017, 100, 37-54.	3.6	106

#	ARTICLE	IF	CITATIONS
3922	Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications. <i>European Journal of Neuroscience</i> , 2017, 45, 192-197.	1.2	32
3923	An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease. <i>Neuropathology</i> , 2017, 37, 129-149.	0.7	28
3924	Profile of cognitive impairment and underlying pathology in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 405-413.	2.2	95
3925	Stem cell therapies in age-related neurodegenerative diseases and stroke. <i>Ageing Research Reviews</i> , 2017, 34, 39-50.	5.0	46
3926	Aging of cerebral white matter. <i>Ageing Research Reviews</i> , 2017, 34, 64-76.	5.0	191
3927	Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of $\alpha\pm$ -Synuclein Fibrils. <i>Journal of Virology</i> , 2017, 91, .	1.5	73
3928	Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. <i>Movement Disorders</i> , 2017, 32, 94-105.	2.2	127
3929	Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal $\alpha\pm$ -motoneurons in sporadic amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2017, 133, 79-90.	3.9	68
3930	Molecular Imaging of Extrapyrmidal Movement Disorders. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 18-30.	2.5	4
3931	Cortical Manifestations in Amyotrophic Lateral Sclerosis. , 2017, , 223-242.		1
3932	Relationship Between Obesity, Alzheimerâ€™s Disease, and Parkinsonâ€™s Disease: an Astrocentric View. <i>Molecular Neurobiology</i> , 2017, 54, 7096-7115.	1.9	50
3933	Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 372, 471-476.	0.3	15
3934	Clinical anatomy of the most common dementias. <i>Clinical Anatomy</i> , 2017, 30, 53-57.	1.5	0
3935	Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures. <i>Journal of Ethnopharmacology</i> , 2017, 197, 46-51.	2.0	37
3936	The effect of L-dopa in Parkinsonâ€™s disease as revealed by neurophysiological studies of motor and sensory functions. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 181-192.	1.4	29
3937	123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 358-365.	3.3	24
3938	TDPâ€™43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. <i>Brain Pathology</i> , 2017, 27, 472-479.	2.1	170
3939	A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. <i>Sleep Medicine Reviews</i> , 2017, 35, 33-50.	3.8	240

#	ARTICLE	IF	CITATIONS
3940	Continuous intranigral infusion is not associated with observable behavioral deficits or marked pathology: a preclinical safety study. <i>Journal of Neurosurgery</i> , 2017, 126, 1253-1262.	0.9	2
3941	Clinical Assessment of the Autonomic Nervous System. , 2017, , .		7
3942	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. <i>Neurobiology of Disease</i> , 2017, 97, 179-188.	2.1	40
3943	Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. <i>Neurochemical Research</i> , 2017, 42, 1772-1786.	1.6	15
3944	Like prions: the propagation of aggregated tau and α -synuclein in neurodegeneration. <i>Brain</i> , 2017, 140, 266-278.	3.7	248
3945	Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α -synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model. <i>Journal of Nutritional Biochemistry</i> , 2017, 39, 15-21.	1.9	25
3946	Self-Reported Symptoms of Parkinson's Disease by Sex and Disease Duration. <i>Western Journal of Nursing Research</i> , 2017, 39, 1412-1428.	0.6	11
3947	Fatigue in early Parkinson's disease: the Norwegian ParkWest study. <i>European Journal of Neurology</i> , 2017, 24, 105-111.	1.7	29
3948	Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 315-329.	1.8	44
3949	Leucine-rich repeat kinase 2 and Parkinson's disease. <i>Proteomics</i> , 2017, 17, 1600092.	1.3	22
3950	Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2017, 30, 121-125.	1.1	67
3951	Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: From history to the interaction with the monoaminergic systems. <i>Progress in Neurobiology</i> , 2017, 151, 139-156.	2.8	35
3952	Body weight and dysautonomia in early Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 560-567.	1.0	15
3953	Tau pathology in Creutzfeldt-Jakob disease revisited. <i>Brain Pathology</i> , 2017, 27, 332-344.	2.1	61
3954	Overview of quantitative susceptibility mapping. <i>NMR in Biomedicine</i> , 2017, 30, e3569.	1.6	228
3955	Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 17-24.	1.1	43
3956	The Threshold Theory for Parkinson's Disease. <i>Trends in Neurosciences</i> , 2017, 40, 4-14.	4.2	153
3957	First-in-human assessment of PRX002, an anti- α -synuclein monoclonal antibody, in healthy volunteers. <i>Movement Disorders</i> , 2017, 32, 211-218.	2.2	193

#	ARTICLE	IF	CITATIONS
3958	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	3.9	200
3960	Defining thalamic nuclei and topographic connectivity gradients in vivo. <i>NeuroImage</i> , 2017, 158, 466-479.	2.1	80
3961	Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications. <i>Biological Chemistry</i> , 2017, 398, 77-100.	1.2	50
3962	Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated α -Synuclein in the Enteric Nervous System of A53T Mutant Human α -Synuclein Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 1046-1057.	0.9	36
3963	Comparative Analysis of Cortical Microinfarcts and Microbleeds using 3.0-Tesla Postmortem Magnetic Resonance Images and Histopathology. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 951-959.	1.2	18
3964	Axonal Mitochondrial Transport. , 2017, , 113-137.		4
3965	Glucocerebrosidase Mutations in Parkinson Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 411-422.	1.5	108
3966	Synaptic phosphorylated α -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	3.7	90
3967	Any Prediction of Neurodegeneration by Excessive Daytime Sleepiness in Idiopathic RBD?. <i>Sleep</i> , 2017, 40, .	0.6	3
3968	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1139-1152.	1.2	63
3969	Neuropathology of dementia. , 2016, , 94-122.		5
3970	Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 43-56.	1.2	7
3971	Mechanisms for Successful Rehabilitation of Cough in Parkinson's Disease Using Expiratory Muscle Strength Training. <i>Perspectives of the ASHA Special Interest Groups</i> , 2017, 2, 93-102.	0.4	1
3972	The Synucleinopathies: Twenty Years On. <i>Journal of Parkinson's Disease</i> , 2017, 7, S51-S69.	1.5	350
3973	Vertebrate food products as a potential source of prion-like α -synuclein. <i>Npj Parkinson's Disease</i> , 2017, 3, 33.	2.5	21
3974	Functional assessment of the nigrostriatal system in a rat preclinical model of Parkinson's disease. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2017, 53, 435-438.	0.2	4
3975	Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2017, 6, 33.	3.6	10
3976	Anosmia and Ageusia in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 541-556.	0.9	71

#	ARTICLE	IF	CITATIONS
3978	Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia. <i>Medicine (United States)</i> , 2017, 96, e9195.	0.4	3
3979	MRI Morphometry of the Brain and Neurological Diseases. , 2017, , .		3
3980	Neuropathological findings in entorhinal cortex of subjects aged 50 years or older and their correlation with dementia in a sample from Southern Brazil. <i>Dementia E Neuropsychologia</i> , 2017, 11, 24-31.	0.3	5
3981	Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. <i>Chinese Medical Journal</i> , 2017, 130, 1856-1866.	0.9	12
3982	Recent advances in treating Parkinsonâ€™s disease. <i>F1000Research</i> , 2017, 6, 260.	0.8	92
3983	Depression in Parkinsonâ€™s Disease: The Contribution from Animal Studies. <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	0.6	13
3984	Major Developments in the Design of Inhibitors along the Kynurenine Pathway. <i>Current Medicinal Chemistry</i> , 2017, 24, 2471-2495.	1.2	50
3986	Membrane Trafficking Illuminates a Path to Parkinsonâ€™s Disease. <i>Tohoku Journal of Experimental Medicine</i> , 2017, 242, 63-76.	0.5	36
3987	Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2017, 11, 26.	1.4	110
3988	Anatomy and Physiology of Normal Sleep. , 2017, , 1-28.		5
3989	Sleep and the Autonomic Nervous System. , 2017, , 227-244.		13
3990	Neurodegenerative Disorders. , 2017, , 1-16.		18
3991	Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. <i>International Journal of Molecular Sciences</i> , 2017, 18, 227.	1.8	24
3992	Potential Modes of Intercellular Î±-Synuclein Transmission. <i>International Journal of Molecular Sciences</i> , 2017, 18, 469.	1.8	76
3993	Overview of Autophagy. , 2017, , 1-122.		1
3994	Colonic Oxidative and Mitochondrial Function in Parkinsonâ€™s Disease and Idiopathic REM Sleep Behavior Disorder. <i>Parkinson's Disease</i> , 2017, 2017, 1-7.	0.6	3
3995	Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinsonâ€™s Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and Î±-Synuclein Expression. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 78.	1.7	16
3996	A Life-Long Approach to Physical Activity for Brain Health. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 147.	1.7	52

#	ARTICLE	IF	CITATIONS
3997	The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 214.	1.7	348
3998	Disrupted Functional Connectivity of Basal Ganglia across Tremor-Dominant and Akinetic/Rigid-Dominant Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 360.	1.7	31
3999	Biological and Clinical Implications of Comorbidities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 394.	1.7	67
4000	Perspective on the Road toward Gene Therapy for Parkinson's Disease. <i>Frontiers in Neuroanatomy</i> , 2017, 10, 128.	0.9	24
4001	The Olfactory System Revealed: Non-Invasive Mapping by using Constrained Spherical Deconvolution Tractography in Healthy Humans. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 32.	0.9	37
4002	Differential Effects of Parkinson's Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 113.	0.9	19
4003	Pattern of Reduced Functional Connectivity and Structural Abnormalities in Parkinson's Disease: An Exploratory Study. <i>Frontiers in Neurology</i> , 2016, 7, 243.	1.1	30
4004	Exploring Braak's Hypothesis of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 37.	1.1	210
4005	The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. <i>Frontiers in Neurology</i> , 2017, 8, 42.	1.1	93
4006	Auditory- and Vestibular-Evoked Potentials Correlate with Motor and Non-Motor Features of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 55.	1.1	47
4007	Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. <i>Frontiers in Neurology</i> , 2017, 8, 89.	1.1	35
4008	Autonomic Function Impairment and Brain Perfusion Deficit in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 246.	1.1	21
4009	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 432.	1.1	50
4010	Among Early Appearing Non-Motor Signs of Parkinson's Disease, Alteration of Olfaction but Not Electroencephalographic Spectrum Correlates with Motor Function. <i>Frontiers in Neurology</i> , 2017, 8, 545.	1.1	9
4011	The Effects of Age, from Young to Middle Adulthood, and Gender on Resting State Functional Connectivity of the Dopaminergic Midbrain. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 52.	1.0	19
4012	Rapid Alleviation of Parkinson's Disease Symptoms via Electrostimulation of Intrinsic Auricular Muscle Zones. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 338.	1.0	20
4013	Associations among Cognitive Functions, Plasma DNA, and White Matter Integrity in Patients with Early-Onset Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 9.	1.4	19
4014	Mest/Peg1 Is Essential for the Development and Maintenance of a SNc Neuronal Subset. <i>Frontiers in Molecular Neuroscience</i> , 2017, 9, 166.	1.4	13

#	ARTICLE	IF	CITATIONS
4015	MPTP-Induced Dopamine Depletion in Basolateral Amygdala via Decrease of D2R Activation Suppresses GABAA Receptors Expression and LTD Induction Leading to Anxiety-Like Behaviors. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 247.	1.4	18
4016	The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 311.	1.4	17
4017	Cognitive Function Characteristics of Parkinson's Disease with Sleep Disorders. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	0.6	8
4018	Roles of Microglia in Inflammation-Mediated Neurodegeneration: Models, Mechanisms, and Therapeutic Interventions for Parkinson's Disease. <i>Advances in Neurotoxicology</i> , 2017, 1, 185-209.	0.7	6
4019	Pesticides and Parkinson's Disease: Current Experimental and Epidemiological Evidence. <i>Advances in Neurotoxicology</i> , 2017, 1, 83-117.	0.7	15
4020	REM sleep behaviour disorder: not just a bad dream. <i>Medical Journal of Australia</i> , 2017, 207, 262-268.	0.8	7
4021	The Contribution of α -Synuclein Spreading to Parkinson's Disease Synaptopathy. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	70
4022	Accumulation of α -Synuclein in Cerebellar Purkinje Cells of Diabetic Rats and Its Potential Relationship with Inflammation and Oxidative Stress Markers. <i>Neurology Research International</i> , 2017, 2017, 1-6.	0.5	11
4023	Live calcium and mitochondrial imaging in the enteric nervous system of Parkinson patients and controls. <i>ELife</i> , 2017, 6, .	2.8	19
4024	Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	29
4025	Overview of Autophagy. , 2017, , 3-90.		1
4026	Animal Models for the Study of Human Neurodegenerative Diseases. , 2017, , 1109-1129.		4
4027	6.19 Biomaterials for Central Nervous System Regeneration. , 2017, , 321-333.		1
4028	Clinical utility and research frontiers of neuroimaging in movement disorders. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 372-385.	0.4	3
4029	High-Intensity Exercise Acutely Increases Substantia Nigra and Prefrontal Brain Activity in Parkinson's Disease. <i>Medical Science Monitor</i> , 2017, 23, 6064-6071.	0.5	41
4030	Electron Transport Chain. , 2017, , 41-75.		2
4031	CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0171748.	1.1	6
4032	BGRAPH: A graph theory software for the analysis of brain connectivity. <i>PLoS ONE</i> , 2017, 12, e0178798.	1.1	187

#	ARTICLE	IF	CITATIONS
4033	Nonmotor Aspects of Parkinson's Disease—How Do They Help Diagnosis?. <i>International Review of Neurobiology</i> , 2017, 133, 519-539.	0.9	7
4034	Imaging the Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 179-257.	0.9	14
4035	Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α -synucleinopathy. <i>Molecular Neurodegeneration</i> , 2017, 12, 52.	4.4	73
4036	The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases. <i>Molecular Neurodegeneration</i> , 2017, 12, 78.	4.4	63
4037	O-GlcNAc regulation of autophagy and α -synuclein homeostasis; implications for Parkinson's disease. <i>Molecular Brain</i> , 2017, 10, 32.	1.3	67
4038	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. <i>Acta Neuropathologica Communications</i> , 2017, 5, 75.	2.4	85
4040	Are exosomes the vehicle for protein aggregate propagation in neurodegenerative diseases?. <i>Acta Neuropathologica Communications</i> , 2017, 5, 64.	2.4	56
4041	Comment on "Classification of Advanced Stages of Parkinson's Disease: Translation into Stratified Treatments". <i>International Journal of Neurorehabilitation</i> , 2017, 04, .	0.1	0
4042	Amygdala α -Synuclein Pathology in the Population-Based Vantaa 85+ Study. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 669-674.	1.2	6
4043	Investigating Basal Autophagic Activity in Brain Regions Associated with Neurodegeneration using In Vivo and Ex Vivo Models. , 2017, 07, .		3
4044	Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	1.9	8
4045	A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders. <i>Internal Medicine</i> , 2017, 56, 2871-2878.	0.3	12
4046	Sleep, Adenosine, and Neurodegeneration. , 2017, , 111-130.		0
4047	Relationship between Erectile Dysfunction, Comorbidity, and Parkinson's Disease: Evidence from a		

#	ARTICLE	IF	CITATIONS
4052	Evidence from spatial pattern analysis for the anatomical spread of α -synuclein pathology in Parkinson's disease dementia. <i>Folia Neuropathologica</i> , 2017, 1, 23-30.	0.5	2

4053 Cardiovascular Autonomic Dysfunction in Patients with Drug-Induced Parkinsonism. *Journal of*

#	ARTICLE	IF	CITATIONS
4071	Correlations between CSF proteins and spontaneous neuronal activity in Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 673, 61-66.	1.0	7
4072	Basal Ganglia. , 0, , 103-123.		1
4073	Measurements of autoantibodies to α -synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 489-503.	2.1	47
4074	Brain Morphometry: Parkinson's Disease. <i>Neuromethods</i> , 2018, , 267-277.	0.2	0
4075	Differential α -synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. <i>Acta Neuropathologica</i> , 2018, 135, 855-875.	3.9	94
4076	Lysosomal response in relation to α -synuclein pathology differs between Parkinson's disease and multiple system atrophy. <i>Neurobiology of Disease</i> , 2018, 114, 140-152.	2.1	13
4077	Inflammation kinase PKR phosphorylates α -synuclein and causes α -synuclein-dependent cell death. <i>Neurobiology of Disease</i> , 2018, 115, 17-28.	2.1	21
4078	Quantitative Analysis of Catecholamines in the Pink1 α -syn ^{+/+} Rat Model of Early-onset Parkinson's Disease. <i>Neuroscience</i> , 2018, 379, 126-141.	1.1	30
4079	Analysis of respiratory movements in a mouse model of late Parkinson's disease submitted to stress. <i>Respiratory Physiology and Neurobiology</i> , 2018, 251, 50-56.	0.7	7
4080	Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. <i>NeuroImage: Clinical</i> , 2018, 18, 456-466.	1.4	47
4081	White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1139-1150.	2.2	11
4082	Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV- α -synuclein is normalized by LRRK2 modulation. <i>Neurobiology of Disease</i> , 2018, 116, 13-27.	2.1	21
4083	Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy. <i>Cell Transplantation</i> , 2018, 27, 349-363.	1.2	111
4084	Lateralisation in Parkinson disease. <i>Cell and Tissue Research</i> , 2018, 373, 297-312.	1.5	67
4085	Amyloid assembly and disassembly. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	138
4086	Epothilone D inhibits microglia-mediated spread of alpha-synuclein aggregates. <i>Molecular and Cellular Neurosciences</i> , 2018, 89, 80-94.	1.0	17
4087	Emergence of non-motor fluctuations with reference to motor fluctuations in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 79-83.	1.1	12
4088	TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 797-802.	1.0	102

#	ARTICLE	IF	CITATIONS
4089	Treadmill training in Parkinson's patients after deep brain stimulation: Effects on gait kinematic. <i>NeuroRehabilitation</i> , 2018, 42, 149-158.	0.5	7
4090	Re-examining the Parkinsonian Personality hypothesis: A systematic review. <i>Personality and Individual Differences</i> , 2018, 130, 41-50.	1.6	9
4091	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 11.	2.5	169
4092	Amyloid β 1-40 is associated with alterations in NG2+ pericyte population <i>ex vivo</i> and <i>in vitro</i> . <i>Aging Cell</i> , 2018, 17, e12728.	3.0	49
4093	When Do α -Synucleinopathies Start? An Epidemiological Timeline. <i>JAMA Neurology</i> , 2018, 75, 503.	4.5	69
4094	Parkinson's disease from the gut. <i>Brain Research</i> , 2018, 1693, 201-206.	1.1	145
4095	Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 112, 136-148.	2.1	123
4096	Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model. <i>Neurochemistry International</i> , 2018, 114, 71-79.	1.9	27
4097	Long-lasting pathological consequences of overexpression-induced α -synuclein spreading in the rat brain. <i>Aging Cell</i> , 2018, 17, e12727.	3.0	25
4098	The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. <i>Cell and Tissue Research</i> , 2018, 373, 327-336.	1.5	31
4099	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. <i>Neuroscientist</i> , 2018, 24, 540-559.	2.6	81
4100	The changing role of the senses in food choice and food intake across the lifespan. <i>Food Quality and Preference</i> , 2018, 68, 80-89.	2.3	67
4101	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <i>Neuroscience</i> , 2018, 374, 326-334.	1.1	28
4102	RBD: a red flag for cognitive impairment in Parkinson's disease?. <i>Sleep Medicine</i> , 2018, 44, 38-44.	0.8	33
4103	Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. <i>Experimental Neurology</i> , 2018, 303, 95-107.	2.0	26
4104	Neurodegenerative Chemosensory Disorders. , 0, , 293-386.		0
4105	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. <i>Neuroradiology</i> , 2018, 60, 247-254.	1.1	23
4106	Association of grey matter changes with stability and flexibility of prediction in akinetic-rigid Parkinson's disease. <i>Brain Structure and Function</i> , 2018, 223, 2097-2111.	1.2	5

#	ARTICLE	IF	CITATIONS
4107	The role of glucocerebrosidase in Parkinson disease pathogenesis. <i>FEBS Journal</i> , 2018, 285, 3591-3603.	2.2	99
4108	Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia. <i>Current Geriatrics Reports</i> , 2018, 7, 1-11.	1.1	75
4109	YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity. <i>Neurobiology of Disease</i> , 2018, 112, 14-23.	2.1	23
4110	Pathophysiologic Basis of Movement Disorders. <i>Progress in Neurological Surgery</i> , 2018, 33, 13-24.	1.3	19
4111	Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. <i>Neurobiology of Disease</i> , 2018, 112, 106-118.	2.1	127
4112	Release and uptake of pathologic alpha-synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 175-182.	1.5	57
4113	Do subjects with minimal motor features have prodromal Parkinson disease?. <i>Annals of Neurology</i> , 2018, 83, 562-574.	2.8	31
4114	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. <i>Journal of Neural Transmission</i> , 2018, 125, 591-613.	1.4	16
4115	Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2018, 55, 7588-7605.	1.9	17
4116	Neuroprotective effects of voluntary running on cognitive dysfunction in an α -synuclein rat model of Parkinson's disease. <i>Neurobiology of Aging</i> , 2018, 65, 60-68.	1.5	16
4117	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinson's Disease</i> , 2018, 4, 2.	2.5	47
4118	Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia. <i>Journal of Neural Transmission</i> , 2018, 125, 1273-1286.	1.4	33
4119	Principles of diffusion kurtosis imaging and its role in early diagnosis of neurodegenerative disorders. <i>Brain Research Bulletin</i> , 2018, 139, 91-98.	1.4	72
4120	Neuropathology correlates of cognitive assessments. <i>Irish Journal of Medical Science</i> , 2018, 187, 835-844.	0.8	1
4121	Oral administration of <i>Proteus mirabilis</i> damages dopaminergic neurons and motor functions in mice. <i>Scientific Reports</i> , 2018, 8, 1275.	1.6	119
4122	Constipation in Parkinson's Disease: a Nuisance or Nuanced Answer to the Pathophysiological Puzzle?. <i>Current Gastroenterology Reports</i> , 2018, 20, 1.	1.1	25
4123	Novel models for Parkinson's disease and their impact on future drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 229-239.	2.5	22
4124	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2018, , 659-680.		3

#	ARTICLE	IF	CITATIONS
4125	Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. <i>Neuroscience Letters</i> , 2018, 666, 48-57.	1.0	85
4126	Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients. <i>Brain Research</i> , 2018, 1681, 1-13.	1.1	12
4127	Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson's progression: Evidence from clinical studies and neurotoxin models. <i>Progress in Neurobiology</i> , 2018, 165-167, 1-25.	2.8	35
4128	The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. <i>Journal of Neural Transmission</i> , 2018, 125, 1217-1223.	1.4	26
4129	Update on Molecular Imaging in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2018, 34, 330-340.	1.5	19
4130	Alpha-synucleinopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.0	50
4131	Color vision as a biological marker able to differentiate two phenotypically similar neurological diseases. <i>Neurological Sciences</i> , 2018, 39, 951-952.	0.9	3
4132	Editorial: Pathogenic templating proteins in Neurodegenerative Disease. <i>Neurobiology of Disease</i> , 2018, 109, 175-177.	2.1	2
4133	Sex differences in sleep apnea and comorbid neurodegenerative diseases. <i>Steroids</i> , 2018, 133, 28-33.	0.8	16
4134	Biomechanistic insights into the roles of oxidative stress in generating complex neurological disorders. <i>Biological Chemistry</i> , 2018, 399, 305-319.	1.2	23
4135	Polyphenols of mulberry fruits as multifaceted compounds: Compositions, metabolism, health benefits, and stability—A structural review. <i>Journal of Functional Foods</i> , 2018, 40, 28-43.	1.6	101
4136	Relationships between lewy and tau pathologies in 375 consecutive non-Alzheimer's olfactory bulbs. <i>Movement Disorders</i> , 2018, 33, 333-334.	2.2	1
4137	Parkinson disease with constipation: clinical features and relevant factors. <i>Scientific Reports</i> , 2018, 8, 567.	1.6	80
4138	Synapsin III is a key component of α -synuclein fibrils in Lewy bodies of PD brains. <i>Brain Pathology</i> , 2018, 28, 875-888.	2.1	37
4139	Astroglial and microglial contributions to iron metabolism disturbance in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 967-973.	1.8	41
4140	Neurotoxins as Preclinical Models for Parkinson's Disease. <i>Neurotoxicity Research</i> , 2018, 34, 870-877.	1.3	14
4141	Multiple Proteinopathies in Familial ALS Cases With Optineurin Mutations. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 128-138.	0.9	25
4142	A refined concept: α -synuclein dysregulation disease. <i>Neurochemistry International</i> , 2018, 119, 84-96.	1.9	24

#	ARTICLE	IF	CITATIONS
4143	Network connectivity determines cortical thinning in early Parkinson's disease progression. <i>Nature Communications</i> , 2018, 9, 12.	5.8	198
4144	Neuropathology of autonomic dysfunction in synucleinopathies. <i>Movement Disorders</i> , 2018, 33, 349-358.	2.2	144
4145	Prion-like Propagation of α -Synuclein Is Regulated by the Fc γ RIIB-SHP-1/2 Signaling Pathway in Neurons. <i>Cell Reports</i> , 2018, 22, 136-148.	2.9	48
4146	Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 149-161.	0.9	42
4147	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?. <i>BMC Medicine</i> , 2018, 16, 34.	2.3	232
4148	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. <i>Journal of Neuroinflammation</i> , 2018, 15, 129.	3.1	131
4149	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	1.5	12
4150	Pink1 α -Syn Rats Show Early-Onset Swallowing Deficits and Correlative Brainstem Pathology. <i>Dysphagia</i> , 2018, 33, 749-758.	1.0	31
4151	Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2018, 19, 130-136.	1.4	17
4152	α -Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. <i>Cell and Tissue Research</i> , 2018, 373, 195-212.	1.5	93
4153	Neuropsychology in a Memory Disorder Clinic. <i>Archives of Clinical Neuropsychology</i> , 2018, 33, 301-309.	0.3	6
4154	6-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1331-1339.	2.2	28
4155	Non-pharmacological therapies for sleep disturbances in people with Parkinson's disease: A systematic review. <i>Journal of Advanced Nursing</i> , 2018, 74, 1741-1751.	1.5	7
4156	Phosphorylated α -Synuclein Accumulations and Lewy Body-like Pathology Distributed in Parkinson's Disease-Related Brain Areas of Aged Rhesus Monkeys Treated with MPTP. <i>Neuroscience</i> , 2018, 379, 302-315.	1.1	24
4158	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	2.0	88
4159	Clinical characteristics and quality of life in Chinese patients with Parkinson's disease beyond 20 years. <i>Neurological Research</i> , 2018, 40, 312-317.	0.6	4
4160	Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease. <i>Behavioural Pharmacology</i> , 2018, 29, 199-210.	0.8	36
4161	Neurotransmitter activity is linked to outcome following subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 54-60.	1.1	12

#	ARTICLE	IF	CITATIONS
4162	Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. <i>Molecular Neurobiology</i> , 2018, 55, 8728-8737.	1.9	38
4163	Investigation of non-motor symptoms in first-degree relatives of patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 62-68.	1.1	7
4164	The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 21-35.	2.0	47
4165	Cerebrospinal fluid levels of alpha-synuclein in PARKINSON'S disease: Another long and winding road. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 1-3.	1.1	4
4166	Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. <i>Brain</i> , 2018, 141, 1501-1516.	3.7	148
4167	Imaging Parkinsonian Pathology in Substantia Nigra with MRI. <i>Current Radiology Reports</i> , 2018, 6, 1.	0.4	16
4168	REM Sleep Behavior Disorder and Alzheimer's Disease: Definitely No Relationship?. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1-11.	1.2	35
4169	Hippocampal microvasculature changes in association with oxidative stress in Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2018, 120, 192-203.	1.3	15
4170	Parkinson's Disease: Contemporary Concepts and Clinical Management. , 2018, , 349-378.		0
4171	14-3-3 protein sigma isoform co-localizes with phosphorylated α -synuclein in Lewy bodies and Lewy neurites in patients with Lewy body disease. <i>Neuroscience Letters</i> , 2018, 674, 171-175.	1.0	11
4172	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. <i>Neurobiology of Disease</i> , 2018, 115, 9-16.	2.1	35
4173	Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in <i>de novo</i> Parkinson's disease and its phenotypes. <i>European Journal of Neurology</i> , 2018, 25, 949.	1.7	71
4174	Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies. <i>Acta Neuropathologica</i> , 2018, 135, 877-886.	3.9	59
4175	Neurite orientation dispersion and density imaging of the nigrostriatal pathway in Parkinson's disease: Retrograde degeneration observed by tract-profile analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 55-60.	1.1	47
4176	Agaricus blazei extract attenuates rotenone-induced apoptosis through its mitochondrial protective and antioxidant properties in SH-SY5Y neuroblastoma cells. <i>Nutritional Neuroscience</i> , 2018, 21, 97-107.	1.5	14
4177	Mitochondrial activity in the frontal cortex area 8 and angular gyrus in Parkinson's disease and Parkinson's disease with dementia. <i>Brain Pathology</i> , 2018, 28, 43-57.	2.1	27
4178	The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2018, 109, 226-248.	2.1	214
4179	Non-human primate models of PD to test novel therapies. <i>Journal of Neural Transmission</i> , 2018, 125, 291-324.	1.4	29

#	ARTICLE	IF	CITATIONS
4180	Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 109, 249-257.	2.1	504
4181	How to choose the right MR sequence for your research question at 7 T and above?. <i>NeuroImage</i> , 2018, 168, 119-140.	2.1	41
4182	Î±-Synuclein nonhuman primate models of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 385-400.	1.4	27
4183	A probabilistic template of human mesopontine tegmental nuclei from in vivo 7 T MRI. <i>NeuroImage</i> , 2018, 170, 222-230.	2.1	45
4184	TDP-43 Prions. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a024463.	2.9	34
4185	Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3 β /Î²-Catenin Signaling Pathway. <i>Molecular Neurobiology</i> , 2018, 55, 1607-1619.	1.9	14
4186	Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease. <i>Molecular Psychiatry</i> , 2018, 23, 459-466.	4.1	54
4187	The dark side of dopaminergic therapies in Parkinson's disease: shedding light on aberrant salience. <i>CNS Spectrums</i> , 2018, 23, 347-351.	0.7	3
4188	Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. <i>Neurobiology of Disease</i> , 2018, 109, 219-225.	2.1	80
4189	Transcriptional network analysis in frontal cortex in <scp>L</scp>ewy body diseases with focus on dementia with <scp>L</scp>ewy bodies. <i>Brain Pathology</i> , 2018, 28, 315-333.	2.1	35
4190	The use of nonhuman primate models to understand processes in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 325-335.	1.4	19
4191	Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease. <i>Neurochemistry International</i> , 2018, 117, 126-138.	1.9	46
4192	Locus coeruleus. <i>Cell and Tissue Research</i> , 2018, 373, 221-232.	1.5	134
4193	Facial emotion recognition in Parkinson's disease: Association with age and olfaction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 274-284.	0.8	11
4194	Promising rodent models in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S10-S14.	1.1	9
4195	Distinct Î±-Synuclein strains and implications for heterogeneity among Î±-Synucleinopathies. <i>Neurobiology of Disease</i> , 2018, 109, 209-218.	2.1	121
4196	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a033118.	2.3	616
4197	Inhibition of BDNF production by MPP + through up-regulation of miR-210-3p contributes to dopaminergic neuron damage in MPTP model. <i>Neuroscience Letters</i> , 2018, 675, 133-139.	1.0	23

#	ARTICLE	IF	CITATIONS
4198	Critical appraisal of pathology transmission in the α -synuclein fibril model of Lewy body disorders. <i>Experimental Neurology</i> , 2018, 299, 172-196.	2.0	33
4199	Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra. <i>Behavioural Pharmacology</i> , 2018, 29, 327-335.	0.8	3
4200	A review of genome-wide transcriptomics studies in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2018, 47, 1-16.	1.2	99
4201	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
4202	Are rodent models of Parkinson's disease behaving as they should?. <i>Behavioural Brain Research</i> , 2018, 352, 133-141.	1.2	46
4203	Intercellular transfer of pathogenic α -synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. <i>Neurobiology of Aging</i> , 2018, 61, 52-65.	1.5	63
4204	Spinal α -synuclein pathology in older adults without an antemortem diagnosis of Parkinson's disease. <i>Brain Pathology</i> , 2018, 28, 560-568.	2.1	18
4205	Therapeutics in Neurodegenerative Disorders: Emerging Compounds of Interest. , 2018, , 37-56.		2
4206	Does Parkinson's disease start in the gut?. <i>Acta Neuropathologica</i> , 2018, 135, 1-12.	3.9	161
4207	Multiple System Atrophy: An Oligodendroglioneuronal Synucleinopathy1. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1141-1179.	1.2	127
4208	Glucocerebrosidase expression patterns in the non-human primate brain. <i>Brain Structure and Function</i> , 2018, 223, 343-355.	1.2	9
4209	Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 337-363.	1.4	51
4210	Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases. <i>Neuropathology</i> , 2018, 38, 64-71.	0.7	40
4211	Noradrenergic Deficits in Parkinson Disease Imaged with ^{11}C -MeNER. <i>Journal of Nuclear Medicine</i> , 2018, 59, 659-664.	2.8	40
4212	REM sleep behavior disorder, autonomic dysfunction and synuclein-related neurodegeneration: where do we stand?. <i>Clinical Autonomic Research</i> , 2018, 28, 519-533.	1.4	25
4213	Physical aggression among patients with dementia, neuropathologically confirmed post-mortem. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, e242-e248.	1.3	18
4214	The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2018, 33, 88-98.	2.2	428
4215	How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. <i>Movement Disorders</i> , 2018, 33, 48-57.	2.2	114

#	ARTICLE	IF	CITATIONS
4216	Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. <i>Dysphagia</i> , 2018, 33, 41-50.	1.0	114
4218	The pathophysiological mechanisms of motivational deficits in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 138-152.	2.5	10
4219	In vivo models of alpha-synuclein transmission and propagation. <i>Cell and Tissue Research</i> , 2018, 373, 183-193.	1.5	51
4220	Neocortical origin and progression of gray matter atrophy in nonamnesic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 75-87.	1.5	61
4221	Characterization of early-onset motor deficits in the Pink1 ^{0/0} mouse model of Parkinson disease. <i>Brain Research</i> , 2018, 1680, 1-12.	1.1	32
4222	Î±-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton. <i>Neuron</i> , 2018, 97, 108-124.e6.	3.8	181
4223	Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2018, 131, 223-237.	2.0	41
4224	Neuroprotection afforded by circadian regulation of intracellular glutathione levels: A key role for miRNAs. <i>Free Radical Biology and Medicine</i> , 2018, 119, 17-33.	1.3	23
4225	Complex Dynamics in the Basal Ganglia: Health and Disease Beyond the Motor System. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 101-114.	0.9	17
4226	The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. <i>Neurobiology of Disease</i> , 2018, 110, 68-81.	2.1	38
4227	Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies. <i>Cell and Tissue Research</i> , 2018, 373, 233-243.	1.5	36
4228	Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. <i>Autophagy</i> , 2018, 14, 98-119.	4.3	193
4229	Spread of aggregates after olfactory bulb injection of Î±-synuclein fibrils is associated with early neuronal loss and is reduced long term. <i>Acta Neuropathologica</i> , 2018, 135, 65-83.	3.9	154
4230	Analysis of white matter characteristics with tract-based spatial statistics according to diffusion tensor imaging in early Parkinson's disease. <i>Neuroscience Letters</i> , 2018, 675, 127-132.	1.0	37
4231	Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. <i>Journal of Neural Transmission</i> , 2018, 125, 615-650.	1.4	200
4232	Characterization of oromotor and limb motor dysfunction in the DJ1 ^{-/-} model of Parkinson disease. <i>Behavioural Brain Research</i> , 2018, 339, 47-56.	1.2	19
4233	The effects of cysteamine in a mouse model of levodopa-induced dyskinesias. <i>Neuroscience Letters</i> , 2018, 662, 395-401.	1.0	1
4234	A critical review of the prion hypothesis of human synucleinopathies. <i>Cell and Tissue Research</i> , 2018, 373, 213-220.	1.5	30

#	ARTICLE	IF	CITATIONS
4235	Parkinson's disease: experimental models and reality. <i>Acta Neuropathologica</i> , 2018, 135, 13-32.	3.9	89
4236	Impaired long contact white matter fibers integrity is related to depression in Parkinson's disease. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 108-114.	1.9	38
4237	Olfactory dysfunctions in drug-naïve Parkinson's disease with mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 69-73.	1.1	28
4238	Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease. <i>European Neurology</i> , 2018, 79, 27-32.	0.6	14
4239	The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S1-S5.	1.1	35
4240	Untangling the tauopathies: Current concepts of tau pathology and neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S34-S38.	1.1	11
4241	Facial emotion decoding in patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2018, 128, 71-78.	0.8	12
4242	Noninvasive delivery of an α -synuclein gene silencing vector with magnetic resonance-guided focused ultrasound. <i>Movement Disorders</i> , 2018, 33, 1567-1579.	2.2	49
4243	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. <i>Advanced Materials</i> , 2018, 30, e1801362.	11.1	415
4244	Brain-gut axis after stroke. <i>Brain Circulation</i> , 2018, 4, 165.	0.7	108
4245	Reduced workforce participation 5 years prior to first Parkinson's disease sick-leave. <i>Npj Parkinson's Disease</i> , 2018, 4, 36.	2.5	2
4246	Gastrointestinal nervous system α -synuclein as a potential biomarker of Parkinson disease. <i>Medicine (United States)</i> , 2018, 97, e11337.	0.4	44
4247	Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 479.	1.8	14
4248	East Indian sandalwood (<i>Santalum album</i>) oil confers neuroprotection and geroprotection in <i>Caenorhabditis elegans</i> via activating SKN-1/Nrf2 signaling pathway. <i>RSC Advances</i> , 2018, 8, 33753-33774.	1.7	36
4249	A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies. <i>Current Protein and Peptide Science</i> , 2018, 19, 598-611.	0.7	17
4250	A Network Explanation of Alzheimer's Regional Vulnerability. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2018, 83, 193-200.	2.0	11
4251	Sleep Architecture Changed Without RBD in Patients With FTDP-17. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1735-1739.	1.4	7
4253	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	1.5	48

#	ARTICLE	IF	CITATIONS
4254	The Gut and Parkinson's Disease: Hype or Hope?. <i>Journal of Parkinson's Disease</i> , 2018, 8, S31-S39.	1.5	70
4255	Immune system responses in Parkinson's disease: Early and dynamic. <i>European Journal of Neuroscience</i> , 2019, 49, 364-383.	1.2	104
4256	Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 860.	1.1	130
4257	Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2955-2964.	1.0	26
4258	Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 159, 173-193.	1.0	22
4259	The neuropathology of chronic traumatic encephalopathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 158, 297-307.	1.0	66
4260	Endothelial damage, vascular bagging and remodeling of the microvascular bed in human microangiopathy with deep white matter lesions. <i>Acta Neuropathologica Communications</i> , 2018, 6, 128.	2.4	33
4261	Changes in Cortical Thickness in Patients With Early Parkinson's Disease at Different Hoehn and Yahr Stages. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 469.	1.0	27
4262	Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy. <i>Trends in Molecular Medicine</i> , 2018, 24, 1007-1020.	3.5	26
4263	Sensing α -Synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration. <i>Movement Disorders</i> , 2018, 33, 1675-1684.	2.2	19
4264	What Is the Evidence that Parkinson's Disease Is a Prion Disorder, Which Originates in the Gut?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3573.	1.8	39
4265	Neuroimaging in Movement Disorders. , 2018, , 1-36.		2
4266	Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2018, 50, 79-92.	0.0	7
4267	New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 370.	1.7	80
4268	Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4129.	1.8	24
4269	Production of the Neurotoxin Salsolinol by a Gut-Associated Bacterium and Its Modulation by Alcohol. <i>Frontiers in Microbiology</i> , 2018, 9, 3092.	1.5	16
4270	Advances in Parkinson's Disease: 200 Years Later. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 113.	0.9	102
4271	Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. <i>Frontiers in Neurology</i> , 2018, 9, 1094.	1.1	16

#	ARTICLE	IF	CITATIONS
4272	Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 488.	1.8	482
4273	N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice. <i>Molecular Neurobiology</i> , 2018, 55, 8455-8472.	1.9	21
4274	Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. <i>PLoS Biology</i> , 2018, 16, e2006265.	2.6	44
4275	EriB targeted inhibition of microglia activity attenuates MPP+ induced DA neuron injury through the NF- κ B signaling pathway. <i>Molecular Brain</i> , 2018, 11, 75.	1.3	20
4276	Recent advances in stem cells therapy: A focus on cancer, Parkinson's and Alzheimer's. <i>Journal of Genetic Engineering and Biotechnology</i> , 2018, 16, 427-432.	1.5	29
4277	MR approaches in neurodegenerative disorders. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2018, 108, 1-16.	3.9	23
4278	High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 999.	1.1	15
4279	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	2.8	88
4280	Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2018, 97, 346-361.	1.3	24
4281	Multi-classification of Parkinson's Disease via Sparse Low-Rank Learning. , 2018, , .		2
4282	Vestibular Evoked Myogenic Potentials Are Abnormal in Idiopathic REM Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 911.	1.1	18
4283	α -Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models. <i>ASN Neuro</i> , 2018, 10, 175909141881258.	1.5	12
4284	Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 413.	1.8	9
4285	Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 462.	1.0	21
4286	Androgens modulate chronic intermittent hypoxia effects on brain and behavior. <i>Hormones and Behavior</i> , 2018, 106, 62-73.	1.0	31
4287	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 131-172.	0.9	18
4288	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 804-822.	21.5	178
4289	Fatigue in Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2018, 33, 1712-1723.	2.2	141

#	ARTICLE	IF	CITATIONS
4290	Imaging the Autonomic Nervous System in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 79.	2.0	14
4291	Parkinson's disease research: adopting a more human perspective to accelerate advances. <i>Drug Discovery Today</i> , 2018, 23, 1950-1961.	3.2	15
4292	Î±-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis. <i>Frontiers in Neuroscience</i> , 2018, 12, 626.	1.4	28
4293	Patterns of striatal and cerebellar functional connectivity in early-stage drug-naïve patients with Parkinson's disease subtypes. <i>Neuroradiology</i> , 2018, 60, 1323-1333.	1.1	20
4294	Epigenetic Study in Parkinson's Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain. <i>Cells</i> , 2018, 7, 150.	1.8	25
4295	Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 229-237.	1.2	30
4296	Recent Advances in Biomarkers for Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 305.	1.7	120
4297	Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 83.	2.0	21
4298	Selective vulnerability in neurodegenerative diseases. <i>Nature Neuroscience</i> , 2018, 21, 1350-1358.	7.1	384
4299	Molecular Imaging of the Cholinergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 211-250.	0.9	40
4300	Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson's disease patients. <i>Scientific Reports</i> , 2018, 8, 14328.	1.6	18
4301	Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. <i>Acta Neuropathologica Communications</i> , 2018, 6, 96.	2.4	56
4302	N-Terminal Fusion Potentiates Î±-Synuclein Secretion. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 1551-1554.	1.7	1
4303	Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis. <i>CoDAS</i> , 2018, 30, e20170200.	0.2	22
4304	Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3082.	1.8	221
4305	Anodal transcranial direct current stimulation prevents methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity by modulating autophagy in an in vivo mouse model of Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 15165.	1.6	18
4306	Effects of Parkinson's disease and dopamine on digit span measures of working memory. <i>Psychopharmacology</i> , 2018, 235, 3443-3450.	1.5	16
4307	Advances in PET Methodology. <i>International Review of Neurobiology</i> , 2018, 141, 3-30.	0.9	7

#	ARTICLE	IF	CITATIONS
4308	Medaka Fish Model of Parkinson's Disease. , 2018, , 235-249.		2
4309	Urological dysfunctions in patients with Parkinson's disease: clues from clinical and non-invasive urological assessment. BMC Neurology, 2018, 18, 148.	0.8	7
4310	The Olfactory System: Part III: Central Processing of Olfaction and Central Olfactory Dysfunction. Neurographics, 2018, 8, 298-316.	0.0	1

4311 Clinical Predictors of Excessive Daytime Sleepiness in Patients with Parkinson's Disease. Journal of

#	ARTICLE	IF	CITATIONS
4327	Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity. <i>Neuroscience</i> , 2018, 391, 140-153.	1.1	18
4328	Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 347-363.	0.9	15
4329	Negative impact of severity of pain on mood, social life and general activity in Parkinson's disease. <i>Neurological Research</i> , 2018, 40, 1054-1059.	0.6	10
4330	Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 621.	1.4	32
4331	A Cortical Pathogenic Theory of Parkinson's Disease. <i>Neuron</i> , 2018, 99, 1116-1128.	3.8	108
4332	Striatal cholinergic interneurons regulate cognitive and affective dysfunction in partially dopamine-depleted mice. <i>European Journal of Neuroscience</i> , 2018, 48, 2988-3004.	1.2	25
4333	The presence of depression in de novo Parkinson's disease reflects poor motor compensation. <i>PLoS ONE</i> , 2018, 13, e0203303.	1.1	23
4334	Alpha-synuclein and the prion hypothesis in Parkinson's disease. <i>Revue Neurologique</i> , 2018, 174, 644-652.	0.6	26
4335	Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 251-274.	0.9	13
4336	Apathy in rapid eye movement sleep behaviour disorder is associated with serotonin depletion in the dorsal raphe nucleus. <i>Brain</i> , 2018, 141, 2848-2854.	3.7	21
4337	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1643-1653.	0.9	9
4338	Converging Patterns of α -Synuclein Pathology in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 1005-1016.	0.9	26
4339	Subtle Esophageal Motility Alterations in Parkinsonian Syndromes: Synucleinopathies vs. Tauopathies. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 406-412.	0.8	13
4340	Investigation of Behavioral Dysfunctions Induced by Monoamine Depletions in a Mouse Model of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 241.	1.8	26
4341	Cognitive deficits in Parkinson's disease: current perspectives. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2018, Volume 8, 1-11.	0.8	2
4342	Parkinson Disease. <i>Annals of Internal Medicine</i> , 2018, 169, ITC33-ITC48.	2.0	62
4343	Correlation among olfactory function, motor symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1764-1771.	1.8	68
4344	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. <i>NeuroImage: Clinical</i> , 2018, 19, 652-660.	1.4	23

#	ARTICLE	IF	CITATIONS
4345	Cerebral Microbleeds in Advanced Dementia: Clinical and Pathological Correlates. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 362-372.	0.9	4
4346	Short-term temporal memory in idiopathic and Parkin-associated Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7637.	1.6	10
4347	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. <i>Movement Disorders</i> , 2018, 33, 1006-1010.	2.2	33
4349	Complex networks reveal early MRI markers of Parkinson's disease. <i>Medical Image Analysis</i> , 2018, 48, 12-24.	7.0	112
4350	The cholinergic contribution to the resting-state functional network in non-demented Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 7683.	1.6	13
4351	The REM sleep circuit and how its impairment leads to REM sleep behavior disorder. <i>Cell and Tissue Research</i> , 2018, 373, 245-266.	1.5	63
4352	New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease. <i>Experimental Neurology</i> , 2018, 306, 199-208.	2.0	41
4353	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. <i>Lancet Neurology</i> , The, 2018, 17, 618-628.	4.9	228
4354	Dissecting premotor Parkinson's disease with multimodality neuroimaging. <i>Lancet Neurology</i> , The, 2018, 17, 574-576.	4.9	3
4355	Gangliosides, α -Synuclein, and Parkinson's Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 156, 435-454.	0.9	56
4356	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. <i>Neuropathology</i> , 2018, 38, 347-360.	0.7	5
4357	Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. <i>Journal of Proteome Research</i> , 2018, 17, 2460-2469.	1.8	56
4358	Relation of Enteric α -Synuclein to Gastrointestinal Dysfunction in Patients With Parkinson's Disease and in Neurologically Intact Subjects. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 469-478.	0.8	30
4359	Impaired topographic organization in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 52-57.	1.1	25
4360	Parkinson's disease-related non-motor features as risk factors for post-operative delirium in spinal surgery. <i>PLoS ONE</i> , 2018, 13, e0195749.	1.1	19
4361	Mechanisms of protein toxicity in neurodegenerative diseases. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3159-3180.	2.4	103
4362	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. <i>Autophagy</i> , 2018, 14, 1404-1418.	4.3	87
4363	Distinctive Olfactory Pattern in Parkinson's Disease and Non-Neurodegenerative Causes of Hyposmia. <i>Neurodegenerative Diseases</i> , 2018, 18, 143-149.	0.8	8

#	ARTICLE	IF	CITATIONS
4364	Longitudinal white matter microstructural change in Parkinson's disease. <i>Human Brain Mapping</i> , 2018, 39, 4150-4161.	1.9	37
4365	Long-term immunosuppression for CNS mouse xenotransplantation: Effects on nigrostriatal neurodegeneration and neuroprotective carotid body cell therapy. <i>Xenotransplantation</i> , 2018, 25, e12410.	1.6	10
4366	Alzheimer's disease and alpha-synuclein pathology in the olfactory bulbs of infants, children, teens and adults ≤ 40 years in Metropolitan Mexico City. APOE4 carriers at higher risk of suicide accelerate their olfactory bulb pathology. <i>Environmental Research</i> , 2018, 166, 348-362.	3.7	71
4367	Aqueous Extract of <i>Dendropanax morbiferus</i> Leaves Effectively Alleviated Neuroinflammation and Behavioral Impediments in MPTP-Induced Parkinson's Mouse Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	1.9	25
4368	Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	327
4369	Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson's Disease. <i>ASN Neuro</i> , 2018, 10, 175909141878188.	1.5	75
4370	Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 369-381.	1.0	16
4371	Comorbidities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 573-577.	1.0	4
4372	Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2018, 39, 1460-1467.	1.2	51
4373	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 150, 131-141.	1.0	8
4374	Gangliosides of the Nervous System. <i>Methods in Molecular Biology</i> , 2018, 1804, 19-55.	0.4	52
4375	In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease. <i>Contemporary Clinical Neuroscience</i> , 2018, , 143-170.	0.3	1
4376	Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 47-51.	1.1	31
4377	Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 9-15.	1.1	58
4378	Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease. <i>Cell Death and Disease</i> , 2018, 9, 818.	2.7	85
4379	Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra. <i>FASEB Journal</i> , 2018, 32, 4420-4427.	0.2	8
4380	Increased DNA Copy Number Variation Mosaicism in Elderly Human Brain. <i>Neural Plasticity</i> , 2018, 2018, 1-9.	1.0	10
4381	Inoculation of α -synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. <i>Molecular Neurodegeneration</i> , 2018, 13, 21.	4.4	206

#	ARTICLE	IF	CITATIONS
4382	An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. <i>Frontiers in Neuroscience</i> , 2018, 12, 464.	1.4	247
4383	A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics. <i>Molecular Neurodegeneration</i> , 2018, 13, 40.	4.4	69
4384	Oligodendroglial pathology in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. <i>Progress in Neurobiology</i> , 2018, 169, 24-54.	2.8	49
4385	Sequential stages and distribution patterns of aging-related tau astroglial pathology (ARTAG) in the human brain. <i>Acta Neuropathologica Communications</i> , 2018, 6, 50.	2.4	77
4386	Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 325.	1.6	42
4387	Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. <i>Frontiers in Pharmacology</i> , 2018, 9, 417.	1.6	42
4388	The Microbiome-Mitochondria Dance in Prodromal Parkinson's Disease. <i>Frontiers in Physiology</i> , 2018, 9, 471.	1.3	34
4390	Disruption of Inferior Longitudinal Fasciculus Microstructure in Parkinson's Disease: A Systematic Review of Diffusion Tensor Imaging Studies. <i>Frontiers in Neurology</i> , 2018, 9, 598.	1.1	23
4391	Very old onset parkinsonism: A clinical-pathological study. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 39-43.	1.1	8
4392	The Functional Alterations in Top-Down Attention Streams of Parkinson's disease Measured by EEG. <i>Scientific Reports</i> , 2018, 8, 10609.	1.6	14
4393	INDEL Length and Haplotypes in the α -Synuclein Gene: A Key to Differentiate Dementia with Lewy Bodies?1. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 207-219.	1.2	4
4394	Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant α -Synuclein. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1651.	1.8	19
4395	Hemispheric specialization of the basal ganglia during vocal emotion decoding: Evidence from asymmetric Parkinson's disease and 18FDG PET. <i>Neuropsychologia</i> , 2018, 119, 1-11.	0.7	19
4396	Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 757-768.	0.9	74
4397	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , 2018, 34, 545-568.	4.0	99
4398	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <i>Acta Neuropathologica Communications</i> , 2018, 6, 64.	2.4	36
4399	Non-Motor Symptom Burdens Are Not Associated with Iron Accumulation in Early Parkinson's Disease: a Quantitative Susceptibility Mapping Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e96.	1.1	16
4400	Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 441.	1.7	115

#	ARTICLE	IF	CITATIONS
4401	A Review of the Pedunculopontine Nucleus in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 99.	1.7	84
4402	Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 122.	1.7	38
4403	Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 127.	1.7	48
4404	Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methyltransferase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α -Synuclein. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 173.	1.7	14
4405	Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 178.	1.7	39
4406	Gait Analysis for Early Detection of Motor Symptoms in the 6-OHDA Rat Model of Parkinson's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 39.	1.0	34
4407	The Exosomal/Total α -Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 125.	1.8	66
4408	Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview. <i>Frontiers in Neurology</i> , 2018, 9, 37.	1.1	43
4409	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. <i>Frontiers in Neurology</i> , 2018, 9, 156.	1.1	136
4410	Hypertension and Diagnosis of Parkinson's Disease: A Meta-Analysis of Cohort Studies. <i>Frontiers in Neurology</i> , 2018, 9, 162.	1.1	48
4411	Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients. <i>Frontiers in Neurology</i> , 2018, 9, 170.	1.1	78
4412	Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. <i>Frontiers in Neurology</i> , 2018, 9, 295.	1.1	138
4413	Alterations of Brain Structural Network in Parkinson's Disease With and Without Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 334.	1.1	21
4414	Gait Stability Has Phase-Dependent Dual-Task Costs in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 373.	1.1	26
4415	On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 455.	1.1	272
4416	Brain Atrophy and Reorganization of Structural Network in Parkinson's Disease With Hemiparkinsonism. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 117.	1.0	25
4417	Mechanisms of α -Synuclein Induced Synaptopathy in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 80.	1.4	255
4418	Impairment in the Intention Formation and Execution Phases of Prospective Memory in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 98.	1.4	4

#	ARTICLE	IF	CITATIONS
4419	“Till Death Do Us Part”: A Potential Irreversible Link Between Aberrant Cell Cycle Control and Neurodegeneration in the Adult Olfactory Bulb. <i>Frontiers in Neuroscience</i> , 2018, 12, 144.	1.4	13
4420	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. <i>Frontiers in Neuroscience</i> , 2018, 12, 185.	1.4	32
4421	Improvement of Olfactory Function With High Frequency Non-invasive Auricular Electrostimulation in Healthy Humans. <i>Frontiers in Neuroscience</i> , 2018, 12, 225.	1.4	29
4422	Autophagy Disruptions Associated With Altered Optineurin Expression in Extranigral Regions in a Rotenone Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 289.	1.4	9
4423	Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 430.	1.4	32
4424	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α -Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 447.	1.4	28
4425	Degenerative Movement Disorders of the Central Nervous System. , 2018, , 321-325.e3.		0
4426	Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson's disease. <i>Translational Neurodegeneration</i> , 2018, 7, 13.	3.6	31
4427	Recent Advances in the Detection of Neurotransmitters. <i>Chemosensors</i> , 2018, 6, 1.	1.8	154
4428	Sparse feature learning for multi-class Parkinson's disease classification. <i>Technology and Health Care</i> , 2018, 26, 193-203.	0.5	20
4429	Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts. <i>Journal of Virology</i> , 2018, 92, .	1.5	28
4430	Non-cell-autonomous actions of α -synuclein: Implications in glial synucleinopathies. <i>Progress in Neurobiology</i> , 2018, 169, 158-171.	2.8	21
4431	Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 57.	2.4	11
4432	Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease. <i>Frontiers in Neurology</i> , 2018, 9, 260.	1.1	12
4433	In vivo quantification of glial activation in minipigs overexpressing human α -synuclein. <i>Synapse</i> , 2018, 72, e22060.	0.6	15
4434	Reduced gray matter volume and respiratory dysfunction in Parkinson's disease: a voxel-based morphometry study. <i>BMC Neurology</i> , 2018, 18, 73.	0.8	17
4435	Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. <i>Acta Neuropathologica Communications</i> , 2018, 6, 54.	2.4	48
4436	Structural signature of SCA3: From presymptomatic to late disease stages. <i>Annals of Neurology</i> , 2018, 84, 401-408.	2.8	90

#	ARTICLE	IF	CITATIONS
4437	Oxidative stress and neurodegeneration: the involvement of iron. <i>BioMetals</i> , 2018, 31, 715-735.	1.8	120
4439	Testing the Protein Propagation Hypothesis of Parkinson Disease. <i>Journal of Experimental Neuroscience</i> , 2018, 12, 117906951878671.	2.3	21
4440	Spreading of Tau Pathology in Sporadic Alzheimer's Disease Along Cortico-cortical Top-Down Connections. <i>Cerebral Cortex</i> , 2018, 28, 3372-3384.	1.6	91
4441	The accuracy of the clinical diagnosis of Parkinson disease. The HUNT study. <i>Journal of Neurology</i> , 2018, 265, 2120-2124.	1.8	20
4442	Sensor Array for Detection of Early Stage Parkinson's Disease before Medication. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2548-2553.	1.7	25
4443	REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB). <i>Behavioural Neurology</i> , 2018, 2018, 1-10.	1.1	26
4444	Untangling the Tauopathy for Alzheimer's disease and parkinsonism. <i>Journal of Biomedical Science</i> , 2018, 25, 54.	2.6	37
4445	Analysis of the clinical features of early Parkinson's disease with comparatively integrated intestinal function. <i>Neurological Sciences</i> , 2018, 39, 1847-1856.	0.9	7
4446	A new model to study cell-to-cell transfer of α -Synuclein in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1385-1393.	1.0	7
4447	Co-aggregation of pro-inflammatory S100A9 with α -synuclein in Parkinson's disease: ex vivo and in vitro studies. <i>Journal of Neuroinflammation</i> , 2018, 15, 172.	3.1	50
4448	JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss. <i>Journal of Neuroinflammation</i> , 2018, 15, 184.	3.1	16
4449	Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 236.	1.4	200
4450	A survey of subjective constipation in Parkinson's disease patients in shanghai and literature review. <i>BMC Neurology</i> , 2018, 18, 29.	0.8	21
4451	α -Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons. <i>Acta Neuropathologica Communications</i> , 2018, 6, 35.	2.4	62
4452	HIV-1 Tat at regulation of dopamine transmission and microglial reactivity is brain region specific. <i>Glia</i> , 2018, 66, 1915-1928.	2.5	13
4453	Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. <i>Acta Neuropathologica</i> , 2018, 136, 57-67.	3.9	173
4454	Historical and cross-cultural perspectives on Parkinson's disease. <i>Journal of Complementary and Integrative Medicine</i> , 2018, 15, .	0.4	2
4455	Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study. <i>BMC Neurology</i> , 2018, 18, 9.	0.8	27

#	ARTICLE	IF	CITATIONS
4456	Parkinson's Disease and Other Synucleinopathies. , 2018, , 117-143.		0
4457	Two-pore channels and disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1678-1686.	1.9	52
4458	The total number of myelinated nerve fibers is reduced in corpus callosum in brains from patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 69, 58-64.	1.5	8
4459	A53T- α -synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. <i>Acta Neuropathologica Communications</i> , 2018, 6, 39.	2.4	51
4460	Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 72-76.	1.1	6
4461	Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics. <i>Acta Neuropathologica Communications</i> , 2018, 6, 75.	2.4	47
4462	Multimodal imaging in RBD " present and future. <i>Nature Reviews Neurology</i> , 2018, 14, 574-576.	4.9	1
4463	Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0202770.	1.1	35
4464	Diagnostic biomarkers for Parkinson's disease at a glance: where are we?. <i>Journal of Neural Transmission</i> , 2018, 125, 1417-1432.	1.4	65
4465	LRRK2 kinase regulates α -synuclein propagation via RAB35 phosphorylation. <i>Nature Communications</i> , 2018, 9, 3465.	5.8	121
4466	Longer δ oscillatory episodes reliably identify pathological subthalamic activity in Parkinsonism. <i>Movement Disorders</i> , 2018, 33, 1609-1618.	2.2	83
4467	Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 247.	1.8	152
4468	Chemosensory perception is specifically impaired in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 68-71.	1.1	13
4469	A role for viral infections in Parkinson's etiology?. <i>Neuronal Signaling</i> , 2018, 2, NS20170166.	1.7	37
4470	Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies. <i>Genes</i> , 2018, 9, 63.	1.0	25
4471	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> , 2018, 91, e894-e905.	1.5	112
4472	Association between olfactory loss and cognitive deficits in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 120-123.	0.6	21
4473	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33

#	ARTICLE	IF	CITATIONS
4474	CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in Î±-Synuclein Causing Parkinson's Disease. <i>Scientific Reports</i> , 2018, 8, 12420.	1.6	38
4475	Association between depression and the subsequent risk of Parkinson's disease: A meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 186-192.	2.5	62
4476	Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type Î±-synuclein. <i>Neurobiology of Disease</i> , 2018, 117, 170-180.	2.1	24
4477	Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?. <i>Cell and Tissue Research</i> , 2018, 373, 267-286.	1.5	32
4478	Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?. <i>Cell and Tissue Research</i> , 2018, 373, 149-160.	1.5	44
4479	ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinson's Disease. <i>Neuron</i> , 2018, 98, 1155-1169.e6.	3.8	77
4480	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	1.1	77
4481	Gastric emptying in Parkinson's disease – A mini-review. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 18-25.	1.1	36
4482	Excessive daytime sleepiness, objective napping and 11-year risk of Parkinson's disease in older men. <i>International Journal of Epidemiology</i> , 2018, 47, 1679-1686.	0.9	37
4483	Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 127-132.	0.8	14
4484	Depression in Parkinson's disease: A case-control study. <i>PLoS ONE</i> , 2018, 13, e0192050.	1.1	11
4485	Olfactory Dysfunction in Neurodegenerative Diseases. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 42.	2.4	159
4486	The Neuroimaging of Brain Diseases. <i>Contemporary Clinical Neuroscience</i> , 2018, , .	0.3	1
4487	Neuroinflammation in Age-Related Neurodegenerative Diseases. , 2018, , 477-507.		0
4488	Early occurrence of inspiratory muscle weakness in Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0190400.	1.1	55
4489	Special issue – Parkinson's disease. <i>Cell and Tissue Research</i> , 2018, 373, 1-7.	1.5	9
4490	Prion-like propagation of pathology in Parkinson disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 153, 321-335.	1.0	58
4491	Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies. <i>Clinical Neurophysiology</i> , 2018, 129, 1551-1564.	0.7	62

#	ARTICLE	IF	CITATIONS
4492	Developmental dynamics of prepiriform cortex in prenatal human ontogenesis. <i>Journal of Chemical Neuroanatomy</i> , 2018, 92, 61-70.	1.0	3
4493	Excess amounts of 3-iodo-L-tyrosine induce Parkinson-like features in experimental approaches of Parkinsonism. <i>NeuroToxicology</i> , 2018, 67, 178-189.	1.4	10
4494	Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation. <i>Metabolic Brain Disease</i> , 2018, 33, 1493-1500.	1.4	31
4495	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- α -Synuclein Monoclonal Antibody, in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2018, 75, 1206.	4.5	217
4496	More than a drainage fluid: the role of CSF in signaling in the brain and other effects on brain tissue. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 146, 33-46.	1.0	14
4497	Non-motor Parkinson disease: new concepts and personalised management. <i>Medical Journal of Australia</i> , 2018, 208, 404-409.	0.8	77
4498	The enteric nervous system in PD: gateway, bystander victim, or source of solutions. <i>Cell and Tissue Research</i> , 2018, 373, 313-326.	1.5	19
4499	Analysis of nocturnal hypokinesia and sleep quality in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 54, 96-101.	0.8	17
4500	Somatic copy number gains of α -synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains. <i>Brain</i> , 2018, 141, 2419-2431.	3.7	63
4501	Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder. <i>International Journal of Neuroscience</i> , 2019, 129, 55-93.	0.8	57
4502	GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution. <i>Neuropharmacology</i> , 2019, 147, 28-36.	2.0	30
4503	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. <i>European Journal of Neuroscience</i> , 2019, 49, 328-338.	1.2	137
4504	Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration. <i>Molecular Neurobiology</i> , 2019, 56, 2653-2669.	1.9	50
4505	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. <i>European Journal of Neuroscience</i> , 2019, 49, 805-816.	1.2	20
4506	Differential insular cortex subregional vulnerability to α -synuclein pathology in Parkinson's disease and dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 262-277.	1.8	36
4507	Neuroimaging in Lewy body dementia. <i>Journal of Neurology</i> , 2019, 266, 1-26.	1.8	45
4508	Is Braak staging valid for all types of Parkinson's disease?. <i>Journal of Neural Transmission</i> , 2019, 126, 423-431.	1.4	73
4509	Objective intestinal function in patients with idiopathic REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 28-34.	1.1	18

#	ARTICLE	IF	CITATIONS
4510	Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?. <i>European Journal of Neuroscience</i> , 2019, 49, 422-439.	1.2	2
4511	Spike discharge characteristic of the caudal mesencephalic reticular formation and pedunculopontine nucleus in MPTP-induced primate model of Parkinson disease. <i>Neurobiology of Disease</i> , 2019, 128, 40-48.	2.1	3
4512	Protein misassembly and aggregation as potential convergence points for non-genetic causes of chronic mental illness. <i>Molecular Psychiatry</i> , 2019, 24, 936-951.	4.1	47
4513	Effects of levodopa therapy on voxel-based degree centrality in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 1202-1219.	1.1	22
4514	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. <i>Chemical Reviews</i> , 2019, 119, 1221-1322.	23.0	360
4515	Stem cell-based therapy for Parkinson's disease with a focus on human endometrium-derived mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 1326-1335.	2.0	32
4516	Treatment options for postural instability and gait difficulties in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1229-1251.	1.4	22
4517	Ribosylation-Derived Advanced Glycation End Products Induce Tau Hyperphosphorylation Through Brain-Derived Neurotrophic Factor Reduction. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 291-305.	1.2	23
4518	Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging. <i>Frontiers in Neurology</i> , 2019, 10, 777.	1.1	23
4519	Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson's disease monkeys. <i>BMC Neuroscience</i> , 2019, 20, 42.	0.8	15
4520	Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson's Disease: A South Korean Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1191.	1.0	60
4521	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	3.9	14
4522	Calling α -synuclein a prion is scientifically justifiable. <i>Acta Neuropathologica</i> , 2019, 138, 505-508.	3.9	14
4523	Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. <i>Human Brain Mapping</i> , 2019, 40, 5094-5107.	1.9	71
4524	Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. <i>Movement Disorders</i> , 2019, 34, 1262-1273.	2.2	25
4525	Fluctuating cognition in the Lewy body dementias. <i>Brain</i> , 2019, 142, 3338-3350.	3.7	27
4526	Neuroprotective Effects of Ginseng Phytochemicals: Recent Perspectives. <i>Molecules</i> , 2019, 24, 2939.	1.7	77
4527	Spreading Model for Patients with Parkinson's Disease Based on Connectivity Differences. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
4528	Molecular pathology of neurodegenerative diseases: principles and practice. <i>Journal of Clinical Pathology</i> , 2019, 72, 725-735.	1.0	130
4529	Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-321111.	0.9	80
4530	Effect of Photobiomodulation in Rescuing Lipopolysaccharide-Induced Dopaminergic Cell Loss in the Male Sprague-Dawley Rat. <i>Biomolecules</i> , 2019, 9, 381.	1.8	23
4531	Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1566-1570.	2.2	9
4532	Neuroimaging in Movement Disorders. , 2019, , 1327-1361.		0
4534	Can infections trigger alpha-synucleinopathies?. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 299-322.	0.9	55
4535	Sleep as a Therapeutic Target in the Aging Brain. <i>Neurotherapeutics</i> , 2019, 16, 554-568.	2.1	35
4536	Intervention changes acoustic peak frequency and mesolimbic neurochemistry in the Pink1 ^{-/-} rat model of Parkinson disease. <i>PLoS ONE</i> , 2019, 14, e0220734.	1.1	10
4537	The therapeutic effect of deep brain stimulation on olfactory functions and clinical scores in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 55-61.	0.8	13
4538	Depressed caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 132, 104563.	2.1	14
4539	Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	1.6	76
4540	COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of home-based, online cognitive training on cognition and brain networks in Parkinson's disease. <i>BMC Neurology</i> , 2019, 19, 179.	0.8	11
4541	Antibody-based therapies for Huntington's disease: current status and future directions. <i>Neurobiology of Disease</i> , 2019, 132, 104569.	2.1	17
4542	Improving sensitivity, specificity, and reproducibility of individual brainstem activation. <i>Brain Structure and Function</i> , 2019, 224, 2823-2838.	1.2	11
4543	The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 23.	3.6	200
4544	REM Sleep without atonia correlates with abnormal vestibular-evoked myogenic potentials in isolated REM sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	0.6	17
4545	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	3.7	44
4546	Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography. <i>Frontiers in Neuroscience</i> , 2019, 13, 617.	1.4	54

#	ARTICLE	IF	CITATIONS
4547	New models show gut-brain transmission of Parkinson disease pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 491-491.	4.9	10
4548	Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies. <i>Human Brain Mapping</i> , 2019, 40, 4537-4550.	1.9	24
4549	The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 886-889.	0.6	1
4550	Atrophic Myenteric and Submucosal Neurons Are Observed in Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-5.	0.6	18
4551	REM sleep without atonia and the relation with Lewy body disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 90-98.	1.1	21
4552	Exosomes from patients with Parkinson's disease are pathological in mice. <i>Journal of Molecular Medicine</i> , 2019, 97, 1329-1344.	1.7	58
4553	Higher zinc concentrations in hair of Parkinson's disease are associated with psychotic complications and depression. <i>Journal of Neural Transmission</i> , 2019, 126, 1291-1301.	1.4	8
4554	Misconceptions about speech impairment in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1471-1475.	2.2	17
4555	Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	5
4556	Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1069-1087.	1.4	30
4557	The locus coeruleus: Another vulnerability target in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1423-1429.	2.2	29
4558	Role of the endolysosomal system in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2019, 150, 487-506.	2.1	98
4559	The challenge of pain in the pharmacological management of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1847-1854.	0.9	16
4560	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. <i>Brain</i> , 2019, 142, 2558-2571.	3.7	219
4561	Isolated rapid eye movement sleep behavior disorder and cyclic alternating pattern: is sleep microstructure a predictive parameter of neurodegeneration?. <i>Sleep</i> , 2019, 42, .	0.6	27
4562	Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 171.	1.4	100
4563	Saccades in Parkinson's disease: Hypometric, slow, and maladaptive. <i>Progress in Brain Research</i> , 2019, 249, 81-94.	0.9	14
4564	Dysregulation of Respiratory Center Drive (P0.1) and Muscle Strength in Patients With Early Stage Idiopathic Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 724.	1.1	22

#	ARTICLE	IF	CITATIONS
4565	Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2019, 13, 176.	1.0	14
4566	Re-thinking the Etiological Framework of Neurodegeneration. <i>Frontiers in Neuroscience</i> , 2019, 13, 728.	1.4	56
4567	Connectomics of neurodegeneration. <i>Nature Neuroscience</i> , 2019, 22, 1200-1202.	7.1	5
4568	Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinson's Disease Post-Mortem Brain through a New AlphaScreen-Based Assay. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3600.	1.8	40
4569	Spread of α -synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. <i>Nature Neuroscience</i> , 2019, 22, 1248-1257.	7.1	187
4570	New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy. <i>International Review of Neurobiology</i> , 2019, 146, 281-295.	0.9	13
4571	Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's patients. <i>PLoS ONE</i> , 2019, 14, e0214352.	1.1	12
4572	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. <i>Parkinson's Disease</i> , 2019, 2019, 1-12.	0.6	23
4573	Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread. <i>Brain</i> , 2019, 142, 3072-3085.	3.7	32
4574	Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1440-1451.	2.2	81
4575	Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 374-387.	2.0	36
4576	Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4589-4611.	2.4	73
4577	Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. <i>Acta Neuropathologica</i> , 2019, 138, 535-550.	3.9	210
4578	α -synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. <i>Journal of Neurochemistry</i> , 2019, 150, 522-534.	2.1	201
4579	Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 129.	3.1	283
4580	Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 74-89.	1.1	59
4581	Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update. <i>Frontiers in Neurology</i> , 2019, 10, 617.	1.1	18
4583	Effect of L-DOPA/Benserazide on Propagation of Pathological α -Synuclein. <i>Frontiers in Neuroscience</i> , 2019, 13, 595.	1.4	15

#	ARTICLE	IF	CITATIONS
4584	Parkinson's disease biomarkers based on α -synuclein. <i>Journal of Neurochemistry</i> , 2019, 150, 626-636.	2.1	104
4585	The physiological role of α -synuclein and its relationship to Parkinson's Disease. <i>Journal of Neurochemistry</i> , 2019, 150, 475-486.	2.1	217
4588	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , 2019, 93, e476-e484.	1.5	23
4589	Microelectrode Arrays Modified with Nanocomposites for Monitoring Dopamine and Spike Firings under Deep Brain Stimulation in Rat Models of Parkinson's Disease. <i>ACS Sensors</i> , 2019, 4, 1992-2000.	4.0	57
4590	Prion-Like Mechanisms in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 552.	1.4	88
4591	Plasma pS129- α -Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1601.	1.0	24
4592	Animal models of olfactory dysfunction in neurodegenerative diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 164, 431-452.	1.0	12
4593	Tau progression in single severe frontal traumatic brain injury in human brains. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116495.	0.3	13
4594	The Appendix in Parkinson's Disease: From Vestigial Remnant to Vital Organ?. <i>Journal of Parkinson's Disease</i> , 2019, 9, S345-S358.	1.5	20
4595	Gastrointestinal Immunity and Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, S313-S322.	1.5	41
4596	Involvement of CGRP receptor RAMP1 in cluster headache: A Swedish case-control study. <i>Cephalalgia Reports</i> , 2019, 2, 251581631987988.	0.2	2
4597	Lower nucleus accumbens α -synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. <i>Brain</i> , 2019, 142, 3580-3591.	3.7	17
4598	Mutations in CHCHD2 cause α -synuclein aggregation. <i>Human Molecular Genetics</i> , 2019, 28, 3895-3911.	1.4	48
4599	Inflammatory Bowel Diseases and Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S331-S344.	1.5	81
4600	Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S359-S370.	1.5	31
4601	MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan. <i>Human Brain Mapping</i> , 2019, 40, 5269-5288.	1.9	55
4602	Image Segmentation and Feature Analyses of Imitated Intense X-ray Spot Radiation Source. , 2019, , .		0
4603	Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an α -synuclein based rat model for Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 160.	2.4	9

#	ARTICLE	IF	CITATIONS
4604	Behavioral symptomatology and psychopharmacology of Lewy body dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 59-70.	1.0	9
4605	Critical Role of Oxidatively Damaged DNA in Selective Noradrenergic Vulnerability. Neuroscience, 2019, 422, 184-201.	1.1	3
4606	Caffeic acid reduces A53T α -synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease. Pharmacological Research, 2019, 150, 104538.	3.1	71
4607	Hsp110 mitigates α -synuclein pathology in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24310-24316.	3.3	44
4608	Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease. International Journal of Molecular Sciences, 2019, 20, 5481.	1.8	6
4609	Prion-like propagation of α -synuclein in neurodegenerative diseases. Progress in Molecular Biology and Translational Science, 2019, 168, 323-348.	0.9	18
4610	Intrastriatal injection of alpha-synuclein fibrils induces Parkinson-like pathology in macaques. Brain, 2019, 142, 3321-3322.	3.7	11
4611	The microbiome of the upper respiratory tract in health and disease. BMC Biology, 2019, 17, 87.	1.7	243
4612	The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1155.	1.1	89
4614	Initiation and Transmission of α -Synuclein Pathology in Parkinson's Disease. Neurochemical Research, 2019, 44, 2685-2694.	1.6	6
4615	Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinson's Disease Cohort. Parkinson's Disease, 2019, 2019, 1-6.	0.6	4
4616	Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1087.	1.1	29
4617	Polymeric Nanomedicine. , 2019, , 233-267.		1
4618	Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson's Disease Models. International Journal of Molecular Sciences, 2019, 20, 5208.	1.8	21
4619	The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. International Journal of Molecular Sciences, 2019, 20, 5312.	1.8	78
4620	Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α -Synuclein. Neuron, 2019, 104, 869-884.e11.	3.8	50
4621	Lesion of the Locus Coeruleus Damages Learning and Memory Performance in Paraquat and Maneb-induced Mouse Parkinson's Disease Model. Neuroscience, 2019, 419, 129-140.	1.1	33
4622	Adrenergic Receptors as Pharmacological Targets for Neuroinflammation and Neurodegeneration in Parkinson's Disease. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
4623	Human NPCs can degrade α -syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures. <i>Neurobiology of Disease</i> , 2019, 132, 104609.	2.1	17
4624	Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 262.	1.4	101
4625	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. <i>Movement Disorders</i> , 2019, 34, 1406-1422.	2.2	62
4626	Enriched Environmental Conditions Modify the Gut Microbiome Composition and Fecal Markers of Inflammation in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1032.	1.4	17
4627	Why would Parkinson's disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 100, 129-165.	2.9	17
4628	Dynamic interaction of genetic risk factors and cocaine abuse in the background of Parkinsonism – a case report. <i>BMC Neurology</i> , 2019, 19, 260.	0.8	5
4629	Early defects in translation elongation factor ϵ levels at excitatory synapses in α -synucleinopathy. <i>Acta Neuropathologica</i> , 2019, 138, 971-986.	3.9	14
4630	Specific intranasal and central trigeminal electrophysiological responses in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2942-2951.	1.8	6
4631	A Stage-Based Approach to Therapy in Parkinson's Disease. <i>Biomolecules</i> , 2019, 9, 388.	1.8	41
4632	Preclinical development of a high affinity α -synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α -synuclein and attenuate α -synuclein spreading in vivo. <i>Neurobiology of Disease</i> , 2019, 132, 104582.	2.1	68
4633	Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101986.	1.4	26
4634	Immunotherapy in Parkinson's disease: Current status and future directions. <i>Neurobiology of Disease</i> , 2019, 132, 104587.	2.1	41
4635	Exploring the Peripheral Initiation of Parkinson's Disease in Animal Models. <i>Neuron</i> , 2019, 103, 547-549.	3.8	5
4636	Synuclein Meeting 2019: where we are and where we need to go. <i>Journal of Neurochemistry</i> , 2019, 150, 462-466.	2.1	3
4637	The road ahead in clinical network neuroscience. <i>Network Neuroscience</i> , 2019, 3, 969-993.	1.4	37
4638	Unique α -synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 142.	2.4	49
4639	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	3.6	70
4640	Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease. <i>PLoS ONE</i> , 2019, 14, e0222002.	1.1	20

#	ARTICLE	IF	CITATIONS
4641	Parkinson's disease and changes in the appreciation of art: A comparison of aesthetic and formal evaluations of paintings between PD patients and healthy controls. <i>Brain and Cognition</i> , 2019, 136, 103597.	0.8	12
4642	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. <i>Acta Neuropathologica</i> , 2019, 138, 771-782.	3.9	46
4643	Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. <i>Journal of Parkinson's Disease</i> , 2019, 9, S281-S295.	1.5	201
4644	Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. <i>Neuropharmacology</i> , 2019, 160, 107758.	2.0	14
4645	Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2019, 12, 67-83.	0.7	65
4646	The Causative and Curative Roles of Brain-Derived Neurotrophic Factor in Parkinson's Disease. , 0, , .		0
4647	Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons. <i>Cell Stem Cell</i> , 2019, 25, 514-530.e8.	5.2	96
4648	Spatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11. <i>Journal of Chemical Neuroanatomy</i> , 2019, 100, 101664.	1.0	1
4649	Nonpharmacological Modulation of Chronic Inflammation in Parkinson's Disease: Role of Diet Interventions. <i>Parkinson's Disease</i> , 2019, 2019, 1-12.	0.6	13
4650	Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. <i>Npj Parkinson's Disease</i> , 2019, 5, 20.	2.5	58
4651	Gastrointestinal Dysfunction in Chinese Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	10
4652	Neocortical Lewy bodies are associated with impaired odor identification in community-dwelling elders without clinical PD. <i>Journal of Neurology</i> , 2019, 266, 3108-3118.	1.8	15
4653	Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 1471-1478.	1.4	43
4654	Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurons: Effects in wild type and human A30P mutant α -synuclein mice. <i>Neuroscience Letters</i> , 2019, 711, 134437.	1.0	19
4655	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2019, 78, 891-899.	0.9	44
4656	Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance. <i>Neurochemistry International</i> , 2019, 131, 104551.	1.9	13
4657	Gut Inflammation in Association With Pathogenesis of Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 218.	1.4	63
4658	Neuroglia in Neurodegenerative Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	18

#	ARTICLE	IF	CITATIONS
4659	Expression Profiling of Blood microRNAs 885, 361, and 17 in the Patients with the Parkinson's disease: Integrating Interaction Data to Uncover the Possible Triggering Age-Related Mechanisms. <i>Scientific Reports</i> , 2019, 9, 13759.	1.6	21
4660	Inhibition of nSMase2 Reduces the Transfer of Oligomeric α -Synuclein Irrespective of Hypoxia. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 200.	1.4	44
4661	Large-Fiber Neuropathy in Parkinson's Disease: Clinical, Biological, and Electroneurographic Assessment of a Romanian Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1533.	1.0	7
4662	Characterization of the Basic Membrane Properties of Neurons of the Rat Dorsal Motor Nucleus of the Vagus in Paraquat-Induced Models of Parkinsonism. <i>Neuroscience</i> , 2019, 418, 122-132.	1.1	6
4664	Gene-environment interaction and Mendelian randomisation. <i>Revue Neurologique</i> , 2019, 175, 597-603.	0.6	9
4665	Anti-neuroinflammatory effect of Iresine celosia on lipopolysaccharide-stimulated microglial cells and mouse. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 1359-1366.	2.5	10
4666	Assessing blink reflex circuits by three different afferent routes in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2019, 130, 582-587.	0.7	6
4667	Cortical thinning across Parkinson's disease stages and clinical correlates. <i>Journal of the Neurological Sciences</i> , 2019, 398, 31-38.	0.3	51
4668	Aquaporin-4 deficiency reduces TGF β 1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2568-2582.	1.6	38
4669	The prion-like spreading of α -synuclein: From in vitro to in vivo models of Parkinson's disease. <i>Ageing Research Reviews</i> , 2019, 50, 89-101.	5.0	59
4670	Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. <i>Scientific Reports</i> , 2019, 9, 544.	1.6	94
4671	GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease. <i>Human Molecular Genetics</i> , 2019, 28, 1894-1904.	1.4	41
4672	The effects of rotenone on TH, BDNF and BDNF-related proteins in the brain and periphery: Relevance to early Parkinson's disease. <i>Journal of Chemical Neuroanatomy</i> , 2019, 97, 23-32.	1.0	8
4673	Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 979-985.	1.7	73
4674	Dementia with Lewy bodies: an update and outlook. <i>Molecular Neurodegeneration</i> , 2019, 14, 5.	4.4	203
4675	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
4676	EZH2 Influences mdDA Neuronal Differentiation, Maintenance and Survival. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 491.	1.4	20
4677	Imaging in prodromal dementia with Lewy bodies: Where do we stand?. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 635-646.	1.3	10

#	ARTICLE	IF	CITATIONS
4678	Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease. ACS Chemical Neuroscience, 2019, 10, 812-823.	1.7	41
4679	Newly identified sleep-wake and circadian circuits as potential therapeutic targets. Sleep, 2019, 42, .	0.6	29
4680	Potential Role of Mic60/Mitofilin in Parkinson's Disease. Frontiers in Neuroscience, 2018, 12, 898.	1.4	13
4681	More Research Is Needed on Lifestyle Behaviors That Influence Progression of Parkinson's Disease. Frontiers in Neurology, 2019, 10, 452.	1.1	9
4682	Ages at Onset of Anxiety and Depressive Disorders in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 346-352.	0.9	26
4683	NF- κ B/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice. Translational Neurodegeneration, 2019, 8, 16.	3.6	21
4684	Drug treatment strategies for depression in Parkinson disease. Expert Opinion on Pharmacotherapy, 2019, 20, 1351-1363.	0.9	61
4685	Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions. Cellular and Molecular Neurobiology, 2019, 39, 901-915.	1.7	29
4686	Variants in the SNCA Locus Are Associated With the Progression of Parkinson's Disease. Frontiers in Aging Neuroscience, 2019, 11, 110.	1.7	8
4687	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. Lancet Neurology, The, 2019, 18, 748-759.	4.9	70
4688	Structural Imaging in Parkinson's Disease: New Developments. Current Neurology and Neuroscience Reports, 2019, 19, 50.	2.0	27
4689	Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. BioMed Research International, 2019, 2019, 1-6.	0.9	15
4690	Prion Properties of Alpha-Synuclein. Molecular Biology, 2019, 53, 335-341.	0.4	5
4691	Sleep Disturbance as Potential Risk and Progression Factor for Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 603-614.	1.5	77
4692	Differential impairment of short working and spatial memories in a rat model of progressive Parkinson's disease onset: A focus on the prodromal stage. Brain Research Bulletin, 2019, 150, 307-316.	1.4	14
4693	Quantitative magnetization transfer imaging of the human locus coeruleus. NeuroImage, 2019, 200, 191-198.	2.1	30
4694	Oral and intravenous transmission of α -synuclein fibrils to mice. Acta Neuropathologica, 2019, 138, 515-533.	3.9	55
4695	Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease. Lancet Neurology, The, 2019, 18, 713-714.	4.9	8

#	ARTICLE	IF	CITATIONS
4696	A traffic jam leads to Lewy bodies. <i>Nature Neuroscience</i> , 2019, 22, 1043-1045.	7.1	11
4697	Extracellular α -synuclein enters dopaminergic cells by modulating flotillin α -assisted dopamine transporter endocytosis. <i>FASEB Journal</i> , 2019, 33, 10240-10256.	0.2	16
4698	Rapid Eye Movement Sleep Behavior Disorder: Pathological Neural Circuits and Association with Parkinson's Disease. <i>Handbook of Behavioral Neuroscience</i> , 2019, 30, 723-730.	0.7	0
4699	Interactions between iron and α -synuclein pathology in Parkinson's disease. <i>Free Radical Biology and Medicine</i> , 2019, 141, 253-260.	1.3	51
4700	α -Synuclein in Parkinson's disease: causal or bystander?. <i>Journal of Neural Transmission</i> , 2019, 126, 815-840.	1.4	88
4701	Transneuronal Propagation of Pathologic α -Synuclein from the Gut to the Brain Models Parkinson's Disease. <i>Neuron</i> , 2019, 103, 627-641.e7.	3.8	830
4702	Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 585-594.	0.9	9
4703	α -Synuclein pathology in Parkinson's disease and related α -synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	1.0	177
4704	Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α -synucleinopathy. <i>Acta Neuropathologica</i> , 2019, 138, 551-574.	3.9	58
4705	A secret that underlies Parkinson's disease: The damaging cycle. <i>Neurochemistry International</i> , 2019, 129, 104484.	1.9	21
4706	A cullin-RING ubiquitin ligase targets exogenous α -synuclein and inhibits Lewy body-like pathology. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	30
4707	Cathepsin Oxidation Alters Alpha-Synuclein Processing. <i>Frontiers in Neurology</i> , 2019, 10, 530.	1.1	2
4708	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019, 126, 1061-1072.	1.4	16
4709	Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 103, 305-315.	2.9	87
4710	Alteration of Tremor Dominant and Postural Instability Gait Difficulty Subtypes During the Progression of Parkinson's Disease: Analysis of the PPMI Cohort. <i>Frontiers in Neurology</i> , 2019, 10, 471.	1.1	40
4711	Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease. <i>Neuroscience</i> , 2019, 411, 270-278.	1.1	25
4712	Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. <i>Drugs</i> , 2019, 79, 1037-1051.	4.9	48
4713	Diffusion tensor and restriction spectrum imaging reflect different aspects of neurodegeneration in Parkinson's disease. <i>PLoS ONE</i> , 2019, 14, e0217922.	1.1	17

#	ARTICLE	IF	CITATIONS
4714	Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics. <i>Journal of Clinical Neuroscience</i> , 2019, 66, 26-32.	0.8	3
4715	Spreading of alpha-synuclein – relevant or epiphenomenon?. <i>Journal of Neurochemistry</i> , 2019, 150, 605-611.	2.1	34
4716	Continual Treatment with the Peels of <i>Citrus kawachiensis</i> (Kawachi Bankan) Protects against Dopaminergic Neuronal Cell Death in a Lipopolysaccharide-Induced Model of Parkinson's Disease. <i>Journal of Nutritional Science and Vitaminology</i> , 2019, 65, 205-208.	0.2	8
4717	Linking the Endoplasmic Reticulum to Parkinson's Disease and Alpha-Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2019, 13, 560.	1.4	95
4718	“Cognitive freezing”: A newly recognized episodic phenomenon in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 49-54.	1.1	1
4719	Autonomic impairment as a potential biomarker in idiopathic REM-sleep-behavior disorder. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2019, 220, 102553.	1.4	13
4720	Systematic review of the pharmacoeconomics of Parkinson disease medications. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1659-1670.	0.9	6
4721	Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery. <i>Cells</i> , 2019, 8, 565.	1.8	54
4722	Preclinical Experimentation in Neurology. , 2019, , 583-606.		0
4723	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. <i>Clinical Biochemistry</i> , 2019, 72, 15-23.	0.8	4
4724	Salidroside Protects Dopaminergic Neurons by Preserving Complex I Activity via DJ-1/Nrf2-Mediated Antioxidant Pathway. <i>Parkinson's Disease</i> , 2019, 2019, 1-10.	0.6	15
4725	α-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1024-1032.	1.7	63
4726	Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. <i>Brain</i> , 2019, 142, 2051-2067.	3.7	215
4727	Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 7567.	1.6	65
4728	An association between bipolar disorder and Parkinson disease. <i>Neurology</i> , 2019, 92, 1125-1126.	1.5	6
4729	Glucocerebrosidase regulators SCARB2 and TFEB are up-regulated in Lewy body disease brain. <i>Neuroscience Letters</i> , 2019, 706, 164-168.	1.0	2
4730	Erectile Dysfunction Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study in Olmsted County. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	7
4731	Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein. <i>Acta Neuropathologica Communications</i> , 2019, 7, 81.	2.4	15

#	ARTICLE	IF	CITATIONS
4732	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. <i>NeuroImage: Clinical</i> , 2019, 23, 101848.	1.4	73
4733	Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 369.	1.4	84
4734	Spreading of α -Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 107.	1.4	79
4735	Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson's disease. <i>European Journal of Pain</i> , 2019, 23, 1475-1485.	1.4	6
4736	Editor's note: Prodromal Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 664-664.	2.2	2
4737	Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment. <i>Movement Disorders</i> , 2019, 34, 1164-1173.	2.2	56
4738	Effects of inspiratory muscle training on respiratory muscle strength, lung function, functional capacity and cardiac autonomic function in Parkinson's disease: Randomized controlled clinical trial protocol. <i>Physiotherapy Research International</i> , 2019, 24, e1777.	0.7	7
4739	Norepinephrine-Fe(III)-ATP Ternary Complex and Its Relevance to Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2777-2785.	1.7	4
4740	Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2224.	1.8	15
4741	The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy. <i>Drug Discovery Today</i> , 2019, 24, 1769-1783.	3.2	46
4742	Selective vulnerability in α -synucleinopathies. <i>Acta Neuropathologica</i> , 2019, 138, 681-704.	3.9	58
4743	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e2472-e2482.	1.5	16
4744	Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration. <i>Neurochemical Research</i> , 2019, 44, 2413-2422.	1.6	25
4745	Play in advance against neurodegeneration: exploring enteric glial cells in gut-brain axis during neurodegenerative diseases. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 555-564.	1.3	22
4746	Longitudinal progression of grey matter atrophy in non-amnesic Alzheimer's disease. <i>Brain</i> , 2019, 142, 1701-1722.	3.7	37
4747	Monoaminergic regulation of nociceptive circuitry in a Parkinson's disease rat model. <i>Experimental Neurology</i> , 2019, 318, 12-21.	2.0	17
4748	Role of tangeritin against cognitive impairments in transgenic Drosophila model of Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 705, 112-117.	1.0	11
4749	Sleep and risk of parkinsonism and Parkinson's disease: a population-based study. <i>Brain</i> , 2019, 142, 2013-2022.	3.7	63

#	ARTICLE	IF	CITATIONS
4750	Autonomic Dysfunction in α -Synucleinopathies. <i>Frontiers in Neurology</i> , 2019, 10, 363.	1.1	87
4751	Meta-analyses identify differentially expressed microRNAs in Parkinson's disease. <i>Annals of Neurology</i> , 2019, 85, 835-851.	2.8	84
4752	Depression in neurodegenerative diseases: Common mechanisms and current treatment options. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 102, 56-84.	2.9	159
4753	Ultrasonication-based rapid amplification of α -synuclein aggregates in cerebrospinal fluid. <i>Scientific Reports</i> , 2019, 9, 6001.	1.6	28
4754	Neurodegeneration and contralateral α -synuclein induction after intracerebral α -synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model. <i>Acta Neuropathologica Communications</i> , 2019, 7, 56.	2.4	13
4755	Dysregulated Lipid Metabolism and Its Role in α -Synucleinopathy in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 328.	1.4	169
4756	Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. <i>Journal of Nutritional Biochemistry</i> , 2019, 69, 73-86.	1.9	128
4757	Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 6559.	1.6	41
4758	Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions. <i>Journal of Neurochemistry</i> , 2019, 150, 467-474.	2.1	98
4759	Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. <i>Neurology</i> , 2019, 92, e1821-e1830.	1.5	88
4760	<i>Network Neuroscience</i> , 2019, , 490-532.		0
4761	Unbalanced calcium channel activity underlies selective vulnerability of nigrostriatal dopaminergic terminals in Parkinsonian mice. <i>Scientific Reports</i> , 2019, 9, 4857.	1.6	13
4762	Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 990-998.	1.3	3
4763	The A30P α -synuclein mutation decreases subventricular zone proliferation. <i>Human Molecular Genetics</i> , 2019, 28, 2283-2294.	1.4	18
4764	Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson's disease. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 146-150.	0.8	5
4765	<i>Neurodegenerative Diseases and Ageing</i> . <i>Sub-Cellular Biochemistry</i> , 2019, 91, 75-106.	1.0	8
4766	Neuropsychiatric Symptoms and Cognitive Impairment in Chinese Patients with Parkinson's Disease in Han and Hui Ethnicity. <i>Current Medical Science</i> , 2019, 39, 122-126.	0.7	4
4767	Circuit Mechanisms of Parkinson's Disease. <i>Neuron</i> , 2019, 101, 1042-1056.	3.8	296

#	ARTICLE	IF	CITATIONS
4768	Detecting Single-Molecule Dynamics on Lipid Membranes with Quenchers in Liposome FRET. <i>Angewandte Chemie</i> , 2019, 131, 5633-5637.	1.6	8
4769	Predictive model of spread of Parkinson's pathology using network diffusion. <i>NeuroImage</i> , 2019, 192, 178-194.	2.1	61
4770	Translational methods to detect asymmetries in temporal and spatial walking metrics in parkinsonian mouse models and human subjects with Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 2437.	1.6	7
4771	Risk of dementia after Parkinson's disease in Taiwan: a population-based retrospective cohort study using National Health Insurance claims. <i>BMJ Open</i> , 2019, 9, e025274.	0.8	6
4772	Detecting Single-Molecule Dynamics on Lipid Membranes with Quenchers in Liposome FRET. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 5577-5581.	7.2	18
4773	Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. <i>Nature Communications</i> , 2019, 10, 973.	5.8	217
4774	Clinical Features and Correlates of Excessive Daytime Sleepiness in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 121.	1.1	38
4775	A systematic review of MEG-based studies in Parkinson's disease: The motor system and beyond. <i>Human Brain Mapping</i> , 2019, 40, 2827-2848.	1.9	57
4776	Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?. <i>Current Opinion in Neurology</i> , 2019, 32, 279-291.	1.8	30
4777	Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease. <i>Molecular Brain</i> , 2019, 12, 16.	1.3	52
4778	LRRK2 inhibition does not impart protection from α -synuclein pathology and neuron death in non-transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 28.	2.4	39
4780	The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease. <i>Neurological Sciences</i> , 2019, 40, 1351-1356.	0.9	11
4781	Prodromal Parkinson's Disease: The Decade Past, the Decade to Come. <i>Movement Disorders</i> , 2019, 34, 665-675.	2.2	120
4782	Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism. <i>Journal of Clinical Neuroscience</i> , 2019, 64, 242-251.	0.8	18
4783	Acoustic Voice Modifications in Individuals with Parkinson Disease Submitted to Deep Brain Stimulation. <i>International Archives of Otorhinolaryngology</i> , 2019, 23, 203-208.	0.3	6
4784	α -Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 890-908.	1.1	241
4785	Microbiome, Parkinson's Disease and Molecular Mimicry. <i>Cells</i> , 2019, 8, 222.	1.8	56
4786	Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder. <i>Sleep</i> , 2019, 42, .	0.6	41

#	ARTICLE	IF	CITATIONS
4787	The center of olfactory bulb-seeded α -synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice. <i>Brain Pathology</i> , 2019, 29, 741-770.	2.1	18
4788	Young adult-onset, very slowly progressive cognitive decline with spastic paraparesis in Alzheimer's disease with cotton wool plaques due to a novel presenilin1 G417S mutation. <i>Acta Neuropathologica Communications</i> , 2019, 7, 19.	2.4	11
4789	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. <i>NeuroImage: Clinical</i> , 2019, 22, 101698.	1.4	25
4790	Classic animal models of Parkinson's disease: a historical perspective. <i>Behavioural Pharmacology</i> , 2019, 30, 291-310.	0.8	23
4791	Neuropathological lesions in the very old: results from a large Brazilian autopsy study. <i>Brain Pathology</i> , 2019, 29, 771-781.	2.1	20
4792	Autoimmunity in Parkinson's Disease: The Role of α -Synuclein-Specific T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 303.	2.2	120
4793	Effects of Enteric Environmental Modification by Coffee Components on Neurodegeneration in Rotenone-Treated Mice. <i>Cells</i> , 2019, 8, 221.	1.8	36
4794	Emerging therapies in Parkinson disease – repurposed drugs and new approaches. <i>Nature Reviews Neurology</i> , 2019, 15, 204-223.	4.9	189
4795	Th17 cells: a promising therapeutic target for Parkinson's disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 309-314.	1.5	18
4796	Entanglement of Genetics and Epigenetics in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 277.	1.4	51
4797	Investigation of urinary storage symptoms in Parkinson's disease utilizing structural MRI techniques. <i>Neurourology and Urodynamics</i> , 2019, 38, 1168-1175.	0.8	14
4798	Glial phagocytic clearance in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2019, 14, 16.	4.4	104
4799	Effect of naturally occurring α -synuclein-antibodies on toxic α -synuclein-fragments. <i>Neuroscience Letters</i> , 2019, 704, 181-188.	1.0	8
4800	Relationship between Lower Urinary Tract Dysfunction and Clinical Features in Chinese Parkinson's Disease Patients. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	6
4801	The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 57.	1.7	18
4802	Exercise-induced hypoalgesia is present in people with Parkinson's disease: Two observational cross-sectional studies. <i>European Journal of Pain</i> , 2019, 23, 1329-1339.	1.4	12
4803	The Roles of Post-translational Modifications on α -Synuclein in the Pathogenesis of Parkinson's Diseases. <i>Frontiers in Neuroscience</i> , 2019, 13, 381.	1.4	136
4804	Parkinson's disease: Mechanisms, translational models and management strategies. <i>Life Sciences</i> , 2019, 226, 77-90.	2.0	331

#	ARTICLE	IF	CITATIONS
4805	Neuroimaging and neuropathological findings in essential tremor. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 491-496.	1.0	11
4806	Review: Clinical, neuropathological and genetic features of Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 635-654.	1.8	26
4807	Targeting α -Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. <i>Drugs</i> , 2019, 79, 797-810.	4.9	67
4808	Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2019, 56, 7003-7021.	1.9	22
4809	Imaging in Neurodegeneration: Movement Disorders. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 262-274.	2.7	4
4810	Astrocyte Heterogeneity: Impact to Brain Aging and Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 59.	1.7	256
4811	LRRK2 modifies α -syn pathology and spread in mouse models and human neurons. <i>Acta Neuropathologica</i> , 2019, 137, 961-980.	3.9	142
4812	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α -synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 97-105.	1.1	22
4813	Why Is Aging a Risk Factor for Cognitive Impairment in Parkinson's Disease? A Resting State fMRI Study. <i>Frontiers in Neurology</i> , 2019, 10, 267.	1.1	10
4814	Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus. <i>Movement Disorders</i> , 2019, 34, 884-892.	2.2	49
4815	Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	31
4816	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	1.2	30
4817	Chronic Traumatic Encephalopathy (CTE) Is Absent From a European Community-Based Aging Cohort While Cortical Aging-Related Tau Astroglial Pathology (ARTAG) Is Highly Prevalent. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 398-405.	0.9	43
4818	Biomarkers of Parkinson's disease: 20 years later. <i>Journal of Neural Transmission</i> , 2019, 126, 803-813.	1.4	22
4819	Lmx1b Influences Correct Post-mitotic Coding of Mesodiencephalic Dopaminergic Neurons. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 62.	1.4	6
4820	Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein. <i>Chemical Senses</i> , 2019, 44, 311-318.	1.1	23
4821	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. <i>Neurology</i> , 2019, 92, e2015-e2026.	1.5	28
4822	Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T α -synuclein-expressing mice. <i>Neurobiology of Aging</i> , 2019, 80, 29-37.	1.5	16

#	ARTICLE	IF	CITATIONS
4823	Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but "failure to fit" is highly dependent on staging system applied. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 124-131.	1.1	21
4824	Impaired sleep quality and cognition in patients of Parkinson's disease with REM sleep behavior disorder: a comparative study. <i>Sleep Medicine</i> , 2019, 62, 1-5.	0.8	17
4825	Chronic sleep restriction in the rotenone Parkinson's disease model in rats reveals peripheral early-phase biomarkers. <i>Scientific Reports</i> , 2019, 9, 1898.	1.6	17
4826	Î±-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. <i>Acta Neuropathologica</i> , 2019, 138, 1-21.	3.9	109
4827	Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-Î±B signaling pathway. <i>Life Sciences</i> , 2019, 223, 120-127.	2.0	36
4828	Dysautonomia is associated with structural and functional alterations in Parkinson disease. <i>Neurology</i> , 2019, 92, e1456-e1467.	1.5	21
4829	Do multiple system atrophy and Parkinson's disease show distinct patterns of volumetric alterations across hippocampal subfields? An exploratory study. <i>European Radiology</i> , 2019, 29, 4948-4956.	2.3	17
4830	Local Gastrointestinal Injury Exacerbates Inflammation and Dopaminergic Cell Death in Parkinsonian Mice. <i>Neurotoxicity Research</i> , 2019, 35, 918-930.	1.3	9
4831	Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach. <i>Neuroscience Bulletin</i> , 2019, 35, 229-243.	1.5	18
4832	Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 967.	1.4	14
4833	Seeding variability of different alpha synuclein strains in synucleinopathies. <i>Annals of Neurology</i> , 2019, 85, 691-703.	2.8	85
4834	Accumulation of prion protein in the vagus nerve in creutzfeldt-jakob disease. <i>Annals of Neurology</i> , 2019, 85, 782-787.	2.8	12
4835	Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. <i>Acta Neuropathologica</i> , 2019, 137, 455-466.	3.9	45
4836	The Effect of Different Exercise Modes on Domain-Specific Cognitive Function in Patients Suffering from Parkinson's Disease: A Systematic Review of Randomized Controlled Trials. <i>Journal of Parkinson's Disease</i> , 2019, 9, 73-95.	1.5	29
4837	Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. <i>Brain Sciences</i> , 2019, 9, 30.	1.1	17
4838	Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease?. <i>Cells</i> , 2019, 8, 118.	1.8	100
4839	Brainstem avenues in Parkinson's disease research. <i>Clinical Neurophysiology</i> , 2019, 130, 554-555.	0.7	4
4840	NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 991-998.	2.8	17

#	ARTICLE	IF	CITATIONS
4841	HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies. <i>Journal of Parkinson's Disease</i> , 2019, 9, 97-107.	1.5	17
4842	Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. <i>Methods in Molecular Biology</i> , 2019, 1948, 45-57.	0.4	21
4843	Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 156-161.	1.1	9
4844	Investigation of Nonmotor Symptoms in First-Degree Relatives of Patients with Different Clinical Types of Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	0.6	1
4845	Serum Amyloid Alpha Is Downregulated in Peripheral Tissues of Parkinson's Disease Patients. <i>Frontiers in Neuroscience</i> , 2019, 13, 13.	1.4	19
4846	Altered functional network topology correlates with clinical measures in very early-stage, drug-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 3-9.	1.1	19
4847	Age- and α -Synuclein-Dependent Degeneration of Dopamine and Noradrenaline Neurons in the Annual Killifish <i>Nothobranchius furzeri</i> . <i>Cell Reports</i> , 2019, 26, 1727-1733.e6.	2.9	51
4848	The prion-like propagation hypothesis in Alzheimer's and Parkinson's disease. <i>Current Opinion in Neurology</i> , 2019, 32, 266-271.	1.8	45
4849	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019, 8, 5.	3.6	54
4850	Movement Disorders with Dementia in Older Adults. <i>Clinical Handbooks in Neuropsychology</i> , 2019, , 543-575.	0.1	0
4851	Reducing the Amyloidogenicity of Functional Amyloid Protein FapC Increases Its Ability To Inhibit α -Synuclein Fibrillation. <i>ACS Omega</i> , 2019, 4, 4029-4039.	1.6	26
4852	Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 2604.	1.6	27
4853	N1 and P1 Components Associate With Visuospatial-Executive and Language Functions in Normosmic Parkinson's Disease: An Event-Related Potential Study. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 18.	1.7	10
4854	Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 63.	1.8	99
4855	Association Between Parkinson's Disease and Atrial Fibrillation: A Population-Based Study. <i>Frontiers in Neurology</i> , 2019, 10, 22.	1.1	21
4856	Adult Neurogenesis in Health and Disease. , 2019, , 183-219.		0
4857	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 145-158.	1.2	56
4858	Roles of microRNAs in Parkinson's and other neurodegenerative diseases. , 2019, , 209-232.		3

#	ARTICLE	IF	CITATIONS
4859	Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. <i>NeuroImage: Clinical</i> , 2019, 22, 101720.	1.4	34
4860	Automated Subfield Volumetric Analysis of Hippocampus in Patients with Drug-Naïve Nondementia Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-5.	0.6	2
4861	Heritability in frontotemporal tauopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	1.2	17
4862	Nucleic Acid-Based Therapeutics for Parkinson's Disease. <i>Neurotherapeutics</i> , 2019, 16, 287-298.	2.1	45
4863	Parkinson's disease: Is it a consequence of human brain evolution?. <i>Movement Disorders</i> , 2019, 34, 453-459.	2.2	37
4864	Transmission of α -synuclein seeds in neurodegenerative disease: recent developments. <i>Laboratory Investigation</i> , 2019, 99, 971-981.	1.7	74
4865	Effects of α -Synuclein Monomers Administration in the Gigantocellular Reticular Nucleus on Neurotransmission in Mouse Model. <i>Neurochemical Research</i> , 2019, 44, 968-977.	1.6	1
4866	10 Parkinson Disease Evaluation and Medical Treatment. , 2019, , .		0
4868	The gut-brain axis in the pathogenesis of Parkinson's disease. <i>Brain Science Advances</i> , 2019, 5, 73-81.	0.3	10
4869	Diabetes Mellitus and Amyloid Beta Protein Pathology in Dementia. , 0, , .		2
4870	The Pharmacology of Visual Hallucinations in Synucleinopathies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1379.	1.6	36
4871	Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, , .	1.2	29
4872	Alpha-synuclein as therapeutic target in Parkinson's disease. <i>Neuroforum</i> , 2019, 25, 129-136.	0.2	6
4873	Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?. <i>Annals of Translational Medicine</i> , 2019, 7, S351-S351.	0.7	1
4874	Reduced central sympathetic activity in Parkinson's disease. <i>Brain and Behavior</i> , 2019, 9, e01463.	1.0	17
4875	Cingulate cortex in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 166, 253-266.	1.0	34
4876	Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1294.	1.6	28
4877	α -Synuclein in blood cells differentiates Parkinson's disease from healthy controls. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2426-2436.	1.7	23

#	ARTICLE	IF	CITATIONS
4878	Autonomic dysfunction: Diagnosis and management. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 123-137.	1.0	23
4879	Parkinson's disease: Diagnosis and appreciation of comorbidities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 257-277.	1.0	7
4880	Oscillation-specific nodal alterations in early to middle stages Parkinson's disease. Translational Neurodegeneration, 2019, 8, 36.	3.6	11
4881	Î±-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb. Acta Neuropathologica Communications, 2019, 7, 221.	2.4	70
4882	Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behavioural Pharmacology, 2019, 30, 641-651.	0.8	31
4883	Editorial: Non-motor Symptoms in Primary Motor Neurological Disorders: From Molecular Pathways to Clinical and Therapeutic Implications. Frontiers in Neuroscience, 2019, 13, 1296.	1.4	1
4884	Sleep Disorders in Rodent Models of Parkinson's Disease. Frontiers in Pharmacology, 2019, 10, 1414.	1.6	29
4886	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTD cases. Acta Neuropathologica Communications, 2019, 7, 189.	2.4	22
4887	In Vivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	2.9	26
4888	A longitudinal fixel-based analysis of white matter alterations in patients with Parkinson's disease. NeuroImage: Clinical, 2019, 24, 102098.	1.4	35
4889	Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. PLoS Biology, 2019, 17, e3000495.	2.6	79
4890	Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of Î±-Synuclein Protect Against Diverse Î±-Synuclein Mediated Dysfunctions. Scientific Reports, 2019, 9, 16947.	1.6	25
4891	Decreased Striatal Vesicular Monoamine Transporter Type 2 Correlates With the Nonmotor Symptoms in Parkinson Disease. Clinical Nuclear Medicine, 2019, 44, 707-713.	0.7	16
4892	Development of a Joint Commission Disease-Specific Care Certification Program for Parkinson Disease in an Acute Care Hospital. Journal of Neuroscience Nursing, 2019, 51, 313-319.	0.7	12
4893	Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review. Cognitive and Behavioral Neurology, 2019, 32, 179-184.	0.5	5
4894	Diffusion Kurtosis Imaging for Detection of Early Brain Changes in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1285.	1.1	17
4895	Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity. Frontiers in Neurology, 2019, 10, 1329.	1.1	11
4896	Dysregulated Long Non-coding RNAs in Parkinson's Disease Contribute to the Apoptosis of Human Neuroblastoma Cells. Frontiers in Neuroscience, 2019, 13, 1320.	1.4	43

#	ARTICLE	IF	CITATIONS
4897	Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 299.	1.4	215
4898	Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. <i>Acta Neuropathologica Communications</i> , 2019, 7, 213.	2.4	45
4899	Pain in Parkinson's disease: new concepts in pathogenesis and treatment. <i>Current Opinion in Neurology</i> , 2019, 32, 579-588.	1.8	61
4900	Luminescent conjugated oligothiophenes distinguish between α -synuclein assemblies of Parkinson's disease and multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 193.	2.4	35
4901	Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. <i>Scientific Reports</i> , 2019, 9, 18950.	1.6	17
4902	α -Synuclein oligomers mediate the aberrant form of spike-induced calcium release from IP3 receptor. <i>Scientific Reports</i> , 2019, 9, 15977.	1.6	8
4903	Boxing for Parkinson's Disease: Has Implementation Accelerated Beyond Current Evidence?. <i>Frontiers in Neurology</i> , 2019, 10, 1222.	1.1	33
4904	Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2019, 44, 855-859.	0.7	8
4905	ZPD-2, a Small Compound That Inhibits α -Synuclein Amyloid Aggregation and Its Seeded Polymerization. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 306.	1.4	32
4906	REM Sleep Behavior Disorder Associated with Parkinson's Disease and Multiple System Atrophy. , 2019, , 53-65.		2
4907	Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α -synuclein levels. <i>Neurobiology of Disease</i> , 2019, 121, 205-213.	2.1	43
4908	Accelerated accumulation of retinal α -synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 121, 1-16.	2.1	41
4909	Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 777-782.	1.7	37
4910	Early ophthalmologic features of Parkinson's disease: a review of preceding clinical and diagnostic markers. <i>Journal of Neurology</i> , 2019, 266, 2103-2111.	1.8	20
4911	The importance of preclinical diagnostics in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 20-28.	1.1	37
4912	Swallowing in Parkinson's disease: How is it affected?. <i>Clinical Neurology and Neurosurgery</i> , 2019, 177, 37-41.	0.6	18
4913	Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 973-990.	1.7	39
4914	Polysomnographic data in Dementia with Lewy Bodies: correlation with clinical symptoms and comparison with other α -synucleinopathies. <i>Sleep Medicine</i> , 2019, 55, 62-68.	0.8	20

#	ARTICLE	IF	CITATIONS
4915	Bottoms up: the role of gut microbiota in brain health. <i>Environmental Microbiology</i> , 2019, 21, 3197-3211.	1.8	17
4916	Dementia with Lewy bodies " from scientific knowledge to clinical insights. <i>Nature Reviews Neurology</i> , 2019, 15, 103-112.	4.9	49
4917	Genetically engineered animal models of Parkinson's disease: From worm to rodent. <i>European Journal of Neuroscience</i> , 2019, 49, 533-560.	1.2	27
4918	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	1.8	28
4919	Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 480-496.	4.3	117
4920	Prediagnostic markers of idiopathic Parkinson's disease: Gait, visuospatial ability and executive function. <i>Gait and Posture</i> , 2019, 68, 500-505.	0.6	15
4921	The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. <i>International Immunopharmacology</i> , 2019, 67, 458-464.	1.7	294
4922	Functional MRI in Parkinson's Disease Cognitive Impairment. <i>International Review of Neurobiology</i> , 2019, 144, 29-58.	0.9	13
4923	Molecular Imaging of Dementia With Lewy Bodies. <i>International Review of Neurobiology</i> , 2019, 144, 59-93.	0.9	10
4924	Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. <i>Acta Neuropathologica</i> , 2019, 137, 585-598.	3.9	95
4925	Effect of istradefylline on mood disorders in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 396, 78-83.	0.3	35
4926	Iron-related nigral degeneration influences functional topology mediated by striatal dysfunction in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 75, 83-97.	1.5	35
4927	Parkinson's disease and multiple system atrophy have distinct α -synuclein seed characteristics. <i>Journal of Biological Chemistry</i> , 2019, 294, 1045-1058.	1.6	141
4928	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 397-416.	2.1	34
4929	The prodromes of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 320-327.	1.2	30
4930	Parkinson's disease: Evolution of the scientific literature from 1983 to 2017 by countries and journals. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 10-18.	1.1	17
4931	Can the gut be the missing piece in uncovering PD pathogenesis?. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 26-31.	1.1	42
4932	Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2019, 29, 383-396.	1.6	17

#	ARTICLE	IF	CITATIONS
4933	Association of SNCA variants with α -synuclein of gastric and colonic mucosa in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 151-155.	1.1	10
4934	The role of dopamine in the brain - lessons learned from Parkinson's disease. <i>NeuroImage</i> , 2019, 190, 79-93.	2.1	123
4935	Review: PrP 106 Δ 126 Δ 25 years after. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 430-440.	1.8	19
4936	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 263-289.	4.2	80
4937	Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 377-396.	1.4	26
4938	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 141.	1.8	52
4939	Gut-brain axis and the spread of α -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	2.2	144
4940	The α -great-controlling nucleotide coenzymes. <i>IUBMB Life</i> , 2019, 71, 565-579.	1.5	40
4941	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 470.	4.5	205
4942	The usual suspects, dopamine and α -synuclein, conspire to cause neurodegeneration. <i>Movement Disorders</i> , 2019, 34, 167-179.	2.2	62
4943	Gut microbiota in neurodegenerative disorders. <i>Journal of Neuroimmunology</i> , 2019, 328, 98-104.	1.1	220
4944	Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism. <i>Brain Research Bulletin</i> , 2019, 146, 213-223.	1.4	10
4945	Radiotracers for imaging of Parkinson's disease. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 75-89.	2.6	24
4946	Propagation of α -Synuclein Strains within Human Reconstructed Neuronal Network. <i>Stem Cell Reports</i> , 2019, 12, 230-244.	2.3	99
4947	Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells. <i>Stem Cells</i> , 2019, 8, 26.	1.8	82
4948	Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings. <i>International Review of Neurobiology</i> , 2019, 144, 1-28.	0.9	24
4949	Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. <i>Trends in Neurosciences</i> , 2019, 42, 4-13.	4.2	216
4950	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.	0.8	17

#	ARTICLE	IF	CITATIONS
4951	InÂvivo visualization of age-related differences in the locus coeruleus. <i>Neurobiology of Aging</i> , 2019, 74, 101-111.	1.5	117
4952	The hidden side of Parkinsonâ€™s disease: Studying pain, anxiety and depression in animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 335-352.	2.9	42
4953	Cellular and Molecular Mechanisms of Prion Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 497-516.	9.6	83
4954	IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?. <i>Journal of Autoimmunity</i> , 2019, 96, 14-23.	3.0	31
4955	A Proposed Roadmap for Parkinsonâ€™s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	1.5	45
4956	Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. <i>Brain, Behavior, and Immunity</i> , 2019, 76, 61-73.	2.0	32
4957	Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder. <i>Experimental Neurology</i> , 2019, 311, 265-273.	2.0	8
4958	Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease. <i>Neurological Sciences</i> , 2019, 40, 283-291.	0.9	15
4959	A physics-based model explains the prion-like features of neurodegeneration in Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis. <i>Journal of the Mechanics and Physics of Solids</i> , 2019, 124, 264-281.	2.3	83
4960	Development of an aggregate-selective, human-derived Î±-synuclein antibody B1B054 that ameliorates disease phenotypes in Parkinson's disease models. <i>Neurobiology of Disease</i> , 2019, 124, 276-288.	2.1	125
4961	Neurological effects of glucocerebrosidase gene mutations. <i>European Journal of Neurology</i> , 2019, 26, 388.	1.7	30
4962	REM sleep behavior disorder in patients with Parkinsonâ€™s disease: clinical and polysomnographic characteristics. <i>Sleep and Biological Rhythms</i> , 2019, 17, 113-122.	0.5	5
4963	Iron quantification in Parkinson's disease using an age-based threshold on susceptibility maps: The advantage of local versus entire structure iron content measurements. <i>Magnetic Resonance Imaging</i> , 2019, 55, 145-152.	1.0	18
4964	Episodic recognition memory and the hippocampus in Parkinson's disease: A review. <i>Cortex</i> , 2019, 113, 191-209.	1.1	72
4965	Non-motor predictors of freezing of gait in Parkinsonâ€™s disease. <i>Gait and Posture</i> , 2019, 68, 311-316.	0.6	41
4966	Dopamin, oxidativer Stress und Proteinâ€Chinonmodifikationen bei Parkinson und anderen neurodegenerativen Erkrankungen. <i>Angewandte Chemie</i> , 2019, 131, 6580-6596.	1.6	7
4967	Dopamine, Oxidative Stress and Proteinâ€Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 6512-6527.	7.2	160
4968	Reduced lateral occipital gray matter volume is associated with physical frailty and cognitive impairment in Parkinsonâ€™s disease. <i>European Radiology</i> , 2019, 29, 2659-2668.	2.3	33

#	ARTICLE	IF	CITATIONS
4969	Marmosets in Neurologic Disease Research. , 2019, , 415-435.		1
4970	The Prion Diseases. , 2019, , 123-155.		0
4971	Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology, 2019, 92, e148-e160.	1.5	56
4972	Emerging Immunotherapies for Parkinson Disease. Neurology and Therapy, 2019, 8, 29-44.	1.4	49
4973	Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease. Movement Disorders, 2019, 34, 516-525.	2.2	42
4974	FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis. NeuroImage: Clinical, 2019, 21, 101594.	1.4	53
4975	Functional Effects of a Neuromelanin Analogue on Dopaminergic Neurons in 3D Cell Culture. ACS Biomaterials Science and Engineering, 2019, 5, 308-317.	2.6	5
4976	Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study. Movement Disorders, 2019, 34, 138-141.	2.2	19
4977	Incidence of Parkinson's disease in a large patient cohort with idiopathic smell and taste loss. Journal of Neurology, 2019, 266, 339-345.	1.8	68
4978	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. Brain Pathology, 2019, 29, 414-424.	2.1	24
4980	The Role of Neuroinflammation in Neurodegenerative Disorders. , 2019, , 241-267.		7
4981	Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder. International Review of Neurobiology, 2019, 144, 185-210.	0.9	23
4982	Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease. Cerebellum, 2019, 18, 212-224.	1.4	16
4983	Selective Polysomnographic Findings in REM Sleep Behavior Disorder (RBD) and Parkinson's Disease. , 2019, , 271-279.		1
4984	REM Sleep Behavior Disorder Associated with Dementia with Lewy Bodies. , 2019, , 67-76.		2
4985	Biomarkers of Neurodegenerative Disease in Idiopathic RBD. , 2019, , 527-540.		0
4986	The PPARGC1A locus and CNS-specific PGC-1 β isoforms are associated with Parkinson's Disease. Neurobiology of Disease, 2019, 121, 34-46.	2.1	23
4987	Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling. Neurobiology of Aging, 2019, 73, 123-134.	1.5	48

#	ARTICLE	IF	CITATIONS
4988	Stimulation of the subparafascicular thalamic nucleus modulates dopamine release in the inferior colliculus of rats. <i>Synapse</i> , 2019, 73, e22073.	0.6	11
4989	Gene Dysfunction Mediates Immune Response to Dopaminergic Degeneration in Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 803-811.	1.7	7
4990	Brain Imaging in RBD. , 2019, , 403-445.		3
4991	Alpha Synuclein and Parkinson's Disease. , 2019, , 1-14.		3
4992	Increased Cholinergic Response in α -Synuclein Transgenic Mice (h α -synL62). <i>ACS Chemical Neuroscience</i> , 2019, 10, 1915-1922.	1.7	11
4994	Molecular Mechanisms of Neurodegeneration: Insights from the Studies of Genetic Model of Parkinson's Disease. , 2019, , 15-29.		0
4995	Pathology and Cell-Based Therapy of Parkinson's Disease. , 2019, , 31-38.		0
4996	Therapeutic Application of Stem Cell and Gene Therapy in Parkinson's Disease. , 2019, , 159-171.		2
4997	Application of N-Acetylcysteine in Neurological Disorders. , 2019, , 181-202.		0
4998	Mechanistic Insights into Neurodegenerative Diseases: The Potential for the Development of Novel Therapeutics. , 2019, , 225-240.		0
4999	Neural correlates of emotional valence processing in Parkinson's disease: dysfunction in the subcortex. <i>Brain Imaging and Behavior</i> , 2019, 13, 189-199.	1.1	12
5000	Exploring white matter microstructure and olfaction dysfunction in early parkinson disease: diffusion MRI reveals new insight. <i>Brain Imaging and Behavior</i> , 2019, 13, 210-219.	1.1	27
5001	White Matter Changes Correlates of Peripheral Neuroinflammation in Patients with Parkinson's Disease. <i>Neuroscience</i> , 2019, 403, 70-78.	1.1	26
5002	Neurophysiology of the pedunculopontine tegmental nucleus. <i>Neurobiology of Disease</i> , 2019, 128, 19-30.	2.1	26
5003	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 1450-1499.	2.5	90
5004	Enteric Pathologic Manifestations of Alpha-Synucleinopathies. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 543-548.	0.6	10
5005	Quantitative susceptibility mapping as a biomarker for evaluating white matter alterations in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2019, 13, 220-231.	1.1	30
5006	A neuroscience perspective of the gut theory of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 817-823.	1.2	16

#	ARTICLE	IF	CITATIONS
5007	Semi-Supervised Discriminative Classification Robust to Sample-Outliers and Feature-Noises. <i>IEEE Transactions on Pattern Analysis and Machine Intelligence</i> , 2019, 41, 515-522.	9.7	71
5008	The Effect of Parkinson Disease Tremor Phenotype on Cepstral Peak Prominence and Transglottal Airflow in Vowels and Speech. <i>Journal of Voice</i> , 2019, 33, 580.e11-580.e19.	0.6	24
5009	Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients. <i>Brain Imaging and Behavior</i> , 2019, 13, 232-240.	1.1	24
5010	A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging. <i>NeuroImage</i> , 2019, 190, 69-78.	2.1	66
5011	Spinal cord involvement in Lewy body-related α -synucleinopathies. <i>Journal of Spinal Cord Medicine</i> , 2020, 43, 832-845.	0.7	14
5012	Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 552-562.	2.4	33
5013	CCAAT/enhancer binding protein β is a transcriptional repressor of α -synuclein. <i>Cell Death and Differentiation</i> , 2020, 27, 509-524.	5.0	14
5014	Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 170-175.	1.1	25
5015	Variability and Coupling of Olfactory Identification and Episodic Memory in Older Adults. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2020, 75, 577-584.	2.4	7
5016	The Role of Sex and Sex Hormones in Neurodegenerative Diseases. <i>Endocrine Reviews</i> , 2020, 41, 273-319.	8.9	118
5017	Evidence of corticofugal tau spreading in patients with frontotemporal dementia. <i>Acta Neuropathologica</i> , 2020, 139, 27-43.	3.9	29
5018	Lack of association between appendectomy and Parkinson's disease: a systematic review and meta-analysis. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 2201-2209.	1.4	13
5019	Early-onset Parkinsonian behaviors in female <i>Pink1</i> ^{-/-} rats. <i>Behavioural Brain Research</i> , 2020, 377, 112175.	1.2	24
5020	The noradrenergic system is necessary for survival of vulnerable midbrain dopaminergic neurons: implications for development and Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 85, 22-37.	1.5	21
5021	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 483-498.	2.8	30
5022	Intervening Effects of Orthostatic Blood Pressure Change on Subcortical Atrophy and Cognition in De Novo and Drug-Naïve Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 153-160.	1.5	6
5023	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. <i>Brain</i> , 2020, 143, 31-46.	3.7	53
5024	Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation. <i>Neurobiology of Disease</i> , 2020, 134, 104623.	2.1	57

#	ARTICLE	IF	CITATIONS
5025	Understanding the Links Between Cardiovascular Disease and Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 55-74.	2.2	71
5026	Pricing Vulnerable Options with Stochastic Volatility and Stochastic Interest Rate. <i>Computational Economics</i> , 2020, 56, 391-429.	1.5	14
5027	The interplay between aging-associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. <i>Journal of Neuroscience Research</i> , 2020, 98, 262-283.	1.3	21
5028	Radiopharmaceuticals. , 2020, , .		3
5029	A single intranigral administration of $\hat{1}^2$ -sitosterol $\hat{1}^2$ -d-glucoside elicits bilateral sensorimotor and non-motor alterations in the rat. <i>Behavioural Brain Research</i> , 2020, 378, 112279.	1.2	12
5030	Protective role of cinnabar and realgar in Hua-Feng-Dan against LPS plus rotenone-induced neurotoxicity and disturbance of gut microbiota in rats. <i>Journal of Ethnopharmacology</i> , 2020, 247, 112299.	2.0	28
5031	The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 96, 109745.	2.5	21
5032	Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. <i>Molecular Psychiatry</i> , 2020, 25, 254-274.	4.1	78
5033	Diffusion Kurtosis Imaging as a Tool in Neurotoxicology. <i>Neurotoxicity Research</i> , 2020, 37, 41-47.	1.3	3
5034	Open questions on the nature of Parkinson's disease: from triggers to spreading pathology. <i>Journal of Medical Genetics</i> , 2020, 57, 73-81.	1.5	17
5035	Cell Death and Neurodegeneration. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036434.	2.3	60
5036	Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort. <i>Journal of Neurology</i> , 2020, 267, 513-521.	1.8	3
5037	Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease. <i>Medical Hypotheses</i> , 2020, 134, 109436.	0.8	26
5038	Heterogeneity of dopamine release sites in health and degeneration. <i>Neurobiology of Disease</i> , 2020, 134, 104633.	2.1	15
5039	The apparent mechanical effect of isolated amyloid β and $\hat{1}$ -synuclein aggregates revealed by multi-frequency MRE. <i>NMR in Biomedicine</i> , 2020, 33, e4174.	1.6	12
5040	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. <i>Movement Disorders</i> , 2020, 35, 5-19.	2.2	60
5041	Abnormal intrinsic brain activity of the putamen is correlated with dopamine deficiency in idiopathic rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2020, 75, 73-80.	0.8	14
5042	Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys. <i>Neurobiology of Disease</i> , 2020, 134, 104643.	2.1	7

#	ARTICLE	IF	CITATIONS
5043	Evaluation of white matter microstructure in patients with Parkinson's disease using microscopic fractional anisotropy. <i>Neuroradiology</i> , 2020, 62, 197-203.	1.1	7
5044	Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review. <i>European Journal of Neurology</i> , 2020, 27, 229-234.	1.7	35
5045	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. <i>Journal of Sleep Research</i> , 2020, 29, e12939.	1.7	19
5046	Nigral overexpression of α -synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13726.	1.6	61
5047	Cognitive and motor effects of Kinect-based games training in people with and without Parkinson disease: A preliminary study. <i>Physiotherapy Research International</i> , 2020, 25, e1807.	0.7	17
5048	Electrochemical deduction of levodopa by utilizing modified electrodes: A review. <i>Microchemical Journal</i> , 2020, 152, 104287.	2.3	8
5049	Parkinson disease. <i>European Journal of Neurology</i> , 2020, 27, 27-42.	1.7	757
5050	Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. <i>Neuropathology</i> , 2020, 40, 30-39.	0.7	43
5051	Locus coeruleus neurons are most sensitive to chronic neuroinflammation-induced neurodegeneration. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 359-368.	2.0	33
5052	La maladie de Parkinson est aussi une maladie du tube digestif. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, 66-71.	0.0	0
5053	Dysbiosis in Parkinson's disease might be triggered by certain antibiotics. <i>Medical Hypotheses</i> , 2020, 137, 109564.	0.8	24
5054	Parkinson's disease: proteinopathy or lipidopathy?. <i>Npj Parkinson's Disease</i> , 2020, 6, 3.	2.5	138
5055	A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α -synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α -synuclein research. <i>Journal of Neurochemistry</i> , 2020, 153, 103-119.	2.1	44
5056	<i>In situ</i> derivatization of Au nanoclusters via aurophilic interactions of a triphenylphosphine gold($\text{Au}(\text{PPh}_3)_3$) salt with neurotransmitters and their rapid MALDI-TOF-MS detection in mice brain tissue extracts. <i>Journal of Materials Chemistry B</i> , 2020, 8, 38-44.	2.9	7
5057	Low thalamic monoamine transporter availability is related to excessive daytime sleepiness in early Parkinson's disease. <i>Neurological Sciences</i> , 2020, 41, 1081-1087.	0.9	7
5058	To stage, or not to stage. <i>Current Opinion in Neurobiology</i> , 2020, 61, 10-22.	2.0	37
5059	Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson's disease. <i>Drug Discovery Today</i> , 2020, 25, 392-405.	3.2	7
5060	Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta. <i>Neurobiology of Aging</i> , 2020, 87, 89-97.	1.5	31

#	ARTICLE	IF	CITATIONS
5061	Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α -Synuclein Insult. <i>Neuron</i> , 2020, 105, 822-836.e7.	3.8	89
5062	Non-motor symptoms depending on motor severity in Japanese patients with Parkinson's disease: A multicenter cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116641.	0.3	4
5063	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 1-12.	1.0	487
5064	Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2020, 35, 161-170.	2.2	31
5065	Tin disulfide nanorod-graphene- β -cyclodextrin nanocomposites for sensing dopamine in rat brains and human blood serum. <i>Materials Science and Engineering C</i> , 2020, 108, 110367.	3.8	31
5066	Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease" Parkinsonism and Related Disorders, 2020, 74, 78-79.	1.1	3
5067	Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 119-130.	1.0	38
5068	The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAcHt in the brain of nonhuman primates. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105152.	1.9	4
5069	The future of stem cell therapies for Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2020, 21, 103-115.	4.9	178
5070	Longitudinal volume changes of hippocampal subfields and cognitive decline in Parkinson's disease. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 220-232.	1.1	26
5071	Sleep Health: An Opportunity for Public Health to Address Health Equity. <i>Annual Review of Public Health</i> , 2020, 41, 81-99.	7.6	168
5072	Preserved Serotonergic Activity in Early-Onset Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 344-349.	0.3	8
5073	Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α -synuclein inclusions. <i>Neurobiology of Disease</i> , 2020, 134, 104708.	2.1	47
5074	Characterization of novel conformation-selective α -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
5075	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 619-632.	1.2	6
5076	Excessive daytime sleepiness is associated to the development of swallowing impairment in a cohort of early stage drug-naïve Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116626.	0.3	15
5077	Innate and adaptive immune responses in Parkinson's disease. <i>Progress in Brain Research</i> , 2020, 252, 169-216.	0.9	64
5078	Human subiculo-fornico-mamillary system in Alzheimer's disease: Tau seeding by the pillar of the fornix. <i>Acta Neuropathologica</i> , 2020, 139, 443-461.	3.9	10

#	ARTICLE	IF	CITATIONS
5079	Systemic disorders that affect gastrointestinal motility. , 2020, , 601-618.		3
5080	Sodium butyrate causes α -synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. <i>Experimental Cell Research</i> , 2020, 387, 111772.	1.2	62
5081	The Neuropsychological Profile of Mild Cognitive Impairment in Lewy Body Dementias. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 210-225.	1.2	15
5082	MR Biomarkers of Degenerative Brain Disorders Derived From Diffusion Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1620-1636.	1.9	75
5083	Initiation of Parkinson's disease from gut to brain by α -secretase. <i>Cell Research</i> , 2020, 30, 70-87.	5.7	69
5084	Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease. <i>Acta Neuropathologica</i> , 2020, 139, 319-345.	3.9	17
5085	Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?. <i>Human Brain Mapping</i> , 2020, 41, 1416-1434.	1.9	28
5086	Limited spread of pathology within the brainstem of α -synuclein BAC transgenic mice inoculated with preformed fibrils into the gastrointestinal tract. <i>Neuroscience Letters</i> , 2020, 716, 134651.	1.0	25
5087	Twice subacute MPTP administrations induced time-dependent dopaminergic neurodegeneration and inflammation in midbrain and ileum, as well as gut microbiota disorders in PD mice. <i>NeuroToxicology</i> , 2020, 76, 200-212.	1.4	23
5088	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. <i>Neurology</i> , 2020, 94, e15-e29.	1.5	25
5089	Nigrostriatal Degeneration in the Cognitive Part of the Striatum in Parkinson Disease Is Associated With Frontomedial Hypometabolism. <i>Clinical Nuclear Medicine</i> , 2020, 45, 95-99.	0.7	12
5090	Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 522-545.	1.8	72
5091	Neural Correlates of Cognitive Performance in Alzheimer's Disease- and Lewy Bodies-Related Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 873-885.	1.2	4
5092	Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 77-88.	1.5	20
5093	Novel self-replicating α -synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons. <i>Science Advances</i> , 2020, 6, .	4.7	49
5094	Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 979.	1.1	12
5095	Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic. <i>Frontiers in Neurology</i> , 2020, 11, 995.	1.1	5
5096	Changes in Gastrointestinal Microbiome Composition in PD: A Pivotal Role of Covariates. <i>Frontiers in Neurology</i> , 2020, 11, 1041.	1.1	23

#	ARTICLE	IF	CITATIONS
5097	Detection of Phosphorylated Alpha-Synuclein in the Muscularis Propria of the Gastrointestinal Tract Is a Sensitive Predictor for Parkinson's Disease. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	5
5098	Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients – A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 573696.	1.8	43
5099	Cortical thinning pattern according to differential nigrosome involvement in patients with Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102382.	1.4	2
5100	Olfactory bulb surroundings can help to distinguish Parkinson's disease from non-parkinsonian olfactory dysfunction. <i>NeuroImage: Clinical</i> , 2020, 28, 102457.	1.4	15
5101	Classic and evolving animal models in Parkinson's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173060.	1.3	19
5102	Imbalance of Circulating Tfh/Tfr Cells in Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 572205.	1.1	9
5103	Diagnostic Ability of Radiofrequency Ultrasound in Parkinson's Disease Compared to Conventional Transcranial Sonography and Magnetic Resonance Imaging. <i>Diagnostics</i> , 2020, 10, 778.	1.3	0
5104	The prion-like nature of amyotrophic lateral sclerosis. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 175, 261-296.	0.9	14
5105	Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa098.	1.5	9
5106	Novel dominant MPAN family with a complex genetic architecture as a basis for phenotypic variability. <i>Neurology: Genetics</i> , 2020, 6, e515.	0.9	9
5107	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	2.2	7
5108	Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2225-2234.	1.4	3
5109	VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. <i>Neurobiology of Disease</i> , 2020, 145, 105056.	2.1	19
5110	Is there a close association of depression with either constipation or dysosmia in Parkinson's disease?. <i>Scientific Reports</i> , 2020, 10, 15476.	1.6	11
5111	Huntingtin Aggregates in the Olfactory Bulb in Huntington's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 261.	1.7	16
5112	CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 4885.	5.8	39
5113	Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation. <i>Seminars in Immunopathology</i> , 2020, 42, 681-696.	2.8	9
5114	Increased conceptual switching by dopaminergic treatment in patients with Parkinson's disease. <i>Brain and Cognition</i> , 2020, 144, 105611.	0.8	5

#	ARTICLE	IF	CITATIONS
5115	Potential therapeutic role of fibroblast growth factor 21 in neurodegeneration: Evidence for ameliorating parkinsonism via silent information regulator 2 homolog 1 and implication for gene therapy. <i>Neuropharmacology</i> , 2020, 181, 108335.	2.0	6
5116	Sensory Neuropathy in Parkinson Disease: Electrodiagnostic Evaluation. <i>Neurodiagnostic Journal</i> , the, 2020, 60, 177-184.	0.1	5
5117	Molecular Chaperones: A Double-Edged Sword in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 581374.	1.7	58
5118	Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review. <i>Frontiers in Neurology</i> , 2020, 11, 531993.	1.1	43
5119	From Synaptic Protein to Prion: The Long and Controversial Journey of α -Synuclein. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 584536.	1.3	20
5120	L-Theanine: Neuroprotective against Trichloroethylene-induced Parkinsons disease hallmarks. <i>Journal of Toxicology and Environmental Health Sciences</i> , 2020, 12, 36-45.	0.6	1
5121	α -Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. <i>Redox Biology</i> , 2020, 37, 101695.	3.9	26
5122	Gray matter atrophy patterns within the cerebellum-neostriatum-cortical network in SCA3. <i>Neurology</i> , 2020, 95, e3036-e3044.	1.5	21
5123	Histone Deacetylase 6 and the Disease Mechanisms of α -Synucleinopathies. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 586453.	1.3	17
5124	Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 146, 105134.	2.1	18
5125	Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients. <i>Methods and Protocols</i> , 2020, 3, 66.	0.9	19
5126	Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110788.	2.5	11
5127	Respiratory dysfunction in Parkinson's disease: a narrative review. <i>ERJ Open Research</i> , 2020, 6, 00165-2020.	1.1	17
5128	Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. <i>Acta Neuropathologica</i> , 2020, 140, 831-849.	3.9	37
5129	Quadruple abnormal protein aggregates in brainstem pathology and exogenous metal-rich magnetic nanoparticles (and engineered Ti-rich nanorods). The substantia nigrae is a very early target in young urbanites and the gastrointestinal tract a key brainstem portal. <i>Environmental Research</i> , 2020, 191, 110139.	3.7	50
5130	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 213-218.	1.1	8
5131	Mesenchymal stem cells modulate misfolded α -synuclein in parkinsonian disorders: A multitarget disease-modifying strategy. <i>Stem Cell Research</i> , 2020, 47, 101908.	0.3	10
5132	RestÅActivity Pattern Alterations in Idiopathic REM Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2020, 88, 817-829.	2.8	19

#	ARTICLE	IF	CITATIONS
5133	Electrocardiographic changes predate Parkinson's disease onset. <i>Scientific Reports</i> , 2020, 10, 11319.	1.6	16
5134	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 103.	2.4	10
5135	Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective. <i>Frontiers in Neurology</i> , 2020, 11, 595.	1.1	7
5136	Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system. <i>European Journal of Neurology</i> , 2020, 27, 2348-2360.	1.7	51
5137	Pattern of paresis in ALS is consistent with the physiology of the corticomotoneuronal projections to different muscle groups. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 991-998.	0.9	24
5138	Accelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC. <i>Advanced Science</i> , 2020, 7, 2001299.	5.6	47
5139	The unfolded protein response is activated in the olfactory system in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 109.	2.4	22
5140	Neurodegenerative disease-associated protein aggregates are poor inducers of the heat shock response in neuronal cells. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	6
5141	Classification of α -synuclein-induced changes in the AAV α -synuclein rat model of Parkinson's disease using electrophysiological measurements of visual processing. <i>Scientific Reports</i> , 2020, 10, 11869.	1.6	4
5142	IL-1 β /IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-synuclein pathology in the olfactory bulb, substantia nigra and striatum. <i>Brain Pathology</i> , 2020, 30, 1102-1118.	2.1	37
5143	Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 689.	1.1	4
5144	The Relationship between Side of Onset and Cerebral Regional Homogeneity in Parkinson's Disease: A Resting-State fMRI Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	5
5145	Distinct Effects of Motor Training on Resting-State Functional Networks of the Brain in Parkinson's Disease. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 795-803.	1.4	18
5146	α -Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome. <i>Science China Life Sciences</i> , 2020, 63, 1850-1859.	2.3	16
5147	Aberrant Fiber Coherence of Amygdala-Accumbens-Pallidum Pathway Is Associated With Disorganized Nigrostriatal-Nigropallidal Pathway in Parkinson's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1799-1808.	1.9	9
5148	Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson's disease. <i>Psychopharmacology</i> , 2020, 237, 3225-3236.	1.5	13
5149	The cerebral blood flow deficits in Parkinson's disease with mild cognitive impairment using arterial spin labeling MRI. <i>Journal of Neural Transmission</i> , 2020, 127, 1285-1294.	1.4	16
5150	Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 598446.	1.8	18

#	ARTICLE	IF	CITATIONS
5151	Neurodegenerative Disorders of Speech and Language: Non-language-dominant Diseases. , 2022, , 66-80.		4
5152	Approach to Cognitive Impairment in Parkinson's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1495-1510.	2.1	29
5153	Improved functional and histochemical outcomes in L-DOPA plus tolcapone treated VMAT2-deficient mice. <i>Neuropharmacology</i> , 2020, 181, 108353.	2.0	1
5154	Extracellular Vesicles in Alzheimer's and Parkinson's Disease: Small Entities with Large Consequences. <i>Cells</i> , 2020, 9, 2485.	1.8	36
5155	Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8630.	1.8	32
5156	Longitudinal Macro/Microstructural Alterations of Different Callosal Subsections in Parkinson's Disease Using Connectivity-Based Parcellation. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 572086.	1.7	6
5157	Co-administration of TiO ₂ -nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury. <i>Progress in Brain Research</i> , 2020, 258, 101-155.	0.9	16
5158	Neuropsychiatric sequelae of Parkinson's disease: what every clinician needs to know. <i>BJ Psych Advances</i> , 2020, 26, 343-345.	0.5	0
5159	Optimized Electrode Placements for Non-invasive Electrical Stimulation of the Olfactory Bulb and Olfactory Mucosa. <i>Frontiers in Neuroscience</i> , 2020, 14, 581503.	1.4	6
5160	Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. <i>Translational Neurodegeneration</i> , 2020, 9, 42.	3.6	883
5161	Network Protein Interaction in Parkinson's Disease and Periodontitis Interplay: A Preliminary Bioinformatic Analysis. <i>Genes</i> , 2020, 11, 1385.	1.0	11
5162	Neuroprotective effects of natural cordycepin on LPS-induced Parkinson's disease through suppressing TLR4/NF- κ B/NLRP3-mediated pyroptosis. <i>Journal of Functional Foods</i> , 2020, 75, 104274.	1.6	9
5163	Parkinson's disease and translational research. <i>Translational Neurodegeneration</i> , 2020, 9, 43.	3.6	13
5164	Novel antibodies detect additional α -synuclein pathology in synucleinopathies: potential development for immunotherapy. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 159.	3.0	26
5165	Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?. <i>Movement Disorders</i> , 2020, 35, 1922-1932.	2.2	0
5167	Determinants of seeding and spreading of α -synuclein pathology in the brain. <i>Science Advances</i> , 2020, 6, .	4.7	61
5168	Brain White-Matter Degeneration Due to Aging and Parkinson Disease as Revealed by Double Diffusion Encoding. <i>Frontiers in Neuroscience</i> , 2020, 14, 584510.	1.4	18
5169	Association Between Amyloid Accumulation and Sleep in Patients With Idiopathic REM Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 547288.	1.1	6

#	ARTICLE	IF	CITATIONS
5170	Pathological Functions of LRRK2 in Parkinson's Disease. <i>Cells</i> , 2020, 9, 2565.	1.8	44
5171	Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease. <i>Cells</i> , 2020, 9, 2580.	1.8	16
5172	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9199.	1.8	35
5173	Pathological findings in a patient with alpha-synuclein p.A53T and familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 183-187.	1.1	6
5174	Propagated α -synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. <i>Brain</i> , 2020, 143, 3374-3392.	3.7	42
5175	Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish. <i>Neuroepidemiology</i> , 2020, 54, 392-397.	1.1	1
5176	Neurodegeneration and Inflammation: An Interesting Interplay in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8421.	1.8	160
5177	The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease in a nationwide cohort: A comparison to patients with cerebral infarction. <i>PLoS ONE</i> , 2020, 15, e0236728.	1.1	9
5178	Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1047-1064.	1.4	11
5179	Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1977-1986.	2.2	52
5180	Simultaneous structural and elemental nano-imaging of human brain tissue. <i>Chemical Science</i> , 2020, 11, 8919-8927.	3.7	12
5181	Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies. <i>Pharmacological Reports</i> , 2020, 72, 1195-1217.	1.5	38
5182	Glibenclamide modulates microglial function and attenuates $A\beta$ deposition in 5XFAD mice. <i>European Journal of Pharmacology</i> , 2020, 884, 173416.	1.7	9
5183	Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5030.	1.8	19
5184	The Role of Magnetic Resonance Imaging for the Diagnosis of Atypical Parkinsonism. <i>Frontiers in Neurology</i> , 2020, 11, 665.	1.1	22
5185	A Parkinson's disease CircRNA Resource reveals a link between circSLC8A1 and oxidative stress. <i>EMBO Molecular Medicine</i> , 2020, 12, e11942.	3.3	93
5186	Modeling α -Synucleinopathy in Organotypic Brain Slice Culture with Preformed α -Synuclein Amyloid Fibrils. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1397-1410.	1.5	6
5187	Glia Crosstalk in Neuroinflammatory Diseases. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 209.	1.8	87

#	ARTICLE	IF	CITATIONS
5188	LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models. <i>Frontiers in Neuroscience</i> , 2020, 14, 719.	1.4	13
5189	mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in Neurodegeneration. <i>Frontiers in Neuroscience</i> , 2020, 14, 775.	1.4	7
5190	The Neuropathological Diagnosis of Alzheimer's Disease—The Challenges of Pathological Mimics and Concomitant Pathology. <i>Brain Sciences</i> , 2020, 10, 479.	1.1	22
5191	Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 673-685.	8.2	116
5192	Attention-Guided Hybrid Network for Dementia Diagnosis With Structural MR Images. <i>IEEE Transactions on Cybernetics</i> , 2022, 52, 1992-2003.	6.2	43
5193	The Neuropathology of Chronic Traumatic Encephalopathy: The Status of the Literature. <i>Seminars in Neurology</i> , 2020, 40, 359-369.	0.5	49
5194	Vascular Inflammation Is a Risk Factor Associated with Brain Atrophy and Disease Severity in Parkinson's Disease: A Case-Control Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	1.9	20
5195	Effects of Subthalamic Nucleus Deep Brain Stimulation on Facial Emotion Recognition in Parkinson's Disease: A Critical Literature Review. <i>Behavioural Neurology</i> , 2020, 2020, 1-18.	1.1	9
5196	High β -Aminobutyric Acid Content Within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 2184-2192.	2.2	15
5197	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020, 10, 267.	2.4	30
5198	Differential protein expression in diverse brain areas of Parkinson's and Alzheimer's disease patients. <i>Scientific Reports</i> , 2020, 10, 13149.	1.6	38
5199	Where and how alpha-synuclein pathology spreads in Parkinson's disease. <i>Neuropathology</i> , 2020, 40, 415-425.	0.7	35
5200	Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences. <i>Psychogeriatrics</i> , 2020, 20, 737-745.	0.6	31
5201	Role of Prefrontal Cortex on Recognition Memory Deficits in Rats following 6-OHDA-Induced Locus Coeruleus Lesion. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-10.	1.9	6
5202	Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson's disease. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 196, 111302.	2.5	18
5203	Effects of pharmacological modulators of α -synuclein and tau aggregation and internalization. <i>Scientific Reports</i> , 2020, 10, 12827.	1.6	29
5204	α -Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?. <i>Neuroscientist</i> , 2021, 27, 107385842094318.	2.6	5
5205	A glycomics and proteomics study of aging and Parkinson's disease in human brain. <i>Scientific Reports</i> , 2020, 10, 12804.	1.6	37

#	ARTICLE	IF	CITATIONS
5206	Expanding the brain researcher's toolkit. <i>Science</i> , 2020, 369, 637-637.	6.0	7
5207	Polymannuronic acid prevents dopaminergic neuronal loss via brain-gut-microbiota axis in Parkinson's disease model. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 994-1005.	3.6	34
5208	Cortical thickness in Parkinson disease. <i>Medicine (United States)</i> , 2020, 99, e21403.	0.4	5
5209	Late-life falling and depressive symptoms associated with the risk of Parkinson's disease: a nationwide cohort data analysis. <i>BMC Geriatrics</i> , 2020, 20, 284.	1.1	3
5210	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 230.	1.7	18
5211	NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin. <i>Neuroscience</i> , 2020, 446, 323-334.	1.1	48
5212	Molecular Mediation of Prion-like α -Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. <i>ACS Applied Bio Materials</i> , 2020, 3, 6096-6102.	2.3	8
5214	NODDI in clinical research. <i>Journal of Neuroscience Methods</i> , 2020, 346, 108908.	1.3	120
5215	Gut Microbiota Approach—A New Strategy to Treat Parkinson's Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 570658.	1.8	24
5216	Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes. <i>Frontiers in Neuroscience</i> , 2020, 14, 567129.	1.4	31
5217	Chronic pesticides exposure on the farmers in Tanjung Wangi Village: Focus on Alpha-Synuclein as a Biomarker of Parkinson-sporadic. <i>Journal of Physics: Conference Series</i> , 2020, 1469, 012180.	0.3	1
5218	FGF2 Affects Parkinson's Disease-Associated Molecular Networks Through Exosomal Rab8b/Rab31. <i>Frontiers in Genetics</i> , 2020, 11, 572058.	1.1	12
5219	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 89-93.	1.1	14
5220	Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7670.	1.8	39
5221	Part Two: Extracellular Vesicles as a Risk Factor in Neurodegenerative Diseases. , 2020, , .		0
5222	Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. <i>Biomarker Insights</i> , 2020, 15, 117727192096407.	1.0	7
5223	Loss of Olfactory Function—Early Indicator for Covid-19, Other Viral Infections and Neurodegenerative Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 569333.	1.1	42
5224	Predictors of Conversion to α -Synucleinopathy Diseases in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1443-1455.	1.5	15

#	ARTICLE	IF	CITATIONS
5225	From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 557928.	1.1	5
5226	Predictors of fatigue severity in early, de novo Parkinson disease patients: A 1-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 3-8.	1.1	11
5227	Impaired cortical beta-band modulation presages innovation of neuromodulation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2020, 131, 2484-2485.	0.7	0
5228	Brain Morphological Alterations Are Detected in Early-Stage Parkinson's Disease with MRI Morphometry. <i>Journal of Neuroimaging</i> , 2020, 30, 786-792.	1.0	8
5229	The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 34.	3.6	40
5230	Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 1751-1751.	2.2	0
5231	Multimodal Evaluation of Neurovascular Functionality in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 831.	1.1	13
5232	Determination of Oxyphylla A Enantiomers in the Fruits of <i>Alpinia oxyphylla</i> by a Chiral High-Performance Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Method and Comparison of Their In Vivo Biological Activities. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 11170-11181.	2.4	9
5233	Predictors of Pharyngeal Dysphagia in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1727-1735.	1.5	9
5234	Akinetic rigid symptoms are associated with decline in a cortical motor network in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 19.	2.5	16
5235	Grey matter changes in Meige syndrome: a voxel-based morphology analysis. <i>Scientific Reports</i> , 2020, 10, 14533.	1.6	12
5236	Blood pressure lability is associated with subcortical atrophy in early Parkinson's disease. <i>Journal of Hypertension</i> , 2020, 38, 2043-2049.	0.3	7
5237	Proteomic Characterization of the Olfactory Molecular Imbalance in Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6371.	1.8	6
5239	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1343-1353.	1.5	50
5240	Perturbation of in vivo Neural Activity Following α -Synuclein Seeding in the Olfactory Bulb. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1411-1427.	1.5	13
5241	Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6914.	1.8	28
5242	Associations of sleep characteristics with alpha-synuclein in cerebrospinal fluid in older adults. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2026-2034.	1.7	11
5243	Alzheimer's Dementia. , 2020, , 1-19.		0

#	ARTICLE	IF	CITATIONS
5244	Primary Progressive Aphasia. , 2020, , 20-42.		1
5246	Mild Cognitive Impairment. , 2020, , 68-94.		0
5247	Parkinsonâ€™s Disease Dementia. , 2020, , 95-132.		0
5248	Huntingtonâ€™s Disease. , 2020, , 133-166.		0
5256	Gene expression within the periaqueductal gray is linked to vocal behavior and early-onset parkinsonism in Pink1 knockout rats. BMC Genomics, 2020, 21, 625.	1.2	13
5257	<scp>GDNF</scp>/<scp>RET</scp> Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons. Movement Disorders, 2020, 35, 2279-2289.	2.2	27
5259	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 21.	2.5	17
5260	Locus coeruleus: a new look at the blue spot. Nature Reviews Neuroscience, 2020, 21, 644-659.	4.9	316
5261	Comparisons of cardiovascular dysautonomia and cognitive impairment between de novo Parkinsonâ€™s disease and de novo dementia with Lewy bodies. BMC Neurology, 2020, 20, 350.	0.8	19
5262	Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies. Acta Neuropathologica Communications, 2020, 8, 153.	2.4	10
5263	Risk factors of Parkinson disease. Neurology, 2020, 95, e2500-e2508.	1.5	41
5264	Gutâ€™Brain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 849.	1.1	13
5265	Brain-first versus body-first Parkinsonâ€™s disease: a multimodalÂ­imaging case-control study. Brain, 2020, 143, 3077-3088.	3.7	398
5266	The Rotenone Models Reproducing Central and Peripheral Features of Parkinsonâ€™s Disease. NeuroSci, 2020, 1, 1-14.	0.4	14
5267	The Effect of Conduction Exercise and Self-Acupressure in Treatment of Parkinsonâ€™s Disease: A Pilot Study. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	0.5	5
5268	Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease. Medicine (United States), 2020, 99, e21458.	0.4	3
5269	Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities. Frontiers in Cell and Developmental Biology, 2020, 8, 729.	1.8	65
5270	C. elegans Models to Study the Propagation of Prions and Prion-Like Proteins. Biomolecules, 2020, 10, 1188.	1.8	7

#	ARTICLE	IF	CITATIONS
5271	Defining the Protein Seeds of Neurodegeneration using Real-Time Quaking-Induced Conversion Assays. <i>Biomolecules</i> , 2020, 10, 1233.	1.8	7
5272	Synuclein Deficiency Results in Age-Related Respiratory and Cardiovascular Dysfunctions in Mice. <i>Brain Sciences</i> , 2020, 10, 583.	1.1	4
5273	Norepinephrine depleting toxin DSP-4 and LPS alter gut microbiota and induce neurotoxicity in $\hat{1}\pm$ -synuclein mutant mice. <i>Scientific Reports</i> , 2020, 10, 15054.	1.6	14
5274	Aluminum and Neurofibrillary Tangle Co-Localization in Familial Alzheimer's Disease and Related Neurological Disorders. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 139-149.	1.2	18
5275	Calcium, Bioenergetics, and Parkinson's Disease. <i>Cells</i> , 2020, 9, 2045.	1.8	46
5276	Shedding Light on Nocturnal Movements in Parkinson's Disease: Evidence from Wearable Technologies. <i>Sensors</i> , 2020, 20, 5171.	2.1	18
5277	Extracellular Alpha-Synuclein Promotes a Neuroinhibitory Secretory Phenotype in Astrocytes. <i>Life</i> , 2020, 10, 183.	1.1	7
5278	Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD). <i>Neurotherapeutics</i> , 2020, 17, 1331-1338.	2.1	8
5279	Luteolin, a Potent Human Monoamine Oxidase-A Inhibitor and Dopamine D ₄ and Vasopressin V _{1A} Receptor Antagonist. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 10719-10729.	2.4	14
5280	Hippocampal subfield pathologic burden in Lewy body diseases <i>vs</i> . Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 707-721.	1.8	21
5281	$\hat{1}\pm$ -Synuclein Overexpression Induces Lysosomal Dysfunction and Autophagy Impairment in Human Neuroblastoma SH-SY5Y. <i>Neurochemical Research</i> , 2020, 45, 2749-2761.	1.6	21
5282	In Search of Effective Treatments Targeting $\hat{1}\pm$ -Synuclein Toxicity in Synucleinopathies: Pros and Cons. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 559791.	1.8	14
5283	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
5284	Epigenomic analysis of Parkinson's disease neurons identifies Tet2 loss as neuroprotective. <i>Nature Neuroscience</i> , 2020, 23, 1203-1214.	7.1	57
5286	Anti- $\hat{1}\pm$ -synuclein ASO delivered to monoamine neurons prevents $\hat{1}\pm$ -synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. <i>EBioMedicine</i> , 2020, 59, 102944.	2.7	45
5287	Dementia-related psychosis and the potential role for pimavanserin. <i>CNS Spectrums</i> , 2022, 27, 7-15.	0.7	8
5288	Oxidative stress in the medullary respiratory neurons contributes to respiratory dysfunction in the 6 \hat{a} -OHDA model of Parkinson's disease. <i>Journal of Physiology</i> , 2020, 598, 5271-5293.	1.3	9
5289	Risk factors for possible REM sleep behavior disorders. <i>Neurology</i> , 2020, 95, e2214-e2224.	1.5	13

#	ARTICLE	IF	CITATIONS
5290	Molecular events underlying the cell-to-cell transmission of α -Synuclein. <i>FEBS Journal</i> , 2021, 288, 6593-6602.	2.2	27
5291	Olfactory Dysfunction and Its Association With Neuropathologic Proteins in Cerebrospinal Fluid From Patients With Parkinson Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 594324.	1.7	8
5292	Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease. <i>Nutritional Neuroscience</i> , 2022, 25, 1374-1391.	1.5	25
5293	Insights Into the Proteomic Profiling of Extracellular Vesicles for the Identification of Early Biomarkers of Neurodegeneration. <i>Frontiers in Neurology</i> , 2020, 11, 580030.	1.1	29
5294	Olfactory Dysfunction Predicts Disease Progression in Parkinson's Disease: A Longitudinal Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 569777.	1.4	25
5295	MMP13 Expression Is Increased Following Mutant α -Synuclein Exposure and Promotes Inflammatory Responses in Microglia. <i>Frontiers in Neuroscience</i> , 2020, 14, 585544.	1.4	12
5296	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580634.	1.8	40
5297	Association of Postural Instability with Autonomic Dysfunction in Early Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3786.	1.0	5
5298	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	1.1	65
5299	Sirt1/FoxO1-Associated MAO-A Upregulation Promotes Depressive-Like Behavior in Transgenic Mice Expressing Human A53T α -Synuclein. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3838-3848.	1.7	11
5300	Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Neurology</i> , 2020, 11, 577874.	1.1	10
5301	Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinson's disease over five years follow-up. <i>Scientific Reports</i> , 2020, 10, 19014.	1.6	15
5302	Neuropathological features of cognitive decline in Lewy body dementia. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 356-361.	0.2	0
5303	A Han Chinese Family With Early-Onset Parkinson's Disease Carrying Novel Frameshift Mutation and Compound Heterozygous Mutation of PRKN Appearing Incompatible With MDS Clinical Diagnostic Criteria. <i>Frontiers in Neurology</i> , 2020, 11, 582323.	1.1	2
5304	A Hybrid Fuzzy Clustering Approach for the Recognition and Visualization of MRI Images of Parkinson's Disease. <i>IEEE Access</i> , 2020, 8, 25041-25051.	2.6	22
5305	Cell-to-Cell Transmission of Tau and α -Synuclein. <i>Trends in Molecular Medicine</i> , 2020, 26, 936-952.	3.5	91
5306	Peripheral neuropathy in Parkinson's disease. <i>Neurological Sciences</i> , 2020, 41, 2691-2701.	0.9	26
5307	The Braak hypothesis in prion disease with a focus on Creutzfeldt-Jakob disease. <i>Neuropathology</i> , 2020, 40, 436-449.	0.7	8

#	ARTICLE	IF	CITATIONS
5308	Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110145.	2.5	18
5309	A <sc>Postâ€œCOVID</sc>â€œ19 Parkinsonism in the Future?. <i>Movement Disorders</i> , 2020, 35, 1094-1094.	2.2	22
5310	Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Diseaseâ€œViewpoint. <i>Frontiers in Neurology</i> , 2020, 11, 556.	1.1	28
5311	Propagation of Pathological Î±-Synuclein from the Urogenital Tract to the Brain Initiates MSA-like Syndrome. <i>IScience</i> , 2020, 23, 101166.	1.9	18
5312	Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Dischargeâ€œA New Hypothesis With Potential Implications for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2020, 11, 371.	1.1	27
5313	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	3.9	210
5314	Tobacco smoking and the risk of Parkinson disease. <i>Neurology</i> , 2020, 94, e2132-e2138.	1.5	81
5315	Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature. <i>Journal of Neurology</i> , 2021, 268, 3144-3179.	1.8	63
5316	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. <i>Brain</i> , 2020, 143, 1462-1475.	3.7	135
5317	Nonmotor Symptoms Affect Sleep Quality in Early-Stage Parkinson's Disease Patients With or Without Cognitive Dysfunction. <i>Frontiers in Neurology</i> , 2020, 11, 292.	1.1	9
5318	Molecular Mechanism for the Suppression of Alpha Synuclein Membrane Toxicity by an Unconventional Extracellular Chaperone. <i>Journal of the American Chemical Society</i> , 2020, 142, 9686-9699.	6.6	15
5319	The dual role of câ€œsrc in cellâ€œtoâ€œcell transmission of Î±â€œsynuclein. <i>EMBO Reports</i> , 2020, 21, e48950.	2.0	15
5320	Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinsonâ€œTM's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3254.	1.8	56
5321	Role of Mesenchymal Stem Cells in Counteracting Oxidative Stressâ€œRelated Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3299.	1.8	23
5322	Hippocampal Î±-synuclein pathology correlates with memory impairment in multiple system atrophy. <i>Brain</i> , 2020, 143, 1798-1810.	3.7	31
5323	Identification of distinct pathological signatures induced by patient-derived Î±-synuclein structures in nonhuman primates. <i>Science Advances</i> , 2020, 6, eaaz9165.	4.7	34
5324	Integrin CD11b mediates locus coeruleus noradrenergic neurodegeneration in a mouse Parkinsonâ€œTM's disease model. <i>Journal of Neuroinflammation</i> , 2020, 17, 148.	3.1	23
5325	Infections or Sepsis Preceding Clinically Diagnosed Î±â€œSynucleinopathies : A Caseâ€œControl Study. <i>Movement Disorders</i> , 2020, 35, 1684-1689.	2.2	3

#	ARTICLE	IF	CITATIONS
5326	Experimental models of prion-like protein propagation. <i>Neuropathology</i> , 2020, 40, 460-466.	0.7	6
5328	Assessing White Matter Pathology in Early-Stage Parkinson Disease Using Diffusion MRI: A Systematic Review. <i>Frontiers in Neurology</i> , 2020, 11, 314.	1.1	25
5329	Olfactory Dysfunction in Familial and Sporadic Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 447.	1.1	16
5330	Clinical and Imaging Markers of Prodromal Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 395.	1.1	88
5331	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 864-872.	0.9	22
5332	Epigenetic regulation in the pathophysiology of Lewy body dementia. <i>Progress in Neurobiology</i> , 2020, 192, 101822.	2.8	10
5333	Insulin resistance and Parkinson's disease. , 2020, , 293-347.		0
5334	Event-related potential changes due to early-onset Parkinson's disease in parkin (PARK2) gene mutation carriers and non-carriers. <i>Clinical Neurophysiology</i> , 2020, 131, 1444-1452.	0.7	7
5335	Increased α -synuclein oligomerization is associated with decreased activity of glucocerebrosidase in the aging human striatum and hippocampus. <i>Neuroscience Letters</i> , 2020, 733, 135093.	1.0	4
5336	Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson's disease by regulating NLRP3 pathway through sponging miR-223-3p. <i>International Immunopharmacology</i> , 2020, 85, 106614.	1.7	56
5337	Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 760-769.	1.0	8
5338	Depressive symptoms effect subjective sleep quality in Chinese patients with Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105950.	0.6	4
5339	The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 248.	1.8	109
5340	Brain Functional and Structural Signatures in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 125.	1.7	4
5341	Neurobiology of cue-reactivity, craving, and inhibitory control in non-substance addictive behaviors. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116952.	0.3	72
5342	Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 1270.	4.5	68
5343	The role of nicotinic cholinergic neurotransmission in delusional thinking. <i>NPJ Schizophrenia</i> , 2020, 6, 16.	2.0	31
5344	Evidence of Rehabilitative Impact of Progressive Resistance Training (PRT) Programs in Parkinson Disease: An Umbrella Review. <i>Parkinson's Disease</i> , 2020, 2020, 1-9.	0.6	6

#	ARTICLE	IF	CITATIONS
5345	Cortical complexity and gyrification patterns in Parkinson's disease. <i>NeuroReport</i> , 2020, 31, 565-570.	0.6	12
5346	Propionic Acid and Fasudil as Treatment against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease. <i>Molecules</i> , 2020, 25, 2502.	1.7	25
5347	Down regulation of miR-218, miR-124, and miR-144 relates to Parkinson's disease via activating NF- κ B signaling. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 786-792.	0.8	39
5348	Biophysical studies of protein misfolding and aggregation in vivo models of Alzheimer's and Parkinson's diseases. <i>Quarterly Reviews of Biophysics</i> , 2020, 53, e22.	2.4	13
5349	The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases. <i>Translational Neurodegeneration</i> , 2020, 9, 22.	3.6	62
5350	Gender-specific effect of urate on white matter integrity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 41-47.	1.1	7
5351	Stimulation of retrotrapezoid nucleus Phox2b-expressing neurons rescues breathing dysfunction in an experimental Parkinson's disease rat model. <i>Brain Pathology</i> , 2020, 30, 926-944.	2.1	9
5352	LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons. <i>Frontiers in Neuroscience</i> , 2020, 14, 442.	1.4	30
5353	Remodeling microglia to a protective phenotype in Parkinson's disease?. <i>Neuroscience Letters</i> , 2020, 735, 135164.	1.0	17
5354	Origins of atrophy in Parkinson linked to early onset and local transcription patterns. <i>Brain Communications</i> , 2020, 2, fcaa065.	1.5	9
5355	LRRK2 and α -Synuclein: Distinct or Synergistic Players in Parkinson's Disease?. <i>Frontiers in Neuroscience</i> , 2020, 14, 577.	1.4	49
5356	Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen-encapsulated human umbilical cord mesenchymal stem cells. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1077-1086.	1.3	4
5357	Evidence-based Positron Emission Tomography. , 2020, , .		3
5358	Serum microRNA expression levels in Turkish patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2021, 131, 1181-1189.	0.8	21
5359	Meta-Analysis of Gut Dysbiosis in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1626-1635.	2.2	208
5360	Approaches to the Early Diagnosis of Parkinson's Disease. <i>Neuroscience and Behavioral Physiology</i> , 2020, 50, 393-400.	0.2	0
5361	A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms. <i>Frontiers in Neurology</i> , 2020, 11, 454.	1.1	64
5362	LRRK2-Related Parkinson's Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis. <i>Frontiers in Neuroscience</i> , 2020, 14, 556.	1.4	19

#	ARTICLE	IF	CITATIONS
5363	Anti-aggregation Effects of Phenolic Compounds on α -synuclein. <i>Molecules</i> , 2020, 25, 2444.	1.7	18
5364	Neuroinflammatory Responses and Parkinson's Disease: Pathogenic Mechanisms and Therapeutic Targets. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 830-837.	2.1	41
5365	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. <i>Biomolecules</i> , 2020, 10, 912.	1.8	18
5366	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. <i>Npj Parkinson's Disease</i> , 2020, 6, 11.	2.5	140
5367	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020, 139, 1001-1024.	3.9	46
5368	Microglia clear neuron-released α -synuclein via selective autophagy and prevent neurodegeneration. <i>Nature Communications</i> , 2020, 11, 1386.	5.8	279
5369	A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA. <i>Schizophrenia Bulletin</i> , 2020, 46, 999-1008.	2.3	20
5370	Parkinson's Disease: A Comprehensive Analysis of Fungi and Bacteria in Brain Tissue. <i>International Journal of Biological Sciences</i> , 2020, 16, 1135-1152.	2.6	37
5371	Nurr1 Cd11bcre conditional knockout mice display inflammatory injury to nigrostriatal dopaminergic neurons. <i>Glia</i> , 2020, 68, 2057-2069.	2.5	12
5372	Editorial: Pathophysiologic Insights From Biomarker Studies in Neurological Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 151.	1.1	0
5373	Animal Model for Prodromal Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1961.	1.8	27
5374	The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding. <i>Scientific Reports</i> , 2020, 10, 4895.	1.6	53
5376	Initiation and propagation of α -synuclein aggregation in the nervous system. <i>Molecular Neurodegeneration</i> , 2020, 15, 19.	4.4	156
5377	Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1021-1027.	2.2	65
5378	Hemispheric asymmetry in the human brain and in Parkinson's disease is linked to divergent epigenetic patterns in neurons. <i>Genome Biology</i> , 2020, 21, 61.	3.8	40
5379	Potential Roles of Exosomes in Parkinson's Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 86.	1.8	84
5380	Central auditory processing in parkinsonian disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 111-132.	2.9	12
5381	Disruption of cellular proteostasis by H1N1 influenza A virus causes α -synuclein aggregation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6741-6751.	3.3	85

#	ARTICLE	IF	CITATIONS
5382	“Smelling and Tasting” Parkinson's Disease: Using Senses to Improve the Knowledge of the Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 43.	1.7	30
5383	miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA. <i>Brain and Behavior</i> , 2020, 10, e01567.	1.0	24
5384	Circle of Willis abnormalities and their clinical importance in ageing brains: A cadaveric anatomical and pathological study. <i>Journal of Chemical Neuroanatomy</i> , 2020, 106, 101772.	1.0	11
5385	Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease. <i>Human Molecular Genetics</i> , 2020, 29, 1180-1191.	1.4	20
5386	Targeting α -Synuclein for PD Therapeutics: A Pursuit on All Fronts. <i>Biomolecules</i> , 2020, 10, 391.	1.8	43
5387	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104831.	2.1	49
5388	Transcriptomic signatures of brain regional vulnerability to Parkinson's disease. <i>Communications Biology</i> , 2020, 3, 101.	2.0	58
5389	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	4.9	330
5390	α -Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. <i>Journal of Biological Chemistry</i> , 2020, 295, 6652-6664.	1.6	23
5391	Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis. <i>Parkinson's Disease</i> , 2020, 2020, 1-8.	0.6	1
5392	Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 72.	1.7	24
5393	Damaged Insula Network Contributes to Depression in Parkinson's Disease. <i>Frontiers in Psychiatry</i> , 2020, 11, 119.	1.3	18
5394	Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α -Synuclein in Mouse Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2230.	1.8	28
5395	Cytoplasmic mislocalization and mitochondrial colocalization of TDP-43 are common features between normal aged and young mice. <i>Experimental Biology and Medicine</i> , 2020, 245, 1584-1593.	1.1	7
5396	Salient Features of Monomeric Alpha-Synuclein Revealed by NMR Spectroscopy. <i>Biomolecules</i> , 2020, 10, 428.	1.8	14
5397	Human-Specific Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons. <i>Annals of Neurology</i> , 2020, 87, 853-868.	2.8	22
5398	Role of Glia in the Regulation of Sleep in Health and Disease. , 2020, 10, 687-712.		30
5399	Autonomic failure in Parkinson's disease is associated with striatal dopamine deficiencies. <i>Journal of Neurology</i> , 2020, 267, 1922-1930.	1.8	28

#	ARTICLE	IF	CITATIONS
5400	Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside. <i>Experimental Neurology</i> , 2020, 329, 113284.	2.0	41
5401	Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 491-496.	1.3	8
5402	<i>In vivo</i> signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder. <i>European Journal of Neurology</i> , 2020, 27, 1285-1295.	1.7	17
5403	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 20.	4.4	264
5404	Histological correlates of postmortem ultra-high-resolution single-section MRI in cortical cerebral microinfarcts. <i>Acta Neuropathologica Communications</i> , 2020, 8, 33.	2.4	16
5405	Parkinson's Disease in Louisiana, 1999-2012: Based on Hospital Primary Discharge Diagnoses, Incidence, and Risk in Relation to Local Agricultural Crops, Pesticides, and Aquifer Recharge. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1584.	1.2	12
5406	A neutrosophic-entropy based adaptive thresholding segmentation algorithm: A special application in MR images of Parkinson's disease. <i>Artificial Intelligence in Medicine</i> , 2020, 104, 101838.	3.8	25
5407	Clinically relevant connectivity features define three subtypes of Parkinson's disease patients. <i>Human Brain Mapping</i> , 2020, 41, 4077-4092.	1.9	12
5408	Current clinical approaches in neurodegenerative diseases. , 2020, , 79-124.		1
5409	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	1.8	17
5410	Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 105960.	0.6	3
5411	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
5412	Perspective: Current Pitfalls in the Search for Future Treatments and Prevention of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 686.	1.1	6
5414	The Shaky Six and the "Second Reality", 2020, , 1-10.		0
5415	Pieces of a Puzzle?. , 2020, , 11-24.		0
5416	Disease "Redefinition": A Tough Pill to Swallow. , 2020, , 25-32.		0
5417	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
5418	Protein Paradox. , 2020, , 41-56.		0

#	ARTICLE	IF	CITATIONS
5419	The Fault in Our Models. , 2020, , 57-70.		0
5420	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
5421	Lessons from Oncology. , 2020, , 81-86.		0
5422	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
5423	Our Living Dissonance. , 2020, , 105-110.		0
5424	The Scientific and Lay Narratives. , 2020, , 111-124.		0
5425	Challenges Viewed from Afar. , 2020, , 125-132.		0
5426	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
5427	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
5428	Note Added at Press Time “ Reviving LOF. , 2020, , 150-150.		0
5430	Development of early diagnosis of Parkinson's disease: Illusion or reality?. CNS Neuroscience and Therapeutics, 2020, 26, 997-1009.	1.9	45
5432	The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process. Cells, 2020, 9, 1552.	1.8	33
5433	Basal ganglia beta oscillations during sleep underlie Parkinsonian insomnia. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17359-17368.	3.3	31
5434	Genomic Analysis Identifies New Loci Associated With Motor Complications in Parkinson's Disease. Frontiers in Neurology, 2020, 11, 570.	1.1	12
5435	Safety of Plasma Infusions in Parkinson's Disease. Movement Disorders, 2020, 35, 1905-1913.	2.2	8
5436	Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. International Journal of Molecular Sciences, 2020, 21, 4718.	1.8	15
5437	Identification of Conserved Proteomic Networks in Neurodegenerative Dementia. Cell Reports, 2020, 31, 107807.	2.9	49
5438	Vortioxetine improves rapid eye movement sleep behavior disorder. Medicine (United States), 2020, 99, e21003.	0.4	5

#	ARTICLE	IF	CITATIONS
5439	The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson's Disease. , 2020, , .		5
5440	Virtual reality in research and rehabilitation of gait and balance in Parkinson disease. <i>Nature Reviews Neurology</i> , 2020, 16, 409-425.	4.9	101
5441	Erythrocytic α -synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 102.	2.4	26
5442	Effect of Dopamine D ₂ Receptor Antagonists on [¹⁸ F]-FEOBV Binding. <i>Molecular Pharmaceutics</i> , 2020, 17, 865-872.	2.3	3
5443	Neurocognitive and psychiatric disorders-related axonal degeneration in Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2020, 98, 936-949.	1.3	15
5444	Thalamostriatal degeneration contributes to dystonia and cholinergic interneuron dysfunction in a mouse model of Huntington's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 14.	2.4	8
5445	Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1115.	1.8	70
5446	Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 231-250.	1.4	13
5447	Numerous ballooned neurons in a 94-year-old man with dementia with Lewy bodies. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116722.	0.3	1
5448	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. <i>Molecules</i> , 2020, 25, 977.	1.7	68
5449	Prodromal PD: A new nosological entity. <i>Progress in Brain Research</i> , 2020, 252, 331-356.	0.9	25
5450	Methods for detecting toxic α -synuclein species as a biomarker for Parkinson's disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 291-307.	2.7	13
5451	Mixed neuropathology in frontotemporal lobar degeneration. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 301-308.	1.1	2
5452	Chemical Chaperones as Novel Drugs for Parkinson's Disease. <i>Trends in Molecular Medicine</i> , 2020, 26, 408-421.	3.5	43
5453	The Properties of α -Synuclein Secondary Nuclei Are Dominated by the Solution Conditions Rather than the Seed Fibril Strain. <i>ACS Chemical Neuroscience</i> , 2020, 11, 909-918.	1.7	29
5454	Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. <i>European Journal of Neurology</i> , 2020, 27, 779-786.	1.7	20
5455	Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease. <i>Archives of Toxicology</i> , 2020, 94, 813-831.	1.9	8
5456	The role of tissue biopsy as a biomarker in REM sleep behavior disorder. <i>Sleep Medicine Reviews</i> , 2020, 51, 101283.	3.8	11

#	ARTICLE	IF	CITATIONS
5457	Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 47.	1.1	18
5458	Altered Amplitude of Low-Frequency Fluctuations and Functional Connectivity in Excessive Daytime Sleepiness in Parkinson Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 29.	1.4	11
5459	Implications of the Gut Microbiome in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 921-933.	2.2	95
5460	When does cerebral β -amyloid deposition begin in Lewy body dementia?. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 362-371.	0.2	2
5461	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.5	103
5462	Fabry Disease With Concomitant Lewy Body Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 378-392.	0.9	16
5463	Diagnosis and Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 548.	3.8	1,376
5464	Auditory Dysfunction in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 537-550.	2.2	27
5465	Mind and Brain. , 2020, , .		5
5466	Network degeneration in Parkinsonâ€™s disease: multimodal imaging of nigro-striato-cortical dysfunction. <i>Brain</i> , 2020, 143, 944-959.	3.7	74
5467	Chemical composition and health properties of coffee and coffee by-products. <i>Advances in Food and Nutrition Research</i> , 2020, 91, 65-96.	1.5	68
5468	Adaptive sparse learning using multi-template for neurodegenerative disease diagnosis. <i>Medical Image Analysis</i> , 2020, 61, 101632.	7.0	33
5469	Dementia in long-term Parkinsonâ€™s disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	2.5	32
5470	Mechanisms of alpha-synuclein toxicity: An update and outlook. <i>Progress in Brain Research</i> , 2020, 252, 91-129.	0.9	49
5471	Synucleinopathies: Where we are and where we need to go. <i>Journal of Neurochemistry</i> , 2020, 153, 433-454.	2.1	62
5472	Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. <i>Frontiers in Neuroscience</i> , 2019, 13, 1399.	1.4	104
5474	Hypomania and saccadic changes in Parkinsonâ€™s disease: influence of D2 and D3 dopaminergic signalling. <i>Npj Parkinson's Disease</i> , 2020, 6, 5.	2.5	4
5475	Brainstem Ventilatory Dysfunction: A Plausible Mechanism for Dyspnea in Parkinson's Disease?. <i>Movement Disorders</i> , 2020, 35, 379-388.	2.2	18

#	ARTICLE	IF	CITATIONS
5476	Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. <i>Annals of Neurology</i> , 2020, 87, 329-338.	2.8	112
5477	A neutrosophic-entropy based clustering algorithm (NEBCA) with HSV color system: A special application in segmentation of Parkinson's disease (PD) MR images. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 189, 105317.	2.6	20
5478	Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy. <i>Movement Disorders</i> , 2020, 35, 825-832.	2.2	17
5479	Differential Membrane Binding and Seeding of Distinct α -Synuclein Fibrillar Polymorphs. <i>Biophysical Journal</i> , 2020, 118, 1301-1320.	0.2	59
5480	Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies. <i>Frontiers in Neuroscience</i> , 2019, 13, 1381.	1.4	20
5481	Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α -synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 131-147.	1.4	41
5482	The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2020, 52, 3256-3268.	1.2	25
5483	Could Heat Therapy Be an Effective Treatment for Alzheimer's and Parkinson's Diseases? A Narrative Review. <i>Frontiers in Physiology</i> , 2019, 10, 1556.	1.3	31
5484	Intracerebral seeding of amyloid- β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with α -synuclein. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 112, 1-27.	2.9	31
5485	Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms. <i>BMC Neurology</i> , 2020, 20, 26.	0.8	51
5486	Voice changes in Parkinson's disease: What are they telling us?. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 1-7.	0.8	60
5487	Parkinson's disease: From bench to bedside. <i>Revue Neurologique</i> , 2020, 176, 543-559.	0.6	46
5488	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
5489	Microglia and Parkinson's disease: footprints to pathology. <i>Journal of Neural Transmission</i> , 2020, 127, 149-158.	1.4	37
5490	Alpha-synuclein fragments trigger distinct aggregation pathways. <i>Cell Death and Disease</i> , 2020, 11, 84.	2.7	19
5491	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	102
5492	<i>Burkholderia pseudomallei</i> invades the olfactory nerve and bulb after epithelial injury in mice and causes the formation of multinucleated giant glial cells in vitro. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008017.	1.3	17
5493	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2407-2416.	3.3	12

#	ARTICLE	IF	CITATIONS
5494	Parkinson's Disease Rehabilitation: Effectiveness Approaches and New Perspectives. , 0, , .		5
5495	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle <scp>2A</scp> in Early <scp>Drug-Naive</scp> Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.	2.2	48
5496	Regulation of microglia by neuromodulators: Modulations in major and minor modes. <i>Neuroscience Letters</i> , 2020, 733, 135000.	1.0	18
5497	Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological α -synuclein. <i>Science Advances</i> , 2020, 6, eaba1193.	4.7	41
5498	Modeling Parkinson's Disease With the Alpha-Synuclein Protein. <i>Frontiers in Pharmacology</i> , 2020, 11, 356.	1.6	195
5499	Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson's Disease: Molecular Mechanisms Connecting Neuroinflammation to α -Synuclein Spreading Pathology. <i>Biology</i> , 2020, 9, 86.	1.3	19
5500	Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1208-1217.	2.2	180
5501	Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update. , 2020, 11, 315.		61
5502	Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 720-729.	0.9	148
5503	Uncoupling the roles of firing rates and spike bursts in shaping the STN-GPe beta band oscillations. <i>PLoS Computational Biology</i> , 2020, 16, e1007748.	1.5	16
5504	New players in basal ganglia dysfunction in Parkinson's disease. <i>Progress in Brain Research</i> , 2020, 252, 307-327.	0.9	9
5505	Selective neuronal vulnerability in Parkinson's disease. <i>Progress in Brain Research</i> , 2020, 252, 61-89.	0.9	43
5506	Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. <i>Journal of Neuroscience Methods</i> , 2020, 338, 108685.	1.3	16
5507	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. <i>Nature Communications</i> , 2020, 11, 1712.	5.8	74
5508	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. <i>Brain Pathology</i> , 2020, 30, 766-778.	2.1	19
5509	Mitochondrial Dysfunction and Parkinson's Disease: Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 89.	1.7	31
5510	Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Neuroscience</i> , 2020, 14, 296.	1.4	12
5511	The Noradrenergic System in Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2020, 11, 435.	1.6	71

#	ARTICLE	IF	CITATIONS
5512	Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study. <i>Neurological Sciences</i> , 2020, 41, 2867-2873.	0.9	6
5513	Computational Modeling for Neuropsychological Assessment of Bradyphrenia in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1158.	1.0	9
5514	Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. <i>Nature Genetics</i> , 2020, 52, 482-493.	9.4	216
5515	Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications. <i>Chemical Reviews</i> , 2020, 120, 4355-4454.	23.0	149
5516	The therapeutic potential of exercise for neuropsychiatric diseases: A review. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116763.	0.3	23
5517	How would defining Parkinson's as a prion disease impact the search of a cure?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 417-420.	1.4	0
5518	A Single-institution Study on Predictors of Short-term Progression from Mild Cognitive Impairment in Parkinson's Disease to Parkinson's Disease with Dementia. <i>Yonago Acta Medica</i> , 2020, 63, 28-33.	0.3	3
5519	Gut Microbiota and Pathogenesis of Organ Injury. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
5520	Neurobiological findings underlying depressive behavior in Parkinson's disease: A review. <i>International Immunopharmacology</i> , 2020, 83, 106434.	1.7	16
5521	From cell lines to pluripotent stem cells for modelling Parkinson's Disease. <i>Journal of Neuroscience Methods</i> , 2020, 340, 108741.	1.3	26
5522	Î±-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson's disease olfactory bulb. <i>Scientific Reports</i> , 2020, 10, 6682.	1.6	42
5523	Unilateral intranigral administration of Î²-sitosterol Î²-D-glucoside triggers pathological Î±-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat. <i>Acta Neuropathologica Communications</i> , 2020, 8, 56.	2.4	12
5524	Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	0.6	49
5525	5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment. <i>Parkinson's Disease</i> , 2020, 2020, 1-6.	0.6	20
5526	A role for Î±-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 24.	4.4	18
5527	Biological links between traumatic brain injury and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 45.	2.4	78
5528	Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 238.	2.0	98
5529	Nuclear Factor-Î²B Dysregulation and Î±-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 68.	1.7	56

#	ARTICLE	IF	CITATIONS
5530	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. <i>Cells</i> , 2020, 9, 841.	1.8	51
5531	Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology. <i>Annals of Neurology</i> , 2020, 87, 950-961.	2.8	30
5532	Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 16-24.	2.2	133
5533	Past appendectomy may be related to early cognitive dysfunction in Parkinson's disease. <i>Neurological Sciences</i> , 2021, 42, 123-130.	0.9	2
5534	Modelling neurodegenerative disease using brain organoids. <i>Seminars in Cell and Developmental Biology</i> , 2021, 111, 60-66.	2.3	25
5535	An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex. <i>Journal of Neuroscience Research</i> , 2021, 99, 163-179.	1.3	6
5536	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <i>Movement Disorders</i> , 2021, 36, 632-641.	2.2	3
5537	Anti-inflammatory activity of ayahuasca: therapeutic implications in neurological and psychiatric diseases. <i>Behavioural Brain Research</i> , 2021, 400, 113003.	1.2	16
5538	From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?. <i>Experimental Neurology</i> , 2021, 336, 113525.	2.0	21
5539	MT2 melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease. <i>European Journal of Pharmacology</i> , 2021, 891, 173722.	1.7	8
5540	Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. <i>Acta Neuropathologica</i> , 2021, 141, 25-37.	3.9	43
5541	Clinical presentations of gastroparesis. , 2021, , 19-33.		0
5542	Clinicopathological investigation of the background of cognitive decline in elderly schizophrenia. <i>Acta Neuropsychiatrica</i> , 2021, 33, 85-91.	1.0	2
5543	Translation, Adaptation and Validation of the European Portuguese Version of the NMS-Quest for Parkinson's Disease. <i>Acta Medica Portuguesa</i> , 2021, 34, 6.	0.2	2
5544	RAB39B is redistributed in dementia with Lewy bodies and is sequestered within α^2 plaques and Lewy bodies. <i>Brain Pathology</i> , 2021, 31, 120-132.	2.1	11
5545	STochastic Optical Reconstruction Microscopy (STORM) reveals the nanoscale organization of pathological aggregates in human brain. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 127-142.	1.8	22
5546	COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?. <i>Journal of Neurology</i> , 2021, 268, 409-419.	1.8	112
5548	Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease. <i>Medicinal Research Reviews</i> , 2021, 41, 785-802.	5.0	42

#	ARTICLE	IF	CITATIONS
5549	Increased rapid eye movement density in Chinese patients with Parkinson's disease and RBD. <i>Neurological Sciences</i> , 2021, 42, 961-968.	0.9	4
5550	A new swallowing supplement for dysphagia in patients with Parkinson's disease. <i>Neurological Sciences</i> , 2021, 42, 1949-1958.	0.9	5
5551	Non-invasive brain stimulation for Parkinson's disease: Clinical evidence, latest concepts and future goals: A systematic review. <i>Journal of Neuroscience Methods</i> , 2021, 347, 108957.	1.3	37
5552	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	0.9	2
5553	Non-motor symptoms are associated with REM sleep behavior disorder in Parkinson's disease: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2021, 42, 47-60.	0.9	18
5554	Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more. <i>Revue Neurologique</i> , 2021, 177, 260-271.	0.6	14
5555	BDNF and Netrin-1 repression by C/EBP β in the gut triggers Parkinson's disease pathologies, associated with constipation and motor dysfunctions. <i>Progress in Neurobiology</i> , 2021, 198, 101905.	2.8	24
5556	The gut microbiota-brain axis in behaviour and brain disorders. <i>Nature Reviews Microbiology</i> , 2021, 19, 241-255.	13.6	864
5557	Antisense Drugs Make Sense for Neurological Diseases. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 831-852.	4.2	54
5558	Apoptotic Neuron-Derived Histone Amyloid Fibrils Induce α -Synuclein Aggregation. <i>Molecular Neurobiology</i> , 2021, 58, 867-876.	1.9	1
5559	Clinical Trial Highlights of Parkinson's Disease Cognition. <i>Journal of Parkinson's Disease</i> , 2021, 11, 9-30.	1.5	0
5560	The Spectrum of Sleep Disorders in Parkinson Disease. <i>Chest</i> , 2021, 159, 818-827.	0.4	35
5561	A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease OFF episodes. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 169-177.	1.4	8
5562	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. <i>Movement Disorders</i> , 2021, 36, 948-954.	2.2	26
5563	Histamine-4 receptor antagonist ameliorates Parkinson-like pathology in the striatum. <i>Brain, Behavior, and Immunity</i> , 2021, 92, 127-138.	2.0	20
5564	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	2.8	21
5565	Levodopa regulates α -synuclein accumulation in experimental parkinsonism. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 532-543.	1.8	11
5566	Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review. <i>Movement Disorders</i> , 2021, 36, 327-339.	2.2	71

#	ARTICLE	IF	CITATIONS
5567	Seven Solutions for Neuroprotection in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 306-316.	2.2	33
5568	Protection by rhynchophylline against MPTP/MPP ⁺ -induced neurotoxicity via regulating PI3K/Akt pathway. <i>Journal of Ethnopharmacology</i> , 2021, 268, 113568.	2.0	19
5569	Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning. <i>Molecular Neurobiology</i> , 2021, 58, 1517-1534.	1.9	8
5570	A Prodromal Brain's Clinical Pattern of Cognition in Synucleinopathies. <i>Annals of Neurology</i> , 2021, 89, 341-357.	2.8	28
5571	Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 201-209.	0.9	11
5572	Tardive neurotoxicity of anticholinergic drugs: A review. <i>Journal of Neurochemistry</i> , 2021, 158, 1334-1344.	2.1	10
5573	Cell Death-Osis of Dopaminergic Neurons and the Role of Iron in Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 453-473.	2.5	5
5574	Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death. <i>Neuropathology</i> , 2021, 41, 174-182.	0.7	5
5575	Nanozyme scavenging ROS for prevention of pathologic α -synuclein transmission in Parkinson's disease. <i>Nano Today</i> , 2021, 36, 101027.	6.2	78
5576	From <i>scip>iPS</scip></i> Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 832-841.	2.2	10
5577	Connectivity Correlates of Anxiety Symptoms in Drug-naïve Parkinson's Disease Patients. <i>Movement Disorders</i> , 2021, 36, 96-105.	2.2	16
5578	Robust Bayesian Analysis of Early-Stage Parkinson's Disease Progression Using DaTscan Images. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 549-561.	5.4	5
5579	Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling. <i>Neurology</i> , 2021, 96, e460-e471.	1.5	18
5580	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 177, 175-202.	0.9	21
5581	STW5 (Iberogast®) for constipation in Parkinson's disease. <i>Revue Neurologique</i> , 2021, 177, 296-301.	0.6	1
5582	Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. <i>Movement Disorders</i> , 2021, 36, 25-36.	2.2	69
5583	Pathogenic and protective roles of extracellular vesicles in neurodegenerative diseases. <i>Journal of Biochemistry</i> , 2021, 169, 181-186.	0.9	9
5584	Parkinson's disease in older people. <i>Medicine</i> , 2021, 49, 56-61.	0.2	3

#	ARTICLE	IF	CITATIONS
5585	Probiotics for Parkinson's disease: Current evidence and future directions. <i>JGH Open</i> , 2021, 5, 414-419.	0.7	41
5586	Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 2.	2.0	27
5587	Proteomic Complexity in Parkinson's Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. <i>Neuroscience</i> , 2021, 453, 287-300.	1.1	6
5588	Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading. <i>Movement Disorders</i> , 2021, 36, 360-369.	2.2	12
5589	The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 369-382.	2.0	11
5590	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. <i>Journal of Parkinson's Disease</i> , 2021, 11, 71-92.	1.5	21
5591	Disruption of neocortical synchronisation during slow-wave sleep in the rotenone model of Parkinson's disease. <i>Journal of Sleep Research</i> , 2021, 30, e13170.	1.7	7
5592	Nocturnal eye movements in patients with idiopathic rapid eye movement sleep behaviour disorder and patients with Parkinson's disease. <i>Journal of Sleep Research</i> , 2021, 30, e13125.	1.7	4
5593	Changes of olfactory tract in Parkinson's disease: a DTI tractography study. <i>Neuroradiology</i> , 2021, 63, 235-242.	1.1	13
5594	Disorders of synaptic vesicle fusion machinery. <i>Journal of Neurochemistry</i> , 2021, 157, 130-164.	2.1	44
5595	A 2-Year-Old Boy With an Unusual Bacterial Meningitis and Multiple Brain Abscesses. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 207-209.	0.6	1
5596	Systemic α -synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. <i>Molecular Psychiatry</i> , 2021, 26, 556-567.	4.1	24
5597	Gut Microbiota-Derived Epigenetic Alterations During Onset of Diseases. , 2022, , 223-233.		0
5598	Illusions, hallucinations, and visual snow. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 178, 311-335.	1.0	12
5599	Microbiota and Neurodegenerative Diseases. , 2022, , 175-180.		0
5600	Serotonergic imaging in Parkinson's disease. <i>Progress in Brain Research</i> , 2021, 261, 303-338.	0.9	11
5601	Brainstem evoked potentials in the idiopathic parkinson's disease (PD). <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 128.	0.2	2
5602	The role of viruses in the pathogenesis of Parkinson's disease. <i>Neural Regeneration Research</i> , 2021, 16, 1200.	1.6	8

#	ARTICLE	IF	CITATIONS
5603	Personality dimensions of patients can change during the course of parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0245142.	1.1	5
5604	Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease. MEDICC Review, 2021, 23, 49-54.	0.5	5
5605	The contribution of gut microbiota in the pathogenesis of Parkinsonâ€™s disease. , 2021, , 123-141.		0
5606	Treatment of Neurogenic Dysphagia. , 2021, , 267-351.		1
5607	Common Marmoset Model of. Methods in Molecular Biology, 2021, 2322, 131-139.	0.4	2
5608	Î±-Synuclein Seeding Assay Using RT-QuIC. Methods in Molecular Biology, 2021, 2322, 3-16.	0.4	6
5609	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 189-205.	1.0	12
5610	Lewy Body Disease. , 2021, , 18-41.		0
5611	Neural mechanisms of emotions, alexithymia, and depression. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 183, 299-313.	1.0	8
5612	A <sc>Doubleâ€™Blind</sc>, Randomized, Controlled Trial of Lovastatin in <sc>Earlyâ€™Stage</sc> Parkinson's Disease. Movement Disorders, 2021, 36, 1229-1237.	2.2	22
5613	ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 381.	1.0	23
5614	Dynamic sleep stage transition process analysis in patients with Parkinson's disease having sleep apnea syndrome. Informatics in Medicine Unlocked, 2021, 25, 100656.	1.9	3
5615	Skin Î±-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurology, 2021, 78, 30.	4.5	125
5616	Hsp70 chaperone blocks Î±-synuclein oligomer formation via a novel engagement mechanism. Journal of Biological Chemistry, 2021, 296, 100613.	1.6	29
5617	Exosomes in Parkinson disease. Journal of Neurochemistry, 2021, 157, 413-428.	2.1	62
5618	Degenerative Diseases of the CNS. , 2021, , 353-389.		0
5619	Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16.		2
5620	Analysis of heart rate response to obstructive apnea/hypopnea events in patients with Parkinson's disease with relatively severe sleep apnea syndrome. Informatics in Medicine Unlocked, 2021, 23, 100554.	1.9	1

#	ARTICLE	IF	CITATIONS
5621	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2021, 80, 102-111.	0.9	35
5622	Clinical and neuroendocrinological characteristics of delayed orthostatic hypotension in Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 425-431.	1.4	1
5623	Extracellular Vesicles for the Diagnosis and Treatment of Parkinson's Disease. , 2021, 12, 1438.		46
5624	Oxidative stress in paraquat-induced damage to nervous tissues. , 2021, , 69-78.		3
5625	Crucial Role of FABP3 in α -Syn-Induced Reduction of Septal GABAergic Neurons and Cognitive Decline in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 400.	1.8	2
5626	Abnormal Topological Organization of Sulcal Depth-Based Structural Covariance Networks in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 575672.	1.7	6
5627	A New Kind of Pathogen – Prion diseases and amyloid fibrils. , 2021, , 89-111.		0
5628	Autonomic Dysfunction in Parasomnias of REM Sleep. , 2021, , 249-260.		0
5629	Lewy bodies in the olfactory system and the hypothalamus. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 182, 235-244.	1.0	2
5630	Assessing autonomic dysfunction with functional imaging in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, , 91-118.	0.1	0
5631	Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1160-1170.	2.8	11
5632	Parkinson disease and sleep. , 2021, , .		0
5633	Neurophysiological investigation of auditory intensity dependence in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 345-356.	1.4	4
5634	The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 13-15.	2.2	1
5635	Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021, 183, 175-196.	1.0	4
5636	Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. <i>Progress in Brain Research</i> , 2021, 261, 265-285.	0.9	3
5637	Clinical, Imaging, and Laboratory Markers of Premanifest Spinocerebellar Ataxia 1, 2, 3, and 6: A		

#	ARTICLE	IF	CITATIONS
5639	Potential roles of functional bacterial amyloid proteins, bacterial biosurfactants and other putative gut microbiota products in the etiopathogeny of Parkinson's Disease. <i>Biocell</i> , 2021, 45, 1-16.	0.4	9
5640	Translational medicine of the glutamate AMPA receptor. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2021, 97, 1-21.	1.6	6
5641	Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α -Lipoic Acid. <i>International Journal of Molecular Sciences</i> , 2021, 22, 403.	1.8	39
5642	Parkinson's pharmacological therapy. , 2021, , 173-185.		0
5643	Preclinical models based on endogenous neurotoxins. , 2021, , 263-282.		0
5644	Preclinical studies of transcranial photobiomodulation in the neurological diseases. <i>Translational Biophotonics</i> , 2021, 3, e202000024.	1.4	3
5645	Functional connectivity of spoken language processing in early-stage Parkinson's disease: An MEG study. <i>NeuroImage: Clinical</i> , 2021, 32, 102718.	1.4	13
5646	Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 578339.	1.7	51
5647	Alpha-Synucleinopathies. , 2021, , 387-410.		0
5648	Olfaction as an early marker of Parkinson's disease and Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 317-329.	1.0	22
5649	Hypothalamic α -synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.0	2
5650	Disorders of vocal emotional expression and comprehension: The aprosodias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 183, 63-98.	1.0	5
5651	Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 795.	1.8	12
5652	Reverse engineering Lewy bodies: how far have we come and how far can we go?. <i>Nature Reviews Neuroscience</i> , 2021, 22, 111-131.	4.9	104
5653	Electrophysiological evaluation of audiovestibular pathway dysfunction in parkinson's disease and its correlates: A case control study. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 531.	0.2	4
5654	An Update on Medical and Surgical Treatments of Parkinson's Disease. , 2021, 12, 1021.		25
5655	Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 725.	1.8	7
5656	Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. <i>Molecular Psychiatry</i> , 2021, 26, 2685-2706.	4.1	18

#	ARTICLE	IF	CITATIONS
5657	Autonomic dysfunction during sleep in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 1, 251-283.	0.1	0
5658	Single-Cell Technologies in Parkinson's Disease. , 2021, , 15-30.		0
5659	Extracellular Vesicles in Neurological Disorders. <i>Sub-Cellular Biochemistry</i> , 2021, 97, 411-436.	1.0	3
5660	Serotonergic control of the glutamatergic neurons of the subthalamic nucleus. <i>Progress in Brain Research</i> , 2021, 261, 423-462.	0.9	3
5662	Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α -Synuclein Levels in Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 616357.	1.7	3
5663	The role of type 2 Diabetes mellitus as a risk factor for Alzheimer's and Parkinson's diseases. <i>Research, Society and Development</i> , 2021, 10, e23410111673.	0.0	3
5664	Degenerative Movement Disorders of the Central Nervous System. , 2021, , 972-982.		0
5665	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 211-222.	1.0	3
5667	Seeding Propensity and Characteristics of Pathogenic α -Syn Assemblies in Formalin-Fixed Human Tissue from the Enteric Nervous System, Olfactory Bulb, and Brainstem in Cases Staged for Parkinson's Disease. <i>Cells</i> , 2021, 10, 139.	1.8	16
5668	Interaction between Parkin and α -Synuclein in PARK2-Mediated Parkinson's Disease. <i>Cells</i> , 2021, 10, 283.	1.8	31
5669	α -Synuclein evokes NLRP3 inflammasome-mediated IL-1 β secretion from primary human microglia. <i>Glia</i> , 2021, 69, 1413-1428.	2.5	58
5671	Viral infections and their relationship to neurological disorders. <i>Archives of Virology</i> , 2021, 166, 733-753.	0.9	60
5672	Metabolomics in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2021, 104, 107-149.	1.8	7
5673	The Membrane Interactions of Synuclein: Physiology and Pathology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 465-485.	9.6	32
5674	Genetic Diversity of SARS-CoV2 and Environmental Settings: Possible Association with Neurological Disorders. <i>Molecular Neurobiology</i> , 2021, 58, 1917-1931.	1.9	8
5675	Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model. <i>Journal of Neuroinflammation</i> , 2021, 18, 4.	3.1	70
5676	White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1411-1419.	2.2	22
5677	The role of oxidative stress and the underlying biological pathways in the pathogenesis of Parkinson's Disease. <i>International Journal of Complementary & Alternative Medicine</i> , 2021, 14, 17-24.	0.1	0

#	ARTICLE	IF	CITATIONS
5678	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. <i>Annals of Medicine</i> , 2021, 53, 611-625.	1.5	39
5679	Correlation between Alzheimer's Disease and Dementia with Lewy Bodies Scores Using VSRAD Advance. <i>Advances in Alzheimer's Disease</i> , 2021, 10, 33-45.	0.3	0
5680	Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 11.	2.5	23
5681	Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis. <i>Aging</i> , 2021, 13, 4007-4023.	1.4	7
5683	Identification of potential Parkinson's disease biomarkers using computational biology approaches. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 1.	1.2	0
5684	Imaging the Functional Neuroanatomy of Parkinson's Disease: Clinical Applications and Future Directions. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2356.	1.2	9
5686	Aquatic exercise associated or not with grape juice consumption-modulated oxidative parameters in Parkinson disease patients: A randomized intervention study. <i>Heliyon</i> , 2021, 7, e06185.	1.4	3
5687	Are the 50's, the transition decade, in choroid plexus aging?. <i>GeroScience</i> , 2021, 43, 225-237.	2.1	6
5688	Gastrectomy, vitamin B12 supplementation and the risk of Parkinson's disease: A nationwide cohort study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 15-21.	1.1	4
5689	Evaluation of the pharynx and upper esophageal sphincter motility using high-resolution pharyngeal manometry for Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2021, 201, 106447.	0.6	14
5690	Ecto-GPR37: a potential biomarker for Parkinson's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 8.	3.6	19
5691	Spectrum of Non-Motor Symptoms in Parkinson's Disease. <i>Cureus</i> , 2021, 13, e13275.	0.2	13
5692	Glucocerebrosidase reduces the spread of protein aggregation in a <i>Drosophila melanogaster</i> model of neurodegeneration by regulating proteins trafficked by extracellular vesicles. <i>PLoS Genetics</i> , 2021, 17, e1008859.	1.5	20
5693	α-Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in SNCA Mice. <i>Movement Disorders</i> , 2021, 36, 2036-2047.	2.2	34
5694	Seeded assembly <i>in vitro</i> does not replicate the structures of α-synuclein filaments from multiple system atrophy. <i>FEBS Open Bio</i> , 2021, 11, 999-1013.	1.0	95
5695	The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 636545.	1.7	111
5696	Temporal orienting in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 2713-2725.	1.2	7
5697	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. <i>Neurobiology of Disease</i> , 2021, 149, 105229.	2.1	36

#	ARTICLE	IF	CITATIONS
5698	Different patterns of hippocampal subfield pathology in Lewy body disease and Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 705-706.	1.8	2
5699	Sexual Disorders and Quality of Life in Parkinson's Disease. <i>Sexual Medicine</i> , 2021, 9, 100280-100280.	0.9	16
5700	Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease. <i>Neuroscientist</i> , 2022, 28, 530-542.	2.6	8
5701	Vulnerability of Subcellular Structures to Pathogenesis Induced by Rotenone in SH-SY5Y Cells. <i>Physiological Research</i> , 2021, 70, 89-99.	0.4	3
5703	Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic—A nationwide retrospective study. <i>PLoS ONE</i> , 2021, 16, e0246342.	1.1	2
5704	The Two Faces of Exosomes in Parkinson's Disease: From Pathology to Therapy. <i>Neuroscientist</i> , 2022, 28, 180-193.	2.6	9
5705	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 25.	2.4	23
5706	Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. <i>Frontiers in Neuroscience</i> , 2020, 14, 580311.	1.4	15
5707	Novel targeted therapies for Parkinson's disease. <i>Molecular Medicine</i> , 2021, 27, 17.	1.9	54
5709	The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. <i>Nutrients</i> , 2021, 13, 732.	1.7	90
5710	microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. <i>Sleep Medicine</i> , 2021, 78, 160-168.	0.8	6
5711	Regional Cerebral Cortical Atrophy is Related to Urinary Tract Symptoms in Parkinson's Disease. <i>Journal of Neuroimaging</i> , 2021, 31, 363-371.	1.0	4
5712	Impact of rapid eye movement sleep behavior disorder and autonomic disorders on Parkinson's disease: a review. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 156-166.	0.3	1
5713	Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives. <i>Frontiers in Immunology</i> , 2021, 12, 611761.	2.2	22
5714	Advances of Mechanisms-Related Metabolomics in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 614251.	1.4	6
5715	Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 2724.	1.6	10
5716	Is Attention-Deficit/Hyperactivity Disorder a Risk Syndrome for Parkinson's Disease?. <i>Harvard Review of Psychiatry</i> , 2021, 29, 142-158.	0.9	6
5717	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. <i>Cells</i> , 2021, 10, 375.	1.8	54

#	ARTICLE	IF	CITATIONS
5718	Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 207-229.	1.6	10
5719	Amyloid related cerebral microbleed and plasma A β 240 are associated with cognitive decline in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 7115.	1.6	14
5720	Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 623659.	1.4	12
5721	Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. <i>Brain</i> , 2021, 144, 1787-1798.	3.7	44
5722	Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities. <i>Antioxidants</i> , 2021, 10, 453.	2.2	33
5723	EEG-Derived Functional Connectivity Patterns Associated with Mild Cognitive Impairment in Parkinson's Disease. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021, 11, 40.	1.0	14
5724	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences. <i>Cells</i> , 2021, 10, 656.	1.8	25
5725	Non-motor symptoms related to quality of life and dependency in Parkinson patients at San Pedro de Alc�ntara Hospital: Differences between men and women. <i>Revista Cient�fica De La Sociedad De Enfermer�a Neurol�gica (English Ed)</i> , 2021, , .	0.0	0
5726	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 155-163.	1.1	4
5727	Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. <i>Brain Research Bulletin</i> , 2021, 168, 165-177.	1.4	13
5728	The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 315-332.	1.7	47
5729	Treatment response and age of onset as risk indicators for parkinson disease in patients with major depressive disorder: A nationwide longitudinal study. <i>Journal of Affective Disorders</i> , 2021, 283, 329-334.	2.0	3
5730	Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview. <i>Current Drug Research Reviews</i> , 2021, 13, 166-171.	0.7	8
5731	Sympathetic and sensory nerve fiber function in multiple system atrophy and idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 3435-3443.	1.8	8
5732	Medical aromatherapy in geriatric syndrome. <i>Geriatrics and Gerontology International</i> , 2021, 21, 377-385.	0.7	8
5733	O tempo de balan�o como vari�vel preditiva da doen�a de Parkinson. <i>Fisioterapia E Pesquisa</i> , 2021, 28, 95-100.	0.3	0
5734	The Nigral Coup in Parkinson's Disease by α -Synuclein and Its Associated Rebels. <i>Cells</i> , 2021, 10, 598.	1.8	19
5735	Potential of extracellular vesicles in the Parkinson's disease — Pathological mediators and biomarkers. <i>Neurochemistry International</i> , 2021, 144, 104974.	1.9	21

#	ARTICLE	IF	CITATIONS
5736	The role of innate immunity and inflammation in Parkinson's disease. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13022.	1.3	23
5737	Much ado about nothing? Off-target amplification can lead to false-positive bacterial brain microbiome detection in healthy and Parkinson's disease individuals. <i>Microbiome</i> , 2021, 9, 75.	4.9	31
5738	Autonomic Function in Patients With Parkinson's Disease: From Rest to Exercise. <i>Frontiers in Physiology</i> , 2021, 12, 626640.	1.3	10
5739	Progression in Parkinson's disease: a potpourri of plots and probabilities. <i>Brain</i> , 2021, 144, 708-711.	3.7	0
5740	Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study. <i>Journal of the Neurological Sciences</i> , 2021, 422, 117309.	0.3	11
5741	CD33 rs3865444 as a risk factor for Parkinson's disease. <i>Neuroscience Letters</i> , 2021, 748, 135709.	1.0	7
5742	Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia. <i>Journal of Neurochemistry</i> , 2021, 159, 305-317.	2.1	8
5743	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. <i>Brain</i> , 2021, 144, 2513-2526.	3.7	53
5744	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111426.	2.2	14
5745	Genetic basis of susceptibility to low-dose paraquat and variation between the sexes in <i>Drosophila melanogaster</i> . <i>Molecular Ecology</i> , 2021, 30, 2040-2053.	2.0	11
5746	Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models. <i>Cell Calcium</i> , 2021, 94, 102362.	1.1	23
5747	Widespread Decreases in Cerebral Copper Are Common to Parkinson's Disease Dementia and Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 641222.	1.7	21
5749	Thalamic morphology predicts the onset of freezing of gait in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 20.	2.5	19
5750	Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder. <i>Movement Disorders</i> , 2021, 36, 1720-1726.	2.2	18
5751	Progression of phosphorylated α -synuclein in <i>Macaca fuscata</i> . <i>Brain Pathology</i> , 2021, 31, e12952.	2.1	6
5752	Upper brainstem GABA levels in Parkinson's disease. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 689-696.	1.1	8
5753	α -Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms. <i>Science Advances</i> , 2021, 7, .	4.7	9
5754	Sleep Disorders and Cognitive Dysfunctions in Parkinson's Disease: A Meta-Analytic Study. <i>Neuropsychology Review</i> , 2021, 31, 643-682.	2.5	31

#	ARTICLE	IF	CITATIONS
5755	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. <i>Brain</i> , 2021, 144, 2186-2198.	3.7	100
5756	Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?. <i>Npj Parkinson's Disease</i> , 2021, 7, 26.	2.5	46
5757	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson's Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. <i>Metabolites</i> , 2021, 11, 145.	1.3	11
5758	Central nervous system diseases related to pathological microglial phagocytosis. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 528-539.	1.9	27
5759	Association of Parkinson's Disease With Microbes and Microbiological Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 619354.	1.8	22
5760	Super-resolving Microscopy in Neuroscience. <i>Chemical Reviews</i> , 2021, 121, 11971-12015.	23.0	40
5761	Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 534-540.	0.8	13
5762	Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 626128.	1.8	38
5763	The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. <i>Molecular Therapy</i> , 2021, 29, 949-972.	3.7	10
5764	Brain Molecular Connectivity in Neurodegenerative Conditions. <i>Brain Sciences</i> , 2021, 11, 433.	1.1	7
5765	Active lifestyle enhances protein expression profile in subjects with Lewy body pathology. <i>Dementia & Neuropsychologia</i> , 2021, 15, 41-50.	0.3	4
5766	Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics. <i>Archives of Microbiology</i> , 2021, 203, 2895-2910.	1.0	8
5767	Evaluation of blood flow as a route for propagation in experimental synucleinopathy. <i>Neurobiology of Disease</i> , 2021, 150, 105255.	2.1	5
5768	The role of noradrenaline in cognition and cognitive disorders. <i>Brain</i> , 2021, 144, 2243-2256.	3.7	81
5769	Effects of α -Synuclein-Associated Post-Translational Modifications in Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1061-1071.	1.7	35
5770	The cell biology of Parkinson's disease. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	77
5771	Role of the Peripheral Nervous System in PD Pathology, Diagnosis, and Treatment. <i>Frontiers in Neuroscience</i> , 2021, 15, 598457.	1.4	5
5773	Decreased Risk of Parkinson's Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls. <i>Journal of Parkinson's Disease</i> , 2021, 11, 821-832.	1.5	12

#	ARTICLE	IF	CITATIONS
5774	Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 133-140.	1.1	32
5775	Distinct neural circuits are associated with subclinical neuropsychiatric symptoms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117365.	0.3	12
5777	The Î±-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. <i>Journal of Parkinson's Disease</i> , 2021, 11, 455-474.	1.5	81
5778	Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases. <i>Journal of Neural Transmission</i> , 2021, 128, 687-699.	1.4	13
5779	Synucleinopathy-associated pathogenesis in Parkinson's disease and the potential for brain-derived neurotrophic factor. <i>Npj Parkinson's Disease</i> , 2021, 7, 35.	2.5	26
5780	Effects of domotics on cognitive, social and personal functioning in patients with Parkinson's disease: A pilot study. <i>Assistive Technology</i> , 2022, 34, 423-428.	1.2	3
5782	The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 638208.	1.7	20
5784	Delayed orthostatic hypotension in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 37.	2.5	10
5785	Baroreflex dysfunction in Parkinson's disease: integration of central and peripheral mechanisms. <i>Journal of Neurophysiology</i> , 2021, 125, 1425-1439.	0.9	12
5786	The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 1354-1368.	0.7	3
5787	LeSCoD: a new clinical scale for the detection of Lewy body disease in neurocognitive disorders. <i>Journal of Neurology</i> , 2021, 268, 3886-3896.	1.8	0
5788	Roles of Motor Cortex Neuron Classes in Reach-Related Modulation for Hemiparkinsonian Rats. <i>Frontiers in Neuroscience</i> , 2021, 15, 645849.	1.4	4
5789	Molecular and Genetic Factors Involved in Olfactory and Gustatory Deficits and Associations with Microbiota in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4286.	1.8	14
5790	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. <i>Neurotherapeutics</i> , 2021, 18, 686-708.	2.1	19
5791	Perampanel Inhibits Î±-Synuclein Transmission in Parkinson's Disease Models. <i>Movement Disorders</i> , 2021, 36, 1554-1564.	2.2	21
5792	Exploring the Use of Intracranial and Extracranial (Remote) Photobiomodulation Devices in Parkinson's Disease: A Comparison of Direct and Indirect Systemic Stimulations. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1399-1413.	1.2	18
5793	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2085-2093.	2.2	23
5794	Prodromal Parkinson disease subtypes â€” key to understanding heterogeneity. <i>Nature Reviews Neurology</i> , 2021, 17, 349-361.	4.9	171

#	ARTICLE	IF	CITATIONS
5795	Quantification of long-term accumulation of inhaled ultrafine particles via human olfactory-brain pathway due to environmental emissions – a pilot study. <i>NanoImpact</i> , 2021, 22, 100322.	2.4	11
5797	Activation-Induced Rigidity in Neurologically and Cognitively Healthy Individuals Aged 18–90 Years: A Cross-Sectional Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 847-856.	1.5	0
5798	Molecular Imaging of Neurodegenerative Parkinsonism. <i>PET Clinics</i> , 2021, 16, 261-272.	1.5	0
5799	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 62.	2.4	79
5801	LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2021, 142, 117-137.	3.9	15
5802	Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3960.	1.8	0
5803	Prodromal neuroinvasion of pathological α -synuclein in brainstem reticular nuclei and white matter lesions in a model of α -synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcab104.	1.5	7
5804	Morphological differences between dementia with Lewy bodies and Parkinson's disease–dementia. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	7
5805	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2192-2199.	1.7	6
5807	Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein. <i>Acta Neuropathologica Communications</i> , 2021, 9, 64.	2.4	20
5809	The Neurotransmitter Receptor Architecture of the Mouse Olfactory System. <i>Frontiers in Neuroanatomy</i> , 2021, 15, 632549.	0.9	1
5810	Postprandial Increase in Mesenteric Blood Flow is Attenuated in Parkinson's Disease: A Dynamic PC-MRI Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 545-557.	1.5	1
5811	Beyond the average patient: how neuroimaging models can address heterogeneity in dementia. <i>Brain</i> , 2021, 144, 2946-2953.	3.7	46
5812	Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 44-51.	1.1	10
5813	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 1118-1126.	3.7	92
5814	A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis. <i>Biochemistry and Cell Biology</i> , 2021, 99, 173-194.	0.9	3
5815	Respiratory Dysfunctions in Parkinson's Disease Patients. <i>Brain Sciences</i> , 2021, 11, 595.	1.1	16
5816	Insights into Lewy body disease from rare neurometabolic disorders. <i>Journal of Neural Transmission</i> , 2021, 128, 1567-1575.	1.4	7

#	ARTICLE	IF	CITATIONS
5818	The Intersection of Parkinson's Disease, Viral Infections, and COVID-19. <i>Molecular Neurobiology</i> , 2021, 58, 4477-4486.	1.9	25
5819	Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes in <i>Drosophila</i> . <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	9
5821	Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2021, 42, 1444-1451.	1.2	4
5822	Nanomedicine against Alzheimer's and Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 1507-1545.	0.9	7
5824	Epigenetic Regulation of Neuroinflammation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4956.	1.8	40
5825	Decreased Exosomal Acetylcholinesterase Activity in the Plasma of Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 665400.	1.7	12
5827	Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666675.	1.8	10
5828	A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms. <i>Biomedicines</i> , 2021, 9, 598.	1.4	18
5829	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	1.0	13
5830	Karyopherin abnormalities in neurodegenerative proteinopathies. <i>Brain</i> , 2021, 144, 2915-2932.	3.7	20
5831	Templated β -synuclein inclusion formation is independent of endogenous tau. <i>ENeuro</i> , 2021, 8, ENEURO.0458-20.2021.	0.9	9
5833	Region-specific vulnerability in neurodegeneration: lessons from normal ageing. <i>Ageing Research Reviews</i> , 2021, 67, 101311.	5.0	27
5834	Association between Fatigue and Hoehn-Yahr Staging in Parkinson's Disease: Eight-Year Follow-Up Study. <i>Neurology International</i> , 2021, 13, 224-231.	1.3	4
5835	Brain Oximetry and the Quest for Quantified Metabolic Rate: Applications Using MRI and Near-Infrared Spectroscopy. <i>Applied Magnetic Resonance</i> , 2021, 52, 1343-1377.	0.6	5
5836	Abnormal center of mass feedback responses during balance: A potential biomarker of falls in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0252119.	1.1	21
5837	Machine Learning for the Diagnosis of Parkinson's Disease: A Review of Literature. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 633752.	1.7	150
5838	An autopsy case of corticobasal syndrome with pure diffuse Lewy Body Disease. <i>Neurocase</i> , 2021, 27, 231-237.	0.2	4
5840	Ráp'i loá²;n khá²£ nÄfng vá²n Äá»™ng trÄ³n mÄ' hÄ-nh ruá»™i giá²¥m biá»fu híá»²n Protein Alpha-Synuclein gÄ²y bá»²nh Parkinson. <i>Ta Nghién Cuu Y Hoc</i> , 2021, 138, 28-36.	0.0	0

#	ARTICLE	IF	CITATIONS
5841	Diffusion Magnetic Resonance Imaging-Based Biomarkers for Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5216.	1.8	39
5842	Oxidative stress and regulated cell death in Parkinson's disease. <i>Ageing Research Reviews</i> , 2021, 67, 101263.	5.0	162
5843	Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2293-2302.	2.2	7
5844	Role of the endolysosomal pathway and exosome release in tau propagation. <i>Neurochemistry International</i> , 2021, 145, 104988.	1.9	9
5845	Serum Ceruloplasmin Depletion is Associated With Magnetic Resonance Evidence of Widespread Accumulation of Brain Iron in Parkinson's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1098-1106.	1.9	9
5846	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , 2021, 53, 787-793.	9.4	82
5847	The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 589-613.	1.4	14
5848	Apathy and Anhedonia: Clinical and Neurophysiological Assessment of a Romanian Cohort. <i>Brain Sciences</i> , 2021, 11, 729.	1.1	1
5849	Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline. <i>Movement Disorders</i> , 2021, 36, 2066-2076.	2.2	26
5850	Update on alpha-synuclein-based biomarker approaches in the skin, submandibular gland, gastrointestinal tract, and biofluids. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 572-577.	1.8	6
5851	Electrogastrography for diagnosis of early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 61-66.	1.1	8
5852	Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19. <i>Journal of Dietary Supplements</i> , 2023, 20, 218-253.	1.4	5
5853	Hyposmia may predict development of freezing of gait in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 763-770.	1.4	5
5854	Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 672594.	2.0	18
5855	Parkinsonism-like Disease Induced by Rotenone in Rats: Treatment Role of Curcumin, Dopamine Agonist and Adenosine A2A Receptor Antagonist. <i>Current Aging Science</i> , 2022, 15, 65-76.	0.4	5
5856	Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. <i>Current Biology</i> , 2021, 31, 2140-2154.e6.	1.8	99
5857	Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α -synuclein, tau, amyloid β or vascular pathology. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1080-1091.	1.8	14
5858	Harnessing the immune system for the treatment of Parkinson's disease. <i>Brain Research</i> , 2021, 1758, 147308.	1.1	10

#	ARTICLE	IF	CITATIONS
5859	â€œJanus-Facedâ€-Synuclein: Role in Parkinsonâ€™s Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 673395.	1.8	8
5860	Phytochemicals as Potential Inhibitors of Advanced Glycation End Products: Health Aspects and Patent Survey. <i>Recent Patents on Food, Nutrition & Agriculture</i> , 2022, 13, 3-16.	0.5	0
5861	Patterns of Sulcal depth and cortical thickness in Parkinsonâ€™s disease. <i>Brain Imaging and Behavior</i> , 2021, 15, 2340-2346.	1.1	6
5863	Alpha-Synuclein and Mitochondrial Dysfunction in Parkinsonâ€™s Disease: The Emerging Role of VDAC. <i>Biomolecules</i> , 2021, 11, 718.	1.8	29
5864	Update on neuroimaging for categorization of Parkinson's disease and atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2021, 34, 514-524.	1.8	7
5865	The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. <i>Neuroscience Letters</i> , 2021, 753, 135865.	1.0	6
5866	The <i>O</i> -Glycome of Human Nigrostriatal Tissue and Its Alteration in Parkinsonâ€™s Disease. <i>Journal of Proteome Research</i> , 2021, 20, 3913-3924.	1.8	20
5867	Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683457.	1.8	9
5868	Is either anosmia or constipation associated with cognitive dysfunction in Parkinsonâ€™s disease?. <i>PLoS ONE</i> , 2021, 16, e0252451.	1.1	4
5869	Deficits in or preservation of basic number processing in Parkinsonâ€™s disease? A registered report. <i>Journal of Neuroscience Research</i> , 2021, 99, 2390-2405.	1.3	0
5870	Î±-Synuclein Responses in the Laterodorsal Tegmentum, the Pedunculo-pontine Tegmentum, and the Substantia Nigra: Implications for Early Appearance of Sleep Disorders in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1-18.	1.5	3
5871	Complicity of Î±-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease. <i>Archives of Pharmacal Research</i> , 2021, 44, 564-573.	2.7	1
5872	The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111428.	2.5	29
5873	Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 636139.	1.1	26
5874	R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. <i>Acta Neuropathologica</i> , 2021, 142, 475-494.	3.9	44
5875	Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. <i>Journal of Neurochemistry</i> , 2021, 158, 960-979.	2.1	22
5876	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of Î±-synuclein. <i>Cell Reports</i> , 2021, 35, 109189.	2.9	8
5877	Intranasal Carnosine Mitigates Î±-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinsonâ€™s Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2347-2359.	1.7	9

#	ARTICLE	IF	CITATIONS
5878	Drosophila tubulin polymerization promoting protein mutants reveal pathological correlates relevant to human Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 13614.	1.6	7
5879	Ameliorative Role of Nutraceuticals on Neurodegenerative Diseases Using the <i>Drosophila melanogaster</i> as a Discovery Model to Define Bioefficacy. <i>Journal of the American College of Nutrition</i> , 2022, 41, 511-539.	1.1	14
5880	Association of Lewy Bodies With Age-Related Clinical Characteristics in Black and White Decedents. <i>Neurology</i> , 2021, 97, e825-e835.	1.5	4
5881	Suppression of α -synuclein propagation after intrastriatal injection in FABP3 null mice. <i>Brain Research</i> , 2021, 1760, 147383.	1.1	9
5882	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
5883	Mechanistic basis for receptor-mediated pathological α -synuclein fibril cell-to-cell transmission in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	59
5884	Nociception alterations precede motor symptoms in a progressive model of parkinsonism induced by reserpine in middle-aged rats. <i>Brain Research Bulletin</i> , 2021, 171, 1-9.	1.4	4
5885	Parkinson mice show functional and molecular changes in the gut long before motoric disease onset. <i>Molecular Neurodegeneration</i> , 2021, 16, 34.	4.4	29
5886	Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. <i>Biomedicines</i> , 2021, 9, 684.	1.4	14
5887	Diagnosis of Dementia with Lewy Bodies: Fluctuations, Biomarkers, and beyond. , 0, , .		2
5889	GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 153, 105298.	2.1	18
5890	α -Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. <i>Acta Neuropathologica Communications</i> , 2021, 9, 105.	2.4	17
5891	SARS-CoV-2 infection in patients with serious mental illness and possible benefits of prophylaxis with Memantine and Amantadine. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 61, 1007-1022.	0.4	6
5892	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. <i>Frontiers in Neurology</i> , 2021, 12, 681369.	1.1	10
5893	Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 82-89.	1.1	10
5894	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6517.	1.8	38
5895	Treating Parkinson's disease by astrocyte reprogramming: Progress and challenges. <i>Science Advances</i> , 2021, 7, .	4.7	27
5896	Fasting gallbladder volume is increased in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 56-60.	1.1	3

#	ARTICLE	IF	CITATIONS
5898	Altered regional homogeneity and connectivity in cerebellum and visual-motor relevant cortex in Parkinson's disease with rapid eye movement sleep behavior disorder. <i>Sleep Medicine</i> , 2021, 82, 125-133.	0.8	10
5899	Differential seeding and propagating efficiency of α -synuclein strains generated in different conditions. <i>Translational Neurodegeneration</i> , 2021, 10, 20.	3.6	11
5900	Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. <i>Neurochemical Research</i> , 2021, 46, 2317-2332.	1.6	12
5901	α -Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?. <i>Biomolecules</i> , 2021, 11, 931.	1.8	14
5902	Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 681413.	1.1	12
5903	Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 689723.	1.4	41
5905	Peripheral administration of SOD1 aggregates does not transmit pathogenic aggregation to the CNS of SOD1 transgenic mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 111.	2.4	4
5906	The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy. <i>Acta Neuropathologica</i> , 2021, 142, 423-448.	3.9	65
5907	The Add-On Effect of <i>Lactobacillus plantarum</i> PS128 in Patients With Parkinson's Disease: A Pilot Study. <i>Frontiers in Nutrition</i> , 2021, 8, 650053.	1.6	36
5908	Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment. <i>Food and Chemical Toxicology</i> , 2021, 152, 112164.	1.8	16
5909	Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment. <i>Archives of Pharmacal Research</i> , 2021, 44, 588-604.	2.7	28
5911	Disrupted rich-club organization of brain structural networks in Parkinson's disease. <i>Brain Structure and Function</i> , 2021, 226, 2205-2217.	1.2	15
5912	Neurodegenerative diseases, art and creativity: therapeutic implications. <i>Neurodegenerative Disease Management</i> , 2021, 11, 187-192.	1.2	3
5913	First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1485-1494.	0.8	2
5914	Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6277.	1.8	11
5915	Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 656623.	1.7	7
5916	Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C1141-C1152.	2.1	9
5918	Lewy Body Dementias: A Coin with Two Sides?. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021, 11, 94.	1.0	8

#	ARTICLE	IF	CITATIONS
5919	Distribution of the Alpha-Synuclein in the Brain and the Primary Organs of the Rhesus Monkey. <i>Applied Biochemistry and Biotechnology</i> , 2021, 193, 3187-3201.	1.4	5
5920	Sleep Disorders in Parkinson Disease. <i>Sleep Medicine Clinics</i> , 2021, 16, 323-334.	1.2	5
5921	Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. <i>Biochemical and Biophysical Research Communications</i> , 2021, 556, 16-22.	1.0	5
5922	Movement of prion-like α -synuclein along the gut-brain axis in Parkinson's disease: A potential target of curcumin treatment. <i>European Journal of Neuroscience</i> , 2021, 54, 4695-4711.	1.2	14
5923	The Air We Breathe: Air Pollution as a Prevalent Proinflammatory Stimulus Contributing to Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 647643.	1.8	41
5924	Identification of amyloidogenic proteins in the microbiomes of a rat Parkinson's disease model and wild-type rats. <i>Protein Science</i> , 2021, 30, 1854-1870.	3.1	5
5925	Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6016.	1.8	28
5926	Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease. <i>Brain Imaging and Behavior</i> , 2022, 16, 118-129.	1.1	7
5927	A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 508-518.	2.3	8
5929	Caprylic acid ameliorates rotenone induced inflammation and oxidative stress in the gut-brain axis in Zebrafish. <i>Molecular Biology Reports</i> , 2021, 48, 5259-5273.	1.0	25
5930	Parkinson's disease. <i>Lancet, The</i> , 2021, 397, 2284-2303.	6.3	1,176
5932	Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers. <i>Medicine (United States)</i> , 2021, 100, e26534.	0.4	1
5933	Advances in protein-protein interaction network analysis for Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 155, 105395.	2.1	31
5934	Central Nervous System Cell-Derived Exosomes in Neurodegenerative Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	1.9	12
5936	Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1069.	2.2	53
5937	Trojan horses and tunneling nanotubes enable α -synuclein pathology to spread in Parkinson disease. <i>PLoS Biology</i> , 2021, 19, e3001331.	2.6	6
5938	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. <i>Journal of Neural Transmission</i> , 2021, 128, 1481-1494.	1.4	6
5939	Neurodegenerative disorders and gut-brain interactions. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	55

#	ARTICLE	IF	CITATIONS
5940	Neurodegenerative proteinopathies associated with neuroinfections. <i>Journal of Neural Transmission</i> , 2021, 128, 1551-1566.	1.4	17
5941	The Upper Motor Neuronâ€™Improved Knowledge from ALS and Related Clinical Disorders. <i>Brain Sciences</i> , 2021, 11, 958.	1.1	3
5942	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. <i>Frontiers in Medicine</i> , 2021, 8, 655123.	1.2	11
5943	Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats. <i>Brain Research</i> , 2021, 1762, 147442.	1.1	5
5944	Monoamine Levels and Parkinsonâ€™s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study. <i>Frontiers in Neuroscience</i> , 2021, 15, 605887.	1.4	11
5945	The Neural Gutâ€™Brain Axis of Pathological Protein Aggregation in Parkinsonâ€™s Disease and Its Counterpart in Peroral Prion Infections. <i>Viruses</i> , 2021, 13, 1394.	1.5	3
5946	Norepinephrine Protects against Methamphetamine Toxicity through β 2-Adrenergic Receptors Promoting LC3 Compartmentalization. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7232.	1.8	7
5947	Diffusion kurtosis imaging detects the timeâ€dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 158, 779-797.	2.1	12
5948	Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model. <i>Experimental Neurology</i> , 2021, 341, 113707.	2.0	3
5949	Imaging of the dopamine system with focus on pharmacological MRI and neuromelanin imaging. <i>European Journal of Radiology</i> , 2021, 140, 109752.	1.2	11
5950	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. <i>Acta Neuropathologica</i> , 2021, 142, 449-474.	3.9	27
5951	Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinsonâ€™s Disease. <i>Biomedicines</i> , 2021, 9, 918.	1.4	46
5952	Parkinsonâ€™s Disease: A Prionopathy?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8022.	1.8	12
5953	Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinsonâ€™s disease rats. <i>Brain Research Bulletin</i> , 2021, 172, 1-13.	1.4	12
5954	A Systematic Review of Parkinsonâ€™s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7213.	1.8	5
5955	PIAS2-mediated blockade of IFN- β signaling: a basis for sporadic Parkinson disease dementia. <i>Molecular Psychiatry</i> , 2021, 26, 6083-6099.	4.1	30
5956	α -Synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes. <i>PLoS Biology</i> , 2021, 19, e3001287.	2.6	45
5957	Title of the manuscript: Mechanistic insights into chalcone butein-induced inhibition of α -synuclein fibrillation: Biophysical and insilico studies. <i>Journal of Molecular Liquids</i> , 2021, 334, 116105.	2.3	10

#	ARTICLE	IF	CITATIONS
5958	Parkinson's Disease Genetics and Pathophysiology. Annual Review of Neuroscience, 2021, 44, 87-108.	5.0	92
5959	Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease. Scientific Reports, 2021, 11, 15185.	1.6	43
5961	Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Scientific Reports, 2021, 11, 14992.	1.6	14
5962	Rat Models of Vocal Deficits in Parkinson's Disease. Brain Sciences, 2021, 11, 925.	1.1	12
5963	Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus. Frontiers in Cell and Developmental Biology, 2021, 9, 691560.	1.8	9
5964	Association of NO ₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease. JAMA Neurology, 2021, 78, 800.	4.5	74
5965	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	1.5	34
5966	Cellular transplantation for Parkinson's disease: a strategy whose time has passed. Journal of Neurosurgery, 2021, 135, 1898-1902.	0.9	2
5967	Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to step up. Clinical Genetics, 2021, 100, 659-677.	1.0	8
5968	Arousal characteristics in patients with Parkinson's disease and isolated rapid eye movement sleep behavior disorder. Sleep, 2021, 44, .	0.6	5
5969	Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota. Journal of Parkinson's Disease, 2021, 11, 1491-1505.	1.5	21
5970	Hot Topics in Recent Parkinson's Disease Research: Where We are and Where We Should Go. Neuroscience Bulletin, 2021, 37, 1735-1744.	1.5	19
5971	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 1-11.	1.5	1
5973	Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease. Brain and Behavior, 2021, 11, e2280.	1.0	6
5974	Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents. Molecular Diversity, 2021, 25, 1517-1539.	2.1	8
5975	SIRT1 Protects Dopaminergic Neurons in Parkinson's Disease Models via PGC-1 β -Mediated Mitochondrial Biogenesis. Neurotoxicity Research, 2021, 39, 1393-1404.	1.3	16
5976	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. Brain, 2021, 144, 2732-2744.	3.7	57
5977	Vagotomy and insights into the microbiota-gut-brain axis. Neuroscience Research, 2021, 168, 20-27.	1.0	33

#	ARTICLE	IF	CITATIONS
5978	Different resting-state network disruptions in newly diagnosed drug-naïve Parkinson's disease patients with mild cognitive impairment. <i>BMC Neurology</i> , 2021, 21, 327.	0.8	11
5979	Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1091-1115.	1.5	10
5980	The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson's Disease. <i>Life</i> , 2021, 11, 804.	1.1	10
5981	In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung. <i>Brain Research</i> , 2021, 1765, 147503.	1.1	6
5982	Gut brain axis: an insight into microbiota role in Parkinson's disease. <i>Metabolic Brain Disease</i> , 2021, 36, 1545-1557.	1.4	10
5983	The Cholinergic Brain in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1012-1026.	0.8	42
5984	The role of endoplasmic reticulum stress in astrocytes. <i>Glia</i> , 2022, 70, 5-19.	2.5	30
5985	Myrtenol complexed with β -cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpine-induced animal model of Parkinsonism. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 1488-1499.	0.9	5
5986	Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson's Disease Dementia. <i>Metabolites</i> , 2021, 11, 569.	1.3	17
5988	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 177.	3.1	18
5989	Galectin-3 Deletion Reduces LPS and Acute Colitis-Induced Pro-Inflammatory Microglial Activation in the Ventral Mesencephalon. <i>Frontiers in Pharmacology</i> , 2021, 12, 706439.	1.6	6
5990	Diagnosis of Parkinson Disease: Imaging and Non-Imaging Techniques. <i>Series in Bioengineering</i> , 2022, , 61-78.	0.3	0
5991	Increased oscillatory power in a computational model of the olfactory bulb due to synaptic degeneration. <i>Physical Review E</i> , 2021, 104, 024405.	0.8	1
5992	Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2306-2325.	5.7	134
5993	Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model. <i>Radiology</i> , 2021, 300, 390-399.	3.6	19
5994	Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 656379.	1.1	7
5995	Brain iron enrichment attenuates α -synuclein spreading after injection of preformed fibrils. <i>Journal of Neurochemistry</i> , 2021, 159, 554-573.	2.1	11
5996	Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108746.	1.6	7

#	ARTICLE	IF	CITATIONS
5997	Determinants of self-efficacy in patients with Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 686-691.	0.3	2
5998	Morphine attenuates neurotoxic effects of MPTP in zebrafish embryos by regulating oxidant/antioxidant balance and acetylcholinesterase activity. <i>Drug and Chemical Toxicology</i> , 2022, 45, 2439-2447.	1.2	13
5999	The Human Hippocampus in Parkinson's Disease: An Integrative Stereological and Proteomic Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1345-1365.	1.5	27
6000	Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 709878.	1.7	6
6001	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1189-1193.	0.8	1
6002	GAPDH siRNA Regulates SH-SY5Y Cell Apoptosis Induced by Exogenous α -Synuclein Protein. <i>Neuroscience</i> , 2021, 469, 91-102.	1.1	5
6003	Effect of Coffee, Tobacco, and Alcohol on Parkinson's Disease. <i>Journal of the Korean Neurological Association</i> , 2021, 39, 129-133.	0.0	0
6004	Structural network topology and microstructural alterations of the anterior insula associate with cognitive and affective impairment in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 16021.	1.6	10
6005	Epigenetic inactivation of the autophagy-lysosomal system in appendix in Parkinson's disease. <i>Nature Communications</i> , 2021, 12, 5134.	5.8	18
6006	Glutathione and Related Molecules in Parkinsonism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8689.	1.8	30
6009	The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683459.	1.8	94
6010	Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 98-104.	1.1	57
6011	Association Between Globular Glial Tauopathies and Frontotemporal Dementia—Expanding the Spectrum of Gliocentric Disorders. <i>JAMA Neurology</i> , 2021, 78, 1004.	4.5	16
6012	Respiratory Disorders in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 993-1010.	1.5	9
6013	Lewy Body-like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α -Synuclein Mutations. <i>Annals of Neurology</i> , 2021, 90, 490-505.	2.8	43
6014	The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8338.	1.8	47
6015	Exploring human-genome gut-microbiome interaction in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 74.	2.5	15
6016	Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 680765.	1.1	10

#	ARTICLE	IF	CITATIONS
6017	Time-Specific Pattern of Iron Deposition in Different Regions in Parkinson's Disease Measured by Quantitative Susceptibility Mapping. <i>Frontiers in Neurology</i> , 2021, 12, 631210.	1.1	8
6018	Comparison of early F-18 Florbetaben PET/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis. <i>Scientific Reports</i> , 2021, 11, 16738.	1.6	4
6019	Piperine promotes autophagy flux by P2RX4 activation in <i>SNCA</i> β -synuclein-induced Parkinson disease model. <i>Autophagy</i> , 2022, 18, 559-575.	4.3	29
6020	Modelling the functional genomics of Parkinson's disease in <i>Caenorhabditis elegans</i> <i>LRRK2</i> and beyond. <i>Bioscience Reports</i> , 2021, 41, .	1.1	8
6021	Roles of β -synuclein in gastrointestinal microbiome dysbiosis-related Parkinson's disease progression (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19
6022	Is There a Better Way to Assess Parkinsonian Motor Symptoms?—Experimental and Modelling Approach. <i>Series in Bioengineering</i> , 2022, , 151-167.	0.3	2
6023	Hippocampal and Reticulo-Thalamic Parvalbumin Interneurons and Synaptic Re-Organization during Sleep Disorders in the Rat Models of Parkinson's Disease Neuropathology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8922.	1.8	2
6024	Early-Onset Parkinson's Disease With Multiple Positive Intraoperative Spinal Tissue Cultures for <i>Cutibacterium acnes</i> . <i>Cureus</i> , 2021, 13, e17607.	0.2	2
6025	Braak's Unfinished Hypothesis: A Clinicopathological Case Report of β -Synuclein Peripheral Neuropathy Preceding Parkinsonism by 20 Years. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1129-1133.	0.8	4
6026	Noninvasive vagus nerve stimulation in Parkinson's disease: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2021, 18, 971-984.	1.4	15
6027	Altered Cortical Cholinergic Network in Parkinson's Disease at Different Stage: A Resting-State fMRI Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 723948.	1.7	4
6029	Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. <i>Journal of Neuroscience Research</i> , 2021, 99, 2922-2931.	1.3	1
6030	The role of neuroimaging in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 159, 660-689.	2.1	35
6031	Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. <i>Nature Aging</i> , 2021, 1, 850-863.	5.3	16
6032	Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy. <i>Journal of Movement Disorders</i> , 2022, 15, 1-14.	0.7	12
6033	Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. <i>Frontiers in Medicine</i> , 2021, 8, 665520.	1.2	9
6034	Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association. <i>Biomolecules</i> , 2021, 11, 1333.	1.8	21
6035	Structural and Functional Insights into β -Synuclein Fibril Polymorphism. <i>Biomolecules</i> , 2021, 11, 1419.	1.8	39

#	ARTICLE	IF	CITATIONS
6036	Identification of Potential Core Genes in Parkinson's Disease Using Bioinformatics Analysis. <i>Parkinson's Disease</i> , 2021, 2021, 1-10.	0.6	7
6037	She Doesn't Even Go Here: The Role of Inflammatory Astrocytes in CNS Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 704884.	1.8	20
6038	The Role of Vitamin D in Neurodegeneration and Other Pathological Processes of the Central Nervous System. , 0, , .		1
6039	The neuromicrobiology of Parkinson's disease: A unifying theory. <i>Ageing Research Reviews</i> , 2021, 70, 101396.	5.0	24
6040	Association between heart rate variability and striatal dopamine depletion in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1835-1840.	1.4	5
6041	Brain Networks and Cognitive Impairment in Parkinson's Disease. <i>Brain Connectivity</i> , 2022, 12, 465-475.	0.8	15
6043	Activated microglia facilitate the transmission of α -synuclein in Parkinson's disease. <i>Neurochemistry International</i> , 2021, 148, 105094.	1.9	20
6044	Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies. <i>Journal of Parkinson's Disease</i> , 2021, 11, S189-S197.	1.5	5
6045	Quantification of brainstem norepinephrine relative to vocal impairment and anxiety in the Pink1 ^{-/-} rat model of Parkinson disease. <i>Behavioural Brain Research</i> , 2021, 414, 113514.	1.2	19
6046	Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson's Disease Model Mice. <i>Biomolecules and Therapeutics</i> , 2021, 29, 483-491.	1.1	4
6047	Neurodegenerative disorders and the current state, pathophysiology and management of Parkinson's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, .	0.8	0
6048	Impaired brain insulin signalling in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	22
6049	Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9839.	1.8	7
6050	Olfactory dysfunction in aging and neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2021, 70, 101416.	5.0	56
6051	Neurotoxic or neuroprotective: Post-translational modifications of α -synuclein at the cross-roads of functions. <i>Biochimie</i> , 2022, 192, 38-50.	1.3	5
6052	Cortical alpha-synuclein preformed fibrils do not affect interval timing in mice. <i>Neuroscience Letters</i> , 2021, 765, 136273.	1.0	8
6053	Parkinson's disease and the gut: Models of an emerging relationship. <i>Acta Biomaterialia</i> , 2021, 132, 325-344.	4.1	15
6054	Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs. <i>Movement Disorders</i> , 2021, 36, 2888-2900.	2.2	37

#	ARTICLE	IF	CITATIONS
6055	The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?. <i>Frontiers in Immunology</i> , 2021, 12, 718220.	2.2	38
6056	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	4.9	220
6057	Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2022, 2389, 209-220.	0.4	2
6058	The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer's dementia in older persons. <i>Acta Neuropathologica Communications</i> , 2021, 9, 156.	2.4	20
6059	A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1555-1567.	1.5	15
6060	Association Between Irritable Bowel Syndrome and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 720958.	1.1	10
6061	Twenty-four-hour blood pressure profile in idiopathic REM sleep behavior disorder. <i>Sleep</i> , 2022, 45, .	0.6	5
6062	Auditory dysfunction in central nervous system diseases. <i>Otorhinolaryngology(Italy)</i> , 2021, 71, .	0.1	0
6063	Heat Shock Protein 70 as a Sex-Skewed Regulator of α -Synucleinopathy. <i>Neurotherapeutics</i> , 2021, 18, 2541-2564.	2.1	5
6064	The Regulation of Rab GTPases by Phosphorylation. <i>Biomolecules</i> , 2021, 11, 1340.	1.8	15
6066	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. <i>Cells</i> , 2021, 10, 2438.	1.8	22
6067	Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α -synuclein. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 57-61.	1.1	3
6068	Cerebral dopamine neurotrophic factor reduces α -synuclein aggregation and propagation and alleviates behavioral alterations in vivo. <i>Molecular Therapy</i> , 2021, 29, 2821-2840.	3.7	26
6069	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. <i>Acta Neuropathologica</i> , 2021, 142, 961-984.	3.9	31
6070	The Histaminergic System in Neuropsychiatric Disorders. <i>Biomolecules</i> , 2021, 11, 1345.	1.8	9
6071	Dual-Task-Based Drum Playing with Rhythmic Cueing on Motor and Attention Control in Patients with Parkinson's Disease: A Preliminary Randomized Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10095.	1.2	10
6072	Editorial: Intracellular Mechanisms of α -Synuclein Processing. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 752378.	1.8	0
6073	Elderly-Onset Multiple System Atrophy with Lewy Body Pathology: A Case Report. <i>Case Reports in Neurology</i> , 2021, 13, 613-619.	0.3	0

#	ARTICLE	IF	CITATIONS
6074	Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. <i>Brain</i> , 2021, 144, 3674-3691.	3.7	13
6075	The Functions of Thioredoxin 1 in Neurodegeneration. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 1023-1036.	2.5	10
6076	Role of Inflammation in Lewy Body Dementia. , 2021, , 190-212.		0
6077	Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 158, 105478.	2.1	15
6078	Interactions between the microbiota and enteric nervous system during gut-brain disorders. <i>Neuropharmacology</i> , 2021, 197, 108721.	2.0	27
6079	Body Weight Support Gait Training for Patients With Parkinson Disease: A Systematic Review and Meta-analyses. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 2012-2021.	0.5	10
6080	Alterations of gut microbiota and metabolome with Parkinson's disease. <i>Microbial Pathogenesis</i> , 2021, 160, 105187.	1.3	38
6081	Neuroaspis PLP10 α , ϕ , a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial. <i>Clinical Neurology and Neurosurgery</i> , 2021, 210, 106954.	0.6	10
6082	Transcutaneous vagus nerve stimulation (tVNS) as a potential therapeutic application for neurodegenerative disorders "A focus on dysautonomia in Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 235, 102858.	1.4	2
6083	Nanotherapeutics approaches for targeting alpha synuclein protein in the management of Parkinson disease. <i>Process Biochemistry</i> , 2021, 110, 181-194.	1.8	8
6084	Measurement of the facial nerve thickness and its correlation with freezing phenomenon and hypomimia in Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> , 2021, 210, 106960.	0.6	0
6085	Frontal lobe dysfunction is associated with reduced DAT-SPECT accumulation in Lewy body disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 119998.	0.3	3
6086	Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. , 2021, 227, 107873.		17
6087	Potential applications of nanomedicine for treating Parkinson's disease. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 66, 102793.	1.4	7
6088	Circulating extracellular vesicles: friends and foes in neurodegeneration. <i>Neural Regeneration Research</i> , 2022, 17, 534.	1.6	20
6089	Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine. <i>Neural Regeneration Research</i> , 2022, 17, 523.	1.6	21
6091	Effect of Modified Wumei Wan on Non-Motor Symptoms of Parkinson's Disease. <i>Traditional Chinese Medicine</i> , 2021, 10, 193-199.	0.1	0
6092	Species-barrier on the cross-species oral transmission of bovine AA amyloidosis in mice. <i>Journal of Veterinary Medical Science</i> , 2021, 83, 962-967.	0.3	2

#	ARTICLE	IF	CITATIONS
6093	Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 254-263.	0.8	5
6094	Cross-seeding of alpha-synuclein aggregation by amyloid fibrils of food proteins. <i>Journal of Biological Chemistry</i> , 2021, 296, 100358.	1.6	24
6095	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
6097	Predicting Working Memory Training Responsiveness in Parkinson's Disease: Both "System Hardware" and Room for Improvement Are Needed. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 117-130.	1.4	3
6098	Tau in the Pathophysiology of Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 2179-2191.	1.1	47
6099	Alteration of brain structural connectivity in progression of Parkinson's disease: A connectome-wide network analysis. <i>NeuroImage: Clinical</i> , 2021, 31, 102715.	1.4	16
6100	The enigma and implications of brain hemispheric asymmetry in neurodegenerative diseases. <i>Brain Communications</i> , 2021, 3, fcab211.	1.5	34
6101	Regulation of sleep in <i>Drosophila melanogaster</i> . <i>Advances in Insect Physiology</i> , 2021, , 119-168.	1.1	0
6102	Gastrointestinal Dysfunction in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 493.	1.0	37
6103	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	3.9	107
6104	The development and convergence of co-pathologies in Alzheimer's disease. <i>Brain</i> , 2021, 144, 953-962.	3.7	76
6105	Targeted attenuation of elevated histone marks at <i>SNCA</i> alleviates α -synuclein in Parkinson's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e12188.	3.3	43
6106	Gastrointestinal dysfunction in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 1, 179-208.	0.1	0
6107	Single-Cell Approaches for Studying the Role of Mitochondrial DNA in Neurodegenerative Disease. <i>Methods in Molecular Biology</i> , 2021, 2277, 299-329.	0.4	1
6108	Microbiota-Gut-Brain Axis. , 2021, , 423-423.		0
6109	The aging brain and brain banking. , 2021, , 103-112.		0
6110	Comprehensive Perspectives on Experimental Models for Parkinson's Disease. , 2021, 12, 223.		12
6111	Appendix "Alpha-synuclein in the gut, Crohn's disease, and the possible protective role of the synucleins in innate immune response. , 2021, , 209-226.		0

#	ARTICLE	IF	CITATIONS
6114	Olfactory impairment as an early marker of Parkinson's disease in REM sleep behaviour disorder: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 271-281.	0.9	13
6115	Î±-Synuclein Propagation Mouse Models of Parkinson's Disease. <i>Methods in Molecular Biology</i> , 2021, 2322, 119-130.	0.4	2
6116	Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases. <i>Progress in Brain Research</i> , 2021, 261, 41-81.	0.9	15
6117	Progrediente Erkrankungen. , 2021, , 341-373.		0
6118	Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. <i>Acta Neuropathologica</i> , 2021, 141, 173-192.	3.9	35
6119	Opicapone: From Preclinical Data to Real-world Evidence. <i>Touch Reviews in Neurology</i> , 2021, 17, 32.	0.1	0
6125	Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease. , 0, , 325-351.		2
6126	Dopamine transporter imaging predicts clinically defined <i>α</i> -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	1.7	37
6127	Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models. <i>Current Protocols in Neuroscience</i> , 2020, 91, e88.	2.6	36
6128	Kognitive Störungen: Koma, Delir, Demenz. , 2006, , 221-295.		8
6130	Biomarkers for Early Detection of Parkinson's Disease: An Essential Challenge. , 2008, , 35-49.		2
6131	Protein-Based Neuropathology and Molecular Classification of Human Neurodegenerative Diseases. <i>Focus on Structural Biology</i> , 2009, , 251-272.	0.1	5
6132	Modeling Nonmotor Symptoms of Parkinson's Disease in Genetic Mouse Models. <i>Advances in Behavioral Biology</i> , 2009, , 483-491.	0.2	3
6133	Motor and Non-motor Effects of PPN-DBS in PD Patients: Insights from Intra-operative Electrophysiology. <i>Advances in Behavioral Biology</i> , 2009, , 573-587.	0.2	4
6134	Neuropsychology of Movement Disorders and Motor Neuron Disease. , 2010, , 315-333.		2
6135	Mitochondrion- and Endoplasmic Reticulum-Induced SK Channel Dysregulation as a Potential Origin of the Selective Neurodegeneration in Parkinson's Disease. , 2012, , 57-79.		3
6136	Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson's Disease. , 2013, , 361-384.		3
6137	Metabolic Networks in Parkinson's Disease. , 2013, , 403-415.		3

#	ARTICLE	IF	CITATIONS
6138	Alpha Synuclein in Parkinson's Disease. , 2014, , 691-726.		4
6139	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. , 2014, , 237-275.		3
6140	Neuroinflammation and Parkinson's Disease. , 2014, , 885-912.		1
6141	Rotenone as Preclinical Model Compound in Parkinson Disease. , 2014, , 995-1012.		3
6142	Parasomnias. , 2017, , 1087-1113.		1
6143	Dopamine Replacement Therapy in Parkinson's Disease: Past, Present and Future. , 2009, , 1-26.		1
6144	Physiological and Pathophysiological Aspects of 5-HT _{2c} Receptors in Basal Ganglia. Receptors, 2011, , 351-382.	0.2	3
6145	The Role of the Pedunculo-pontine Tegmental Nucleus in Motor Disorders. Neuromethods, 2011, , 321-342.	0.2	4
6146	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease. Methods in Molecular Biology, 2012, 795, 45-54.	0.4	2
6149	A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2020, 1131, 131-161.	0.8	39
6150	Non-motor Symptoms in Parkinson's Disease. , 2020, , 109-118.		1
6151	Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. , 2006, , 123-132.		26
6152	Pathology associated with sporadic Parkinson's disease " where does it end?. , 2006, , 89-97.		110
6153	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. , 2006, , 99-103.		77
6154	Detection of preclinical Parkinson's disease along the olfactory tract. , 2006, , 321-325.		42
6155	"Good" and "Bad" Microglia in Parkinson's Disease: An Understanding of Homeostatic Mechanisms in Immunomodulation. , 2014, , 105-126.		3
6156	Nutrition, Microbiotics, and the Brain's Neuroinflammatory Response. , 2016, , 157-167.		1
6157	Magnetic Resonance Spectroscopy in Parkinsonian Disorders. Contemporary Clinical Neuroscience, 2016, , 71-102.	0.3	1

#	ARTICLE	IF	CITATIONS
6158	The Limbic System. , 2011, , 633-710.		2
6159	Notes on Techniques. , 2011, , 107-131.		1
6160	Automated Segmentation of the Locus Coeruleus from Neuromelanin-Sensitive 3T MRI Using Deep Convolutional Neural Networks. Informatik Aktuell, 2020, , 61-66.	0.4	5
6162	Etiology and Pathogenesis of Parkinsonâ€™s Disease. , 2017, , 95-101.		3
6163	The Natural History of Parkinsonâ€™s Disease. , 2017, , 129-137.		1
6164	Neurochemistry of the Sleep-Wake Cycle in Parkinsonâ€™s Disease. , 2015, , 19-33.		4
6165	Adult Neurogenesis in Parkinsonâ€™s Disease. , 2011, , 23-36.		5
6166	Parkinsonâ€™s Disease; Neurodegeneration as Systemic Disease. , 2015, , 69-87.		1
6167	Melatonin in Parkinsonâ€™s Disease and Its Therapeutic Potential. , 2014, , 249-261.		3
6168	The Use of Biomarkers for Prediction and Prevention of Alzheimerâ€™s and Parkinsonâ€™s Diseases. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 95-140.	0.6	2
6169	Microglia in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1175, 335-353.	0.8	137
6170	Gut Microbiota and Neurologic Diseases and Injuries. Advances in Experimental Medicine and Biology, 2020, 1238, 73-91.	0.8	22
6171	Inhibitory Role of Î²-Casein on the Î±-Synuclein Aggregation Associated with Parkinsonâ€™s Disease In Vitro. International Journal of Peptide Research and Therapeutics, 2018, 24, 179-187.	0.9	3
6172	Complexins âˆ†. , 2017, , .		3
6173	Linking diffusion tensor imaging, microstructures and Parkinson's disease. , 2020, , 295-311.		3
6174	Olfactory disturbances in Parkinsonâ€™s disease. , 2020, , 539-552.		2
6175	Disturbances of Smell and Taste. , 2008, , 255-262.		2
6176	The Dementias. , 2008, , 1855-1907.		1

#	ARTICLE	IF	CITATIONS
6178	Neuropathology of Movement Disorders. , 2011, , 871-898.		2
6179	Enfermedad de Parkinson. , 2009, , 176-185.		1
6180	Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 203-234.	0.9	50
6181	Quantitative sudomotor abnormalities in clinically isolated rapid eye movement sleep behavior disorder. Autonomic Neuroscience: Basic and Clinical, 2020, 224, 102645.	1.4	2
6182	REM sleep without atonia is associated with increased rigidity in patients with mild to moderate Parkinson's disease. Clinical Neurophysiology, 2020, 131, 2008-2016.	0.7	15
6183	Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?. Experimental Neurology, 2020, 330, 113357.	2.0	11
6184	The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse. Neurobiology of Disease, 2017, 105, 179-193.	2.1	29
6185	Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α -synuclein-preformed fibril-induced toxicity and motor deficits. Neurobiology of Disease, 2020, 141, 104947.	2.1	24
6186	Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. Parkinsonism and Related Disorders, 2017, 42, 28-33.	1.1	34
6187	The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Medicine, 2017, 37, 210-215.	0.8	22
6188	Ensemencement et propagation des lésions dans les maladies neurodégénératives: un nouveau paradigme. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 809-819.	0.0	8
6193	Depressivität und Depression bei der Parkinson-Erkrankung. Zeitschrift für Neuropsychologie = Journal of Neuropsychology, 2007, 18, 207-232.	0.2	1
6194	Partial lesion of the nigrostriatal dopamine pathway in rats impairs egocentric learning but not spatial learning or behavioral flexibility.. Behavioral Neuroscience, 2017, 131, 135-142.	0.6	4
6195	Idiopathic REM sleep behaviour disorder and neurodegeneration – an update. Nature Reviews Neurology, 2018, 14, 40-55.	4.9	386
6196	CHAPTER 1. Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets. RSC Drug Discovery Series, 2013, , 3-25.	0.2	1
6197	CHAPTER 2. Molecular Pathogenesis and Pathophysiology of Parkinson's Disease: New Targets for New Therapies. RSC Drug Discovery Series, 2013, , 26-57.	0.2	1
6198	CHAPTER 8. Synuclein and Parkinson's Disease: An Update. RSC Drug Discovery Series, 2013, , 175-216.	0.2	7
6199	Systematic Audiological Assessment of Auditory Functioning in Patients With Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2019, 62, 4564-4577.	0.7	10

#	ARTICLE	IF	CITATIONS
6200	Research-Based Updates in Swallowing and Communication Dysfunction in Parkinson Disease: Implications for Evaluation and Management. Perspectives of the ASHA Special Interest Groups, 2019, 4, 825-841.	0.4	13
6202	Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11029-E11036.	3.3	23
6203	The emerging role of α -synuclein truncation in aggregation and disease. Journal of Biological Chemistry, 2020, 295, 10224-10244.	1.6	99
6204	Cortical thickness and gyrification index measuring cognition in Parkinson's disease. International Journal of Neuroscience, 2021, 131, 984-993.	0.8	17
6205	RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy. Prion, 2020, 14, 88-94.	0.9	22
6206	Personalized dynamic transport of magnetic nanorobots inside the brain vasculature. Nanotechnology, 2020, 31, 495706.	1.3	17
6207	14 Amyloid Imaging and (What is "Normal") Aging. , 2009, , 191-244.		2
6208	CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease. Brain, 2020, 143, 3717-3733.	3.7	115
6236	Parkinson's Disease Detection Using Ensemble Architecture from MR Images. , 2020, , .		9
6237	TARDBP mutation p.L383V associated with semantic dementia and complex proteinopathy. Neuropathology and Applied Neurobiology, 2014, 40, 225-230.	1.8	48
6238	Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe26-pe26.	0.9	106
6239	Superficial siderosis associated with abundant α and β -synuclein accumulation. BMJ Case Reports, 2011, 2011, bcr1020114925-bcr1020114925.	0.2	6
6240	Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. Journal of Innate Immunity, 2017, 9, 437-440.	1.8	43
6241	Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease. Neurodegenerative Diseases, 2020, 20, 55-64.	0.8	17
6242	Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α -synuclein transfer. Journal of Clinical Investigation, 2019, 129, 3738-3753.	3.9	126
6243	Oxidative stress and α -synuclein conspire in vulnerable neurons to promote Parkinson's disease progression. Journal of Clinical Investigation, 2019, 129, 3530-3531.	3.9	25
6245	Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathologica Communications, 2014, 2, 90.	2.4	94
6246	Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by Paraffin Embedded Tissue (PET) blot. Acta Neuropathologica Communications, 2014, 2, 130.	2.4	5

#	ARTICLE	IF	CITATIONS
6247	Forensic Aspects of Adult General Neuropathology. , 2008, , 79-246.		1
6249	Parkinsonian Tremor. Neurological Disease and Therapy, 2005, , 195-220.	0.0	8
6250	Lewy Body Dementias. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 435-463.	0.4	104
6251	Diagnosing Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 1047-1063.	0.4	18
6252	Brain Circuitry Controlling Sleep and Wakefulness. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 955-972.	0.4	12
6253	Synucleinopathies. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 72-92.	0.4	13
6254	Cohort Study in Parkinsonism. Neurology: Clinical Practice, 2021, 11, e407-e413.	0.8	9
6255	Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinsonâ€™s disease. Neurology, 2004, 63, S13-22.	1.5	57
6256	Nocturnal problems occurring in Parkinsonâ€™s disease. Neurology, 2004, 63, S8-11.	1.5	55
6257	Etiology of Parkinsonâ€™s disease. Neurology, 2006, 66, S10-23.	1.5	179
6258	The need for neuroprotective therapies in Parkinsonâ€™s disease. Neurology, 2006, 66, S2-9.	1.5	79
6259	Proteasomal dysfunction in sporadic Parkinson's disease. Neurology, 2006, 66, S37-49.	1.5	56
6260	Rationale for considering that propargylamines might be neuroprotective in Parkinsonâ€™s disease. Neurology, 2006, 66, S69-79.	1.5	67
6261	Gene transfer of trophic factors and stem cell grafting as treatments for Parkinsonâ€™s disease. Neurology, 2006, 66, S89-103.	1.5	54
6262	New pharmacologic horizons in the treatment of Parkinson disease. Neurology, 2006, 67, S30-8.	1.5	81
6263	Recent developments in the treatment of Parkinson's Disease. F1000Research, 2020, 9, 862.	0.8	84
6264	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. Dementia and Neurocognitive Disorders, 2012, 11, 38.	0.4	2
6265	Immunotherapies Targeting α -Synuclein in Parkinson Disease. , 2020, 37, 375-379.		4

#	ARTICLE	IF	CITATIONS
6266	REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders. <i>Archives Italiennes De Biologie</i> , 2015, 152, 129-46.	0.1	21
6267	Clinical Biomarkers of Neurodegeneration in REM Sleep Behavior Disorder. <i>Journal of Sleep Medicine</i> , 2015, 12, 27-33.	0.4	13
6268	The Prevalence of Rapid Eye Movement Sleep Behavior Disorder in Amyloid Positron Emission Tomography Positive Alzheimer's Disease. <i>Journal of Sleep Medicine</i> , 2019, 16, 102-108.	0.4	1
6269	No evidence of impaired gastric emptying in early Huntington's Disease. <i>PLOS Currents</i> , 2011, 3, RRN1284.	1.4	4
6271	shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. <i>PLoS Genetics</i> , 2016, 12, e1005995.	1.5	68
6272	Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study. <i>PLoS Medicine</i> , 2017, 14, e1002267.	3.9	90
6273	Aberrant α -Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy. <i>PLoS ONE</i> , 2009, 4, e5515.	1.1	304
6274	Stereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson's Disease. <i>PLoS ONE</i> , 2009, 4, e7878.	1.1	94
6275	Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e17269.	1.1	44
6276	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. <i>PLoS ONE</i> , 2011, 6, e17299.	1.1	142
6277	The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of α -Synuclein. <i>PLoS ONE</i> , 2011, 6, e29460.	1.1	120
6278	Binding of the Radioligand SIL23 to α -Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. <i>PLoS ONE</i> , 2013, 8, e55031.	1.1	97
6279	Triggering of Inflammasome by Aggregated α -Synuclein, an Inflammatory Response in Synucleinopathies. <i>PLoS ONE</i> , 2013, 8, e55375.	1.1	465
6280	Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and Aging In Vivo. <i>PLoS ONE</i> , 2013, 8, e58596.	1.1	30
6281	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e61786.	1.1	29
6282	Impairment of Mitochondria in Adult Mouse Brain Overexpressing Predominantly Full-Length, N-Terminally Acetylated Human α -Synuclein. <i>PLoS ONE</i> , 2013, 8, e63557.	1.1	38
6283	Diagnostic Value of the Impairment of Olfaction in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e64735.	1.1	39
6284	Impaired Sense of Smell in a <i>Drosophila</i> Parkinson's Model. <i>PLoS ONE</i> , 2013, 8, e73156.	1.1	32

#	ARTICLE	IF	CITATIONS
6285	Intranasal LPS-Mediated Parkinsonâ€™s Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins. PLoS ONE, 2013, 8, e78418.	1.1	57
6286	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	1.1	407
6287	Mild Parkinsonian Signs in the Elderly â€” Is There an Association with PD? Crosssectional Findings in 992 Individuals. PLoS ONE, 2014, 9, e92878.	1.1	25
6288	N-Terminal Truncated UCH-L1 Prevents Parkinson's Disease Associated Damage. PLoS ONE, 2014, 9, e99654.	1.1	22
6289	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. PLoS ONE, 2014, 9, e102909.	1.1	74
6290	Mucuna pruriens (Velvet bean) Rescues Motor, Olfactory, Mitochondrial and Synaptic Impairment in PINK1B9 Drosophila melanogaster Genetic Model of Parkinsonâ€™s Disease. PLoS ONE, 2014, 9, e110802.	1.1	39
6291	Cortical Thickness, Surface Area and Volume Measures in Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. PLoS ONE, 2014, 9, e114167.	1.1	45
6292	Assessment of Brainstem Function with Auricular Branch of Vagus Nerve Stimulation in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0120786.	1.1	36
6293	Neural Substrates of Motor and Non-Motor Symptoms in Parkinsonâ€™s Disease: A Resting fMRI Study. PLoS ONE, 2015, 10, e0125455.	1.1	20
6294	Motor Sequence Learning and Consolidation in Unilateral De Novo Patients with Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0134291.	1.1	37
6295	Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients. PLoS ONE, 2015, 10, e0135287.	1.1	19
6296	Alteration of Brain Functional Networks in Early-Stage Parkinsonâ€™s Disease: A Resting-State fMRI Study. PLoS ONE, 2015, 10, e0141815.	1.1	63
6297	Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0142164.	1.1	381
6298	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	1.1	25
6299	Altered Activation in Cerebellum Contralateral to Unilateral Thalamotomy May Mediate Tremor Suppression in Parkinsonâ€™s Disease: A Short-Term Regional Homogeneity fMRI Study. PLoS ONE, 2016, 11, e0157562.	1.1	7
6300	Progression of Regional Microstructural Degeneration in Parkinsonâ€™s Disease: A Multicenter Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0165540.	1.1	73
6301	Propagated but Topologically Distributed Forebrain Neurons Expressing Alpha-Synuclein in Aged Macaques. PLoS ONE, 2016, 11, e0166861.	1.1	7
6302	Impact of Prolonged Temporal Discrimination Threshold on Finger Movements of Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0167034.	1.1	16

#	ARTICLE	IF	CITATIONS
6303	Longitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis. PLoS ONE, 2017, 12, e0170492.	1.1	30
6304	Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study. PLoS ONE, 2017, 12, e0171524.	1.1	29
6305	Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of β -synuclein via exosome. PLoS ONE, 2017, 12, e0180892.	1.1	43
6306	Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS ONE, 2017, 12, e0181844.	1.1	27
6307	Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE, 2017, 12, e0187307.	1.1	195
6308	The role of microbial amyloid in neurodegeneration. PLoS Pathogens, 2017, 13, e1006654.	2.1	270
6309	Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson's Disease. , 2016, 7, 220.		12
6310	Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson's Disease Patients. , 2019, 10, 601.		27
6311	Entorhinal Cortex Atrophy in Early, Drug-naïve Parkinson's Disease with Mild Cognitive Impairment. , 2019, 10, 1221.		35
6312	NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2009, .	0.2	5
6313	On the heterogeneity of depression in Parkinson's disease. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 46-52.	0.2	2
6314	Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease?. Prague Medical Report, 2018, 119, 85-96.	0.4	9
6315	The Neuropathologic Substrate of Parkinson Disease Dementia. Journal of Movement Disorders, 2009, 2, 1-3.	0.7	2
6316	Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson's Disease. Journal of Movement Disorders, 2011, 4, 1-7.	0.7	13
6317	Analysis of the Substantia Innominata Volume in Patients with Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Alzheimer's Disease. Journal of Movement Disorders, 2011, 4, 68-72.	0.7	18
6318	Apathy and Olfactory Dysfunction in Early Parkinson's Disease. Journal of Movement Disorders, 2015, 8, 21-25.	0.7	24
6319	Gastrointestinal Autonomic Dysfunction in Patients with Parkinson's Disease. Journal of Movement Disorders, 2015, 8, 76-82.	0.7	49
6320	Cardiovascular Autonomic Dysfunction in Mild and Advanced Parkinson's Disease. Journal of Movement Disorders, 2016, 9, 97-103.	0.7	36

#	ARTICLE	IF	CITATIONS
6321	Cerebrospinal Fluid Amyloid β_{1-42} , Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2016, 9, 89-96.	0.7	22
6322	Oro-Pharyngeal Dysphagia in Parkinson's Disease and Related Movement Disorders. <i>Journal of Movement Disorders</i> , 2019, 12, 152-160.	0.7	41
6323	Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2020, 13, 133-141.	0.7	22
6324	Emerging Concepts of Motor Reserve in Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2020, 13, 171-184.	0.7	30
6325	Strains of Pathological Protein Aggregates in Neurodegenerative Diseases. <i>Discoveries</i> , 2017, 5, e78.	1.5	8
6326	<i>Sncg</i> -GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding. <i>ENeuro</i> , 2020, 7, ENEURO.0007-20.2020.	0.9	14
6327	Pronounced β -Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala. <i>ENeuro</i> , 2020, 7, ENEURO.0110-20.2020.	0.9	8
6328	Long-Term Exposure to PFE-360 in the AAV- β -Synuclein Rat Model: Findings and Implications. <i>ENeuro</i> , 2019, 6, ENEURO.0453-18.2019.	0.9	4
6329	Intestinal microbiota and nutrients as determinants of nervous system function. Part I. Gastrointestinal microbiota. <i>Aktualnosci Neurologiczne</i> , 2017, 17, 181-188.	0.1	4
6332	Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. , 0, , 3-26.		140
6333	Immunogenetics of Parkinson's Disease. , 0, , 27-44.		3
6334	The Differential Diagnosis of Parkinson's Disease. , 0, , 109-128.		20
6335	An Overview of Parkinson's Disease and Oxidative Stress: Herbal Scenario. <i>Neuropathological Diseases</i> , 2012, 1, 95-122.	0.1	1
6342	Orthostatic Hypotension and Cognitive Function in Parkinson's Disease. <i>Journal of the Korean Neurological Association</i> , 2018, 36, 302-309.	0.0	1
6343	Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , 2012, 7, 35.	0.5	3
6344	New Magnetic Resonance Imaging Biomarkers Advance the Characterisation of Parkinson's Disease. <i>European Neurological Review</i> , 2013, 8, 85.	0.5	5
6345	Emerging Role of Safinamide in Parkinson's Disease Therapy. <i>European Neurological Review</i> , 2015, 9, 108.	0.5	7
6346	Olfaction in Parkinson's Disease – A Clinical Approach. <i>European Neurological Review</i> , 2020, 15, 37.	0.5	2

#	ARTICLE	IF	CITATIONS
6347	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α -syn) oligomerization and secretion. <i>Aging</i> , 2017, 9, 1677-1697.	1.4	7
6348	Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. <i>Aging</i> , 2020, 12, 9515-9533.	1.4	35
6349	Asymmetrical nigral iron accumulation in Parkinson's disease with motor asymmetry: an explorative, longitudinal and test-retest study. <i>Aging</i> , 2020, 12, 18622-18634.	1.4	10
6350	Age- and brain region-dependent α -synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α -synuclein phosphorylation in aging monkey brains. <i>Oncotarget</i> , 2016, 7, 8466-8480.	0.8	25
6351	Parkinson's disease cluster: the wind of change. <i>International Journal of Clinical Neurosciences and Mental Health</i> , 2014, , 7.	0.7	1
6352	Characteristics of Smell Identification Test in Patients With Parkinson Disease. <i>Clinical and Experimental Otorhinolaryngology</i> , 2019, 12, 206-211.	1.1	5
6353	Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits. <i>Acta Neurobiologiae Experimentalis</i> , 2016, 76, 199-211.	0.4	20
6354	Prodromal non-motor symptoms of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 145-151.	1.0	83
6355	Adenosine Receptors in Modulation of Central Nervous System Disorders. <i>Current Pharmaceutical Design</i> , 2019, 25, 2808-2827.	0.9	17
6356	Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2020, 25, 4510-4522.	0.9	17
6357	The Impact of Mitochondrial DNA and Nuclear Genes Related to Mitochondrial Functioning on the Risk of Parkinson's Disease. <i>Current Genomics</i> , 2014, 14, 543-559.	0.7	21
6358	A New Interpretative Paradigm for Conformational Protein Diseases. <i>Current Protein and Peptide Science</i> , 2013, 14, 141-160.	0.7	5
6359	Parkinson's Disease: A Review from Pathophysiology to Treatment. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 754-767.	1.1	103
6360	Cytoskeletal Pathologies of Age-Related Diseases between Elderly Sri Lankan (Colombo) and Indian (Bangalore) Brain Samples. <i>Current Alzheimer Research</i> , 2016, 13, 268-280.	0.7	8
6361	Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1142-1153.	1.0	28
6362	Changes in Rat 50-kHz Ultrasonic Vocalizations During Dopamine Denervation and Aging: Relevance to Neurodegeneration. <i>Current Neuropharmacology</i> , 2015, 13, 211-219.	1.4	25
6363	Recent Progress of Imaging Agents for Parkinson's Disease. <i>Current Neuropharmacology</i> , 2015, 12, 551-563.	1.4	11
6364	Cognitive Impairment Associated with Parkinson's Disease: Role of Mitochondria. <i>Current Neuropharmacology</i> , 2016, 14, 584-592.	1.4	18

#	ARTICLE	IF	CITATIONS
6365	Cheminformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold. <i>Current Neuropharmacology</i> , 2017, 15, 1117-1135.	1.4	5
6366	Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy. <i>Current Neuropharmacology</i> , 2018, 16, 1086-1097.	1.4	46
6367	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. <i>Current Neuropharmacology</i> , 2019, 17, 563-579.	1.4	48
6368	An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 659-669.	0.8	22
6369	Drug Targets from Genetics: Alpha-Synuclein. <i>CNS and Neurological Disorders - Drug Targets</i> , 2011, 10, 712-723.	0.8	9
6370	Targeting Parkinson's - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 369-380.	0.8	34
6371	Motor and Non-Motor Features of Parkinson's Disease - A Review of Clinical and Experimental Studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 439-449.	0.8	60
6372	A Brief Overview of Tyrosine Hydroxylase and α -Synuclein in the Parkinsonian Brain. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 456-462.	0.8	14
6373	Time Perception Distortion in Neuropsychiatric and Neurological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 567-582.	0.8	51
6374	The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1160-1168.	0.8	16
6375	Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 313-324.	0.8	68
6376	Anti-Inflammatory Treatments for Chronic Diseases: A Review. <i>Inflammation and Allergy: Drug Targets</i> , 2013, 12, 349-361.	1.8	229
6377	Role of Environmental and Inflammatory Toxicity in Neuronal Cell Death. <i>The Open Toxicology Journal</i> , 2008, 2, 26-41.	1.0	1
6378	Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application. <i>Current Molecular Pharmacology</i> , 2017, 10, 115-140.	0.7	12
6379	Substance Abuse and Movement Disorders. <i>Current Drug Abuse Reviews</i> , 2009, 2, 273-278.	3.4	13
6380	Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities. <i>Current Drug Abuse Reviews</i> , 2012, 5, 243-253.	3.4	65
6381	Methods for Studying and Structure-Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
6382	Functional Magnetic Resonance Imaging Biomarkers Predicting Cognitive Progression in Parkinson Disease: Protocol for a Prospective Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e12870.	0.5	4

#	ARTICLE	IF	CITATIONS
6384	Current trends in etiology, prognosis and therapeutic aspects of Parkinson's disease: a review. <i>Acta Biomedica</i> , 2017, 88, 249-262.	0.2	20
6385	A Pragmatic Approach to the Postmortem Neuropathological Diagnosis of Dementia. <i>Academic Forensic Pathology</i> , 2012, 2, 2-9.	0.3	2
6386	Automatic Extraction of the Cingulum Bundle in Diffusion Tensor Tract-specific Analysis: Feasibility Study in Parkinson's Disease with and without Dementia. <i>Magnetic Resonance in Medical Sciences</i> , 2013, 12, 201-213.	1.1	3
6388	Neuropsychological aspects. , 2013, , 144-170.		2
6389	Effects of treadmill training on gait of elders with Parkinson's disease: a literature review. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eRW5233.	0.3	8
6390	Postmortem studies in Parkinson's disease. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 281-293.	1.8	74
6391	Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 259-280.	1.8	345
6392	Smell and taste disorders. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2011, 10, Doc04.	0.8	103
6393	Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. <i>Behavioural Neurology</i> , 2013, 27, 479-93.	1.1	52
6394	Emotional dysfunction in Parkinson's disease. <i>Behavioural Neurology</i> , 2011, 24, 201-17.	1.1	46
6395	Alzheimer's Disease-Related Lesions. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S173-S179.	1.2	4
6396	Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Psychiatrists, and Psychiatrists. <i>Journal of Korean Medical Science</i> , 2020, 35, e230.	1.1	8
6397	FLIM Analysis of Intracellular Markers Associated With the Development of Parkinson's Disease in Cellular Model. <i>Physiological Research</i> , 2018, 67, S673-S683.	0.4	5
6398	Respiratory Function and Dysfunction in Parkinson-Type Neurodegeneration. <i>Physiological Research</i> , 2020, 69, S69-S79.	0.4	17
6401	Chemically Induced Models of Parkinson's Disease: History and Perspectives for the Involvement of Ferroptosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 581191.	1.8	27
6402	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 443.	1.4	47
6403	Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms. <i>Biology</i> , 2020, 9, 103.	1.3	57
6404	Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinson's Disease. <i>Biomolecules</i> , 2021, 11, 30.	1.8	13

#	ARTICLE	IF	CITATIONS
6405	The Pathology of Parkinson's Disease and Potential Benefit of Dietary Polyphenols. <i>Molecules</i> , 2020, 25, 4382.	1.7	58
6406	Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain-Gut Axis. <i>Nutrients</i> , 2021, 13, 88.	1.7	48
6407	Etiopatogenia da Doença de Parkinson. <i>Revista Neurociencias</i> , 2005, 13, 201-214.	0.0	6
6408	Neuroprotective effects of lithium on a chronic MPTP mouse model of Parkinson's disease via regulation of α -synuclein methylation. <i>Molecular Medicine Reports</i> , 2019, 19, 4989-4997.	1.1	16
6409	The effect of REM sleep behaviour disorder on clinical severity in Parkinson's disease. <i>Turkish Journal of Medical Sciences</i> , 0, , .	0.4	2
6410	Psychosis in Parkinson's Disease. <i>Psychiatric Annals</i> , 2020, 50, 113-120.	0.1	1
6411	Biofluid-based microRNA Biomarkers for Parkinson's Disease: an Overview and Update. <i>AIMS Medical Science</i> , 2015, 2, 15-25.	0.2	11
6412	Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. <i>Neural Regeneration Research</i> , 2012, 7, 611-9.	1.6	13
6413	Changes of brain gray matter structure in Parkinson's disease patients with dementia. <i>Neural Regeneration Research</i> , 2013, 8, 1276-85.	1.6	11
6414	Magnetic resonance morphometry of the loss of gray matter volume in Parkinson's disease patients. <i>Neural Regeneration Research</i> , 2013, 8, 2557-65.	1.6	11
6415	Toward precision medicine in Parkinson's disease. <i>Annals of Translational Medicine</i> , 2016, 4, 26.	0.7	18
6416	Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. <i>Neural Regeneration Research</i> , 2014, 9, 759.	1.6	23
6417	MicroRNAs in Parkinson's disease and emerging therapeutic targets. <i>Neural Regeneration Research</i> , 2017, 12, 1945.	1.6	65
6418	Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. <i>Neural Regeneration Research</i> , 2018, 13, 1136.	1.6	49
6419	Targeting prion-like protein spreading in neurodegenerative diseases. <i>Neural Regeneration Research</i> , 2018, 13, 1875.	1.6	16
6420	Assessing gray matter volume in patients with idiopathic rapid eye movement sleep behavior disorder. <i>Neural Regeneration Research</i> , 2019, 14, 868.	1.6	12
6421	Locus coeruleus-norepinephrine: basic functions and insights into Parkinson's disease. <i>Neural Regeneration Research</i> , 2020, 15, 1006.	1.6	53
6422	Advanced diffusion magnetic resonance imaging in patients with Alzheimer's and Parkinson's diseases. <i>Neural Regeneration Research</i> , 2020, 15, 1590.	1.6	28

#	ARTICLE	IF	CITATIONS
6423	Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies. , 2015, 6, 45.		98
6424	Prevalence of non-motor symptoms in Parkinson's disease and its impact on quality of life in tertiary care center in India. Annals of Indian Academy of Neurology, 2020, 23, 270.	0.2	7
6425	Auditory and vestibular dysfunction in patients with Parkinson's disease. The Egyptian Journal of Otolaryngology, 2019, 35, 313-321.	0.1	5
6426	Early stages of Alzheimer's disease are alarming signs in injury deaths caused by traffic accidents in elderly people (≥60 years of age): A neuropathological study. Indian Journal of Psychiatry, 2017, 59, 471-477.	0.4	1
6427	Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. , 2017, 8, 65.		50
6428	Neurodegenerative Diseases and Stem Cell Transplantation. Journal of Stem Cell Research & Therapy, 2015, 05, .	0.3	3
6429	Norepinephrine in Neurodegeneration: A Coerulean Target. , 2012, 02, .		1
6430	Impact of Deep Brain Stimulation Therapy on Autonomic Disturbances and Related Symptoms of Parkinson's Disease. Brain Disorders & Therapy, 2015, 04, .	0.1	1
6431	Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid. Advances in Biological Chemistry, 2012, 02, 176-190.	0.2	10
6432	Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson's Disease: An Update on the Effects of Cognitive Functions. Advances in Parkinson S Disease, 2017, 06, 13-23.	0.2	7
6433	Nigrostriatal Degeneration in Parkinson Disease: Evaluation by Diffusion Tensor Tract-Specific Analysis. Open Journal of Radiology, 2015, 05, 199-204.	0.1	2
6434	Using induced pluripotent stem cells for modeling Parkinson's disease. World Journal of Stem Cells, 2019, 11, 634-649.	1.3	24
6435	Drugs and clinical trials in neurodegenerative diseases. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 49-54.	0.2	22
6436	The Universal Non-Neuronal Nature of Parkinson's Disease: A Theory. Central Asian Journal of Global Health, 2016, 5, 231.	0.6	4
6437	Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. , 2010, 29, 271-288.		68
6438	The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Reports, 2010, 43, 225-232.	1.1	134
6439	Peripheral nerve involvement and severity of motor disorder in Parkinson's disease: a correlational study. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2009, 153, 59-62.	0.2	9
6440	Neuropathic alterations of the myenteric plexus neurons following subacute intraperitoneal administration of salsolinol. Folia Histochemica Et Cytobiologica, 2015, 53, 49-61.	0.6	17

#	ARTICLE	IF	CITATIONS
6441	Topographical Propagation of α -synuclein Pathology in Parkinson's Disease: Phenomenology and Hypothetical Mechanism. <i>Experimental Neurobiology</i> , 2009, 18, 19.	0.7	1
6442	Oxidative Stress in Parkinson's Disease; Parallels Between Current Animal Models, Human Studies and Cells. , 0, , .		2
6443	New Insights into Toxicity and Drug Testing. , 2013, , .		6
6444	Towards New Therapies for Parkinson's Disease. , 2011, , .		10
6445	Inhibition of synucleinopathic seeding by rationally designed inhibitors. <i>ELife</i> , 2020, 9, .	2.8	54
6446	Phagocytic glia are obligatory intermediates in transmission of mutant huntingtin aggregates across neuronal synapses. <i>ELife</i> , 2020, 9, .	2.8	24
6447	The Relationship of Rapid Eye Movement Sleep Behavior Disorder and Freezing of Gait in Parkinson's Disease. <i>Cureus</i> , 2020, 12, e12385.	0.2	8
6448	Is there a Premotor Phase of Essential Tremor?. <i>Tremor and Other Hyperkinetic Movements</i> , 2017, 7, 498.	1.1	14
6449	PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 317.	1.1	22
6450	Cerebellar pathology of a dual clinical diagnosis: patients with essential tremor and dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2012, 2, .	1.1	14
6451	Pathogenic Factors and Treatment of Parkinson's Disease. <i>Bioprocess</i> , 2021, 11, 67-75.	0.1	0
6452	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. , 2021, , 1-41.		0
6453	Target-binding behavior of IDPs via pre-structured motifs. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 183, 187-247.	0.9	4
6454	Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy. <i>Progress in Brain Research</i> , 2021, 266, 1-73.	0.9	15
6455	Brain regions susceptible to alpha-synuclein spreading. <i>Molecular Psychiatry</i> , 2022, 27, 758-770.	4.1	24
6456	Progressive Pontine-Medullary Dysfunction Leads to REM Sleep Behavior Disorder Symptoms in a Chronic Model of Parkinson's Disease. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1723-1736.	1.4	6
6458	Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 223-228.	1.0	10
6459	Transgenic Mice Expressing Human α -Synuclein 1-103 Fragment as a Novel Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 760781.	1.7	5

#	ARTICLE	IF	CITATIONS
6461	Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinsonâ€™s disease. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 137-147.	1.0	6
6462	Disease-modifying treatment of Parkinsonâ€™s disease by phytochemicals: targeting multiple pathogenic factors. <i>Journal of Neural Transmission</i> , 2022, 129, 737-753.	1.4	11
6463	Biomarkers in Parkinsonâ€™s Disease. <i>Neuromethods</i> , 2022, , 155-180.	0.2	27
6464	Interaction between coxsackievirus B3 infection and Î±-synuclein in models of Parkinsonâ€™s disease. <i>PLoS Pathogens</i> , 2021, 17, e1010018.	2.1	8
6465	Examining the Toxicity of Î±-Synuclein in Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 1126.	1.1	4
6466	The Microbiota-Gut-Brain Axis as a Key to Neuropsychiatric Disorders: A Mini Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4640.	1.0	23
6467	T-cell based immunotherapies for Parkinsonâ€™s disease. , 2021, 1, .		3
6468	Parkinson's disease: the nutrition perspective. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 12-26.	0.4	9
6469	Glucocerebrosidase 1 and leucineâ€”rich repeat kinase 2 in Parkinson disease and interplay between the two genes. <i>Journal of Neurochemistry</i> , 2021, 159, 826-839.	2.1	7
6472	Disbalance of the Duodenal Epithelial Cell Turnover and Apoptosis Accompanies Insensitivity of Intestinal Redox Homeostasis to Inhibition of the Brain Glucose-Dependent Insulinotropic Polypeptide Receptors in a Rat Model of Sporadic Alzheimerâ€™s Disease. <i>Neuroendocrinology</i> , 2022, 112, 744-762.	1.2	15
6473	Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies. <i>Frontiers in Neurology</i> , 2021, 12, 742625.	1.1	9
6474	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
6475	The Effect of Transcranial Direct Current Stimulation Combined with Visual Cueing Training on Motor Function, Balance, and Gait Ability of Patients with Parkinsonâ€™s Disease. <i>Medicina (Lithuania)</i> , 2021, 57, 1146.	0.8	8
6476	The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinsonâ€™s disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2022, 269, 1834-1850.	1.8	2
6477	Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 698979.	1.7	2
6478	Viral alpha-synuclein knockdown prevents spreading synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcab247.	1.5	5
6479	Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2021, 128, 1577-1598.	1.4	35
6481	Frontal white matter lesions in Alzheimerâ€™s disease are associated with both small vessel disease and AD-associated cortical pathology. <i>Acta Neuropathologica</i> , 2021, 142, 937-950.	3.9	45

#	ARTICLE	IF	CITATIONS
6482	Chronic Rhinosinusitis and Alzheimer's Disease—A Possible Role for the Nasal Microbiome in Causing Neurodegeneration in the Elderly. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11207.	1.8	11
6483	Severe and Regionally Widespread Increases in Tissue Urea in the Human Brain Represent a Novel Finding of Pathogenic Potential in Parkinson's Disease Dementia. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 711396.	1.4	9
6484	Parkinsonism and dementia. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120015.	0.3	8
6485	Anatomic survey of seeding in Alzheimer's disease brains reveals unexpected patterns. <i>Acta Neuropathologica Communications</i> , 2021, 9, 164.	2.4	17
6487	Gastric <i>Helicobacter suis</i> Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinson's Disease Mouse Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11328.	1.8	2
6488	Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Neurodegenerative Diseases</i> , 2021, 21, 30-35.	0.8	9
6489	Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. <i>Scientific Reports</i> , 2021, 11, 20945.	1.6	14
6490	Diffusion Tensor Imaging of the Olfactory System in Older Adults With and Without Hyposmia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 648598.	1.7	8
6491	Transposable elements as new players in neurodegenerative diseases. <i>FEBS Letters</i> , 2021, 595, 2733-2755.	1.3	24
6493	Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. <i>Journal of Biomedical Science</i> , 2021, 28, 70.	2.6	23
6494	White matter changes in drug-naïve Parkinson's disease patients with impulse control & probable REM sleep behavior disorders. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120032.	0.3	3
6495	Genetics of Parkinson's Disease. , 0, , 40-40.		0
6496	Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson's Disease. , 2005, , 475-502.		0
6497	THE SIX NEUROPATHOLOGICAL STAGES OF PARKINSON DISEASE. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2005, 5, 45-46.	0.0	0
6499	Genetics Of Parkinson's Disease. <i>Neurological Disease and Therapy</i> , 2005, , 611-631.	0.0	0
6500	Immunohistology of the Nervous System. , 2006, , 746-816.		1
6501	LRRK2-Associated Parkinsonism. , 2007, , 45-59.		0
6502	Nonmotor Problems in Parkinson Disease. , 2007, , 193-204.		1

#	ARTICLE	IF	CITATIONS
6535	Cognitive Dysfunction in Genetic Mouse Models of Parkinsonism. <i>Neuromethods</i> , 2011, , 485-492.	0.2	2
6536	Lesions Associated with Sleep Disturbances. , 2010, , 167-186.		0
6537	Assessing Non-Motor Symptoms: An Overview of Scales and Questionnaires. , 2011, , 27-35.		0
6539	Å%tiopathogÃ©nie. , 2011, , 9-19.		0
6540	Parasomnias. , 2011, , 591-605.		0
6541	UN MODELO EN RATA FRL DETERIORO COGNITIVO EN LA ENFERMEDAD DE PARKINSON. <i>Revista Mexicana De Analisis De La Conducta</i> , 2011, 32, .	0.7	0
6548	DetecciÃ³n y manejo de sÃntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia. <i>Revista Medica De Chile</i> , 2011, 139, 1032-1038.	0.1	0
6549	CFS Biomarkers in Parkinsonâ€™s Disease. , 0, , .		0
6550	Â¿Es la atrofia del hipocampo en la enfermedad de Parkinson un predictor de demencia?. <i>Alzheimer Realidades E InvestigaciÃ³n En Demencia</i> , 2011, , 5-11.	0.1	1
6552	Pathophysiology of Non-Dopaminergic Monoamine Systems in Parkinson's Disease: Implications for Mood Dysfunction. , 0, , .		0
6553	Parkin and Parkinsonâ€™s Disease. , 0, , .		0
6554	Role of Microglia in Inflammatory Process in Parkinsonâ€™s Disease. , 0, , .		0
6555	Targeting Î±-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinsonâ€™s Disease Therapy. , 0, , .		0
6556	Calculating Stage Duration Statistics in Multistage Diseases. <i>PLoS ONE</i> , 2011, 6, e28298.	1.1	0
6557	Chapter 28 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2012, , 309-316.		0
6558	Is There a Place for Clinical Neurophysiology Assessments in Synucleinopathies?. , 0, , .		0
6559	Early Marker for the Diagnosis of Parkinson's Disease. , 0, , .		0
6560	Neuropsychiatric Side Effects of Deep Brain Stimulation in Parkinsonâ€™s Disease. , 2012, , 159-173.		1

#	ARTICLE	IF	CITATIONS
6561	Non-motor signs and symptoms in Parkinson's disease. Health, 2012, 04, 1133-1137.	0.1	0
6562	Mortalin in Neurological Diseases. , 2012, , 139-158.		0
6563	Systematrophien. , 2012, , 223-249.		0
6564	Sleep Disorders in Parkinson's Disease and Parkinsonian Syndromes. , 2012, , 330-344.		0
6565	Parkinson Disease. , 2012, , 122-130.e2.		0
6566	The interaction between the dopaminergic and the serotonergic systems in the 6-OHDA rat model of Parkinson's disease. Health, 2012, 04, 1218-1224.	0.1	0
6567	Regulation of α -Synuclein Membrane Binding and Its Implications. , 0, , .		0
6568	Inflammation in Parkinson's Disease: Causes and Consequences. , 0, , .		0
6570	O papel do estresse oxidativo e do exercÍcio fÍsico na doena de Parkinson. Revista Brasileira De Fisiologia Do ExercÍcio, 2012, 11, 174.	0.0	1
6571	James Parkinson. , 2012, , 3-12.		1
6572	Olfactory Dysfunction. , 2013, , 335-348.		1
6573	Excessive Daytime Sleepiness in Parkinson's Disease. , 2013, , 267-290.		0
6575	CHAPTER 16. Carotid Body Transplants as a Therapy for Parkinson's Disease. RSC Drug Discovery Series, 2013, , 363-375.	0.2	0
6576	Comparison of continuous versus pulsatile dopaminergic therapy in the elderly with Parkinson's Disease. Advances in Parkinson S Disease, 2013, 02, 43-46.	0.2	0
6577	Morphometric Analyses in Movement Disorders. , 2013, , 25-47.		0
6578	Basal ganglia disorders. , 2013, , 601-630.		5
6579	Can population genomics guide future therapeutic gene transfer strategies for Parkinson's disease?. Open Journal of Genetics, 2013, 03, 19-29.	0.1	0
6580	Premotor symptoms. , 2013, , 93-102.		0

#	ARTICLE	IF	CITATIONS
6581	Autonomic dysfunction and management. , 2013, , 103-119.		0
6582	Chapter 33 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2013, , 361-368.		0
6583	Morbus Parkinson und verwandte Demenzen. , 2013, , 186-203.		0
6584	Challenges in the Neuropathological Diagnosis of Dementias. International Journal of Neuropathology, 0, , .	0.0	2
6585	Investigational surgical therapies. , 2013, , 496-519.		0
6586	Parkinsonâ€™s Disease: Involvement of Iron and Oxidative Stress. 2-Oxoglutarate-Dependent Oxygenases, 2013, , 58-79.	0.8	0
6587	Accumulating Evidence Suggests that Parkinsonâ€™s Disease Is a Prion-Like Disorder. Research and Perspectives in Alzheimer's Disease, 2013, , 97-113.	0.1	0
6588	Sleep dysfunction. , 2013, , 120-143.		0
6590	Magnetic resonance spectroscopy imaging of medulla oblongata and substantia nigra in idiopathic Parkinson's disease. Asian Journal of Medical Sciences, 2013, 4, 76-85.	0.0	0
6592	Dementia with Lewy Bodies. , 2014, , 155-177.		0
6594	Anhedonia in Parkinsonâ€™s Disease and Other Movement Disorders. , 2014, , 265-290.		0
6595	Dopaminergic Neurons in Parkinsonâ€™s Disease. , 2014, , 753-788.		5
6596	Biomarkers of Parkinsonâ€™s Disease. , 2014, , 1-18.		0
6597	Protein seeding in Alzheimerâ€™s disease and Parkinsonâ€™s disease: Similarities and differences. World Journal of Neurology, 2014, 4, 23.	0.6	0
6598	Neuromelanin and Parkinsonâ€™s Disease. , 2014, , 913-932.		1
6599	Chrelin and Parkinsonâ€™s Disease. , 2014, , 205-211.		0
6600	Enteric Glial Cells: Implications in Gut Pathology. , 2014, , 493-518.		0
6601	SPECT/PET Findings in Lewy Body Dementia. , 2014, , 373-415.		2

#	ARTICLE	IF	CITATIONS
6602	In Vivo Imaging in Neurodegenerative Diseases. , 2014, , 45-80.		1
6603	Yokukansan Ameliorates Psychiatric Problems in Parkinson's Disease. Juntendo Medical Journal, 2014, 60, 529-535.	0.1	0
6604	Neuropsychological Features of Mild Cognitive Impairment in Parkinson's Disease: A Critical Review of the Literature.. Journal of Aging and Gerontology, 2014, 2, 100-114.	0.4	0
6607	Sleep Disordered Breathing in Parkinson's Disease. , 2015, , 93-106.		0
6608	Conformational Disease and RNA Disease Theory in the Context of Neurodegenerative Diseases. , 2015, , 3-22.		0
6609	A Microarray Analysis of Parkinson's Disease: New Clues and Evaluation. Journal of Biosciences and Medicines, 2015, 03, 55-60.	0.1	0
6611	Effects of Cholinesterase Inhibitors in Cognition on Parkinson's Disease Dementia: A Systematic Review and Meta-Analysis. Advances in Parkinson S Disease, 2015, 04, 90-96.	0.2	0
6612	Neuropathologie. , 2015, , 33-44.e2.		0
6614	Sleep in Neurodegenerative Diseases. , 2015, , 271-283.		3
6616	Neuropathologie. , 2015, , 13-19.e2.		0
6617	Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson's Disease. Current Topics in Neurotoxicity, 2015, , 183-205.	0.4	0
6620	Prions et transconformation protéique: une perspective historique. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 787-796.	0.0	0
6621	De la neurodégénérescence motrice comme limitation interne du «pouvoir-faire». Les Cahiers Philosophiques De Strasbourg, 2015, , 241-267.	0.0	0
6623	Difficulties Experienced by Spouses Caring for Their Partners with Parkinson's Disease before They Become Bedridden. Nihon Kango Kagakkai Shi = Journal of Japan Academy of Nursing Science, 2016, 36, 204-212.	0.1	2
6624	Toxin-Mediated Complex I Inhibition and Parkinson's Disease. , 2016, , 115-137.		3
6625	Joint Feature-Sample Selection and Robust Classification for Parkinson's Disease Diagnosis. Lecture Notes in Computer Science, 2016, , 127-136.	1.0	2
6626	Diffusion-tensor MRI is the most up-to-date method to research microstructural changes in white matter (publications review). Vestnik of Saint Petersburg University Medicine, 2016, 11, 39-54.	0.0	3
6627	Der Begriff der Nerventätigkeit in der Pathogenese neurodegenerativer Erkrankungen und ganzheitliche Therapiemöglichkeiten bei M. Parkinson. Der Merkurstab, 2016, 69, 345-354.	0.0	6

#	ARTICLE	IF	CITATIONS
6628	Temporal Aspects of Global Coherence during Discourse Production in Early Stage Parkinsonâ€™s Disease. <i>Advances in Parkinson S Disease</i> , 2016, 05, 41-49.	0.2	2
6629	The Role of Chronic Inflammation in the Etiology of Parkinsonâ€™s Disease. , 2016, , 63-74.		0
6630	Krankheiten der Basalganglien. <i>Springer-Lehrbuch</i> , 2016, , 589-623.	0.1	1
6631	Parkinsonâ€™s Disease and Sleep/Wake Disturbances. , 2016, , 115-146.		2
6633	Findings of 123I-MIBG Cardiac Scintigraphy: Parkinsonâ€™s Disease and Related Disorders and Others (RBD,) Tj ETQq0 0 0 rgBT /Overlo		0
6634	Sleep Quality and Cognitive Impairment in Patients with Parkinsonâ€™s Disease in Iran. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2016, 22, 121-126.	0.1	1
6636	Pathological Background of Reduced Cardiac MIBG Uptake. , 2017, , 291-311.		1
6637	An Autopsy Case of Sporadic Parkinsonâ€™s Disease that Died of Pneumonia. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 209-213.	0.0	0
6638	Application of Imaging Techniques in the Clinical Diagnosis of Parkinsonâ€™s Disease. <i>Medical Diagnosis</i> , 2017, 07, 35-41.	0.0	0
6639	Gastrointestinal Dysfunction. , 2017, , 101-116.		0
6640	Sleep Disturbances in Neurodegenerative Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 309-318.	0.0	0
6644	Clinicopathological Research of Alpha-Synucleinopathy. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 235-239.	0.0	0
6645	The Non-motor Parkinsonâ€™s Disease. , 2017, , 117-127.		0
6646	Multi-modal and targeted imaging improves automated mid-brain segmentation. , 2017, 10133, .		3
6647	Fluoxetine does not Impair Motor Function in Patients with Parkinsonâ€™s Disease: Correlation Between Mood and Motor Functions with Plasma Concentrations of Fluoxetine/ Norfluoxetine. <i>Journal of Neurology & Stroke</i> , 2017, 6, .	0.0	0
6648	The Effect of Treadmill Exercise on Expression of α -synuclein and miRNA in MPTP Induced-mouse Models of Parkinsonâ€™s Disease. <i>Exercise Science</i> , 2017, 26, 129-138.	0.1	0
6652	Neurodegenerative Disease. , 2017, , 289-318.		2
6654	Effect of clinical autonomic dysfunction on cognitive functions in Parkinsonâ€™s disease. <i>Dicle Medical Journal</i> , 0, , 225-230.	0.2	3

#	ARTICLE	IF	CITATIONS
6655	Changes in the Immune System in Parkinson's Disease. , 2018, , 1-21.		0
6656	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
6657	Neuropsychologie du vieillissement normal et des syndromes d'Alzheimer. , 2018, , 417-540.		0
6658	Traitement de la maladie de Parkinson. , 2018, , 611-625.e1.		0
6660	Central Pain in Parkinson's Disease: A Case Report. Case Reports in Clinical Medicine, 2018, 07, 297-305.	0.1	0
6662	The Foundation of the International RBD Study Group (IRBDSC). , 2019, , 19-30.		2
6664	RBD and the Autonomic Nervous System. , 2019, , 465-474.		0
6665	REM Sleep Behavior Disorder: The Link Between Synucleinopathies and REM Sleep Circuits. , 2019, , 625-637.		1
6666	Cardiac Scintigraphy in RBD. , 2019, , 475-489.		0
6667	Immunohistochemical Revealing of Alpha-Synuclein in Synaptic Contact Area of Hippocampal CA3 Zone. Journal of Anatomy and Histopathology, 2018, 7, 23-28.	0.1	0
6668	Gustatory Rhinorrhea: A Rare Presentation of Parkinson's Disease. Cureus, 2018, 10, e3224.	0.2	0
6669	RBD, Antidepressant Medications, and Psychiatric Disorders. , 2019, , 123-134.		2
6675	Plasma catecholamine levels in the early stages of treatment-naïve Parkinson's disease. Al-Manah KliniĀeskoj Mediciny, 2018, 46, 792-801.	0.2	1
6676	Indications for Deep Brain Stimulation Therapy in Parkinson's Disease. , 2019, , 3-19.		0
6677	Neuroprotective Effects of Metformin Versus Selegiline on Parkinson's Disease Model By Reserpine through the Interrelation of α -Synuclein and Antioxidants on Behavioral Changes in Rats. Egyptian Journal of Basic and Clinical Pharmacology, 2019, 9, .	0.7	0
6679	Progranulin Regulations of Lysosomal Homeostasis and Its Involvement in Neurodegenerative Diseases. , 2019, , 85-103.		1
6680	Changes in the Immune System in Parkinson's Disease. , 2019, , 2353-2373.		0
6681	Nanobiotechnology in Parkinson's Disease. , 2019, , 177-208.		0

#	ARTICLE	IF	CITATIONS
6682	Neurodegenerative Diseases: Parkinson Disease. , 2019, , 1001-1020.		1
6685	Neuropsychology of Movement Disorders and Motor Neuron Disease: Parkinsonâ€™s Disease, Progressive Supranuclear Palsy, Essential Tremor, Huntingtonâ€™s Disease, and Amyotrophic Lateral Sclerosis. , 2019, , 415-440.		0
6688	The pedunculopontine nucleus: From posture and locomotion to neuroepigenetics. AIMS Neuroscience, 2019, 6, 219-230.	1.0	6
6690	Bayesian Longitudinal Modeling of Early Stage Parkinsonâ€™s Disease Using DaTscan Images. Lecture Notes in Computer Science, 2019, , 405-416.	1.0	3
6692	Lewy Body Disease. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 298-321.	0.1	0
6693	Notch Signaling: From Neurogenesis to Neurodegeneration. , 2019, , 185-221.		0
6694	Treatment of Parkinsonâ€™s Disease: Early, Late, and Combined. , 2019, , 1-26.		0
6695	Alpha-Synucleinopathies. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 274-297.	0.1	2
6696	Psychodiagnostics of suicide. Likars'ka Sprava, 2019, , 3-9.	0.2	0
6697	Autonomic Disorders Associated with Parkinson's Disease. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 204-208.	0.0	0
6703	Parkinsonism and Related Disorders. , 0, , .		0
6708	The role of monoamine oxidase B inhibitor rasagiline in the treatment of Parkinsonâ€™s disease. International Neurological Journal, 2019, .	0.2	0
6715	Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes. , 2020, , 1-29.		0
6716	The features of the pathogenesis and clinical picture of Parkinson's disease that has developed in essential tremor. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 94-98.	0.2	1
6719	An autopsied case of dementia with Lewy bodies with clinical course of depression, parkinsonism, hallucinatory-delusional disorders and dementia.. Kyushu Neuropsychiatry, 2019, 65, 113-122.	0.1	0
6720	Early stages of Parkinsonâ€™s disease: aspects of the diagnosis and therapy. Meditsinskiy Sovet, 2019, , 61-70.	0.1	0
6722	Parkinsonâ€™s Disease and Hypotensive Syndromes. , 2020, , 157-166.		0
6723	The loss of dopaminergic neurons in DEC1 deficient mice potentially involves the decrease of PI3K/Akt/GSK3 ^{Î²} signaling. Aging, 2019, 11, 12733-12753.	1.4	3

#	ARTICLE	IF	CITATIONS
6724	Retinal nerve fiber layer thickness in patients with essential tremor and Parkinson's disease. Journal of Surgery and Medicine, 0, , .	0.0	1
6727	REM sleep behavior disorder as a prodromal Parkinson's disease feature. , 2020, , 61-76.		0
6729	The Role of Dysphonia and Voice Recordings in Diagnosis of Parkinson's Disease. International Journal of Applied Mathematics Electronics and Computers, 0, , 21-26.	0.6	1
6731	Chronic α -Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments. ENeuro, 2020, 7, ENEURO.0009-20.2020.	0.9	11
6733	Dyspnea in Parkinson's disease: an approach to diagnosis and management. Expert Review of Neurotherapeutics, 2020, 20, 619-626.	1.4	5
6734	The Enteric Glial Network Acts in the Maintenance of Intestinal Homeostasis and in Intestinal Disorders. , 0, , .		2
6742	for Cognitive Impairment and Dementia in Parkinson's. Neuromethods, 2021, , 193-225.	0.2	0
6746	for in Parkinson's. Neuromethods, 2021, , 379-394.	0.2	0
6747	Assessment of Nonmotor Symptoms in Rodent Models of Parkinson's. Neuromethods, 2021, , 21-36.	0.2	0
6748	The Gut Brain-Axis in Neurological Diseases. International Journal of Cardiovascular Sciences, 2020, , .	0.0	4
6749	Effects of miRNAs in exosomes derived from α -synuclein overexpressing SH-SY5Y cells on autophagy and inflammation of microglia. Cellular Signalling, 2022, 89, 110179.	1.7	3
6750	Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. International Journal of Molecular Sciences, 2021, 22, 11663.	1.8	16
6751	Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance. Molecular Psychiatry, 2022, 27, 269-280.	4.1	6
6752	Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort. Frontiers in Neuroscience, 2021, 15, 756951.	1.4	15
6753	Current challenges in reliably targeting the noradrenergic locus coeruleus using transcutaneous auricular vagus nerve stimulation (taVNS). Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102900.	1.4	19
6754	The psychosocial genomics paradigm of hypnosis and mind-body integrated psychotherapy: experimental evidence. American Journal of Clinical Hypnosis, 2021, 64, 1-16.	0.3	4
6755	Linking and comparing non-motor symptoms in aging and Parkinson's disease. , 2020, , 251-265.		0
6756	Investigation of structure and dynamics of α -synuclein on membrane by quenchers-in-a-liposome fluorescence resonance energy transfer method. Wuli Xuebao/Acta Physica Sinica, 2020, 69, 038701.	0.2	0

#	ARTICLE	IF	CITATIONS
6757	Parkinson Disease. , 2020, , 143-159.		1
6758	Basal Ganglia. , 2020, , 591-667.		2
6759	Notes on Techniques. , 2020, , 127-167.		0
6760	Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases. , 2020, , 241-268.		0
6761	Differential Changes in Arteriolar Cerebral Blood Volume between Parkinsonâ€™s Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorderâ€™An Exploratory Study. Tomography, 2020, 6, 333-342.	0.8	7
6762	The 2019 Incentive Award of the Okayama Medical Association in Neuroscience (2019 Niimi Prize). Okayama Igakkai Zasshi, 2020, 132, 123-125.	0.0	0
6764	A Simplified Brain Blocking Protocol Optimized for the Diagnosis of Neurodegenerative Disease Saves Time and Money While Preserving Anatomic Relationships. Archives of Pathology and Laboratory Medicine, 2021, 145, 960-968.	1.2	2
6765	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinsonâ€™s disease?. Brain, 2020, 143, 3518-3521.	3.7	3
6766	Modelling Non-motor Symptoms of Parkinsonâ€™s Disease: AAV Mediated Overexpression of Alpha-synuclein in Rat Hippocampus and Basal Ganglia. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2020, 26, 322-329.	0.1	0
6768	Diet-Induced Obesity Disrupts Trace Element Homeostasis and Gene Expression in the Olfactory Bulb. Nutrients, 2020, 12, 3909.	1.7	6
6769	Pharmacotherapy of Psychosis in Parkinsonâ€™s Disease. , 2021, , 1-39.		1
6770	Depression Is Associated With Constipation in Patients With Parkinson's Disease. Frontiers in Neurology, 2020, 11, 567574.	1.1	7
6771	Letter: Stem Cell Transplantation for Parkinson Disease: DÃ©jÃ Vu All Over Again?. Neurosurgery, 2021, 88, E216-E217.	0.6	3
6772	Treatment of Parkinsonâ€™s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 847-861.	0.6	7
6774	Microfabrication atomic layer deposited Pt NPs/TiN thin film on silicon as a nanostructure signal Transducer: Electrochemical characterization toward neurotransmitter sensing. Applied Surface Science, 2022, 573, 151444.	3.1	4
6775	Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs, 2021, 13, 1994690.	2.6	10
6776	Deep Brain Stimulation for Parkinsonâ€™s Disease. , 2020, , 171-191.		0
6777	Reactive Oxygen Species Affects on Mitochondrial Dynamicity Which May Leads to Parkinsonâ€™s Disease. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
6778	Disorders of Taste and Smell. , 2020, , 119-147.		0
6779	Facial emotion recognition in Parkinson's disease: methodological, clinical, and pathophysiological factors. , 2020, , 91-106.		0
6780	STRUCTURAL BASES OF GASTROINTESTINAL MOTILITY CHANGES IN PARKINSON'S DISEASE: STUDY IN RATS. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2020, 33, e1548.	0.5	1
6781	Schlaf-wach-Störungen bei Alzheimer- und Parkinson-Krankheit. , 2020, , 417-430.		0
6782	Parkinson's Disease Detection from fMRI-Derived Brainstem Regional Functional Connectivity Networks. Lecture Notes in Computer Science, 2020, , 33-43.	1.0	2
6783	Serotonin in Parkinson's disease. Handbook of Behavioral Neuroscience, 2020, 31, 969-979.	0.7	2
6784	Motivation and motivational aspects of Parkinson's disease. , 2020, , 497-509.		0
6785	Central Nervous System Pain. , 2020, , 307-387.		0
6786	Evidence-Based PET for Neurological Diseases. , 2020, , 125-136.		0
6788	Alpha-synuclein and neuroinflammation in Parkinson's disease. , 2020, , 431-446.		1
6789	Motoneuronkrankungen. , 2020, , 153-177.		0
6790	Sleep-Related Breathing Disorders. , 2020, , 61-66.		0
6791	Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. Brain Communications, 2020, 2, fcaa167.	1.5	9
6792	Cell transplantation therapy for Parkinson's disease. , 2020, , 627-651.		0
6793	Sleep disturbances in Parkinson's disease. , 2020, , 139-155.		0
6794	Vagal motoneurons in Parkinson's disease. , 2020, , 327-343.		1
6795	Progression of motor symptoms in Parkinson's disease. , 2020, , 267-281.		0
6796	Unawareness of hyposmia in patients with idiopathic Parkinson's disease. Annals of Movement Disorders, 2020, 3, 163.	0.3	1

#	ARTICLE	IF	CITATIONS
6797	Etude acoustique de la production de glides dans la maladie de Parkinson. SHS Web of Conferences, 2020, 78, 09006.	0.1	0
6798	The Limbic System. , 2020, , 745-830.		3
6799	Parkinsonian Toxins: From MPTP to Endogenous Neurotoxins. , 2020, , 1-20.		0
6800	Role of fungi in neurodegenerative diseases. , 2020, , 71-79.		1
6802	Dementia and bladder dysfunction: a focus on treatments with anticholinergics. , 2020, , 233-250.		0
6803	Possible Therapeutic Potential of Flavonoids and Phenolic Acids from Honey in Age-Related Neurodegenerative Diseases Via Targeting NAD+ Degradation. , 2020, , 19-43.		0
6804	Impaired Motor Recycling during Action Selection in Parkinsonâ€™s Disease. ENeuro, 2020, 7, ENEURO.0492-19.2020.	0.9	0
6805	Les protÃ©inopathies infectieuses de Parkinson et dâ€™Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 224-231.	0.0	0
6808	Signaling Mechanisms in Cognition. FASEB Journal, 2020, 34, 1-1.	0.2	0
6812	An Update on the Critical Role of Î±-Synuclein in Parkinsonâ€™s Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Molecular Neurobiology, 2022, 59, 620-642.	1.9	21
6813	Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects. Brain Imaging and Behavior, 2021, , 1.	1.1	8
6816	Case Report: Concomitant Alzheimer's and Lewy-Related Pathology Extending the Spectrum of Underlying Pathologies of Corticobasal Syndrome. Frontiers in Neuroscience, 2021, 15, 742042.	1.4	0
6817	Neuropathology of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 173-185.	2.1	83
6818	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	2.1	72
6819	Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics, 2021, 13, 1897.	2.0	27
6820	Association between Sleep, Alzheimerâ€™s, and Parkinsonâ€™s Disease. Biology, 2021, 10, 1127.	1.3	13
6821	Parkinsonâ€™s disease â€“ a review of pathogenesis, recent advances in management, and challenges of care in sub-Saharan Africa. Journal of Global Medicine, 0, , e35.	0.0	0
6822	Is pseudoexfoliation glaucoma a neurodegenerative disorder?. Journal of Biosciences, 2021, 46, 1.	0.5	4

#	ARTICLE	IF	CITATIONS
6823	High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 179.	2.4	86
6824	Nanomaterials as novel agents for amelioration of Parkinson's disease. <i>Nano Today</i> , 2021, 41, 101328.	6.2	18
6828	Il sogno: un punto di vista neurologico. , 2007, , 371-409.		0
6829	Early Behavioral Phenotypes in Mouse Models of Huntington's and Parkinson's Diseases. , 2005, , 349-359.		0
6830	Parkinson's Disease and Related Disorders. , 2006, , 199-212.		0
6832	Novel Proteins in α -Synucleinopathies. <i>Focus on Structural Biology</i> , 2009, , 207-224.	0.1	0
6833	Cranio-cerebral Trauma and Vertebrospinal Trauma. , 2007, , 519-606.		0
6834	Neuroimaging in Parkinson's disease. <i>Neurotherapeutics</i> , 2004, 1, 243-254.	2.1	0
6840	Two Types of Parkinson's Disease Pathologies: Body-First Versus Brain-First. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2020, 20, 40-41.	0.0	0
6842	Disorders of Sleep and Wakefulness in Parkinson's Disease and Other Movement Disorders. , 2021, , 269-287.		0
6843	Neurobiology of Parasomnias. , 2021, , 121-145.		0
6844	Epidemiology of Parkinson's disease. <i>Neurologie Pro Praxi</i> , 2020, 21, 390-394.	0.0	1
6845	MRI-visible perivascular spaces are associated with cerebrospinal fluid biomarkers in Parkinson's disease. <i>Aging</i> , 2020, 12, 25805-25818.	1.4	15
6846	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. , 2014, , 209-248.		3
6847	Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 467-74.	0.9	37
6848	Genetic neuropathology of Parkinson's disease. <i>International Journal of Clinical and Experimental Pathology</i> , 2008, 1, 217-31.	0.5	70
6849	Rasagiline in treatment of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 23-32.	1.0	13
6850	Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 619-25.	1.0	36

#	ARTICLE	IF	CITATIONS
6851	Neuropathology of non-Alzheimer degenerative disorders. <i>International Journal of Clinical and Experimental Pathology</i> , 2009, 3, 1-23.	0.5	68
6852	Cognitive impairment and dementia in patients with Parkinson disease. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 903-12.	1.0	58
6853	Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. <i>Core Evidence</i> , 2010, 5, 1-10.	4.7	7
6854	Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. <i>Sleep</i> , 2011, 34, 619-25.	0.6	88
6855	Positron emission tomography neuroimaging in Parkinson's disease. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 323-41.	0.0	48
6857	Exosomes-associated neurodegeneration and progression of Parkinson's disease. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 217-25.	0.1	55
6858	Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. <i>American Journal of Neurodegenerative Disease</i> , 2013, 2, 266-75.	0.1	19
6859	Evaluation of non-motor symptoms in Parkinson's Disease: An underestimated necessity. <i>Hippokratia</i> , 2013, 17, 214-9.	0.3	26
6860	Motor unit number estimation in normal and parkinsonism model of medial gastrocnemius muscle in rats. <i>International Journal of Molecular and Cellular Medicine</i> , 2013, 2, 72-9.	1.1	3
6864	Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. <i>P and T</i> , 2015, 40, 504-32.	1.0	153
6865	Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9897-903.	1.3	5
6866	Gray matter atrophy in patients with Parkinson's disease and those with mild cognitive impairment: a voxel-based morphometry study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15383-92.	1.3	17
6867	Silencing of SIAH1 in SH-SY5Y affects α -synuclein degradation pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12885-92.	0.5	5
6868	Association between changes in visual evoked magnetic fields and non-motor features in Parkinson's disease. <i>Nagoya Journal of Medical Science</i> , 2017, 79, 147-155.	0.6	3
6869	Molecular mechanisms of omega-3 fatty acids in the migraine headache. <i>Iranian Journal of Neurology</i> , 2017, 16, 210-217.	0.5	13
6871	New perspectives in the care of Parkinson disease. <i>Missouri Medicine</i> , 2012, 109, 328-32.	0.3	1
6872	Conditioning Against the Pathology of Parkinson's disease. <i>Conditioning Medicine</i> , 2018, 1, 143-162.	1.3	6
6873	A Comparative Study of Early and Late Onset Freezing of Gait in Parkinson's Disease. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 256-262.	0.2	7

#	ARTICLE	IF	CITATIONS
6874	ConvNets with Smooth Adaptive Activation Functions for Regression. Proceedings of Machine Learning Research, 2017, 54, 430-439.	0.3	2
6875	Early and Accurate Identification of Parkinson Disease Among US Veterans. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S18-S23.	0.6	1
6876	Association of Cardinal Motor Symptoms with Region-Specific Dopamine Transporter Activity in Mild to Moderate Parkinson's Disease. European Neurological Journal, 2013, 4, 1-7.	0.0	1
6878	Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting. Innovations in Clinical Neuroscience, 2020, 17, 14-19.	0.1	0
6879	Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons. ENeuro, 2021, 8, .	0.9	0
6880	Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. European Radiology Experimental, 2021, 5, 36.	1.7	2
6881	Modeling synucleinopathies in rodents. International Review of Movement Disorders, 2021, 2, 65-154.	0.1	1
6882	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. International Review of Movement Disorders, 2021, 2, 155-191.	0.1	0
6883	Pathology-associated change in levels and localization of SIDT2 in postmortem brains of Parkinson's disease and dementia with Lewy bodies patients. Neurochemistry International, 2022, 152, 105243.	1.9	10
6884	DA-9805 protects dopaminergic neurons from endoplasmic reticulum stress and inflammation. Biomedicine and Pharmacotherapy, 2022, 145, 112389.	2.5	6
6885	Olive fruit and olive oil bioactive polyphenols in the promotion of health. , 2022, , 203-220.		1
6886	Development of Early Diagnosis of Parkinsonâ€™s Disease Using Premotor Symptoms and Blood Changes as Biomarkers. Neuroscience and Behavioral Physiology, 2021, 51, 1050-1058.	0.2	2
6887	Clinical and Biochemical Heterogeneity of Parkinsonâ€™s Disease. Neuroscience and Behavioral Physiology, 2021, 51, 1073-1078.	0.2	0
6888	Brain atrophy progression in Parkinsonâ€™s disease is shaped by connectivity and local vulnerability. Brain Communications, 2021, 3, fcab269.	1.5	22
6889	Progression of myoclonus subtypes in subacute sclerosing panencephalitis. Neurophysiologie Clinique, 2021, 51, 533-540.	1.0	5
6890	Correlation between head tremble and the severity of Parkinsonâ€™s disease. CNS Neuroscience and Therapeutics, 2022, 28, 218-225.	1.9	5
6891	Cardiac and Autonomic Dysfunctions Assessed Through Recurrence Quantitative Analysis of Electrocardiogram Signals and an Application to the 6-Hydroxydopamine Parkinsonâ€™s Disease Animal Model. Frontiers in Physiology, 2021, 12, 725218.	1.3	2
6892	Characterizing mild cognitive impairment in prodromal Parkinsonâ€™s disease: A communityâ€based study in China. CNS Neuroscience and Therapeutics, 2022, 28, 259-268.	1.9	9

#	ARTICLE	IF	CITATIONS
6893	Subcortical Aphasia. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 73.	2.0	9
6895	Microglial Potassium Channels: From Homeostasis to Neurodegeneration. <i>Biomolecules</i> , 2021, 11, 1774.	1.8	8
6896	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, , .	0.3	0
6897	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. <i>Life</i> , 2021, 11, 1239.	1.1	18
6898	Impact of α -synuclein spreading on the nigrostriatal dopaminergic pathway depends on the onset of the pathology. <i>Brain Pathology</i> , 2022, 32, e13036.	2.1	12
6899	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. <i>Frontiers in Neuroscience</i> , 2021, 15, 781722.	1.4	1
6900	Dementia with Lewy Bodies. , 2022, , 291-301.		0
6901	Animal models of Parkinson's disease: a guide to selecting the optimal model for your research. <i>Neuronal Signaling</i> , 2021, 5, NS20210026.	1.7	28
6902	Assembly of α -synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of α -synuclein seeds. <i>Acta Neuropathologica Communications</i> , 2021, 9, 189.	2.4	10
6903	Gastrointestinal mucosal biopsies in Parkinson's disease: beyond alpha-synuclein detection. <i>Journal of Neural Transmission</i> , 2022, 129, 1095-1103.	1.4	4
6904	Alginate and its Two Components Acted Differently Against Dopaminergic Neuronal Loss in Parkinson's Disease Mice Model. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100739.	1.5	5
6905	Footprints of a microbial toxin from the gut microbiome to mesencephalic mitochondria. <i>Gut</i> , 2023, 72, 73-89.	6.1	22
6906	Basal ganglia atrophy-associated causal structural network degeneration in Parkinson's disease. <i>Human Brain Mapping</i> , 2022, 43, 1145-1156.	1.9	19
6907	Disrupted dynamic pattern of regional neural activity in early-stage cognitively normal Parkinson's disease. <i>Acta Radiologica</i> , 2022, 63, 1669-1677.	0.5	4
6909	Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder: a two-phase study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1010-1017.	0.9	14
6910	Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern. <i>Movement Disorders</i> , 2021, , .	2.2	6
6911	α -Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. <i>Cell and Bioscience</i> , 2021, 11, 196.	2.1	8
6912	Ultrasound imaging of vagus nerves in patients with Parkinson's disease. <i>Bulletin of Russian State Medical University</i> , 2021, , .	0.3	0

#	ARTICLE	IF	CITATIONS
6913	Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson-like Symptoms Without Loss of Dopaminergic Neurons. <i>Neurotoxicity Research</i> , 2021, , 1.	1.3	10
6914	Characteristics of Autonomic Dysfunction in Parkinson's Disease: A Large Chinese Multicenter Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 761044.	1.7	15
6915	Is Olfactory Impairment Associated With 10-year Mortality Mediating by Neurodegenerative Diseases in Older Adults? The Four-Way Decomposition Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 771584.	1.3	0
6916	Cognitive and Behavior Deficits in Parkinson's Disease with Alteration of FDG-PET Irrespective of Age. <i>Geriatrics (Switzerland)</i> , 2021, 6, 110.	0.6	1
6917	Fully automated deep learning-based localization and segmentation of the locus coeruleus in aging and Parkinson's disease using neuromelanin-sensitive MRI. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2021, 16, 2129-2135.	1.7	8
6918	Correlation of Dopaminergic Denervation and the Progression of Autonomic Dysfunctions in Different Clinical Subtypes of Parkinson's Disease. <i>Parkinson's Disease</i> , 2021, 2021, 1-5.	0.6	2
6919	Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2022, 12, 69-83.	1.5	3
6920	Cognitive Influences in Parkinson's Disease Patients and Their Caregivers: Perspectives From an Australian Cohort. <i>Frontiers in Neurology</i> , 2021, 12, 673816.	1.1	3
6921	Dysprosody in Isolated REM Sleep Behavior Disorder with Impaired Olfaction but Intact Nigrostriatal Pathway. <i>Movement Disorders</i> , 2021, , .	2.2	5
6922	Smell tests can discriminate Parkinson's disease patients from healthy individuals: A meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2021, 211, 107024.	0.6	5
6923	Reduction of tyrosine hydroxylase expression and increase of α -synuclein in the substantia nigra in a rat model of benign prostatic hyperplasia. <i>Neuroscience Letters</i> , 2022, 769, 136386.	1.0	1
6924	Disturbances in Redox Homeostasis in the Ageing Brain. <i>Healthy Ageing and Longevity</i> , 2022, , 45-64.	0.2	0
6925	Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms. <i>Neurobiology of Disease</i> , 2022, 163, 105580.	2.1	20
6926	Autonomic Dysfunction in Parkinson's Disease: Results from the Faroese Parkinson's Disease Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
6927	Immune response during idiopathic Parkinson's disease: From humans to animal models. <i>International Review of Movement Disorders</i> , 2021, 2, 261-301.	0.1	1
6929	Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors. <i>International Review of Movement Disorders</i> , 2021, 2, 1-63.	0.1	0
6930	Neurotransmitter Transporters and Their Role in the Pharmacological Actions of Therapeutic and Abused Drugs. , 2021, , .		0
6933	α -Synuclein Aggregation and Propagation in the Pathomechanisms of Parkinson's Disease. <i>Juntendo Medical Journal</i> , 2021, 67, 530-536.	0.1	0

#	ARTICLE	IF	CITATIONS
6934	Brain functional network abnormalities in parkinsonâ€™s disease with mild cognitive impairment. Cerebral Cortex, 2022, 32, 4857-4868.	1.6	14
6935	Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-Î± and IL-1Î²; evidence from early experimental model of Parkinsonâ€™s disease. Neurological Research, 2022, 44, 544-553.	0.6	4
6936	Loss of Corticostriatal Mu-Opioid Receptors in Î±-Synuclein Transgenic Mouse Brains. Life, 2022, 12, 63.	1.1	2
6937	Abnormal connectivity model of raphe nuclei with sensory-associated cortex in Parkinsonâ€™s disease with chronic pain. Neurological Sciences, 2022, 43, 3175-3185.	0.9	4
6938	Etiologies of insomnia in Parkinson's disease â€“ Lessons from human studies and animal models. Experimental Neurology, 2022, 350, 113976.	2.0	16
6939	Body-first Parkinsonâ€™s disease and variant Creutzfeldtâ€“Jakob disease â€“ similar or different?. Neurobiology of Disease, 2022, 164, 105625.	2.1	2
6940	White matter damage in patients with mild cognitive impairment in Parkinsonâ€™s disease. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1290-1298.	1.1	0
6941	Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinsonâ€™s disease. Trends in Endocrinology and Metabolism, 2022, 33, 147-157.	3.1	14
6942	Animal models of brain-first and body-first Parkinson's disease. Neurobiology of Disease, 2022, 163, 105599.	2.1	38
6943	Forschung: Parkinson-Krankheit â€“ Hautbiopsie unterstÃ¼tzt Diagnose in Prodromalphase. , 0, , .		0
6944	Palidotomia associada a talamotomia no tratamento da DoenÃ§a de Parkinson: Relato de caso. Jbnc - Jornal Brasileiro De Neurocirurgia, 2021, 31, 347-352.	0.0	0
6945	Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons. ENeuro, 2021, 8, ENEURO.0234-20.2020.	0.9	0
6947	Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases. Current Topics in Behavioral Neurosciences, 2021, , 1.	0.8	2
6948	Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. European Radiology Experimental, 2021, 5, 36.	1.7	10
6949	The effect of water-soluble pristine C60 fullerene on 6-OHDA-induced Parkinsonâ€™s disease in rats. Regulatory Mechanisms in Biosystems, 2021, 12, 599-607.	0.5	3
6950	Non-motor manifestations in patients with Parkinson's disease. Ãno-Rossiiskij Ãurnal TerapevtiÃeskoj Praktiki, 2021, 2, 73-78.	0.1	1
6951	Colonic Leucine-Rich Repeat Kinase 2 Expression Is Increased and Associated With Disease Severity in Patients With Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 819373.	1.7	6
6952	Brain Surface Area Alterations Correlate With Gait Impairments in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 806026.	1.7	5

#	ARTICLE	IF	CITATIONS
6953	Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α -Synuclein Converge on Fatty Acid Homeostasis. <i>Journal of Neuroscience</i> , 2022, 42, 2116-2130.	1.7	7
6954	Spreading of Aggregated α -Synuclein in Sagittal Organotypic Mouse Brain Slices. <i>Biomolecules</i> , 2022, 12, 163.	1.8	4
6955	T cells, α -synuclein and Parkinson disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, 184, 439-455.	1.0	8
6956	Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease. <i>Toxins</i> , 2022, 14, 94.	1.5	4
6957	Passive Immunization in Alpha-Synuclein Preclinical Animal Models. <i>Biomolecules</i> , 2022, 12, 168.	1.8	13
6960	Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells. <i>Molecular Neurobiology</i> , 2022, 59, 1273-1284.	1.9	15
6961	A Comprehensive Study of miRNAs in Parkinson's Disease: Diagnostics and Therapeutic Approaches. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, .	0.8	2
6963	The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 135, 104541.	2.9	4
6964	Age-dependent aggregation of α -synuclein in the nervous system of gut-brain axis is associated with caspase-1 activation. <i>Metabolic Brain Disease</i> , 2022, 37, 1669-1681.	1.4	2
6965	Systemic deficiency of GM1 ganglioside in Parkinson's disease tissues and its relation to the disease etiology. <i>Glycoconjugate Journal</i> , 2022, 39, 75.	1.4	12
6966	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. <i>Journal of Neurology</i> , 2022, 269, 3636-3652.	1.8	8
6968	Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase. <i>Antioxidants</i> , 2022, 11, 296.	2.2	11
6969	Education, but not occupation, is associated with cognitive impairment: The role of cognitive reserve in a sample from a low-to-middle income country. <i>Alzheimer's and Dementia</i> , 2022, 18, 2079-2087.	0.4	8
6971	Emerging Roles of Microfluidics in Brain Research: From Cerebral Fluids Manipulation to Brain-on-a-Chip and Neuroelectronic Devices Engineering. <i>Chemical Reviews</i> , 2022, 122, 7142-7181.	23.0	21
6972	Alpha-synuclein as a biomarker in Parkinson's disease: focus on neural derived extracellular vesicles. <i>Neural Regeneration Research</i> , 2022, 17, 1503.	1.6	7
6973	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. <i>Journal of Neurochemistry</i> , 2023, 164, 346-363.	2.1	10
6974	Normalization effect of levodopa on hierarchical brain function in Parkinson's disease. <i>Network Neuroscience</i> , 2022, 6, 552-569.	1.4	3
6976	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12

#	ARTICLE	IF	CITATIONS
6977	A Case Report on a Novel PINK1 Gene Mutation in a Female with a Neurodegenerative Disorder. <i>European Medical Journal Neurology</i> , 0, , .	0.0	0
6979	Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102941.	1.4	4
6980	Gut Microbiota Across Early Stages of Alpha-Synucleinopathy: From High-Risk Relatives, REM Sleep Behavior Disorder to Early Parkinson's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
6981	Brain Perfusion Single-Photon Emission Computed Tomography Using an Easy Z-Score Imaging System Predicts Progression to Neurodegenerative Dementia in Rapid Eye Movement Sleep Behavior Disorder. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 577-584.	0.7	1
6982	Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia. <i>Neuropathology</i> , 2022, 42, 82-89.	0.7	4
6983	Longitudinal metabolomics profiling of serum amino acids in rotenone-induced Parkinson's mouse model. <i>Amino Acids</i> , 2022, 54, 111-121.	1.2	3
6984	Lewy body disease or diseases with Lewy bodies?. <i>Npj Parkinson's Disease</i> , 2022, 8, 3.	2.5	26
6985	Circumpapillary Retinal Nerve Fiber Layer OCT Imaging in a Parkinson's Disease Cohort: A Multidisciplinary Approach in a Clinical Research Hospital. <i>Journal of Personalized Medicine</i> , 2022, 12, 80.	1.1	1
6986	Cofilin 1 promotes the pathogenicity and transmission of pathological α -synuclein in mouse models of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 1.	2.5	26
6987	Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease. <i>Glia</i> , 2022, 70, 935-960.	2.5	30
6989	Strong Predictive Algorithm of Pathogenesis-Based Biomarkers Improves Parkinson's Disease Diagnosis. <i>Molecular Neurobiology</i> , 2022, 59, 1476-1485.	1.9	3
6990	Gastrointestinal Dysfunction in Parkinson's Disease. <i>Drugs</i> , 2022, 82, 169-197.	4.9	9
6991	Therapeutics in the Pipeline Targeting α -Synuclein for Parkinson's Disease. <i>Pharmacological Reviews</i> , 2022, 74, 207-237.	7.1	39
6994	Air Pollution and the Risk of Parkinson's Disease: A Review. <i>Movement Disorders</i> , 2022, 37, 894-904.	2.2	28
6995	Silica Nanoparticles Promote α -Synuclein Aggregation and Parkinson's Disease Pathology. <i>Frontiers in Neuroscience</i> , 2021, 15, 807988.	1.4	9
6996	Recent Advances in Drug Therapy for Parkinson's Disease. <i>Internal Medicine</i> , 2023, 62, 33-42.	0.3	8
6997	LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2022, 11, 5.	3.6	21
6998	Vibrotactile coordinated reset stimulation for the treatment of Parkinson's disease. <i>Neural Regeneration Research</i> , 2022, 17, 1495.	1.6	4

#	ARTICLE	IF	CITATIONS
6999	From chronic stress and anxiety to neurodegeneration: Focus on neuromodulation of the axon initial segment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 481-495.	1.0	2
7000	Targeting α -Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models. Frontiers in Neurology, 2021, 12, 786835.	1.1	3
7001	Correcting Differential Gene Expression Analysis for Cytoarchitectural Alterations in Substantia Nigra of Parkinson's Disease Patients Reveals Known and Potential Novel Disease-Associated Genes and Pathways. Cells, 2022, 11, 198.	1.8	0
7002	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future. Journal of Neuropathology and Experimental Neurology, 2022, 81, 2-15.	0.9	26
7003	Proteomic screen reveals diverse protein transport between connected neurons in the visual system. Cell Reports, 2022, 38, 110287.	2.9	10
7004	Cause of Death Determined by Full-body Autopsy in Neuropathologically Diagnosed Dementias. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	0.6	0
7005	How Lazy Reading and Semantic Sloppiness May Harm Progress in Synucleinopathy Research. Biomolecules, 2022, 12, 228.	1.8	5
7006	The Key Role of GM1 Ganglioside in Parkinson's Disease. Biomolecules, 2022, 12, 173.	1.8	14
7007	Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial. Annals of Neurology, 2022, 91, 203-216.	2.8	83
7008	Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?. Frontiers in Neurology, 2022, 13, 827338.	1.1	5
7009	Stem Cell-based and Advanced Therapeutic Modalities for Parkinson's Disease: A Risk-effectiveness Patient-centered Analysis. Current Neuropharmacology, 2022, 20, 2320-2345.	1.4	1
7010	Multisystem screening reveals SARS-CoV-2 in neurons of the myenteric plexus and in megakaryocytes. Journal of Pathology, 2022, 257, 198-217.	2.1	16
7011	Clinical and imaging evidence of brain-first and body-first Parkinson's disease. Neurobiology of Disease, 2022, 164, 105626.	2.1	52
7012	Sleep alterations are related to cognitive symptoms in Parkinson's disease: A 24-hour ambulatory polygraphic EEG study. International Journal of Psychophysiology, 2022, 173, 93-103.	0.5	6
7013	Les troubles olfactifs au cours de la sénescence et de deux principales pathologies neurodégénératives. HEGEL - Hépatogastroentérologie Libérale, 2016, N° 2, 140-145.	0.0	0
7014	Neuroimaging approaches to cognition in Parkinson's disease. Progress in Brain Research, 2022, 269, 257-286.	0.9	3
7015	Comorbidities in patients with Parkinson's disease. Buletinul AȘM: AȘtiința Medicală, 2022, 71, 30-34.	0.0	0
7016	Sudden unexpected death in Parkinson's disease: Insights from clinical practice. Clinics, 2022, 77, 100001.	0.6	5

#	ARTICLE	IF	CITATIONS
7017	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 345-371.	0.9	8
7018	Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 407-434.	0.9	5
7019	Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity. <i>Neural Regeneration Research</i> , 2022, 17, 1861.	1.6	23
7020	Cognition and serotonin in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 373-403.	0.9	8
7021	Neuropathological substrates of cognition in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 177-193.	0.9	4
7022	Consequences of variability in α -synuclein fibril structure on strain biology. <i>Acta Neuropathologica</i> , 2022, 143, 311-330.	3.9	15
7023	Neuronal endolysosomal transport and lysosomal functionality in maintaining axonostasis. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	17
7024	Assessment of the Clinical Use of Vestibular Evoked Myogenic Potentials and the Video Head Impulse Test in the Diagnosis of Early-Stage Parkinson's Disease. <i>Annals of Otology, Rhinology and Laryngology</i> , 2023, 132, 41-49.	0.6	4
7025	Psychiatric symptoms of frontotemporal dementia and subcortical (co-)pathology burden: new insights. <i>Brain</i> , 2023, 146, 307-320.	3.7	10
7026	Evaluation of oropharyngeal deglutitive pressure dynamics in patients with Parkinson's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G421-G430.	1.6	5
7028	<i>Akkermansia muciniphila</i> induces mitochondrial calcium overload and α -synuclein aggregation in an enteroendocrine cell line. <i>IScience</i> , 2022, 25, 103908.	1.9	35
7029	Serum Uric Acid Levels in Parkinson's Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania. <i>Medicina (Lithuania)</i> , 2022, 58, 245.	0.8	5
7030	Genetic lesions of the noradrenergic system trigger induction of oxidative stress and inflammation in the ventral midbrain. <i>Neurochemistry International</i> , 2022, 155, 105302.	1.9	3
7031	Autonomic and Depression Symptoms in Parkinson's Disease: Clinical Evidence for Overlapping Physiology. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1059-1067.	1.5	8
7032	The potential utility of smell testing to screen for neurodegenerative disorders. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 139-148.	1.5	1
7033	Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by α -synuclein conformations. <i>Acta Neuropathologica</i> , 2022, 143, 453-469.	3.9	14
7034	White Matter Microstructural Alterations in Newly Diagnosed Parkinson's Disease: A Whole-Brain Analysis Using dMRI. <i>Brain Sciences</i> , 2022, 12, 227.	1.1	1
7035	Computational Strategies to Identify New Drug Candidates against Neuroinflammation. <i>Current Medicinal Chemistry</i> , 2022, 29, 4756-4775.	1.2	6

#	ARTICLE	IF	CITATIONS
7036	Fluid markers of synapse degeneration in synucleinopathies. <i>Journal of Neural Transmission</i> , 2022, 129, 187-206.	1.4	4
7037	Microbes and Parkinson's disease: from associations to mechanisms. <i>Trends in Microbiology</i> , 2022, 30, 749-760.	3.5	9
7038	Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 479-489.	2.2	27
7039	Interaction of Alpha Synuclein and Microtubule Organization Is Linked to Impaired Neuritic Integrity in Parkinson's Patient-Derived Neuronal Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1812.	1.8	15
7040	Protective Role of Capsaicin in Neurological Disorders: An Overview. <i>Neurochemical Research</i> , 2022, 47, 1513-1531.	1.6	9
7041	Involvement of molecular chaperone in protein-misfolding brain diseases. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112647.	2.5	17
7042	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. <i>Brain</i> , 2022, 145, 584-595.	3.7	65
7043	Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns. <i>Brain</i> , 2022, 145, 1743-1756.	3.7	34
7044	Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease. <i>Cells</i> , 2021, 10, 3547.	1.8	28
7045	Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight. <i>Molecules</i> , 2021, 26, 7351.	1.7	6
7046	An Integrated Genomic Approach to Dissect the Genetic Landscape Regulating the Cell-to-Cell Transfer of α -Synuclein. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7047	Detection of neuron-derived pathological α -synuclein in blood. <i>Brain</i> , 2022, 145, 3058-3071.	3.7	82
7048	Assessment of retinal manifestations of Parkinson's disease using spectral domain optical coherence tomography: A study in Indian eyes. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 448.	0.5	1
7049	Autonomic Dysfunction in Sleep Disorders: From Neurobiological Basis to Potential Therapeutic		

#	ARTICLE	IF	CITATIONS
7054	Respiratory dysfunction in parkinson's disease: Relation with dysautonomia. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 683.	0.2	1
7056	Improvement effect of acupuncture on locomotor function in Parkinson disease via regulating gut microbiota and inhibiting inflammatory factor release. <i>Journal of Acupuncture and Tuina Science</i> , 2022, 20, 339-353.	0.1	3
7057	Leukotriene Signaling as a Target in α -Synucleinopathies. <i>Biomolecules</i> , 2022, 12, 346.	1.8	5
7059	LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2022, 11, 10.	3.6	13
7061	Natural Products as Novel Neuroprotective Agents; Computational Predictions of the Molecular Targets, ADME Properties, and Safety Profile. <i>Plants</i> , 2022, 11, 549.	1.6	5
7062	Current Progress in the Development of Probes for Targeting α -Synuclein Aggregates. <i>ACS Chemical Neuroscience</i> , 2022, 13, 552-571.	1.7	8
7063	Cerebrospinal Fluid TNF- α and Orexin in Patients With Parkinson's Disease and Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2022, 13, 826013.	1.1	2
7064	Bone Quality in Patients with Parkinson's Disease Determined by Quantitative Ultrasound (QUS) of the Calcaneus: Influence of Sex Differences. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2804.	1.2	3
7065	Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation. <i>Human Molecular Genetics</i> , 2022, 31, 3613-3628.	1.4	12
7066	Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson's disease. <i>Neurological Sciences</i> , 2022, 43, 4193-4201.	0.9	8
7067	Ischemic stroke causes Parkinson's disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein. <i>Acta Neuropathologica Communications</i> , 2022, 10, 26.	2.4	14
7069	Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 3180.	1.6	10
7070	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, 50.	3.1	26
7071	Monitoring the interactions between alpha-synuclein and Tau in vitro and in vivo using bimolecular fluorescence complementation. <i>Scientific Reports</i> , 2022, 12, 2987.	1.6	10
7072	Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease. <i>Medicinal Chemistry</i> , 2022, 18, 757-771.	0.7	3
7073	The role of the locus coeruleus/norepinephrine system in the pathogenesis of neurodegenerative disorders: An update. <i>Current Opinion in Neurology</i> , 2022, 35, 220-229.	1.8	3
7074	Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling. <i>Biomedicines</i> , 2022, 10, 436.	1.4	71
7075	Unique Lewy pathology in myotonic dystrophy type 1. <i>Neuropathology</i> , 2022, 42, 104-116.	0.7	3

#	ARTICLE	IF	CITATIONS
7076	Characterization of a Novel Monoclonal Antibody for Serine-129 Phosphorylated α -Synuclein: A Potential Application for Clinical and Basic Research. <i>Frontiers in Neurology</i> , 2022, 13, 821792.	1.1	2
7077	Ginsenoside Rg1 Plays a Neuroprotective Role in Regulating the Iron-Regulated Proteins and Against Lipid Peroxidation in Oligodendrocytes. <i>Neurochemical Research</i> , 2022, , 1.	1.6	7
7078	Rethinking Parkinson Disease: Exploring Gut-Brain Interactions and the Potential Role of Exercise. <i>Physical Therapy</i> , 2022, 102, .	1.1	2
7079	Implications of Gut Microbiota in Neurodegenerative Diseases. <i>Frontiers in Immunology</i> , 2022, 13, 785644.	2.2	37
7080	Evaluation of ABT-888 in the amelioration of α -synuclein fibril-induced neurodegeneration. <i>Brain Communications</i> , 2022, 4, fcac042.	1.5	1
7081	Parkinson's disease: Let food be thy medicine and medicine be thy food (Hippocrates). <i>Parkinsonism and Related Disorders</i> , 2022, 95, 113-114.	1.1	0
7082	Exposure of α -Synuclein Aggregates to Organotypic Slice Cultures Recapitulates Key Molecular Features of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2022, 13, 826102.	1.1	4
7083	Conformation-specific Antibodies Targeting Aggregated Forms of α -synuclein Block the Propagation of Synucleinopathy. <i>Experimental Neurobiology</i> , 2022, 31, 29-41.	0.7	4
7085	Acupuncture in the Treatment of Parkinson's Disease with Sleep Disorders and Dose Response. <i>BioMed Research International</i> , 2022, 2022, 1-7.	0.9	8
7086	Chicago sky blue 6B inhibits α -synuclein aggregation and propagation. <i>Molecular Brain</i> , 2022, 15, 27.	1.3	2
7088	Neuroimaging Studies in Non-Motor Parkinson's Disease Symptoms. , 2022, , 46-61.		0
7089	Current Concepts of Mixed Pathologies in Neurodegenerative Diseases. <i>Canadian Journal of Neurological Sciences</i> , 2023, 50, 329-345.	0.3	22
7090	Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy. <i>Cells</i> , 2022, 11, 906.	1.8	14
7091	Functional Covariance Connectivity of Gray and White Matter in Olfactory-Related Brain Regions in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 853061.	1.4	3
7092	Cardiac Alpha-Synuclein Is Present in Alpha-Synucleinopathies. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1125-1131.	1.5	4
7093	"Seeding" the idea of early diagnostics in synucleinopathies. <i>Brain</i> , 2022, , .	3.7	0
7094	Regional changes of brain structure during progression of idiopathic Parkinson's disease – A longitudinal study using deformation based morphometry. <i>Cortex</i> , 2022, 151, 188-210.	1.1	11
7095	Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson's disease. <i>Cell Death and Disease</i> , 2022, 13, 227.	2.7	3

#	ARTICLE	IF	CITATIONS
7096	The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 32.	2.5	19
7097	Inflammation and immune dysfunction in Parkinson disease. <i>Nature Reviews Immunology</i> , 2022, 22, 657-673.	10.6	360
7098	Sleep Disturbances in Patients with Parkinson's Disease. <i>Chronobiology in Medicine</i> , 2022, 4, 2-7.	0.2	0
7099	Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1219-1230.	1.5	18
7100	Picornavirus May Be Linked to Parkinson's Disease through Viral Antigen in Dopamine-Containing Neurons of Substantia Nigra. <i>Microorganisms</i> , 2022, 10, 599.	1.6	2
7101	Comparative efficacy of surgical approaches to disease modification in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 33.	2.5	3
7102	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. <i>Npj Parkinson's Disease</i> , 2022, 8, 31.	2.5	53
7103	Similarities, differences and overlaps between frailty and Parkinson's disease. <i>Geriatrics and Gerontology International</i> , 2022, 22, 259-270.	0.7	5
7104	Neuropathology of Non-Motor Parkinson's Disease Symptoms. , 2022, , 35-45.		0
7105	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. <i>Biomolecules</i> , 2022, 12, 440.	1.8	5
7106	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson's disease patients. <i>Npj Parkinson's Disease</i> , 2022, 8, 27.	2.5	8
7107	Distribution of α -Synuclein Aggregation in the Peripheral Tissues. <i>Neurochemical Research</i> , 2022, , 1.	1.6	4
7108	α -Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword. <i>Biomolecules</i> , 2022, 12, 507.	1.8	4
7109	Initiation and progression of α -synuclein pathology in Parkinson's disease. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 210.	2.4	33
7110	Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3499.	1.8	8
7111	Pathophysiology and Symptomatology of Drooling in Parkinson's Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 516.	1.0	5
7112	α -Synuclein Fibrils as Penrose Machines: A Chameleon in the Gear. <i>Biomolecules</i> , 2022, 12, 494.	1.8	2
7115	Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. <i>Movement Disorders</i> , 2022, 37, 1245-1255.	2.2	8

#	ARTICLE	IF	CITATIONS
7117	Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 4195-4203.	1.8	11
7118	The Role of Olfactory System in the Etiogenesis of Parkinson's Diseases: An Overview. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 31-39.	0.2	2
7119	To the Gut Microbiome and Beyond: The Brain-First or Body-First Hypothesis in Parkinson's Disease. <i>Frontiers in Microbiology</i> , 2022, 13, 791213.	1.5	7
7120	Combined Application of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Techniques to Investigate the Effect of Iron Deposition on Microstructural Changes in the Brain in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 792778.	1.7	3
7121	Low dose DMSO treatment induces oligomerization and accelerates aggregation of α -synuclein. <i>Scientific Reports</i> , 2022, 12, 3737.	1.6	6
7122	Oral Mucosa Derived α -Synuclein as a Potential Diagnostic Biomarker for Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 867528.	1.7	5
7123	α -Synuclein Radiotracer Development and <i>In Vivo</i> Imaging: Recent Advancements and New Perspectives. <i>Movement Disorders</i> , 2022, 37, 936-948.	2.2	24
7124	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 174.	2.4	45
7125	Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation <i>In Vitro</i> and <i>In Vivo</i> . <i>Biomolecules</i> , 2022, 12, 469.	1.8	9
7126	Therapeutically harnessing extracellular vesicles. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 379-399.	21.5	263
7127	Propagation of tau and α -synuclein in the brain: therapeutic potential of the glymphatic system. <i>Translational Neurodegeneration</i> , 2022, 11, 19.	3.6	15
7128	Computational design of a β -wrapin's N-terminal domain with canonical and non-canonical amino acid modifications mimicking curcumin's proposed inhibitory function. <i>Biophysical Chemistry</i> , 2022, 286, 106805.	1.5	1
7129	Spatial sequestration of misfolded proteins in neurodegenerative diseases. <i>Biochemical Society Transactions</i> , 2022, 50, 759-771.	1.6	4
7130	Neuropathology of α -synuclein in Parkinson's disease. <i>Neuropathology</i> , 2022, 42, 93-103.	0.7	14
7131	Monogenetic Forms of Parkinson's Disease – Bridging the Gap Between Genetics and Biomarkers. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 822949.	1.7	1
7133	Olfactory Dysfunction in Parkinson's Disease and Related Disorders. , 2022, , 99-114.		0
7135	Effects of behavioural swallowing therapy in patients with Parkinson's disease: A systematic review. <i>International Journal of Speech-Language Pathology</i> , 2023, 25, 269-280.	0.6	5
7136	Neurons with Cat's Eyes: A Synthetic Strain of α -Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions. <i>Biomolecules</i> , 2022, 12, 436.	1.8	8

#	ARTICLE	IF	CITATIONS
7137	Group I mGluRs in Therapy and Diagnosis of Parkinson's Disease: Focus on mGluR5 Subtype. <i>Biomedicines</i> , 2022, 10, 864.	1.4	4
7138	Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 329-336.	0.3	7
7139	Autophagy and protein aggregation as a mechanism of dopaminergic degeneration in a primary human dopaminergic neuronal model. <i>Toxicology Reports</i> , 2022, , .	1.6	0
7140	Sleep and Autonomic Manifestations in Parkinson's Disease Complicated With Probable Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neuroscience</i> , 2022, 16, 874349.	1.4	3
7141	Neuropathological changes in advanced Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2023, 11, 189-193.	0.2	1
7142	Cognitive impairment in advanced Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.2	0
7143	Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, , 1.	1.4	2
7144	Striatal dopamine transporter imaging in Parkinson's disease drug-naïve patients: focus on sexual dysfunction. <i>Neurological Sciences</i> , 2022, 43, 4769-4776.	0.9	6
7145	Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease. <i>Ageing Research Reviews</i> , 2022, 78, 101618.	5.0	28
7146	GBA Variants and Parkinson Disease: Mechanisms and Treatments. <i>Cells</i> , 2022, 11, 1261.	1.8	61
7147	Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 169, 105721.	2.1	6
7148	A co-expression network based molecular characterization of genes responsive for Braak stages in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2022, 55, 1873-1886.	1.2	1
7149	Prevalence of Prodromal Symptoms of Parkinson's Disease in the Late Middle-Aged Population. <i>Journal of Parkinson's Disease</i> , 2022, 12, 967-974.	1.5	17
7150	Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review. <i>Neurotoxicity Research</i> , 2022, , 1.	1.3	5
7151	Poly (ADP-Ribose) and α -synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. <i>PLoS ONE</i> , 2022, 17, e0264446.	1.1	6
7152	Effects of Age and Parkinson's Disease on the Relationship between Vocal Fold Abductory Kinematics and Relative Fundamental Frequency. <i>Journal of Voice</i> , 2022, , .	0.6	5
7153	Linking circadian rhythms to microbiome-gut-brain axis in aging-associated neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 78, 101620.	5.0	23
7154	Biomarker of Neuroinflammation in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4148.	1.8	50

#	ARTICLE	IF	CITATIONS
7155	Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD ⁺ pathway. <i>Human Molecular Genetics</i> , 2022, 31, 2918-2933.	1.4	5
7156	Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for α -Synucleinopathy?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 356-362.	0.9	1
7157	Matrix Inversion and Subset Selection (MISS): A pipeline for mapping of diverse cell types across the murine brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2111786119.	3.3	5
7158	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases. <i>Neurochemistry International</i> , 2022, 155, 105307.	1.9	5
7159	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. <i>Neurobiology of Disease</i> , 2022, 166, 105663.	2.1	34
7160	Nuclear imaging in Parkinson's disease: The past, the present, and the future. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120220.	0.3	5
7161	Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 151-160.	2.0	12
7162	Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish. <i>Journal of Ethnopharmacology</i> , 2022, 292, 115234.	2.0	10
7163	The roles of connectivity and neuronal phenotype in determining the pattern of α -synuclein pathology in Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 168, 105687.	2.1	14
7164	Extracellular alpha-synuclein: Sensors, receptors, and responses. <i>Neurobiology of Disease</i> , 2022, 168, 105696.	2.1	14
7165	Rodent models for gait network disorders in Parkinson's disease – a translational perspective. <i>Experimental Neurology</i> , 2022, 352, 114011.	2.0	9
7166	Brain-gut-microbiota axis in Parkinson's disease: A historical review and future perspective. <i>Brain Research Bulletin</i> , 2022, 183, 84-93.	1.4	17
7167	Long-term exposure to particulate air pollution and incidence of Parkinson's disease: A nationwide population-based cohort study in South Korea. <i>Environmental Research</i> , 2022, 212, 113165.	3.7	10
7168	Lipid Metabolism Influence on Neurodegenerative Disease Progression: Is the Vehicle as Important as the Cargo?. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 788695.	1.4	28
7169	Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?. <i>PLoS ONE</i> , 2021, 16, e0261302.	1.1	7
7170	Deep Transfer Learning for Parkinson's Disease Monitoring by Image-Based Representation of Resting-State EEG Using Directional Connectivity. <i>Algorithms</i> , 2022, 15, 5.	1.2	9
7171	Low plasma serotonin linked to higher nigral iron in Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 24384.	1.6	7
7172	Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. <i>Current Research in Nutrition and Food Science</i> , 2021, 9, 1017-1045.	0.3	0

#	ARTICLE	IF	CITATIONS
7173	Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease (ZEAL Study): A Protocol for Randomized Controlled Trials. <i>Frontiers in Neurology</i> , 2021, 12, 741307.	1.1	1
7174	Mitochondria-Microbiota Interaction in Neurodegeneration. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 776936.	1.7	7
7176	Analysis of REM sleep without atonia in 22q11.2 deletion syndrome determined by domiciliary polysomnography: a cross sectional study. <i>Sleep</i> , 2022, 45, .	0.6	6
7177	Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13488.	1.8	18
7178	Multiscale Entropy of Resting-State Functional Magnetic Resonance Imaging Differentiates Progressive Supranuclear Palsy and Multiple System Atrophy. <i>Life</i> , 2021, 11, 1411.	1.1	0
7179	A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 795-817.	0.8	4
7181	Layer-Specific Vesicular Glutamate Transporter 1 Immunofluorescence Levels Delineate All Layers of the Human Hippocampus Including the Stratum lucidum. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 789903.	1.8	5
7182	Neuropathology and molecular diagnosis of Synucleinopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 83.	4.4	101
7183	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. <i>Nature Reviews Neuroscience</i> , 2022, 23, 115-128.	4.9	92
7184	Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?. <i>Brain Sciences</i> , 2021, 11, 1654.	1.1	22
7185	Acute Exposure to the Food-Borne Pathogen <i>Listeria monocytogenes</i> Does Not Induce α -Synuclein Pathology in the Colonic ENS of Nonhuman Primates. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7265-7279.	1.6	2
7188	A Comparative Study of Site-Specific Distribution of Aging-Related Tau Astroglialopathy and Its Risk Factors Between Alzheimer Disease and Cognitive Healthy Brains: The Hisayama Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 106-116.	0.9	1
7189	The Myelin-Weighted Connectome in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 724-733.	2.2	10
7190	The Role of TRPA1 Channels in the Central Processing of Odours Contributing to the Behavioural Responses of Mice. <i>Pharmaceuticals</i> , 2021, 14, 1336.	1.7	6
7191	Slow-wave sleep affects synucleinopathy and regulates proteostatic processes in mouse models of Parkinson's disease. <i>Science Translational Medicine</i> , 2021, 13, eabe7099.	5.8	29
7192	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. <i>Acta Neuropathologica</i> , 2022, 143, 15-31.	3.9	29
7193	Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. <i>Brain</i> , 2022, 145, 3488-3499.	3.7	6
7194	Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson's Disease. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3499-3508.	1.0	2

#	ARTICLE	IF	CITATIONS
7195	Neurodegenerative brain changes are associated with area deprivation in the United Kingdom: findings from the Brains for Dementia Research study. <i>Acta Neuropathologica Communications</i> , 2021, 9, 198.	2.4	4
7196	An electrophysiological perspective on Parkinson's disease: symptomatic pathogenesis and therapeutic approaches. <i>Journal of Biomedical Science</i> , 2021, 28, 85.	2.6	11
7197	CHAPTER 1. Etiology and Pathogenesis of Parkinson's Disease. <i>Issues in Toxicology</i> , 0, , 1-26.	0.2	3
7198	Association of Glial Tau Pathology and Late-Nc in the Ageing Brain. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7199	On cell loss in Parkinson's disease, and the citations that followed. <i>Npj Parkinson's Disease</i> , 2022, 8, 38.	2.5	0
7200	Increased blood pressure variability is associated with probable rapid eye movement sleep behaviour disorder in elderly hypertensive patients. <i>Blood Pressure</i> , 2022, 31, 40-46.	0.7	1
7201	Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson's Disease? A Systematic Review of the Current Literature. <i>Brain Sciences</i> , 2022, 12, 513.	1.1	17
7202	Neurophysiological mechanisms of gait disturbance in advanced Parkinson's disease patients. <i>Neurology and Clinical Neuroscience</i> , 0, , .	0.2	0
7203	Clinical Sphingolipids Pathway in Parkinson's Disease: From GCaase to Integrated-Biomarker Discovery. <i>Cells</i> , 2022, 11, 1353.	1.8	7
7204	Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1345-1351.	1.5	6
7205	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. <i>Journal of Neural Transmission</i> , 2022, 129, 1155-1167.	1.4	19
7206	The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade. <i>Acta Neuropathologica Communications</i> , 2022, 10, 55.	2.4	7
7207	Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein. <i>Frontiers in Neurology</i> , 2022, 13, 787059.	1.1	9
7208	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 411-425.	1.5	4
7209	Parkinson's disease and the spectrum of Lewy body disease. , 0, , 10-26.		0
7212	Clinical aspects of movement disorders. , 0, , 29-50.		0
7213	Synucleinopathies. , 2014, , 149-175.		0
7214	CHAPTER 8. Redox Signalling in Dopaminergic Cell Death and Survival. <i>Issues in Toxicology</i> , 0, , 210-254.	0.2	0

#	ARTICLE	IF	CITATIONS
7215	CHAPTER 11. At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products. <i>Issues in Toxicology</i> , 0, , 325-388.	0.2	0
7216	Evolution of Parkinson's Disease and Treatment Requirements: What New Treatments are Needed and the Role of Striatal Grafting. , 2006, , 50-64.		0
7217	Aging and Brain Pathology. , 2006, , 619-640.		0
7314	The Ubiquitinâ€”Proteasome System in Parkinson's Disease. , 0, , 169-194.		0
7316	Abnormal Pulmonary Function in Early Parkinsonâ€™s Disease: A Preliminary Prospective Observational Study. <i>Lung</i> , 2022, 200, 325-329.	1.4	3
7317	Binding Stability of Antibodyâ€”Î±-Synuclein Complexes Predicts the Protective Efficacy of Anti-Î±-synuclein Antibodies. <i>Molecular Neurobiology</i> , 2022, 59, 3980-3995.	1.9	3
7318	Cholinergic nucleus 4 grey matter density is associated with apathy in Parkinsonâ€™s disease. <i>Clinical Neuropsychologist</i> , 2023, 37, 676-694.	1.5	2
7320	Glial Cells as Possible Targets of Neuroprotection through Neurotrophic and Antioxidative Molecules in the Central and Enteric Nervous Systems in Parkinson's Disease. <i>Acta Medica Okayama</i> , 2021, 75, 549-556.	0.1	3
7322	Imaging beyond the striatonigral dopaminergic system in Parkinson's disease. <i>Hellenic Journal of Nuclear Medicine</i> , 2012, 15, 224-32.	0.2	13
7323	Identification of the Raman Salivary Fingerprint of Parkinsonâ€™s Disease Through the Spectroscopicâ€”Computational Combinatory Approach. <i>Frontiers in Neuroscience</i> , 2021, 15, 704963.	1.4	12
7325	A comparative study of early and late onset freezing of gait in Parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 256.	0.2	10
7326	Advanced diffusion imaging to track progression in Parkinsonâ€™s disease, multiple system atrophy, and progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2022, 34, 103022.	1.4	12
7327	Convergent pathways of the gut microbiotaâ€”brain axis and neurodegenerative disorders. <i>Gastroenterology Report</i> , 2022, 10, goac017.	0.6	16
7328	Functional amyloids from bacterial biofilms â€” structural properties and interaction partners. <i>Chemical Science</i> , 2022, 13, 6457-6477.	3.7	28
7329	Tau accelerates Î±-synuclein aggregation and spreading in Parkinsonâ€™s disease. <i>Brain</i> , 2022, 145, 3454-3471.	3.7	36
7331	Elevated Î±-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinsonâ€™s disease. <i>GeroScience</i> , 2022, 44, 1551-1562.	2.1	9
7332	Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 54.	2.5	42
7333	Dopaminergic Modulation of Local Non-oscillatory Activity and Global-Network Properties in Parkinsonâ€™s Disease: An EEG Study. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 846017.	1.7	8

#	ARTICLE	IF	CITATIONS
7334	Early disturbance of dynamic synchronization and neurovascular coupling in cognitively normal Parkinson's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1719-1731.	2.4	8
7336	Eye tracking identifies biomarkers in α -synucleinopathies versus progressive supranuclear palsy. <i>Journal of Neurology</i> , 2022, 269, 4920-4938.	1.8	6
7337	Toward Novel [18 F]Fluorine-Labeled Radiotracers for the Imaging of α -Synuclein Fibrils. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 830704.	1.7	5
7338	"On the nose" Could olfactory testing be a reliable bedside marker of prodromal DLB?. <i>International Psychogeriatrics</i> , 2022, , 1-10.	0.6	0
7339	Stepping up to meet the challenge of freezing of gait in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2022, 11, 23.	3.6	10
7340	Ultrastructural and biochemical classification of pathogenic tau, α -synuclein and TDP-43. <i>Acta Neuropathologica</i> , 2022, 143, 613-640.	3.9	22
7341	Cognitive Impact of Deep Brain Stimulation in Parkinson's Disease Patients: A Systematic Review. <i>Frontiers in Human Neuroscience</i> , 2022, 16, .	1.0	6
7342	Environmental neurotoxic pesticide exposure induces gut inflammation and enteric neuronal degeneration by impairing enteric glial mitochondrial function in pesticide models of Parkinson's disease: Potential relevance to gut-brain axis inflammation in Parkinson's disease pathogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 147, 106225.	1.2	11
7343	Evaluating the Different Stages of Parkinson's Disease Using Electroencephalography With Holo-Hilbert Spectral Analysis. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	6
7344	Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 170, 105744.	2.1	15
7345	Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently. <i>Neuromodulation</i> , 2023, 26, 382-393.	0.4	5
7346	Peripheral inflammation and neurodegeneration; a potential for therapeutic intervention in Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). <i>Egyptian Journal of Neurosurgery</i> , 2022, 37, .	0.2	4
7348	Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. <i>Nature Neuroscience</i> , 2022, 25, 588-595.	7.1	155
7349	Exploring the Causal Effect of Constipation on Parkinson's Disease Through Mediation Analysis of Microbial Data. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	10
7350	Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson's disease. <i>Neurological Sciences</i> , 2022, 43, 4745-4752.	0.9	6
7351	The cross-sectional area of the vagus nerve is not reduced in Parkinson's disease patients. <i>ENeurologicalSci</i> , 2022, 27, 100400.	0.5	6
7352	Neurogenesis in aging and age-related neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 78, 101636.	5.0	41
7353	Bewegungsstörungen " Morbus Parkinson. , 2021, , 64-79.		0

#	ARTICLE	IF	CITATIONS
7354	Modelling α -Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons. <i>Cells</i> , 2022, 11, 1640.	1.8	8
7355	Calcium carbonate supplementation causes motor dysfunction. <i>Experimental Animals</i> , 2022, 71, 399-410.	0.7	2
7356	Molecular mechanisms of amyloid formation in living systems. <i>Chemical Science</i> , 2022, 13, 7080-7097.	3.7	21
7357	Locus Coeruleus Integrity from ^{7}T MRI Relates to Apathy and Cognition in Parkinsonian Disorders. <i>Movement Disorders</i> , 2022, 37, 1663-1672.	2.2	23
7358	In vivo Illustration of Altered Dopaminergic and GABAergic Systems in Early Parkinson's Disease. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	3
7359	Clinicopathological correlates of pyramidal signs in multiple system atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2022, , .	1.7	2
7360	Electroencephalographic-Based Functional Connectivity Networks of Visual Hallucinations and Visuospatial Dysfunctions in Parkinson's Disease. <i>European Neurology</i> , 2022, , 1-6.	0.6	0
7361	Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
7372	Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. <i>Nature Reviews Neuroscience</i> , 2022, 23, 523-534.	4.9	43
7373	Neuroinflammation in Parkinson's Disease – Putative Pathomechanisms and Targets for Disease-Modification. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	42
7374	Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. <i>Brain</i> , 2022, 145, 3162-3178.	3.7	13
7376	Inflammatory Animal Models of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S165-S182.	1.5	9
7378	Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α -synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	3
7379	Early Forms of α -Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson's Disease. <i>Biomolecules</i> , 2022, 12, 747.	1.8	6
7381	A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α -synuclein in a mouse model of Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	17
7382	Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	41
7383	Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	3
7384	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	6
7386	Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?. <i>Parkinsonism and Related Disorders</i> , 2022, 100, 24-32.	1.1	17
7387	Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the <i>LRRK2</i> G2019S Variant. <i>Neurology</i> , 2022, 99, .	1.5	2
7388	Pathogenic Impact of α -Synuclein Phosphorylation and Its Kinases in α -Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6216.	1.8	25
7389	Neuroimaging signatures predicting motor improvement to focused ultrasound subthalamotomy in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	9
7390	GABAA receptor subunit expression and cellular localization in the human parkinsonian globus pallidus. <i>World Neurosurgery</i> , 2022, , .	0.7	2
7391	Exploration of the α -syn/T199678/miR-519-3p/KLF9 pathway in a PD-related α -syn pathology. <i>Brain Research Bulletin</i> , 2022, 186, 50-61.	1.4	7
7395	Vieillessement cérébral pathologique. , 2021, , 681-777.		0
7396	Surface-based morphological patterns associated with neuropsychological performance, symptom severity, and treatment response in Parkinson's disease. <i>Annals of Translational Medicine</i> , 2022, 10, 741-741.	0.7	3

#	ARTICLE	IF	CITATIONS
7397	Histoire naturelle de la maladie de Parkinson idiopathique. , 2022, , 239-251.		0
7398	Processus neurodégénératifs et inflammation. , 2022, , 3-16.		0
7399	Electrodeposited Copper Nanocubes on Multi-Layer Graphene: A Novel Nanozyme for Ultrasensitive Dopamine Detection from Biological Samples. SSRN Electronic Journal, 0, , .	0.4	0
7401	Pathogénie et physiopathologie de la maladie de Parkinson. , 2022, , 29-38.		0
7402	Symptômes non moteurs dans la maladie de Parkinson. , 2022, , 267-276.		0
7403	Mass Spectrometry-Based Analysis of Serum N-Glycosylation Changes in Patients with Parkinson's Disease. ACS Chemical Neuroscience, 2022, 13, 1719-1726.	1.7	18
7404	Linking α -synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease. Brain Communications, 2022, 4, .	1.5	14
7405	Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis. Genes, 2022, 13, 1034.	1.0	4
7406	Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson's Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
7407	Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	11
7408	Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. Neurobiology of Disease, 2022, 171, 105804.	2.1	12
7409	Knowledge Mapping of Olfactory Dysfunction: A Bibliometric Study. Frontiers in Systems Neuroscience, 0, 16, .	1.2	6
7410	Dual-Hit Model of Parkinson's Disease: Impact of Dysbiosis on 6-Hydroxydopamine-Insulted Mice's Neuroprotective and Anti-Inflammatory Effects of Butyrate. International Journal of Molecular Sciences, 2022, 23, 6367.	1.8	13
7411	Attenuated brain white matter functional network interactions in Parkinson's disease. Human Brain Mapping, 2022, 43, 4567-4579.	1.9	4
7412	Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	7
7413	Morphological basis of Parkinson disease-associated cognitive impairment: an update. Journal of Neural Transmission, 2022, 129, 977-999.	1.4	18
7414	Using Extracellular Vesicles Released by GDNF-Transfected Macrophages for Therapy of Parkinson Disease. Cells, 2022, 11, 1933.	1.8	5
7415	Neurodegeneration and Neuroinflammation in Parkinson's Disease: a Self-Sustained Loop. Current Neurology and Neuroscience Reports, 2022, 22, 427-440.	2.0	21

#	ARTICLE	IF	CITATIONS
7416	Î±-Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. <i>Acta Neuropathologica</i> , 2022, 144, 167-185.	3.9	12
7417	Structural Insights of Fe ³⁺ Induced Î±-synuclein Fibrillation in Parkinsonâ€™s Disease. <i>Journal of Molecular Biology</i> , 2023, 435, 167680.	2.0	7
7418	Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1921-1935.	1.5	7
7419	The microbiomeâ€™gutâ€™brain axis in Parkinson disease â€™ from basic research to the clinic. <i>Nature Reviews Neurology</i> , 2022, 18, 476-495.	4.9	94
7420	Depression in Patients with Parkinsonâ€™s Disease: Current Understanding of its Neurobiology and Implications for Treatment. <i>Drugs and Aging</i> , 2022, 39, 417-439.	1.3	34
7421	The Gut Microbiomeâ€™Brain Crosstalk in Neurodegenerative Diseases. <i>Biomedicines</i> , 2022, 10, 1486.	1.4	20
7422	Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S129-S136.	1.5	9
7423	The effect of hypocalcemia on motor symptoms of Parkinsonâ€™s disease. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	0.4	2
7424	Psychosis in Parkinsonâ€™s Disease: A Lesson from Genetics. <i>Genes</i> , 2022, 13, 1099.	1.0	5
7425	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. <i>Neuroepidemiology</i> , 2022, 56, 309-318.	1.1	13
7427	Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson's disease and its medications. <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, .	1.1	5
7428	Disease modification in Parkinsonism: obstacles and ways forward. <i>Journal of Neural Transmission</i> , 0, .	1.4	7
7429	Investigating key factors underlying neurodegeneration linked to alphaâ€™synuclein spread. <i>Neuropathology and Applied Neurobiology</i> , 0, .	1.8	1
7430	A Brief Introduction to Magnetoencephalography (MEG) and Its Clinical Applications. <i>Brain Sciences</i> , 2022, 12, 788.	1.1	16
7431	Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinsonâ€™s disease mice. <i>Scientific Reports</i> , 2022, 12, .	1.6	15
7432	Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinsonâ€™s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial. <i>Chinese Medicine</i> , 2022, 17, .	1.6	0
7433	Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases. <i>Molecular Imaging and Biology</i> , 2022, 24, 950-958.	1.3	2
7434	Protocol for rapid obtention and fractionation of anaerobic bacterial conditioned media to study calcium signaling in enteroendocrine cells. <i>STAR Protocols</i> , 2022, 3, 101486.	0.5	0

#	ARTICLE	IF	CITATIONS
7435	Î±-synucleinopathy exerts sex-dimorphic effects on the multipurpose DNA repair/redox protein APE1 in mice and humans. Progress in Neurobiology, 2022, 216, 102307.	2.8	5
7436	Neuroprotective approaches to halt Parkinson's disease progression. Neurochemistry International, 2022, 158, 105380.	1.9	7
7437	Regional Metabolic Changes Influencing Three-Dimensional Perception in Parkinsonâ€™s Disease. Journal		

#	ARTICLE	IF	CITATIONS
7458	Heparan sulfate proteoglycans mediate prion-like α -synuclein toxicity in Parkinson's in vivo models. <i>Life Science Alliance</i> , 2022, 5, e202201366.	1.3	11
7459	Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson's Disease and Obesity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7503.	1.8	9
7460	Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	24
7461	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia. <i>Brain Communications</i> , 2022, 4, .	1.5	3
7462	Nasal Microbiota, Olfactory Health, Neurological Disorders and Aging—A Review. <i>Microorganisms</i> , 2022, 10, 1405.	1.6	14
7463	Wearable sensor device-based detection of decreased heart rate variability in Parkinson's disease. <i>Journal of Neural Transmission</i> , 0, , .	1.4	2
7464	Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease. <i>Brain</i> , 2023, 146, 195-208.	3.7	35
7465	Neuronal and glial characterization in the rostrocaudal axis of the human anterior olfactory nucleus: Involvement in Parkinson's disease. <i>Frontiers in Neuroanatomy</i> , 0, 16, .	0.9	2
7466	TNF- α promotes α -synuclein propagation through stimulation of senescence-associated lysosomal exocytosis. <i>Experimental and Molecular Medicine</i> , 2022, 54, 788-800.	3.2	18
7467	Neuroimaging of rapid eye movement sleep behavior disorder and its relation to Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2022, 100, 1815-1833.	1.3	8
7468	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1203-1228.	1.2	7
7469	Therapeutic functions of astrocytes to treat α -synuclein pathology in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	15
7470	Alterations of Regional Homogeneity in Parkinson's Disease: A Resting-State Functional Magnetic Resonance Imaging (fMRI) Study. <i>Cureus</i> , 2022, , .	0.2	2
7471	Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	8
7472	Predictive models for the incidence of Parkinson's disease: systematic review and critical appraisal. <i>Reviews in the Neurosciences</i> , 2022, .	1.4	2
7473	Exosomes in Alpha-Synucleinopathies: Propagators of Pathology or Potential Candidates for Nanotherapeutics?. <i>Biomolecules</i> , 2022, 12, 957.	1.8	8
7474	Intestinal Transit in Early Moderate Parkinson's Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate. <i>Parkinson's Disease</i> , 2022, 2022, 1-8.	0.6	0
7475	Loss of tau expression attenuates neurodegeneration associated with α -synucleinopathy. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	7

#	ARTICLE	IF	CITATIONS
7476	Autonomic dysfunction in Parkinson's disease: Results from the Faroese Parkinson's disease cohort. <i>Neuroscience Letters</i> , 2022, 785, 136789.	1.0	3
7477	Parkinson's Progression Markers Initiative brain autopsy program. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 62-65.	1.1	2
7478	Enteric glial cell reactivity in colonic layers and mucosal modulation in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. <i>Brain Research Bulletin</i> , 2022, 187, 111-121.	1.4	10
7479	Effect of bacteriophage-encoded chaperonins on amyloid transformation of α -synuclein. <i>Biochemical and Biophysical Research Communications</i> , 2022, 622, 136-142.	1.0	4
7480	The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. <i>Neurobiology of Disease</i> , 2022, 172, 105806.	2.1	7
7481	The role of inflammation in neurodegenerative diseases. , 2023, , 403-421.		2
7482	Role of the gut microbiome in the pathophysiology of brain disorders. , 2023, , 913-928.		0
7483	Parkinson disease and other synucleinopathies. , 2023, , 253-274.		0
7484	The intricate debate on neurodegeneration and neuroinflammation in Parkinson's disease: which came first?. <i>Neural Regeneration Research</i> , 2023, 18, 125.	1.6	3
7488	Rapid macropinocytic transfer of α -synuclein to lysosomes. <i>Cell Reports</i> , 2022, 40, 111102.	2.9	22
7489	Promising Role of Oral Cavity Mesenchymal Stem Cell-Derived Extracellular Vesicles in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 0, , .	1.9	3
7490	Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2022, 59, 6107-6124.	1.9	13
7491	The large neuron involvement in the neostriatum in Lewy body diseases. <i>Neuropathology</i> , 2022, 42, 459-463.	0.7	0
7492	Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	11
7493	Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
7494	Association between Functional Connectivity of Entorhinal Cortex and Olfactory Performance in Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 963.	1.1	0
7495	Nigral neuropathology of Parkinson's motor subtypes coincide with circuitopathies: a scoping review. <i>Brain Structure and Function</i> , 2022, 227, 2231-2242.	1.2	4
7496	α -Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1463-1466.	2.8	7

#	ARTICLE	IF	CITATIONS
7497	Porphyromonas gingivalis: A key role in Parkinson's disease with cognitive impairment?. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	5
7498	Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	10
7499	The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	31
7500	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. <i>Brain</i> , 2022, 145, 4506-4518.	3.7	15
7501	Is peripheral alpha synuclein a marker for gait velocity in Parkinson's disease?. <i>Neuroscience Letters</i> , 2022, 786, 136819.	1.0	2
7503	Multifactor Progression of Parkinson's Disease: Role of Diet and Exposure to Microbiome-Borne Curli. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7504	Sex and gender differences in movement disorders: Parkinson's disease, essential tremor, dystonia and chorea. <i>International Review of Neurobiology</i> , 2022, , 101-128.	0.9	2
7505	Sleep-controlling neurons are sensitive and vulnerable to multiple forms of α -synuclein: implications for the early appearance of sleeping disorders in α -synucleinopathies. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
7506	NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT- α -synuclein mouse model of Parkinson's disease. <i>PLoS ONE</i> , 2022, 17, e0272085.	1.1	5
7507	Management of Sleep Disturbances in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2029-2058.	1.5	15
7508	Olfactory swab sampling optimization for α -synuclein aggregate detection in patients with Parkinson's disease. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	16
7509	α -Synuclein fibril-specific nanobody reduces prion-like α -synuclein spreading in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	23
7510	Norovirus Intestinal Infection and Lewy Body Disease in an Older Patient with Acute Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8376.	1.8	1
7511	Impact of aging on animal models of Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	18
7512	Heparin induces α -synuclein to form new fibril polymorphs with attenuated neuropathology. <i>Nature Communications</i> , 2022, 13, .	5.8	20
7513	Neuroinflammation in neurodegeneration via microbial infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
7515	Role of the Gut-Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson's Disease. <i>Microorganisms</i> , 2022, 10, 1544.	1.6	15
7517	Nitrosative stress in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	20

#	ARTICLE	IF	CITATIONS
7518	Imperative Role of Machine Learning Algorithm for Detection of Parkinsonâ€™s Disease: Review, Challenges and Recommendations. <i>Diagnostics</i> , 2022, 12, 2003.	1.3	31
7519	Fine Particulate Matter Triggers Î±-Synuclein Fibrillization and Parkinsonâ€™like Neurodegeneration. <i>Movement Disorders</i> , 2022, 37, 1817-1830.	2.2	15
7520	Artificial intelligence-enabled detection and assessment of Parkinsonâ€™s disease using nocturnal breathing signals. <i>Nature Medicine</i> , 2022, 28, 2207-2215.	15.2	74
7521	Harmol promotes Î±-synuclein degradation and improves motor impairment in Parkinsonâ€™s models via regulating autophagy-lysosome pathway. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	7
7522	Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinsonâ€™s Disease. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1603-1618.	1.0	3
7523	NADPH and Mitochondrial Quality Control as Targets for a Circadian-Based Fasting and Exercise Therapy for the Treatment of Parkinsonâ€™s Disease. <i>Cells</i> , 2022, 11, 2416.	1.8	16
7524	Hunting for the cause: Evidence for prion-like mechanisms in Huntingtonâ€™s disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	6
7525	Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2247-2256.	2.2	5
7526	Role of Protein Damage Inflicted by Dopamine Metabolites in Parkinsonâ€™s Disease: Evidence, Tools, and Outlook. <i>Chemical Research in Toxicology</i> , 2022, 35, 1789-1804.	1.7	9
7527	The role of voltage-gated calcium channels in the pathogenesis of Parkinsonâ€™s disease. <i>International Journal of Neuroscience</i> , 0, , 1-10.	0.8	6
7528	Lysosomal exocytosis releases pathogenic Î±-synuclein species from neurons in synucleinopathy models. <i>Nature Communications</i> , 2022, 13, .	5.8	28
7529	Elevation of gangliosides in four brain regions from Parkinsonâ€™s disease patients with a GBA mutation. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	6
7530	Spreading of alpha-synuclein between different cell types. <i>Behavioural Brain Research</i> , 2023, 436, 114059.	1.2	6
7531	Lewy Body Disease Primate Model with Î±-Synuclein Propagation from the Olfactory Bulb. <i>Movement Disorders</i> , 2022, 37, 2033-2044.	2.2	6
7532	Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinsonâ€™s disease patients. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	21
7533	A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 0, , .	1.8	0
7535	Distribution Patterns of Astrocyte Populations in the Human Cortex. <i>Neurochemical Research</i> , 2023, 48, 1222-1232.	1.6	6
7536	Altered resting state brain metabolic connectivity in dementia with Lewy bodies. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
7537	Parkinson's Disease: A Multisystem Disorder. <i>Neuroscience Bulletin</i> , 2023, 39, 113-124.	1.5	20
7538	Response times for reflexive saccades correlate with cognition in parkinson's disease, not disease severity or duration. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
7539	NF- β in neurodegenerative diseases: Recent evidence from human genetics. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	21
7540	Research progress in the early diagnosis of Parkinson's disease. <i>Neurological Sciences</i> , 0, , .	0.9	3
7541	Measurement of α -Synuclein Dynamics In Vivo Using Microdialysis with a Novel Homogeneous Immunoassay. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2557-2564.	1.7	1
7542	Metabolic connectivity of resting-state networks in alpha synucleinopathies, from prodromal to dementia phase. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	7
7544	Gray Matter Volume Loss in Proposed Brain and Body Parkinson's Disease Subtypes. <i>Movement Disorders</i> , 2022, 37, 2066-2074.	2.2	8
7546	Noradrenaline and Movement Initiation Disorders in Parkinson's Disease: A Pharmacological Functional MRI Study with Clonidine. <i>Cells</i> , 2022, 11, 2640.	1.8	5
7547	Air Pollution-Related Neurotoxicity Across the Life Span. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 143-163.	4.2	15
7548	Can we really read art to see the changing brain? A review and empirical assessment of clinical case reports and published artworks for systematic evidence of quality and style changes linked to damage or neurodegenerative disease. <i>Physics of Life Reviews</i> , 2022, 43, 32-95.	1.5	17
7549	Toward preventing Parkinson's disease. <i>Science</i> , 2022, 377, 818-819.	6.0	12
7550	Characterizing Lewy Pathology in 231 Essential Tremor Brains From the Essential Tremor Centralized Brain Repository. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, Publish Ahead of Print, .	0.9	7
7551	Macroscopic diagnostic clue for parkinsonism. <i>Neuropathology</i> , 2022, 42, 394-419.	0.7	3
7552	Quantification of noradrenergic, dopaminergic, and tectal neurons during aging in the short-lived killifish <i>Nothobranchius furzeri</i> . <i>Aging Cell</i> , 2022, 21, .	3.0	14
7553	NLRP3 inflammasome in neurodegenerative disease. <i>Translational Research</i> , 2023, 252, 21-33.	2.2	25
7554	Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology. <i>Nature Communications</i> , 2022, 13, .	5.8	15
7555	Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8586.	1.8	6
7556	Neurofilaments in neurologic disorders and beyond. <i>Journal of the Neurological Sciences</i> , 2022, 441, 120380.	0.3	5

#	ARTICLE	IF	CITATIONS
7557	Association of glial tau pathology and LATE-NC in the ageing brain. <i>Neurobiology of Aging</i> , 2022, 119, 77-88.	1.5	9
7558	Removal of proteinase K resistant α -Syn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model. <i>Neuropharmacology</i> , 2022, 218, 109213.	2.0	6
7559	Electrodeposited copper nanocubes on multi-layer graphene: A novel nanozyme for ultrasensitive dopamine detection from biological samples. <i>Applied Surface Science</i> , 2022, 604, 154392.	3.1	16
7560	The gut-brain axis in the pathogenesis of Parkinson's disease. <i>Brain Science Advances</i> , 2019, 5, 73-81.	0.3	1
7561	Screening for non-motor symptoms in Egyptian patients with Parkinson's disease. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	0.4	2
7562	Adaptive structural changes in the motor cortex and white matter in Parkinson's disease. <i>Acta Neuropathologica</i> , 2022, 144, 861-879.	3.9	17
7563	Post-mortem brain histological examination in the substantia nigra and subthalamic nucleus in Parkinson's disease following deep brain stimulation. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	8
7564	HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease. <i>Neuropeptides</i> , 2022, 96, 102287.	0.9	2
7565	Imaging the Limbic System in Parkinson's Disease—A Review of Limbic Pathology and Clinical Symptoms. <i>Brain Sciences</i> , 2022, 12, 1248.	1.1	13
7566	Single-cell RNA sequencing of CSF reveals neuroprotective RAC1+ NK cells in Parkinson's disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
7567	Relation between event segmentation and memory dysfunction in Parkinson's disease. <i>Brain and Cognition</i> , 2022, 163, 105912.	0.8	2
7568	Effective R2 relaxation rate, derived from dual-contrast fast-spin-echo MRI, enables detection of hemisphere differences in iron level and dopamine function in Parkinson's disease and healthy individuals. <i>Journal of Neuroscience Methods</i> , 2022, 382, 109708.	1.3	5
7569	Subgrouping and structural brain connectivity of Parkinson's disease — past studies and future directions. <i>Neuroscience Informatics</i> , 2022, 2, 100100.	2.8	4
7570	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. , 2023, , 455-492.		0
7571	Role of Impaired Insulin Signaling in the Pathogenesis of Dementia. , 2022, , 63-84.		0
7572	The Neuroprotective Effect of the HLDF-6 Peptides in the Experimental Model of Preclinical Stage of Parkinson's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7573	Evaluation of non-motor symptoms in wilson disease using the parkinson's disease nonmotor symptoms questionnaire: A pilot cross-sectional study and critical assessment. <i>Annals of Indian Academy of Neurology</i> , 2022, 25, 1062.	0.2	1
7574	Neuropathology of the temporal lobe. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, , 407-427.	1.0	2

#	ARTICLE	IF	CITATIONS
7575	Alterations in Large-Scale Intrinsic Connectivity Networks in the Parkinson's Disease-Associated Cognitive Impairment Continuum: A Systematic Review. <i>Noropsikiyatri Arsivi</i> , 2022, , .	0.2	0
7576	Interplay of alpha-synuclein pathology and gut microbiome in Parkinsonâ€™s disease. , 2022, , 159-178.		1
7577	Evaluation of Inflammatory Cytokine and Anti <i>Helicobacter Pylori</i> Antibodies in the Pathogenesis of Parkinsonâ€™s Disease. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 96-102.	0.2	5
7578	Development of autophagy enhancers for Parkinsonâ€™s disease therapy. , 2022, , 305-320.		0
7579	The many genomes of Parkinson's disease. <i>International Review of Neurobiology</i> , 2022, , .	0.9	2
7580	An antibody scanning method for the detection of Î±-synuclein oligomers in the serum of Parkinson's disease patients. <i>Chemical Science</i> , 2022, 13, 13815-13828.	3.7	4
7581	Autophagy in Lewy body diseases and multiple system atrophy. , 2022, , 227-244.		0
7582	Dissociation between function and manipulation in semantic representations of motor impaired subjects: A new test. <i>Cognitive Neuropsychology</i> , 2022, 39, 208-226.	0.4	0
7583	Sparsity Dependent Metrics Depict Alteration of Brain Network Connectivity in Parkinson's Disease. , 2022, , .		4
7584	Emerging roles of leptin in Parkinsonâ€™s disease: Chronic inflammation, neuroprotection and more?. <i>Brain, Behavior, and Immunity</i> , 2023, 107, 53-61.	2.0	5
7585	Post-COVID-19 Parkinsonism and Parkinsonâ€™s Disease Pathogenesis: The Exosomal Cargo Hypothesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9739.	1.8	8
7586	Abnormal cortical atrophy and functional connectivity are associated with depression in Parkinsonâ€™s disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	8
7587	Cortical atrophy is associated with cognitive impairment in Parkinsonâ€™s disease: a combined analysis of cortical thickness and functional connectivity. <i>Brain Imaging and Behavior</i> , 2022, 16, 2586-2600.	1.1	5
7588	Ursolic acid enhances autophagic clearance and ameliorates motor and non-motor symptoms in Parkinsonâ€™s disease mice model. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 752-765.	2.8	10
7589	Genetics and Pathogenesis of Parkinson's Syndrome. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2023, 18, 95-121.	9.6	49
7590	Mapping neuromodulatory systems in Parkinsonâ€™s disease: lessons learned beyond dopamine. , 2022, 1, .		1
7591	Metabolism and memory: Î±-synuclein level in children with obesity and children with type 1 diabetes; relation to glucotoxicity, lipotoxicity and executive functions. <i>International Journal of Obesity</i> , 0, , .	1.6	0
7592	Mitochondrial dysfunction is a key pathological driver of early stage Parkinsonâ€™s. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	28

#	ARTICLE	IF	CITATIONS
7594	Inhibition of Spinal 5-HT ₃ Receptor and Spinal Dorsal Horn Neuronal Excitability Alleviates Hyperalgesia in a Rat Model of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2022, 59, 7253-7264.	1.9	6
7595	Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay. <i>Journal of Alzheimer's Disease</i> , 2023, 94, S399-S428.	1.2	15
7596	Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11059.	1.8	13
7597	Interaction of RAGE with α -synuclein fibrils mediates inflammatory response of microglia. <i>Cell Reports</i> , 2022, 40, 111401.	2.9	14
7598	Ghrelin Bridges DMV Neuropathology and GI Dysfunction in the Early Stages of Parkinson's Disease. <i>Advanced Science</i> , 2022, 9, .	5.6	6
7600	Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology. <i>Neurology</i> , 2022, 99, .	1.5	3
7601	New Insights on the Role of Bioactive Food Derivatives in Neurodegeneration and Neuroprotection. <i>Current Pharmaceutical Design</i> , 2022, 28, 3068-3081.	0.9	2
7602	Neuronal hyperactivity-induced oxidant stress promotes in vivo α -synuclein brain spreading. <i>Science Advances</i> , 2022, 8, .	4.7	8
7603	Neural Correlates of Oral Stereognosis: An fMRI Study. <i>Dysphagia</i> , 0, , .	1.0	0
7604	The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. <i>IBRO Neuroscience Reports</i> , 2022, 13, 330-343.	0.7	4
7605	Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α -Synucleinopathy Animal Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11394.	1.8	12
7607	The Role of Glymphatic System in Alzheimer's and Parkinson's Disease Pathogenesis. <i>Biomedicines</i> , 2022, 10, 2261.	1.4	19
7608	Power spectral analysis of heart rate variability is useful as a screening tool for detecting sympathetic and parasympathetic nervous dysfunctions in Parkinson's disease. <i>BMC Neurology</i> , 2022, 22, .	0.8	5
7609	A minute fraction of α -synuclein in extracellular vesicles may be a major contributor to α -synuclein spreading following autophagy inhibition. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	1
7610	Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	18
7611	The neurology of space flight; How does space flight effect the human nervous system?. <i>Life Sciences in Space Research</i> , 2023, 36, 105-115.	1.2	8
7612	Regulation of microglial physiology by the microbiota. <i>Gut Microbes</i> , 2022, 14, .	4.3	14
7613	Small soluble α -synuclein aggregates are the toxic species in Parkinson's disease. <i>Nature Communications</i> , 2022, 13, .	5.8	51

#	ARTICLE	IF	CITATIONS
7614	Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10138.	1.8	3
7615	Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action. <i>Current Neuropharmacology</i> , 2023, 21, 1214-1223.	1.4	3
7616	Prosaposin Reduces α -Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 2313-2325.	1.1	4
7617	Neuropathological correlates of neuropsychiatric symptoms in dementia. <i>Alzheimer's and Dementia</i> , 2023, 19, 1372-1382.	0.4	16
7618	Potential Link Between Cognition and Motor Reserve in Patients With Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2022, 15, 249-257.	0.7	4
7619	REM sleep behavior and olfactory dysfunction: Enhancing the utility and translation of animal models in the search for precision medicines for Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 143, 104897.	2.9	1
7620	Receptors for Advanced Glycation End Products (RAGE): Promising Targets Aiming at the Treatment of Neurodegenerative Conditions. <i>Current Neuropharmacology</i> , 2023, 21, 219-234.	1.4	7
7621	REM sleep behavior disorder correlates with constipation in de novo Chinese Parkinson's disease patients. <i>Neurological Sciences</i> , 2023, 44, 191-197.	0.9	7
7622	Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 2301-2307.	2.2	7
7623	In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	3
7624	Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	1
7625	Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease. <i>Psychopharmacology</i> , 2022, 239, 3633-3656.	1.5	1
7626	APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	62
7627	Characterization of exogenous α -SN response genes and their relation to Parkinson's disease using network analyses. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
7628	Synthesis and Evaluation of ¹⁸ F-Labeled Chalcone Analogue for Detection of α -Synuclein Aggregates in the Brain Using the Mouse Model. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2982-2990.	1.7	3
7629	Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes. <i>Neurobiology of Disease</i> , 2022, 174, 105883.	2.1	2
7630	The role of neurotransmitter systems in mediating deep brain stimulation effects in Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	5
7632	Soluble LRP-1 in Parkinson's disease: clues for paradoxical effects. <i>International Journal of Neuroscience</i> , 0, , 1-8.	0.8	2

#	ARTICLE	IF	CITATIONS
7633	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2022, 59, 7513-7540.	1.9	5
7634	Gut dysfunction may be the source of pathological aggregation of alpha-synuclein in the central nervous system through Paraquat exposure in mice. <i>Ecotoxicology and Environmental Safety</i> , 2022, 246, 114152.	2.9	6
7635	Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study. <i>Parkinsonism and Related Disorders</i> , 2022, 104, 15-20.	1.1	2
7636	Comparison of Olfactory Thresholds between Elderly with Parkinson Disease and Controls. <i>Journal of Aging and Gerontology</i> , 2014, 2, 5-12.	0.4	1
7637	Learning Interpretable Regularized Ordinal Models from 3D Mesh Data for Neurodegenerative Disease Staging. <i>Lecture Notes in Computer Science</i> , 2022, , 115-124.	1.0	2
7638	Neuropathic Pain in Parkinson's Disease. <i>Neurology India</i> , 2022, 70, 1879.	0.2	3
7639	Efficiency of positron-emission tomography with 18F-DOPA for Parkinson's disease diagnostics. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
7640	A role of human microbiota in the development of neurodegenerative diseases. <i>Zhurnal Nevrologii i Psikiatrii Imeni S S Korsakova</i> , 2022, 122, 57.	0.1	3
7641	Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease. <i>Neural Regeneration Research</i> , 2023, 18, 1450.	1.6	12
7642	Management of advanced Parkinson's disease in Israel: Clinicians viewpoint and action items. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
7643	Analysis of Influencing Factors of Apathy in Patients with Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 1343.	1.1	1
7644	Diagnosis and Medical Management of Parkinson Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1281-1300.	0.4	1
7645	Non-Reproducibility of Oral Rotenone as a Model for Parkinson's Disease in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12658.	1.8	0
7646	Radiomic features of amygdala nuclei and hippocampus subfields help to predict subthalamic deep brain stimulation motor outcomes for Parkinson's disease patients. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	0
7647	Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2397-2422.	1.5	2
7648	Effects of odors on posture. <i>Journal of Sensory Studies</i> , 2023, 38, .	0.8	1
7649	The use of neurotoxins in fundamental, medical and biological sciences on the example of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Toxicological Review</i> , 2022, 30, 307-314.	0.2	0
7650	Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2479-2492.	1.5	2

#	ARTICLE	IF	CITATIONS
7651	The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates. <i>Journal of Neural Transmission</i> , 2022, 129, 1487-1511.	1.4	3
7652	Differential, Stage Dependent Detection of Peptidylarginine Deiminases and Protein Deimination in Lewy Body Diseases—Findings from a Pilot Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13117.	1.8	1
7653	Gangliosides in Neurodegenerative Diseases. <i>Advances in Neurobiology</i> , 2023, , 391-418.	1.3	6
7654	Clinical application of prion-like seeding in α -synucleinopathies: Early and non-invasive diagnosis and therapeutic development. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	0
7655	Modified SqueezeNet Architecture for Parkinson's Disease Detection Based on Keypress Data. <i>Biomedicines</i> , 2022, 10, 2746.	1.4	8
7658	The inter-relationship between various non-motor symptoms and with habitual physical activity in Parkinsonism: a scoping review protocol. <i>Physical Therapy Reviews</i> , 2022, 27, 444-452.	0.3	0
7659	Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis. <i>BMC Neurology</i> , 2022, 22, .	0.8	1
7661	Perceptions of people with Parkinson's and their caregivers of falling and falls-related healthcare services- a qualitative study. <i>PLoS ONE</i> , 2022, 17, e0276588.	1.1	1
7662	Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations. <i>Neuroradiology</i> , 2023, 65, 361-370.	1.1	2
7663	Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson's disease. <i>Cognitive Neurodynamics</i> , 2023, 17, 1309-1320.	2.3	2
7664	Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	12
7665	Motor progression marker for newly diagnosed drug-naïve patients with Parkinson's disease: A resting-state functional MRI study. <i>Human Brain Mapping</i> , 0, , .	1.9	3
7666	Neurodegenerative Microbially-Shaped Diseases: Oxidative Stress Meets Neuroinflammation. <i>Antioxidants</i> , 2022, 11, 2141.	2.2	6
7667	Regulation of α -synuclein homeostasis and inflammasome activation by microglial autophagy. <i>Science Advances</i> , 2022, 8, .	4.7	12
7669	Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease. <i>Movement Disorders</i> , 2023, 38, 68-81.	2.2	12
7670	Association of Glial Activation and α -Synuclein Pathology in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2023, 39, 479-490.	1.5	11
7671	Global, in situ analysis of the structural proteome in individuals with Parkinson's disease to identify a new class of biomarker. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 978-989.	3.6	16
7672	Intestine-derived α -synuclein initiates and aggravates pathogenesis of Parkinson's disease in <i>Drosophila</i> . <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	13

#	ARTICLE	IF	CITATIONS
7673	Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study. <i>Biomedicine</i> , 2022, 10, 2649.	1.4	4
7674	Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease. <i>Genes</i> , 2022, 13, 1937.	1.0	4
7675	Pericytes take up and degrade α -synuclein but succumb to apoptosis under cellular stress. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
7676	Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13043.	1.8	7
7677	Articulatory undershoot of vowels in isolated REM sleep behavior disorder and early Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	5
7678	Brain Serotonin Release Is Reduced in Patients With Depression: A [¹¹ C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge. <i>Biological Psychiatry</i> , 2023, 93, 1089-1098.	0.7	22
7679	Prodromal α -Synucleinopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1268-1280.	0.4	0
7680	(Dis)Connected Dots in Dementia with Lewy Bodies: A Systematic Review of Connectivity Studies. <i>Movement Disorders</i> , 2023, 38, 4-15.	2.2	10
7682	Mapping Cholinergic Synaptic Loss in Parkinson's Disease: An [¹⁸ F]FEOBV PET Case-Control Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2493-2506.	1.5	7
7684	Extracellular vesicles: A new paradigm in understanding, diagnosing and treating neurodegenerative disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
7685	Plant-derived bioactive components regulate gut microbiota to prevent depression and depressive-related neurodegenerative diseases: Focus on neurotransmitters. <i>Trends in Food Science and Technology</i> , 2022, 129, 581-590.	7.8	3
7686	Non-REM sleep electrophysiology in REM sleep behaviour disorder: A narrative mini-review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 142, 104909.	2.9	3
7687	Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment. <i>Journal of Advanced Research</i> , 2023, 50, 83-105.	4.4	9
7688	Reelin protects against pathological α -synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 175, 105898.	2.1	3
7689	Pharmacological inhibition of AIMP2 aggregation attenuates α -synuclein aggregation and toxicity in Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113908.	2.5	2
7690	Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance. <i>Ageing Research Reviews</i> , 2022, 82, 101759.	5.0	10
7691	Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson's disease. <i>Neural Regeneration Research</i> , 2023, 18, 1099.	1.6	4
7692	Corpora Amylacea in Aging Brain and Age-Related Brain Disorders. <i>Journal of Aging and Gerontology</i> , 2014, 2, 33-57.	0.4	9

#	ARTICLE	IF	CITATIONS
7693	Parkinsonian Toxins: From MPTP to Endogenous Neurotoxins. , 2022, , 2973-2992.		0
7694	Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes. , 2022, , 2917-2945.		0
7695	Treatment of Parkinsonâ€™s Disease: Early, Late, and Combined. , 2022, , 2891-2915.		0
7696	Pharmacotherapy of Psychosis in Parkinsonâ€™s Disease. , 2022, , 4231-4269.		0
7697	Calcium Channels and Selective Neuronal Vulnerability in Parkinsonâ€™s Disease. , 2022, , 575-598.		2
7698	Structural MRI in familial and idiopathic PD. , 2023, , 151-199.		0
7699	Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinsonâ€™s disease. , 2023, , 121-150.		0
7700	Serotonergic molecular imaging in familial and idiopathic PD. , 2023, , 105-119.		0
7701	Dopaminergic molecular imaging in familial and idiopathic Parkinson's disease. , 2023, , 69-104.		0
7702	Molecular imaging in prodromal Parkinsonâ€™s disease. , 2023, , 251-272.		0
7703	Molecular imaging evidence in favor or against PDD and DLB overlap. , 2023, , 275-295.		1
7704	Low skull bone density is associated with poor motor prognosis in women with Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
7705	The mechanism of exercise for pain management in Parkinsonâ€™s disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	2
7706	Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease. Annals of Internal Medicine, 2022, 175, 1666-1674.	2.0	20
7707	Chronobiology of Parkinson's disease: Past, present and future. European Journal of Neuroscience, 2023, 57, 178-200.	1.2	5
7709	Bile acids and neurological disease. , 2022, 240, 108311.		13
7710	Morphoâ€™Functional Changes of Nigral Dopamine Neurons in an Î±â€™Synuclein Model of Parkinson's Disease. Movement Disorders, 2023, 38, 256-266.	2.2	6
7711	Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always. Annals of Neurology, 2023, 93, 184-195.	2.8	15

#	ARTICLE	IF	CITATIONS
7713	Neurophysiological mechanisms of gait disturbance in advanced Parkinson's disease patients. <i>Neurology and Clinical Neuroscience</i> , 2023, 11, 201-217.	0.2	5
7715	Microstructural but not macrostructural cortical degeneration occurs in Parkinson's disease with mild cognitive impairment. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	6
7716	DOPA-nitrosylation of tyrosine in α -synuclein by tyrosine hydroxylase leads to the formation of oligomers. <i>Nature Communications</i> , 2022, 13, .	5.8	6
7717	Mesoscale connections and gene expression empower whole-brain modeling of α -synuclein spread, aggregation, and decay dynamics. <i>Cell Reports</i> , 2022, 41, 111631.	2.9	2
7718	A prebiotic diet modulates microglial states and motor deficits in α -synuclein overexpressing mice. <i>eLife</i> , 0, 11, .	2.8	18
7719	Protein kinase R dependent phosphorylation of α -synuclein regulates its membrane binding and aggregation. , 2022, 1, .		3
7720	Inflammatory rheumatic diseases and the risk of Parkinson's disease: A systematic review and meta-analysis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
7721	Is congenital anosmia protective for Parkinson's disease triggered by pathogenic entrance through the nose?. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	4
7722	Analysis of slow and fast sleep spindle properties in Parkinson's disease – A comparative EEG study. <i>International Journal of Psychophysiology</i> , 2022, 182, 220-230.	0.5	0
7723	Major advances in Parkinson's disease over the past two decades and future research directions. <i>Lancet Neurology</i> , The, 2022, 21, 1076-1079.	4.9	4
7724	Principal Disorders Associated with Tremor. <i>Synthesis Lectures on Biomedical Engineering</i> , 2008, , 55-80.	0.1	0
7725	Bilirubin Prevents the TH+ Dopaminergic Neuron Loss in a Parkinson's Disease Model by Acting on TNF- α . <i>International Journal of Molecular Sciences</i> , 2022, 23, 14276.	1.8	4
7726	Unsupervised physiological noise correction of functional magnetic resonance imaging data using phase and magnitude information (<sc>PREPAIR</sc>). <i>Human Brain Mapping</i> , 2023, 44, 1209-1226.	1.9	4
7727	Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson's Disease. <i>Molecular Neurobiology</i> , 2023, 60, 979-1003.	1.9	4
7728	Gut microbiota, pathogenic proteins and neurodegenerative diseases. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
7729	Human pericytes degrade diverse α -synuclein aggregates. <i>PLoS ONE</i> , 2022, 17, e0277658.	1.1	6
7732	Locus coeruleus integrity correlates with inhibitory functions of the fronto-subthalamic "hyperdirect" pathway in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2022, 36, 103276.	1.4	1
7733	Interstitial Fluidopathy of the Central Nervous System: An Umbrella Term for Disorders with Impaired Neurofluid Dynamics. <i>Magnetic Resonance in Medical Sciences</i> , 2024, 23, 1-13.	1.1	7

#	ARTICLE	IF	CITATIONS
7734	Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials. <i>Neural Regeneration Research</i> , 2023, .	1.6	0
7735	Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4. <i>Life Sciences</i> , 2023, 312, 121258.	2.0	7
7736	6-Hydroxydopamine (6-OHDA) rodent model of Parkinsonâ€™s disease: Investigating neural control of cardiorespiratory function. , 2023, , 493-506.		0
7737	The use of the proteasome inhibitor lactacystin for modeling Parkinsonâ€™s disease: Early neurophysiological biomarkers and candidates for intranigral and extranigral neuroprotection. , 2023, , 507-523.		1
7738	Risk disclosure in prodromal Parkinson's disease â€“ A survey of neurologists. <i>Parkinsonism and Related Disorders</i> , 2023, 106, 105240.	1.1	3
7739	Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinsonâ€™s disease induced by MPTP. <i>Behavioural Brain Research</i> , 2023, 440, 114257.	1.2	1
7740	Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimerâ€™s disease: relevance for precision medicine in neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2023, 84, 101819.	5.0	9
7741	Parkinsonâ€™s disease: Pathology and treatment. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
7742	Management of Fluctuating Parkinsonâ€™s Disease: From Science to Clinical Wisdom. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 34-39.	3.0	0
7743	Parkinson's Disease: Risk Factor Modification and Prevention. <i>Seminars in Neurology</i> , 2022, 42, 626-638.	0.5	8
7744	Artificial Intelligence towards Parkinsonâ€™s disease Diagnosis: A systematic Review of Contemporary Literature. , 2022, , .		0
7746	Pathogenesis of Î±-Synuclein in Parkinsonâ€™s Disease: From a Neuron-Glia Crosstalk Perspective. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14753.	1.8	14
7747	A postmortem study suggests a revision of the dual-hit hypothesis of Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	39
7748	Extracellular vesicles as personalized medicine. <i>Molecular Aspects of Medicine</i> , 2023, 91, 101155.	2.7	20
7749	Time-dependent alterations in the rat nigrostriatal system after intrastriatal injection of fibrils formed by Î±-Syn and tau fragments. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
7751	The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinsonâ€™s disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	1
7752	How Well Do Rodent Models of Parkinsonâ€™s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. <i>Biomedicines</i> , 2022, 10, 3026.	1.4	6
7753	Isolated dreamâ€“enactment behaviours as a prodromal hallmark of rapid eye movement sleep behaviour disorder. <i>Journal of Sleep Research</i> , 2023, 32, .	1.7	5

#	ARTICLE	IF	CITATIONS
7754	An Update on Peripheral Blood Extracellular Vesicles as Biomarkers for Parkinson's Disease Diagnosis. <i>Neuroscience</i> , 2023, 511, 131-146.	1.1	4
7755	Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 6964.	1.0	11
7756	Iron Brain Menace: The Involvement of Ferroptosis in Parkinson Disease. <i>Cells</i> , 2022, 11, 3829.	1.8	15
7757	Distribution of Lewy-related pathology in the brain, spinal cord, and periphery: the population-based Vantaa 85+ study. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	4
7758	Non-motor manifestation of Parkinson's disease: a cross-sectional study in a teaching hospital in Jordan. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	0.4	4
7759	Constipation in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2023, 86, 34-44.	0.6	7
7760	Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
7761	Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota. <i>Parkinsonism and Related Disorders</i> , 2023, 107, 105244.	1.1	4
7762	Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimer's and Parkinson's Diseases. <i>Current Neuropharmacology</i> , 2023, 21, 1421-1432.	1.4	4
7764	Mediterranean Diet and Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 42.	1.8	14
7765	Î±-Synuclein in synaptic function and dysfunction. <i>Trends in Neurosciences</i> , 2023, 46, 153-166.	4.2	26
7766	Parkin regulates neuronal lipid homeostasis through SREBP2-lipoprotein lipase pathway implications for Parkinson's disease. <i>Human Molecular Genetics</i> , 0, , .	1.4	2
7768	The Hidden Cell-to-Cell Trail of Î±-Synuclein Aggregates. <i>Journal of Molecular Biology</i> , 2023, 435, 167930.	2.0	9
7769	Exercise-Boosted Mitochondrial Remodeling in Parkinson's Disease. <i>Biomedicines</i> , 2022, 10, 3228.	1.4	7
7770	Predicting longitudinal brain atrophy in Parkinson's disease using a Susceptible-Infected-Removed agent-based model. <i>Network Neuroscience</i> , 2023, 7, 906-925.	1.4	6
7771	Elevated Monoamine Oxidase-A in Anterior Cingulate of Post-Mortem Human Parkinson's Disease: A Potential Surrogate Biomarker for Lewy Bodies?. <i>Cells</i> , 2022, 11, 4000.	1.8	7
7772	Anti-Î±-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, , 105969.	2.1	4
7773	Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems. <i>Pharmaceutics</i> , 2023, 15, 13.	2.0	2

#	ARTICLE	IF	CITATIONS
7774	Nanozymes for Neurodegenerative Diseases. , 2023, , 77-95.		2
7776	Aberrant corticospinal tract characteristics in prodromal PD: A diffusion tensor imaging study. <i>Clinical Parkinsonism & Related Disorders</i> , 2023, 8, 100182.	0.5	0
7777	Post-translational modification of lysine residues in erythrocyte α -synuclein. <i>Journal of Biochemistry</i> , 2023, 173, 177-184.	0.9	4
7778	Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease. <i>Journal of Molecular Biology</i> , 2023, 435, 167927.	2.0	2
7779	Effects of nasal inflammation on the olfactory bulb. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	7
7780	Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy. <i>Neurology</i> , 2023, 100, .	1.5	10
7781	Recent research progress on metabolic syndrome and risk of Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2023, 34, 719-735.	1.4	6
7783	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	5
7784	Conformational change of α -synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson's disease. <i>Structure</i> , 2023, 31, 78-87.e5.	1.6	13
7785	Functional brain networks in the evaluation of patients with neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2023, 19, 73-90.	4.9	17
7786	Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2023, 57, 511-526.	1.2	4
7788	Impact of Depression on Cognitive Function and Disease Severity in Idiopathic Cervical Dystonia Patients: One-Center Data in Cross-Sectional Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1793.	0.8	1
7789	Gut microbiota in dementia with Lewy bodies. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	7
7790	Motor symptoms in Parkinson's disease are related to the interplay between cortical curvature and thickness. <i>NeuroImage: Clinical</i> , 2023, 37, 103300.	1.4	1
7791	Overexpression-Induced α -Synuclein Brain Spreading. <i>Neurotherapeutics</i> , 2023, 20, 83-96.	2.1	4
7792	Brain and Cerebrospinal Fluid α -Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in α -Synuclein PD. <i>Movement Disorders</i> , 2023, 38, 333-338.	2.2	10
7793	Intranasal Rotenone Induces Alpha-Synuclein Accumulation, Neuroinflammation and Dopaminergic Neurodegeneration in Middle-Aged Mice. <i>Neurochemical Research</i> , 2023, 48, 1543-1560.	1.6	1
7794	High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimer's and Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4

#	ARTICLE	IF	CITATIONS
7795	Design and application of a customizable relational <sc>DataBase</sc> to assess clinicopathological correlations and concomitant pathology in neurodegenerative diseases. Brain Pathology, 2023, 33, .	2.1	3
7796	Hypoxic stress accelerates the propagation of pathological alpha–synuclein and degeneration of dopaminergic neurons. CNS Neuroscience and Therapeutics, 0, , .	1.9	1
7799	Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. Alzheimer's and Dementia, 2023, 19, 2182-2196.	0.4	11
7800	Uncovering the Molecular Link Between Lead Toxicity and Parkinson's Disease. Antioxidants and Redox Signaling, 2023, 39, 321-335.	2.5	0
7801	Age-Related Decline in Gangliosides GM1 and GD1a in Non-CNS Tissues of Normal Mice: Implications for Peripheral Symptoms of Parkinson–s Disease. Biomedicines, 2023, 11, 209.	1.4	5
7802	Rotenone-Induced Model of Parkinson–s Disease: Beyond Mitochondrial Complex I Inhibition. Molecular Neurobiology, 2023, 60, 1929-1948.	1.9	16
7803	Seeding Activity of Skin Misfolded Proteins as a Biomarker in Prion and Prion-Like Diseases. , 2023, , 653-673.		2
7804	<sc>Neuromelanin–Sensitive Magnetic Resonance Imaging</sc> Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism. Movement Disorders, 2023, 38, 479-484.	2.2	4
7805	Early and Accurate Identification of Parkinson Disease Among US Veterans. , 2019, 36, .		3
7806	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson–s Disease. , 2022, , 443-483.		0
7807	Pharmacological characterization of the small molecule O3A10 as an inhibitor of Î±-synuclein aggregation for Parkinson–s disease treatment. Acta Pharmacologica Sinica, 2023, 44, 1122-1134.	2.8	7
7808	Application value of multiparametric MRI for evaluating iron deposition in the substantia nigra in Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	3
7809	Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective. International Journal of Pharmaceutics, 2023, 633, 122614.	2.6	2
7810	Using Features Extracted From Upper Limb Reaching Tasks to Detect Parkinson–s Disease by Means of Machine Learning Models. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2023, 31, 1056-1063.	2.7	6
7811	C/EBPÎ²/AEP is age-dependently activated in Parkinson–s disease and mediates Î±-synuclein in the gut and brain. Npj Parkinson's Disease, 2023, 9, .	2.5	10
7812	Parkinson's disease constipation effect of electroacupuncture at ST25 through colonic motility and enteric neuropathology. Frontiers in Neurology, 0, 13, .	1.1	4
7813	Efficacy and safety of probiotics in Parkinson–s constipation: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	4
7814	Neuromapping olfactory stimulation using magnetoencephalography - visualizing smell, a proof-of-concept study. Frontiers in Allergy, 0, 3, .	1.2	0

#	ARTICLE	IF	CITATIONS
7815	The Genetic Etiology of Parkinson's Disease Does Not Robustly Affect Subthalamic Physiology. <i>Movement Disorders</i> , 2023, 38, 484-489.	2.2	3
7816	Paroxysmal Slow-Wave Events Are Uncommon in Parkinson's Disease. <i>Sensors</i> , 2023, 23, 918.	2.1	0
7817	Relationship Between Iron Distribution in Deep Gray Matter Nuclei Measured by Quantitative Susceptibility Mapping and Motor Outcome After Deep Brain Stimulation in Patients With Parkinson's Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 581-590.	1.9	3
7818	Mechanism of pyroptosis in neurodegenerative diseases and its therapeutic potential by traditional Chinese medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
7819	Challenges in the clinical advancement of cell therapies for Parkinson's disease. <i>Nature Biomedical Engineering</i> , 2023, 7, 370-386.	11.6	9
7820	Nucleic acid drug vectors for diagnosis and treatment of brain diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	19
7821	Insoluble Cellular Prion Protein and Other Neurodegeneration-Related Protein Aggregates in the Brain of Asymptomatic Individuals. , 2023, , 63-86.		0
7823	Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1842.	1.8	6
7824	Spatial Transcriptome Profiling of Mouse Hippocampal Single Cell Microzone in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1810.	1.8	4
7825	Unconventional secretion of α -synuclein mediated by palmitoylated DJA1C5 oligomers. <i>ELife</i> , 0, 12, .	2.8	5
7826	The Effects of Speech Task on Lexical Stress in Parkinson's Disease. <i>American Journal of Speech-Language Pathology</i> , 2023, 32, 506-522.	0.9	0
7827	Microglial depletion exacerbates motor impairment and dopaminergic neuron loss in a 6-OHDA model of Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2023, 375, 578019.	1.1	10
7828	Effects of a probiotic suspension <i>Symprove</i> on a rat early-stage Parkinson's disease model. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
7829	α -Synuclein Pathology and Reduced Neurogenesis in the Olfactory System Affect Olfaction in a Mouse Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2023, 43, 1051-1071.	1.7	5
7830	C/EBP β Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1459.	1.8	3
7831	ATP13A2 Gene Silencing in <i>Drosophila</i> Affects Autophagic Degradation of A53T Mutant α -Synuclein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1775.	1.8	6
7832	Sleep and wakefulness disturbances in Parkinson's disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. <i>Sleep Medicine Reviews</i> , 2023, 68, 101759.	3.8	23
7833	Comparative efficacy of transcranial magnetic stimulation on different targets in Parkinson's disease: A Bayesian network meta-analysis. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1

#	ARTICLE	IF	CITATIONS
7834	Fluid dynamics in aging-related dementias. <i>Neurobiology of Disease</i> , 2023, 177, 105986.	2.1	8
7835	Extracellular transportation of α -synuclein by HLA class II molecules. <i>Biochemical and Biophysical Research Communications</i> , 2023, 644, 25-33.	1.0	3
7836	Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia. <i>Neuropharmacology</i> , 2023, 226, 109411.	2.0	6
7837	Cura manuale integrata nella malattia di Parkinson. <i>Pnei Review</i> , 2022, , 45-56.	0.1	0
7838	Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease. <i>Neurology</i> , 2023, 100, .	1.5	4
7839	<i>Actaea racemosa</i> L. Rhizome Protect against MPTP-Induced Neurotoxicity in Mice by Modulating Oxidative Stress and Neuroinflammation. <i>Antioxidants</i> , 2023, 12, 40.	2.2	2
7840	Neuroprotection in Parkinson's Disease. , 2011, , 162-176.		0
7841	Animal Models of Parkinson's Disease. , 2011, , 86-112.		0
7842	Functional connectome automatically differentiates multiple system atrophy (parkinsonian type) from idiopathic Parkinson's disease at early stages. <i>Human Brain Mapping</i> , 2023, 44, 2176-2190.	1.9	7
7843	The association between Parkinson's disease and autoimmune diseases: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
7844	α -Synuclein-Induced Destabilized BMAL1 mRNA Leads to Circadian Rhythm Disruption in Parkinson's Disease. <i>Neurotoxicity Research</i> , 0, , .	1.3	0
7845	Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels. <i>Clinical Parkinsonism & Related Disorders</i> , 2023, 8, 100187.	0.5	1
7846	Severity-dependent functional connectome and the association with glucose metabolism in the sensorimotor cortex of Parkinson's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	0
7847	Mitochondrial calcium cycling in neuronal function and neurodegeneration. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	10
7848	Preservation of Dopamine Levels in a Mouse Model of Parkinson's Disease by Carboxymethylated Silica and Starch Nanoparticles Coupled to Silybin. <i>ChemistrySelect</i> , 2023, 8, .	0.7	0
7849	Low Levels of Adenosine and GDNF Are Potential Risk Factors for Parkinson's Disease with Sleep Disorders. <i>Brain Sciences</i> , 2023, 13, 200.	1.1	8
7850	Molecular Mechanisms Underlying Neuroinflammation Elicited by Occupational Injuries and Toxicants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2272.	1.8	17
7851	The Use of Surface Plasmon Resonance to Study the Interactions of Proteins Involved in Conformational Diseases: Experimental Approaches for New Therapeutic Perspectives. <i>Current Medicinal Chemistry</i> , 2023, 30, 4072-4095.	1.2	0

#	ARTICLE	IF	CITATIONS
7852	A case of the development of early mental and autonomic disorders in a patient with Parkinson's disease. differential diagnosis with atypical parkinsonism. Vestnik Nevrologii, Psichiatrii I Nejrohirurgii, 2023, , 40-43.	0.0	0
7853	Phytotherapeutic alternatives for neurodegenerative dementias: Scientific review, discussion and therapeutic proposal. Phytotherapy Research, 2023, 37, 1176-1211.	2.8	2
7854	A novel histological staging of hippocampal sclerosis that is evident in gray matter loss in vivo. Alzheimer's and Dementia, 0, , .	0.4	3
7856	Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	3
7857	Cutaneous Î±-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. Neurology, 2023, 100, .	1.5	22
7858	A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (â€œeline) Tj ETQq ₁₋₁ 0.7843 ₁₄ rgBT	2.1	5
7859	Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinsonâ€™s disease dementia. Translational Neurodegeneration, 2023, 12, .	3.6	8
7860	Dynamic Regulation of DNA Methylation and Brain Functions. Biology, 2023, 12, 152.	1.3	9
7861	Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. Brain Communications, 2022, 5, .	1.5	4
7862	The theoretical problems of â€œprodromeâ€ and â€œphenoconversionâ€ in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 155-167.	1.0	0
7863	Role of rodent models in advancing precision medicine for Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 3-16.	1.0	2
7864	Influence of cognitive reserve on cognitive and motor function in Î±-synucleinopathies: A systematic review protocol. Annals of the New York Academy of Sciences, 2023, 1522, 15-23.	1.8	0
7865	Interneuronal In Vivo Transfer of Synaptic Proteins. Cells, 2023, 12, 569.	1.8	0
7866	Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study. Biomedicine, 2023, 11, 573.	1.4	1
7867	The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinsonâ€™s disease. Journal of Neural Transmission, 2023, 130, 611-625.	1.4	17
7869	Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease. Neurobiology of Disease, 2023, 179, 106048.	2.1	3
7870	Gut-to-Brain Î±-Synuclein Transmission in Parkinsonâ€™s Disease: Evidence for Prion-like Mechanisms. International Journal of Molecular Sciences, 2023, 24, 7205.	1.8	5
7871	Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease. Movement Disorders, 2023, 38, 1068-1076.	2.2	1

#	ARTICLE	IF	CITATIONS
7872	Serotonin in synucleinopathies. Behavioural Brain Research, 2023, 445, 114367.	1.2	2
7873	Low serum uric acid levels may be a potential biomarker of poor sleep quality in patients with Parkinson's disease. Sleep Medicine, 2023, 105, 9-13.	0.8	1
7874	Lithium engages autophagy for neuroprotection and neuroplasticity: Translational evidence for therapy. Neuroscience and Biobehavioral Reviews, 2023, 148, 105148.	2.9	2
7875	Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using \pm -synuclein seed amplification: a cross-sectional study. Lancet Neurology, The, 2023, 22, 407-417.	4.9	130
7876	Presence but not the timing of onset of REM sleep behavior disorder distinguishes evolution patterns in Parkinson's disease. Neurobiology of Disease, 2023, 180, 106084.	2.1	3
7877	Selecting the Best Animal Model of Parkinson's Disease for Your Research Purpose: Insight from <i>in vivo</i> PET Imaging Studies. Current Neuropharmacology, 2023, 21, 1241-1272.	1.4	2
7878	Dopamine-independent development and maintenance of mouse striatal medium spiny neuron dendritic spines. Neurobiology of Disease, 2023, 181, 106096.	2.1	1
7879	Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing. Neuroscience and Biobehavioral Reviews, 2023, 149, 105167.	2.9	8
7880	The unique neuropathological vulnerability of the human brain to aging. Ageing Research Reviews, 2023, 87, 101916.	5.0	4
7881	Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis. Npj Parkinson's Disease, 2023, 9, .	2.5	5
7882	Ca^{2+} -Calmodulin-Calcineurin Signaling Modulates \pm -Synuclein Transmission. Movement Disorders, 2023, 38, 1056-1067.	2.2	3
7883	Mood disturbances in Parkinson's disease: From prodromal origins to application of animal models. Neurobiology of Disease, 2023, 181, 106115.	2.1	2
7886	Alpha-Synuclein Toxicity: An Insight on Controversial Issues. , 2022, , 1489-1506.		0
7887	Neuromelanin and Parkinson's Disease. , 2022, , 1593-1612.		0
7888	Current Concepts of Neurodegenerative Diseases. European Medical Journal Neurology, 0, , 10-11.	0.0	2
7889	Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinson's disease: current evidence and future perspectives. Expert Review of Neurotherapeutics, 2023, 23, 25-43.	1.4	5
7890	Vestibular evoked myogenic potential abnormalities in early and late stage Parkinson patients. , 0, , .		0
7891	An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson's disease. Journal of Clinical Sleep Medicine, 2023, 19, 1133-1144.	1.4	2

#	ARTICLE	IF	CITATIONS
7892	Prognostic biomarkers in prodromal α -synucleinopathies: DAT binding and REM sleep without atonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 532-540.	0.9	4
7893	Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	3
7894	Smelling the Disease: Diagnostic Potential of Breath Analysis. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 321-347.	1.6	19
7895	Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders. <i>Chemico-Biological Interactions</i> , 2023, 373, 110375.	1.7	1
7896	T-type calcium channels as therapeutic targets in essential tremor and Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 462-483.	1.7	5
7898	Towards early detection of neurodegenerative diseases: A gut feeling. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	7
7899	D-685 Reverses Motor Deficits and Reduces Accumulation of Human α -Synuclein Protein in Two Different Parkinson's Disease Animal Models. <i>ACS Chemical Neuroscience</i> , 2023, 14, 885-896.	1.7	0
7900	Classification and staging of Parkinson's disease using video-based eye tracking. <i>Parkinsonism and Related Disorders</i> , 2023, 110, 105316.	1.1	14
7901	Review of Technological Challenges in Personalised Medicine and Early Diagnosis of Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3321.	1.8	6
7903	Dysfunction of the noradrenergic system drives inflammation, α -synucleinopathy, and neuronal loss in mouse colon. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
7904	Prolonged Differentiation of Neuron-Astrocyte Co-Cultures Results in Emergence of Dopaminergic Neurons. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3608.	1.8	2
7905	Neurodegeneration cell per cell. <i>Neuron</i> , 2023, 111, 767-786.	3.8	8
7906	Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 35-55.	1.0	0
7907	The Role of α -Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features. <i>Biomedicines</i> , 2023, 11, 541.	1.4	7
7908	The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 3-20.	1.0	1
7909	α -Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/NF- κ B pathway in Schwann cells of vagus nerve in a rat model. <i>Journal of Neuroinflammation</i> , 2023, 20, .	3.1	6
7910	α -Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases. <i>Journal of Molecular Biology</i> , 2023, 435, 168011.	2.0	7
7911	Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson's Disease. <i>Cells</i> , 2023, 12, 621.	1.8	2

#	ARTICLE	IF	CITATIONS
7912	Detection of <i>ATXN2</i> Expansions in an Exome Dataset: An Underdiagnosed Cause of Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 664-669.	0.8	2
7913	Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α -synuclein accumulation in Parkinson's disease. <i>Biochemical Society Transactions</i> , 2023, 51, 245-257.	1.6	1
7915	Subthalamic Nucleus (STN)-Deep Brain Stimulation Reduces the Power of Mu and Beta Rhythms and Enhances Synchrony at the Motor Cortices in Parkinson's Disease: A Report of Two Cases. <i>Cureus</i> , 2023, , .	0.2	0
7916	LRRK2: Genetic mechanisms vs genetic subtypes. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 133-154.	1.0	2
7917	Integrin Mac1 mediates paraquat and maneb-induced learning and memory impairments in mice through NADPH oxidase α -NLRP3 inflammasome axis-dependent microglial activation. <i>Journal of Neuroinflammation</i> , 2023, 20, .	3.1	3
7918	Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide. <i>Molecular Brain</i> , 2023, 16, .	1.3	2
7919	Cerebral cortical thinning in Parkinson α ™s disease depends on the age of onset. <i>PLoS ONE</i> , 2023, 18, e0281987.	1.1	1
7920	Signaling pathways in Parkinson α ™s disease: molecular mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	37
7921	Functional and structural alterations as diagnostic imaging markers for depression in de novo Parkinson α ™s disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
7923	Antioxidant Activity of Panax ginseng to Regulate ROS in Various Chronic Diseases. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 2893.	1.3	6
7924	Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson α ™s and Alzheimer α ™s Disease. <i>Biomedicines</i> , 2023, 11, 728.	1.4	6
7925	CRISPR-Cas9-Edited α -SNCA α ™s Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity. <i>Biological and Pharmaceutical Bulletin</i> , 2023, 46, 517-522.	0.6	3
7926	Clinical Phenotype Imprints on Brain Atrophy Progression in Parkinson α ™s Disease. <i>Clinical and Translational Neuroscience</i> , 2023, 7, 8.	0.4	1
7927	Multilingual evaluation of interpretable biomarkers to represent language and speech patterns in Parkinson's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	6
7928	Fecal microbiota transplantation in Parkinson's disease α ™s A randomized repeat-dose, placebo-controlled clinical pilot study. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	16
7929	hPSC-derived sacral neural crest enables rescue in a severe model of Hirschsprung α ™s disease. <i>Cell Stem Cell</i> , 2023, 30, 264-282.e9.	5.2	15
7931	Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson α ™s. <i>Neurological Sciences</i> , 2023, 44, 2265-2275.	0.9	1
7933	Mechanisms of 1 α ™s Hz Inhibitory and 5 α ™s Hz Excitatory Repetitive Transcranial Magnetic Stimulations in Parkinson's Disease: A Functional Magnetic Resonance Imaging Study. <i>Brain Connectivity</i> , 2023, 13, 247-263.	0.8	1

#	ARTICLE	IF	CITATIONS
7934	Development of Small Molecules Targeting α -Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease. <i>Pharmaceutics</i> , 2023, 15, 839.	2.0	10
7935	Circadian Rhythmicity in Aging and Parkinson's Disease. <i>Healthy Ageing and Longevity</i> , 2023, , 237-255.	0.2	0
7936	A synthetic normative template for Parkinson's disease studies using structural and neuromelanin-sensitive magnetic resonance imaging. , 2023, , .		0
7937	Brain-wide transcriptome-based metabolic alterations in Parkinson's disease: human inter-region and human-experimental model correlations. <i>Molecular Omics</i> , 2023, 19, 522-537.	1.4	1
7938	A Preclinical Model for Parkinson's Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies. <i>Antioxidants</i> , 2023, 12, 673.	2.2	5
7939	Engineered inhalable nanocatalytic therapeutics for Parkinson's disease by inducing mitochondrial autophagy. <i>Materials and Design</i> , 2023, 228, 111808.	3.3	1
7941	Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	5
7943	Synaptic Density and Glucose Consumption in Patients with <i>Lewy Body Diseases</i> : An [¹¹ C]UCB ϵ and [¹⁸ F]FDG PET Study. <i>Movement Disorders</i> , 2023, 38, 796-805.	2.2	6
7944	α -Synuclein oligomers and fibrils: partners in crime in synucleinopathies. <i>Neural Regeneration Research</i> , 2023, 18, 2332-2342.	1.6	3
7945	α -Synuclein conformers reveal link to clinical heterogeneity of α -synucleinopathies. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	4
7946	Paradoxical kinesis may no longer be a paradox waiting for 100 years to be unraveled. <i>Reviews in the Neurosciences</i> , 2023, .	1.4	0
7947	Exercise suppresses neuroinflammation for alleviating Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2023, 20, .	3.1	19
7948	Rapid eye movement sleep behavior disorder is associated with decreased quality of life and stigma in people with Parkinson's disease. <i>Acta Neurologica Belgica</i> , 0, , .	0.5	0
7949	Alpha Synuclein: Neurodegeneration and Inflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5914.	1.8	11
7950	Neuronal identity defines α -synuclein and tau toxicity. <i>Neuron</i> , 2023, 111, 1577-1590.e11.	3.8	10
7951	Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872311643.	1.2	0
7952	Pink1 ^{-/-} Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease. <i>Dysphagia</i> , 0, , .	1.0	2
7953	Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease. <i>Movement Disorders</i> , 2023, 38, 774-782.	2.2	2

#	ARTICLE	IF	CITATIONS
7955	Structural connectivity and brain network analyses in Parkinson's disease: A cross-sectional and longitudinal study. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
7956	Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	2
7957	Inflammasome inhibition protects dopaminergic neurons from α -synuclein pathology in a model of progressive Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2023, 20, .	3.1	7
7958	Influence of RBD onset on the clinical characteristics of Parkinson's disease patients: a retrospective study. <i>Journal of Neurology</i> , 2023, 270, 3171-3178.	1.8	4
7959	Microglia Mediated Neuroinflammation in Parkinson's Disease. <i>Cells</i> , 2023, 12, 1012.	1.8	19
7960	Association between Inflammatory Bowel Disease and Subsequent Development of Restless Legs Syndrome and Parkinson's Disease: A Retrospective Cohort Study of 35,988 Primary Care Patients in Germany. <i>Life</i> , 2023, 13, 897.	1.1	0
7961	Dysphagia in Parkinson Disease: Part I – Pathophysiology and Diagnostic Practices. <i>Current Physical Medicine and Rehabilitation Reports</i> , 0, , .	0.3	0
7962	Voxel-Based and Surface-Based Morphometry Analysis in Patients with Pathologically Confirmed Argyrophilic Grain Disease and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 379-387.	1.2	4
7963	Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis. <i>Brain Communications</i> , 2023, 5, .	1.5	3
7964	Salivary gland immunohistochemistry vs substantia nigra sonography: comparative analysis of diagnostic significance. <i>Annals of Clinical and Experimental Neurology</i> , 2023, 17, 36-42.	0.1	0
7965	Olfactory Bulb Volume, Olfactory Sulcus Depth in Parkinson's Disease, Atypical Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 794-801.	0.8	0
7966	A scoping review of neurodegenerative manifestations in explainable digital phenotyping. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5
7967	Pattern of prefrontal cortical activation and network revealed by task-based and resting-state fNIRS in Parkinson's disease patients with overactive bladder symptoms. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	0
7968	Neuroprotective Effects of Lactoferrin in Alzheimer's and Parkinson's Diseases: A Narrative Review. <i>ACS Chemical Neuroscience</i> , 0, , .	1.7	4
7969	Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinson's disease. <i>Brain Structure and Function</i> , 0, , .	1.2	0
7970	Cholinergic basal forebrain atrophy in Parkinson's disease with freezing of gait. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	1.7	0
7973	Clinical Evaluation of Sleep Disorders in Parkinson's Disease. <i>Brain Sciences</i> , 2023, 13, 609.	1.1	1
7974	Dysphagia Requiring Medical Attention in Parkinson's Disease: A Korean Population-Based Study. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0

#	ARTICLE	IF	CITATIONS
7975	Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy. <i>Biomolecules</i> , 2023, 13, 644.	1.8	0
7976	MALAT1 Mediates α -Synuclein Expression through miR-23b-3p to Induce Autophagic Impairment and the Inflammatory Response in Microglia to Promote Apoptosis in Dopaminergic Neuronal Cells. <i>Mediators of Inflammation</i> , 2023, 2023, 1-17.	1.4	6
7977	Cognitive heterogeneity in Parkinson's disease: A mechanistic view. <i>Neuron</i> , 2023, 111, 1531-1546.	3.8	10
7978	Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson's Disease. <i>Antioxidants</i> , 2023, 12, 894.	2.2	5
7979	Localization and neurochemistry of sleep-wake physiology and pathophysiology. , 2024, , 29-35.e1.		0
7980	State of the Art of microRNAs Signatures as Biomarkers and Therapeutic Targets in Parkinson's and Alzheimer's Diseases: A Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2023, 11, 1113.	1.4	7
7981	Proposal for a Biologic Staging System of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2023, 13, 297-309.	1.5	23
7982	Punding in Parkinson's Disease: An Update. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 1035-1047.	0.8	4
7983	Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2023, 13, 279-296.	1.5	2
7984	Movement disorders are linked to TDP-43 burden in the substantia nigra of FTL-D-TDP brain donors. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	1
7985	In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts. <i>PLoS ONE</i> , 2023, 18, e0282684.	1.1	4
7987	Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord. <i>Pharmaceutics</i> , 2023, 15, 1230.	2.0	3
7989	α -Synuclein Structural Diversity and the Cellular Environment in α -Synuclein Transmission Models and Humans. <i>Neurotherapeutics</i> , 2023, 20, 67-82.	2.1	2
7990	Loss of hypothalamic MCH decreases food intake in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 0, .	3.9	2
7991	The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models. <i>Journal of Neural Transmission</i> , 2023, 130, 737-753.	1.4	10
7992	Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease. <i>Journal of Neural Transmission</i> , 2023, 130, 627-646.	1.4	8
7993	Association between Respiratory Function and Motor Function in Different Stages of Parkinson's Disease. <i>European Neurology</i> , 2023, 86, 242-249.	0.6	0
7995	Attenuation of α -synuclein aggregation by catalytic photo-oxygenation. <i>Chemical Communications</i> , 2023, 59, 5745-5748.	2.2	2

#	ARTICLE	IF	CITATIONS
7996	Explainable classification of Parkinson's disease using deep learning trained on a large multi-center database of T1-weighted MRI datasets. <i>NeuroImage: Clinical</i> , 2023, 38, 103405.	1.4	5
7997	Interstitial Cells of Cajal and Enteric Nervous System in Gastrointestinal and Neurological Pathology, Relation to Oxidative Stress. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3552-3572.	1.0	4
7998	Molecular Mechanisms of Cellular Senescence in Neurodegenerative Diseases. <i>Journal of Molecular Biology</i> , 2023, 435, 168114.	2.0	9
7999	Multi-regional alterations in glucose and purine metabolic pathways in the Parkinson's disease dementia brain. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5
8000	New Indole-3-Propionic Acid and 5-Methoxy-Indole Carboxylic Acid Derived Hydrazone Hybrids as Multifunctional Neuroprotectors. <i>Antioxidants</i> , 2023, 12, 977.	2.2	2
8022	EVALUATION OF PRODROMAL STAGE BIOMARKERS IN PARKINSON'S DISEASE AND THEIR ROLE IN DISEASE PROGRESSION USE OF MODERN DIGITAL TECHNOLOGIES. , 2022, , .		0
8027	Decision-making under ambiguity and risk and executive functions in Parkinson's disease patients: A scoping review of the studies investigating the Iowa Gambling Task and the Game of Dice. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 0, , .	1.0	0
8031	Laser-induced Graphene Sensor Interfaced with Machine Learning Classifiers for Hand Tremor Identification. , 2023, , .		0
8032	The α -synucleinopathy syndicate: multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 0, , .	1.4	0
8034	Parkinson's disease in a patient with olfactory hypoplasia: a model case of α -synuclein-first Lewy body disease—providing insights into the progression of α -synuclein accumulation. <i>Journal of Neurology</i> , 0, , .	1.8	1
8037	Dystonia and Parkinson's disease: Do they have a shared biology?. <i>International Review of Neurobiology</i> , 2023, , .	0.9	0
8064	The Role of the Serotonergic System of the Brain in the Pathogenesis of Parkinson's Disease. <i>Neurochemical Journal</i> , 2023, 17, 30-41.	0.2	0
8066	Prebiotics and probiotics and Parkinson's disease. , 2023, , 641-673.		0
8077	Clinical cases on functional neurosurgery and motor speech disorders. , 2023, , 357-418.		0
8082	Fluid and Biopsy Based Biomarkers in Parkinson's Disease. <i>Neurotherapeutics</i> , 2023, 20, 932-954.	2.1	6
8101	Exercise and Parkinson's disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors. , 2023, , 137-147.		0
8122	More than meets the eye in Parkinson's disease and other synucleinopathies: from proteinopathy to lipidopathy. <i>Acta Neuropathologica</i> , 2023, 146, 369-385.	3.9	8
8131	Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5

#	ARTICLE	IF	CITATIONS
8146	Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. Handbook of Experimental Pharmacology, 2023, , .	0.9	2
8156	Non-Motor Symptoms in Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 25-45.	0.1	2
8157	Neuropathology of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 82-101.	0.1	2
8158	Potential Role of Probiotics and Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 296-317.	0.1	2
8162	Autonomic failure: Clinicopathologic, physiologic, and genetic aspects. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 55-102.	1.0	0
8163	Pretectum p1 (Prosomere 1). , 2023, , 499-535.		0
8175	The prevalence of sarcopenia in Parkinsonâ€™s disease and related disorders- a systematic review. Neurological Sciences, 0, , .	0.9	0
8180	Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight. Nature Reviews Neuroscience, 2023, 24, 620-639.	4.9	9
8184	Cholinergic Imaging and Dementia. , 2023, , 127-143.		0
8191	Diffusion Magnetic Resonance Imaging (MRI)-Biomarkers for Diagnosis of Parkinsonâ€™s Disease. , 0, , .		0
8208	Linking the cerebellum to Parkinson disease: an update. Nature Reviews Neurology, 0, , .	4.9	1
8213	Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature, 2023, 621, 701-710.	13.7	18
8219	Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases. Neuroscience Bulletin, 2024, 40, 241-254.	1.5	0
8224	The variance in phosphorylated, insoluble α -synuclein in humans, rats, and mice is not mainly driven by biological sex. Acta Neuropathologica, 2023, 146, 651-654.	3.9	0
8226	Symptomatology and Clinical Features of Parkinson's Disease. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 14-24.	0.1	1
8227	Relationship Between Short-chain Fatty Acids and Parkinsonâ€™s Disease: A Review from Pathology to Clinic. Neuroscience Bulletin, 0, , .	1.5	4
8229	Parkinsonâ€™s Disease and Other Movement Disorders. , 2023, , 1-24.		0
8238	Chapter 4. Bilingualism and language control. Bilingual Processing and Acquisition, 2023, , 130-158.	0.2	0

#	ARTICLE	IF	CITATIONS
8249	The Mechanistic Approach Involved in the Progression of Neurodegenerative Disorders. , 2023, , 33-56.		0
8250	Molecular Investigation of Protein-Protein Interaction Candidates Related to the Mammalian Brain. , 2023, , 81-107.		0
8266	Correlation of glymphatic system abnormalities with Parkinson's disease progression: a clinical study based on non-invasive fMRI. Journal of Neurology, 0, , .	1.8	1
8281	Stem Cell-Based Therapy for Parkinson's Disease. , 2023, , 1-33.		0
8296	Cardiac sympathetic comorbidity might reflect the neurobiology of early Parkinson's disease. Journal of Neurology, 2024, 271, 944-954.	1.8	1
8312	Inflammation as common link to progressive neurological diseases. Archives of Toxicology, 0, , .	1.9	1
8317	Morphological Features of Human Dendritic Spines. Advances in Neurobiology, 2023, , 367-496.	1.3	0
8325	A multiple hits hypothesis for memory dysfunction in Parkinson disease. Nature Reviews Neurology, 2024, 20, 50-61.	4.9	2
8358	Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson's disease. International Review of Neurobiology, 2024, , 1-58.	0.9	1
8370	Reduced tear fluid production in neurological diseases: a cohort study in 708 patients. Journal of Neurology, 0, , .	1.8	0
8379	Macro and micro-sleep dysfunctions as translational biomarkers for Parkinson's disease. International Review of Neurobiology, 2024, , 187-209.	0.9	0
8395	Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease. Journal of Neurology, 2024, 271, 1959-1972.	1.8	1
8399	Neuroinflammation and Immune Dysfunction in the Mechanisms of Development of Parkinson's Disease. Neuroscience and Behavioral Physiology, 0, , .	0.2	0
8403	Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. Nature Reviews Neuroscience, 2024, 25, 111-130.	4.9	0
8406	Toxic interactions between dopamine, α -synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease. Journal of Neural Transmission, 0, , .	1.4	0
8409	Insight gained from using animal models to study pain in Parkinson's disease. International Review of Neurobiology, 2024, , 99-118.	0.9	0
8419	Neurotoxicity induced by glycotoxins. , 2024, , 1021-1058.		0
8426	Nutraceuticals in the management of Parkinson's disease and dementia. , 2024, , 441-466.		0

#	ARTICLE	IF	CITATIONS
8448	Gut Microbes in Parkinson's Disease. , 2024, , 217-240.		0
8450	Morbus Parkinson. , 2024, , 98-112.		0
8454	Metabolomics in neurodegenerative disordersâ€™ Parkinsonâ€™s disease. Comprehensive Analytical Chemistry, 2024, , 161-181.	0.7	0
8468	Calpain Mediated Neurodegeneration in Parkinsonâ€™s disease. Neurochemical Journal, 2023, 17, 632-638.	0.2	0
8472	Comparative Molecular Docking Studies of Selected Phytoconstituents on the Dopamine D3 Receptor (PDB ID: 3PBL) as Potential Anti-Parkinsonâ€™s Agents. , 0, , .		0
8474	Digital outcomes. , 2024, , 91-107.		0
8479	Therapeutic Role of Nanocurcumin in Alzheimerâ€™s and Parkinsonâ€™s Disease. , 2023, , 337-352.		0
8503	Neurological Diseases. , 2023, , 295-314.		0
8509	Parkinsonâ€™s Disease and Other Movement Disorders. , 2024, , 1073-1096.		0
8513	Emerging Nanotechnology for the Treatment and Diagnosis of Parkinsonâ€™s Disease (PD) and Alzheimerâ€™s Disease (AD). Pancreatic Islet Biology, 2024, , 139-174.	0.1	0
8519	The Gut Microbiota and NDG: What Is the Interplay. , 2024, , 1-34.		0
8521	Proteomic-Based Studies on Memory Formation in Normal and Neurodegenerative Disease-Affected Brains. Advances in Experimental Medicine and Biology, 2024, , 129-158.	0.8	0
8530	Parkinsonâ€™s Disease MRIs Analysis Using Neutrosophic-Entropy Segmentation Approach. Brain Informatics and Health, 2024, , 29-50.	0.1	0
8531	Parkinsonâ€™s Disease MRIs Analysis Using Fuzzy Clustering Approach. Brain Informatics and Health, 2024, , 9-27.	0.1	0
8532	Pathophysiology and Management Approaches for Parkinsonâ€™s Disease. , 2023, , 103-153.		0
8551	Lewy Body Dementia. , 2024, , .		0
8567	Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2024, , 51-65.	0.8	0